<SUBMISSION>
<ACCESSION-NUMBER>0000950123-05-015104
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>7
<PERIOD>20051222
<FILING-DATE>20051222
<DATE-OF-FILING-DATE-CHANGE>20051222
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>051282613
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>y15751e6vk.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE>FORM 6-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 6-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>REPORT OF FOREIGN ISSUER<BR>
Pursuant to Rule&nbsp;13a-16 or 15d-16 of<BR>
the Securities Exchange Act of 1934</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>For the month of December&nbsp;2005</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><B>Commission File Number 000-5112</B>2
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>pSivida Limited</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Translation of registrant&#146;s name into English)</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 6pt">Level 12 BGC Centre<BR>
28 The Esplanade<BR>
Perth WA 6000<BR>
(Address of principal executive offices)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F).
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Form&nbsp;20-F <FONT face="Wingdings">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40-F <FONT face="Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation&nbsp;S-T Rule&nbsp;101(b)(1):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation&nbsp;S-T Rule&nbsp;101(b)(7):
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark whether the registrant by furnishing the information contained in this Form
is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the
Securities Exchange Act of 1934.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Yes <FONT face="Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No <FONT face="Wingdings">&#254;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with
Rule&nbsp;12g3-2(b): 82- &#95;&#95;&#95;.
</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURE</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant, pSivida
Limited, has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Date:
December&nbsp;22, 2005
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">pSivida Limited<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/Aaron Finlay
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Aaron Finlay&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left"><I>Chief Financial Officer and Company Secretary</I>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>



<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B><I>EXHIBIT INDEX</I></B></U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="12%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="85%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>EXHIBIT 99.1:</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Supplemental Disclosure of pSivida
Limited related to its Information Statement, dated December&nbsp;22, 2005</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>y15751exv99w1.htm
<DESCRIPTION>EX-99.1: SUPPLEMENTAL DISCLOSURE
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 99.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SUPPLEMENTAL
DISCLOSURE OF PSIVIDA LIMITED RELATED TO ITS INFORMATION STATEMENT,
DATED DECEMBER 22, 2005</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As previously announced, pSivida Limited (the &#147;Company&#148;) has entered into a definitive
agreement and plan of merger, dated October&nbsp;3, 2005 (the &#147;Merger Agreement&#148;), with Control Delivery
Systems, Inc. (&#147;CDS&#148;) and pSivida Inc. (&#147;Acquisition Sub&#148;), a wholly owned subsidiary of the
Company, pursuant to which CDS will merge with and into Acquisition Sub and become a wholly owned
subsidiary of the Company (the &#147;Merger&#148;). In connection with issuance of the Company&#146;s American
Depositary Shares (&#147;ADSs&#148;) in the transactions contemplated by the Merger Agreement, the Company is
distributing a confidential information statement to the stockholders of CDS. The Company is
furnishing as an exhibit to a Report of Foreign Issuer on Form 6-K this Supplemental Disclosure
regarding its business which was contained in the confidential information statement relating to
the merger.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>THE ADSs ISSUED IN THE MERGER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION OR AN APPLICABLE
EXEMPTION FROM REGISTRATION REQUIREMENTS.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>THIS SUPPLEMENTAL DISCLOSURE SHALL NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO
BUY ANY SECURITIES.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise indicated in the supplemental information set forth below, or as the
context may otherwise require references to &#147;pSivida &#147; or like terms refer to pSivida Limited and
its subsidiaries and references to &#147;CDS&#148; refer to Control Delivery Systems, Inc.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">YOU SHOULD ASSUME THAT THE INFORMATION CONTAINED IN THIS SUPPLEMENTAL DISCLOSURE IS ACCURATE AS OF
THE DATE HEREOF ONLY. PSIVIDA&#146;S AND CDS&#146; BUSINESS, FINANCIAL CONDITION, RESULTS OF OPERATIONS AND
PROSPECTS MAY HAVE CHANGED SINCE THAT DATE. THE PARTIES RESERVE THE RIGHT TO, BUT ARE NOT
OBLIGATED TO, REVISE THE INFORMATION OR THE MATERIALS CONTAINED THEREIN.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with General Instruction B of Form 6-K, the information set forth in this
Supplemental Disclosure shall not be deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the
Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the
liabilities of that section, nor shall such information be deemed incorporated by reference in any
filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by
specific reference in such a filing. The information set forth in this Supplemental Disclosure
shall not be deemed an admission as to the materiality of any information in this Supplemental
Disclosure.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Special Information Regarding Forward-Looking Statements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Risk Factors </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Unaudited Pro Forma Consolidated Financial Information</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">pSivida Information</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">CDS Information</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">72</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Consolidated Statements of Financial Position of pSivida Limited and Subsidiaries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">F-1</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Consolidated Financial Statements of Control Delivery Systems, Inc</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">G-2</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV align="center" style="font-size: 10pt; margin-top: 18pt">
<B>SPECIAL INFORMATION REGARDING FORWARD-LOOKING STATEMENTS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This information statement contains forward-looking statements that involve risks and
uncertainties. Words such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;plan,&#148; &#147;expect,&#148; &#147;intend,&#148;
&#147;could,&#148; &#147;estimate,&#148; &#147;may,&#148; &#147;should,&#148; &#147;will,&#148; &#147;future,&#148; &#147;potential&#148; and similar
expressions to identify such forward-looking statements. There is no assurance that the
expectations reflected in such forward-looking statements will prove to be correct. Given these
uncertainties, readers are cautioned not to place undue reliance on such forward-looking
statements. pSivida&#146;s and CDS&#146; actual results could differ materially from those anticipated in
these forward-looking statements due to many important factors some of which are contained in
cautionary statements in this information statement, including, without limitation, the
forward-looking statements included in this information statement and specifically under &#147;Risk
Factors.&#146;&#146;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All subsequent written and oral forward-looking statements attributable to pSivida and/or CDS are expressly qualified in their entirety by reference to these cautionary statements.
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0"> </DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>RISK FACTORS</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>You should carefully read and consider the risks described
below, together with all of the information included in this
information statement.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Risks Relating to
pSivida</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Risks Relating to pSivida&#146;s Business</I></B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>All of pSivida&#146;s products and planned products are based
    upon new and unproven technologies.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida is currently developing products based upon BioSilicon,
a biocompatible and biodegradable form of the element silicon,
for multiple applications across many sectors of healthcare.
pSivida&#146;s core product focus is on controlled slow release
drug delivery and diagnostics. Other potential applications for
BioSilicon include uses in orthopedics and tissue engineering.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
BioSilicon is a new and unproven technology. The successful
development and market acceptance of BioSilicon is subject to
many risks. These risks include the potential for
ineffectiveness, lack of safety, unreliability, failure to
receive necessary regulatory clearances or approvals and the
emergence of superior or equivalent products, as well as the
effect of changes in future general economic conditions.
pSivida&#146;s failure to develop products based on BioSilicon
that overcome these risks would have a material adverse effect
on pSivida&#146;s business, financial condition and results of
operations.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>pSivida has a history of losses; pSivida expects to continue
    to incur losses; and pSivida may never become profitable.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida was formed in 2000. As pSivida is primarily a research
and development company, it has incurred operating losses in
every year of existence. It has incurred a net loss of
A$14.7&nbsp;million, A$3.7&nbsp;million and A$2.8&nbsp;million
for the years ended June&nbsp;30, 2005, 2004 and 2003,
respectively. As of June&nbsp;30, 2005, it had an accumulated
loss of A$27.9&nbsp;million. pSivida has not achieved
profitability and expects to continue to incur net losses
through at least 2007, and it may incur losses beyond that time,
particularly if it is not successful in having BrachySil
approved and widely marketed by that time. Even if BrachySil is
approved and being marketed at some point in 2007 or beyond,
pSivida may not achieve sufficient sales of BrachySil or any
other product to become profitable at that time or at any other
time. The extent of future losses and whether or how long it may
take for pSivida to achieve profitability are uncertain.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>pSivida relies heavily upon patents, trade secrets and other
    proprietary technologies and any future claims that its rights
    to such intellectual property are invalid could seriously harm
    pSivida&#146;s business.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Protection of intellectual property rights is crucial to
pSivida&#146;s business, since that is how it keeps others from
copying the innovations which are central to its proposed
products. pSivida&#146;s success is dependent on whether it can
obtain patents, defend its existing patents and operate without
infringing on the proprietary rights of third parties. pSivida
currently has 34 patents and 82 pending patent applications,
including patents and pending applications covering BioSilicon
and various of its uses. pSivida expects to aggressively patent
and protect its proprietary technologies. However, pSivida
cannot be sure that any additional patents will be issued as a
result of its pending or future patent applications or that any
of its patents will withstand challenges by others. If pSivida
were determined to be infringing any third party patent, it
could be required to pay damages, alter its products or
processes, obtain licenses or cease certain operations. pSivida
may not be able to obtain any required licenses on commercially
favorable terms, if at all. pSivida&#146;s failure to obtain a
license for any technology that it may require to commercialize
BioSilicon could have a material adverse effect on
pSivida&#146;s business, financial condition and results of
operations. In addition, many of the laws of foreign countries
in which pSivida intends to operate may treat the protection of
proprietary rights differently from, and may offer less
protection than, the laws in Australia, the United States and
other Patent Co-operation Treaty countries.
</DIV>

<P align="center" style="font-size: 10pt;">2

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
While pSivida has not been and is not currently involved in any
litigation over intellectual property, such litigation may be
necessary to enforce any patents issued or licensed to pSivida
or to determine the scope and validity of third party
proprietary rights. pSivida may also be sued by a third party
alleging that pSivida infringes its intellectual property
rights. Any intellectual property litigation would be likely to
result in substantial costs to pSivida and diversion of its
efforts. If pSivida&#146;s competitors claim technology also
claimed by pSivida and if they prepare and file patent
applications in the U.S., pSivida may have to participate in
interference proceedings declared by the U.S.&nbsp;Patent and
Trademark office to determine priority of invention, which could
result in substantial cost to pSivida and diversion of its
efforts. Any such litigation or interference proceedings,
regardless of the outcome, could be expensive and time
consuming. Litigation could subject pSivida to significant
liabilities to third parties, requiring disputed rights to be
licensed from third parties or require pSivida to cease using
certain technologies and, consequently, could have a material
adverse effect on its business, financial condition and results
of operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida relies, in part, on confidentiality agreements with
employees, advisors, vendors and consultants to protect
pSivida&#146;s proprietary expertise. These agreements may be
breached and pSivida may not have adequate remedies in the event
of a breach. In addition, pSivida&#146;s un-patented proprietary
technological expertise may otherwise become known or
independently discovered by competitors.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>pSivida has a limited ability to market products itself, and
    if pSivida is unable to find marketing partners for, or
    pSivida&#146;s marketing partners do not successfully market,
    its future products, pSivida&#146;s business will suffer.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida presently has no marketing or sales staff. Achieving
acceptance for the use of BioSilicon will require extensive and
substantial efforts by experienced personnel as well as
expenditure of significant funds. pSivida may not be able to
establish sufficient capabilities necessary to achieve market
penetration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida intends to license and/or sell BioSilicon to companies
that will be responsible in large part for sales, marketing and
distribution of products utilizing BioSilicon. The amount and
timing of resources that may be devoted to the performance of
their contractual responsibilities by these licensees are not
expected to be within pSivida&#146;s control. These partners may
not perform their obligations as expected. pSivida may not
derive any revenue from such arrangements from royalties,
license or option fees, milestone payments or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Moreover, pSivida&#146;s licensees are expected to have rights
of termination under pSivida&#146;s agreements with them.
Exercise of termination rights by those parties may leave
pSivida temporarily or permanently without any marketing or
sales resources which may have an adverse effect on its
business, financial condition and results of operations.
Additionally, pSivida&#146;s interests may not continue to
coincide with those of its partners, and its partners may
develop independently or with third parties products or
technologies that compete with pSivida&#146;s products. Further,
disagreements over rights or technologies or other proprietary
interests may occur.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
To the extent that pSivida chooses not to or pSivida is unable
to enter into future license agreements with marketing and sales
partners, it would experience increased capital requirements to
develop the ability to market and sell future products. pSivida
may not be able to market or sell its technology or future
products independently in the absence of such agreements.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>pSivida&#146;s markets are competitive, and its competitors
    could develop more effective products, making pSivida&#146;s
    proposed products uncompetitive, uneconomical or obsolete,
    thereby impacting its future operations.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida is or plans to be engaged in the rapidly evolving and
competitive fields of drug delivery, tissue engineering,
diagnostics and orthopedics technologies. Its competitors
include many major pharmaceutical companies and other
biotechnology, drug delivery, diagnostics and medical products
companies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Many of pSivida&#146;s potential competitors have substantially
greater financial, technological, research and development,
marketing and personnel resources. pSivida&#146;s competitors
may succeed in developing
</DIV>

<P align="center" style="font-size: 10pt;">2

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
alternate technologies and products that are more effective,
easier to use, more economical than those that pSivida is
seeking to develop or that would render pSivida&#146;s
technologies and proposed products obsolete, uncompetitive or
uneconomical in these fields. These competitors may also have
greater experience in developing products, conducting clinical
trials, obtaining regulatory approvals or clearances and
manufacturing and marketing such products and technologies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s competitive position will be based upon its
ability to:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    create and maintain scientifically-advanced technology and
    proprietary products and processes;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    attract and retain qualified personnel;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    develop safe and efficacious products, alone or in collaboration
    with others;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    obtain patent or other protection for its products and processes;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    obtain required government approvals on a timely basis;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    manufacture products on a cost-effective basis;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    successfully market products.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If pSivida is not successful in meeting these goals, its
business could be adversely affected.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>pSivida faces risks in expanding its efforts beyond its core
    areas of experience and expertise.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida plans to expand its focus outside of its areas of
experience and expertise to seek to broaden its product pipeline
and will require additional internal expertise or external
collaborations in areas in which it currently does not have
internal resources and expertise. Such expertise and
collaborations may be difficult to obtain. pSivida may have to
enter into collaboration arrangements with others that may
require it to relinquish rights to certain of its technologies
or products that pSivida would otherwise pursue independently.
pSivida may be unable to acquire the necessary expertise or
enter into collaboration agreements on acceptable terms.
</DIV>


<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Problems
associated with international business operations could
adversely affect pSivida&#146;s ability to manufacture and sell
its products.</I></TD>
</TR>

</TABLE>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida currently maintains offices in Australia and the UK and,
assuming the successful completion of the merger, the U.S.;
BioSilicon is produced for pSivida in Germany and the UK;
pSivida is conducting product trials in Singapore and intends to
seek to license and/or sell products based on BioSilicon in most
major world healthcare markets. A number of risks are inherent
in pSivida&#146;s international strategy. In order for pSivida
to license and manufacture products based on BioSilicon, it must
obtain country-specific regulatory approvals or clearances or
comply with regulations regarding safety and quality in each
jurisdiction. pSivida may not be able to obtain or maintain
regulatory approvals or clearances in such countries, and it may
be required to incur significant costs in obtaining or
maintaining foreign regulatory approvals or clearances. In
addition, if pSivida obtains such approvals, its international
operations will be subject to a number of risks associated with
foreign commerce, including the following:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    managing foreign distributors;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    staffing and managing foreign operations;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    political and economic instability;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    foreign currency exchange fluctuations;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    foreign tax laws, tariffs and freight rates and charges;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    timing and availability of export licenses;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">3

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    inadequate protection of intellectual property rights in some
    countries;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    obtaining required governmental approvals.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>There
are risks relating to product manufacturing which could cause
delays in product development and commercialization and impact
pSivida&#146;s future profitability.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s ability to conduct timely preclinical and
clinical research and development programs, obtain regulatory
approval, and commercialize its product candidates will depend,
in part, upon pSivida&#146;s ability to manufacture its
products, either directly or through third parties, in
accordance with U.S.&nbsp;Food and Drug Administration, or FDA,
and other regulatory requirements. pSivida currently has
BioSilicon production capability at its own facilities in the
UK, which may be augmented where required by QinetiQ&#146;s UK
production facilities for use in internal and collaborative
research. pSivida&#146;s lead product candidate, BrachySil, is
currently manufactured under contract by Hosokawa Micron Group,
Atomising Systems Ltd, HighForce Ltd and AEA Technology QSA GmbH.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If pSivida is unable to manufacture BioSilicon or BrachySil or
other product candidates itself or acquire BioSilicon from
QinetiQ or acquire BioSilicon or BrachySil or other product
candidates from third parties, pSivida would be unable to
proceed with or could experience delays in development and
commercialization of its proposed products. pSivida, may not be
able to manufacture its proposed products successfully or in a
cost-effective manner at its own or third party facilities. If
pSivida is unable to develop its own manufacturing facilities or
to obtain or retain third-party manufacturing on acceptable
terms, it may not be able to conduct certain future preclinical
and clinical testing or to supply commercial quantities of
pSivida&#146;s products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s dependence upon third parties for the manufacture
of some of its products may adversely affect its profit margins
and its ability to develop and deliver products on a timely and
competitive basis.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>pSivida&#146;s ability to commercialize its proposed products
    depends on its ability to achieve regulatory approvals.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s current and future activities are and will be
subject to regulation by governmental authorities in the U.S.,
Europe, Singapore and other countries. To clinically test,
produce and market medical products for human use, pSivida and
those that license the use of BioSilicon for such uses must
satisfy mandatory procedural, safety and efficacy requirements
established by the FDA and comparable state and foreign
regulatory agencies. Typically, such rules require that products
be approved by the government agency as safe and effective for
their intended use prior to being marketed. The approval process
is expensive, time consuming and subject to unanticipated
delays. BrachySil and other product candidates utilizing
BioSilicon may not be approved. In addition, while pSivida
intends to apply to have BioSilicon regulated as a device, the
FDA may determine to regulate it as a drug, in which case
pSivida would incur significant additional cost and time in
order to achieve the required regulatory approvals. Any product
approvals pSivida achieves could also be withdrawn for failure
to comply with regulatory standards or due to unforeseen
problems after the product&#146;s marketing approval.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Testing is necessary to determine safety and efficacy before a
submission may be filed with the FDA to obtain authorization to
market regulated products. In addition, the FDA imposes various
requirements on manufacturers and sellers of products under its
jurisdiction, such as labeling, manufacturing practices, record
keeping and reporting requirements. The FDA also may require
post-marketing testing and surveillance programs to monitor a
product&#146;s effects. Furthermore, changes in existing
regulations or the adoption of new regulations could prevent
pSivida from obtaining, or affect the timing of, future
regulatory approvals.
</DIV>

<P align="center" style="font-size: 10pt;">4

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Sivida&#146;s
proposed products will be subject to the uncertainty of
third-party reimbursement and healthcare reform measures which
may limit market acceptance.</I></TD>
</TR>

</TABLE>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In both domestic and foreign markets, pSivida&#146;s ability to
commercialize its proposed products will depend, in part, upon
the availability of reimbursement from third-party payors, such
as government health administration authorities, private health
insurers and other organizations. Third-party payors are
increasingly challenging the price and cost-effectiveness of
medical products. If pSivida&#146;s products are not considered
cost-effective, third-party payors may limit reimbursement.
Government and other third-party payors are increasingly
attempting to contain healthcare costs by limiting both coverage
and the level of reimbursement for new therapeutic products
approved for marketing by the FDA and by refusing, in some
cases, to provide any coverage for uses of approved products for
disease indications for which the FDA has not granted marketing
approval. If government and third-party payors do not provide
adequate coverage and reimbursement levels for uses of
pSivida&#146;s products, the market acceptance of its products
would be limited.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
There have been a number of U.S.&nbsp;federal and state
proposals during the last few years to subject the pricing of
pharmaceuticals to government control and to make other changes
to the healthcare system of the U.S.&nbsp;It is uncertain what
legislative proposals will be adopted or what actions federal,
state or private payors for healthcare goods and services may
take in response to any healthcare reform proposals or
legislation. pSivida cannot predict the effect healthcare
reforms may have on its business.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>The loss of some or all of pSivida&#146;s key personnel could
    harm its business.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida is dependent upon the principal members of its
management and scientific staff. In addition, pSivida believes
that its future success in developing BioSilicon and achieving a
competitive position will depend to a large extent on whether it
can attract and retain additional qualified management and
scientific personnel. There is strong competition for such
personnel within the industry in which pSivida operates, and it
may not be able to continue to attract such personnel to Malvern
in the United Kingdom where pSivida&#146;s research and
development is conducted. As pSivida does not have large numbers
of employees and BioSilicon is a unique and highly specialized
product, the loss of the services of one or more of the senior
management or scientific staff and the inability to attract and
retain additional personnel and develop expertise as needed
could have a material adverse effect on pSivida&#146;s results
of operations and financial condition.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>pSivida may be subject to product liability suits, and it may
    not have sufficient insurance to cover damages.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The testing, manufacturing, and future marketing and sale of the
products utilizing BioSilicon involves risks that product
liability claims may be asserted against pSivida or any future
licensees. pSivida&#146;s current clinical trial insurance may
not be adequate or continue to be available, and pSivida may be
unable to obtain adequate product liability insurance, on
reasonable commercial terms, if at all. In the event such
insurance is not adequate or is not available, pSivida&#146;s
ability to continue with planned research and development or to
market and sell its proposed products could be negatively
impacted.
</DIV>



<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>pSivida
will need additional capital to conduct its operations and
develop its products, and pSivida&#146;s ability to obtain the
necessary funding is uncertain.</I></TD>
</TR>

</TABLE>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida expects to require additional capital resources in order
to conduct its operations and develop its proposed products. The
timing and degree of any future capital requirements will depend
on many factors, including:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the accuracy of the assumptions underlying pSivida&#146;s
    estimates for its capital needs in the near and long term;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    continued scientific progress in pSivida&#146;s research and
    development programs;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the magnitude and scope of pSivida&#146;s research and
    development programs;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">5

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pSivida&#146;s ability to maintain and establish strategic
    arrangements for research, development, clinical testing,
    manufacturing and marketing;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pSivida&#146;s progress with preclinical and clinical trials;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the time and costs of obtaining regulatory approvals;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the costs of preparing, filing, prosecuting, maintaining,
    defending and enforcing patent claims.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If and when required, pSivida will attempt to acquire additional
funding through strategic collaborations, public or private
equity or debt financings, capital lease transactions or other
financing techniques and sources that may be available.
Additional financing may not be available on acceptable terms,
or at all. Additional equity financings could result in
significant dilution to stockholders. Further, in the event that
additional funds are obtained through arrangements with
collaborative partners, these arrangements may require pSivida
to relinquish rights to some of its technologies, product
candidates or products that pSivida would otherwise seek to
develop and commercialize itself. If sufficient capital is not
available, pSivida may be required to delay, reduce the scope of
or eliminate one or more of its research or development
programs, each of which could have a material adverse effect on
its business.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>pSivida has experienced rapid growth and change in its
    business, and pSivida&#146;s failure to manage this and any
    future growth and change could harm its business.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
As evidenced by pSivida&#146;s purchase of the remaining shares
of pSiMedica as of August&nbsp;4, 2004 and the incorporation and
potential spin-off of AION Diagnostics, pSivida&#146;s business
is rapidly changing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida expects to continue increasing the number of its
employees and expanding its business, and pSivida may suffer if
it does not manage and train its new employees effectively and
operate efficiently. Further, pSivida&#146;s efforts span
various geographies. Continued rapid growth and operation in
multiple geographies may place significant strains on
pSivida&#146;s managerial, financial and other resources. The
rate of any future expansion, in combination with pSivida&#146;s
complex technologies and products, will demand managerial
effectiveness in anticipating, planning, coordinating and
meeting pSivida&#146;s operational needs which pSivida cannot
assure it will provide.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In addition, if pSivida makes acquisitions, such as the merger,
or divestitures, it could encounter difficulties that harm its
business. pSivida may acquire companies, products or
technologies that it believes to be complementary to its
business. If it does so, pSivida may have difficulty integrating
the acquired personnel, operations, products or technologies. In
addition, acquisitions may distract its management and employees
and increase pSivida&#146;s expenses, which could harm its
business. pSivida may also sell businesses or assets as part of
its strategy or if it receives offers from third parties. If
pSivida does so, it may sell an asset or business for less than
its full value or may lose valuable opportunities attendant to
such asset or business.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>If pSivida fails to comply with environmental laws and
    regulations, its ability to manufacture and commercialize
    products may be adversely affected.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Medical and biopharmaceutical research and development involves
the controlled use of hazardous materials, such as radioactive
compounds and chemical solvents. pSivida is subject to federal,
state and local laws and regulations governing the use,
manufacture, storage, handling and disposal of such materials
and waste products. pSivida could be subject to both criminal
liability and civil damages in the event of an improper or
unauthorized release of, or exposure of individuals to,
hazardous materials. In addition, claimants may sue pSivida for
injury or contamination that results from its use or the use by
third parties of these materials, and pSivida&#146;s liability
may exceed its total assets. Compliance with environmental laws
and regulations is expensive, and current or future
environmental regulations may impair pSivida&#146;s research,
development or production efforts or harm its operating results.
</DIV>

<P align="center" style="font-size: 10pt;">6

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Risks Relating to pSivida&#146;s Location Outside of the
    United States</I></B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>You may have difficulty in effecting service of legal process
    and enforcement of judgments against pSivida or its
    management.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida is a public company limited by shares, registered and
operating under the Australian Corporations Act 2001. Several of
pSivida&#146;s directors and all of its current officers reside
outside the U.S.&nbsp;Substantially all or a substantial portion
of the assets of those persons are located outside the
U.S.&nbsp;As a result, it may not be possible to effect service
on such persons in the U.S.&nbsp;or to enforce, in foreign
courts, judgments against such persons obtained in
U.S.&nbsp;courts and predicated on the civil liability
provisions of the federal securities laws of the
U.S.&nbsp;Furthermore, substantially all of pSivida&#146;s
directly owned assets are outside the U.S., and, as such, any
judgment obtained in the U.S.&nbsp;against pSivida may not be
collectible within the U.S.&nbsp;There is doubt as to the
enforceability in the Commonwealth of Australia, in original
actions or in actions for enforcement of judgments of
U.S.&nbsp;courts, of civil liabilities predicated solely upon
federal or state securities laws of the U.S., especially in the
case of enforcement of judgments of U.S.&nbsp;courts where the
defendant has not been properly served in Australia.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>As a foreign private issuer, pSivida does not have to provide
    you with the same information as an issuer of securities based
    in the U.S.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Because pSivida is a foreign private issuer within the meaning
of the rules under the Exchange Act, it is exempt from certain
provisions of that law that are applicable to U.S.&nbsp;public
companies, including (i)&nbsp;the rules under the Exchange Act
requiring the filing with the SEC of quarterly reports on
Form&nbsp;10-Q and current reports on Form&nbsp;8-K;
(ii)&nbsp;the sections of the Exchange Act regulating the
solicitation of proxies, consents or authorizations in respect
of a registered security; and (iii)&nbsp;the sections of the
Exchange Act requiring insiders to file public reports of their
stock ownership and trading activities and liability for
insiders who profit from trades made in a short period of time.
Thus, you are not afforded the same protections or information
that would be made available to you by a U.S.&nbsp;public
corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In accordance with the requirements of the Australian Stock
Exchange, pSivida discloses annual and semi-annual results.
pSivida&#146;s results are presented in accordance with
Australian accounting principles. Its annual results are fully
audited with limited reconciliation to U.S.&nbsp;generally
accepted accounting principles, and its semi-annual results
undergo a limited review by pSivida&#146;s independent auditors.
Subject to certain exceptions, pSivida is also required to
immediately disclose to the Australian Stock Exchange any
information concerning it that a reasonable person would expect
to have a material effect on the price or value of its shares.
This would include matters such as (i)&nbsp;any major new
development relating to pSivida&#146;s business which are not
public knowledge and may lead to a substantial movement in
pSivida&#146;s share price; (iii)&nbsp;any changes in
pSivida&#146;s board of directors; (iv)&nbsp;any purchase or
redemption by pSivida of pSivida&#146;s own equity securities;
(v)&nbsp;interests of directors in pSivida&#146;s shares or
debentures; and (vi)&nbsp;changes in pSivida&#146;s capital
structure. pSivida is required to provide its semi-annual
results and other material information that it discloses in
Australia in the U.S.&nbsp;under the cover of SEC Form&nbsp;6-K.
Nevertheless, this information may not be the same or as much
information as would be made available to you were you investing
in a U.S.&nbsp;public corporation. Further, pSivida is not
subject to the requirements of Sarbanes Oxley Act of 2002 to the
same extent as U.S.&nbsp;issuers.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Risks Relating to pSivida&#146;s Ordinary Shares and
    ADSs</I></B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>If pSivida is a passive foreign investment company, holders
    of pSivida shares and ADSs may suffer adverse tax
    consequences.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
U.S.&nbsp;holders of pSivida&#146;s ADSs can experience
unfavorable tax consequences if pSivida is treated as a passive
foreign investment company, or PFIC, under the
U.S.&nbsp;Internal Revenue Code of 1986, as amended, for any
year during which the U.S.&nbsp;holder owns pSivida&#146;s ADSs.
For example, if a U.S.&nbsp;holder disposes of a pSivida ADS at
a gain, and during any year of its holding period pSivida was a
PFIC, then such gain would be taxable as ordinary income and not
as capital gain and would be subject to additional taxation
based on the length of time the U.S.&nbsp;holder held such stock.
</DIV>

<P align="center" style="font-size: 10pt;">7

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In general, pSivida will be a PFIC for any taxable year if
either (1)&nbsp;75% or more of its gross income in the taxable
year is passive income, or (2)&nbsp;50% or more of the average
value of pSivida&#146;s assets in the taxable year produces, or
is held for the production of, passive income. pSivida does not
yet know whether it will be classified as a PFIC in the year
ending June&nbsp;30, 2006 or thereafter. Most of the tax
consequences of pSivida being a PFIC can be mitigated if the
U.S.&nbsp;holder makes certain mitigating elections as described
in this information statement under &#147;Certain Income Tax
Consequences of Owning pSivida&#146;s ADSs.&#148; In the event
it is classified as a PFIC, pSivida intends to provide
U.S.&nbsp;holders with sufficient information to enable them to
make a mitigating election if so desired. However, pSivida may
fail to provide such information, and if it does, you may not be
aware of its status as a PFIC and may be subject to additional
taxes and penalties.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Holders of ADSs may have limited rights relative to holders
    of pSivida&#146;s ordinary shares in certain circumstances.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The rights of holders of pSivida ADSs with respect to voting of
ordinary shares and the right to receive certain distributions
may be limited in certain respects by the deposit agreement
entered into by pSivida and Citibank, N.A. For example, although
pSivida ADS holders are entitled under the deposit agreement,
subject to any applicable provisions of Australian law and of
pSivida&#146;s constitution, to instruct the depositary as to
the exercise of the voting rights pertaining to the ordinary
shares represented by the pSivida ADSs, and the depositary has
agreed that it will, as far as practical, vote the ordinary
shares so represented in accordance with such instructions;
pSivida may not provide voting materials to the depositary in
time for the depositary to solicit instructions from ADS
holders. This means that holders of pSivida ADSs may not be able
to exercise their right to vote. In addition, under the deposit
agreement, the depositary has the right to restrict
distributions to holders of the pSivida ADSs in the event that
it is unlawful or impractical to make such distributions.
pSivida has no obligation to take any action to permit
distributions to holders of its ADSs. As a result, holders of
pSivida ADSs may not receive distributions made by pSivida.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>The trading prices of pSivida&#146;s ordinary shares and ADSs
    are volatile and can fluctuate significantly based on events
    both within and outside pSivida&#146;s control including general
    market and industry conditions.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Since December 2000, the price of pSivida&#146;s ordinary shares
has ranged from A$0.09 to A$1.44&nbsp;per share, and since
January&nbsp;27, 2005, the price of pSivida&#146;s ADSs has
ranged from US$4.15 to US$12.14, The price of pSivida&#146;s
common shares and ADSs may be affected by developments directly
affecting pSivida and by developments out of its control or
unrelated to pSivida. The biotechnology sector in particular and
the stock market generally are vulnerable to abrupt changes in
investor sentiment. Prices of securities and trading volume of
companies in the biotechnology industry, including
pSivida&#146;s, can swing dramatically, in ways unrelated or
that bear a disproportionate relationship to operating
performance. pSivida&#146;s share and ADS prices and their
trading volume may fluctuate based a number of factors
including, but not limited to:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    clinical trial results and other product and technological
    developments and innovations;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    FDA and other governmental regulatory actions, receipt and
    timing of approvals of pSivida&#146;s proposed products, and any
    denials and withdrawals of approvals;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    competitive factors including new product ideas and
    technologies, clinical trial results and approvals of
    competitive products in pSivida&#146;s markets;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    advancements with respect to treatment of the diseases targeted
    by pSivida&#146;s proposed products;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    developments relating to collaborative partners including
    execution and termination of agreements, achievement of
    milestones and receipt of payments;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">8

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    availability and cost of capital and pSivida&#146;s financial
    and operating results;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    changes in reimbursement policies or other practices related to
    pSivida&#146;s proposed products or the pharmaceutical industry
    generally;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    meeting, exceeding or failing to meet analysts&#146; or
    investors&#146; expectations, and changes in evaluations and
    recommendations by securities analysts;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    economic, industry and market conditions, changes or
    trends;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    other factors unrelated to pSivida and the biotechnology
    industry.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In addition, low trading volume may increase the volatility of
the price of pSivida&#146;s ADSs. Trading volume in
pSivida&#146;s ordinary shares on other markets has not been
historically high, and trading volume of its ADSs on NASDAQ may
also be low. Further, because each of pSivida&#146;s ADSs
represents ten of its ordinary shares, trading volume in
pSivida&#146;s ADSs may be lower than that for its ordinary
shares. A thin trading market could cause the price of
pSivida&#146;s ADSs to fluctuate significantly more than the
stock market as a whole. For example, trades involving a
relatively small number of pSivida&#146;s ADSs may have a
greater impact on the trading price for its ADSs than would be
the case if their trading volume were higher.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>The fact that pSivida does not expect to pay cash dividends
    may lead to decreased prices for its stock.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida has never paid a cash dividend on its ordinary shares,
and it does not anticipate paying any cash dividends as
pSivida&#146;s future profitability is uncertain. pSivida
intends to retain future cash earnings, if any, for reinvestment
in the development and expansion of its business. pSivida&#146;s
convertible note agreement limits pSivida&#146;s ability to pay
cash dividends.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Future issuances and sales of pSivida&#146;s ordinary shares
    or ordinary share derivatives could dilute your ownership in
    pSivida and cause its stock and ADS prices to decline.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
As of September&nbsp;30, 2005, pSivida has outstanding options
to purchase 19,561,713 of its ordinary shares, representing 8.7%
of the total outstanding ordinary shares, and has received
shareholder approval to grant options with respect to an
additional 10,574,790 ordinary shares. In 2005, pSivida raised
capital through the issuance of 665,000 pSivida ADSs and
warrants to acquire 133,000 pSivida ADSs and issued a
convertible note currently convertible into 2,112,676 pSivida
ADSs together with warrants to acquire an additional 633,803
pSivida ADSs. In addition, under certain circumstances, the
convertible note will become convertible into a larger number of
pSivida ADSs and the accrued interest on the principal amount of
the note may be converted, in either case, potentially resulting
in the issuance of a substantially larger number of pSivida
ADSs. Exercise and conversion of these options, warrants and
convertible securities would dilute existing shareholders.
Further, pSivida intends to continue to finance its operations
through the issuance of equity securities, if feasible.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Certain of pSivida&#146;s shareholders own a significant
    percentage of its ordinary shares and therefore may be able to
    influence its business in ways that are less beneficial to
    you.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Excluding QinetiQ Group, pSivida&#146;s executive officers,
directors and their affiliates beneficially own or control
approximately 11.98% of its outstanding ordinary shares (based
on the number of pSivida&#146;s ordinary shares outstanding on
September&nbsp;30, 2005 and assuming the issuance of ordinary
shares upon the exercise of options vested or vesting within
92&nbsp;days of September&nbsp;30, 2005). QinetiQ, which
independently owns approximately 15.8% of pSivida&#146;s
outstanding ordinary shares (computed on the same basis), has
pledged that, until October&nbsp;26, 2009, as long as it holds
10% or more of pSivida&#146;s outstanding ordinary shares it
will vote all of its ordinary shares along with the vote of the
majority of the proxy votes exercisable by validly appointed
proxies in relation to the relevant resolution. Therefore,
QinetiQ&#146;s ordinary shares are effectively not counted
toward any vote of pSivida&#146;s shareholders on a resolution
that is required to be passed by a simple majority. As a result,
if pSivida&#146;s executive officers and directors were all to
vote in the same way, their votes would constitute up to
approximately 14.0% of the voting power of its
</DIV>

<P align="center" style="font-size: 10pt;">9

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
ordinary shares which would give them ability to exert
significant influence over pSivida&#146;s board of directors and
how pSivida operates its business. The concentration of
ownership may also have the effect of delaying, deferring or
preventing a change in control of pSivida.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Risks Relating to CDS
and CDS&#146; Business</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following risks relate to CDS and its business on an
independent, stand-alone basis and do not reflect any changes
that may be effected by the merger, if it is consummated.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Additional capital, which CDS expects to require, may not be
    available at the right times, on acceptable terms or at all, and
    CDS may need to further curtail or cease operations.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Since 2003, CDS has significantly cut back its research and
development program, undertaken two workforce reductions,
significantly reduced its operations and sold its real estate to
reduce expenditures and conserve cash following
Bausch&nbsp;&#38; Lomb&#146;s decision to cease funding research
and development by CDS. In order to continue, alone or with
others, the research, development, clinical testing,
manufacturing and commercialization of its proposed products,
CDS will require additional funding. CDS expects that royalties
from Retisert sales will provide one source of funding but
cannot predict the amount or timing of such royalties. If the
merger is not completed and additional financing is not
available on acceptable terms, or at all, CDS may need to delay,
reduce the scope of, or eliminate one or more of its development
programs or cease operations altogether.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>CDS has a history of losses and, if CDS does not generate
    sufficient revenue from licensing and sale of its products and
    proposed products, CDS may not achieve profitability.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS has incurred net losses in each of its last five fiscal
years, and in the nine months ended September&nbsp;30, 2005.
Royalties from sales of CDS&#146; first commercial product,
Vitrasert, have declined in each of the past four years, and CDS
expects that they will not comprise a significant portion of its
future revenue. Although CDS expects to receive royalties from
sales of Retisert, CDS is unable to predict the amount or timing
of such royalties. CDS&#146; ability to generate net income in
the future depends upon its ability to generate revenue through
royalties generated by sales of Retisert, collaborative research
funding, licensing fees and milestone payments from licensing
its proposed products to collaborative partners and its ability,
alone or with others, to develop, obtain required regulatory
clearances for, and manufacture and market its proposed
products. If CDS does not generate sufficient revenue from
licensing and sales of its products and proposed products, CDS
may not achieve profitability.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>If the clinical trials necessary to obtain regulatory
    approval of CDS&#146; proposed products are not successful, CDS
    or any marketing partner will be unable to sell them.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Vitrasert and Retisert are the only CDS products that have been
approved for sale in the U.S.&nbsp;Before CDS or any development
partner can obtain approval from the FDA and foreign regulatory
authorities to manufacture and sell CDS&#146; proposed products,
pre-clinical studies and clinical trials must demonstrate that
each of these products is safe for human use and effective for
its targeted disease. CDS&#146; proposed products are in various
stages of pre-clinical and clinical testing. If clinical trials
for any of these products are not successful, that product
cannot be manufactured and sold and will not generate revenue
from sales. Clinical trials for CDS&#146; product candidates may
fail or be delayed by many factors, including the following:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    inability to attract clinical investigators for trials;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    inability to recruit patients in sufficient numbers or at the
    expected rate;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    adverse side effects;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    failure of the trials to demonstrate a product&#146;s safety or
    efficacy;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">10

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    failure to meet FDA requirements for clinical trial design or
    for demonstrating efficacy for a particular product;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    inability to follow patients adequately after treatment;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    changes in the design or manufacture of a product;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    inability to manufacture sufficient quantities of materials for
    use in clinical trials;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    governmental or regulatory delays.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Results from pre-clinical testing and early clinical trials
often do not accurately predict results of later clinical
trials. Data obtained from pre-clinical and clinical activities
are susceptible to varying interpretations which may delay,
limit or prevent regulatory approval. Data from pre-clinical
studies, early clinical trials and interim periods in multi-year
trials are preliminary and may change, and final data from
pivotal trials for such products may differ significantly.
Adverse side effects may develop that delay, limit or prevent
the regulatory approval of products, or cause their regulatory
approvals to be limited or even rescinded. Additional trials
necessary for approval may not be undertaken or may ultimately
fail to establish the safety and efficacy of proposed products.
The FDA may not approve proposed products for manufacture and
sale.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The failure of one of CDS&#146; product candidates to
demonstrate safety and efficacy in clinical trials may delay or
prevent development or approval of CDS&#146; other product
candidates that employ the same delivery technology or deliver
the same drug and hinder CDS&#146; ability to conduct related
pre-clinical testing and clinical trials.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Fast track status may not actually lead to faster
    development, regulatory review or approval.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The FDA has granted fast track designation to Medidur for the
treatment of DME. Although this designation makes this product
eligible for expedited approval procedures, it does not ensure
faster development, review or approval compared to the
conventional FDA procedures. Further, the FDA may withdraw the
fast track designation if it determines that the designation is
no longer supported by emerging data from clinical trials or if
it determines that the criteria for the designation is no longer
satisfied. See &#147;CDS Information&nbsp;&#151; CDS&#146;
Business&nbsp;&#151; Government Regulation&#148; for a more
detailed description of fast track designation and related
approval procedures.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>CDS depends on collaborations with third parties to develop
    and commercialize its products, and such arrangements may not be
    available or scientifically or commercially successful or may be
    terminated.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS&#146; business strategy includes entering into collaborative
agreements for the development and commercialization of its
product candidates. The curtailment or termination of any of
these agreements, such as Bausch&nbsp;&#38; Lomb&#146;s 2003
decision to conduct licensed research directly and not to fund
such research by CDS, could adversely affect CDS and its ability
to develop and commercialize its products and proposed products
and fund its operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The success of these and future collaboration agreements will
depend heavily on the experience, resources efforts and
activities of CDS&#146; collaborators. CDS&#146; collaborators
have and are expected to have significant discretion in making
these decisions. Risks that CDS faces in connection with its
collaboration strategy include:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    collaboration agreements are, and are expected to be, subject to
    termination under various circumstances, including, in some
    cases, on short notice and without cause;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    CDS is required, and expects to be required, under its
    collaboration agreements not to conduct specified types of
    research and development in the field that is the subject of the
    collaboration. These agreements may have the effect of limiting
    the areas of research and development that CDS can pursue;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">11

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    CDS&#146; collaborators may develop and commercialize, either
    alone or with others, products that are similar to or
    competitive with CDS&#146; products;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    CDS&#146; collaborators may change the focus of their
    development and commercialization efforts. Pharmaceutical and
    biotechnology companies have historically re-evaluated and
    changed their priorities for many reasons. The ability of
    CDS&#146; products to reach their potential could be limited if
    its collaborators decrease or fail to increase spending related
    to such products;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    CDS&#146; collaborators may lack the funding or experience to
    develop and commercialize CDS products successfully or may
    otherwise fail to do so.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS has exclusively licensed its technology to Bausch&nbsp;&#38;
Lomb with respect to Vitrasert, Retisert and certain other
ophthalmic uses and to Alimera Sciences with respect to Medidur
for DME and certain other ophthalmic uses. Bausch&nbsp;&#38;
Lomb is responsible for funding and managing the development and
commercialization of all products under its agreement with CDS
and can terminate the agreement at any time upon
90&nbsp;days&#146; written notice. Alimera Sciences and CDS are
jointly funding the development of products licensed under that
agreement, and Alimera Sciences may terminate its agreement with
CDS if CDS fails to make a development payment or may terminate
the agreement with respect to a particular product if Alimera
Sciences abandons the product or upon 30&nbsp;days&#146; notice
following CDS&#146; failure to make development payments
exceeding $2&nbsp;million for that product. Either
Bausch&nbsp;&#38; Lomb or Alimera Sciences may decide not to
continue with or commercialize any or all of the licensed
products, change strategic focus, pursue alternative
technologies, develop competing products or terminate their
agreements with CDS. While Bausch&nbsp;&#38; Lomb has
significant experience in the ophthalmic field and substantial
resources, there is no assurance as to whether and the extent to
which that experience and those resources will be devoted to
CDS&#146; technologies. Alimera Sciences was only incorporated
in June 2003 and has limited resources. Because CDS does not
currently have sufficient funding or internal capabilities to
develop and commercialize its products and proposed products,
decisions, actions, breach or termination of these agreements by
Bausch&nbsp;&#38; Lomb or Alimera Sciences could delay or stop
the development or commercialization of Retisert, Medidur for
DME or other CDS products licensed to such entities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In addition, CDS faces significant competition in seeking
additional appropriate collaborators, which generally have
substantial opportunities for collaboration. Collaboration
arrangements are often complex to negotiate and time consuming
to document. CDS may not be successful in establishing
additional collaborations or other alternative arrangements, and
the terms of any future collaborations may not be favorable to
CDS. Moreover, CDS&#146; existing and future collaboration
arrangements may not be scientifically or commercially
successful.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>CDS is reliant on third parties to manufacture its products,
    and if they fail to meet FDA and other governmental requirements
    for the manufacture of CDS&#146; products, sales of CDS products
    may be limited or stopped.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS has limited manufacturing experience and has exclusively
licensed Bausch&nbsp;&#38; Lomb the rights to manufacture
Vitrasert, Retisert and other products covered by its license
agreement with CDS and Alimera Sciences, the rights to
manufacture Medidur for DME, if approved for marketing, and
other products covered by its license agreement with CDS.
Although CDS may decide to develop the facilities and capacity
to manufacture its products on a commercial scale in the future,
its current reliance on third party manufacturers entails risks,
including:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the possibility that third parties may not comply with the
    FDA&#146;s current good manufacturing practices, regulations,
    other regulatory requirements, and those of similar foreign
    regulatory bodies, and employ adequate quality assurance
    practices;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    supply disruption, deterioration in product quality or breach of
    a manufacturing or license agreement by the third party because
    of factors beyond CDS&#146; control;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">12

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the possible termination or non-renewal of a manufacturing or
    licensing agreement with a third party at a time that is costly
    or inconvenient to CDS;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    inability to identify or qualify an alternative manufacturer in
    a timely manner, even if contractually permitted to do so.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The consequence of any disruption to third party manufacturing
could negatively impact product development efforts, sales of
CDS products and CDS&#146; reputation.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>If users of CDS&#146; proposed products are unable to obtain
    adequate reimbursement from third-party payors, market
    acceptance of its proposed products may be limited.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Successful commercialization of our proposed products will
depend in part on the extent to which healthcare providers
receive appropriate reimbursement levels from governmental
authorities, private health insurers and other organizations for
our products and related treatments. Currently, Medicaid and
Medicare, most major health maintenance organizations and most
health insurance carriers reimburse $4,240 for the cost of the
CDS&#146; Vitrasert implant, and the Centers for Medicare and
Medicaid Services recently designated Retisert as eligible for
Medicare reimbursement at the rate of $19,345. Third-party
payors are increasingly challenging the prices charged for
medical products and services, however. If healthcare providers
do not receive adequate reimbursement for CDS&#146; products,
they or their patients may not use them.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>If CDS is unable to attract and retain highly qualified
    personnel, it may hinder its future success.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Since 2003, CDS terminated most of its highly qualified
personnel and is largely reliant on its collaborative partners.
CDS&#146; ability to develop future products and achieve future
success will depend in part upon its ability to fund, attract
and retain highly skilled management, technical and scientific
personnel, in addition to its current personnel. Competition for
qualified personnel in CDS&#146; industry is intense, and the
process of hiring and integrating qualified personnel is often
lengthy. CDS may be unable to recruit adequate numbers of
qualified personnel on a timely basis, and CDS management and
other employees may voluntarily terminate their employment with
CDS at any time. The inability to attract and retain qualified
personnel could result in delays or failures in product
development or approval, loss of sales and diversion of
management resources.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>CDS expects intense competition from alternative treatments
    for its targeted diseases that may reduce or eliminate the
    demand for CDS&#146; products and proposed products.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS expects that its products and proposed products, if
approved, will compete with existing approved and off-label
treatments for its targeted diseases as well as new treatments
that may be developed to treat these diseases, their symptoms
and their underlying causes and off-label use of products
approved to treat other diseases. CDS believes that
pharmaceutical, drug delivery and biotechnology companies,
research organizations, governmental entities, universities,
hospitals, other nonprofit organizations and individual
scientists are seeking to develop the drugs, therapies,
products, approaches or methods to treat CDS&#146; targeted
diseases or their underlying causes. For many of its targeted
diseases, competitors have alternate therapies that are already
commercialized or are in various stages of development ranging
from discovery to advanced clinical trials. Any of these drugs,
therapies, products, approaches or methods may receive
government approval or gain market acceptance more rapidly than
CDS&#146; products and proposed products, may offer therapeutic
or cost advantages or may cure CDS&#146; targeted diseases or
their underlying causes completely, which could reduce demand
for CDS&#146; products and proposed products and could render
them noncompetitive or obsolete. For example, sales of CDS&#146;
Vitrasert product for the treatment of CMV retinitis, a disease
which affects people with late-stage AIDS, have declined
significantly, because of new treatments that delay the onset of
late-stage AIDS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The financial resources, research and development, clinical
trial, regulatory, manufacturing and marketing experience,
research and development and manufacturing facilities of many of
CDS&#146; competitors
</DIV>

<P align="center" style="font-size: 10pt;">13

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
and potential competitors are much greater than those of CDS. In
addition, they may succeed in obtaining patents that would make
it difficult or impossible for CDS to compete with their
products.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Patent protection for CDS&#146; products is important and
    uncertain. If CDS does not protect its intellectual property,
    CDS will be subject to increased competition.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS&#146; commercial success will depend in part on its ability
to protect its proprietary products and processes from
unauthorized use by third parties by obtaining valid and
enforceable patents or effectively maintaining them as trade
secrets. CDS seeks to obtain and license U.S. and foreign
patents related to proprietary technology, inventions and
improvements that may be important to the development of its
business. However, CDS&#146; patent position, like that of other
biotechnology, pharmaceutical and medical device companies, is
highly uncertain and involves complex legal and factual
questions. The standards that the United States Patent and
Trademark Office and its foreign counterparts use to grant
patents are not always applied predictably or uniformly and can
change. There is no uniform worldwide jurisprudence or policy
among patent offices regarding the subject matter and scope of
claims allowable or granted in medical device or pharmaceutical
patents. Consequently, CDS cannot be certain as to the type and
scope of patent claims that may be issued to CDS or its
licensors, or the extent to which any issued claims may be
upheld, may be enforceable or may be substantially narrowed by
litigation or government agency actions. In addition, the
agreements under which CDS licenses third-party patents require
that it meet specified diligence requirements in order to keep
its licenses. CDS cannot be certain that it will satisfy these
requirements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Prior art may reduce the scope or protection of, or invalidate,
patents. Previously conducted research or published discoveries
may prevent patents from being granted, invalidate issued
patents or narrow the scope of any protection obtained.
Reduction in scope of protection or invalidation of CDS&#146;
licensed or owned patents, or its inability to obtain patents,
may enable other companies to develop products that compete with
CDS&#146; products and product candidates on the basis of the
same or similar technology. As a result, patents of CDS and its
licensors may not provide any or sufficient protection against
competitors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS also relies on trade secrets, know-how and technology that
are not protected by patents to maintain its competitive
position. CDS tries to protect this information by entering into
confidentiality agreements with parties that have access to it,
such as CDS&#146; corporate partners, collaborators, employees,
and consultants. Any of these parties could breach these
agreements and disclose CDS&#146; confidential information, or
CDS&#146; competitors might learn of the information in some
other way. If any material trade secret, know-how or other
technology not protected by a patent were to be disclosed to or
independently developed by a competitor, CDS&#146; competitive
position could be materially harmed.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Protecting CDS&#146; proprietary technology is expensive, and
    if CDS&#146; technology infringes the intellectual property
    rights of others, CDS may be harmed if it is unable to
    manufacture and sell its products or it is required to pay
    substantial damages or license fees.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Obtaining and protecting patent and proprietary rights is
expensive. Patents must be prosecuted and may be challenged,
invalidated or circumvented or may interfere with the patents of
others. CDS or its licensors may need to participate in
proceedings before patent offices or resort to litigation to
enforce patents or to determine the scope and validity of
CDS&#146;, CDS&#146; licensor&#146;s or a third party&#146;s
proprietary rights. CDS could incur substantial costs in
connection with any proceeding or litigation, and its
management&#146;s attention could be diverted, regardless of the
results of the proceeding or litigation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Issued patents or patents that issue may restrict or prevent the
manufacture and sale of CDS&#146; products or proposed products,
and CDS or its development partners may be subject to
infringement claims based on current or later granted patents.
An unfavorable decision in any proceeding or litigation could
result in significant liabilities, require CDS and its
development partners to cease manufacturing or selling the
affected products or using the affected processes, prevent CDS
from extending its technologies into new products and areas or
require CDS to license the disputed rights from third parties.
In such an event, CDS&#146; business would be harmed if damages
were substantial, if it could not obtain a license on
</DIV>

<P align="center" style="font-size: 10pt;">14
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
commercially reasonable terms or at all, or if CDS were unable
to redesign the affected products or processes to avoid
infringement.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>CDS could be exposed to significant product liability claims
    which could be time-consuming and costly, divert management
    attention and adversely affect its ability to obtain and
    maintain insurance coverage or its financial condition.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS&#146; products and product candidates involve an inherent
risk of product liability claims against CDS. CDS has insured
against claims that may be brought against it in connection with
clinical trials and commercial sales of its products. However,
this insurance may not fully cover the costs of claims or
damages CDS might be required to pay. Product liability claims
or other claims related to its products, regardless of their
outcome, could require CDS to spend significant time and money
in litigation, divert management time and attention, require it
to pay significant damages, harm CDS&#146; reputation or hinder
acceptance of CDS&#146; products. Any successful product
liability claim may prevent CDS from obtaining adequate product
liability insurance in the future in sufficient amounts on
commercially reasonable terms. An inability to obtain sufficient
insurance coverage at an acceptable cost or otherwise to protect
against potential product liability claims could prevent or
inhibit the commercialization of CDS&#146; products. Product
liability claims could also significantly harm CDS&#146;
reputation, delay or prevent market acceptance of its products
or proposed products and damage its financial condition.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>If they act together, CDS&#146; directors, officers and
    significant shareholders can control matters requiring
    stockholder approval because they beneficially own a large
    percentage of CDS&#146; voting stock, and they may vote in a way
    with which you do not agree.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS&#146; directors, officers and significant shareholders
beneficially own a majority of the outstanding shares of its
stock. As a result, if these persons act together, they will
have the ability to exercise substantial control over CDS&#146;
affairs and corporate actions requiring stockholder approval,
including the election of directors, a sale of substantially all
CDS&#146; assets, a merger with another entity or an amendment
to its certificate of incorporation. If they act together, these
stockholders could use their ownership position to delay, deter
or prevent a change in control. Also, their aggregate ownership
could adversely affect the price that investors might be willing
to pay in the future for shares of CDS&#146; common stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><FONT style="font-variant: SMALL-CAPS"><B>Risks Related to pSivida&#146;s Acquisition of CDS and Other Recent Transactions</B></FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left:25px"><I>pSivida may fail to successfully integrate its operations with CDS. As a result, pSivida and CDS
may not achieve the anticipated benefits of the merger, which could adversely affect the price of
ADSs.</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pSivida entered into the merger agreement with the expectation that the merger will result in
benefits to the combined companies, including the opportunities to combine the two companies&#146;
technologies, products and product candidates and the opportunity for pSivida to establish a
substantial presence in the U.S. facilitating access to U.S. markets. However, these expected
benefits may not be fully realized. Failure of the combined company to meet the challenges involved
with successfully integrating the personnel, products, technology and research and development
operations of the two companies following the merger or to realize any of the other anticipated
benefits of the merger, could have a material adverse effect on the business, financial condition
and results of operations of pSivida and its subsidiaries, including CDS. These integration efforts
may be difficult and time consuming, especially considering the highly technical and complex nature
of each company&#146;s products. The challenges involved in this integration include the following:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>coordinating research and development operations in a rapid and efficient manner;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>combining platform technologies of disparate sources;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>demonstrating to collaboration partners that the merger will not result in adverse
changes in technology focus or development standards;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>retaining key alliances with collaboration partners;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>absorbing costs and delays in implementing overlapping systems and procedures,
including financial accounting systems;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>persuading employees that pSivida&#146;s and CDS&#146; business cultures are compatible,
maintaining employee morale and retaining key employees; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>overcoming potential distraction of management attention and resources from the
business of the combined company.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pSivida may not successfully integrate the operations and technology of pSivida and CDS in a
timely manner, or at all, and may not realize the anticipated benefits of the merger to the extent,
or in the timeframe, anticipated, which could significantly harm its business.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left:25px"><I>pSivida&#146;s operating results could be adversely affected as a result of purchase accounting
treatment, and the corresponding impact of amortization or impairment of other intangibles relating
to the merger, if the results of the combined company do not offset these additional expenses.</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under accounting
principles generally accepted in the U.S., pSivida will account for the merger using
the purchase method of accounting. Under purchase accounting, pSivida will record the market value of its
ADSs, cash, and other consideration issued in connection with the merger and the amount of direct
transaction costs as the cost of acquiring the business of CDS. pSivida will allocate that cost to the
individual assets acquired and liabilities assumed, including identifiable intangible assets based on their fair
values. Intangible assets generally will be amortized over a twelve year period. The amount of purchase
price allocated to goodwill will be approximately A$55.8&nbsp;million, the amount allocated to identifiable
intangible assets will be approximately A$120.0&nbsp;million, giving rise to a gross deferred tax liability of
approximately A$48.0&nbsp;million (approximately $29.1&nbsp;million net of deferred tax assets), and approximately
A$2.7&nbsp;million will be allocated to in-process research and development. Goodwill is not subject to
amortization but is subject to at least an annual impairment analysis, which may result in an impairment
charge if the carrying value exceeds its implied fair value. If identifiable intangible assets were amortized
in equal quarterly amounts over a twelve-year period following completion of the merger, the amortization
attributable to these items would be approximately A$2.5&nbsp;million
per quarter and A$10.0&nbsp;million per fiscal
year. As a result, purchase accounting treatment of the merger could
increase pSivida&#146;s net loss or
decrease its net income in the foreseeable future, which could have a material and adverse effect on the
market value of pSivida ADSs following completion of the merger.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left:25px"><I>pSivida expects to incur significant costs associated with the merger.</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pSivida estimates that it will incur direct transaction costs of approximately $2.7&nbsp;million
associated with the merger, which will be included as a part of the total purchase consideration
for accounting purposes. In addition, CDS estimates that it will incur direct transaction costs for
accounting, investment banking and legal services of approximately $2.5&nbsp;million, which are in part
determined at closing and are expensed in the quarter in which they are incurred. pSivida believes
the combined entity may incur charges to operations, which currently are not reasonably estimable,
in the quarter in which the merger is completed or the following quarters, to reflect costs
associated with integrating the two companies and that such charges may be material.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left:25px"><I>Failure to complete the merger could negatively impact pSivida&#146;s stock price and its future business and operations.</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the merger is not completed for any reason, pSivida may be subject to a number of material
risks, including the following:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>pSivida would not realize any anticipated benefits from being a part of the
anticipated combined company;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>pSivida may be obligated to pay CDS a fee of $1.05&nbsp;million in liquidated damages if
the merger agreement is terminated in certain circumstances;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>pSivida may experience difficulties in attracting strategic investors, collaborators
and partners who were expecting to use the technology proposed to be offered by the
combined company; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>pSivida must pay all or a portion of certain costs relating to the merger, such as
legal, accounting, financial advisor and printing fees, even if the merger is not
completed, which costs will be substantial.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left:25px"><I>Regulatory agencies, private parties, state attorneys general and other antitrust authorities may
raise challenges to the merger on antitrust grounds.</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pSivida believes that the merger may be completed without making any filings with the Federal
Trade Commission, or FTC, the Antitrust Division of the U.S. Department of Justice, or the
Antitrust Division, or any other governmental authority whether under the Hart-Scott-Rodino
Antitrust Improvements Act of 1976, as amended, or the HSR Act, or otherwise or the expiration of
any waiting period requirements have been satisfied. However, the FTC and the Antitrust Division
frequently scrutinize the legality under the antitrust laws of transactions like the merger, and at
any time before or after the completion of the merger, the FTC or the Antitrust Division could take
any action under the antitrust laws as it deems necessary or desirable in the public interest,
including seeking to enjoin the completion of the merger or seeking the divestiture of substantial
assets of pSivida or CDS. In addition, certain private parties, as well as state attorneys general
and other antitrust authorities, may challenge the transaction under antitrust laws under certain
circumstances.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition, the merger may be subject to the antitrust laws of Australia or other foreign
jurisdictions. Anti-competitive mergers or acquisitions in Australia are regulated under sections
50 and 50A of the Commonwealth Trade Practices Act, or TPA, which generally prohibits any
acquisition of shares or assets which is likely to have the effect of substantially lessening
competition in a market in Australia. The Australian antitrust regulator, the Australian
Competition and Consumer Commission, or ACCC, may on its own initiative, apply to an Australian
Court under that law in order to block a merger, or to obtain orders for the divestiture of assets,
or for other remedies. A private party may also apply to an Australian Court under that law for a
more limited range of remedies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There is no mandatory requirement to notify the ACCC of a proposed merger. However, if a
proposed merger is likely to give rise to antitrust concerns, or to be perceived by the ACCC as
doing so, it is common practice to approach the ACCC to obtain its assurance that it will not
oppose the merger. This process is known as seeking informal &#147;clearance&#148;. A formal &#147;authorization&#148;
process is also available. pSivida and CDS believe that the merger can be completed without
seeking authorization or informal clearance from the ACCC. However, the ACCC may independently
scrutinize the merger and could take any action under the Trade Practices Act of 1974 (Cth) it
deems necessary or desirable in the public interest, including seeking an injunction or an order
for divestment of substantial assets of pSivida or CDS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There can be no assurance that a challenge to the merger on antitrust grounds will not be
made, or, if such a challenge is made, what the result will be.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left:25px"><I>If CDS stockholders sell substantial amounts of ADSs after the merger, the market price of ADSs may decline.</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The resale by CDS stockholders of pSivida ADSs after the merger could cause the market price
of pSivida ADSs to decline. In connection with the merger, pSivida expects to issue approximately
16,000,000 ADSs. While the pSivida ADSs will not initially be freely tradable, pSivida has agreed
to register their resale within six months for stockholders entering into the registration rights
agreement. Therefore, approximately 16,000,000 pSivida ADSs issued in the merger are expected to
become freely tradable six months from the closing date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>If pSivida fails to register the resale of pSivida ADSs by the applicable deadlines, pSivida may be
subject to substantial penalties.</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the acquisition of CDS, pSivida&#146;s recent $4.2&nbsp;million private placement
structured as a private investment in public equity, referred to herein as the PIPE, and pSivida&#146;s
recent issuance to an institutional investor of a $15&nbsp;million convertible note, pSivida has entered
into agreements to register with the SEC the resale of the pSivida ADSs issued to CDS stockholders
and the investors in the PIPE and note issuance. pSivida&#146;s obligation to register ADSs in each of
these transactions is subject to deadlines, and our failure to meet any of these deadlines may
result in monetary penalties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pSivida is required to complete the registration no later than one hundred eighty days from
the date of the definitive agreements related to the PIPE, or on or about February&nbsp;23, 2006. If
pSivida fails to cause the registration statement registering the resale of pSivida ADSs to become
effective beginning one month after this deadline, pSivida may be subject to monthly cash penalties
equal to one percent of the PIPE purchase price, or $42,000 per month, until such registration
statement becomes effective. With respect to the convertible note financing, we are required to
complete the initial registration no later than one hundred eighty days from the closing date of
the issuance, or on or about May&nbsp;16, 2006. Failure to comply with this deadline will result in
pSivida having to pay monthly cash penalties equal to one and one-half percent of the convertible
note purchase price, or $225,000 per month, until the registration statement becomes effective.
With respect to the merger, we are required to complete the registration no later than one hundred
eighty days from the closing. If the merger closes in early January of 2006 as pSivida expects,
the deadline would be on or about early July of 2006. Failure to comply with this deadline will
result in pSivida having to pay monthly cash penalties equal to one percent of the average closing
price of pSivida ADSs during the ten trading days ending on the day that is four trading days prior
to the closing of the merger, multiplied by the number of outstanding unregistered ADSs, until the
registration statement becomes effective. Based on a price of $6.50 per ADS, such penalties could
amount to approximately $1&nbsp;million per month.
</DIV>


<P align="center" style="font-size: 10pt;">15
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In December 2005, pSivida is expected to complete the acquisition
of 100% of the issued capital of CDS, an unlisted U.S. company
specializing in the development of sustained-release drug
delivery products. The acquisition of CDS will be accounted for
under the purchase method of accounting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The unaudited pro forma consolidated financial statements are
presented in accordance with accounting principles generally
accepted in the United States of America, or U.S.&nbsp;GAAP, and
are derived from the historical consolidated financial
statements of pSivida and CDS included elsewhere in this
information statement, as if the acquisition of CDS had occurred
on July&nbsp;1, 2004 for the consolidated statement of
operations and June&nbsp;30, 2005 for the consolidated statement
of financial position. Although pSivida and CDS have different
fiscal year ends, the historical consolidated financial
statements of CDS have been adjusted to reflect the same fiscal
year as pSivida.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The adjustments necessary to present fairly the unaudited pro
forma consolidated financial statements have been made based on
available information and assumptions that pSivida&#146;s
management believes are reasonable. The unaudited pro forma
consolidated financial statements are for informational purposes
only and do not purport to present what pSivida&#146;s results
would actually have been had the acquisition occurred on the
dates presented or to project pSivida&#146;s results of
operations or financial position for any future period. The
unaudited pro forma consolidated financial statements reflect
preliminary estimates of the allocation of the purchase price
for the acquisition of CDS and may be adjusted.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The unaudited pro forma consolidated financial statements should
be read in conjunction with the audited consolidated financial
statements of pSivida and CDS included elsewhere in this
information statement.
</DIV>

<P align="center" style="font-size: 10pt;">16

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF FINANCIAL
POSITION</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>As of June&nbsp;30, 2005</B>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>pSivida</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>CDS</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Historical</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Historical</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Pro Forma</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(3a)</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(3b)</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Adjustments</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Pro Forma</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="14" align="center" nowrap><B>(In Australian dollars)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="17" align="center" valign="top">
    <B>ASSETS</B></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Current assets:</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash and cash equivalents</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,892,061</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,450,442</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,420,308)</TD>
    <TD align="left" valign="bottom" nowrap>(3c)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,922,195</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Receivables</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>709,418</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>79,413</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>788,831</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>322,933</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>137,450</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>460,383</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="17">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total current assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13,924,412</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,667,305</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,420,308)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,171,409</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Non-current assets:</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Property, plant and equipment, net</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,273,663</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>865,412</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,139,075</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Intangible assets, net</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>50,703,262</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>120,000,000</TD>
    <TD align="left" valign="bottom" nowrap>(3d)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>170,703,262</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Goodwill</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>32,161,939</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>55,761,654</TD>
    <TD align="left" valign="bottom" nowrap>(3e)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>87,923,593</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="17">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>100,063,276</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,532,717</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>168,341,346</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>273,937,339</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="17">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="17" align="center" valign="top">
    <B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Current liabilities:</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Payables</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,967,718</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,344,075</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,311,793</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Payables, related party</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>50,102</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>50,102</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deferred revenue</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,864,484</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,864,484</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Provisions</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,879</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,879</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="17">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total current liabilities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,047,699</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,208,559</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,256,258</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deferred tax liability, net</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,365,240</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,100,000</TD>
    <TD align="left" valign="bottom" nowrap>(3f)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>39,465,240</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total liabilities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,412,939</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,208,559</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,100,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>46,721,498</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Commitments and contingencies</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Series&nbsp;A redeemable convertible preferred stock</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>38,035,845</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(38,035,845</TD>
    <TD align="left" valign="bottom" nowrap>)(3g)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="17">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Stockholders&#146; equity:</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Common stock and additional paid-in capital</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>117,798,149</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>16,362,738</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>125,944,472</TD>
    <TD align="left" valign="bottom" nowrap>(3h)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>260,105,359</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deferred stock based compensation</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,213,574</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,213,574</TD>
    <TD align="left" valign="bottom" nowrap>(3i)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accumulated other comprehensive loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(272,067</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(272,067</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deficit accumulated prior to development stage</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deficit accumulated during development stage</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(26,062,564</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,741,706</TD>
    <TD align="left" valign="bottom" nowrap>)(3j)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(28,804,270</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accumulated deficit</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(52,860,851</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>52,860,851</TD>
    <TD align="left" valign="bottom" nowrap>(3k)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total stockholders&#146; equity (deficit)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>87,650,337</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(37,711,687</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>177,277,191</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>227,215,841</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total liabilities and stockholders&#146; equity</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>100,063,276</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,532,717</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>168,341,346</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>273,937,339</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="center" style="font-size: 10pt; margin-top: 9pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
See accompanying notes to the unaudited pro forma consolidated
financial statements.
</DIV>

<P align="center" style="font-size: 10pt;">17

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>Year Ended June&nbsp;30, 2005</B>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="43%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>pSivida</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>CDS</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Historical</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Historical</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Pro Forma</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(3l)</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(3m)</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Adjustments</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Pro Forma</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="14" align="center" nowrap><B>(In Australian dollars except number of shares)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Revenues</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Collaborative research and development&nbsp;&#151; related party</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,626,181</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,626,181</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Collaborative research and development&nbsp;&#151; other</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>161,666</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>158,385</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>320,051</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Royalties&nbsp;&#151; related party</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,142,445</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,142,445</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Total revenues</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>161,666</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,927,011</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13,088,677</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="17">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Operating expenses:</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Depreciation and amortization expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,207,733</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(495,177</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(10,000,000</TD>
    <TD align="left" valign="bottom" nowrap>)(3n)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(16,702,910</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Research and development expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(8,287,930</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,831,869</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(11,119,799</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Royalties expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(79,479</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(79,479</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Employee benefits expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,165,025</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,165,025</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Foreign currency loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,623,484</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,623,484</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Corporate office expenses</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,130,096</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,944,035</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(11,074,131</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Total operating expenses</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(21,414,268</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(10,350,560</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(10,000,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(41,764,828</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>


<TR>
    <TD colspan="17">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Income (Loss) from operations before income tax benefit</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(21,252,602</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,576,451</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(10,000,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(28,676,151</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Interest and other income (expense), net</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>667,310</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(213,568</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>453,742</TD>
    <TD>&nbsp;</TD>
</TR>


<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="17">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Income (loss) before income tax benefit</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(20,585,292</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,362,883</TD>
    <TD align="left" valign="bottom" nowrap></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(10,000,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(28,222,409</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD colspan="17">&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Income tax benefit</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,645,504</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,055,000</TD>
    <TD align="left" valign="bottom" nowrap>(3o)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,700,504</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="17">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Income (loss) before outside equity interest</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(16,939,788</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,362,883</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,945,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(21,521,905</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD colspan="17">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Net loss attributable to outside equity interest</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>378,276</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>378,276</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="17">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Net income (loss)</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(16,561,512</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,362,883</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,945,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(21,143,629</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD colspan="17">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Accretion of redeemable convertible preferred stock</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,246,135</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,246,135</TD>
    <TD align="left" valign="bottom" nowrap>(3p)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>


<TR>
    <TD colspan="17">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Net loss attributable to common stockholders</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(16,561,512</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(883,252</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,698,865</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(21,143,629</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="17">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Basic and diluted loss per common share</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(0.08</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(0.43</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(0.06</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD colspan="17">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Basic and diluted weighted average number of shares</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>207,802,540</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,068,990</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>(5)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>367,802,540</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="center" style="font-size: 10pt; margin-top: 9pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
See accompanying notes to the unaudited pro forma consolidated
financial statements.
</DIV>

<P align="center" style="font-size: 10pt;">18

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL
STATEMENTS</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(In Australian dollars)</B>
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>1.</B></TD>
    <TD>
    <B>Basis of Presentation</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The unaudited pro forma consolidated financial statements have
been prepared in accordance with U.S.&nbsp;GAAP and are
presented in Australian dollars.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>2.</B></TD>
    <TD>
    <B>Purchase Price Allocation</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The estimated purchase price of $149,727,518 consisted of:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    $655,308 cash;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    160,000,000 ordinary full paid shares of pSivida, represented by
    16,000,000 American Depositary Shares, or ADSs, with an
    estimated fair value of $141,798,165 ($0.886&nbsp;per share,
    represented by US$6.762&nbsp;per ADS);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    1,761,760&nbsp;share options in pSivida, represented by 176,176
    warrants over ADSs with an estimated fair value of
    $509,045;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    direct acquisition costs of $6,765,000.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A final determination of required purchase accounting
adjustments, including the allocation of the purchase price, has
not yet been made. Accordingly, the purchase accounting
adjustments made in connection with these unaudited pro forma
consolidated financial statements are preliminary and have been
made solely for the purposes of developing such pro forma
consolidated financial statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Following is a preliminary estimate of the allocation of the
purchase price:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="70%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="13%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Total Fair Value</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(In Australian dollars)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,450,442</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Receivables</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>79,413</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>137,450</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Patents</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>120,000,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    In-Process Research and Development</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,741,706</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Property, Plant and Equipment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>865,412</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Payables</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,344,075</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deferred Revenue</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,864,484</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deferred Tax Liability, Net</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(29,100,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>93,965,864</TD>
    <TD align="left" valign="bottom" nowrap>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Purchase Price</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>149,727,518</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Goodwill</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>55,761,654</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>3.</B></TD>
    <TD>
    <B>Pro Forma Adjustments</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Footnotes to the pro forma statements
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</TD>
    <TD></TD>
    <TD valign="top">
    Reflects the historical financial position of pSivida as of
    June&nbsp;30, 2005 on a U.S.&nbsp;GAAP basis. Refer to
    Note&nbsp;27 of pSivida&#146;s audited consolidated financial
    statements included elsewhere in this information statement for
    a description of the differences between accounting principles</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">19

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="top">
    generally accepted in Australia (A-GAAP) and U.S.&nbsp;GAAP as
    they relate to pSivida and for a reconciliation to
    U.S.&nbsp;GAAP of equity for the periods indicated therein.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</TD>
    <TD></TD>
    <TD valign="top">
    Reflects the historical financial position of CDS as of
    June&nbsp;30, 2005 on a U.S.&nbsp;GAAP basis. The historical
    statement of financial position data was translated from
    U.S.&nbsp;dollars to Australian dollars using an exchange rate
    of $0.76 as at June&nbsp;30, 2005.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</TD>
    <TD></TD>
    <TD valign="top">
    Reflects the payment of the estimated $655,308 cash as partial
    consideration for the acquisition plus the payment of $6,765,000
    for direct acquisition costs.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</TD>
    <TD></TD>
    <TD valign="top">
    Reflects the fair value of patents acquired (see Note&nbsp;2).
    Such amount will be amortized over its estimated useful life
    which has been assumed to be 12&nbsp;years for purposes of these
    pro forma financial statements.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</TD>
    <TD></TD>
    <TD valign="top">
    Reflects the residual value of goodwill attributable to the
    acquisition. Goodwill is based on a provisional purchase price
    allocation and is equal to the difference between the purchase
    consideration and the estimated fair value of identifiable net
    assets acquired, as set forth above in Note&nbsp;2. Goodwill is
    not amortized under U.S.&nbsp;GAAP but is assessed for
    impairment at least annually.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)</TD>
    <TD></TD>
    <TD valign="top">
Reflects a deferred tax liability of $48,000,000 attributable to the
difference between the fair value and tax basis of the acquired
patents, offset by a deferred tax asset of $18,900,000 attributable
to the acquired net operating loss carryforwards, using the CDS
combined federal and state statutory tax rate of 40%. No valuation
allowance has been recorded against the deferred tax assets taking
into consideration the future reversal of taxable temporary
differences. The actual utilization of the acquired net operating
loss carryforwards may be subject to limitation due to the
&#147;change of ownership&#148; provision of Section&nbsp;382 of the
Internal Revenue Code. The Company has not yet completed the
calculation of this
annual limitation. See Note&nbsp;2.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)</TD>
    <TD></TD>
    <TD valign="top">
    Reflects the elimination of CDS Series&nbsp;A redeemable
    preferred stock.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)</TD>
    <TD></TD>
    <TD valign="top">
    Reflects the following adjustments:</TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="81%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Fair value of 160,000,000 pSivida ordinary shares issued (see
    Note&nbsp;2)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>141,798,165</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Fair value of 1,761,760 pSivida share options issued (see
    Note&nbsp;2)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>509,045</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Elimination of CDS common stock and APIC</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(16,362,738</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>125,944,472</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)</TD>
    <TD></TD>
    <TD valign="top">
    Reflects the elimination of CDS deferred stock compensation as
    all outstanding CDS options will be exchanged for pSivida
    options.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)</TD>
    <TD></TD>
    <TD valign="top">
    Reflects the estimated write-off of in-process research and
    development related to the acquisition of CDS (see Note&nbsp;2).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)</TD>
    <TD></TD>
    <TD valign="top">
    Reflects the elimination of CDS accumulated deficit.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)</TD>
    <TD></TD>
    <TD valign="top">
    Reflects the historical financial results of operations of
    pSivida for the year ended June&nbsp;30, 2005 on a
    U.S.&nbsp;GAAP basis. Refer to Note&nbsp;27 of pSivida&#146;s
    audited consolidated financial statements included elsewhere in
    this information statement for a description of the differences
    between A-GAAP and U.S.&nbsp;GAAP as they relate to pSivida and
    for a reconciliation to U.S.&nbsp;GAAP of net loss for the
    periods indicated therein.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)</TD>
    <TD></TD>
    <TD valign="top">
    Reflects the historical results of operations of CDS on a
    U.S.&nbsp;GAAP basis for the period July&nbsp;1 2004 to
    June&nbsp;30, 2005, which have been derived by combining the
    U.S.&nbsp;GAAP results of operations for the 12&nbsp;months to
    December&nbsp;31, 2004 (which are included elsewhere in this
    Information Statement) minus the U.S.&nbsp;GAAP results of
    operations for the six months to June&nbsp;30, 2004 plus the
    U.S.&nbsp;GAAP results of operations for the six months to
    June&nbsp;30, 2005. The historical statement of operations data
    was translated from U.S.&nbsp;dollars to Australian dollars
    using a weighted average exchange rate of $0.754 for the year
    ended June&nbsp;30, 2005.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">20

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV style="margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)</TD>
    <TD></TD>
    <TD valign="top">
    Reflects the amortization of patents over an estimated useful
    life of 12&nbsp;years as described in adjustment&nbsp;(d) above.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)</TD>
    <TD></TD>
    <TD valign="top">Reflects the tax benefit attributable to the total of the historical CDS income before
income tax benefit and the pro forma amortization of intangibles, using the
CDS combined federal and state statutory tax rate of 40%. There is no
impact on current income taxes due to net operating losses of the
combined entity.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p)</TD>
    <TD></TD>
    <TD valign="top">
    Reflects the elimination of accretion of the CDS Series&nbsp;A
    redeemable preferred stock due to the elimination of the stock
    as described in adjustment&nbsp;(g) above.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>4.</B></TD>
    <TD>
    <B>In-process research and development</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
As indicated in Note&nbsp;2, pSivida incurred a charge related
to this transaction for in-process research and development of
$2,741,706. Such adjustment has been excluded from the pro forma
consolidated statement of operations as the charge is a
non-recurring charge directly attributable to the acquisition.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>5.</B></TD>
    <TD>
    <B>Loss per share</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Pro forma per share data is based on the number of shares of
pSivida&#146;s ordinary shares that would have been outstanding
had the acquisition of CDS occurred on July&nbsp;1, 2004. In
order to compute the number of ordinary shares used in the
calculation of pro forma basic and diluted earnings per common
share, the number of ordinary shares (represented by ADSs) to be
issued by pSivida to former holders of shares in CDS common
stock and preferred stock was added to the weighted average
number shares of pSivida ordinary shares outstanding for the
year ended June&nbsp;30, 2005. Under the terms of the agreement
a total of 160&nbsp;million ordinary shares (represented by
16&nbsp;million ADSs) will be issued in exchange for the
outstanding CDS&#146; common and preferred shares on the date of
the acquisition. A reconciliation of shares used to compute
historical basic and diluted loss per share to shares used to
compute pro forma basic and diluted loss per common share
follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="77%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Year Ended</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>June&nbsp;30, 2005</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Ordinary shares used to compute pSivida historical basic and
    diluted loss per share</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>207,802,540</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Ordinary shares to be issued to former holders of shares of CDS
    common stock</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>84,350,410</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Ordinary shares to be issued to former holders of shares of CDS
    convertible redeemable preferred stock</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>75,649,590</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Ordinary shares used to compute pro forma basic and diluted loss
    per share</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>367,802,540</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Outstanding options and warrants to purchase pSivida ordinary
shares are not included in the computation of pro forma diluted
loss per share because the effect would be antidilutive due to
the net loss attributable to common stockholders.
</DIV>

<P align="center" style="font-size: 10pt;">21

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>PSIVIDA INFORMATION</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Selected Historical
Financial Data</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following table presents pSivida&#146;s selected historical
consolidated financial data as of the dates and for each of the
periods indicated. The information set forth below is not
necessarily indicative of future results and should be read in
conjunction with &#147;pSivida&#146;s Management&#146;s
Discussion and Analysis of Financial Condition and Results of
Operations&#148; as well as pSivida&#146;s audited consolidated
financial statements and the notes thereto appearing elsewhere
in this information statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The selected consolidated financial data as of June&nbsp;30,
2005 and 2004 and for each of the three years in the period
ended June&nbsp;30, 2005 have been derived from pSivida&#146;s
audited consolidated financial statements and the notes thereto
included elsewhere in this information statement. The selected
consolidated financial data as of June&nbsp;30, 2003, 2002 and
2001, for the year ended June&nbsp;30, 2002, and for the period
from December&nbsp;1, 2000 to June&nbsp;30, 2001 have been
derived from pSivida&#146;s audited consolidated financial
statements and notes thereto which are not included in this
information statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida prepares its consolidated financial statements in
accordance with accounting principles generally accepted in
Australia, or A-GAAP, which differ in certain significant
respects from accounting principles generally accepted in the
United States, or U.S.&nbsp;GAAP. Please refer to Note&nbsp;27
to the consolidated financial statements for a description of
the differences between A-GAAP and U.S.&nbsp;GAAP as they relate
to us, and a reconciliation of net loss and total equity to
U.S.&nbsp;GAAP for the periods and as of the dates indicated.
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Period from</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Inception of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Development</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Stage (Dec&nbsp;1,</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="15">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2000) to</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="14" align="center" nowrap><B>Years Ended June&nbsp;30,</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>June&nbsp;30,</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="14" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2001(1)</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2002</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap><B>(In Australian Dollars except number of shares)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>STATEMENT OF FINANCIAL PERFORMANCE DATA:</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>A-GAAP</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Revenues from ordinary activities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>113,145</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>916,600</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>110,675</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>381,679</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>828,976</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Depreciation and amortization expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(11,681</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(38,502</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(37,835</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(39,360</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,029,382</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Research and development expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(226,132</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,186,863</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,586,182</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,011,666</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(8,287,930</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Interest expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,635</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Employee benefits expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(25,486</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(22,999</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(522,977</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,238,381</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,040,007</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Foreign currency (loss)/ gain</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(995</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,203</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,461,368</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,623,484</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Corporate office expenses</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(701,576</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,664,265</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(318,806</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,066,981</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,973,892</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Loss from ordinary activities before income tax</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(851,730</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,997,024</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,356,328</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,518,976</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,125,719</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Income tax expense relating to ordinary activities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss before outside equity interest</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(851,730</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,497,024</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,356,328</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,518,976</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,125,719</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">22

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; ">

<TR style="font-size: 1pt;">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Period from</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Inception of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Development</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Stage (Dec&nbsp;1,</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="15">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2000) to</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="14" align="center" nowrap><B>Years Ended June&nbsp;30,</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>June&nbsp;30,</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="14" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2001(1)</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2002</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap><B>(In Australian Dollars except number of shares)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss attributable to outside equity interest</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>113,229</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,806,605</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,591,175</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,835,771</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>399,196</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(738,501</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,190,419</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,765,153</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,683,205</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(14,726,523</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Loss per share&nbsp;&#151; basic and diluted</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(0.01</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(0.02</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(0.03</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(0.03</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(0.07</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Weighted average number of ordinary shares
    outstanding&nbsp;&#151; basic and diluted</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>69,053,359</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>89,834,844</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>101,281,292</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>126,990,066</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>207,802,540</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>US GAAP</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Revenue from ordinary activities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>56,200</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>161,666</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss (restated(2))</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,268,603</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,019,974</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(16,561,512</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Loss per share&nbsp;&#151; basic and diluted (restated(2))</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(0.02</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(0.04</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(0.08</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Weighted average number of ordinary shares
    outstanding&nbsp;&#151; basic and diluted</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>101,281,292</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>126,990,066</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>207,802,540</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="37%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap><B>As of June&nbsp;30,</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2001(1)</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2002</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>STATEMENT OF FINANCIAL POSITION DATA:</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>A-GAAP</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,270,093</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,051,509</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,180,134</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31,350,656</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,892,061</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Working capital</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,107,966</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,643,187</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>433,609</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,791,981</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,876,713</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total assets </DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,247,729</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,273,860</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,175,342</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>40,367,058</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>82,035,313</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Contributed equity</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,107,849</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>14,649,616</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>15,602,184</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>49,957,982</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>107,883,835</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deficit accumulated prior to development stage</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deficit accumulated during development stage</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(738,501</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,928,920</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,694,073</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(9,377,278</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(24,103,801</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total parent entity interest in equity</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,585,467</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,939,515</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,095,165</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>36,845,743</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>79,987,614</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total outside equity interest</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,376,663</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,773,306</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>204,354</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,583,200</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total equity</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,962,180</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,712,821</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,299,519</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>38,428,943</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>79,987,614</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>U.S.&nbsp;GAAP</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total assets (restated (2))</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,220,492</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>41,295,099</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>100,063,276</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total equity (restated(2))</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,140,316</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>37,794,705</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>87,650,337</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Contributed equity</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>15,434,340</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>51,030,718</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>117,798,149</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>(1)&nbsp;</TD>
    <TD align="left">
    The legal entity that became pSivida was incorporated as the
    Sumich Group Ltd in April 1987. The Sumich Group operated an
    agriculture business which was placed into administration or
    receivership</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">23

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD align="left">
    on September&nbsp;30, 1998. pSivida was subsequently formed on
    December&nbsp;1, 2000 following upon entering into a
    court-approved arrangement with Sumich Group&#146;s creditors
    which fully extinguished all prior liabilities as of that time.
    pSivida then appointed new directors and officers and re-listed
    on the Australian Stock Exchange under its new name.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(2)&nbsp;</TD>
    <TD align="left">
    The U.S. GAAP financial information as of and for the years ended
June 30, 2004 and 2003 has been restated. Refer to Note&nbsp;27 to
the Company&#146;s audited consolidated financial statements included
elsewhere herein for a description and summary of the significant
effects of the restatement.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Exchange Rates</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following tables set forth for the periods and dates
indicated certain information concerning the rates of exchange
of A$1.00 into U.S.$ based on the noon market buying rate in New
York City for cable transfers in Australian dollars as certified
for customs purposes by the Federal Reserve Bank of New York,
which pSivida refers to as the noon buying rate.
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="79%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Month</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>High</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Low</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    June 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7792</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7498</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    July 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7661</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7403</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    August 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7739</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7469</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    September 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7731</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7537</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    October 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7644</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7436</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    November 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7451</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7267</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The noon buying rate on December&nbsp;20, 2005 was $0.7328 =
A$1.00.
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="49%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Year Ended June&nbsp;30,</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>At Period End</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Average Rate</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>High</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Low</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2001</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.5100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.5320</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.5996</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.4828</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2002</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.5628</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.5682</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.5748</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.4841</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.6713</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.5884</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.6729</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.5280</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.6952</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7155</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7979</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.6390</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7618</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7568</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7974</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.6880</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">pSivida&#146;s
Management&#146;s Discussion And Analysis of Financial Condition
and Results of Operations</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following discussion of pSivida&#146;s financial condition
and results of operations is presented in A-GAAP and should be
read in conjunction with &#147;Selected Historical Financial
Data of pSivida&#148; and the audited consolidated financial
statements and other financial information appearing elsewhere
in this information statement. In addition to historical
consolidated financial information, the following discussion and
analysis contains forward-looking statements that reflect
pSivida&#146;s plans, estimates, intentions, expectations and
beliefs. pSivida&#146;s actual results could differ materially
from those anticipated in the forward-looking statements as a
result of many factors, including those discussed under
&#147;Risk Factors&#148; and elsewhere in this information
statement.
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Overview</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida is a development stage enterprise at an early stage in
the development of BioSilicon. It has incurred net losses since
inception and expects to incur substantial and increasing losses
for the next few years as pSivida expands its research and
development activities and moves its product candidates into
later stages of development. All of pSivida&#146;s product
candidates are in early stages of development and it faces the
risks of failure inherent in developing drugs based on new
technologies. The process of carrying out the development of its
products to later stages of development may require significant
additional research and development expenditures, including
pre-clinical testing and clinical trials, as well as for
obtaining regulatory approval. To date, pSivida has funded its
operations primarily through private placements of equity
securities, the exercise of options and share purchase plans.
</DIV>

<P align="center" style="font-size: 10pt;">24

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s revenues are generated in both Australian dollars
and Pounds Sterling, and a majority of its expenses are incurred
in either Australian dollars, Pounds Sterling or U.S. dollars.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Results of Operations</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following table is intended to illustrate a tabular analysis
of certain consolidated statement of financial performance data
as a percentage of net loss before outside equity interest for
all periods presented.
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="71%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss before outside equity interest</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>100</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>100</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>100</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Revenue from ordinary activities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5.5</TD>
    <TD align="left" valign="bottom" nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5.1</TD>
    <TD align="left" valign="bottom" nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2.0</TD>
    <TD align="left" valign="bottom" nowrap>)%</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Depreciation and amortization expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6.8</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.5</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.7</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Research and development expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>54.8</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>93.2</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>85.6</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Interest expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.1</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Employee benefits expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6.9</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>16.5</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9.8</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Foreign currency (loss)/gain</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10.7</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(19.4</TD>
    <TD align="left" valign="bottom" nowrap>)%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Corporate office expenses</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>26.3</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>14.2</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5.9</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The level of research and development expenditure has increased
during the past three years. This is a direct result of the
continued development of the BioSilicon technology and its
applications such as the human trials of BrachySil which are
being undertaken in Singapore. The increasing level of general
corporate activity has also led to an increase in corporate
costs over the three years.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
It should be noted, when considering the above table that other
income/(expenses) from ordinary activities, net for the years
ended June&nbsp;30, 2005 and 2004 include an amount of
unrealized foreign exchange gain/(loss) on deposits held in
U.S.&nbsp;dollars and Pounds Sterling equal to
A$(1.6)&nbsp;million and A$1.5&nbsp;million respectively. No
such amount arose in prior periods as prior to April 2004, no
material cash deposits were held by pSivida other than in
Australian dollars.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Results of Operations For the Year Ended June&nbsp;30,
    2005 Compared to the Year Ended June&nbsp;30, 2004</I></B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Net Loss</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For reasons described further below, pSivida&#146;s net loss
increased to A$14.7&nbsp;million for the year ended
June&nbsp;30, 2005 from A$3.7&nbsp;million for the year ended
June&nbsp;30, 2004, an increase of A$11.0&nbsp;million, or
299.8%. The increase in net loss in 2005 is primarily
attributable to pSivida&#146;s acquisition of the remaining
outside equity interest in pSiMedica in August 2004, resulting
in the consolidated group recognizing the full costs of
pSiMedica. Other causes include pSivida&#146;s NASDAQ listing in
January 2005 and the associated increased US regulation, an
increase in all areas of corporate administration including
consultants, rent and travel due to the increased levels of
activity.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Revenue from Ordinary Activities</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Revenue from ordinary activities increased to A$828,976 for the
year ended June&nbsp;30, 2005 from A$381,679 for the year ended
June&nbsp;30, 2004, an increase of A$447,297 or 117.2%. Revenue
in the 2005 period consisted of A$667,310 interest income
compared to A$325,479 in interest income in the 2004 period. The
increase in interest income in the 2005 period primarily relates
to interest income earned on pSivida&#146;s higher balances of
cash from previous capital raisings. Additionally, pSivida
recognized A$161,666 as other income in the 2005 period in
connection with the research being undertaken by EpiTan and
pSivida&#146;s top 5 global pharmaceutical company collaboration
partner (see &#147;pSivida&#146;s Business&#148;).
</DIV>

<P align="center" style="font-size: 10pt;">25

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Depreciation and Amortization Expense</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Depreciation and amortization expense (excluding depreciation of
plant and equipment used in research and development activities)
increased to A$1,029,382 for the year ended June&nbsp;30, 2005
from A$39,360 for the year ended June&nbsp;30, 2004, an increase
of A$990,022, or 2515.3%. The level of depreciation expense
increased only slightly through the year as capital expenditure
on plant and equipment for other than research and development
activities also increased slightly. No amount of amortization of
intellectual property was recognized by pSivida because its
intangible assets have not led to a product at a commercial
production stage of development. pSivida recognized a goodwill
amortization expense of $973,923 for the year, representing most
of the increase in the depreciation and amortization expense.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Research and Development Expense</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Research and development expense increased to A$8.3&nbsp;million
or the year ended June&nbsp;30, 2005 from A$7.0&nbsp;million for
the year ended June&nbsp;30, 2004, an increase of
A$1.3&nbsp;million, or 18.2%. This increase is primarily
attributable to an increase in pSivida&#146;s expenditure on the
research and development into the drug delivery platform and
preparations for the planned undertaking of clinical trials in
relation to pancreatic application of BrachySil. (Refer to
&#147;pSivida's Business&#148; for a detailed description of
pSivida&#146;s research and development activities).
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Employee Benefits Expense</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Employee benefits expense decreased to A$1.0&nbsp;million for
the year ended June&nbsp;30, 2005 from A$1.2&nbsp;million for
the year ended June&nbsp;30, 2004, a decrease of A$198,374, or
16.0%. This decrease is attributable to a decrease in employee
bonuses during the full year of operations.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Corporate Office Expenses</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Corporate office expenses increased to A$3,973,892 for the year
ended June&nbsp;30, 2005 from A$1,066,981 for the year ended
June&nbsp;30, 2004, an increase of A$2,906,911, or 272.4%. This
increase is primarily due to pSivida&#146;s NASDAQ listing
during the year, increased U.S.&nbsp;regulation requirements and
an increase in all areas of corporate administration including
consultants, rent and travel due to the increased levels of
activity during the year.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Results of Operations For the Year Ended June&nbsp;30,
    2004 Compared to the Year Ended June&nbsp;30, 2003</I></B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Net Loss</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For reasons described further below, pSivida&#146;s net loss
increased to A$3.7&nbsp;million for the year ended June&nbsp;30,
2004 from A$2.8&nbsp;million for the year ended June&nbsp;30,
2003, an increase of A$918,052, or 33.2%. The increase in net
loss in 2004 is primarily attributable to the increase in
research and development expenditure with the commencement of
human clinical trials of BrachySil in Singapore.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Revenue from Ordinary Activities</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Revenue from ordinary activities increased to A$381,679 for the
year ended June&nbsp;30, 2004 from A$110,675 for the year ended
June&nbsp;30, 2003, an increase of A$271,004, or 244.9%. Revenue
in the 2004 period consisted of A$325,479 interest income
compared to A$110,675 in interest income in the 2003 period. The
increase in interest income in the 2004 period primarily relates
to interest income earned on the A$25.6&nbsp;million net
proceeds received in the private placement of ordinary shares
during April 2004 (Refer to Note&nbsp;10 of the consolidated
financial statements). Additionally, pSivida recognized A$56,200
as other income in the 2004 period in connection with the
research being undertaken by EpiTan (see &#147;pSivida&#146;s
Business&#148;).
</DIV>

<P align="center" style="font-size: 10pt;">26

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Depreciation and Amortization Expense</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Depreciation and amortization expense (excluding depreciation of
plant and equipment used in research and development activities)
increased to A$39,360 for the year ended June&nbsp;30, 2004 from
A$37,835 for the year ended June&nbsp;30, 2003, an increase of
A$1,525, or 4.0%. The level of depreciation and amortization
expense remained constant through the year as capital
expenditure on plant and equipment for other than research and
development activities was similar in amount to the prior year.
No amount of amortization of intangible assets was recognized by
pSivida because its intangible assets have not led to a product
at a commercial production stage of development.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Research and Development Expense</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Research and development expense increased to A$7.0&nbsp;million
for the year ended June&nbsp;30, 2004 from A$4.6&nbsp;million
for the year ended June&nbsp;30, 2003, an increase of
A$2.4&nbsp;million, or 52.9%. This increase is attributable to
an increase in pSivida&#146;s expenditure on the completion of
pre-clinical trials of BrachySil and human clinical trials of
BrachySil which commenced during 2004 in Singapore. (Refer to
&#147;pSivida&#146;s Business&#148; for a detailed description
of pSivida&#146;s research and development activities).
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Employee Benefits Expense</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Employee benefits expense increased to A$1.2&nbsp;million for
the year ended June&nbsp;30, 2004 from A$522,977 for the year
ended June&nbsp;30, 2003, an increase of A$715,404, or 136.8%.
This increase is attributable to the increase in full and part
time permanent staff employed during the year which pSivida
required as a result of increased levels of research and
development activity and additional finance and administration
resource requirements.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Other Income/ Expenses from Ordinary Activities, Net</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Other income/(expenses) from ordinary activities, net increased
to A$394,387 for the year ended June&nbsp;30, 2004 from
A$320,009 for the year ended June&nbsp;30, 2003, an increase of
A$714,396, or 223.2%. This increase is primarily due to the
recognition of a significant unrealized foreign exchange gain of
A$1.5&nbsp;million in 2004 due to favorable movements in the
Pound Sterling and U.S.&nbsp;dollar against Australian dollar
foreign exchange rates on significant cash deposits held in
foreign currencies comprising proceeds of pSivida&#146;s private
placement of ordinary shares during April 2004. Prior to April
2004, pSivida did not hold material cash deposits in foreign
currency. In addition, corporate administration expenses
increased to A$1.1&nbsp;million from the year ended
June&nbsp;30, 2004 from A$318,806 for the year ended
June&nbsp;30, 2003, an increase of A$748,175, or 234.7%. This
increase is due to an increase in all areas of corporate
administration including consultants, rent and travel due to the
increased levels of activity and pSivida&#146;s further
development during the year.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Foreign Currency</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the year ended June&nbsp;30, 2005 an unrealized foreign
exchange loss was recognized of A$1.6&nbsp;million which arose
entirely due to unfavorable movements in the Pound Sterling and
U.S.&nbsp;dollar against Australian dollar foreign exchange
rates. During the year ended June&nbsp;30, 2004 an unrealized
foreign exchange gain of A$1.5&nbsp;million was recognized.
Prior to April 2004, no material cash deposits were held by
pSivida other than in Australian dollars.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida does not utilize financial derivatives instruments or
other financial instruments subject to market risk.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Conditions in Australia</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida is incorporated under the laws of, and its principal
offices are located in the Commonwealth of Australia. Therefore,
it is directly affected by political and economic conditions in
Australia.
</DIV>

<P align="center" style="font-size: 10pt;">27

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Quantitative and Qualitative Disclosures About Market
    Risk</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida has exposure to changes in foreign currency exchange
rates and interest rates. It does not utilize derivative
financial instruments or other financial instruments subject to
market risk.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Foreign Currency Exchange Rates</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida conducts operations in two principal currencies, the
Pound Sterling and the Australian dollar. These two currencies
operate as the two functional currencies for pSivida&#146;s
United Kingdom and Australian operations respectively. Cash to
fund working capital requirements is managed centrally within
each of the two countries with cash deposits managed in
Australia and held in Pounds Sterling, Australian dollars and
U.S.&nbsp;dollars.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the year ended June&nbsp;30, 2005 an unrealized foreign
exchange loss on cash held in currencies other than the
reporting currency was recognized of A$1.6&nbsp;million which
arose due to unfavorable movements in the Pound Sterling and
U.S.&nbsp;dollar against Australian dollar foreign exchange
rates. Prior to April 2004, no material cash deposits were held
by pSivida in foreign currencies other than Australian dollars.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Based on Pounds Sterling and U.S.&nbsp;dollar account balances
at June&nbsp;30, 2005, the following table shows the sensitivity
of pSivida&#146;s consolidated financial performance as a result
of an appreciation or depreciation in the value of the
Australian dollar against the Pounds Sterling and
U.S.&nbsp;dollar.
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>A$ Depreciation</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>A$ Appreciation</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Current</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>-15%</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>-10%</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>-5%</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Rate</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>5%</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>10%</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>15%</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="26" align="center" nowrap><B>(In thousands of Australian dollars)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    &#163;</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>703</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>469</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>234</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(234</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(469</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(703</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    US$</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>818</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>546</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>273</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(273</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(546</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(818</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,521</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,015</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>507</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(507</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,015</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,521</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Interest Rates</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Cash deposits are held in call and deposit accounts and are
subject to variable interest rates. pSivida does not consider
its exposure to interest rates to be significant.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Recently Issued Accounting Pronouncements Applicable to
    pSivida</I></B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Australian Pronouncements</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Impacts of adopting Australian Equivalents to International
Financial Reporting Standards
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(a)</B></TD>
    <TD>
    <B>Management of the transition to AIFRS</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida will be required to prepare financial statements that
comply with Australian Equivalents to International Financial
Reporting Standards, or AIFRS, as adopted by the Australian
Accounting Standards Board for annual reporting periods
beginning on or after January&nbsp;1, 2005. Accordingly,
pSivida&#146;s first half-year report prepared under AIFRS will
be for the half-year reporting period ended December&nbsp;31,
2005, and its first annual financial report prepared under AIFRS
will be for the year ended June&nbsp;30, 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The transitional rules for first time adoption of AIFRS require
that the Company restate its comparative financial statements
using AIFRS, except for AASB&nbsp;132: &#147;Financial
Instruments: Disclosure and Presentation&#148; and
AASB&nbsp;139: &#147;Financial Instruments: Recognition and
Measurement&#148; where comparative information is not required
to be restated. Currently, the Company provides two years of
comparative financial information in its financial statements to
comply with applicable SEC requirements. The SEC has granted a
one-time relief from this requirement for foreign registered
companies preparing their first set of financial statements in
compliance with International Financial Reporting Standards. The
Company has elected to apply this relief and will only provide
one year of comparative information in the 30&nbsp;June 2006
financial statements. For reporting in the 2006 fiscal year,
comparatives will be remeasured
</DIV>

<P align="center" style="font-size: 10pt;">28
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
and restated for the half-year ended 31&nbsp;December 2004 and
the financial year ended 30&nbsp;June 2005. Most of the
adjustments on transition are required to be made to opening
retained profits at the beginning of the first comparative
period (i.e., at 1&nbsp;July 2004).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In 2004, pSivida commenced a review of accounting policies in
preparation for managing the transition to AIFRS. Priority has
been given to considering the preparation of an opening balance
sheet in accordance with AIFRS as at July&nbsp;1, 2004,
pSivida&#146;s transition date to AIFRS. This will form the
basis of accounting for AIFRS in the future and is required when
pSivida prepares its first fully AIFRS-compliant financial
report for the year ended June&nbsp;30, 2006.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(b)</B></TD>
    <TD>
    <B>The likely impacts of AIFRS on the results and financial
    position of pSivida and the consolidated entity</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Set out below are the known key differences in accounting policy
and our known estimable transitional differences identified as
of 30&nbsp;June 2005, where accounting policies are expected to
change on adoption of AIFRS and the likely impacts on the
current year operating results and financial position of the
Company, had the financial statements been prepared using AIFRS,
based on the directors&#146; accounting policy decisions current
at the date of this financial report. The adjustments included
are based on the AIFRS standards released as at June&nbsp;30,
2005. These are subject to ongoing review and any amendments by
the AASB, or by interpretative guidance from the International
Accounting Standards Board or AASB, could change the adjustments
included. The AIFRS standards and interpretations that will
apply to the Company will be those released as at
December&nbsp;31, 2005 being the date of the first half year
financial statements that the Company has to publish under
AIFRS. The disclosures below represent the Company&#146;s
current best estimate of the quantitative impact of the AIFRS
implementation at the date of this report and accordingly they
remain subject to change.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
There are certain items that still require resolution and
additional differences in accounting policy that may be
identified. The directors may, at any time until the completion
of the Company&#146;s first AIFRS compliant financial report,
elect to revisit, and where considered necessary, revise the
accounting policies applied in preparing the disclosures below.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(c)</B></TD>
    <TD>
    <B>Adjustments to balance sheet items under AIFRS (net of
    tax)</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="8%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top">
    <TD><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)</I></B></TD>
    <TD>
    <B><I>Intangibles</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under Australian Accounting Standards AASB 3 Business
Combinations, goodwill will not be permitted to be amortized but
instead is subject to impairment testing on an annual basis or
upon triggers which may indicate a potential impairment. As a
result accumulated amortization of $973,923 (all expensed during
the 2005&nbsp;year) would be added back to the value of
intangibles.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based
    payments</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under AASB 2&nbsp;Share-Based Payment, equity-settled
share-based payments in respect of equity instruments issued
after November&nbsp;7, 2002 that were unvested as at
January&nbsp;1, 2005 are measured at fair value at grant date.
The fair value determined at grant date of equity-settled
share-based payments is expensed on a straight-line basis over
the vesting period, based on the estimated number of equity
instruments that will vest. As a consequence, contributed equity
will increase by $591,900 for the financial year ended
June&nbsp;30, 2005.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency
    translation reserve</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The directors have elected to set the translation reserve to
zero as at AIFRS transition as permitted under AASB 1 First-Time
Adoption of Australian Equivalents to International Financial
Reporting Standards. This results in the transfer of $78,220
from the foreign currency translation reserve to retained
earnings as at AIFRS transition.
</DIV>

<P align="center" style="font-size: 10pt;">29

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated
    losses</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
With limited exceptions, adjustments required on first-time
adoption of AIFRS are recognized directly in accumulated losses
at the date of transition to AIFRS. The cumulative effect of
these adjustments for the consolidated entity will be an
increase in opening accumulated losses of $78,220.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(d)</B></TD>
    <TD>
    <B>Adjustments to current year loss under AIFRS (net of tax)</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="8%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top">
    <TD><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)</I></B></TD>
    <TD>
    <B><I>Intangibles</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under AASB 3 Business Combinations, goodwill would not be
permitted to be amortized but instead is subject to impairment
testing on an annual basis or upon triggers which may indicate a
potential impairment. As a result goodwill amortization expense
of $973,923 recorded in the year ended 30&nbsp;June 2005 would
be added back to the net loss for the year. There is no goodwill
amortization required to be added back to the net loss upon the
transition date of 1&nbsp;July 2004.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based
    payments</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under AASB 2&nbsp;Share-Based Payment, equity-settled
share-based payments in respect of equity instruments issued
after November&nbsp;7, 2002 that were unvested as at
January&nbsp;1, 2005 are measured at fair value at grant date.
The fair value determined at grant date of equity-settled
share-based payments is expensed on a straight-line basis over
the vesting period, based on the estimated number of equity
instruments that will vest. As a consequence, an additional
employee benefit expense of $508,613 and consultancy fees
expense of $83,287 will be recognized in the profit and loss for
the financial year ended June&nbsp;30, 2005.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(e)</B></TD>
    <TD>
    <B>Other impacts</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(i)&nbsp;Management has decided to apply the exemption provided
in <I>AASB 1 First-Time Adoption of Australian Equivalents to
International Financial Reporting Standards </I>which permits
entities not to restate business combinations that occurred
prior to the date of transition to AIFRS. Business combinations
occurring after the date of transition (i.e. 1&nbsp;July 2004)
will be subject to the provisions of <I>AASB 3 Business
Combinations.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(ii)&nbsp;Management has decided to apply the exemption provided
in <I>AASB 1 First-Time Adoption of Australian Equivalents to
International Financial Reporting Standards</I> which permits
entities not to apply the requirements of <I>AASB&nbsp;132
Financial Instruments: Presentation and Disclosures</I> and
<I>AASB&nbsp;139 Financial Instruments: Recognition and
Measurement </I>for the financial year ended June&nbsp;30, 2005.
The standards will be applied from July&nbsp;1, 2005. Management
is in the process of determining the impact that adopting the
standards would have on the financial statements of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(iii)&nbsp;Under <I>AASB&nbsp;136 Impairment of Assets</I>, the
consolidated entity&#146;s assets, including goodwill would be
tested for impairment as part of the cash generating unit to
which they belong, and any impairment losses recognized in the
income statement. At this stage in pSivida&#146;s review process
pSivida is not aware of any impairment issues that would result
in a material adjustment to the financial statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(iv)&nbsp;No material impacts are expected to the cash flows
presented under current A-GAAP on adoption of AIFRS.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(f)</B></TD>
    <TD>
    <B>Acquisition of minority interest</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the year pSivida purchased minority interests in
controlled entity pSiMedica. Under current A-GAAP this
acquisition has been accounted for separately from other
acquisitions (that is, as a step acquisition, which involved the
separate determination and recognition of the fair values of the
net assets of the subsidiary and any goodwill arising on the
acquisition).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>AASB 127 Consolidated and Separate Financial Statements
</I>requires minority interests to be classified as equity.
Consequently the acquisition by pSivida of additional ownership
interests in pSiMedica Limited
</DIV>

<P align="center" style="font-size: 10pt;">30

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
represents an equity transaction. As such, accounting for the
transaction as a step acquisition is inappropriate. The
financial effect of the adjustment required on the restatement
of the June&nbsp;30, 2005 accounts is yet to be determined.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><I>U.S.&nbsp;Pronouncements</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In December 2004, the Financial Accounting Standards Board, or
FASB, issued Statement of Financial Accounting Standards, or
SFAS, No.&nbsp;123 (revised 2004): Share-Based Payments, or
SFAS&nbsp;123R. This statement eliminates the option to apply
the intrinsic value measurement provisions of Accounting
Principles Board, or APB, Opinion No.&nbsp;25 to stock
compensation awards issued to directors and employees. Rather,
SFAS&nbsp;123R requires companies to measure the cost of
director and employee services received in exchange for an award
of equity instruments based on the grant-date fair value of the
award. That cost will be recognized over the period during which
the director, executive or employee is required to provide
services in exchange for the award&nbsp;&#151; the requisite
service period (usually the vesting period). SFAS&nbsp;123R
applies to all awards granted after the required effective date
(July&nbsp;1, 2005 for pSivida) and to awards modified,
repurchased, or cancelled after that date. As permitted by
SFAS&nbsp;123, pSivida accounted for share-based payments to
directors, executives and employees using APB&nbsp;25, the
intrinsic value method through June&nbsp;30, 2005. Accordingly,
the adoption of the SFAS&nbsp;123R fair value method may have a
significant impact on pSivida&#146;s results of operations,
although it will have no impact on its overall financial
position. The full impact of the adoption of SFAS&nbsp;123R
cannot be predicted at this time, as it depends on levels of
share-based payments for future grants. However, had the Company
adopted SFAS&nbsp;123R for director, executive and employee
options in prior periods, the impact of that standard would have
approximated the pro forma impact of SFAS&nbsp;123, as disclosed
in Note&nbsp;27(a), Share-based compensation&nbsp;&#151; Options
issued to directors and employees for services rendered.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In December 2004, the FASB issued SFAS&nbsp;No.&nbsp;153:
&#147;Exchanges of Nonmonetary Assets&#148;&nbsp;&#151; an
amendment of APB Opinion No.&nbsp;29, or SFAS&nbsp;153, which
amends APB Opinion No.&nbsp;29: Accounting for Nonmonetary
Transactions to eliminate the exception for nonmonetary
exchanges of similar productive assets and replaces it with a
general exception for exchanges of nonmonetary assets that do
not have commercial substance. SFAS&nbsp;153 is effective for
nonmonetary assets exchanges occurring in fiscal periods
beginning after June&nbsp;15, 2005 (fiscal 2006 for pSivida). At
this time, management reasonably believes that the adoption of
SFAS&nbsp;153 will not have a material effect on pSivida&#146;s
financial position or results of operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In May 2005, the FASB issued SFAS&nbsp;No.&nbsp;154:
&#147;Accounting Changes and Error Corrections,&#148; or
SFAS&nbsp;154, a replacement of APB Opinion No.&nbsp;20:
&#147;Accounting Changes&#148; and SFAS&nbsp;No.&nbsp;3:
&#147;Reporting Accounting Changes in Interim Financial
Statements,&#148; effective for fiscal years beginning after
December&nbsp;15, 2005 (fiscal 2007 for pSivida). SFAS&nbsp;154
changes the requirements for the accounting for and reporting of
a voluntary change in accounting principle as well as the
changes required by an accounting pronouncement which does not
include specific transition provisions. At this time management
reasonably believes that the adoption of SFAS&nbsp;154 will not
have a material effect on pSivida&#146;s financial position or
results of operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><I>Differences between Australian Accounting Standards and
U.S.&nbsp;Accounting Standards</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s prepares its audited consolidated financial
statements in accordance with A-GAAP, which differ in certain
significant respects from U.S.&nbsp;GAAP. The following table
sets forth a comparison of pSivida&#146;s net loss and total
equity in accordance with A-GAAP and U.S.&nbsp;GAAP as of the
dates and for the periods indicated:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="57%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" align="center" nowrap><B>Years Ended June&nbsp;30,</B></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>2005</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>2004</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>2003</B></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss in accordance with A-GAAP</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    (14,726,523)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    (3,683,205)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    (2,765,153)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss in accordance with US GAAP (restated(1))</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    (16,561,512)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    (5,019,974)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    (2,268,603)</TD>
</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">31

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>(1)&nbsp;</TD>
    <TD align="left">
    Subsequent to the issuance of June&nbsp;30, 2004 consolidated
    financial statements pSivida changed the amounts previously
    reported in the US&nbsp;GAAP reconciliation for the accounting
    for deferred income taxes as described in Note&nbsp;27 to the
    consolidated financial statements.</TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="60%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" align="center" nowrap><B>As at June&nbsp;30,</B></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="5" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>2005</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>2004</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>2003</B></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total equity in accordance with A-GAAP</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    79,987,614</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    38,428,943</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    6,299,519</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total equity in accordance with US GAAP (restated)(1)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    87,650,337</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    37,794,705</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    7,140,316</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
See Note&nbsp;27 to pSivida&#146;s audited consolidated
financial statements for a description of the differences
between A-GAAP and U.S.&nbsp;GAAP as they relate to it, and a
reconciliation to U.S.&nbsp;GAAP of net loss and total equity
for the dates and periods indicated therein. Differences between
A-GAAP and U.S.&nbsp;GAAP that have a material effect on net
loss and total equity primarily relate to share-based
compensation and purchase accounting.
</DIV>






<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="1"></TD>
    <TD width="1%"></TD>
<TD WIDTH="98%"></TD>
</TR>

<TR valign="top">
    <TD colspan="3"><B><I>Restatement of U.S. GAAP Amounts</I></B></TD>
</TR>
<tr><td>&nbsp;</td></tr>

<tr>
<td colspan="3">Subsequent to the issuance of the June&nbsp;30, 2004 consolidated
financial statements, the Company changed the amounts previously
reported in the U.S. GAAP reconciliation for the accounting for
deferred income taxes as follows:</td></tr>
<tr><td>&nbsp;</td></tr>

<tr>
<td valign="top">&#149;</td>
<td>&nbsp;</td>
<td>Deferred tax liability for acquired intangible assets &#151;
Previously, deferred taxes were not recorded on the intangible assets
acquired in connection with the step acquisition of pSiMedica as the
book to tax basis differences were deemed to be permanent as the
amortization of the related intangibles is not deductible for income
tax purposes. The Company has subsequently concluded that, although
under tax law, it will not receive a tax deduction in the future for
recovery of the intangible assets, recognition of a deferred tax
liability on the acquired intangibles is nevertheless required under
U.S. GAAP because it is assumed for financial reporting purposes that
the Company will generate future revenues at least equal to the
recorded amount of the investment, and recovery will result in future
taxable amounts.</td></tr>

<tr><td>&nbsp;</td></tr>


<tr>
<td valign="top">&#149;</td>
<td>&nbsp;</td>
<td>Valuation allowance for deferred income tax assets &#151;
Previously in establishing a valuation allowance, the Company fully
reserved the total balance of the deferred income tax assets related
to tax loss carryforwards as it was deemed more likely than not that
the deferred tax assets would not be realized. As a result of the
recognition of the U.S. GAAP deferred tax liabilities in connection
with the step acquisition of pSiMedica as per the above, the Company
has reevaluated the recoverability of the deferred income tax assets,
taking into consideration the reversal of taxable temporary
differences under U.S. GAAP.</td></tr>

<tr><td>&nbsp;</td></tr>

<tr>
<td valign="top">&#149;</td>
<td>&nbsp;</td>
<td>Amortization of intangible assets &#151; Where the recognition of
a deferred tax liability for acquired intangible assets as per the
above resulted in additional basis of the related intangible, the
additional basis is being amortized over the remaining estimated
useful life of the intangible asset for U.S. GAAP purposes.</td></tr>


<tr><td>&nbsp;</td></tr>

<tr>
<td colspan="3" valign="top">Refer to Note&nbsp;27 to the
Company&#146;s audited consolidated financial statements included
elsewhere herein for a summary of the significant effects of the
restatement.</td></tr>
</table>






<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Critical Accounting Policies</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida prepares its audited consolidated financial statements
in accordance with A-GAAP. As such, pSivida is required to make
certain estimates, judgments, and assumptions that management
believes are reasonable based upon the information available.
These estimates, judgments and assumptions affect the reported
amounts of assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses
during the periods presented. The significant accounting
policies listed in Note&nbsp;1 of the consolidated financial
statements that management believes are the most critical to aid
in fully understanding and evaluating pSivida&#146;s financial
condition and results of operations under A-GAAP are discussed
below.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Valuation of intangible assets</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Other than cash deposits held, the value recognized in
intangible assets on the consolidated statement of financial
position is the most significant asset held by pSivida and the
accounting principles adopted and estimated by management in
recognizing these assets are therefore considered critical.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Intellectual property principally represents the license granted
to pSiMedica from QinetiQ (formerly the Defense Evaluation and
Research Agency in the United Kingdom) and patents granted. The
QinetiQ license is an exclusive worldwide royalty-free license
to the BioSilicon technology in the field of human and animal
healthcare and in vivo diagnostic applications.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida consolidated the results of pSiMedica upon the
acquisition of a controlling economic interest in pSiMedica on
May&nbsp;10, 2001. Prior to this date, pSiMedica had undertaken
little research and development activities and the cost of any
research and development that had been undertaken was expensed
in the accounts of pSiMedica. Upon the acquisition of additional
share capital in pSiMedica in May 2001, it was considered
reasonable to assume that the majority of the value paid by
pSivida at this time should be attributable to the value of the
license. The remainder was attributable to receivables, plant,
property and equipment and payables. Attributing the bulk of the
value paid by pSivida to the license was also considered
reasonable on the basis that prior to acquisition of the
additional share capital in pSiMedica there had not been any
material patent grants.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Therefore, pSivida considered that it was reasonable that the
value of A$5.1&nbsp;million, being the bulk of the value of the
consideration paid on May&nbsp;10, 2001 in acquiring the
additional pSiMedica shares, should be primarily attributable to
the value of the license and represented a reasonable fair value
of the license at the time of the transaction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On August&nbsp;4, 2004 pSivida completed the acquisition of the
pSiMedica shares that it did not already hold such that it now
holds 100% of the issued capital in pSiMedica. Prior to
acquiring 100% of the issued capital in pSiMedica, the most
recent step in the acquisition of pSiMedica took place on
October&nbsp;13,
</DIV>

<P align="center" style="font-size: 10pt;">32

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
2003. At this point in time, management ascribed no value to the
patent portfolio of pSiMedica and as a result the value acquired
was recognized purely as the QinetiQ license. However, since
this time, the company has been granted significant patents and
it was thought appropriate that this position be reviewed. Based
on management&#146;s assessment, the total amount of the
incremental increase in the value of intangible assets of
A$25,000,000 should be attributed to the patents granted since
October 2003. Consequently, based on management&#146;s
assessment pSivida recognizes the intangible assets in the form
of the license at the value of A$64.4&nbsp;million and patents
at the value of A$25&nbsp;million.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In pSivida&#146;s A-GAAP consolidated financial statements,
recognition of the value of intangible assets acquired has been
made with reference to the actual cost of the investment made by
it in acquiring pSiMedica shares. More specifically, the bulk of
this value is attributed to the fair value of the license
granted to pSiMedica by QinetiQ amounting to $35.6&nbsp;million
and patents granted in relation to the BioSilicon technology of
approximately $13.8&nbsp;million and goodwill of approximately
$9.9&nbsp;million. The remainder was attributable to
receivables, plant, property and equipment and payables. Other
than the intangible assets, the value of assets acquired was
considered nominal in value, particularly on the basis that the
costs of research and development were expensed and no
significant patents had been granted at May&nbsp;10, 2001, when
pSiMedica was first recognized in the consolidated financial
statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Intellectual property is recorded at the cost of acquisition and
is carried forward as an asset on the expectation that it will
lead to commercialization. The carrying value of intangibles is
reviewed by pSivida&#146;s board of directors at each reporting
date.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Estimated Useful Economic Life</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Based on the level of development of BioSilicon products, the
competitive nature of the drug delivery industry and what is
considered industry practice, a period of 12&nbsp;years is
considered by management to be a reasonable estimation of the
expected useful economic life of the license.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The pSivida directors gave due consideration to the technical
and commercial life of the intellectual property (being patents
and licenses) concluding that a 12&nbsp;year useful life was
appropriate to determine their useful economic life to be the
lesser of 12&nbsp;years or the average remaining life of the
intellectual property. Amortization will be recognized on the
commencement of commercial production of products calculated on
a straight-line basis over the remaining balance of the
estimated useful life. pSivida reviews the commercial status of
products on at least an annual basis and it is expected that
amortization of intellectual property will commence during the
year ending June&nbsp;30, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Depreciation of plant and equipment is recognized on a
straight-line basis over the estimated useful lives of three
years. As pSivida&#146;s business is competitive and
developmental in nature, plant and equipment is required to be
regularly updated due to technological advancements and three
years therefore is considered by management to be a reasonable
estimation of the expected useful economic life of its plant and
equipment.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Realization of Deferred Tax Assets</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The recognition of deferred tax assets is based upon the
likelihood of recoverability from future taxable income will be
available, against which the reversal of timing differences can
be deducted. To the extent that recovery is not likely, a
valuation allowance is established. (Refer to Note&nbsp;5 of the
consolidated financial statements.) The recognition of deferred
tax balances therefore involves judgment regarding
pSivida&#146;s future financial performance in which the
deferred tax asset is recognized. On this basis pSivida has not
achieved profitability and expects to continue to incur net
losses through to 2007. As pSivida does not expect BrachySil to
be widely marketed before then, no tax asset has been recognized.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Liquidity and Capital Resources</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Cash and cash equivalents totaled A$12.9&nbsp;million at
June&nbsp;30, 2005 compared to A$31.4&nbsp;million at
June&nbsp;30, 2004. pSivida has financed its operations
primarily through private placements of equity
</DIV>

<P align="center" style="font-size: 10pt;">33

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
securities, the exercise of options and share purchase plans. In
Australia, a share purchase plan is a limited offer to a
company&#146;s existing shareholders to acquire a limited number
of previously unissued ordinary shares with a maximum value of
A$5,000&nbsp;per shareholder at a discount of 12.5% to the
market value of pSivida&#146;s stock. Since December&nbsp;1,
2000, the date it commenced business as pSivida, pSivida has not
utilized borrowings and pSivida does not anticipate that
borrowings will be required in the short term, with the
exception of a convertible note entered into by pSivida on
November&nbsp;16, 2005. pSivida has no off-balance sheet
financing and pSivida expects that its current cash levels will
be sufficient to support current levels of research and
development until the second quarter of calendar year 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
However, pSivida may increase its level of research and
development activity which will directly increase its need for
cash reserves as research and development is pSivida&#146;s most
significant cost driver.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On April&nbsp;20, 2004, pSivida raised A$19.4&nbsp;million, net
of issue costs through a private placement of 19,375,000
ordinary shares to institutional and accredited investors at a
subscription price of US$0.80 and on April&nbsp;23, 2004, it
raised an additional A$6.2&nbsp;million net of issue costs
through a private placement of 5,625,000 ordinary shares to
institutional and accredited investors at a subscription price
of US$0.85.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On August&nbsp;23, 2005 pSivida raised US$4.2&nbsp;million
(A$5.6&nbsp;million) before costs via the private placement of
665,000 ADRs to predominantly US investors at US$6.50 (A$8.61)
each, pursuant to a PIPE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On November&nbsp;16, 2005 pSivida issued a convertible note to a
New York based institutional accredited investor, pursuant to
which the investor purchased US$15&nbsp;million
(A$19.7&nbsp;million) subordinated convertible debentures,
convertible into pSivida ADSs at an initial conversion price of
US$7.10 (A$9.50).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Net cash used in operating activities totaled
A$12.3&nbsp;million for the year ended June&nbsp;30, 2005
compared to A$7.8&nbsp;million for the year ended June&nbsp;30,
2004 and A$4.6&nbsp;million for the year ended June&nbsp;30,
2003. Research and development expenditure is the most
significant expenditure item resulting in increased cash flows
during the years ended June&nbsp;30, 2005, 2004 and 2003 and
amounted to A$8.3&nbsp;million, A$6.1&nbsp;million and
A$3.9&nbsp;million respectively. (Refer to &#147;pSivida&#146;s
Business&#148; for a detailed description of pSivida&#146;s
research and development activities). Payments to suppliers and
employees during the years ended June&nbsp;30, 2005, 2004 and
2003 were A$4.8&nbsp;million, A$2.0&nbsp;million and A$787,216,
respectively. The increase in payments from the year ended
June&nbsp;30, 2003 to the year ended June&nbsp;30, 2005
consisted of increased expenses relating to additional
administrative activities and the timing of cash payments
related to these activities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Net cash used in investing activities totaled A$8.1&nbsp;million
for the year ended June&nbsp;30, 2005 compared to A$527,168 for
the year ended June&nbsp;30, 2004 and A$51,948 for the year
ended June&nbsp;30, 2003 principally for the cash paid for the
acquisition of the remaining outside equity interest in
pSiMedica, the construction of a cleanroom facility in Germany
and the purchase of laboratory and computer equipment in
Malvern, United Kingdom and in Perth, Western Australia.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Net cash flows from financing activities totaled
A$3.6&nbsp;million for the year ended June&nbsp;30, 2005
compared to A$37.0&nbsp;million for the year ended June&nbsp;30,
2004 and A$852,567 for the year ended June&nbsp;30, 2003.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Cash flows from financing activities during the year ended
June&nbsp;30, 2005 reflected the following:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    During the year ended June&nbsp;30, 2005 pSivida raised
    A$3.6&nbsp;million on the issue of additional share capital upon
    the exercise of options previously issued. At various times
    during the year, a total of 13,070,000 options were exercised at
    a price of A$0.20, 2,200,000 options were exercised at a price
    of A$0.40, 150,000 were exercised at a price of A$0.50 and
    150,000 options were exercised at a price of A$0.65.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    During the year pSivida incurred $27,422 in issue costs in
    relation to the acquisition of the remaining outside equity
    interest in pSiMedica in August 2004.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">34

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Cash flows from financing activities during the year ended
June&nbsp;30, 2004 reflected the following:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    On August&nbsp;4, 2003, pSivida issued 3,891,572 ordinary shares
    at A$0.24&nbsp;per share, raising A$932,298&nbsp;net of issue
    costs. On October&nbsp;6, 2003, pSivida issued additional share
    capital through a placement of 13,000,000 ordinary shares at
    A$0.50&nbsp;per share to investors, raising A$6.2&nbsp;million
    net of issue costs;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    On April&nbsp;20, 2004, pSivida issued additional share capital
    through a placement of 19,375,000 ordinary shares at
    US$0.80&nbsp;per share to investors, raising A$19.4&nbsp;million
    net of issue costs, and on April&nbsp;23, 2004, pSivida raised
    an additional A$6.2&nbsp;million net of issue costs through the
    issue of additional share capital with a further placement of
    5,625,000 ordinary shares at US$0.85&nbsp;per share to investors;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    On October&nbsp;13, 2003, pSivida subscribed for additional
    share capital in pSiMedica, increasing its direct ownership by
    3.4% to 46.25% with indirect effective control over 53.05%. The
    consideration paid by pSivida in relation to this additional
    investment amounted to &#163;2&nbsp;million
    (A$4.84&nbsp;million). This transaction had no impact on the
    consolidated statement of cash flows. Additional equity
    contributions received by the subsidiary totaled
    A$2.6&nbsp;million;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    During the year a total of 8,130,000 options were exercised
    raising A$1.6&nbsp;million.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Cash flows from financing activities during the year ended
June&nbsp;30, 2003 reflected the following:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    On October&nbsp;14, 2002, pSivida issued additional share
    capital through a placement of 7,000,000 ordinary shares at
    A$0.12&nbsp;per share raising A$792,567&nbsp;net of issue
    costs;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    During the year a total of 300,000 options were exercised
    raising A$60,000.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Cash flows from financing activities during the year ended
June&nbsp;30, 2002 reflected the following:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    On November&nbsp;21, 2001, pSivida issued additional share
    capital through a placement of 12,300,000 ordinary shares at
    A$0.20&nbsp;per share to investors, raising A$2.3&nbsp;million
    net of issue costs;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    On March&nbsp;7, 2002, pSivida subscribed for additional shares
    issued by pSiMedica. This had the effect of increasing
    pSivida&#146;s direct percentage ownership by 2.3% to 42.85% and
    indirect effective control to 50.79%. The consideration paid by
    pSivida in relation to this additional investment amounted to
    &#163;1&nbsp;million (A$2.74&nbsp;million). This transaction had
    no impact on the consolidated statement of cash flows.
    Additional equity contributions received by the subsidiary
    totaled A$2.9&nbsp;million;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    On May&nbsp;9, 2002, pSivida issued 998,500 ordinary shares at
    A$0.22&nbsp;per share under a share purchase plan, raising
    A$209,357&nbsp;net of issue costs.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On September&nbsp;12, 2002, pSivida entered into an agreement
for a fully underwritten A$7.5&nbsp;million equity line of
credit with Global Emerging Markets, also known as GEM, a
New&nbsp;York based private equity group. A commitment fee
equivalent to 1.67% of the total value of the facility is
payable by pSivida to GEM on the proceeds of drawdowns. In
addition, GEM was issued options to acquire 2,000,000 of
pSivida&#146;s ordinary shares at A$0.20&nbsp;per share,
expiring on December&nbsp;31, 2004. These options were exercised
by GEM on February&nbsp;4, 2004. This agreement has now been
terminated and no drawdowns were made by pSivida on this
facility.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
From commencing business as a development stage enterprise to
June&nbsp;30, 2005, pSivida&#146;s capital expenditures have
totaled A$4.8&nbsp;million consisting of computer equipment and
laboratory equipment that is being used in connection with its
research and development activities undertaken in Malvern,
United Kingdom and administration in Perth, Western Australia.
Capital expenditures for plant and equipment and leasehold
improvements are being depreciated on a straight line basis over
the estimated useful lives of three years, with a net balance at
June&nbsp;30, 2005 of A$3,273,663. pSivida does not have
significant capital spending requirements, but expects to
continue to engage in capital spending consistent with
anticipated
</DIV>

<P align="center" style="font-size: 10pt;">35
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
growth in operations and personnel. Capital expenditure has been
funded largely through the private placement of ordinary share
capital.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida believes that pSivida&#146;s existing cash and cash
equivalents as well as anticipated cash flow from the exercise
of options will be sufficient to support its current operating
plan until the second quarter of calendar year 2007. However,
pSivida has based this expectation on assumptions that may prove
to be incorrect. pSivida&#146;s future funding requirements will
depend upon many factors, including, but not limited to:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Costs and timing of obtaining regulatory approvals;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    The costs and timing of obtaining, enforcing and defending
    pSivida&#146;s patent an intellectual property the progress and
    success of pre-clinical and clinical trials of BioSilicon;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    The costs and timings of CDS research programs in development;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    The timing and degree of sales activity leading to revenue on
    the sale of CDS marketed product;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    The progress and number of pSivida&#146;s research programs in
    development.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following table outlines pSivida&#146;s contractual
obligations as of June&nbsp;30, 2005 for payments under its
indebtedness (including capital leases), purchase obligations,
operating leases and other obligations and the effects such
obligations are expected to have on pSivida&#146;s liquidity and
cash flows in future periods:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="45%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap><B>Payments Due by Period</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Less than</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>1-</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>3-</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>More than</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Total</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>1&nbsp;Year</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>3&nbsp;Years</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>5&nbsp;Years</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>5&nbsp;Years</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap><B>(In thousands of Australian Dollars)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Contractual Obligations</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Long-Term Debt Obligations</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Capital (Finance) Lease Obligations</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Operating Lease Obligations</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>448</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>326</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>122</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Purchase Obligations</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other Long-Term Liabilities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Total</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>448</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>326</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>122</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">36

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Capitalization and
Indebtedness</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following table sets forth pSivida&#146;s unaudited actual
and as adjusted capitalization at September&nbsp;30, 2005. The
as adjusted column gives effect to the issuance of
16&nbsp;million pSivida ADSs (representing 160&nbsp;million
ordinary shares) in the merger, based on an assumed price of
US$6.76&nbsp;per share (taking into account the cash/stock
combination in the merger, and the relevance of additional
funding in the adjusted price) after deducting estimated merger
and other expenses payable by pSivida. The actual number of
pSivida ADSs issued, and the amount of cash paid, pursuant to
the merger may be more or less than that estimated and such
variation would affect portions of the as adjusted column of the
following table. Depending on the extent of such variation, the
effect on the as adjusted column could be material.
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="61%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>As of</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>September&nbsp;30, 2005</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Actual</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>As Adjusted</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>(In Australian Dollars)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Indebtedness</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 20px; text-indent: -10px">
    Long-term debt</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Total Debt</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Stockholders&#146; equity (deficit)</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 20px; text-indent: -10px">
    Contributed equity</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>113,661,678</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>255,968,888</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 20px; text-indent: -10px">
    Reserves</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(187,966</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>321,079</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 20px; text-indent: -10px">
    Deficit accumulated prior to development stage</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>


<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 20px; text-indent: -10px">
    Deficit accumulated during development stage</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(27,181,298</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(27,181,298</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>
<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Total stockholders&#146; equity</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>82,479,233</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>225,295,488</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Total capitalization in accordance with A-GAAP</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>82,479,233</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>225,295,488</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 2pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 2pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Dividend
Policy</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida currently intends to retain any future earnings to
finance the growth, development and expansion of its business.
Accordingly, it does not intend to declare or pay any dividends
on pSivida&#146;s ordinary shares for the foreseeable future.
The declaration, payment and amount of future dividends, if any,
will be at the sole discretion of pSivida&#146;s board of
directors after taking into account various factors, including
its financial condition, results of operations, cash flow from
operations, current and anticipated capital requirements and
expansion plans, the income tax laws then in effect and the
requirements of applicable corporate law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Psivida&#146;s
Business</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Overview</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida is a global nanotechnology company focused on the
development of BioSilicon, a novel porous form of nano-sized
silicon, for therapeutic and diagnostic use in healthcare.
BioSilicon is composed of elemental silicon, engineered to
create a &#147;honeycomb&#148; structure of pores. These pores
can be formed into a diverse array of shapes and sizes and can
be filled with various drugs, genes and proteins. pSivida is
working toward developing applications for controlled slow
release drug delivery and diagnostics. Initially, pSivida is
using BioSilicon to target primary liver cancer, but it intends
to investigate BioSilicon&#146;s use as a treatment for other
inoperable tumors such as pancreatic, secondary liver and tumors
within the peritoneum, brain and lung. pSivida is currently
conducting a Phase&nbsp;IIb dose optimization BioSilicon trial
in inoperable primary liver cancer patients at Singapore General
Hospital. Other potential applications for BioSilicon may
include tissue engineering, orthopedics and food science.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida is a public company limited by shares. The legal entity
that became pSivida was incorporated as the Sumich Group Ltd on
April&nbsp;28, 1987. The Sumich Group listed on the ASX on
September&nbsp;17,
</DIV>

<P align="center" style="font-size: 10pt;">37

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
1987 and operated an agriculture business which was placed into
administration or receivership on September&nbsp;30, 1998.
pSivida was subsequently formed on December&nbsp;1, 2000 upon
entering into a court-approved arrangement with Sumich
Group&#146;s creditors which fully extinguished all prior
liabilities as of that time. pSivida then appointed new
directors and officers and re-listed on the ASX under its new
name. pSivida was then recapitalized through a placement to
investors of 9,300,000 ordinary shares at A$0.30&nbsp;per share,
raising A$2.8&nbsp;million.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s ordinary shares are also listed on the Frankfurt,
Berlin, Munich and Stuttgart exchanges under the symbol
&#147;PSI.&#148; pSivida&#146;s ordinary shares also trade in
the United Kingdom on the OFEX International market Service
(IMS)&nbsp;under the symbol &#147;PSD.&#148;
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Strategy</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s commercialization strategy is to concentrate on
internal product development; the licensing of the BioSilicon
technology platform; and the potential sale of non-core
intellectual property.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Internal Product Development</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The focus of pSivida&#146;s internal product development is
BioSilicon drug delivery, with an initial emphasis on
brachytherapy products. Other potential BioSilicon drug delivery
products are localized chemotherapy, slow release drugs and the
delivery of generic drugs (commonly referred to as re-delivered
generics). pSivida has established detailed commercialization
plans for BrachySil, pSivida&#146;s lead product, bearing in
mind market sizes, benefits offered to patients and alternative
competitive therapies. The first step in pSivida&#146;s
commercialization strategy for BrachySil was a validation of
human safety and efficacy through human clinical trials, which
was completed in early 2005. Currently underway is
pSivida&#146;s Phase&nbsp;IIb dose optimization trial with the
first patients now having been treated in Singapore. It is
expected that these trials will be followed directly by
registration trials. pSivida also intends to open up dialogue
with the FDA, the EU regulatory authorities and government
regulators in various other jurisdictions in order to establish
that BrachySil may appropriately be regulated as a device rather
than as a drug. If BrachySil becomes registered as anticipated
in 2007, pSivida intends to investigate BrachySil&#146;s use as
a treatment for other inoperable tumors such as pancreatic,
metastatic ovarian and tumors within the peritoneum, brain and
lung.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Licensing of Core and Non-Core Intellectual
    Property</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida believes that potential range of applications for
BioSilicon will permit early stage licensing for non-core
applications such as biomaterial in orthopedics, tissue
engineering and regenerative medicine. Furthermore, the platform
has now been developed to a stage where licensing BioSilicon to
large pharmaceutical and biotech companies for delivery of their
patented drugs is being explored. For example, pSivida recently
entered a license agreement with Beijing Med-Pharm pursuant to
which Beijing Med-Pharm will be responsible for the clinical
development, marketing and distribution of BrachySil in China.
pSivida also intends to license diagnostic and sensor
applications of the BioSilicon platform technology developed by
its subsidiary, AION Diagnostics. In addition to licensing,
pSivida may also consider opportunities for collaborations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On October&nbsp;27, 2005 pSivida signed a license with Beijing
Med-Pharm Corporation (BJGP: PK) for the clinical development,
marketing and distribution of BrachySil, in China.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under the terms of the license, pSivida will manufacture
BrachySil and Beijing Med-Pharm will be responsible for clinical
development, securing regulatory approval, marketing and
distribution in China. pSivida will retain manufacturing rights
for BrachySil under the license. It is a condition of the
license that a manufacturing and supply agreement for pSivida to
supply BrachySil to Beijing Med-Pharm is concluded within
90&nbsp;days.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The license includes upfront and milestone payments in excess of
US$2&nbsp;million and royalties ranging up to 30%, depending
upon level of sales, payable to pSivida by Beijing Med-Pharm.
</DIV>

<P align="center" style="font-size: 10pt;">38

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Beijing Med-Pharm is a US-based company with Chinese
subsidiaries that offers an end-to-end solution to primarily
Western pharmaceutical companies who wish to sell their products
into the Chinese marketplace. In December 2004, Beijing
Med-Pharm initiated the first ever purchase of a Chinese
pharmaceutical distribution company by a foreign entity after it
signed an agreement to purchase Beijing Wanwei Pharmaceutical
Ltd., a pharmaceutical distributor covering the bulk of
Beijing&#146;s hospitals.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
BrachySil (32-P BioSilicon) will enter a Phase&nbsp;IIb
dose-profiling study shortly as a potential new treatment for
primary liver cancer (also called hepatocellular carcinoma or
HCC). China has the highest incidence of HCC in the world, with
over 345,000 estimated new cases per annum (Globocan),
representing 55% of total worldwide cases. Focused programs are
being prepared to seek to exploit its potentially broader
utility in other significant cancer indications, including
inoperable pancreatic and secondary liver disease.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Sale of Non-Core Applications</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida is also exploring sales of early stage non-core
applications. Such applications include biomaterial in
orthopedics, tissue engineering and regenerative medicine
producing.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>BioSilicon</I><SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant:SMALL-CAPS">tm</FONT></SUP></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
BioSilicon is composed of elemental silicon, one of the most
abundant elements on the earth&#146;s crust, which is engineered
to create a &#147;honeycomb&#148; structure of pores. These
pores can be formed into a diverse array of shapes and sizes and
can be filled with various drugs, genes and proteins. pSivida
believes that BioSilicon&#146;s features include:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Biocompatibility&nbsp;&#151; BioSilicon is biocompatible,
    meaning that it is not injurious and does not cause
    immunological rejection within the body. pSivida has assessed
    the biocompatibility of BioSilicon as follows:</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    BioSilicon wafers implanted in animals for a period of up to
    6&nbsp;months performed similarly to medical grade titanium, a
    well-known biocompatible material, in terms of biocompatibility.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Toxicology studies performed for pSivida by Quintiles
    Transnational and Huntingdon Life Sciences Group in the UK have
    shown that the maximum tolerated dose of BioSilicon is ten to
    one hundred times the dose expected to be used in pSivida&#146;s
    clinical trials in Singapore.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    To date, pSivida&#146;s human trials have produced no apparent
    product-related adverse events.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Non-toxicity&nbsp;&#151; pSivida&#146;s studies have shown that
    BioSilicon degrades in the body into silicic acid, the
    non-toxic, dietary form of silicon which is found in beer,
    cereal grains and wine. pSivida has undertaken both pre-clinical
    studies and clinical trials testing the toxicology of
    BioSilicon. pSivida&#146;s pre-clinical toxicology studies have
    demonstrated a minimum tolerated dose which is substantially in
    excess of the doses expected to be used in initial clinical
    applications. Also, comparative toxicology studies in animals
    comparing BioSilicon and titanium have shown no significant
    differences in toxicology.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Biodegradability&nbsp;&#151; pSivida believes that BioSilicon
    can be made biodegradable <I>in vivo </I>and <I>in&nbsp;vitro
    </I>(in animals and humans and in solution). The rate of
    biodegradation depends on the degree of nanostructuring that is
    imparted on the material. pSivida believes that, as a result,
    BioSilicon can be made to dissolve in suitable environments in
    days, weeks or months, depending upon the size and nature of the
    BioSilicon implanted. This has been demonstrated in various
    models:</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    BioSilicon has been shown to dissolve in synthetic body fluids
    such as serum, plasma and gastric juices.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    While a similar test has not been performed in humans,
    BioSilicon has been shown to dissolve when placed subcutaneously
    in guinea pigs.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pSivida has tested BioSilicon in a variety of buffered solutions
    (salty waters).</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">39

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Because of these qualities, BioSilicon has the potential to
serve as a biomedical device in or on the body. pSivida believes
that BioSilicon may have multiple potential applications in
healthcare. pSivida is currently working toward developing
applications for controlled slow release drug delivery and
diagnostics. It believes that other potential applications may
include tissue engineering, orthopedics and food science (food
sensors and nutraceutical products).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Core Markets</I></B>
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Brachytherapy</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Brachytherapy is a relatively new form of treatment for cancer
involving the localized delivery of radioactive agents directly
into a tumor. The market is currently dominated by the use of
radioactive &#145;seeds&#146; for the treatment of hormone
non-responsive prostate cancer. These are mainly used for the
treatment of prostate cancer and can cause trauma on
application. Current mainline brachytherapy implants are
relatively large, causing trauma and hemorrhaging in tumors.
Such seeds also carry comparatively long-range radio emitters
that cause normal tissue damage and other quality of life
problems to the patient. Other products in this area such as
Yttrium&nbsp;90 (Y90) ceramic spheres are not generally
administered directly into tumors but into the vasculature
feeding tumor-bearing organs such as the liver. The latter
approach causes a significant degree of healthy tissue damage.
These current therapeutic regimens have limited value for
inoperable liver cancer. Liver cancer is currently one of the
world&#146;s major causes of cancer-based mortality.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Drug Delivery</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The market for new drug delivery formulations is rapidly
growing. The value of the global drug delivery market is
currently in excess of US$66&nbsp;billion, and is estimated to
grow to US$114&nbsp;billion by 2007. Drug delivery has proved to
be a critical element in the drug development process, resulting
in enhanced safety and efficacy of many medicines. Improvement
of drug delivery is important for better patient safety and drug
bioavailability. Furthermore, the use of novel drug delivery
systems is an increasingly important strategy for major
pharmaceutical and biotechnology companies as they recognize the
benefits of forging relationships with drug delivery companies
to enable the delivery of new drugs and extend the commercial
life of their current drugs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><I>Core BioSilicon Applications</I></B>
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Brachytherapy</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Brachytherapy is a relatively new form of treatment for cancer
and involves the delivery of radioisotopes directly into the
tumor. With improved tumor location and mapping, this approach
to cancer therapy has grown substantially in recent years
allowing the physician/surgeon/radiologist to specifically
expose tumor tissue to radioisotopes in a targeted manner.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For brachytherapy treatment, pSivida believes BioSilicon has
many significant advantages:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Short range&nbsp;&#151; 32-P isotope has a short active range
    resulting in less damage to healthy tissue</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Range of tumors&nbsp;&#151; fine gauge needle delivery allows
    potential application to all solid tumors, unlike current
    brachytherapy products</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Direct delivery&nbsp;&#151; injection via fine gauge needle
    minimizes side effects and tissue trauma</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Inexpensive device&nbsp;&#151; low cost, abundant availability
    of silicon, with scale up proven</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Distribution&nbsp;&#151; 32-P half-life of 14&nbsp;days allows
    more convenient distribution to hospitals and application in the
    patient</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Immobilization&nbsp;&#151; 32-P device is immobilized in the
    tumor, significantly reducing risk of leakage or systemic side
    effects</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">40
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>BrachySil</I><B><SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant:SMALL-CAPS">tm</FONT></SUP></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
BrachySil, pSivida&#146;s lead product candidate, is a
brachytherapy product that pSivida believes has the potential to
significantly expand the current brachytherapy market size.
BrachySil consists of an injectable BioSilicon structure that
carries 32-phosphorus, or 32P, a radioactive isotope which has
been shown to shrink tumors. The isotope 32P emits beta or
electron radiation which has been shown to be effective at
shrinking tumors. However, this radiation is harmful to healthy
tissue. Therefore, the 32P and its radiation must be confined to
the area of the tumor and not allowed to travel within the body.
Existing 32P-based products do not fully immobilize 32P,
allowing the isotope to dissolve, enter the bloodstream and harm
healthy tissue in other parts of the body. pSivida has
engineered BrachySil to ensure that the 32P is unable to escape
the BioSilicon particle. Therefore, the 32P is in effect
&#147;locked&#148; into BrachySil by producing an amalgam of
phosphorus and silicon. The BrachySil treatment is delivered,
without surgery, via injection through the abdomen using a fine
gauge needle, allowing the clinician to administer a single dose
of BrachySil directly into the tumor site. BrachySil offers
interventional radiologists a short-range longer life isotope
that can be delivered through a fine bore needle making it a
more user friendly and precise product for both patient and
physician.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida is developing products in this growing area through its
wholly-owned, Singapore-based subsidiary pSiOncology in
conjunction with Singapore General Hospital. pSiOncology is also
developing localized chemotherapy products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Phase&nbsp;IIb clinical trials commenced with BrachySil (32-P
BioSilicon) as a potential new brachytherapy treatment for
inoperable primary liver cancer (hepatocellular carcinoma, HCC).
The first patient has successfully received treatment at
Singapore General Hospital using a new fine-gauge needle
multi-injection device which will enable for the first time,
larger and also multiple tumors to be treated. A total of
50&nbsp;patients will be entered into this multi-centre trial
which will be conducted in Singapore, Malaysia and Vietnam.
BrachySil trials for pancreatic cancer are expected to commence
in the first quarter of 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The study, which was designed in collaboration with Singapore
General Hospital and approved by the Singaporean regulatory
authority (Health Sciences Authority) will determine the optimal
dose of BrachySil in treating inoperable HCC. Patients will be
evaluated up to 12&nbsp;months after treatment, and the
endpoints are based on evaluations of patient safety and target
tumor responses, as well as overall survival.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The study is intended to provide pivotal efficacy and safety
data to support future product registration and approval of
BrachySil as an effective treatment for primary liver cancer.
These results are expected to build on the findings of a
Phase&nbsp;IIa study concluded earlier this year on patients
with advanced liver cancer. In this trial, which was also
conducted at Singapore General Hospital, BrachySil was found to
be both safe and well tolerated. It was also found to reduce
significantly the size of some tumors treated even on a lower
dose as used in the earlier trials.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In addition, the Phase&nbsp;IIb trial will include a clinical
evaluation of pSivida&#146;s proprietary
SIMPL<SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant:SMALL-CAPS">tm</FONT></SUP>
implantation system.
SIMPL<SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant:SMALL-CAPS">tm</FONT></SUP>
is a fine-gauge needle, multi-injection device, through which
BrachySil is injected as a liquid suspension directly into
tumors under local anesthetic. The device has been designed to
distribute the implanted dose from a single entry point and to
enable physicians to treat larger tumors. This device is
expected to be a further significant advantage of BrachySil over
existing brachytherapies as well as assist in expanding the
application of BrachySil to other solid tumor cancers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Assuming that trials are successful and an optimal dose is
established, pSivida intends to undertake larger multi-center
clinical trials involving patients in both Asia and Europe to
produce data sufficient to register BrachySil for use as an
approved treatment for primary liver cancer. pSivida expects
completion of its optimization dose study during early 2006,
followed by initiation of regulatory studies, thus registration
could potentially be completed in mid 2007. Following
BrachySil&#146;s registration, pSivida anticipates rapid
adoption of the treatment because it is delivered by means of a
fine gauge direct needle without surgery under local anesthetic
and patients are able to be discharged the following day. If
BrachySil becomes registered as anticipated in 2007, pSivida
intends to investigate BrachySil&#146;s use as a treatment for
other
</DIV>

<P align="center" style="font-size: 10pt;">41
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
inoperable tumors such as pancreatic, metastatic ovarian and
tumors within the peritoneum, brain and lung. pSivida believes
that such approvals may expand the market for brachytherapy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During late 2005, pSivida also intends to open up dialogue with
the FDA in order to establish that BrachySil may appropriately
be regulated as a device rather than as a drug. pSivida is
pursuing a similar strategy with respect to EU regulatory
authorities to qualify for device registration in Europe under
the auspices of a CE mark application. Generally speaking,
obtaining regulatory approval to market a medical device is much
less expensive and time consuming than the process required for
a drug. pSivida also intends to consult with government
regulators in various other jurisdictions to promote this
strategy.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Drug Delivery</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida is also strongly focused on the application of
BioSilicon technology to a controlled, slow release drug
delivery product. pSivida intends to achieve this through the
development of pSivida&#146;s own products such as BrachySil;
the delivery of generic or &#147;off patent&#148; drugs
utilizing new delivery methods comprised of BioSilicon; and
licensing the use of BioSilicon to pharmaceutical companies for
delivery of their patented drugs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following properties make BioSilicon a potentially effective
drug delivery platform:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    high drug loading rates (up to 95.0%);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    ability to control release timing (hours/days/weeks/months);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    ability to vary pore size to accommodate different drug sizes;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    ability to serve as a conductor of electrical charge which can
    be altered to regulate drug delivery rate;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    potential incorporation of diagnostics and delivery intelligence.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
BioSilicon functions as a &#147;honeycomb&#148; structure to
retain drugs within the &#145;cells&#146; within the nanometer
scale structure. In contrast, many polymers cause toxicity and
inflammation and can actually chemically react with the
pharmaceutical being delivered. BioSilicon&#146;s
biodegradability and solubility can be finely tuned without
changing the chemical nature of the material itself. Thus,
unlike polymer-based systems, BioSilicon&#146;s composition is
identical for all potential products whether they are implants
for drug delivery or biodegradable orthopedic devices (pins,
screws, braces, etc.). The only characteristic that is varied is
the level of engineering and shape of the silicon device.
Computer model systems have shown that the rate at which the
BioSilicon structure degrades in the body can be precisely
regulated in order to release a drug over a period of time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida also plans to develop &#147;smart&#148; drug delivery
devices making use of the semi-conductor properties of silicon.
BioSilicon can potentially perform in the same manner as a
silicon chip, thus providing the opportunity to marry the
electronic potential of the material with healthcare
applications. Utilizing these properties may enable processors,
sensors and telemetry to be incorporated into a biodegradable
drug delivery structure. This combination may provide for a more
powerful delivery system than conventional polymer-based systems
which must rely on their natural rate of biodegradation. With a
biodegradable BioSilicon chip, the drug release might be made
&#145;intelligent&#146; through microprocessor control.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida has an agreement with an undisclosed top 5 global
pharmaceutical company for the staged evaluation of BioSilicon
for drug delivery. The agreement covers the evaluation of
BioSilicon for the controlled release of a number of selected
compounds. The pharmaceutical company will fund the direct costs
of the program.
</DIV>

<P align="center" style="font-size: 10pt;">42

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><I>Non-Core Applications</I></B>
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Diagnostics</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida recently incorporated AION Diagnostics in Australia to
develop diagnostic applications for BioSilicon. pSivida intends
to license diagnostic and sensor applications of the BioSilicon
platform technology.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Through AION Diagnostics, pSivida seeks to develop diagnostic
applications using the biodegradable, optical, semiconductor and
micro machining properties of BioSilicon. AION Diagnostics will
look to develop products through strategic collaborations with
universities, research institutions and industry partners. AION
Diagnostics will also seek grant funding in Australia and the
United States. Research currently being undertaken is at a
preliminary stage only and there is no guarantee that BioSilicon
will ultimately be used in the commercialization of a product in
this area.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida has assigned to AION Diagnostics its licensing agreement
with Forschungszentrum J&#252;lich for the use of its porous
silicon optical mirror technology. Forschungszentrum J&#252;lich
is a science and engineering research institution funded jointly
by the Federal Republic of Germany and the State of Nordrhein
Westfalen.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Orthopedics</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida believes that BioSilicon also has potential to be used
as a biodegradable scaffold for orthopedic tissue engineering. A
porous silicon structure could be deliberately sculpted to
provide bone-building cells with a scaffold that the cells can
penetrate and to which cells can anchor. As the bone tissue
deposits itself onto the scaffold, the silicon would slowly
dissolve away, eventually leaving just the new bone.
Silicon&#146;s ability to carry an electrical current charge
bias may also give BioSilicon an advantage in the treatment of
bone conditions, promote bone growth and may have other
orthopedic applications. Data gathered to date in preclinical
studies indicate that cells will grow and divide in BioSilicon
substrates and that BioSilicon can be osteo-conductive,
promoting bone growth and deposition. In July 2003, pSiMedica
entered into a shared revenue agreement with Texas Christian
University , for which Texas Christian University will receive
10.0% of patent royalties for any joint intellectual property
developed in the areas of tissue engineering and orthopedic
applications. Research being undertaken in the orthopedics field
is still at a preliminary stage, and there is no guarantee that
BioSilicon will ultimately lead to a commercializable product in
this area.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Tissue Engineering</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida believes that BioSilicon also has potential uses in
tissue engineering as a biodegradable scaffold or framework.
U.S.-based Cytomatrix is evaluating BioSilicon for the expansion
of stem cells for the treatment of a variety of diseases.
Singapore General Hospital is assessing the use of BioSilicon as
a scaffold to assist the growth of tissue cells for applications
in areas such as craniofacial and reconstructive surgery. The
McComb Foundation, an Australian company, together with its
commercialization partner, Clinical Cell Culture, Ltd., is
evaluating the use of BioSilicon as a scaffold to assist in the
growth of various cells for application in future tissue
engineering products including in the wound healing and burns
area. Depending on results and compatibility with Clinical Cell
Culture&#146;s products, Clinical Cell Culture will have the
right to commercialize products combining its proprietary
technology with BioSilicon. pSivida is also examining the use of
growth and disease inhibiting factors within the BioSilicon
scaffold to assist with tissue regeneration. pSivida is also
active in the area of wound management products, including
research into the development of potentially novel biodegradable
sutures. All of these research initiatives involving the use of
BioSilicon in the area of tissue engineering are at a
preliminary stage only and there is no guarantee that BioSilicon
will ultimately be used in the commercialization of any products
in this area.
</DIV>

<P align="center" style="font-size: 10pt;">43

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Food Technology</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida has entered into an agreement with ITOCHU Corporation to
explore the development and commercialization of new ingestible
BioSilicon products in the rapidly growing area of food
technology. ITOCHU is a large multinational corporation
headquartered in Japan with considerable experience in the food
industry and interests ranging from technology development and
production through to distribution and retail. Further
international collaborations and licensing opportunities are
anticipated in the food industry. pSivida&#146;s research in the
area of food technology is at a preliminary stage only and there
is no guarantee that BioSilicon will ultimately be used in the
commercialization of a product in this area.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Subsidiary Companies</I></B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>pSiMedica</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In December 2000, pSivida co-founded pSiMedica Ltd, a company
incorporated in the United Kingdom. pSiMedica was formed with
QinetiQ Group plc and several individuals and privately held
investment companies. pSivida invested A$1.0&nbsp;million to
acquire an 11.1% interest in pSiMedica. QinetiQ, which was
formerly part of the Defense Evaluation and Research Agency, or
DERA, an agency of the government of the UK, is currently one of
Europe&#146;s largest science and technology solutions
companies. QinetiQ remains 56.0% owned by the UK Ministry of
Defense on behalf of the Government of the United Kingdom, but
has sold interests of 30.5% to the Carlyle Group, one of the
world&#146;s leading private equity firms, and 13.0% to
QinetiQ&#146;s employees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Further significant events in pSiMedica&#146;s history are as
follows:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    In May 2001, pSivida increased its ownership in pSiMedica from
    11.1% to 40.1% by acquiring 28.9% of pSiMedica&#146;s
    outstanding ordinary shares from other minority shareholders.
    This acquisition of shares in pSiMedica was made in
    consideration for A$1.8&nbsp;million in cash and the issuance of
    10,918,535 of pSivida&#146;s ordinary shares at a value of
    A$0.30&nbsp;per share, or a total consideration value of
    A$5.1&nbsp;million. At the same time, pSivida also received
    powers of attorney over the pSiMedica shareholdings of Viaticus
    Capital Pty Ltd, representing 1.5%; Mr.&nbsp;Sam Giacomo,
    representing 1.4%; Mr.&nbsp;David McAuliffe, representing 1.4%;
    and Dr.&nbsp;Aston, representing 7.0%. These transactions
    resulted in pSivida&#146;s holding an indirect 51.4% controlling
    interest in pSiMedica, and thereafter, pSivida began to
    consolidate pSiMedica in pSivida&#146;s consolidated financial
    statements.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    On March&nbsp;7, 2002, pSivida subscribed for additional shares
    issued by pSiMedica. This had the effect of increasing
    pSivida&#146;s direct percentage ownership by 2.8% to 42.9% and
    indirect effective control to 50.8%. The consideration paid by
    pSivida in relation to this additional investment amounted to
    &#163;1&nbsp;million (approximately A$2.7&nbsp;million). This
    investment was required to fund continued research and
    development by pSiMedica.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    On October&nbsp;13, 2003, pSivida again subscribed for
    additional convertible preference share capital in pSiMedica,
    increasing pSivida&#146;s direct ownership by 3.4% to 46.3% with
    indirect effective control over 53.1%. The consideration paid by
    pSivida in relation to this additional investment amounted to
    &#163;2.0&nbsp;million (approximately A$4.8&nbsp;million). This
    investment was required to fund continued research and
    development by pSiMedica.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    On August&nbsp;4, 2004, pSivida acquired the remaining shares in
    pSiMedica that it did not already own. The consideration paid
    was $59,224,568 which comprised of $4,323,622 in cash, a total
    of 49,804,381 ordinary shares of pSivida issued at a value of
    $1.09 for A-GAAP purposes, 638,537 pSivida options with an
    estimated fair value of $292,828 (issued to employees of
    pSiMedica in exchange for their rights being waived in relation
    to options previously issued by pSiMedica) and direct
    acquisition costs totalling $321,342. As a result of this
    transaction QinetiQ became pSivida&#146;s largest shareholder
    holding 17.5% of its issued capital at that time.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">44

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>pSiOncology</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On July&nbsp;24, 2002, pSiOncology Pte Ltd. was formed in
Singapore by pSiMedica, Singapore General Hospital and Biotech
Research Ventures Pte Ltd to develop BioSilicon brachytherapy
products for the treatment of operable and inoperable cancer
tumors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In May 2004, the minority shareholders in pSiOncology, Singapore
General Hospital Technology Ventures Pte Ltd and Biotech
Research Ventures Pte Ltd, exchanged their pSiOncology shares
for newly issued shares in pSiMedica. Since that time, pSiMedica
has been the holder of 100.0% of the issued share capital of
pSiOncology.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>AION Diagnostics</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On August&nbsp;24, 2004, pSivida incorporated AION Diagnostics
Limited in Australia to develop and commercialize diagnostic
applications of BioSilicon. pSivida has licensed diagnostic and
sensor applications of the BioSilicon platform technology to
AION Diagnostics. pSivida capitalized AION Diagnostics with
A$1.2&nbsp;million. In addition, zero exercise price options
have been created over 20.0% of the fully diluted issued capital
to be awarded to directors, staff and consultants of AION
Diagnostics, subject to the achievement of milestones. By
exploiting both the biocompatible and biodegradable properties
of BioSilicon, AION Diagnostics will be seeking to commercialize
diagnostic products that will provide real time continuous
measurement of important diagnostic markers. The move to spin
out AION Diagnostics will enable a separate team to focus on
leveraging the technological opportunities in BioSilicon to
develop and commercialize a diagnostics product portfolio, while
pSivida and its staff remain focused on the core areas of slow
release drug delivery and brachytherapy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Both QinetiQ and pSivida act as strategic partners of AION
Diagnostics as AION Diagnostics looks to develop products
through strategic collaborations with universities, research
institutions and industry partners and seeks grant funding in
Australia and the U.S.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Collaborations</I></B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>QinetiQ</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In connection with the organization of pSivida and pSiMedica, in
December 2000, pSiMedica entered into a technology license
agreement with the Defense Evaluation and Research Agency, or
DERA, an instrumentality of the UK government. The technology
license gave pSiMedica the right to use intellectual property
associated with BioSilicon to develop, manufacture and sell
products for uses on or in the human and animal body. The
intellectual property included patents, patent applications,
various research reports, trademarks, know-how and other
materials. The license was granted on a worldwide, royalty free
basis in exchange for shares in pSiMedica. DERA retained the
right to use the intellectual property in connection with
defense-related, noncommercial purposes. The license provided
that DERA would later assign the intellectual property outright
upon the fulfillment of certain conditions, including pSiMedica
successfully raising additional funds.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In March 2002, subsequent to pSivida&#146;s making an additional
investment in pSiMedica funded by its November 2001 placement of
ordinary shares, pSiMedica entered into an assignment agreement
with QinetiQ. Pursuant to the assignment agreement, QinetiQ, the
successor to DERA&#146;s rights to the intellectual property,
assigned the outright ownership of the intellectual property to
pSiMedica with QinetiQ retain only the right to sublicense the
intellectual property to DERA for noncommercial, defense-related
uses and, subject to reasonable terms, in connection with
purposes outside of pSiMedica&#146;s original field of use.
pSiMedica gave only nominal consideration for assignment, as the
obligation to assign the intellectual property was pursuant to
the earlier license agreement. Pursuant to the assignment
agreement, pSiMedica became the owner of all the relevant
patents, patent applications, research reports, trademarks,
know-how and other materials associated with BioSilicon.
</DIV>

<P align="center" style="font-size: 10pt;">45

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Singapore General Hospital</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During July 2002, pSiMedica entered into an agreement with
Singapore General Hospital related to the incorporation of
pSiOncology Pte Ltd., now an indirect wholly-owned subsidiary of
pSivida and a direct wholly-owned subsidiary of pSiMedica. The
agreement involves the licensing of intellectual property
pertaining to BioSilicon from pSiMedica to explore its potential
as a platform for brachytherapy. During May 2004 pSiMedica
issued shares to Singapore General Hospital in exchange for the
outside equity interest in pSiOncology Pte Ltd and subsequently
as a result of the transaction whereby pSivida acquired the
outside equity interest in pSiMedica, Singapore General Hospital
exchanged its pSiMedica shares for pSivida ordinary shares.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>AEA Technology QSA GmbH</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During March 2004 pSiMedica entered into a three year agreement
with AEA Technology QSA GmbH for the construction of a facility
for the production and manufacture of radioactive 32P-BioSilicon
nano-structured micro particles to meet pSiMedica&#146;s
commercial supply requirements. This facility was completed in
September 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s broader commercialization strategy involves a
high degree of partnering at various levels to lower the costs
to pSivida of the development process. The research and
development process is conducted and coordinated through
pSiMedica as well as through collaborative partnerships. pSivida
anticipates licensing and assigning rights pertaining to
non-core applications, providing pSivida with cash flow and
allowing pSivida to focus on commercialization of core products
strategy. While continuing to develop pSivida&#146;s existing
collaborative partnerships pSivida entered into eight new
arrangements during 2004 and 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Descriptions of several of pSivida&#146;s main collaborations
are included below. pSivida has entered into written agreements
with each of the identified third parties. These agreements
provide for the study and evaluation of potential uses for
BioSilicon in conjunction such third party&#146;s products and
inventions. To date, no specific products have been identified
or marketed pursuant to these collaborations, and in each case
research being undertaken is at a preliminary stage only and
there is no guarantee that BioSilicon will ultimately be used in
the commercialization of a product in the area of the
collaboration. In most instances, the collaboration agreement
provides that pSivida will retain the rights to any discoveries
relating to BioSilicon and the third party will retain the right
to discoveries relating to its product. Where discoveries
involve a combination of both products, generally any rights or
intellectual property arising as a result of that combination
will be shared equally, with the third party having the right to
market the combination product. In connection with
collaborations with universities, pSivida retains the right to
market and commercialize all discoveries, and in some instances,
the university will be granted the right to receive a royalty.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Top Five Global Pharma</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The evaluation of selected compounds from an undisclosed top
five global pharmaceutical company has progressed successfully.
The collaboration agreement covers a staged evaluation of the
pharmaceutical company&#146;s proprietary compounds in
pSivida&#146;s porous silicon, controlled release platform
(BioSilicon). The initial stage of the planned 12&nbsp;month
program has concluded, meeting the agreed technical success
criteria, and in turn triggering the next payment to pSivida
under the terms of the agreement.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>ITOCHU Corporation&nbsp;&#151; Japan, Asia and Food
    Technology</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A non-exclusive agreement was signed with ITOCHU Corporation for
the development and commercialization of BioSilicon in Japan and
Asia and food applications. ITOCHU, one of the world&#146;s
largest corporations is engaged in development of commercial
opportunities and products for BioSilicon in Japan and other
significant markets in Asia. ITOCHU also has significant
experience and expertise in the food industry and is engaged in
the development and commercialization of new products utilizing
BioSilicon technology in the rapidly growing area of food
technology and nutraceuticals.
</DIV>

<P align="center" style="font-size: 10pt;">46

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Cirrus Pharmaceuticals</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida recently entered into a contract with U.S.-based Cirrus
Pharmaceuticals, Inc., an independent R&#38;D organization based
in Research Triangle Park, North Carolina, to accelerate and
expand development of a number of specific drug candidates
formulated in BioSilicon to expand a BioSilicon product pipeline
of reformulated drugs. The development contract has an initial
extendable term of one year and provides a dedicated team of
scientists from Cirrus Pharmaceuticals. The relationship has
been established to seek to generate new products based on
reformulating existing specific generic and proprietary drugs
and their delivery utilizing BioSilicon. To the extent that such
new reformulations or delivery demonstrate improved efficacy,
safety and/or compliance as compared to the original product,
then pSivida will be able to claim patent protection on its new
products. All intellectual property developed through this
collaboration relating to BioSilicon will be wholly-owned by
pSivida.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>EPITAN&nbsp;&#151; Completion of Proof of Concept Study</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida has entered into an agreement with the Institute of
Medical and Veterinary Science in Adelaide, South Australia,
pursuant to which an in vivo study was conducted that indicated
that a single injection of pSivida&#146;s porous BioSilicon
technology successfully released
MELANOTAN<SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant:SMALL-CAPS">tm</FONT></SUP>
over a sustained period. The outcome of this collaboration may
lead to a second-generation liquid-based injectable
MELANOTAN<SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant:SMALL-CAPS">tm</FONT></SUP>
product.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Forschungszentrum&nbsp;&#151; Porous Silicon Mirror
    Technology</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s subsidiary, AION Diagnostics, entered into a
licensing agreement with Forschungszentrum Julich GmbH, part of
Germany&#146;s largest research institute, to acquire rights in
the use of Forschungszentrum&#146;s porous silicon mirror
technology. Combining this technology with its recently acquired
BioSilicon diagnostics platform, AION Diagnostics intends to
examine the development of BioSilicon optical mirrors as an in
vivo diagnostic device, with the ability to provide early
diagnosis and continual monitoring of patients.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Flinders University/ ARC Grant</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida together with the Flinders University of South Australia
was awarded an ARC Industry Linkage Grant. Flinders University
plans to develop a novel ophthalmic bioimplant from BioSilicon.
The project is intended to result in biomaterials for the
treatment of blinding diseases of the eye. Implanted into the
limbus, bioimplants may ameliorate some common corneal diseases.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>University of South Australia&nbsp;&#151; Evaluation of
    Protein&nbsp;&#38; Peptide Delivery</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida entered into a research and development collaboration
with the University of South Australia to evaluate the potential
of the BioSilicon platform for the delivery of protein and
peptide-based therapeutics (or biopharmaceuticals) including
antibodies, hormones and growth factors that account for a
substantial and increasing segment of the pharmaceutical market.
Preliminary investigations using BioSilicon have indicated its
utility for the delivery of biopharmaceuticals, including its
potential for the development of new controlled release
formulations of existing marketed therapeutics.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>University of Pittsburgh (U.S.)&nbsp;&#151; DNA vaccine
    delivery</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s collaboration with the University of Pittsburgh
is exploring the use of BioSilicon in binding and protecting DNA
during vaccine therapy in model systems. pSiMedica has developed
the technology to load and release DNA from BioSilicon matrices
resulting in effective production of immunogen (the antigen for
which the DNA codes). The ability to load and protect DNA during
vaccine regimens is vital to the production of DNA vaccine
products.
</DIV>

<P align="center" style="font-size: 10pt;">47

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>McComb Foundation/ Clinical Cell Culture Ltd
    (Australia)&nbsp;&#151; tissue engineering products</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The McComb Foundation is a research organization established in
1999 to conduct research into tissue engineering. Clinical Cell
Culture, an ASX listed biomedical company, is the McComb
Foundation&#146;s commercialization partner which develops and
distributes tissue-engineered cellular products for autologous
skin replacement. Clinical Cell Culture&#146;s products are
based in part on technologies licensed from the McComb
Foundation. The McComb Foundation and Clinical Cell Culture are
evaluating the use of BioSilicon as a scaffold device to assist
in the growth of various cells for application in future tissue
engineering products including in the wound healing and burns
area. Depending on results and compatibility with Clinical Cell
Culture&#146;s products, Clinical Cell Culture will have the
right to commercialize products combining its proprietary
technology with BioSilicon. The collaboration agreement was
entered into in August 2003.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Singapore General Hospital (Singapore)&nbsp;&#151; tissue
    engineering</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In addition to Singapore General Hospital&#146;s work with
BrachySil, other research programs being conducted at SGH&#146;s
Department of Plastic Surgery are assessing the use of
BioSilicon as a scaffold to assist in the growth of tissue cells
for applications in areas such as craniofacial and
reconstructive surgery.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><I>Manufacturing</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida currently acquires BioSilicon from QinetiQ in the UK for
use in internal and collaborative research. pSivida&#146;s lead
product, BrachySil, is currently manufactured in accordance with
FDA guidelines by Hosokawa Micron Group, Atomising Systems Ltd,
HighForce Ltd and AEA Technology QSA GmbH. pSivida requires that
BrachySil be manufactured in accordance with FDA guidelines
because, in the U.S., the FDA regulates the manufacturing
processes used to produce products such as pSivida&#146;s, and
the U.S.&nbsp;is the largest market into which pSivida hopes to
be able to market BrachySil in the future. pSivida intends to
apply to the FDA to market BrachySil in the U.S., which will
require FDA certification of pSivida&#146;s compliance with its
regulations., pSivida believes that its experience in
manufacturing in compliance with FDA guidelines should
facilitate the application process. To date, pSivida has not
sought nor has pSivida received approval from the FDA of its
manufacturing processes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
BioSilicon is manufactured through the controlled
nano-structuring of elemental silicon. This process consists of
the acid etching of elemental silicon which results in the
creation of interconnected nanowire structures that resemble a
honeycomb. This structure allows elemental silicon to become
biodegradable while also allowing the retention of therapeutic
substances within the honeycomb matrix. In order to produce
suitable drug delivery devices, pSivida has sought to engineer
products that fulfill particular clinical requirements. For
example, in order to administer therapies using fine bore
needles of 18 gauge or smaller, the delivery device must be no
larger than 1.2 millimeters in diameter. The manufacture of
BrachySil requires several steps. These steps include:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    The production of a fine powder of silicon;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Measurement and separation of suitably-sized silicon particles
    for clinical application;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Acid etching to produce biodegradable silicon particles;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Phosphorus coating and neutron transmutation to produce
    particles coated with 32P.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In order to achieve the four steps above, pSivida has sought to
contract with four separate companies, each an expert in one of
the above manufacturing processes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida has developed BioSilicon production capability at
pSivida&#146;s own facilities in the UK.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During March 2004 pSiMedica entered into a three year agreement
with AEA Technology QSA for the construction of a facility for
the production and manufacture of radioactive 32P-BioSilicon
nano-structured microparticles to meet pSiMedica&#146;s
commercial supply requirements. This facility was completed in
September 2005.
</DIV>

<P align="center" style="font-size: 10pt;">48

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><I>Intellectual Property</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida believes that it enjoys a strong intellectual property
position, with core biomaterial patents granted in the valuable
United States and European markets. pSivida owns all
intellectual property rights in relation to BioSilicon for which
there are as at September 2005, 34 granted patents, 29 patent
families and over 80 patent applications. The core patent, which
recognizes BioSilicon as a biomaterial, was granted in the
United Kingdom in 2000 and the United States in 2001.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Product candidates and component materials protected by patents
and patent applications owned by pSiMedica include materials
comprising bioactive, resorbable and biocompatible silicon that
are of value in the fabrication of new generations of
intelligent drug delivery devices, orthopedic implants and
intelligent diagnostic tools.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In December 2000, QinetiQ granted pSiMedica an exclusive,
worldwide, royalty free license to the BioSilicon technology in
the field of human and animal healthcare and diagnostic
applications on or in the body. This license includes rights of
first refusal over technologies developed by QinetiQ related to
this field. QinetiQ was granted 41.7% of the issued share
capital on the founding of pSiMedica in exchange for this
license. In March 2002, after pSivida achieved certain
milestones, including the successful completion of its second
round funding and the investment of an additional one million
pounds in pSiMedica, the license from QinetiQ was converted into
an assignment of such rights, including ownership of patents and
other intellectual property. On August&nbsp;4, 2004 pSivida
acquired the remaining shares QinetiQ held in pSiMedica. The
consideration paid was A$4.3&nbsp;million together with a total
of 49,804,381 ordinary shares of pSivida issued at a value of
A$1.09&nbsp;per share.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s patent portfolio currently consists of 24 granted
patents and 82 patent applications relating to the use of
BioSilicon on or in the body. All intellectual property rights
for BioSilicon are owned royalty free. pSiMedica holds granted
patents that cover the broad use of BioSilicon in healthcare
applications and patents that relate more specifically to
pSivida&#146;s core focus of specialized drug delivery, targeted
internal cancer therapy and diagnostics. The core patent, which
recognizes BioSilicon as a biomaterial, was granted in the UK in
2000 and in the U.S.&nbsp;in 2001.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Potential products protected by patents and patent applications
owned by pSiMedica include materials comprising bioactive,
resorbable and biocompatible silicon that are of value in the
fabrication of new generations of intelligent drug delivery
devices, orthopedic implants and intelligent diagnostic tools.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida currently has 34 granted patents, together with one
application that has been accepted, and which should be granted
within the next few months.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following table provides general details relating to
pSivida&#146;s patents and patent applications; it is based on
information available on September&nbsp;21, 2005.
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 9pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="43%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Priority</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="center" nowrap><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>Status</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>Subject Matter</B></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    9515956.2</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    National applications (EP, JP, CA, KR1)<BR>
     <B>Granted (GB1, GB2, US1, US2, KR2)<BR>
    </B>Divisional (US3)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to resorbable, bioactive, and biocompatible
    forms of silicon. Further claims relate to electronic devices
    and composites comprising bioactive silicon.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    9808052.6</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    National applications (CA, JP, KR, US)<BR>
     <B>Granted (AU, NZ, EP1, CN1)<BR>
    </B>Divisional (EP2, CN2)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to resorbable and biocompatible silicon
    implants for the delivery of beneficial substances to animals or
    humans.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    9815819.9</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    National applications (CA, CN, HK, JP,&nbsp;KR)<BR>
     <B>Granted (US1, AU1, AU2, EP1, NZ)<BR>
     </B>Divisionals (US2, EP3)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to the transfer of material (such as, but not
    limited to, genetic material) into cells using porous or
    polycrystalline silicon. The claims also specifically relate to
    biolistic (also known as microprojectile) delivery.</TD>
</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">49

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 9pt; ">

<TR style="font-size: 1pt;">
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="43%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Priority</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="center" nowrap><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>Status</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>Subject Matter</B></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    9909996.2</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    National applications (CA, CN, JP, KR,&nbsp;US)<BR>
     <B>Granted (AU, EP, NZ)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to the use of derivatised porous silicon as a
    biomaterial and to devices, including electronic devices,
    comprising derivatised porous silicon.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    9924334.7</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    National applications (CA, JP, US)<BR>
     <B>Granted (SG, AU, EP)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to orally administrable pharmaceutical
    products, including products comprising electronic circuitry,
    comprising porous or polycrystalline silicon.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    9928511.6</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    National applications (CA, JP, US)<BR>
     <B>Granted (EP, NZ, AU, SG)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to an invention which is of value in the
    treatment of patients that have taken an overdose.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    9929521.4</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    National applications (CA, EP, JP, SG)<BR>
     <B>Granted (NZ, AU, US1)<BR>
     </B>Divisional (US2)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to a method of fabricating hermetically sealed
    silicon capsules suitable for drug delivery, and for the
    packaging of electronic implants.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0008494.7</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    National applications (EU, JP)<BR>
     <B>Granted (US) or shape)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to substantially monodispersed (having the
    same size porous silicon particles.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0014079.8</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    National applications (US, JP, SG, EP)<BR>
     <B>Granted (AU1) Divisional (AU2)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to a silicon composite material, suitable for
    use in bone repair and bone replacement, comprising silicon and
    a carrier material.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0020276.2</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    National applications (US, CA, JP)<BR>
     <B>Granted (EP, NZ, AU)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to dermatological compositions comprising
    porous and/or polycrystalline silicon.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0104383.5</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    National applications (US, AU, CA, JP, EP,&nbsp;SG)<BR>
     <B>Granted (NZ, SGW)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to products comprising silicon for the
    treatment of cancer.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0118689.9</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    National applications (US, AU, CA, JP, EP,&nbsp;SG)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to the use of silicon for the pulmonary
    delivery of drugs to human or animal patients.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0120202.7</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    National applications (AU, JP, EP, SG)<BR><B>Accepted&nbsp;(US)<BR>
    </B>Divisional (US1)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to sweat patches, including patches comprising
    electronic circuitry, for the collection and detection of sweat
    components.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0130608.3</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    National applications (US, EP, JP, AU, SG, CN,&nbsp;KR)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to silicon fibers or fabrics for medical use.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0212667.0</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    National applications (US, CA, JP, EP, AU,&nbsp;NZ)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    A novel orthopaedic scaffold, and a self-assembly process for
    fabrication of such a scaffold.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0302283.7</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    National applications (US, EP, JP, CN)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to the use of silicon for boron neutron
    capture therapy.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0307453.1</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    International application (All PCT states)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to the use of silicon devices, including
    electronic devices, for the collection and assay of cancer
    markers.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0324483.7</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    International application (All PCT states)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to porous silicon compositions having high
    levels of loading, and to methods of loading.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0324482.9</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    International application (All PCT states)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to chlorambucil/porous silicon and
    taxol/porous silicon compositions for brachytherapy.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0400149.1</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    International application (All PCT states)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate a method of fabricating a phosphorous
    containing silicon material.</TD>
</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">50
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 9pt; ">

<TR style="font-size: 1pt;">
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="42%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="43%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Priority</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="center" nowrap><B>Number</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>Status</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>Subject Matter</B></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0411358.5</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    International application (All PCT states)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to the fabrication of a consolidated silicon
    particulate product. The method is of particular value in the
    fabrication of inexpensive anodised porous silicon.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0419653.1</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    International application (All PCT states)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to a syringe having a curved flexible needle
    for introducing BrachySil into a tumor.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0420676.9</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Priority Application</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to a chronotherapeutic device.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0423383.9</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Priority Application</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to ductile silicon structures, and medical use
    of such structures.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0504657.8</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Priority Application</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to a new treatment for osteoporosis.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0508174.0</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Priority Application</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to Oral hygiene compositions.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0515357.2</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Priority Application</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to a silicon packaging material.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    0515353.1</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Priority Application</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to the use of silicon in food products.</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Not yet known</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Priority Application</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    The claims relate to an analytical device for testing body
    fluids.</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<I>Notes:</I>
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    (a)</TD>
    <TD></TD>
    <TD valign="top">
    Each invention group is identified by the earliest priority
    patent application number. Each priority application is filed at
    the GB Patent Office, and hence the priority numbers are GB
    application numbers.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    (b)</TD>
    <TD></TD>
    <TD valign="top">
    The table shows the status of each invention group. For example
    a case will typically be filed as a priority GB application, it
    will then go on to be filed as an international patent
    application. The final stages are national filing (for example
    in U.S., Europe, etc) and grant.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    (c)</TD>
    <TD></TD>
    <TD valign="top">
    The nature of the protection provided by the claims is given in
    the &#147;Subject Matter&#148; part of the table.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    (d)</TD>
    <TD></TD>
    <TD valign="top">
    Abbreviations are used to indicate the states in which national
    applications have been filed. These abbreviations are as
    follows: AU = Australia, GB = Great Britain, CA = Canada, CN =
    China, EP = Europe, HK = Hong Kong, JP = Japan, KR = Korea, NZ =
    New Zealand, SG = Singapore, US = United States.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    (e)</TD>
    <TD></TD>
    <TD valign="top">
    Divisional applications are indicated by &#147;1&#148;,
    &#147;2&#148;, &#147;3&#148; etc, for example GB1, GB2, EP1,
    EP2, US1, US2, US3.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    (f)</TD>
    <TD></TD>
    <TD valign="top">
    For NZ and AU applications the term &#147;accepted&#148; means
    that a Notice of Acceptance has been received. For the EP
    applications, the term &#147;accepted&#148; means that a
    Rule&nbsp;51(4) EPC Communication, in which the Applicant is
    informed of the intention to grant a patent, has been received.
    For US applications the term &#147;accepted&#148; means that the
    Notice of Allowance has been received. For China the term
    &#147;accepted&#148; means that a Decision on Granting of Patent
    Right has been issued.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida has strengthened its intellectual property portfolio
with the granting of an additional 13 patents during the past
year. In August 2005, pSivida was granted its fifth patent in
the important United States market which provides for the
classification of porous silicon into monodispersed particles
with a tight size distribution. The classification into tight
sized distributions is a key attribute of many micro-engineered
particle products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida was also granted its first patents in China and Korea.
pSivida believes that obtaining patent coverage in China is
important as China has the highest incidence of primary liver
cancer in the world with approximately 350,000 cases in 2002.
The potential lower cost of the Chinese registration pathway and
the vast need of products treating liver cancer make China an
important commercial target.
</DIV>

<P align="center" style="font-size: 10pt;">51

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Korean patent covers the electronic-based properties of
BioSilicon in the stimulation of orthopedic tissue repair and
re-engineering where scaffolds are required to support new bone
growth. The technology also has application for treatment of
fractures that do not heal, such as &#147;bone non-union&#148;.
pSivida believes that Korea&#146;s recognized strength in the
design and manufacture of micro-components for the electronics
industry makes it an important jurisdiction for this technology
pSivida hopes to capitalize on Korea&#146;s technology strengths
as well as the higher margins associated with healthcare
products.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Sales and Marketing</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida has no experience in the sales, marketing and
distribution of healthcare products. If in the future pSivida
fails to reach or elects not to enter into an arrangement with a
collaborative partner with respect to the sales and marketing of
any of pSivida&#146;s future products, pSivida would need to
develop a sales and marketing organization with supporting
distribution capability in order to market such products
directly. Significant additional expenditures would be required
for pSivida to develop such a sales and marketing organization.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Competition</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida is engaged in healthcare product development, an
industry that is characterized by extensive research efforts and
rapid technological progress. Many established biotechnology
companies, universities and other research institutions with
financial, scientific and other resources significantly greater
than pSivida&#146;s are marketing or may develop products that
directly compete with any products pSivida may develop. These
entities may succeed in developing products that are safer, more
effective or less costly than products pSivida may develop. Even
if pSivida can develop products which should prove to be more
effective than those developed by other companies, other
companies may be more successful than pSivida because of greater
financial resources, greater experience in conducting
preclinical studies and clinical trials and in obtaining
regulatory approval, stronger sales and marketing efforts,
earlier receipt of approval for competing products and other
factors. If pSivida commences significant commercial sales of
any products, it or its collaborators will compete in areas in
which pSivida has no experience, such as marketing. There can be
no assurance that pSivida&#146;s products, if commercialized,
will be accepted and prescribed by healthcare professionals.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s principal competitors in this market are the
numerous drug delivery and pharmaceuticals companies that are
attempting to improve the safety and efficiency of
pharmaceuticals by developing and introducing novel delivery
methods. Most of these companies aim to deliver drugs with
polymer-based systems, some of which are not biodegradable.
pSivida does not know of any other company that is developing a
non-polymer&nbsp;&#151; i.e., pure element&nbsp;&#151; drug
delivery system.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Employees</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
As of September&nbsp;30, 2005, pSivida had 53 employees,
excluding directors and consultants. Of such employees, 39 were
employed in research and development, 12 in management and
administration and two in operations; 36 employees are located
in Malvern, United Kingdom, three in Singapore and 14 in Perth,
Western Australia.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Australian and UK labor laws and regulations are applicable to
all of pSivida&#146;s employees depending upon their location of
employment. The laws concern various matters, including
severance pay rights at termination, retirement or death, length
of work day and work week, minimum wage, overtime payments and
insurance for work related accidents.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Facilities</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Facilities pSivida leases approximately 223&nbsp;square meters
of laboratory space and 449&nbsp;square meters of office space
in Malvern, United Kingdom and approximately 305&nbsp;square
meters of office space in Perth, Western Australia.
</DIV>

<P align="center" style="font-size: 10pt;">52

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Property, Plant and Equipment</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s manufacturing partner QSA, has completed the
construction and validation of a state-of-the-art cleanroom
facility, dedicated to the supply of pSivida&#146;s lead cancer
therapy BrachySil, at QSA&#146;s Auriga
Medical<SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant:SMALL-CAPS">tm</FONT></SUP>facility
in Braunschweig, Germany. This GMP facility will fulfill the
final process in the manufacture of BrachySil for future
clinical and commercial use, and represents the crucial final
stage in establishing the manufacturing and supply
infrastructure to support BrachySil as it advances through
clinical trials towards the market.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida owns computer equipment, office furniture and lab
equipment, the majority of which are used in its Malvern
laboratory facilities. pSivida leases approximately
223&nbsp;square meters of laboratory space and 449&nbsp;square
meters of office space in Malvern, United Kingdom and
approximately 305&nbsp;square meters of office space in Perth,
Western Australia.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Legal Proceedings</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida is not presently involved in any legal proceedings nor
has there been any proceeding entered into by pSivida or on
pSivida&#146;s behalf since December&nbsp;1, 2000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">pSivida&#146;s
Management</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Directors and Senior Management</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The members of the board of directors and senior management of
pSivida and its subsidiaries are listed below. The business
address of pSivida&#146;s directors and senior management is:
c/o&nbsp;pSivida Limited, Level&nbsp;12 BGC Centre, 28 The
Esplanade, Perth WA 6000, Australia.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Director Appointments</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida has recently appointed two non-executive directors to
its board in Dr.&nbsp;David J Mazzo and Mr.&nbsp;Michael W.
Rogers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The members of the board of directors of pSivida and their
principal occupations are as follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="26%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date of Appointment</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>Principal Occupation</B></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr. Roger Brimblecombe</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>March&nbsp;5, 2002</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Independent Consultant</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr. Roger Aston*</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>December&nbsp;1, 2000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Independent Consultant</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr. Gavin Rezos</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>December&nbsp;1, 2000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Managing Director, pSivida Limited</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Ms. Alison Ledger</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>July&nbsp;30, 2004</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Independent Consultant</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr. Stephen Lake</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>July&nbsp;30, 2004</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Investment Director, QinetiQ</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr. David Mazzo</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>July&nbsp;25, 2005</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Non-Executive Director, pSivida Limited; President and Chief
    Executive Officer, Chugai Pharma U.S.A</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr. Michael Rogers</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>July&nbsp;27, 2005</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Non-Executive Director, pSivida Limited; Vice President, Chief
    Financial Officer and Treasurer of Indevus Pharmaceuticals
    Incorporated</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top">
    <TD>*&nbsp;</TD>
    <TD align="left">
    Dr Roger Aston retired from pSivida&#146;s board on
    November&nbsp;15, 2005.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Dr.&nbsp;Roger Brimblecombe</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dr.&nbsp;Brimblecombe,&nbsp;Ph.D., D.Sc., F.R.C.Path., C.Biol.,
F.I.Biol., is a former chairman of SmithKline and French
Research Ltd. He is currently chairman of MVM Ltd, the venture
capital arm of the UK Medical Research Council. He is also
non-executive chairman of Oxxon Therapeutics, Inc (U.S.),
DanioLabs Ltd, and a non-executive director of Vertex
Pharmaceuticals Inc (U.S.A), Tissue Science Laboratories Ltd,
and GenPat77 Phamacogenetics AG (Germany). He has provided
strategic consultancy services to research and development
companies in Europe, the U.S. and Japan. He is a fellow of the
</DIV>

<P align="center" style="font-size: 10pt;">53

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
Royal Society of Medicine, the Royal College of Pathologists and
the Institute of Biology. He is consultant editor of Drug
Discovery World magazine. Dr.&nbsp;Brimblecombe is also chairman
of pSiMedica and pSiOncology.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Gavin Rezos</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Mr.&nbsp;Rezos, B.Juris., LL.B., B.A., earned a law degree from
the University of Western Australia and has been admitted as a
barrister and solicitor in Western Australia, England and New
South Wales. He practiced law in London in corporate finance
before joining Midland Montagu, an investment bank now known as
HSBC Investment Bank plc, in 1990. He was an investment banking
director at HSBC in positions based in London, Sydney and Dubai.
Mr.&nbsp;Rezos is currently principal of Viaticus Capital Pty
Ltd, a biotechnology venture capital and corporate advisory
company. He has investment banking experience in a variety of
industries and geographical locations including Europe, Latin
America, the Middle East and Asia. Mr.&nbsp;Rezos is also a
director of pSiMedica, pSiOncology and AiMedics Pty Ltd
(Australia) and non-executive chairman of AION Diagnostics.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Dr.&nbsp;Roger Aston</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dr.&nbsp;Aston has more than 20&nbsp;years experience in the
pharmaceutical and biotechnology industries. His previous
positions have included CEO of Peptech Limited (Australia),
director of Cambridge Antibody Technology Limited (UK)&nbsp;and
chairman of Cambridge Drug Discovery Limited&nbsp;&#151; now
BioFocus plc (UK). Dr.&nbsp;Aston was also founder and CEO of
Biokine Technology Ltd (UK)&nbsp;prior to its acquisition by the
Peptech Group. He was a founder and is the former CEO of
pSiMedica and pSiOncology. Dr.&nbsp;Roger Aston is also chairman
of Australian Cancer Technology Limited (Australia). Dr Roger
Aston retired as a director and executive officer of pSivida and
pSiOncology at the pSivida annual general meeting held on
November&nbsp;15, 2005.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Alison Ledger</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Ms.&nbsp;Ledger was most recently a principal at
McKinsey&nbsp;&#38; Co both in Sydney and London specializing in
financial institutions including banking, asset management,
stock exchanges, insurance and regulatory compliance. She joined
McKinsey in 1995 after holding positions with Bankers Trust in
London marketing investment funds to European corporate and
institutional clients. Ms.&nbsp;Ledger has extensive financial
experience and knowledge of international capital markets with a
breadth of knowledge in strategy, operations, performance
improvement, cost management, new business building and
geographic expansion. She has a Harvard MBA and has lived and
worked in numerous countries including the UK, Australia and the
U.S.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Stephen Lake</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Mr.&nbsp;Lake, BA (Jt. Hons), MBA, ACA, is Investment Director,
QinetiQ Limited. He has over 20&nbsp;years of experience in the
high technology sector as a senior executive in both large
multi-national and early stage venture backed companies. He was
a founding executive of Reuters venture capital arm Greenhouse.
He has extensive international experience having worked in the
U.S.&nbsp;for 10&nbsp;years, as well as in France and the Nordic
countries. Mr.&nbsp;Lake is a UK-qualified chartered accountant
and has an MBA in technology and strategy from the Theseus
Institut (France). He is a non-executive director of Quintel
Technology Limited and QS4 Group Limited, a joint venture
between Rotch and QinetiQ.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Dr.&nbsp;David Mazzo</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dr.&nbsp;Mazzo, BA (Hons), BSc (Hons), MSc, PhD, is President and
Chief Executive Officer of Chugai Pharma U.S.A, and is based in
New Jersey, U.S.A. Chugai Pharma U.S.A is part of the Roche
group of companies and is a subsidiary of Chugai Pharmaceutical
Company Limited (Japan), a global research-based pharmaceutical
company. Dr Mazzo holds a Bachelor of Arts with Honors
(Interdisciplinary Humanities) and a Bachelor of Science with
</DIV>

<P align="center" style="font-size: 10pt;">54

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
Honors in Chemistry from Villanova University, and a Master of
Science in Chemistry and a PhD in Analytical Chemistry from the
University of Massachusetts. He complemented his American
education as a Research Fellow at the ecole Polytechnique
Federale de Lausanne, Switzerland. Dr Mazzo is also a director
of AMEX-listed Avanir Pharmaceuticals (appointed 1&nbsp;August
2005).
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Michael Rogers</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Mr.&nbsp;Michael Rogers, BA, MBA, is Executive Vice President, Chief Financial
Officer and Treasurer of Indevus Pharmaceuticals Incorporated, a
biopharmaceutical company based in Lexington, Massachusetts,
U.S.A. Mr.&nbsp;Rogers received an MBA from the Darden School of
Business, University of Virginia and a BA, Political Science
from Union College, and brings significant financing,
acquisition, investment banking and partnering experience
relating to pharmaceutical and biotechnology companies to the
pSivida board. He will chair the Audit Committee and is the
designated &#147;audit committee financial expert.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
From January&nbsp;7, 2003 until July&nbsp;30, 2004, Nadine
Donovan was a member of pSivida&#146;s board of directors.
Following Mrs.&nbsp;Donovan&#146;s resignation to concentrate on
personal endeavors, Mr.&nbsp;Lake and Ms.&nbsp;Ledger were
appointed directors by a resolution of shareholders at a general
meeting of shareholders held on July&nbsp;30, 2004.
Mrs.&nbsp;Donovan joined pSivida in March 2001 as Company
Secretary/ Financial Controller.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The current executive officers of pSivida and their titles are
as follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="40%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="57%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>Title</B></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr. Gavin Rezos</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Managing Director</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr. Aaron Finlay</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Chief Financial Officer and Company Secretary</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr. Anna Kluczewska</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Head of Diagnostics</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr. Brian Leedman</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Investor Relations Manager</TD>
</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Aaron Finlay</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Mr.&nbsp;Finlay joined pSivida as of May&nbsp;17, 2004, as CFO
and Company Secretary. His most recent role was as INVESCO
Australia&#146;s Chief Financial Officer where he had
responsibility for the operations of finance, as well as the
compliance, legal, and human resources functions. Prior to that
position, Mr.&nbsp;Finlay was head of group tax and treasury for
INVESCO&#146;s global operations in London. Prior to joining
INVESCO, Mr.&nbsp;Finlay worked for PricewaterhouseCoopers (then
Price Waterhouse) in London and Perth. Mr.&nbsp;Finlay is also
chief financial officer and company secretary of AION
Diagnostics.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Dr.&nbsp;Anna Kluczewska</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dr.&nbsp;Kluczewska held the position of global product manager
for Baxter Healthcare&#146;s BioSurgery division. At Baxter, she
oversaw the management of Baxter BioSurgery&#146;s products in
over 50 countries focusing on registration, product launch and
global product management. Dr.&nbsp;Kluczewska is also managing
director of AION Diagnostics.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Brian Leedman</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Mr.&nbsp;Leedman is a marketing and communications specialist
with more than 10&nbsp;years&#146; experience at Westpac Banking
Corporation and Ernst&nbsp;&#38; Young. As the former Group
Marketing Manager of Ernst&nbsp;&#38; Young in Perth, Western
Australia, Mr.&nbsp;Leedman was responsible for building
industry relationships, public relations and brand management.
Mr.&nbsp;Leedman holds a Bachelor of Economics and a Master of
Business Administration from the University of Western Australia.
</DIV>

<P align="center" style="font-size: 10pt;">55

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>pSiMedica Limited</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The members of the board of directors of pSiMedica and their
principal occupations are as follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="43%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="54%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>Principal Occupation</B></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr.&nbsp;Roger Brimblecombe</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Independent Consultant</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr. Gavin Rezos</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Managing Director, pSivida</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr. Mark Parry-Billings</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Research&nbsp;&#38; Development Director</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The executive officers of pSiMedica and their titles are as
follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>Title</B></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Prof. Leigh Canham</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Chief Scientific Officer</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr. Stephen Connor</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Director of Development</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr. Jill Ogden</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Commercial Director</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr. David Petty</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Intellectual Property Manager</TD>
</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Prof. Leigh Canham</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Prof.&nbsp;Canham has 25&nbsp;years of research experience
related to silicon technology. He was awarded an honorary chair
at the University of Birmingham in 1999 for his work on the
optoelectronic properties of nano-structured silicon. Trained at
University College (BSc physics) and Kings College (PhD solid
state physics) in London, Prof. Canham then conducted research
at QinetiQ (formerly, RSRE, DERA) in Malvern UK from 1986 to
2000. In December 2000, he co-founded pSiMedica with
Dr.&nbsp;Aston to develop the BioSilicon technology platform
invented in QinetiQ. He is a frequent speaker on the subject of
the medical applications of silicon technology and is member of
the editorial board of international journal <I>Biomedical
Microdevices</I>.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Dr.&nbsp;Mark Parry-Billings</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dr.&nbsp;Parry-Billings joined pSiMedica in November 2004.
Dr.&nbsp;Parry-Billings earned a BS with first class honors from
the University of Loughborough and subsequently earned a DPhil
from the Department of Biochemistry, University of Oxford where
he conducted post-graduate work before joining Schering
Healthcare. For the six years prior to joining pSiMedica,
Dr.&nbsp;Parry-Billings was Director of Research&nbsp;&#38;
Development at Innovata Biomed Ltd. He joined Innovata BioMed in
1994 from Schering Healthcare Ltd where he was a Senior Clinical
Research Associate.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Stephen Connor</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Mr.&nbsp;Connor joined pSiMedica in November 2001. Previously,
he held increasingly senior positions in Cambridge at Murex
Medical Research Ltd, Quantum Biosystems Ltd, Cantab
Pharmaceuticals Research Ltd, Chiroscience R&#38;D Ltd, and most
recently, Imutran Ltd&nbsp;&#151; a Novartis Pharma company.
From 1978 to 1985, he worked at the Withington Hospital,
Manchester.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Dr.&nbsp;Jill Ogden</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dr.&nbsp;Ogden joined pSiMedica in November 2003. She has
18&nbsp;years of commercial and R&#38;D experience in the
biotechnology, healthcare and drug delivery industries. She
graduated with a BSc and PhD in Genetics from the University of
Sheffield. Following her postdoctoral research at the
Universities of Edinburgh and Oxford, she joined Delta
Biotechnology Ltd. In 1993, Dr.&nbsp;Ogden co-founded and was
principal of Propharma Consultants, a consultancy specializing
in the biopharmaceutical industry. Between 1996 and 2000, she
was business development manager of Andaris Ltd and the Quadrant
Healthcare plc. Following the acquisition of Quadrant by Elan
Corporation, she became director of business development for
Elan Drug Delivery Ltd.
</DIV>

<P align="center" style="font-size: 10pt;">56

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Dr.&nbsp;David Petty</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dr.&nbsp;Petty joined pSiMedica in July 2002. Dr.&nbsp;Petty
graduated in chemistry and subsequently obtained a PhD in
organic semiconductors in 1991 at the University of Nottingham.
After a one year fellowship at The Institute for Molecular
Science, Okazaki, Japan he earned an MSc in intellectual
property management at the University of London and then worked
for a database company specializing in pharmaceutical patents.
Dr.&nbsp;Petty subsequently worked for Fisons Instruments&#146;
patent department from 1994 before joining the Ministry of
Defense IP department in 1996. Over the last five years, he has
been responsible for managing the BioSilicon portfolio of
patents at both DERA/ QinetiQ and pSiMedica.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>pSiOncology Pte Ltd.</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The members of the board of directors of pSiOncology and their
principal occupations are as follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="66%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>Principal Occupation</B></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr. Roger Brimblecombe</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Independent Consultant</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr. Gavin Rezos</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Managing Director, pSivida</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr. Beng Choo Lim</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Clinical Director</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr. Stephen Lake</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Investment Director, QinetiQ</TD>
</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Dr.&nbsp;Beng Choo Lim</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dr.&nbsp;Lim has worked with multinational pharmaceutical
corporations such as Pharmacia (now Pfizer), Glaxo and Smith
Kline Beecham and several start up companies. Dr.&nbsp;Lim
received her doctorate in pharmacology from the National
University of Singapore and is registered with the Singapore
Board of Pharmacy. Her clinical research experience includes
initiation and project management of all phases of clinical
trials to support registration in the U.S., Europe and Asia in
the therapeutic areas of naso-pharyngeal cancer, vitreous
hemorrhage, Hepatitis B, peptic ulcer, respiratory, dermatology
and anti-infectives.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The executive officers of pSiOncology and their titles are as
follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="70%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="27%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>Title</B></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr. Beng Choo Lim</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Clinical Project Manager</TD>
</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>AION Diagnostics Limited</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Wholly-owned subsidiary AION Diagnostics Limited appointed Dr
Jorg Schreiber PhD as a non-executive director in May 2005. Dr
Schreiber has over 20&nbsp;years&#146; experience in the
diagnostics industry, principally with Roche Diagnostics and
Boehringer Mannheim in Germany and brings with him leadership
and expertise in the commercialization of world class diagnostic
products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The members of the board of directors of AION Diagnostics and
their principal occupations are as follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="52%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>Principal Occupation</B></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr. Gavin Rezos</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Managing Director, pSivida</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Prof. Leigh Canham</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Chief Scientific Officer, pSiMedica; Director, AION Diagnostics</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr. Anna Kluczewska</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Head of Diagnostics, pSivida; Managing Director, AION Diagnostics</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr. J&#246;rg Schreiber PhD</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Non-executive Director</TD>
</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">57

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The executive officers of AION Diagnostics and their titles are
as follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="54%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="43%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>Title</B></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr. Anna Kluczewska</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Managing Director</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr. Aaron Finlay</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Chief Financial Officer and Company Secretary</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr. Brian Leedman</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    Investor Relations Manager</TD>
</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Board Practices</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The business of pSivida is managed by its directors. The
directors exercise all of the powers that pSivida&#146;s
constitution, the Corporations Act 2001, the Australian Stock
Exchange or the Australian Stock Exchange Listing Rules do not
reserve to the shareholders in general meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The directors exercise their powers and discharge their duties
as a board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The board&#146;s policies and practices exist within a framework
of:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the Corporations Act 2001;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the general law, including the law relating to directors&#146;
    duties;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the Australian Stock Exchange Corporate Governance
    Council&#146;s Principles of Good Corporate Governance and Best
    Practice Recommendations;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the Australian Stock Exchange Listing Rules.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The overall role of the board, as set out in its charter,
includes:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    setting pSivida&#146;s strategic direction;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    identifying the expectations of pSivida&#146;s shareholders;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    identifying regulatory and ethical expectations and
    obligations;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    identifying areas of significant business risk and ensuring
    arrangements are in place to adequately manage those risks.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The board delegates responsibility for the operation and
administration of pSivida&#146;s company and its subsidiaries to
the Managing Director.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The board ensures management&#146;s objectives and activities
are aligned with those expectations and risks identified by the
board through the mechanisms set out below:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    oversight of pSivida&#146;s business, including its control and
    accountability systems;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    appointing and removing the chief executive officer (or
    equivalent);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    ratifying the appointment and, where appropriate, the removal of
    the chief financial officer and the company secretary;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    input into and final approval of corporate strategy and
    performance objectives;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    reviewing and ratifying systems of risk management and internal
    compliance and control, codes of conduct and legal compliance;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    monitoring senior management&#146;s performance and
    implementation of strategy, and ensuring appropriate resources
    are available;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    approving and monitoring the progress of major capital
    expenditure, capital management, and acquisitions and
    divestitures;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">58

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    approving and monitoring financial and other reporting;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    monitoring compliance of tax processes.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Composition of the
Board</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The composition of the board is determined in accordance with
the following principles and guidelines:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the board must comprise at least three directors;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the board must comprise directors with an appropriate range of
    qualifications and expertise;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the board must meet regularly and follow meeting guidelines set
    down to ensure all directors are made aware of, and have
    available, all necessary information, to participate in an
    informed discussion of all agenda items.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The performance of all directors is reviewed annually by the
chairman of the board in order to ensure that the board
continues to discharge its responsibilities in an appropriate
manner.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s constitution provides that the board may appoint
a director at any time other than during a general meeting.
However, any director so appointed automatically retires at the
next general meeting and must seek re-election at that general
meeting. Otherwise, pSivida&#146;s constitution permits the
election of a director at general meeting and by ordinary
resolution and both Mr.&nbsp;Lake and Ms.&nbsp;Ledger were
appointed directors by a resolution of shareholders at a general
meeting of shareholders held on July&nbsp;30, 2004. Dr Mazzo and
Mr Rogers were appointed by the board and were re-elected at the
pSivida annual general meeting held on November&nbsp;15, 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
One third of directors other than the director who is the
Managing Director (or is one of the Managing Directors and has
been nominated by the board as exempt from retirement) must
retire at each Annual General Meeting. If the applicable number
of directors is not a multiple of three, the nearest whole
number to one third is applied in determining how many directors
must retire from office. This will mean that for the year ending
June&nbsp;30, 2006, (subject to the appointment of any new
directors by pSivida in general meeting prior to the 2006 Annual
General Meeting), two of the current seven directors must retire
and will be eligible for re-election. The directors chosen to
retire will be the directors who have held office the longest
since last being elected or appointed. If additional directors
are appointed and more than two directors are required to
retire, then where two or more directors have held office for
the same amount of time, they may agree which of them will
retire and if they cannot decide they will draw lots.
Dr.&nbsp;Brimblecombe was appointed a director on March&nbsp;5,
2002 and was re-elected at the general meeting held on
November&nbsp;17, 2004. Both Mr.&nbsp;Rezos and Dr.&nbsp;Aston
were appointed directors by a resolution of shareholders at a
general meeting of shareholders on November&nbsp;24, 2000
becoming effective on December&nbsp;1, 2000 and Dr.&nbsp;Aston
was most recently re-elected at a general meeting by ordinary
resolution on October&nbsp;21, 2003.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Furthermore, any director who is not a Managing Director must
retire from office at the conclusion of the third annual general
meeting after which they were elected and are eligible for
re-election.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s constitution does not prescribe any maximum age
limit for directors. This means that automatic retirement from
office is not imposed upon reaching a certain age.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Whether or not a director&#146;s appointment is expressed to be
for a specified period, pSivida&#146;s constitution permits:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    members by ordinary resolution;&nbsp;or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    members holding a majority of pSivida&#146;s issued, voting
    shares by written notice to pSivida,</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
to remove any director from office. The Corporations Act 2001
supports and supplements these members&#146; powers to remove
directors from office.
</DIV>

<P align="center" style="font-size: 10pt;">59

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Compliance with U.S.&nbsp;Law and NASDAQ
    Rules&nbsp;Regarding Director Independence, Etc.</I></B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>General</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Pursuant to the Sarbanes-Oxley Act of 2002, the SEC has issued
new rules that, among other things, require NASDAQ to impose
independence requirements on each member of the audit committee.
The new NASDAQ rules implement two basic criteria for
determining independence: (i)&nbsp;audit committee members would
be barred from accepting any consulting, advisory or other
compensatory fee from the issuer or an affiliate of the issuer,
other than in the member&#146;s capacity as a member of the
board of directors and any board committee, and (ii)&nbsp;audit
committee members of an issuer that is not an investment company
may not be an &#147;affiliated person&#148; of the issuer or any
subsidiary of the issuer apart from his or her capacity as a
member of the board and any board committee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The SEC defines &#147;affiliate&#148; for non-investment
companies as &#147;a person that directly, or indirectly through
one or more intermediaries, controls, or is controlled by, or is
under common control with, the person specified.&#148; The term
&#147;control&#148; is proposed to be consistent with the other
definitions of this term under the Exchange Act, as &#147;the
possession, direct or indirect, of the power to direct or cause
the direction of the management and policies of a person,
whether through the ownership of voting securities, by contract,
or otherwise.&#148; A safe harbor has been proposed by the SEC,
under which a person who is not an executive officer, director
or 10% shareholder of the issuer would be deemed not to have
control of the issuer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For purposes of NASDAQ, an &#147;independent director&#148; is a
person who is not an officer or employee of pSivida or any of
its subsidiaries and who does not have a relationship that, in
the opinion of the board, would interfere with the exercise of
independent judgment in carrying out the responsibilities of a
director.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Recently-adopted SEC and NASDAQ rules have applied to pSivida
since July&nbsp;31, 2005. pSivida has taken appropriate steps
with respect to pSivida&#146;s corporate governance system so
that its board of directors satisfies provisions of
Rule&nbsp;10A-3 under the Exchange Act and the amended corporate
governance standards of NASDAQ implementing the requirements of
Rule&nbsp;10A-3, including the requirements relating to the
independence of the audit committee members and responsibilities
of the audit committee. For so long as pSivida is listed on
NASDAQ and rules applicable to pSivida so require:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pSivida will continue to have a board of directors consisting of
    a majority of independent directors, as defined under
    NASDAQ&#146;s corporate governance rules;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pSivida will continue to have an audit committee of at least
    three members, comprised solely of directors each of whom: (1)
    meets NASDAQ&#146;s definition of independence; (2)&nbsp;meets
    the SEC&#146;s definition of independence; (3)&nbsp;has not
    participated in the preparation of pSivida&#146;s financial
    statements or any of its current subsidiaries at any time during
    the past three years; and (4)&nbsp;is able to read and
    understand fundamental financial statements, including a balance
    sheet, income statement, and cash flow statement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pSivida will continue to have at least one member of the audit
    committee who has past employment experience in finance or
    accounting, requisite professional certification in accounting,
    or any other comparable experience or background which results
    in the individual&#146;s financial sophistication, including
    being or having been a chief executive officer, chief financial
    officer or other senior officer with financial oversight
    responsibilities;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pSivida will have adopted a formal written audit committee
    charter that complies with NASDAQ&#146;s rules, and that the
    audit committee will, among other things, review and assess the
    adequacy of the charter on an annual basis;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pSivida will either ensure that pSivida&#146;s nomination
    committee and remuneration committee have only independent
    directors or that all decisions made by the board in respect of
    compensation of officers and nomination of directors are
    approved by a majority of pSivida&#146;s independent directors;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">60

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pSivida will have adopted a code of conduct applicable to all
    directors, officers and employees which complies with NASDAQ and
    SEC rules, and such code will be publicly available;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pSivida will hold regularly scheduled meetings at which only
    independent directors are present.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida has been granted an exemption from the quorum
requirement under NASDAQ rules which requires each issuer to
provide for a quorum as specified in its by-laws for any meeting
of the holders of common stock, which shall in no case be less
than
33<FONT style="font-size: 70%"><SUP>1</SUP></FONT>/<FONT style="font-size: 60%">3</FONT>%
of the outstanding shares of a company&#146;s common voting
stock. pSivida&#146;s constitution provides for a quorum
requirement of two members at general meetings of pSivida&#146;s
shareholders. This quorum requirement is in accordance with
Australian law and generally accepted business practices in
Australia.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Independence of Directors</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The board of directors considers Ms.&nbsp;Ledger to be an
independent director. She has an indirect interest in 1,900,000
ordinary shares held by her spouse representing 0.84% of the
outstanding ordinary shares as of September&nbsp;30, 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The board of directors considers Messrs.&nbsp;Mazzo and Rogers
to be independent directors. pSivida has recently granted
Dr.&nbsp;Mazzo 200,000 options, and Mr.&nbsp;Rogers 200,000
options. The board of directors considers Mr.&nbsp;Lake to be an
independent director. Mr.&nbsp;Lake was separately recommended
by the nomination committee of the board on the basis of his
extensive experience in building and developing growth
technology businesses. Mr.&nbsp;Lake is currently employed by
and responsible for managing and developing the QinetiQ Ventures
portfolio of spin-out companies. QinetiQ, immediately after the
completion of the transaction whereby pSivida acquired the
remaining shares in pSiMedica that it did not already own, held
approximately 17.5% of pSivida&#146;s issued share capital. The
board does not consider this holding of its ordinary shares to
affect Mr.&nbsp;Lake&#146;s independence on the basis that
QinetiQ has pledged that, until October&nbsp;26, 2009, as long
as it holds 10% or more of pSivida&#146;s outstanding ordinary
shares that it will exercise its voting rights in line with the
majority of proxy votes exercisable by validly appointed proxies
in relation to any resolution of pSivida&#146;s shareholders. In
addition, the board considers there are sufficient and suitably
documented policies and procedures in place at QinetiQ
separating Mr.&nbsp;Lake and the corporate department of QinetiQ
responsible for all dealing in relation to their interest in
pSivida&#146;s ordinary shares.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Existing board committees</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
To assist in the execution of its responsibilities, the board
has established a number of committees including a nomination
committee, a remuneration committee and an audit and compliance
committee.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Nomination Committee</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The primary purpose of the nomination committee is to ensure
that the board is comprised of individuals who are best able to
discharge the responsibilities of directors having regard to the
law and the highest standards of corporate governance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The nomination committee meets this mandate by:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    assessing the skills required on the board and from time to time
    considering the extent to which the required skills are
    represented on the board;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    establishing processes for the review of the performance of
    individual directors and the board as a whole;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    establishing processes for the identification of suitable
    candidates for appointment to the board.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The duties and responsibilities of the nomination committee are:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    to periodically assess the skills required to competently
    discharge the board&#146;s duties, having regard to
    pSivida&#146;s strategic direction, and report the outcome of
    that assessment to the board;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">61

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    to assess the skills represented on the board by the directors
    and determine whether those skills meet the required skills as
    identified, as and when it considers appropriate but in any
    event on each occasion on which an existing director retires;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    to make recommendations to the chairman of the board on means by
    which skill levels of existing directors can be enhanced;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    to implement a process for the identification of suitable
    candidates for appointment to the board;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    to make recommendations to the board on candidates it considers
    appropriate for appointment;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    to inform the board of the names of directors who are retiring
    in accordance with pSivida&#146;s constitution and make
    recommendations to the board as to whether the board should
    support the re-nomination of that retiring director;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    to undertake a process of review of the retiring director&#146;s
    performance during the period in which the director has been a
    member of the board and conduct that review by whatever means it
    considers appropriate including assessment of performance by
    peers and self. However, a member of the nomination committee
    must not participate in the review of his or her own performance.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The decisions of the nomination committee, as contained in its
minutes, constitute recommendations to the full board. The board
has adopted procedures whereby any action taken after
July&nbsp;31, 2005 based on a recommendation of the nomination
committee must be ratified by a majority of the independent
directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The nomination committee must be comprised of at least two
members of the board. The terms of appointment to the nomination
committee are at the discretion of the board and vacancies may
be filled as they arise. From August&nbsp;2, 2004 until
November&nbsp;15, 2005, the members of the nomination committee
were Dr.&nbsp;Brimblecombe (Chairperson), Ms.&nbsp;Ledger and
Dr.&nbsp;Aston. Since November&nbsp;15, 2005, the members of the
nomination committee have been: Dr.&nbsp;Brimblecombe
(Chairperson) and Ms.&nbsp;Ledger.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Remuneration Committee</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The role of the remuneration committee is to assist
pSivida&#146;s board in ensuring that appropriate and effective
remuneration packages and policies for the Managing Director and
executive directors are implemented within pSivida&#146;s and
its subsidiaries. The remuneration committee&#146;s role also
extends to the review of non-executive directors&#146; fees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The duties and responsibilities of the remuneration committee
are to:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    review and recommend to the board remuneration policies and
    packages for the Managing Director and executive directors;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    recommend to the board any changes in remuneration policy
    relating to superannuation, other benefits and remuneration
    structure for the Managing Director and executive directors and
    that are likely to have a material impact on pSivida&#146;s and
    its subsidiaries;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    review and recommend to pSivida&#146;s board proposals employee
    and non-executive director equity plans;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    review and recommend to pSivida&#146;s board proposals for short
    and long term incentive programs for the Managing Director and
    executive directors;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    review and recommend to pSivida&#146;s board any changes to
    non-executive directors&#146; fees;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    ensure there is a proper performance management process in place
    throughout the organization and that it is operating
    effectively;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    be informed of: current trends in executive remuneration and
    associated incentive initiatives; and legislative issues
    associated with executive remuneration programs.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">62

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The decisions of the committee, as contained in its minutes,
shall constitute recommendations to pSivida&#146;s board.
pSivida&#146;s board has adopted procedures whereby any action
taken based on a recommendation of the remuneration committee
must be ratified by a majority of the independent directors. In
addition, the compensation of pSivida&#146;s Chief Executive
Officer will be determined, or recommended to the board for
determination, either by a majority of the independent directors
or a compensation committee comprised solely of independent
directors. Further, pSivida&#146;s Chief Executive Officer may
not be present during voting or deliberations. Compensation of
all other executive officers will also be determined, or
recommended to pSivida&#146;s board for determination, either by
a majority of the independent directors, or a compensation
committee comprised solely of independent directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The remuneration committee is comprised of at least two members
of the board. From August&nbsp;2, 2004 until November&nbsp;15,
2005, the members of the remuneration committee were
Dr.&nbsp;Brimblecombe (Chairperson), Mr.&nbsp;Lake and
Dr.&nbsp;Aston. Since November&nbsp;15, 2005, the members of the
remuneration committee have been Dr.&nbsp;Brimblecombe
(Chairperson) and Mr.&nbsp;Lake.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The terms of appointment to the remuneration committee are at
the discretion of the board and vacancies may be filled as they
arise.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Audit and Compliance Committee</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s board established the audit and compliance
committee to facilitate:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the effective operation of systems and controls which minimize
    financial and operational risk;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    reliable financial and management reporting policies and
    procedures;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    compliance with laws and regulations;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    maintenance of an effective and efficient internal and external
    audit process;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    oversight of the accounting and financial reporting processes of
    pSivida and the audits of pSivida&#146;s financial statements.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The audit and compliance committee is particularly concerned
with audit compliance amongst pSivida&#146;s company and its
subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The audit and compliance committee is directly responsible as a
committee of the board for the following:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    ensuring appropriate accounting policies and procedures are
    defined, adopted and maintained;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    ensuring that operating and management reporting procedures, and
    the system of internal control, are of a sufficiently high
    standard to provide timely, accurate and relevant information;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    reviewing the financial statements prior to their approval by
    pSivida&#146;s board;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    reviewing the scope of work including approval of strategic and
    annual audit plans and effectiveness of both the external and
    internal audit functions;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    monitoring the proper operation of and issues raised through
    pSivida&#146;s subsidiary&#146;s audit and compliance committees;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    ensuring that appropriate processes are in place to ensure
    compliance with all legal requirements;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    ensuring that all internal and industry codes of conduct and
    standards of corporate behavior are being complied with;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    appointment of, on recommendation by the Managing Director, a
    person(s) responsible for internal audit functions as specified
    from time to time by, and in accordance with, the audit and
    compliance committee&#146;s terms of reference;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">63

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    establishing procedures for the receipt, retention, and
    treatment of complaints regarding accounting, internal
    accounting controls, or auditing matters; and the confidential,
    anonymous submission by pSivida&#146;s employees of concerns
    regarding questionable accounting or auditing matters;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    taking action with respect to any other business processes or
    functions that may be referred to it by pSivida&#146;s
    board;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    ensuring its receipt from the outside auditors of a formal
    written statement delineating all relationships between the
    auditor and pSivida, consistent with appropriate standards, and
    actively engaging in a dialogue with the auditor with respect to
    any disclosed relationships or services that may impact the
    objectivity and independence of the auditor and for taking, or
    recommending that the full board take, appropriate action to
    oversee the independence of the outside auditor.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The decisions of the audit and compliance committee, as
contained in its minutes, shall constitute recommendations to
pSivida&#146;s board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s audit and compliance committee is directly
responsible for the appointment, reappointment or replacement
(subject, if applicable, to shareholder ratification),
remuneration, monitoring of effectiveness, and independence of
the external auditors, including resolution of disagreements
between management and the auditor regarding financial reporting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s audit and compliance committee approves all audit
and non-audit services provided by the external auditors and
must not engage the external auditors to perform any
non-audit/assurance services that may impair or appear to impair
the external auditor&#146;s judgment or independence.
pSivida&#146;s audit and compliance committee may delegate
pre-approval authority to a member of the audit and compliance
committee. The decisions of any audit and compliance committee
member to whom approval authority is delegated must be presented
to the full audit and compliance committee at its next scheduled
meeting. pSivida&#146;s audit and compliance committee is
empowered to determine its own procedures, and the charter for
the committee and its adequacy must be reviewed annually by the
committee and pSivida&#146;s board.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
When reviewing the independence of the external auditor,
pSivida&#146;s audit and compliance committee will encourage the
rotation of the audit partner at least once every five years.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s audit and compliance committee is comprised of at
least three members of the board. The shareholders of
pSivida&#146;s audit and compliance committee shall meet the
independence and experience requirements of the SEC and NASDAQ.
At least one of the members of pSivida&#146;s audit and
compliance committee appointed by pSivida&#146;s board shall be
determined by the board to be a financial expert as defined by
the SEC and NASDAQ, and all such members shall be able to read
and understand fundamental financial statements. Since
July&nbsp;28, 2005, the committee&#146;s financial expert has
been Mr.&nbsp;Rogers. The members of pSivida&#146;s audit and
compliance committee as of July&nbsp;31, 2005, were
Mr.&nbsp;Rogers (Chair), Ms.&nbsp;Ledger and Dr.&nbsp;Mazzo.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The terms of appointment to pSivida&#146;s audit and compliance
committee are at the discretion of the board and vacancies may
be filled as they arise.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Conduct and Ethics</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s code of conduct was adopted on June&nbsp;30, 2003
and was made available from the corporate governance sections of
pSivida&#146;s website on July&nbsp;1, 2003. The code of conduct
applies to all employees of pSivida including the Managing
Director and Chief Financial Officer and covers a broad range of
issues and practices necessary to maintain confidence in
pSivida&#146;s integrity, including procedures in relation to:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    compliance with the law;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    financial records;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    contributions to political parties, candidates and campaigns;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    occupational health and safety;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">64

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    confidential information;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    conflict of interest;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    efficiency;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    equal opportunity;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    corporate bribery;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    membership to industry and professional associations.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The code of conduct directs individuals to report any
contraventions of the code to their immediate superior or the
Managing Director.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In addition, pSivida has adopted separate corporate governance
policies relating to insider trading, continuous disclosure,
communications strategy and risk management. Summaries of these
policies are available on pSivida&#146;s corporate website, and
pSivida makes the full policies available to the public upon
request. pSivida believes that its continuous disclosure policy
and its communications strategy policy satisfy the requirements
of the SEC&#146;s rules requiring companies to adopt written
standards relating to the full, fair, accurate, timely, and
understandable disclosure in reports and documents that a
registrant files with, or submits to, the SEC and in other
public communications made by the registrant. These policies
mandate continuous disclosure of material information to the
public by means of an ASX release and pSivida&#146;s corporate
website. In addition, pSivida files with the SEC on
Form&nbsp;6-K a copy of each release which it files with the ASX
and posts on pSivida&#146;s corporate website.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Compensation</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Compensation of directors and officers is recommended by the
remuneration committee of pSivida&#146;s board and approved by
pSivida&#146;s full board including a majority of the
independent directors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Remuneration for the services of pSivida&#146;s executive
directors are formalized in a service agreement. Details of the
nature and amount of each element of the emoluments of each of
pSivida&#146;s directors for the financial year are shown in the
following table. The following table presents all compensation
pSivida paid to all of its directors and to all of its directors
and executive management for the year ended June&nbsp;30, 2005.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Remuneration Policy</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The remuneration committee of pSivida&#146;s board of directors
is responsible for reviewing and recommending compensation
arrangements for the directors, the managing director and the
executive team. The remuneration committee assesses the
appropriateness of the nature and amount of the emoluments of
such officers on a periodic basis by reference to relevant
employment market conditions with the overall objective of
ensuring maximum stakeholder benefit from the retention of a
high quality board and executive team.
</DIV>

<P align="center" style="font-size: 10pt;">65

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Remuneration of Specified Directors and Specified
    Executives</I></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="29%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Primary</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Post</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Salary and</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Employment</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Other</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Equity</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Fees</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Bonus</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Superannuation</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Benefits</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Options</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Total</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>Specified directors</I></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr R Brimblecombe</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>224,459</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>25,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>229,296</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>478,755</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr G Rezos</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>348,062</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>75,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,905</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,361,127</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,795,094</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr R Aston</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>315,683</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>25,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,438</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,189</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>558,592</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>908,902</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr S Lake</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22,917</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>91,718</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>114,635</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Ms A Ledger</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>27,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,475</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>91,718</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>121,693</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mrs N Donovan</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,083</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>188</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,271</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>940,704</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>125,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22,006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,189</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,332,451</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,421,350</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>Specified executives</I>(1)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Prof L Canham</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>193,780</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22,553</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,056</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>353,524</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>575,913</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr A Finlay</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>144,572</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>32,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13,135</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>370,396</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>560,603</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr A Kluczewska</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>208,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>299,808</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>518,141</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr S Connor</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>181,146</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21,738</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,612</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>143,751</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>357,247</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr J Ogden</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>169,816</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20,378</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,060</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>143,751</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>340,005</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>897,647</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>42,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>77,804</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22,728</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,311,230</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,351,909</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>(1)&nbsp;</TD>
    <TD align="left">
    Specified executives are the five highest paid executives of
    pSivida other than members of the board of directors.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Options were granted to specified directors and executives on
August&nbsp;5, 2004 and have a value at the date of grant of
A$0.459&nbsp;per option using a Black-Scholes model, taking into
account time value and the volatility of the stock price. The
options are exercisable at A$1.18, being a 10% premium to the
share price at the time of grant and may be exercised between
August&nbsp;5, 2004 and August&nbsp;5, 2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Options were granted to specified directors (after receiving
shareholder approval at pSivida&#146;s annual general meeting
held on November&nbsp;15, 2005) and executives on April&nbsp;22,
2005 and have values ranging between A$0.296 and
A$0.335&nbsp;per option at the date of grant using a
Black-Scholes model, taking into account time value and the
volatility of the stock price. The options are exercisable at
A$0.80, being a 7%&nbsp;premium to the share price at the time
of grant and may be exercised between April&nbsp;22, 2005 and
March&nbsp;31, 2010 subject to vesting periods of up to
2&nbsp;years.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida has entered into consulting contracts with certain
directors or their related entities for an indefinite period
which may be terminated by either party on three months written
notice or summary notice in the event of a breach in the terms
of the agreement, the consultant is found guilty of any criminal
act, misconduct or negligence or becomes insolvent. There are no
termination benefits other than what applicable statute dictates.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Pension, Retirement or Similar Benefits</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under Australian government regulations, pSivida is legally
required to contribute&nbsp;9% of employees&#146; gross income
to an approved superannuation fund. Employees are entitled to
contribute additional amounts to the fund at their own
discretion. pSivida makes the required contribution to each
employee&#146;s nominated Superannuation Fund. Contributions by
pSivida of up to 9% of employees&#146; wages and salaries are
legally enforceable in Australia.
</DIV>

<P align="center" style="font-size: 10pt;">66

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSiMedica operates a defined contribution pension scheme. The
pension cost charges for the years ended June&nbsp;30, 2005,
2004 and 2003 under the defined contribution scheme were
&#163;79,411 (approximately A$195,863), &#163;30,660
(approximately A$75,149) and &#163;28,672 (approximately
A$77,740) respectively.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Share Ownership</I></B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Beneficial Ownership of Executive Officers and Directors</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following table sets forth certain information as of
September&nbsp;30, 2005 regarding the beneficial ownership by
each of pSivida&#146;s directors and executive officers:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 9pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>


<TR style="font-size: 7pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Options in</B></TD><TD></TD>
</TR>

<TR style="font-size: 7pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Ordinary Shares</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Options</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Subsidiary(14)</B></TD><TD></TD>
</TR>

<TR style="font-size: 7pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Total</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 7pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Held</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Held</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Share</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Held</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Held</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Held</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Held</B></TD><TD></TD>
</TR>

<TR style="font-size: 7pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Directly</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Indirectly</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Ownership</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Directly</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Indirectly</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Directly</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Indirectly</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    R Brimblecombe(7)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>445,067</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>949,111</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    G J Rezos(3),(5)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,018,630</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,300,652</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5.01</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,771,030</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    R Aston(4),(6)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,618,586</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,475,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3.14</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,049,111</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    S Lake</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>242,061</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    A Ledger</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,900,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.84</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    D Mazzo</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    M Rogers</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    A Finlay(8)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>900,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>108,760</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    L Canham(9)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,909,579</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1.73</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>739,289</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>110,840</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    A Kluczewska(10)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,425,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>495,040</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    M Parry-Billings(11)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    J Ogden(12)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>554,708</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    S Connor(13)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>189,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>444,645</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="1%"></TD>
    <TD width="4%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(1)&nbsp;</TD>
    <TD align="left">
    Beneficial ownership is determined in accordance with the rules
    of the SEC, and generally include voting or investment power
    with respect to securities. Ordinary shares relating to options
    currently exercisable or exercisable within 60&nbsp;days of the
    date of this information statement are deemed outstanding for
    computing the percentage of the person holding such securities
    but are not deemed outstanding for computing the percentage of
    any other person. Except as indicated, and subject to community
    property laws where applicable, the persons named in the table
    above have sole voting and investment power with respect to all
    shares shown as beneficially owned by them.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(2)&nbsp;</TD>
    <TD align="left">
    The percentages are based on 225,962,166 ordinary shares issued
    and outstanding as at September&nbsp;30, 2005.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(3)&nbsp;</TD>
    <TD align="left">
    Of such shares, 2,018,630 are directly held by Mr.&nbsp;Rezos,
    3,325,717 are held by Joanne Rezos, Mr.&nbsp;Rezos&#146; wife,
    3,059,333 are held by Mr.&nbsp;and Mrs.&nbsp;Rezos as trustees
    for the Rezos family superannuation Fund, 2,510,607 are held by
    Aymon Pacific Pty Ltd as trustee for the Jerezos Discretionary
    Trust and 376,995 are held by Viaticus Capital Pty Ltd, a
    Australian corporation owned by Mr.&nbsp;Rezos. Mr.&nbsp;Rezos
    may be deemed to be the beneficial owner of the ordinary shares
    held directly by Aymon Pacific Pty Ltd as trustee for the
    Jerezos Discretionary Trust, Mr.&nbsp;and Mrs.&nbsp;Rezos as
    trustees for the Rezos Family Superannuation Fund,
    Mrs.&nbsp;Rezos and Viaticus Capital Pty Ltd.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(4)&nbsp;</TD>
    <TD align="left">
    Of such shares, 5,618,586 are held directly by Dr&nbsp;Aston,
    1,475,000 are held by Equity Insinger (Trust) (Jersey) Ltd, a
    Jersey corporation owned by Dr&nbsp;Aston. Dr&nbsp;Aston may be
    deemed to be the beneficial owner of the ordinary shares held
    directly by Insinger Equity (Trust) (Jersey) Ltd.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(5)&nbsp;</TD>
    <TD align="left">
    Of such options, 2,771,030 are held directly by Mr.&nbsp;Rezos
    available to be exercised into an equal number of ordinary
    shares with an exercise price of A$1.18&nbsp;per share expiring
    in August&nbsp;2009 and 1,200,000 are held by Aymon Pacific Pty
    Ltd as trustee for the Jerezos Discretionary Trust available</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">67

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="1%"></TD>
    <TD width="4%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD></TD>
    <TD align="left">
    to be exercised into an equal number of ordinary shares with an
    exercise price of A$0.61&nbsp;per share expiring on
    December&nbsp;31, 2007.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(6)&nbsp;</TD>
    <TD align="left">
    Of such options, 500,000 are held directly by Dr&nbsp;Aston
    available to be exercised into an equal number of ordinary
    shares with an exercise price of A$0.61&nbsp;per share expiring
    on December&nbsp;31, 2007; 49,111 are held directly by Dr Aston
    available to be exercised into an equal number of ordinary
    shares with an exercise price of A$1.18&nbsp;per share expiring
    in August&nbsp;2009 and 1,000,000 are held by Newtonmore
    Biosciences Pty&nbsp;Ltd, an Australian corporation owned by
    Dr&nbsp;Aston, available to be exercised into an equal number of
    ordinary shares with an exercise price of A$1.18&nbsp;per share
    expiring in August&nbsp;2009. Dr&nbsp;Aston may be deemed to be
    the beneficial owner of the options held directly by Insinger
    (Trust) Jersey Ltd and Newtonmore Biosciences Pty Ltd.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(7)&nbsp;</TD>
    <TD align="left">
    Of such options, 400,000 are held directly by
    Dr&nbsp;Brimblecombe available to be exercised into an equal
    number of ordinary shares with an exercise price of
    A$0.61&nbsp;per share expiring on December&nbsp;31, 2007; and
    549,111 are held directly by Dr&nbsp;Brimblecombe available to
    be exercised into an equal number of ordinary shares with an
    exercise price of A$1.18&nbsp;per share expiring in August 2009.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(8)&nbsp;</TD>
    <TD align="left">
    Of such options 700,000 are held by Mrs.&nbsp;Sophie Finlay as
    trustee for the Aylesford Trust available to be exercised into
    an equal number of ordinary shares with an exercise price of
    A$1.18&nbsp;per share expiring on August&nbsp;5, 2009 and
    200,000 are held by Mrs.&nbsp;Sophie Finlay as trustee for the
    Aylesford Trust available to be exercised into an equal number
    of ordinary shares with an exercise price of A$0.80&nbsp;per
    share expiring on March&nbsp;31, 2010.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(9)&nbsp;</TD>
    <TD align="left">
    Of such options, 739,289 are held directly by Prof Canham
    available to be exercised into an equal number of ordinary
    shares with an exercise price of A$1.18&nbsp;per share expiring
    in August 2009.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>(10)&nbsp;</TD>
    <TD align="left">
    Of such options, 1,200,000 are held directly by
    Dr&nbsp;Kluczewska with one third vesting annually from
    October&nbsp;21, 2003 available to be exercised into an equal
    number of ordinary shares with an exercise price of
    A$0.61&nbsp;per share expiring in December&nbsp;2007; 100,000
    are held directly by Dr&nbsp;Kluczewska available to be
    exercised into an equal number of ordinary shares with an
    exercise price of A$1.18&nbsp;per share expiring in
    August&nbsp;2009 and 125,000 are held directly by
    Dr&nbsp;Kluczewska available to be exercised into an equal
    number of ordinary shares with an exercise price of
    A$0.80&nbsp;per share expiring in 31&nbsp;March 2010.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(11)&nbsp;</TD>
    <TD align="left">
    Of such options, 1,200,000 are held directly by Dr&nbsp;Mark
    Parry-Billings with one third vesting annually from
    April&nbsp;22, 2005 available to be exercised into an equal
    number of ordinary shares with an exercise price of
    A$0.80&nbsp;per share expiring in March 2010.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(12)&nbsp;</TD>
    <TD align="left">
    Of such options, 429,708 are held directly by Dr&nbsp;Ogden
    available to be exercised into an equal number of ordinary
    shares with an exercise price of A$1.18&nbsp;per share expiring
    in August 2009 and 125,000 are held directly by Dr&nbsp;Ogden
    available to be exercised into an equal number of ordinary
    shares with an exercise price of A$0.80&nbsp;per share expiring
    in 31&nbsp;March&nbsp;2010.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(13)&nbsp;</TD>
    <TD align="left">
    Of such options, 319,645 held directly by Mr.&nbsp;Connor
    available to be exercised into an equal number of ordinary
    shares with an exercise price of A$1.18&nbsp;per share expiring
    in August 2009 and 125,000 are held directly by Mr.&nbsp;Connor
    available to be exercised into an equal number of ordinary
    shares with an exercise price of A$0.80&nbsp;per share expiring
    in 31&nbsp;March 2010.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(14)&nbsp;</TD>
    <TD align="left">
    Options in a subsidiary represent options to acquire shares in
    the wholly-owned subsidiary AION Diagnostics Limited at an
    exercise price of nil, expiring 3 February 2008 and subject to
    various vesting conditions.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Stock Option Plan</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
At pSivida&#146;s annual general meeting on November&nbsp;1,
2001, shareholders approved the Employee Share Option Plan, or
ESOP, whereby directors and executives of the consolidated
entity are issued options over the ordinary shares of pSivida.
Shareholders re-approved the ESOP at the Company&#146;s annual
general meeting held on November&nbsp;17, 2004. The options are
issued without consideration in accordance
</DIV>

<P align="center" style="font-size: 10pt;">68


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
with performance guidelines established by the board of
directors of pSivida. The following table presents option grant
information as of September&nbsp;30, 2005.
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="49%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="center" nowrap><B>Options Outstanding</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>Weighted Average Exercise Price</B></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
</TR>

<TR>
    <TD align="center" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    19,561,713</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">
    A$1.00</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
* Note that 2,830,000 of these options were not issued under the
ESOP.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Plan Administration</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The ESOP is administered by pSivida&#146;s board.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Exercise of Options Since June&nbsp;30, 2005</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
As of September&nbsp;30, 2005 no options issued under
the ESOP had been exercised since June 30, 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Principal Shareholders
and Related Party Transactions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Principal Shareholders</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following table sets forth certain information as at
September&nbsp;30, 2005, regarding the beneficial ownership by
all shareholders known to pSivida to own beneficially more than
5% of pSivida&#146;s ordinary shares. The voting rights of
pSivida&#146;s major shareholders do not differ from the voting
rights of other holders of its ordinary shares.
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Percentage of</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Ordinary Shares</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Outstanding</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Beneficially</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Ordinary</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2" align="left" nowrap><B>Shareholder</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Owned(1)</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Shares(2)</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    QinetiQ Group Plc</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>35,699,629</TD>
    <TD align="left" valign="bottom" nowrap>(3)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>15.80</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    Gavin Rezos</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,291,282</TD>
    <TD align="left" valign="bottom" nowrap>(4)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5.00</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directors and Executive Officers as a Group</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>24,856,514</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11.00</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>(1)&nbsp;</TD>
    <TD align="left">
    Beneficial ownership is determined in accordance with the rules
    of the SEC, and generally include voting or investment power
    with respect to securities. Ordinary shares relating to options
    currently exercisable or exercisable within 60&nbsp;days of the
    date of this information statement are deemed outstanding for
    computing the percentage of the person holding such securities
    but are not deemed outstanding for computing the percentage of
    any other person. Except as indicated, and subject to community
    property laws where applicable, the persons named in the table
    above have sole voting and investment power with respect to all
    ordinary shares shown as beneficially owned by them.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(2)&nbsp;</TD>
    <TD align="left">
    The percentages are based on 225,962,166 ordinary shares issued
    and outstanding as at September&nbsp;30, 2005.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(3)&nbsp;</TD>
    <TD align="left">
    Of such shares, 10,053,203 are held directly by QinetiQ Group
    Plc, and 25,646,426 are held indirectly by QinetiQ Group Plc.
    QinetiQ&#146;s address is Cody Technology Park, Ively Road,
    Hampshire GU14oLX, United Kingdom.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(4)&nbsp;</TD>
    <TD align="left">
    Of such shares, 2,018,630 are directly held by Mr.&nbsp;Rezos,
    3,325,717 are held by Joanne Rezos, Mr.&nbsp;Rezos&#146; wife,
    3,059,333 are held by Mr.&nbsp;and Mrs.&nbsp;Rezos as trustees
    for the Rezos Family Superannuation Fund, 2,510,607 are held by
    Aymon Pacific Pty Ltd as trustee for the Jerezos Discretionary
    Trust and 376,995 are held by Viaticus Capital Pty Ltd, a
    Australian corporation owned by Mr.&nbsp;Rezos. Mr.&nbsp;Rezos
    may be deemed to be the beneficial owner of the ordinary shares
    held directly by Aymon Pacific Pty Ltd and Viaticus Capital Pty
    Ltd. Mr.&nbsp;Rezos&#146; address is Level&nbsp;12 BGC Centre,
    28&nbsp;The Esplanade, Perth WA 6000, Australia.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
As of September&nbsp;30, 2005, pSivida had 225,962,166 ordinary
shares on issue, of which 155,143,201 were held by 3,538
Australian resident holders and 70,818,965 were held by 665
foreign holders. 525 of the
</DIV>

<P align="center" style="font-size: 10pt;">69
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
foreign holders, representing 8,487,230 ordinary shares, or less
than 3.8%, are known by pSivida to have U.S.&nbsp;addresses at
September&nbsp;30, 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
As of September&nbsp;30, 2005, pSivida had 19,561,713 options
convertible into ordinary shares on issue, of which 9,715,141
were held by 15 Australian resident holders and 9,846,572 were
held by 44 foreign holders. Twenty of the foreign holders,
representing 3,145,000&nbsp;options, are known by pSivida to
have U.S.&nbsp;addresses as of September&nbsp;30, 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
QinetiQ on behalf of itself and its affiliates has entered into
a deed poll whereby it has pledged that, until October&nbsp;26,
2009, as long as it holds 10% or more of pSivida&#146;s
outstanding ordinary shares, it will exercise its voting rights
in line with the majority of proxy votes exercisable by validly
appointed proxies in relation to any resolution of
pSivida&#146;s shareholders. The deed poll can be enforced by
any of pSivida&#146;s shareholders. In addition, if at some time
QinetiQ owns less than 10% of pSivida&#146;s outstanding
ordinary shares and subsequently again owns 10% or more of
pSivida&#146;s outstanding ordinary shares, QinetiQ&#146;s
obligations under the deed poll would again be effective. The
voluntary restriction on QinetiQ is irrevocable and applies for
a period of five years until October&nbsp;26, 2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida is not aware of any direct or indirect ownership or
control of pSivida by another corporation(s), by any foreign
government or by any other natural or legal person(s) severally
or jointly. pSivida does not know of any arrangements, the
operation of which may at a subsequent date result in a change
in control of pSivida.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Related Party Transactions</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the years ended June&nbsp;30, 2005, 2004 and 2003,
pSivida paid consultancy fees and other amounts totaling
Nil,&nbsp;A$341,362 and A$173,333, respectively to Aymon Pacific
Pty Ltd, a company controlled by Mr.&nbsp;Rezos. These fees and
other amounts have been included in remuneration of directors
and executive remuneration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the years ended June&nbsp;30, 2005, 2004 and 2003,
amounts of &#163;220,689 (approximately A$544,320),
&#163;186,682 (approximately A$457,567) and &#163;207,492
(approximately A$564,033), respectively, were paid or payable to
QinetiQ, then a shareholder of pSiMedica, for the use of
laboratory facilities and for patent filing and administration.
Following the transaction on August&nbsp;4, 2004 to acquire the
shares in pSiMedica that pSivida did not already own, QinetiQ
and its related entities held approximately 17.5% of
pSivida&#146;s issued share capital.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the years ended June&nbsp;30, 2005, 2004 and 2003 pSivida
paid consultancy fees and other amounts totaling A$319,941 and
A$44,000 and Nil, respectively, to Newtonmore Biosciences Pty
Ltd, a company controlled by Dr.&nbsp;Aston. These fees and
other amounts have been included in remuneration of directors
and executive remuneration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the years ended June&nbsp;30, 2005, 2004 and 2003,
pSivida paid consultancy fees of A$2,083, A$71,858 and A$45,000,
respectively, to Blackwood Pty Ltd, a company controlled by
Mrs.&nbsp;Donovan. These fees have been included in remuneration
of directors and executive remuneration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the years ended June&nbsp;30, 2005, 2004 and 2003,
pSivida paid amounts of Nil, A$12,367 and A$52,187,
respectively, to Viaticus Capital Ltd, a company controlled by
Mr.&nbsp;Rezos, for sublease of BGC Centre office space.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the years ended June&nbsp;30, 2005, 2004 and 2003,
pSivida paid Blake Dawson Waldron A$114,832, A$78,068 and
A$22,622, respectively, for various routine arms-length legal
services. Blake Dawson Waldron is a national Australian law
firm, and one of the partners thereof is a relative of a pSivida
director.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the years ended June&nbsp;30, 2005, 2004 and 2003,
amounts of A$125,982, A$149,489, and Nil respectively, were paid
or payable to Albion Capital Partners, of which Mr.&nbsp;Rezos
is a partner, for sublease of BGC Centre office space.
</DIV>

<P align="center" style="font-size: 10pt;">70

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Amounts owing to directors, director-related parties and other
related parties as of June&nbsp;30, 2005, 2004 and 2003 were
A$50,102 A$37,145 and A$31,182, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
From July&nbsp;1, 2005 through to the date of this information
statement, there have been no material related party
transactions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Enforceability of Civil
Liabilities</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida is a public company limited by shares incorporated under
the laws of Western Australia. The majority of pSivida&#146;s
directors and executive officers and all of its current
employees named in this information statement reside outside the
United States, and the assets of those non-resident directors
and all of pSivida&#146;s assets are located outside the United
States. It may be difficult for investors to effect service of
process upon these directors and executive officers. In
addition, there may be difficulties in certain circumstances in
using the courts of Australia to enforce judgments obtained in
United States courts in actions against pSivida or its
directors, including judgments based on the civil liability
provisions of the federal securities laws of the United States.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="1%"></TD>
    <TD width="99%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><FONT style="font-variant:SMALL-CAPS">Independent Registered
    Public Accounting Firm</FONT></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The consolidated financial statements of pSivida Limited and
subsidiaries as of June&nbsp;30, 2005 and 2004 and for each of
the three years in the period ended June&nbsp;30, 2005 and for
the period from December&nbsp;1, 2000 (date of inception of
development stage) to June&nbsp;30, 2005, included in this
information statement have been audited by Deloitte Touche
Tohmatsu, an independent registered public accounting firm, as
stated in their report appearing herein.
</DIV>

<P align="center" style="font-size: 10pt;">71

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>CDS INFORMATION</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Selected Consolidated
Financial Data of CDS</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
You should read the following selected consolidated financial
information in conjunction with the consolidated financial
statements and related notes of CDS as well as
&#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations of CDS&#148; included
elsewhere in this information statement. The consolidated
statement of operations data for the years ended
December&nbsp;31, 2002, 2003 and 2004 and the consolidated
balance sheet data at December&nbsp;31, 2003 and 2004 are
derived from audited financial statements included elsewhere in
the information statement. The statement of operations data for
the years ended December&nbsp;31, 2000 and 2001 and the balance
sheet data at December&nbsp;31, 2000, 2001 and 2002 have been
derived from CDS&#146; audited financial statements that are not
included in this information statement. The consolidated
statement of operations data for the nine months ended
September&nbsp;30, 2004 and 2005 and the consolidated balance
sheet data at September&nbsp;30, 2005 have been taken from
CDS&#146; unaudited condensed consolidated financial statements
that are included elsewhere in this information statement and
include, in the opinion of CDS management, all adjustments
necessary for a fair statement of such data. Historical results
are not necessarily indicative of results to be expected for any
future period.
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 9pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="39%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Nine Months</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="19">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Ended</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap><B>Year Ended December&nbsp;31,</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>September&nbsp;30,</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2000</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2001</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2002</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>(Unaudited)</B></TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="26" align="center" nowrap><B>(In US$ thousands)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Consolidated Statement of Operations Data:</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Revenues<B>:</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Collaborative research and development&nbsp;&#151; related party</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>4,025</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>12,614</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>20,875</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>10,945</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>3,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>3,500</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Collaborative research and development&nbsp;&#151; other</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>176</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Royalties&nbsp;&#151; related party</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>380</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>265</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>168</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>132</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>120</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>89</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,074</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Government research grants</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>524</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>287</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total revenues</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,929</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13,166</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21,043</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,077</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,120</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>89</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,750</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Operating expenses:</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Research and development</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,033</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,915</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>17,983</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,187</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,083</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,336</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,507</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Royalties paid</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>356</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>131</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>82</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>66</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>60</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>44</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>37</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    General and administrative</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,955</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,690</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,022</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,571</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,646</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,539</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,741</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Charge for asset impairment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,575</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total operating expenses</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,344</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21,736</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,087</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>26,399</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,789</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,919</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,285</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Earnings (loss) from operations</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,415</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(8,570</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(8,044</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,322</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,669</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,830</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,465</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Interest income and other, net</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>804</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,346</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>495</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>68</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(207</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(151</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(38</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Earnings (loss) before income taxes</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,611</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,224</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,549</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,254</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,876</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,981</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,427</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net earnings (loss)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,803</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,224</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,549</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,254</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,876</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,981</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,427</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accretion of redeemable convertible preferred stock</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(197</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(472</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(472</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(942</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,124</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,501</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,926</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net (loss) attributable to common stockholders</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(4,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(7,696</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(8,021</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(16,196</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(8,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(8,482</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(499</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">72

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 9pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="42%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap><B>December&nbsp;31,</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>September&nbsp;30,</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2000</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2001</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2002</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Unaudited</B></TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="22" align="center" nowrap><B>(In thousands)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Consolidated Balance Sheet Data:</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash and cash equivalents</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>18,789</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>13,387</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>17,217</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>6,273</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1,015</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1,817</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Working capital</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>23,726</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>15,431</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,229</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,136</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,105</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,814</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>34,304</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>40,604</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31,920</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,434</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,625</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Redeemable convertible preferred stock</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31,376</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31,848</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>32,320</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>27,767</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>28,027</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,677</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total stockholders&#146; deficit</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,194</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(8,592</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(16,197</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(26,494</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(31,126</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(30,932</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">73

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Management&#146;s
Discussion and Analysis of Financial Condition</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt;">
<B><FONT style="font-variant:SMALL-CAPS">and Results of
Operations of CDS</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>You should read the following discussion and analysis of
financial condition and results of operations of CDS in
conjunction with &#147;Selected Consolidated Financial Data of
CDS&#148; and the consolidated financial statements of CDS and
related notes appearing elsewhere in this information statement.
The merger, if completed, may have material effects on the
business of CDS in the future and on the forward-looking
statements contained in this information statement.</I>
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Overview</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS designs and develops innovative sustained-release drug
delivery products. Since it was founded in 1991, CDS has
primarily engaged in the research and development of products
and product candidates using its proprietary technologies. To
date, CDS has developed two commercial products, Vitrasert and
Retisert. Vitrasert, a product for the treatment of
cytomegalovirus retinitis, or CMV retinitis, a blinding eye
disease that affects late-stage AIDS patients, has been marketed
since 1996, and Retisert, a product for the treatment of
posterior uveitis, was approved by the FDA in April 2005 and
received Medicare reimbursement coverage in October 2005. CDS
has an additional product, Medidur for the treatment of diabetic
macular edema, or DME, in Phase&nbsp;III trials and additional
product candidates in various stages of clinical and
pre-clinical development.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Commercialized in 1996, Vitrasert is licensed to and sold by
Bausch&nbsp;&#38; Lomb Incorporated under a 1992 licensing and
development agreement. Improvements in the treatment of AIDS/HIV
have significantly decreased the incidence of CMV retinitis in
the more developed nations that have the resources to provide
advanced medical care, and sales of Vitrasert have declined each
year since 2000. As a result, CDS&#146; royalty revenues from
sales of Vitrasert have also declined, together with the
royalties paid by CDS on those sales pursuant to patent licenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS&#146; revenues during the three years ended
December&nbsp;31, 2004 and during the nine months ended
September&nbsp;30, 2005 were primarily from payments for
research and development, achievement of milestones and license
fees, which CDS recorded as collaborative research and
development revenue.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under a 1999 licensing and development agreement with
Bausch&nbsp;&#38; Lomb, CDS licensed Bausch&nbsp;&#38; Lomb its
technologies for treatment of eye disease, and Bausch&nbsp;&#38;
Lomb committed to fund budgeted research and development
performed by them and by CDS with respect to product candidates
for the treatment of three eye diseases, including posterior
uveitis and DME, and to make license fee and milestone payments
to CDS. Research and development revenue under that agreement
aggregated $20.9&nbsp;million in 2002 and $10.9&nbsp;million in
2003, comprising substantially all of CDS&#146; revenues in
those periods. In June 2003, Bausch&nbsp;&#38; Lomb informed CDS
that all future research and development under the 1999
licensing and development agreement would be undertaken by
Bausch&nbsp;&#38; Lomb and that Bausch&nbsp;&#38; Lomb would no
longer fund research and development by CDS. As a result of this
loss of revenue, CDS terminated the employment of approximately
74 employees, or 70% of its workforce, in June 2003, most of
whose costs were funded directly or indirectly by
Bausch&nbsp;&#38; Lomb, transferred clinical trials to
Bausch&nbsp;&#38; Lomb and significantly cut back its research
and development program. CDS recorded a $6.6&nbsp;million
impairment charge with respect to its assets that would no
longer be used as had been contemplated under the 1999 licensing
agreement. CDS undertook a second reduction in its workforce in
August 2004 as a result of decreasing cash resources.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In December 2003, CDS and Bausch&nbsp;&#38; Lomb amended their
1992 and 1999 licensing and development agreements into one
licensing and development agreement. Retisert for posterior
uveitis and DME are licensed to Bausch&nbsp;&#38; Lomb under the
amended agreement. As a result of the amended Bausch&nbsp;&#38;
Lomb agreement, CDS reacquired significant rights to its
technologies.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In February 2005, CDS entered into a license and development
agreement with Alimera Sciences Inc. to co-develop Medidur for
DME. In the nine months ended September&nbsp;30, 2005, Alimera
Sciences paid
</DIV>

<P align="center" style="font-size: 10pt;">74

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
CDS the license fee and milestone payments provided under that
agreement. The Medidur product for DME entered phase&nbsp;III
trials in 2005.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Critical Accounting Policy</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following is a description of CDS&#146; revenue recognition
policy, which it believes is important to the portrayal of its
financial condition and results and requires its most difficult,
subjective or complex judgments as a result of the need to make
estimates about the effect of matters that are inherently
uncertain. CDS&#146; significant accounting policies are more
fully described in Note 2 to its Consolidated Financial
Statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In accounting for revenue, a key component of CDS&#146; results
of operations, CDS follows the provisions of the Securities and
Exchange Commission&#146;s Staff Accounting Bulletin (SAB) No.
104 (SAB No. 104), <I>Revenue Recognition</I>, Emerging Issues
Task Force (EITF) Issue No. 00-21 (EITF 00-21), <I>Accounting
for Revenue Arrangements with Multiple Deliverables</I>, EITF
Issue No. 99-19 (EITF 99-19), <I>Reporting Revenue Gross as a
Principal Versus Net as an Agent</I>, and EITF Issue No. 01-9
(EITF 01-9), <I>Accounting for Consideration Given by a Vendor
to a Customer (Including a Reseller of the Vendor&#146;s
Products).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Non-refundable license fees are recognized as revenue when CDS
has a contractual right to receive such payment, the contract
price is fixed or determinable, the collection of the resulting
receivable is reasonably assured, and CDS has no further
performance obligations under the license agreement. Multiple
element arrangements, such as license and development
arrangements, are analyzed to determine whether the elements,
the license and the performance obligations can be separated or
whether they must be accounted for as a single unit of
accounting in accordance with EITF 00-21. CDS recognizes
up-front license payments as revenue upon delivery of the
license only if the license has stand-alone value and the fair
value of the undelivered performance obligations can be
determined. If the fair value of the undelivered performance
obligations can be determined, such obligations would then be
accounted for separately as performed. If the license is
considered to either (i) not to have stand-alone value or
(ii)&nbsp;to have stand-alone value but the fair value of any of
the undelivered performance obligations cannot be determined,
the arrangement would then be accounted for as a single unit of
accounting and the license payments and payments for performance
obligations are recognized as revenue over the estimated period
of when the performance obligations are performed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Whenever CDS determines that an arrangement should be accounted
for as a single unit of accounting, CDS must determine the
period over which the performance obligations will be performed
and revenue will be recognized. Revenue will be recognized using
either a relative performance or straight-line method. CDS
recognizes revenue using the relative performance method
provided that it can reasonably estimate the level of effort
required to complete its performance obligations under an
arrangement and such performance obligations are provided on a
best-efforts basis. Direct labor hours, full-time equivalents or
costs may be used as the measure of performance. Revenue
recognized under the relative performance method is determined
by multiplying the total payments under the arrangement
excluding royalties and unearned milestones, by the ratio of
level of effort incurred to date to estimated total level of
effort required to complete CDS&#146; performance obligations
under the arrangement. Revenue is limited to the lesser of the
cumulative amount of payments received or the cumulative amount
of revenue earned, as determined using the relative performance
method, as of each reporting period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If CDS cannot reasonably estimate the level of effort required
to complete its performance obligations under an arrangement and
the performance obligations are provided on a best-efforts
basis, the total payments under the arrangement, excluding
royalties and payments contingent upon achievement of
substantive milestones, are recognized as revenue on a
straight-line basis over the period CDS expects to complete its
performance obligations. Revenue is limited to the lesser of the
cumulative amount of payments received or the cumulative amount
of revenue earned, as determined using the straight-line basis,
as of the period ending date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Significant management judgment is required in determining the
level of effort required under an arrangement and the period
over which CDS is expected to complete its performance
obligations under an
</DIV>

<P align="center" style="font-size: 10pt;">75

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
arrangement. For its 1999 contract with Bausch &#38; Lomb, CDS
used total project costs as a measure of the level of effort
completed and the total level of effort required to complete its
performance obligations under the arrangement. The amount of
revenue recognized was dependent upon CDS estimates of the total
costs, and such estimates are highly judgmental given the
uncertainties involved in clinical development of products. In
June 2003 Bausch &#38; Lomb took over the development efforts
under the 1999 agreement and thus CDS&#146; performance
obligation under the arrangement ended.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Reimbursement of costs is recognized as revenue provided the
provisions of EITF 99-19 are met, the amounts are determinable,
and collection of the related receivable is reasonably assured.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Royalty revenue is recognized upon the sale of the related
products, provided that the royalty amounts are fixed or
determinable, collection of the related receivable is reasonably
assured and CDS has no remaining performance obligations under
the arrangement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For revenue generating arrangements where CDS, as a vendor,
provides consideration to a licensor or collaborator, as a
customer, CDS applies the provisions of EITF 01-9. EITF 01-9
addresses the accounting for revenue arrangements where the
vendor gives consideration to the customer. Cash consideration
paid to a customer is presumed to be a reduction of the selling
price unless CDS receives an identifiable benefit for the
payment and CDS can reasonably estimate the fair value of the
benefit received. Payments to a customer that are deemed a
reduction of selling price are recorded first as a reduction of
revenue, to the extent of both cumulative revenue recorded to
date and of probable future revenues, which include any
unamortized deferred revenue balances, under all arrangements
with such customer and then as an expense. Payments that are not
deemed to be a reduction of selling price would be recorded as
an expense.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Amounts received prior to satisfying the above revenue
recognition criteria are recorded as deferred revenue in the
accompanying consolidated balance sheets.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Results of Operations</I></B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Nine months ended September&nbsp;30, 2005 and 2004</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Revenues.</I> Total revenues increased $6.7&nbsp;million to
$6.8&nbsp;million for the nine months ended September&nbsp;30,
2005, from $89,000 for the nine months ended September&nbsp;30,
2004 as the result of a $3.5&nbsp;million milestone payment
earned in the 2005 period under CDS&#146; agreement with
Bausch&nbsp;&#38; Lomb, $3.0&nbsp;million of royalties from
Bausch&nbsp;&#38; Lomb recognized as a result of a royalty
advance and $176,000 of license fee and milestone payment earned
under CDS&#146; agreement with Alimera Sciences.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Research and Development.</I> Research and development
expenses decreased $.8&nbsp;million, or 35%, to
$1.5&nbsp;million for the nine months ended September&nbsp;30,
2005, from $2.3&nbsp;million for the nine months ended
September&nbsp;30, 2004. The decrease was primarily due to a
significant reduction in the size of CDS&#146; workforce, which
occurred in August 2004. Salary and benefits decreased by
$425,000 and third party research and development costs
decreased by $214,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>General and Administrative.</I> General and administrative
expenses decreased $.8&nbsp;million or 19%, to $3.7&nbsp;million
for the nine months ended September&nbsp;30, 2005, from
$4.5&nbsp;million for the nine months ended September&nbsp;30,
2004. The decrease was due primarily to a significant reduction
in the size of CDS&#146; workforce in August 2004 resulting in a
decrease of $146,000 of salaries and benefits and a decrease of
$1.0&nbsp;million of non-cash stock compensation charges,
partially offset by an increase of $563,000 of investment
banking expenses related to potential financing transactions .
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Interest Expense.</I> Interest expense decreased $120,000 or
67% to $59,000 for the nine months ended September&nbsp;30,
2005, from $179,000 for the nine months ended September&nbsp;30,
2004. The decrease was due to CDS&#146; repayment of its
mortgage financing in April 2005 upon the sale of its real
estate.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Years ended December&nbsp;31, 2004 and 2003</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Revenues.</I> Total revenues decreased $8.0&nbsp;million, or
72%, to $3.1&nbsp;million for the year ended December&nbsp;31,
2004, from $11.1&nbsp;million for the year ended
December&nbsp;31, 2003.
</DIV>

<P align="center" style="font-size: 10pt;">76

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Collaborative research and development revenue-related party
decreased $7.9&nbsp;million, or 73%, to $3.0&nbsp;million for
the year ended December&nbsp;31, 2004, from $10.9&nbsp;million
for the year ended December&nbsp;31, 2003. The decrease was due
to the decision by Bausch&nbsp;&#38; Lomb in mid-2003 to cease
funding CDS&#146; research under CDS&#146; agreement with
Bausch&nbsp;&#38; Lomb and to undertake the research directly.
This reduction in collaborative research and development
revenue-related party was partially offset by a
$3.0&nbsp;million milestone payment earned in 2004 under that
agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Royalty revenue decreased $12,000, or 9%, to $120,000 for the
year ended December&nbsp;31, 2004, from $132,000 for the year
ended December&nbsp;31, 2003. The decrease was due to a decrease
in Vitrasert royalties paid to CDS as the result of lower
Vitrasert sales.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Research and Development.</I> Research and development
expenses decreased $9.1&nbsp;million, or 75%, to
$3.1&nbsp;million for the year ended December&nbsp;31, 2004,
from $12.2&nbsp;million for the year ended December&nbsp;31,
2003. The decrease was primarily due to cessation in mid-2003 of
research and development activities by CDS under its agreement
with Bausch&nbsp;&#38; Lomb as a result of Bausch&nbsp;&#38;
Lomb&#146;s decision to undertake the research directly. This
resulted in a decrease of $3.3&nbsp;million of salaries and
benefits and a decrease of $4.4&nbsp;million of third party
research and development costs. Depreciation expense decreased
by $602,000 from 2003 to 2004, primarily resulting from the
asset impairment charge incurred in June 2003.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Royalties Paid.</I> Royalties expense decreased $6,000, or
9%, to $60,000 for the year ended December&nbsp;31, 2004, from
$66,000 for the year ended December&nbsp;31, 2003. The decrease
was attributable to lower Vitrasert sales.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>General and Administrative.</I> General and administrative
expenses decreased $2.0&nbsp;million, or 25%, to
$5.6&nbsp;million for the year ended December&nbsp;31, 2004,
from $7.6&nbsp;million for the year ended December&nbsp;31,
2003. The decrease was due primarily to significant reductions
in CDS&#146; workforce in June 2003 and August 2004. This
resulted in a decrease of $1.2&nbsp;million of salaries and
benefits costs, $712,000 of legal and accounting costs, $475,000
of facility occupancy and $363,000 of consulting and recruitment
costs. Non-cash stock compensation charges increased by $876,000
from 2003 to 2004.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Interest Income.</I> Interest income, decreased $205,000, or
84%, to $38,000 for the year ended December&nbsp;31, 2004 from
$243,000 for the year ended December&nbsp;31, 2003 primarily as
the result of lower average investments and marketable
securities in 2004.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Years ended December&nbsp;31, 2003 and 2002</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Revenues.</I> Total revenues decreased $9.9&nbsp;million, or
47%, to $11.1&nbsp;million for the year ended December&nbsp;31,
2003, from $21.0&nbsp;million for the year ended
December&nbsp;31, 2002.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Collaborative research and development revenue-related party
decreased $10.0&nbsp;million, or 48%, to $10.9&nbsp;million for
the year ended December&nbsp;31, 2003, from $20.9&nbsp;million
for the year ended December&nbsp;31, 2002, due to the decision
by Bausch&nbsp;&#38; Lomb in mid-2003 to cease funding CDS&#146;
research under the agreement with Bausch&nbsp;&#38; Lomb.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Royalties&nbsp;&#151; related party revenue decreased $36,000,
or 21%, to $132,000 for the year ended December&nbsp;31, 2003,
from $168,000 for the year ended December&nbsp;31, 2002. This
decrease was due to a decrease in Vitrasert royalties paid to
CDS as the result of lower Vitrasert sales.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Research and Development.</I> Research and development
expenses decreased $5.8&nbsp;million, or 32%, to
$12.2&nbsp;million for the year ended December&nbsp;31, 2003,
from $18.0&nbsp;million for the year ended December&nbsp;31,
2002. The decrease was due to reduced research and development
activities in 2003 under CDS&#146; agreement with
Bausch&nbsp;&#38; Lomb. This resulted in a decrease of
$1.2&nbsp;million of salaries and benefits and a decrease of
$4.6&nbsp;million in third party research and development costs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Royalties Paid.</I> Royalties expense decreased $16,000 or
20%, to $66,000 for the year ended December&nbsp;31, 2003, from
$82,000 for the year ended December&nbsp;31, 2002. The decrease
was attributable to decreased royalty payments as the result of
lower Vitrasert sales.
</DIV>

<P align="center" style="font-size: 10pt;">77

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>General and Administrative.</I> General and administrative
expenses decreased $3.5&nbsp;million, or 31%, to
$7.6&nbsp;million for the year ended December&nbsp;31, 2003,
from $11.0&nbsp;million for the year ended December&nbsp;31,
2002. The decrease was due to the significant reduction in the
size of CDS&#146; workforce in June 2003. This resulted in a
decrease of $538,000 of salaries and benefits, $450,000 of
non-cash stock compensation charges, $436,000 of consulting and
recruitment costs. In addition costs of $2.1&nbsp;million
related to a potential initial public offering were recorded in
2002.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Interest Income.</I> Interest income decreased $272,000, or
53%, to $243,000 for the year ended December&nbsp;31, 2003, from
$515,000 for the year ended December&nbsp;31, 2002. The decrease
was due to decreased interest earned from the lower average
outstanding balances of cash and cash equivalents in 2004. The
decrease was also due to higher interest expense in 2004
attributable to a mortgage financing in August 2002.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Liquidity and Capital Resources</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the three years ended December&nbsp;31, 2004, CDS
incurred net losses. For the period from January&nbsp;1, 2002
through September&nbsp;30, 2005, CDS&#146; primary source of
revenues and cash flows were payments under its agreements with
Bausch&nbsp;&#38; Lomb. Because Bausch&nbsp;&#38; Lomb ceased
funding research and development by CDS under the 1999 licensing
and development agreement in mid-2003, CDS&#146; revenues have
decreased significantly, and CDS has significantly reduced
operations and sold its real estate to reduce its expenditures
and conserve cash. Although CDS expects to receive royalties
from Retisert sales, it is unable to predict the amount or
timing of receipt of such royalties. Accordingly, CDS believes
that it will require additional financing. If the merger with
pSivida is not completed, there can be no assurance that CDS
will be able to obtain additional financing, or, if available,
that CDS will be able to obtain such additional financing on
acceptable terms. CDS&#146; future capital requirements will
depend on many factors, including:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the number, rate, progress and results of research programs and
    pre-clinical and clinical trials of CDS and those to whom it has
    licensed and may license its technologies,</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the terms of licensing agreements and collaborations entered
    into by CDS with respect to its technologies, including
    CDS&#146; decisions with respect to funding under the Alimera
    Sciences agreement,</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the decisions of CDS and its licensees with respect to
    commercialization of products and the timing and success of CDS
    and its licensees in commercializing products,&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    costs incurred in obtaining, enforcing and defending patent and
    other intellectual property rights.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Cash used in operating activities was $10.2&nbsp;million for the
year ended December&nbsp;31, 2002, $9.3&nbsp;million for the
year ended December&nbsp;31, 2003, $5.0&nbsp;million for the
year ended December&nbsp;31, 2004, and $4.9&nbsp;million for the
nine months ended September&nbsp;30, 2004. Cash provided by
operating activities was $579,000&nbsp;million for the nine
months ended September&nbsp;30, 2005. The decrease in cash used
in operating activities from the year ended December&nbsp;31,
2002 to the year ended December&nbsp;31, 2003 was primarily due
to significant reductions during 2003 of accounts payable,
accrued expenses and deferred revenue offset by a
$5.8&nbsp;million advance from Bausch and Lomb. The decrease in
cash used in operating activities from the year ended
December&nbsp;31, 2003 to the year ended December&nbsp;31, 2004
was due primarily to a significant reduction in CDS&#146; loss
before taxes, partially offset by the repayment of
$3.0&nbsp;million of advances from Bausch and Lomb. The increase
in cash provided by operating activities from the nine months
ended September&nbsp;30, 2004 to the nine months ended
September&nbsp;30, 2005 was primarily due to improved operating
results in the 2005 period as a result of increased
collaborative research and development and royalty revenues.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Cash provided by investing activities was $868,000 for the year
ended December&nbsp;31, 2002, $6.0&nbsp;million for the year
ended December&nbsp;31, 2003, $1.5&nbsp;million for the year
ended December&nbsp;31, 2004; $1.5&nbsp;million for the nine
months ended September&nbsp;30, 2004 and $3.8&nbsp;million for
the nine months ended September&nbsp;30, 2005. The increase in
cash provided by investing activities from the year ended
</DIV>

<P align="center" style="font-size: 10pt;">78

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
December&nbsp;31, 2002 to the year ended December&nbsp;31, 2003
was primarily due to $4.8&nbsp;million lower purchases of
property and equipment in 2003 than 2002, which included the
purchase of real estate. The decrease in cash provided by
investing activities from the year ended December&nbsp;31, 2003
to the year ended December&nbsp;31, 2004 was primarily due to
the net effects of CDS&#146; short-term investing activities
which resulted in the net sales of $7.4&nbsp;million of
short-term investments during 2003 compared to $1.5&nbsp;million
of net sales in 2004, partially offset by equipment purchases
which were $1.4&nbsp;million lower in 2004. The increase in cash
provided by investing activities from the nine months ended
September&nbsp;30, 2004 to the nine months ended
September&nbsp;30, 2005 was primarily due to proceeds received
from the sale of real estate in the 2005 period offset by no
sales of investments in 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Cash provided by financing activities was $4.1&nbsp;million for
the year ended December&nbsp;31, 2002, cash used in financing
activities was, $205,000 for the year ended December&nbsp;31,
2003; $200,000 for the year ended December&nbsp;31, 2004,
$150,000 for the nine months ended September&nbsp;30, 2004 and
$3.5&nbsp;million for the nine months ended September&nbsp;30,
2005. The decrease in cash provided by financing activities from
the year ended December&nbsp;31, 2002 to the year ended
December&nbsp;31, 2003 was primarily due to $4.0&nbsp;million
provided in 2002 by the proceeds from the issuance of long-term
debt. The increase of approximately $3.4&nbsp;million in cash
used in financing activities from the nine months ended
September&nbsp;30, 2004 to the nine months ended
September&nbsp;30, 2005 was due to $3.5&nbsp;million of payments
of long term debt related to the sale of CDS&#146; facility in
2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS had working capital of $7.2&nbsp;million at
December&nbsp;31, 2002 and $2.1&nbsp;million at
December&nbsp;31, 2003, a working capital deficit of
$4.1&nbsp;million at December&nbsp;31, 2004 and a working
capital deficit of $1.8&nbsp;million at September&nbsp;30, 2005.
The decrease in working capital from December&nbsp;31, 2002 to
December&nbsp;31, 2003 was primarily due to a net loss in 2003
and $1.4&nbsp;million of property and equipment purchases,
partially offset by the reclassification during 2003 of
$3.0&nbsp;million of liabilities to Bausch&nbsp;&#38; Lomb to
long-term liabilities. The decrease in working capital from
December&nbsp;31, 2003 to December&nbsp;31, 2004 was primarily
due to a net loss in 2004. The working capital deficit decreased
from December&nbsp;31, 2004 to September&nbsp;30, 2005 as a
result of net losses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS had cash and cash equivalents of $8.1&nbsp;million at
December&nbsp;31, 2002, $4.7&nbsp;million at December&nbsp;31,
2003, $1.0&nbsp;million at December&nbsp;31, 2004 and
$1.8&nbsp;million at September&nbsp;30, 2005. The decrease of
approximately $3.4&nbsp;million in cash and cash equivalents
from December&nbsp;31, 2002 to December&nbsp;31, 2003 was
primarily due to cash used by operations of $9.2&nbsp;million,
partly offset by sales of short-term investments of
$7.5&nbsp;million net of $1.5&nbsp;million of property and
equipment purchases. The decrease of approximately
$3.7&nbsp;million in cash and cash equivalents from
December&nbsp;31, 2003 to December&nbsp;31, 2004 was primarily
due CDS&#146; operating loss during 2004, partially offset by
net sales of $1.5&nbsp;million of short-term investments. The
increase of $.8&nbsp;million in cash and cash equivalents from
December&nbsp;31, 2004 to September&nbsp;30, 2005 was primarily
due to cash provided by operating activities. Although CDS
expects to receive royalties from Retisert sales, it is unable
to predict the amount or timing of receipt of such royalties.
Accordingly, CDS believes that it will require additional
financing. If the merger with pSivida is not completed, there
can be no assurance that CDS will be able to obtain additional
financing, or, if available, that CDS will be able to obtain
such additional financing on acceptable terms.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following table outlines CDS&#146; contractual obligations
as of September&nbsp;30, 2005 for payments under its
indebtedness (including capital leases), purchase obligations,
operating leases and other obligations:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="45%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap><B>Payments due by period</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap><B>(in thousands of U.S.&nbsp;Dollars)</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Less than 1</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="7">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>More than 5</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Total</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>year</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>1-3 years</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>3-5 years</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>years</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Operating Lease Obligations</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>702</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>226</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>476</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Total</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>702</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>226</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>476</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">79

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The lease commitments in the above table do not include costs
for insurance, real estate taxes and common area maintenance
costs that CDS is obligated to pay.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><I>Recent accounting pronouncements</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In December 2004, the FASB issued SFAS No.&nbsp;153,<I>
&#147;Exchange of Nonmonetary Assets&#148;</I>
(&#147;SFAS&nbsp;153&#148;), which is an amendment to APB
Opinion No.&nbsp;29, <I>&#147;Accounting for Nonmonetary
Transactions&#148; (&#147;APB&nbsp;29&#148;)</I>. The guidance
of APB&nbsp;29, is based on the principle that exchanges of
nonmonetary assets should be measured based on the fair value of
the assets exchanged. The guidance in that opinion, however,
included certain exceptions to that principle. SFAS&nbsp;153
amends APB&nbsp;29 to eliminate the exception for nonmonetary
exchanges of similar productive assets and replaces it with a
general exception for exchanges of nonmonetary assets that do
not have commercial substance. A nonmonetary exchange has
commercial substance if the future cash flows of the entity are
expected to change significantly as a result of the exchange.
The adoption of SFAS&nbsp;153 is not expected to change
significantly as a result of the exchange. the adoption of
SFAS&nbsp;153 is not expected to have a material impact on
CDS&#146; financial position or results of operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In July 2005, the FASB issued a staff position, or FSP,
No.&nbsp;150-5, &#147;<I>Issuer&#146;s Accounting Under FAS 150
for Freestanding Warrants and Other Similar Instruments or
Shares that are Redeemable.</I>&#148; This FSP addresses whether
freestanding warrants and other similar instruments that are
redeemable would be subject to the requirements of FASB
Statement No.&nbsp;150, &#147;<I>Accounting for Certain
Financial Instruments with Characteristics of Both Liabilities
and Equity,</I>&#148; regardless of the timing of the redemption
feature or the redemption price. FSP FAS&nbsp;150-1
&#147;<I>Issuers Accounting for Freestanding Instruments
Composed of More Than One Option or Forward Contract Embodying
Obligations Under FASB Statement No.&nbsp;150,</I>&#148; or FSP
150-1, explains that both warrants for shares that are puttable
and warrants for mandatorily redeemable shares are classified as
liabilities under FAS 150 because they embody obligations to
transfer assets. FSP&nbsp;150-5 clarifies that this treatment as
a liability applies whether the shares are redeemable
immediately after the warrant exercise or at some date in the
future and whether the obligation of the issuer to redeem is
conditional or unconditional. The adoption of FSP FAS&nbsp;150-1
is not expected to have a material impact on CDS&#146; financial
position or results of operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><I>Stock-Based Compensation</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In December 2004, the FASB issued Statement of Financial
Accounting Standards, or SFAS, No.&nbsp;123 (revised 2004),
&#147;Share-Based Payments&#148; or SFAS 123R. This statement
eliminates the option to apply the intrinsic value measurement
provisions of Accounting Principles Board, or APB, Opinion
No.&nbsp;25, &#147;Accounting for Stock Issued to
Employees&#148; to stock compensation awards issued to
employees. Rather, SFAS 123R requires companies to measure the
cost of employee services received in exchange for an award of
equity instruments based on the grant-date fair value of the
award. That cost will be recognized over the period during which
an employee is required to provide services in exchange for the
award&nbsp;&#151; the requisite service period (usually the
vesting period). SFAS 123R applies to all awards granted after
the required effective date and to awards modified, repurchased,
or cancelled after that date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS applied APB No.&nbsp;25, <I>Accounting for Stock Issued to
Employees</I>, and related interpretations, in accounting for
its stock-based compensation plans for the year ended
December&nbsp;31, 2002. CDS had adopted the disclosure only
provisions of SFAS No. 148, <I>Accounting for Stock-Based
Compensation&nbsp;&#151; Transition and Disclosure, an amendment
of FASB Statement No.&nbsp;123</I>; therefore, no compensation
expense was included in the statement of operations for fiscal
year 2002 related to employee options, for which the exercise
price was equal to or greater than the fair market value of
CDS&#146; common stock on the date of grant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Effective January&nbsp;1, 2003, CDS adopted SFAS 148, on a
prospective-basis. Accordingly, for the years ended
December&nbsp;31, 2003 and 2004 and for the nine months ended
September&nbsp;30, 2005, compensation expense related to all
stock options granted during the period is included in the
statement of operations, as calculated under the fair value
method.
</DIV>

<P align="center" style="font-size: 10pt;">80

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>Market Price of and Dividends on the Registrant&#146;s Common
Equity and Related Stockholder Matters</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><I>Market information</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
There is currently no public market for the common stock or
preferred stock of CDS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><I>Security holders</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
As of October&nbsp;31, 2005, there were 77&nbsp;stockholders of
record of the CDS&#146; common stock and 50&nbsp;stockholders of
record of CDS&#146; preferred stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><I>Dividends</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS has never declared or paid dividends on its capital stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><I>Equity compensation plan information</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following table shows information about the securities,
shares of common stock, authorized for issuance under CDS&#146;
equity compensation plans as of October&nbsp;31, 2005:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="32%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="11%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(c)</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(a)</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of Securities</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of Securities</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(b)</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Remaining Available for</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>to be Issued Upon</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted-average</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Future Issuance under</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise Price of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Equity Compensation Plans</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Outstanding Options,</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Outstanding Options,</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(Excluding Securities</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Plan Category</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Warrants and Rights</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Warrants and Rights</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Reflected in Column&nbsp;(a))</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Equity compensation plans approved by security holders</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>49,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>23.77</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>46,167</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Equity compensation plans not approved by security holders</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>49,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>23.77</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>46,167</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">CDS&#146;
Business</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Overview</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS designs and develops innovative sustained-release drug
delivery products. CDS&#146; two proprietary drug delivery
systems, AEON and CODRUG, deliver specific quantities of drugs
directly to a target site in the body at controlled rates for
predetermined periods of time ranging from days to years. These
systems are designed to address drawbacks of systemic drug
delivery for CDS&#146; target diseases: adverse side effects
characteristic of high dosing levels and reduced treatment
benefits due to variations in drug levels at the target site.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS has two commercial products utilizing the AEON system
approved by the FDA for treatment of two sight threatening eye
diseases. These two products, Vitrasert and Retisert, are the
only local sustained-release products approved by the FDA for
the back of the eye. Marketed by Bausch&nbsp;&#38; Lomb and sold
since 1996, Vitrasert is one of the most effective treatments
for CMV retinitis, a disease that afflicts late-stage AIDS
patients. Approved by the FDA in April 2005 and also marketed by
Bausch&nbsp;&#38; Lomb, Retisert treats chronic noninfectious
uveitis affecting the posterior segment of the eye, or posterior
uveitis, a leading cause of vision loss. Bausch&nbsp;&#38; Lomb
is also conducting two long-term multi-center clinical trials of
Retisert for the treatment of diabetic macular edema, or DME,
another leading cause of vision loss. Medidur, an injectable
AEON product, is also designed to treat DME and is currently in
fast-track Phase&nbsp;III clinical trials conducted by Alimera
Sciences Inc. CDS also has two AEON product candidates in
pre-clinical studies for other back of the eye diseases.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
To date, CDS has focused its efforts primarily on research and
development of products based on its AEON system. In
Phase&nbsp;I Studies, CDS has explored the use of its CODRUG
system for the treatment of post-surgical pain and two skin
diseases.
</DIV>

<P align="center" style="font-size: 10pt;">81

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS&#146; products and product candidates are currently at the
following stages of development for the listed diseases:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="16%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2" align="left" nowrap><B>Disease</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Stage of Development</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>AEON System</I></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 25px; text-indent: -10px">
    CMV retinitis</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>FDA approved and commercialized</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 25px; text-indent: -10px">
    Posterior uveitis</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>FDA approved and commercialized</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 25px; text-indent: -10px">
    Diabetic macular edema</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>Phase&nbsp;III trials (fast-track)</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 25px; text-indent: -10px">
    Dry age-related macular degeneration</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>Pre-clinical development</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Retinitis pigmentosa</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>Pre-clinical development</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>CODRUG System</I></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 25px; text-indent: -10px">
    Post-surgical pain</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>Phase&nbsp;I</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 25px; text-indent: -10px">
    Psoriasis/ Actinic keratosis</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom" nowrap>Phase&nbsp;I</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Market Overview</I></B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Drug Delivery Generally</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The therapeutic value of a drug depends on its distribution
throughout the body, reaction with the targeted site, reaction
with other tissues and organs in the body, and clearance from
the body. In an ideal treatment, the appropriate amount of drug
is delivered to the intended site in the body and maintained
there for an adequate period of time without adversely affecting
other tissues and organs. Accordingly, the manner in which a
drug is delivered can be as important to the ultimate
therapeutic value of the treatment as the intrinsic properties
of the drug itself.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Drugs are typically administered systemically by oral dosing or
by injection and are subsequently dispersed throughout the body
via the circulatory system. In many cases, systemic
administration does not deliver drugs to the intended site at an
adequate concentration for a sufficient period of time or fails
to achieve the maximum potential therapeutic benefit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Because systemically delivered drugs disperse throughout the
body, they often must be administered at high dosage levels in
order to achieve sufficient concentrations at the intended site.
Some areas of the body, such as the eyes, joints, brain, and
nervous system, have natural barriers that impede the movement
of drugs to those areas, requiring the administration of even
higher systemic doses. These high dosage levels can cause
harmful side effects when the drug interacts with other tissues
and organs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Timely and repeated administration of drugs by the patient is
often necessary to maintain therapeutic drug levels over an
extended period of time. Patients, however, often fail to take
drugs as prescribed and, as a result, do not receive the
potential therapeutic benefit. The risk of patient noncompliance
increases if multiple drugs are required, if the dosing regimen
is complicated, or if the patient is elderly or cognitively
impaired.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Due to the drawbacks of traditional systemic drug delivery, the
development of novel methods to deliver drugs to patients in a
more precise, controlled fashion over sustained periods of time
has become a multi-billion dollar industry. More recently
developed drug delivery methods include oral and injectable
controlled-release products and skin patches. These methods seek
to improve the consistency of the dosage over time and extend
the duration of delivery. However, most of these methods still
cannot provide constant, controlled dosage or deliver drugs for
a sufficiently long duration. This reduces their effectiveness
for diseases that are chronic or require precise dosing. In
addition, most of these methods still deliver drugs systemically
and, as a result, can still cause adverse systemic side effects.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Ophthalmic Drug Delivery</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Treatment for diseases in the back of the eye is a significant
issue in ophthalmology. Due to the efficiency of the blood/eye
barrier, it is difficult for systematically administered drugs
to reach the eye in sufficient quantities to have a beneficial
effect. There is a need for delivering drugs inside the eye in a
</DIV>

<P align="center" style="font-size: 10pt;">82

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
manner that is safe, effective, and practical for long-term use.
While there are currently many approaches to delivering
medications to the eye, most do not achieve sufficient
concentrations within the eye for the appropriate period of time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Injecting solutions of drugs directly into the back of the eye
can achieve effective but often transient drug levels in the
eye, requiring repeated injections. Examples include
Macugen<SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant:SMALL-CAPS">tm</FONT></SUP>
(pegaptanib sodium) and
Lucentis<SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant:SMALL-CAPS">tm</FONT></SUP>
(ranibizumab, formerly RhuFab V2), both of which must be
injected into the eye approximately every month. Apart from
inconvenience and cost, repeated intravitreal injections carry
the risk of cataract formation, perforated schlera, vitreous
hemorrhage and serious intraocular infection.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>The CDS Technology Systems</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS&#146; two proprietary technology systems, the AEON system
and the CODRUG system, are designed to offer three principal
advantages:
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    <I>Localized Delivery.</I> The AEON and CODRUG systems permit
    implantation, injection or other application directly at the
    target site. CDS&#146; delivery systems use the natural barriers
    of the body to isolate and maintain appropriate concentrations
    of the drug at the target site in an effort to achieve the
    maximum therapeutic effect of a drug while minimizing unwanted
    systemic effects.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    <I>Controlled Release Rate.</I> The AEON and CODRUG systems
    release drugs at a constant or controlled rate. CDS believes
    that this allows its products and product candidates to maintain
    the optimal drug concentration at a target site and eliminate
    variability in dosing over time.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    <I>Extended Delivery.</I> CDS&#146; AEON and CODRUG systems
    deliver drugs for predetermined periods of time ranging from
    days to years. CDS believes that uninterrupted, sustained
    delivery offers the opportunity to develop products that reduce
    the need for repeat applications, eliminates the risk of patient
    noncompliance and provides more effective treatment.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>AEON System</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The AEON system uses a drug core with one or more surrounding
polymer layers. The drug permeates through the polymers into the
body at a controlled rate for a predetermined period of time
ranging from days to years. By changing the design of the AEON
system, CDS can control both the rate and duration of release to
meet different therapeutic needs. CDS believes that its AEON
system might be used to deliver a wide variety of different
drugs. CDS is currently using AEON technology for all of its
ophthalmic products and product candidates. As of the date of
this information statement, CDS either has, or has exclusive
licenses to, 34 issued patents and 133 patent applications
covering different aspects of its AEON technology.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following diagram demonstrates CDS&#146; AEON system:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Vitrasert, Retisert and Medidur represent the evolution of the
AEON system. Vitrasert is a device surgically implanted through
a 5-6&nbsp;mm incision that releases drug from its core for
approximately 6-8&nbsp;months. Retisert is a device implanted
through a 3-4&nbsp;mm incision that releases drug from its core
for 30&nbsp;months. Medidur is a device injected through a
needle to the back of the eye in an in-office procedure designed
to release drug from its core for up to three years. CDS is
working to develop a bioerodible Medidur system.
</DIV>

<P align="center" style="font-size: 10pt;">83

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following picture shows, from left to right, Medidur,
Retisert and Vitrasert.
</DIV>

<DIV align="center" style="font-size: 5pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">

<IMG src="y15751y1497402.gif" alt="(GRAPHIC OF MEDIDUR, RETISERT, AND VITRASERT)">
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>CODRUG Technology</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS&#146; proprietary CODRUG system allows for the simultaneous
release of two or more drugs from the same product at the same
controlled rate over a predetermined period of time. Using this
technology, CDS chemically links together two or more identical
or different drugs. CODRUGs can be administered by virtually any
delivery method. Regardless of delivery method, CODRUGs dissolve
into the body at a predetermined rate and then separate into the
original active drug(s) when the chemical bond breaks apart. CDS
believes that many drugs can be chemically linked with its
CODRUG technology and has synthesized a library of approximately
298 CODRUG compounds. CDS has performed Phase&nbsp;I clinical
trials involving CODRUGs for the treatment of post-surgical pain
and two skin diseases. As of the date of this information
statement, CDS either has, or has exclusive licenses to, three
issued patents and 69 patent applications covering its CODRUG
technology.
</DIV>

<P align="center" style="font-size: 10pt;">84

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following diagrams demonstrate CDS&#146; CODRUG system:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<IMG src="y15751y1497403.gif" alt="(GRAPHIC OF CO-DRUG SYSTEM)">
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<IMG src="y15751y1497404.gif" alt="(GRAPHIC OF CO-DRUG SYSTEM)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Products and Product
Candidates of CDS</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS&#146; products, Vitrasert and Retisert, are the only two
sustained-release products approved by the FDA for back of the
eye diseases. The Vitrasert AEON implant is approved for the
treatment of CMV retinitis and the Retisert AEON implant is
approved for the treatment of posterior uveitis, both leading
causes of vision loss. CDS also has AEON product candidates for
DME, dry age-related macular degeneration, or AMD, and retinitis
pigmentosa, or RP, three other leading causes of vision loss.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS is also developing two products, currently in Phase&nbsp;I
clinical trials, that rely on its CODRUG system to treat
post-surgical pain and the skin disorders psoriasis and actinic
keratosis, or AK.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Sight-Threatening Eye Diseases</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>CMV Retinitis.</I> CDS&#146; Vitrasert implant treats CMV
retinitis, a blinding eye disease that frequently occurs in
individuals with advanced AIDS. Vitrasert provides sustained
treatment of the disease through the intravitreal delivery of
the anti-viral drug ganciclovir for six to eight months.
Vitrasert has been marketed and sold since 1996, first by Chiron
Corporation and subsequently by Bausch&nbsp;&#38; Lomb. Although
CMV retinitis was common in the early 1990s, improvements in the
treatment of AIDS/ HIV have since significantly decreased the
incidence of the disease in more developed countries. CDS&#146;
implant has been used in over 12,000 eyes since 1996. Studies
show that Vitrasert is one of the most effective approved
treatments for CMV retinitis.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Posterior Uveitis.</I> CDS&#146; Retisert implant for
treatment of posterior uveitis was approved by the FDA in April
2005, the first drug approved by the FDA to treat this disease.
Posterior uveitis is an autoimmune condition characterized by
inflammation of the inside of the eye that can cause sudden or
gradual vision loss. Retisert was approved as an orphan drug and
has 7-year exclusive marketing rights that the FDA provides for
orphan drugs first approved for a particular indication.
Retisert is marketed and sold by Bausch&nbsp;&#38; Lomb.
</DIV>

<P align="center" style="font-size: 10pt;">85

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Like Vitrasert, Retisert is implanted into the back of the eye
in a simple, outpatient procedure. It delivers sustained levels
of the anti-inflammatory corticosteroid, fluocinolone acetonide
or FA, for 30&nbsp;months. The most common adverse
events&nbsp;&#151; which are anticipated given the nature of the
disease and the type of drug used&nbsp;&#151; include cataract
progression, which is managed by standard cataract surgery,
increased intraocular pressure, which is managed with the use of
interocular pressure, or IOP-, lowering eye drops or filtering
surgery; and procedural complications and eye pain. Although no
other drugs are approved for posterior uveitis, off-label
treatments include steroidal eye drops, ocular injections of
steroids, orally administered steroids, immunosuppressants, and
chemotherapy. These treatments, if successful, generally only
slow the progression of the disease and can have serious side
effects such as severe osteoporosis, muscle wastage, psychosis,
cancer and stunted growth. Bausch&nbsp;&#38; Lomb estimates that
posterior uveitis affects 175,000 people in the United States
and 800,000 people worldwide.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In two clinical trials involving patients with posterior
uveitis, patients were implanted with either a 2.1&nbsp;mg or a
0.59&nbsp;mg Retisert device. In patients with the 0.59&nbsp;mg
device, the rates of recurrence in the 34&nbsp;weeks after
implantation ranged from approximately 7% to 14% compared to
approximately 40% and 54% for the 34&nbsp;week pre-implantation
period. In the first study involving over 250&nbsp;patients, 10%
of those receiving an implant (either dose) experienced a three
line improvement on the eye chart in vision at 34&nbsp;weeks,
while in the second study of 234&nbsp;patients, 21% experienced
an improvement of three lines at 34&nbsp;weeks. The main side
effects were elevated intraocular pressure and cataracts. After
two years, approximately 30% of patients with posterior uveitis
with a Retisert implant required a second operation to reduce
pressure, and substantially all patients with a Retisert implant
developed cataracts.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<IMG src="y15751y1497405.gif" alt="(GRAPHIC OF RETISERT ON FINGERTIP)">
</DIV>

<DIV align="center" style="font-size: 10pt;">
<IMG src="y15751y1497406.gif" alt="(GRAPHIC OF RETISERT NEXT TO PENCIL TIP)">
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Diabetic Macular Edema.</I> CDS&#146; injectable Medidur
product is currently in Phase&nbsp;III trials for treatment of
diabetic macular edema, a disease causing swelling in the
macula, the most sensitive part of the retina, and a major cause
of vision loss in diabetics. CDS is not aware of any approved
drug treatment for this disease. It is currently treated by
laser therapy, which burns the retina either in specific sites
or in a grid, and vitrectomy, eye surgery that involves the
removal of the vitreous gel from the cavity of the eye. Both
have serious limitations, which include repeat treatments or
invasive surgical procedures. Both treatments generally only
temporarily reverse vision loss and slow the progression of the
disease.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Medidur is an implant small enough to be injected through a
needle to the back of the eye and is expected to release drug
for up to three years. Alimera Sciences is currently conducting
two Phase&nbsp;III clinical trials for Medidur to treat DME
which will follow 900&nbsp;patients in the U.S. and Europe for
36&nbsp;months. If approved, CDS has licensed Alimera Sciences
to market and sell Medidur for DME.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bausch&nbsp;&#38; Lomb is also conducting two randomized,
multi-center trials using the Retisert implant to treat DME,
which follow 277&nbsp;patients for 36&nbsp;months. The FDA has
stated that in order to approve a product for DME, there must be
a statistically significant difference in vision of three lines
at three years. At two years, both Bausch&nbsp;&#38; Lomb
studies showed a statistical difference in vision of three lines
in patients with Retisert implants. Specifically, in the smaller
study at two years, 37% of patients with Retisert implants
experienced an improvement in vision of three lines compared
with 14% of the patients randomized to standard of care. In
addition, more Retisert patients had a complete resolution of
their edema, and fewer patients had a worsening of their
diabetic retinopathy (both also statistically significant). In
the larger study, 28% of patients with Retisert experienced a
three line improvement compared to 9% of patients receiving
standard of care. More patients with Retisert had complete
resolution of their edema at
</DIV>

<P align="center" style="font-size: 10pt;">86

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
two years, and fewer patients with Retisert had a worsening of
their diabetic retinopathy (both statistically significant). As
with Retisert for uveitis, the primary side effects were
elevated intraocular pressure and cataracts. Two years after
receiving the Retisert implant, approximately 20% of patients
with DME needed a second surgery to reduce intraocular pressure
while essentially all Retisert patients developed cataracts. CDS
is unable to predict the outcome of these trials at three years.
CDS has licensed the rights with respect to Retisert for DME to
Bausch&nbsp;&#38; Lomb.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Dry Age-Related Macular Degeneration.</I> CDS is in
pre-clinical development of a Medidur product to treat dry
age-related macular degeneration. AMD is a leading cause of
visual impairment in Americans over 60 and affects over
10&nbsp;million people in the United States. With dry AMD, the
cells in the central retina die slowly resulting in gradual
central vision loss. There are currently no approved treatments
for dry AMD though some studies show that treatment with high
doses of antioxidants and zinc may help delay its development in
individuals with less severe forms of dry AMD.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Retinitis Pigmentosa.</I> CDS is in pre-clinical development
of a Medidur product to treat retinitis pigmentosa. RP comprises
a group of inherited eye diseases that affect the retina,
causing the degeneration of photoreceptor cells and resulting in
progressive vision loss. Approximately 100,000 adults in the
U.S.&nbsp;have RP. RP is currently treated by antioxidants such
as vitamin A palmitate, which have been shown to slightly slow
the progression of the disease.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Non-Ophthalmic Disorders</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Post-Surgical Pain Management.</I> CDS is conducting
Phase&nbsp;I clinical trials for an injectable, biodegradable
product for post-surgical pain based on its CODRUG system.
Post-surgical pain is caused by the trauma inflicted on the body
by surgical intervention. Doctors treat post-surgical pain with
a variety of drugs, including narcotics and local anesthetics.
Narcotics are typically delivered systemically, either orally or
intravenously, and are often used to treat pain that affects
large areas of the body. Narcotics are associated with a variety
of side effects including dizziness, decreased mental and
physical capability, excessive sleepiness and sedation, nausea,
and potential dependency. Local anesthetics work for a short
period of time directly at the incision or surgical site to dull
feeling without causing sleepiness or loss of sensation in other
body parts. Local anesthetics are commonly delivered by
injection and have fewer side effects than narcotics. Local
anesthetics also may be delivered following surgery through an
external pump that delivers the drug to the surgical site
through a catheter. Other than through use of the external pump,
which is expensive and poses a risk of serious infection, local
anesthetics cannot be delivered locally by patients at home,
leading patients to rely on systemic narcotics.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Psoriasis and Actinic Keratosis.</I> CDS is studying another
CODRUG product candidate for the treatment of two chronic skin
disorders, psoriasis and actinic keratosis, and successfully
completed a Phase&nbsp;I trial of this product candidate in the
UK involving 20&nbsp;patients in 2004. Psoriasis is an
autoimmune skin disorder in which the growth cycle of skin cells
speeds up from approximately one month to three or four days,
causing inflamed lesions. In more cases, lesions can cover a
significant portion of the body, including the face, hands, and
feet. Psoriasis has no cure. The National Psoriasis Foundation
estimates that more than 4.5&nbsp;million adults in the United
States have psoriasis. Treatments include topical treatment of
the skin with corticosteroids, phototherapy, or light (including
sunlight) and oral or intravenous medications designed to
suppress the immune system.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
AK is a common skin condition characterized by scaly or crusty
bumps on the skin surface that are horn-like, dry and rough and
range in size from one-quarter to one-inch in diameter. AK
lesions are pre-cancerous, with up to 10% of active lesions
progressing to squamous cell carcinomas. AK affects
approximately 10&nbsp;million people in the United States and AK
lesions are the most common premalignant lesions in the United
States. AK can be treated through surgical removal, electrical
cautery, cryosurgery, chemical peels and topical medications if
caught in an early stage but, if neglected, may metastasize and
spread to internal organs.
</DIV>

<P align="center" style="font-size: 10pt;">87

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A problem in the treatment of both psoriasis and AK has been
effecting the penetration of drugs through the outer skin
layers. The impermeability of many drugs used to treat these
conditions can necessitate systemic delivery, despite the
drawbacks of the associated side effects.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Strategic
Collaborations</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS has entered into three collaboration agreements to develop
and commercialize its initial products and product candidates,
Vitrasert, Retisert and Medidur. In all of these agreements, CDS
retains its rights to the underlying technologies.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Chiron Vision Corporation</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS&#146; first collaboration was with Chiron Vision
Corporation, a subsidiary of Chiron Corporation. Under a 1992
licensing and development agreement, Chiron Vision financed the
development of Vitrasert, and CDS granted Chiron Vision a
worldwide, exclusive license to make and sell products based on
the AEON technology used in Vitrasert for the treatment of
conditions of the eye. Chiron Vision commenced commercial sales
of Vitrasert following FDA approval in 1996. Bausch&nbsp;&#38;
Lomb acquired Chiron Vision in 1997, assumed this agreement and
currently markets and sells Vitrasert. Bausch&nbsp;&#38; Lomb
pays CDS royalties on net sales of Vitrasert under its current
agreement, described further below.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Bausch&nbsp;&#38; Lomb Incorporated</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In 1999, CDS entered into a licensing and development agreement
with Bausch&nbsp;&#38; Lomb for additional products for the
treatment of eye diseases. CDS granted Bausch&nbsp;&#38; Lomb a
worldwide, exclusive license for the life of the relevant
patents to use its technologies for the treatment, prevention or
diagnosis of any disease, disorder or condition of the eye in
humans or in animals.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In December 2003, the two companies entered into an amended and
restated license agreement that significantly revised the 1992
and 1999 agreements. Under this new agreement, CDS granted
Bausch&nbsp;&#38; Lomb a worldwide, exclusive license to certain
of CDS technologies to make and sell Vitrasert and CDS&#146;
first generation products, as defined in the agreement,
including the Retisert device, for the treatment, prevention and
diagnosis of any disease, disorder or condition of the human
eye. Bausch&nbsp;&#38; Lomb agreed to pay CDS royalties based on
net sales for any products that meet the definition of first
generation products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS also granted Bausch&nbsp;&#38; Lomb a non-exclusive license
to these technologies to make and sell certain other products
for the delivery of specified active ingredients, using
specified delivery systems, methods of delivery and anchoring
methods, to be used in specified locations for specified
indications. If Bausch&nbsp;&#38; Lomb does not commence an
Investigational New Drug, or IND, a status granted by the FDA to
investigational drugs approved for administration to humans, for
any such product by December&nbsp;9, 2005, CDS may terminate the
non-exclusive license for such product (unless this breach is
cured within 90&nbsp;days of receipt of notice). To CDS&#146;
knowledge, Bausch&nbsp;&#38; Lomb has not to date commenced an
IND for any such product. If Bausch&nbsp;&#38; Lomb does market
such products, it will pay CDS a royalty based on net sales of
the products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bausch&nbsp;&#38; Lomb is responsible for funding and managing
the development and commercialization of all products under the
agreement. Bausch&nbsp;&#38; Lomb also agreed to pay CDS
specified amounts if it achieved certain milestones related to
certain licensed products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS agreed not to develop, commercialize or license to a third
party rights to develop or commercialize any product to treat
posterior uveitis so long as (1)&nbsp;Bausch&nbsp;&#38; Lomb is
actively pursuing the commercialization of a product to treat
uveitis for which Bausch&nbsp;&#38; Lomb would be required to
pay CDS a specified level of royalty, and
(2)&nbsp;Bausch&nbsp;&#38; Lomb is not selling any other uveitis
product for which it would not be required to pay CDS a
specified level of royalty. CDS also may not develop,
commercialize or license any product that meets the definition
of first generation product as long as Bausch&nbsp;&#38; Lomb
has an exclusive license to such products using CDS technologies.
</DIV>

<P align="center" style="font-size: 10pt;">88

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bausch&nbsp;&#38; Lomb may terminate this agreement, in its
entirety or with respect to Vitrasert or any non-exclusively
licensed product, at any time on 90&nbsp;days&#146; written
notice. In the event Bausch&nbsp;&#38; Lomb terminates the
agreement in its entirety, Bausch&nbsp;&#38; Lomb&#146;s license
to the CDS technologies will terminate. In the event
Bausch&nbsp;&#38; Lomb terminates the agreement with respect to
Vitrasert or a non-exclusively licensed product,
Bausch&nbsp;&#38; Lomb will lose the right to rely upon
CDS&#146; intellectual property to make and sell the relevant
product.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Alimera Sciences Inc.</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In February 2005, CDS granted Alimera Sciences a world-wide
exclusive right to use certain CDS technologies to make and
sell, for the treatment and prevention of eye diseases (except
uveitis) in humans products that have a drug core within a
polymer layer and are approved or designed to be approved to
deliver only specified compounds by a direct delivery method to
the posterior portion of the eye. In addition, CDS granted to
Alimera Sciences a world-wide exclusive right to use certain CDS
technologies to treat DME by delivering a compound or
formulation by a direct delivery method other than through
specified incisions, and which are not exclusively licensed to
Bausch&nbsp;&#38; Lomb.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A joint development team of both parties is responsible for
monitoring the execution of activities under the development
plan for licensed products. CDS and Alimera Sciences each pays
codevelopment costs that are incurred included in the
development budget. The agreement provided for Alimera Sciences
to pay a licensing fee and milestone payment to CDS. Alimera
Sciences has sole responsibility for making commercially
reasonable efforts to commercialize products licensed under the
agreement and for paying all costs and expenses incurred in
connection with such commercialization. After a product becomes
profitable in a country, Alimera Sciences and CDS share the net
profits for that product in that country, subject to Alimera
Sciences&#146; pre-profitability net losses for that product. If
either party fails to pay the other party its share of
development costs, the unpaid amount plus a delay charge is
recouped from net profits and in the case of CDS milestone
payments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Improvements and other inventions developed during the term in
whole or in part by Alimera Sciences that are covered by or
derived from the practice of the licensed CDS technologies are
jointly owned by Alimera Sciences and CDS, except for
improvements specifically related to active ingredients provided
by Alimera Sciences, which are owned by Alimera Sciences. Each
party is free to use and sublicense such improvements, except
that Alimera Sciences shall not have the right to use such
improvements in connection with ophthalmic drug delivery devices
(or related methods or processes) that include a drug core.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Either party may terminate the agreement for the other
party&#146;s failure to make a development payment. Either party
may terminate the agreement with respect to a particular product
if the other party gives written notice of its intent to abandon
the product. The agreement provides for specific, exclusive
remedies in the event of termination resulting from the
occurrence of one of the above events.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Sales and
Marketing</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Bausch&nbsp;&#38; Lomb currently markets and sells both
Vitrasert and Retisert and has rights to market and sell any
other products licensed to Bausch&nbsp;&#38; Lomb. Alimera
Sciences has the rights to market and sell Medidur for DME if
approved and any other products developed under its license
agreement with CDS. In the future, CDS may independently
commercialize and sell some of its other products. In
appropriate cases, CDS may also enter into joint marketing or
license arrangements for other products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Reimbursement</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The successful commercialization of CDS&#146; products will
depend in significant part on the extent to which reimbursement
of the cost of the products and the related implantation or
injection procedures will be available from government health
administration authorities, private health insurers, and other
organizations. Medicaid and Medicare, most major health
maintenance organizations, and most health insurance carriers
reimburse $4,240 for the cost of the Vitrasert implant, with
additional reimbursement for
</DIV>

<P align="center" style="font-size: 10pt;">89

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
associated surgical fees. The Centers for Medicare and Medicaid
Services recently designated Retisert as eligible for Medicare
reimbursement at the rate of $19,345, with associated surgical
fees to be reimbursed separately.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Patents, Licenses and
Intellectual Property</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Intellectual Property Strategy</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS&#146; commercial success will depend, in part, on its
ability to obtain patent protection in the United States and
elsewhere for its products or its processes. CDS therefore
seeks, whenever possible, to obtain protection for these
products and processes. CDS also seeks to expand our product and
process portfolio through collaborations, funded research and
licensing technology from others.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Patents and Patent Applications</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS has filed and continues to file patent applications with
respect to multiple aspects of its technologies, products, and
processes. As of the date of this information statement CDS has,
or has exclusive rights to, 12 United States patents and 26
foreign patents. In addition, as of the date of this information
statement, CDS has, or has exclusive rights to, 40&nbsp;patent
applications pending in the United States and 163&nbsp;patent
applications pending in foreign countries. CDS&#146; patents
expire at various dates starting in 2012.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Of the above-referenced issued patents, the University of
Kentucky Research Foundation holds 6 United States patents and
12 related foreign patents on aspects of CDS&#146; technologies.
CDS has exclusive licenses for these patents and related
know-how and is obligated to pay the University of Kentucky
Research Foundation royalties based on sublicensing of these
patents and sales of products utilizing these patents.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <I>Other Proprietary Rights</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Some elements of CDS&#146; products, processes, and methods of
manufacturing involve unpatented proprietary technology,
processes, know-how, or data. With respect to proprietary
technology, know-how, and data that are not patentable or
potentially patentable or processes other than production
processes for which patents are difficult to enforce, CDS has
chosen or may chose to protect its interests by relying on trade
secret protection and confidentiality agreements with its
employees, consultants and contractors. To maintain the
confidentiality of trade secrets and proprietary information,
CDS maintains a policy of requiring employees, scientific
advisors, consultants and collaborators to execute
confidentiality and invention assignment agreements upon
commencement of a relationship. These agreements are designed
both to enable CDS to protect its proprietary information by
controlling the disclosure and use of technology to which CDS
has rights, and to provide for its ownership of proprietary
technology that CDS develops.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Competition</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The pharmaceutical and drug delivery industries are highly
competitive. Vitrasert primarily competes with treatments
involving the systemic delivery of ganciclovir, a Roche Holdings
AG product, and other drugs. Retisert is the only FDA approved
treatment for posterior uveitis, though steroids and other
existing drugs approved for other uses are commonly administered
systemically or by local injection to treat this condition in
off-label use. In addition, CDS expects that its proposed
products, if approved, will compete with existing therapies for
CDS&#146; targeted diseases as well as new drugs, therapies,
drug delivery systems or technological approaches that may be
developed to treat these diseases or their underlying causes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS expects that its products and product candidates, if
approved, will compete with existing therapies for its targeted
diseases, as well as new drugs, therapies, drug delivery
systems, or technological approaches that may be developed and
approved to treat these diseases or their underlying causes as
well as off-label use of products approved to treat other
diseases. CDS believes that pharmaceutical, drug
</DIV>

<P align="center" style="font-size: 10pt;">90


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
delivery, and biotechnology companies, research organizations,
governmental entities, universities, hospitals, other nonprofit
organizations, and individual scientists are seeking to develop
therapies for CDS&#146; targeted diseases. For many of its
targeted diseases, competitors have alternate therapies that are
already commercialized or are in various stages of development
ranging from discovery to advanced clinical trials. Most of the
entities with whom CDS will or may compete are much larger, have
much greater financial resources and have much more experience
in drug development and sale than CDS.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Many companies are pursuing products to treat back of the eye
diseases. These include the following:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Eli Lilly and Company is in advanced clinical trials for its
    protein kinase C beta inhibitor for the treatment of diabetic
    retinopathy.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Genentech, Inc. has developed an FDA approved cancer drug,
    Avastin, which may be used as an off-label treatment for DME.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Novartis Ophthalmics AG markets cyclosporine, which is used for
    the systemic treatment of uveitis.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Allergan, Inc. is in Phase&nbsp;III clinical trials of its
    product, Posurdex&#174; for the treatment of persistent macular
    edema. If approved by the FDA, this product may be used
    off-label for the treatment of DME or edema associated with
    diabetes. In addition, Allergan and EntreMed, Inc. are
    collaborating on a program to develop a treatment for AMD that
    is at the pre-clinical development stage.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Eyetech Pharmaceuticals, Inc., which recently entered into an
    agreement to be acquired by OSI Pharmaceuticals, Inc., has an
    intraocular injectable product, Macugen, approved to treat wet
    AMD and had commenced pivotal clinical trial for the use of
    Macugen in the treatment of DME. In addition, Eyetech entered
    into a collaboration with Pfizer, Inc. to
    co-promote&nbsp;Macugen.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    SurModics Inc. has initiated a Phase&nbsp;I clinical trial of a
    helical coil coated with drug releasing polymer which is
    implanted in the back of the eye to treat DME.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Neurotech SA has completed Phase&nbsp;I clinical trials of its
    NT-501, a cell-based implant that releases ciliary neurotrophic
    factor for the treatment of RP.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If CDS successfully develops a product for post-surgical pain,
it will compete against numerous options available for the
management of post-surgical pain, including narcotic and
non-narcotic anesthetics delivered orally, by catheter, or by
pump. Products in development in the United States include
Pfizer&#146;s injectable cyclooxygenase-2 inhibitor parecoxib,
SkyePharma&#146;s sustained-release injectable DepoBupivacaine
anesthetic, AP Pharma, Inc.&#146;s APF112, a long acting
anesthetic in Phase&nbsp;I trials, and Omeros Medical Systems,
Inc.&#146;s OMS-103HP, a product in Phase&nbsp;II clinical
trials for the management of pain following orthopedic surgery,
Durect Corporation&#146;s product in Phase&nbsp;III clinical
trials designed to treat post-surgical pain through the
sustained release of a local anesthetic, and a number of
products in clinical trials designed to evaluate the sustained
release of bupivacaine, a local anesthetic.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If CDS successfully develops a product for psoriasis, it is
likely to compete against various products that are currently
marketed or in the final stages of evaluation for the treatment
of psoriasis. Topical agents include Allergan&#146;s
Tazorac&#174; cream and gel and Bristol-Myers Squibb Co.&#146;s
Dovonex&#174; cream and ointment. Allergan also is developing an
oral formulation of its Tazorac product, which is in
Phase&nbsp;III trials. Oral agents also include Roche&#146;s
Soriatane&#174; product. The first of a class of biologic agents
for more severe forms of the disease has recently been approved
for U.S.&nbsp;marketing by Biogen, Inc. Others are currently in
late-stage clinical trials, including the Enbrel&#174; (Amgen,
Inc.) and
Raptiva<SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant:SMALL-CAPS">tm</FONT></SUP>(Genentech,
Inc. and Xoma, Inc.) injectable products. If CDS successfully
develops a product for AK, it will compete against a variety of
AK treatment options currently available, including
5-fluorouracil cream, surgical removal, electrical cautery,
cryosurgery and chemical peels.
</DIV>

<P align="center" style="font-size: 10pt;">91

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>Legal Proceedings</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A potential lender to CDS has claimed a break-up fee as a result
of the royalty advance agreement between CDS and
Bausch&nbsp;&#38; Lomb. An investment banker has claimed an
advisory fee in connection with that agreement as well as the
merger. CDS intends to defend against these claims.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Government
Regulation</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The FDA and comparable regulatory agencies in state and local
jurisdictions and in foreign countries impose substantial
requirements upon the clinical development, manufacture and
marketing of pharmaceutical products. These agencies and other
federal, state and local entities regulate research and
development activities and the testing, manufacture, quality
control, safety, effectiveness, labeling, storage, record
keeping, approval, advertising and promotion of our drug
delivery products. The process required by the FDA under the new
drug provisions of the Federal Food, Drug, and Cosmetic Act
before our products may be marketed in the United States
generally involves the following:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pre-clinical laboratory and animal tests,</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    submission to the FDA of an investigational new drug
    application, or IND, which must become effective before clinical
    trials may begin in the United States,</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    adequate and well-controlled human clinical trials to establish
    the safety and efficacy of the proposed pharmaceutical in
    CDS&#146; intended use,</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    submission to the FDA of a new drug application,&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    FDA review and approval of the new drug application.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The testing and approval process requires substantial time,
effort, and financial resources, and CDS cannot be certain that
any approval will be granted on a timely basis, if at all.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Pre-clinical tests include laboratory evaluation of the product,
its chemistry, formulation and stability, as well as animal
studies to assess the potential safety and efficacy of the
product. The results of the pre-clinical tests, together with
manufacturing information, analytical data and protocols for
proposed human clinical trials, are submitted to the FDA as part
of an IND, which must become effective before CDS may begin
human clinical trials. The IND automatically becomes effective
30&nbsp;days after receipt by the FDA, unless the FDA, within
the 30-day time period, raises concerns or questions about the
conduct of the proposed clinical trials as outlined in the IND
and imposes a clinical hold. In such a case, the IND sponsor and
the FDA must resolve any outstanding concerns before clinical
trials can begin. There is no certainty that pre-clinical trials
will result in the submission of an IND or that submission of an
IND will result in FDA authorization to commence clinical trials.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Clinical trials involve the administration of the
investigational product to human subjects under the supervision
of a qualified principal investigator. Clinical trials are
conducted in accordance with protocols that detail the
objectives of the study, the parameters to be used to monitor
safety and any efficacy criteria to be evaluated. Each protocol
must be submitted to the FDA as part of the IND. Further, each
clinical study must be conducted under the auspices of an
independent institutional review board at the institution where
the study will be conducted. The institutional review board will
consider, among other things, ethical factors, the safety of
human subjects and the possible liability of the institution.
Some clinical trials, called &#147;investigator-sponsored&#148;
clinical trials, are conducted by third-party investigators. The
results of these trials may be used as supporting data by a
company in its application for FDA approval, provided that the
company has contractual rights to use the results.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Human clinical trials are typically conducted in three
sequential phases which may overlap:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    PHASE I: The drug is initially introduced into healthy human
    subjects or patients and tested for safety, dosage tolerance,
    absorption, metabolism, distribution and excretion.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">92

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    PHASE&nbsp;II: Studies are conducted in a limited patient
    population to identify possible adverse effects and safety
    risks, to determine the efficacy of the product for specific
    targeted diseases and to determine dosage tolerance and optimal
    dosage.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    PHASE&nbsp;III: Phase&nbsp;III trials are undertaken to further
    evaluate clinical efficacy and to further test for safety in an
    expanded patient population, often at geographically dispersed
    clinical study sites.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In the case of products for life-threatening diseases such as
cancer, or severe conditions such as blinding eye disease, the
initial human testing is often conducted in patients with the
disease rather than in healthy volunteers. Since these patients
already have the targeted disease or condition, these studies
may provide initial evidence of efficacy traditionally obtained
in Phase&nbsp;II trials and so these trials are frequently
referred to as Phase&nbsp;I/II trials. If a product uses a
combination of drugs, the FDA requires that clinical trials
demonstrate that the combination is safe and effective and that
each drug contributes to efficacy. CDS cannot be certain that it
will successfully complete Phase&nbsp;I, Phase&nbsp;II or
Phase&nbsp;III testing of CDS&#146; product candidates within
any specific time period, if at all. Furthermore, CDS, the FDA,
the institutional review board or the sponsor, if any, may
suspend clinical trials at any time on various grounds,
including a finding that the subjects or patients are being
exposed to an unacceptable health risk.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The results of product development, pre-clinical studies and
clinical studies are submitted to the FDA as part of a new drug
application, or NDA, for approval of the marketing and
commercial shipment of the product. The FDA may deny an NDA if
the applicable regulatory criteria are not satisfied or may
require additional clinical data. Even if the additional data
are submitted, the FDA may ultimately decide that the new drug
application does not satisfy the criteria for approval. As a
condition of approval, the FDA may require post-marketing
&#147;Phase&nbsp;IV&#148; clinical trials to confirm that the
drug is safe and effective for its intended uses. Once issued,
the FDA may withdraw product approval if compliance with
regulatory standards for production and distribution is not
maintained or if safety problems occur after the product reaches
the market. The FDA requires surveillance programs to monitor
approved products which have been commercialized, and the agency
has the power to require changes in labeling or to prevent
further marketing of a product based on the results of these
post-marketing programs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If a drug is intended for the treatment of a serious or
life-threatening condition and has the potential to address
unmet medical needs for this condition, the drug sponsor may
apply for FDA &#147;fast track&#148; designation. The fast track
designation applies only for the specific indications for which
the product satisfies these two requirements. Under fast track
provisions, the FDA is committed to working with the sponsor for
the purpose of expediting the clinical development and
evaluation of the drug&#146;s safety and efficacy for the fast
track indication.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Marketing applications filed by sponsors of products in fast
track development often will qualify for expedited review under
policies or procedures offered by the FDA, but fast track
designation does not assure this qualification.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If a drug treats a disease or condition that affects fewer than
200,000 people in the United States, the drug sponsor may apply
to the FDA for &#147;orphan drug&#148; designation under the
Orphan Drug Act. More than one drug may be given an orphan drug
designation by the FDA for a given disease or condition, but the
first drug with an orphan drug designation to receive marketing
approval for the treatment of that disease or condition is
granted a period of marketing exclusivity. Sponsors are granted
seven years of exclusive rights to market the first approved
orphan drug for treatment of that disease or condition,
independent of any additional patent protection that may apply
to the product. This marketing exclusivity does not prevent a
competitor from obtaining approval to market a different drug
that treats the same disease or condition or the same drug to
treat a different disease or condition. Sponsors also are
granted tax incentives for clinical research undertaken to
support an application for an orphan drug, and grants to defray
some of these clinical costs may also be available. In addition,
the FDA will typically coordinate with the sponsor on research
study design for an orphan drug and may exercise its discretion
to grant marketing approval on the basis of more limited product
safety and efficacy data than would ordinarily be required. If
the FDA withdraws a product&#146;s orphan drug designation,
however, these various benefits no longer apply.
</DIV>

<P align="center" style="font-size: 10pt;">93

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Satisfaction of FDA requirements or similar requirements of
state, local and foreign regulatory agencies typically takes
several years, and the actual time required may vary
substantially based upon factors including the type, complexity
and novelty of the pharmaceutical product. Such government
regulation may delay or prevent marketing of potential products
for a considerable period of time and impose costly procedures
upon CDS&#146; activities. Success in pre-clinical or early
stage clinical trials does not assure success in later stage
clinical trials. Data from pre-clinical and clinical activities
is not always conclusive and may be susceptible to varying
interpretations which could delay, limit or prevent regulatory
approval. Even if a product receives regulatory approval, the
approval may be subject to significant limitations. Further,
even after the FDA approves a product, later discovery of
previously unknown problems with a product may result in
restrictions on the product or even complete withdrawal of the
product from the market.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Any products CDS manufactures or distributes under FDA
clearances or approvals are subject to pervasive and continuing
regulation by the FDA, including record-keeping requirements and
reporting of adverse experiences with the products. Drug
manufacturers and their subcontractors are required to register
with the FDA and state agencies, and are subject to periodic
unannounced inspections by the FDA and state agencies for
compliance with good manufacturing practices, which impose
procedural and documentation requirements upon CDS and CDS&#146;
third-party manufacturers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS is also subject to numerous other federal, state and local
laws relating to such matters as safe working conditions,
manufacturing practices, environmental protection, fire hazard
control, and disposal of hazardous or potentially hazardous
substances. CDS may incur significant costs to comply with such
laws and regulations now or in the future. In addition, CDS
cannot predict what adverse governmental regulations may arise
from future United States or foreign governmental action.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS also is subject to foreign regulatory requirements governing
human clinical trials and marketing approval for pharmaceutical
products which CDS sells outside the U.S.&nbsp;The requirements
governing the conduct of clinical trials, product licensing,
pricing and reimbursement vary widely from country to country.
Whether or not CDS obtains FDA approval, it must obtain approval
of a product by the comparable regulatory authorities of foreign
countries before manufacturing or marketing the product in those
countries. The approval process varies from country to country,
and the time required for these approvals may differ
substantially from that required for FDA approval. There is no
assurance that clinical trials conducted in one country will be
accepted by other countries or that approval in one country will
result in approval in any other country. For clinical trials
conducted outside the United States, the clinical stages
generally are comparable to the phases of clinical development
established by the FDA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Employees</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
As of November&nbsp;30, 2005, CDS had 12&nbsp;full-time
employees. Of these employees, 8 hold Ph.D. or other advanced
degrees. None of CDS&#146; employees is represented by a
collective bargaining unit, and CDS has never experienced a work
stoppage. CDS considers its relations with its employees to be
good.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><FONT style="font-variant:SMALL-CAPS">Facilities</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS&#146; headquarters are in Watertown, Massachusetts, located
approximately eight miles from downtown Boston. CDS leases
13,411&nbsp;square feet of laboratory and office space pursuant
to a lease that expires in October 2006. Annual rent under the
lease is $304,000. CDS has the right to extend, and the landlord
has a separate right to require CDS to extend, this lease for an
additional 18&nbsp;months at the rate of $25,704&nbsp;per month.
</DIV>

<P align="center" style="font-size: 10pt;">94

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT style="font-variant:SMALL-CAPS">Principal
Stockholders of CDS</FONT></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following table sets forth information regarding the
beneficial ownership of CDS&#146; common stock and Series&nbsp;A
preferred stock as of November&nbsp;30, 2005 by the following
persons:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    each stockholder known by CDS to be the beneficial owner of more
    than 5% of CDS&#146; common stock or CDS&#146; Series&nbsp;A
    preferred stock,</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    each director of CDS,</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    each executive officer of CDS,&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    all directors and executive officers of CDS as a group.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The percentage of common stock beneficially owned by each person
is based on 3,189,691&nbsp;shares of CDS&#146; common stock
outstanding as of November&nbsp;30, 2005 on an as-converted
basis, which includes 795,844&nbsp;shares of common stock
issuable upon conversion of Series&nbsp;A preferred stock
outstanding on that date. The percentage of Series&nbsp;A
preferred stock beneficially owned by each person is based on
641,642&nbsp;shares of CDS&#146; Series&nbsp;A preferred stock
outstanding as of November&nbsp;30, 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS has determined beneficial ownership in the table in
accordance with the rules of the Securities and Exchange
Commission. In computing the number of shares beneficially owned
by a person and the percentage ownership of that person, CDS has
deemed shares of common stock subject to options held by that
person that are currently exercisable or will become exercisable
within 60&nbsp;days of November&nbsp;30, 2005 to be outstanding,
but CDS has not deemed these shares to be outstanding for
computing the percentage ownership of any other person. To
CDS&#146; knowledge, except as set forth in the footnotes below,
each stockholder identified in the table possesses sole voting
and investment power with respect to all shares of common stock
shown as beneficially owned by that stockholder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Unless otherwise noted, the address for each person listed in
the chart below is c/o&nbsp;Control Delivery Systems, Inc.,
400&nbsp;Pleasant Street, Watertown, MA 02472.
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="46%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Common Stock</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Series&nbsp;A Preferred Stock</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Shares</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Shares</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Beneficially</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Percentage</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Beneficially</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Percentage</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Owned</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>of Class</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Owned</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>of Class</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Bausch&nbsp;&#38; Lomb Incorporated(1)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>600,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>18.8</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Paul Ashton(2)(3)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>547,280</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>17.0</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Thomas J. Smith(4)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>515,600</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>16.2</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Essex Woodlands Health Ventures(5)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>230,801</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7.2</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>186,081</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29.0</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    James L. Currie(6)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>230,801</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7.2</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>186,081</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29.0</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    T. Rowe Price(7)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>138,480</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4.3</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>111,648</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>17.4</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Morgan Stanley Dean Witter(8)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>115,401</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3.6</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>93,040</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>14.5</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Brookside Capital Partners Fund&nbsp;L.P.(9)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>92,320</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2.9</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>74,432</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11.6</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Essex Private Placement Funds(10)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>69,242</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2.2</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>55,825</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8.7</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    SMALLCAP World Fund&nbsp;Inc.(11)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>69,240</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2.2</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>55,824</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8.7</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Anvil Investment Associates L.P.(12)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>57,700</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1.8</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>46,520</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7.2</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Michael J. Soja</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>80,040</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2.5</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Lori H. Freedman</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>71,700</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2.3</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Stephen C. McCluski(13)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>600,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>18.8</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Alan L. Crane(2)(14)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>24,700</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    William S. Karol(2)(15)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,200</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">95

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; ">

<TR style="font-size: 1pt;">
    <TD width="46%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Common Stock</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Series&nbsp;A Preferred Stock</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Shares</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Shares</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Beneficially</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Percentage</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Beneficially</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Percentage</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Owned</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>of Class</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Owned</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>of Class</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Douglas R. Potter(2)(16)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Joyce Erony (17)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    All directors and officers as a group (9&nbsp;persons)(18)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,576,821</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>48.8</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>186,081</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29.0</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="1%"></TD>
    <TD width="4%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>*</TD>
    <TD align="left">
    Less than 1% of the outstanding shares of common stock.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="1%"></TD>
    <TD width="4%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(1)&nbsp;</TD>
    <TD align="left">
    The address for Bausch&nbsp;&#38; Lomb Incorporated is One
    Bausch&nbsp;&#38; Lomb Place, Rochester, NY 14604.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(2)&nbsp;</TD>
    <TD align="left">
    Number of shares of common stock includes shares issuable upon
    the exercise of options that are exercisable or will become
    exercisable within 60&nbsp;days of October&nbsp;31, 2005 for the
    following individuals: Dr.&nbsp;Ashton (25,000&nbsp;shares),
    Mr.&nbsp;Crane (12,200&nbsp;shares), Mr.&nbsp;Karol
    (4,200&nbsp;shares) and Mr.&nbsp;Potter (3,100&nbsp;shares).</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(3)&nbsp;</TD>
    <TD align="left">
    Number of shares of common stock includes 19,055&nbsp;shares
    held by the Paul Ashton Children&#146;s Irrevocable Trust as to
    which Dr.&nbsp;Ashton disclaims beneficial ownership.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(4)&nbsp;</TD>
    <TD align="left">
    Number of shares of common stock includes 93,555&nbsp;shares
    held by the Thomas J. and Ellen Doble-Smith Family Irrevocable
    Trust, 4,200&nbsp;shares held by the Thomas J. and Ellen
    Doble-Smith Trusts for Minors and 417,845&nbsp;shares held by
    St.&nbsp;James Associates LLC, of which Dr.&nbsp;Smith serves as
    managing member. The address for Dr.&nbsp;Smith is Auritec
    Pharmaceuticals, 2275&nbsp;E&nbsp;Foothill Blvd, Pasadena CA
    91107.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(5)&nbsp;</TD>
    <TD align="left">
    Number of shares of Series&nbsp;A preferred stock includes
    148,865&nbsp;shares held by Essex Woodlands Health Ventures
    Fund&nbsp;V, LP and 37,216&nbsp;shares held by Essex Woodlands
    Health Ventures Fund&nbsp;IV, LP. The address for Essex
    Woodlands Health Ventures is 190&nbsp;South LaSalle Street,
    Suite&nbsp;2800, Chicago, IL 60603.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(6)&nbsp;</TD>
    <TD align="left">
    Number of shares of Series&nbsp;A preferred stock includes
    186,081&nbsp;shares held by entities affiliated with Essex
    Woodlands Health Ventures, with which Mr.&nbsp;Currie is
    affiliated. Mr.&nbsp;Currie disclaims beneficial ownership of
    those shares except to the extent of his pecuniary interest
    therein. The address for Mr.&nbsp;Currie is Essex Woodlands
    Health Ventures, 190&nbsp;South LaSalle Street, Suite&nbsp;2800,
    Chicago, IL 60603.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(7)&nbsp;</TD>
    <TD align="left">
    The address for T. Rowe Price is 100&nbsp;East Pratt Street,
    9th&nbsp;Floor, Baltimore, MD 21202.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(8)&nbsp;</TD>
    <TD align="left">
    Number of shares of Series&nbsp;A preferred stock includes
    44,659&nbsp;shares held by Morgan Stanley Dean Witter Equity
    Funding, Inc., 4,626&nbsp;shares held by Morgan Stanley Dean
    Witter Venture Investors IV,-L.P., 1,555&nbsp;shares held by
    Morgan Stanley Dean Witter Venture Offshore Investors&nbsp;IV,
    L.P., 39,874&nbsp;shares held by Morgan Stanley Dean Witter
    Venture Partners&nbsp;IV, L.P. and 2,326&nbsp;shares held by
    Originators Investment Plan, L.P. The address for Morgan Stanley
    Dean Witter is 1585&nbsp;Broadway, New York, NY 10036.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>(9)&nbsp;</TD>
    <TD align="left">
    The address for Brookside Capital Partners Fund&nbsp;L.P. is
    1111&nbsp;Huntington Avenue, Boston, MA 02199.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD>(10)&nbsp;</TD>
    <TD align="left">
    Number of shares of Series&nbsp;A preferred stock includes
    11,882&nbsp;shares held by Essex Private Placement
    Fund&nbsp;III-A, L.P. and 43,943&nbsp;shares held by Essex
    Private Placement Fund&nbsp;III-B, L.P. The address for Essex
    Private Placement Fund is 125&nbsp;High Street, Boston, MA 02108.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(11)&nbsp;</TD>
    <TD align="left">
    The address for SMALLCAP World Fund, Inc. is c/o&nbsp;Capital
    Research and Management Company, 1&nbsp;Market Street, Stuart
    Tower, Suite&nbsp;1800, San&nbsp;Francisco, CA 94105.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(12)&nbsp;</TD>
    <TD align="left">
    The address for Anvil Investment Associates L.P. is
    c/o&nbsp;Ashford Capital Management, Inc., 3801 Kennett Pike,
    Suite&nbsp;B107, Wilmington, DE 19807.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(13)&nbsp;</TD>
    <TD align="left">
    Number of shares of common stock includes 600,000&nbsp;shares
    held by Bausch&nbsp;&#38; Lomb Incorporated, of which
    Mr.&nbsp;McCluski is an executive officer. Mr.&nbsp;McCluski
    disclaims beneficial ownership of these</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">96

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD align="left">
    shares. The address for Mr.&nbsp;McCluski is Bausch&nbsp;&#38;
    Lomb Incorporated, One Bausch&nbsp;&#38; Lomb Place, Rochester,
    NY 14604.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(14)&nbsp;</TD>
    <TD align="left">
    Number of shares of common stock includes 2,400&nbsp;shares held
    by three family members of Mr.&nbsp;Crane. The address for
    Mr.&nbsp;Crane is Momenta Pharmaceuticals, Inc., 675&nbsp;West
    Kendall St., Cambridge, MA 02142.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(15)&nbsp;</TD>
    <TD align="left">
    The address for Mr.&nbsp;Karol is KODA Enterprises Group, LLC,
    800 South Street, Suite&nbsp;355, Waltham, MA 02453.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(16)&nbsp;</TD>
    <TD align="left">
    The address for Mr.&nbsp;Potter is P.O. Box&nbsp;511, North
    Woodstock, NH 03262.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(17)&nbsp;</TD>
    <TD align="left">
    The address for Ms.&nbsp;Erony is 99 Oliphant Avenue, Dobbs
    Ferry, NY 10522.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(18)&nbsp;</TD>
    <TD align="left">
    Number of shares of common stock includes 44,500&nbsp;shares in
    the aggregate issuable upon the exercise of options that are
    exercisable or will become exercisable within 60&nbsp;days of
    October&nbsp;31, 2005.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">97

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</B>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="90%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Page</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Report of Independent Registered Public Accounting Firm</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>F-2</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Consolidated Statements of Financial Position</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>F-3</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Consolidated Statements of Financial Performance</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>F-4</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Consolidated Statements of Cash Flows</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>F-5</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Consolidated Statements of Changes in Stockholders&#146; Equity</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>F-6</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Notes to Consolidated Financial Statements</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>F-7</TD>
    <TD>&nbsp;</TD>
</TR>


</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-1

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>To The Board of Directors and Shareholders of pSivida
Limited</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
We have audited the accompanying consolidated statements of
financial position of pSivida Limited and subsidiaries (a
development stage company) (the&nbsp;&#147;Company&#148;) as at
June&nbsp;30, 2005 and 2004 and the related consolidated
statements of financial performance, cash flows and changes in
stockholders&#146; equity for each of the three years in the
period ended June&nbsp;30, 2005, and for the period from
December&nbsp;1, 2000 (date of inception of development stage)
to June&nbsp;30, 2005. These consolidated financial statements
are the responsibility of the Company&#146;s management. Our
responsibility is to express an opinion on these financial
statements based on our audits.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
We conducted our audits in accordance with standards of the
Public Company Accounting Oversight Board (United&nbsp;States).
Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial
statements are free of material misstatement. The Company is not
required to have, nor were we engaged to perform, an audit of
its internal control over financial reporting. Our audits
included consideration of internal control over financial
reporting as a basis for designing audit procedures that are
appropriate in the circumstances, but not for the purpose of
expressing an opinion on the effectiveness of the Company&#146;s
internal control over financial reporting. Accordingly, we
express no such opinion. An audit also includes examining, on a
test basis, evidence supporting the amounts and disclosures in
the financial statements, assessing the accounting principles
used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We
believe that our audits provide a reasonable basis for our
opinion.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In our opinion, the consolidated financial statements present
fairly, in all material respects, the financial position of
pSivida Limited and subsidiaries as at June&nbsp;30, 2005 and
2004, and the results of their operations and their cash flows
for each of the three years in the period ended June&nbsp;30,
2005, and for the period from December&nbsp;1, 2000 (date of
inception of development stage) to June&nbsp;30, 2005, in
conformity with accounting principles generally accepted in
Australia.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Accounting principles generally accepted in Australia vary in
certain significant respects from accounting principles
generally accepted in the United States of America
(&#147;US&nbsp;GAAP&#148;). Information relating to the nature
and effect of such differences is presented in Note&nbsp;27 to
the consolidated financial statements. As discussed in
Note&nbsp;27, the Company has restated its reconciliation of
total equity to US&nbsp;GAAP as of June&nbsp;30, 2004, its
opening total equity under US&nbsp;GAAP as of July&nbsp;1, 2003
and its reconciliation of net loss to US&nbsp;GAAP for the years
ended June&nbsp;30, 2004 and 2003 for certain errors related to
deferred income taxes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 36pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
DELOITTE TOUCHE TOHMATSU
</DIV>

<DIV align="left" style="font-size: 10pt;">
Chartered Accountants
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
Perth, Australia
</DIV>

<DIV align="left" style="font-size: 10pt;">
December&nbsp;14, 2005
</DIV>

<P align="center" style="font-size: 10pt;">F-2

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(In Australian Dollars)</B>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="57%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>As at 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Notes</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Current Assets</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>17(a)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,892,061</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31,350,656</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Receivables</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>709,418</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>340,482</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>322,933</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>38,958</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Total Current Assets</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13,924,412</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31,730,096</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Non-Current Assets</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Property, plant and equipment, net</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,273,663</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>669,699</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Intangible assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>55,927,494</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,934,622</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Goodwill, net</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,909,744</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other, net</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>32,641</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Total Non-Current Assets</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>68,110,901</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,636,962</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Total Assets</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>82,035,313</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>40,367,058</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Current Liabilities</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Payables</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,967,718</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,844,960</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Payables, related party</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom" nowrap>10, 21(f)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>50,102</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>37,144</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Provisions</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,879</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>56,011</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Total Current Liabilities</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,047,699</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,938,115</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Total Liabilities</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,047,699</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,938,115</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Net Assets</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>79,987,614</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>38,428,943</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Equity</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Parent entity interest</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Contributed equity</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12(a)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>107,883,835</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>49,957,982</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Reserves</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20,761</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>78,220</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deficit accumulated prior to development stage</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>14</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deficit accumulated during development stage</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>14</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(24,103,801</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(9,377,278</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total parent entity interest</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>79,987,614</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>36,845,743</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total outside equity interest</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>15</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,583,200</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Total Equity</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>79,987,614</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>38,428,943</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The consolidated statements of financial position should be read
in conjunction with the
</DIV>

<DIV align="center" style="font-size: 10pt;">
accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt;">F-3

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>CONSOLIDATED STATEMENTS OF FINANCIAL PERFORMANCE</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(In Australian Dollars)</B>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="36%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Period from</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Inception of</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="11">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Development Stage</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>Years Ended 30&nbsp;June</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(1&nbsp;Dec&nbsp;2000)</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>to 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Notes</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Revenues from ordinary activities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>828,976</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>381,679</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>110,675</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,351,075</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Depreciation and amortization expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,029,382</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(39,360</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(37,835</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,156,849</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Research and development expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(8,287,930</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,011,666</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,586,182</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(23,243,409</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Interest expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,635</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,635</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Employee benefits expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,040,007</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,238,381</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(522,977</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,281,475</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Foreign currency (loss)/ gain, net</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,623,484</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,461,368</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,203</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(163,111</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Corporate office expenses</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,973,892</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,066,981</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(318,806</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,350,373</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Loss from ordinary activities before income tax</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,125,719</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,518,976</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,356,328</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(32,849,777</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Income tax expense relating to ordinary activities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Net loss before outside equity interest</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,125,719</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,518,976</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,356,328</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(32,849,777</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss attributable to outside equity interest</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>15</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>399,196</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,835,771</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,591,175</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,745,976</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Net loss attributable to members of the parent entity</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(14,726,523</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,683,205</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,765,153</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(24,103,801</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    (Decrease)/increase in foreign currency translation reserve
    arising on translation of self-sustaining foreign operations</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(350,287</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>77,985</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(31,765</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(301,367</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total revenue, expense and valuation adjustments attributable to
    members of the parent entity recognized directly in equity</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(350,287</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>77,985</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(31,765</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(301,367</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total changes in equity other than those resulting from
    transactions with owners as owners</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,076,810</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,605,220</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,796,918</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(24,405,168</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Loss per share (basic and diluted)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(0.07</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(0.03</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(0.03</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(N/A</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="center" style="font-size: 10pt; margin-top: 9pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
The consolidated statements of financial performance should be
read in conjunction with the accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt;">F-4

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(In Australian Dollars)</B>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="36%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Period from</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Inception of</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="11">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Development Stage</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>Years Ended 30&nbsp;June</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(1&nbsp;Dec&nbsp;2000)</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>to 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Notes</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Cash flows from operating activities</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Payments to suppliers and employees</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,815,520</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,044,430</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(787,216</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(8,002,194</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Interest received</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>667,310</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>326,576</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>110,675</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,357,745</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Interest paid</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,782</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,782</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Research and development expenditure</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(8,318,054</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,124,304</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,878,326</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(21,126,373</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Income tax paid</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other receipts</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>161,666</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>27,474</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>191,269</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net cash used in operating activities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>17</TD>
    <TD align="left" valign="bottom" nowrap>(b)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(12,304,598</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,821,466</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,554,867</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(27,586,335</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Cash flows from investing activities</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Purchase of property, plant and equipment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,410,218</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(527,168</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(52,956</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,837,357</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Proceeds from sale of property, plant and equipment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>702,554</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash paid for equity increase in controlled entities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,644,964</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(622,656</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,068,020</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net cash held by subsidiaries on acquisition</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>623,664</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,152,962</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net cash used in investing activities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(8,055,182</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(527,168</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(51,948</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(8,049,861</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Cash flows from financing activities</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Proceeds from issue of ordinary shares</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,666,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>36,506,617</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>900,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>46,542,787</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Payment of share issue costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(27,422</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,150,819</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(47,433</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,381,469</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Equity contributions from outside equity interest</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,597,649</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,508,030</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net cash provided by financing activities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,639,078</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>36,953,447</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>852,567</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>49,669,348</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Net (decrease)/ increase in cash held</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(16,720,702</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>28,604,813</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,754,248</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>14,033,152</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Cash at the beginning of the financial period</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31,350,656</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,180,134</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,051,509</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>597,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Effect of exchange rate changes on the balance of cash held in
    foreign currencies</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,737,893</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,565,709</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(117,127</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,738,091</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Cash at the end of the financial period</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>17</TD>
    <TD align="left" valign="bottom" nowrap>(a)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,892,061</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31,350,656</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,180,134</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,892,061</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="center" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
The consolidated statements of cash flows should be read in
conjunction with the accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt;">F-5

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#146;
EQUITY</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(In Australian Dollars except number of shares)</B>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 9pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="23%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Deficit</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Accumulated</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Deficit</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Prior to</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Accumulated</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Contributed</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Development</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>During</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Equity</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Stage</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Development Stage</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Reserves</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Total</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Shares</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance at inception of development stage (1&nbsp;December 2000)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>62,329,947</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,060,181</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,247,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Shares issued, net of issue costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20,218,535</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,047,668</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,047,668</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(738,501</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(738,501</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Foreign currency translation adjustment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,300</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,300</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance, 30&nbsp;June 2001</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>82,548,482</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,107,849</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(738,501</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,300</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,585,467</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Shares issued, net of issue costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13,298,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,541,767</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,541,767</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,190,419</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,190,419</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Foreign currency translation adjustment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,700</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,700</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance, 30&nbsp;June 2002</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>95,846,982</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>14,649,616</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,928,920</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>32,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,939,515</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Shares issued, net of issue costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,069,231</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>952,568</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>952,568</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,765,153</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,765,153</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Foreign currency translation adjustment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(31,765</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(31,765</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance, 30&nbsp;June 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>103,916,213</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>15,602,184</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,694,073</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>235</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,095,165</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Shares issued, net of issue costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>50,021,572</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>34,355,798</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>34,355,798</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,683,205</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,683,205</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Foreign currency translation adjustment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>77,985</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>77,985</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance, 30&nbsp;June 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>153,937,785</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>49,957,982</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(9,377,278</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>78,220</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>36,845,743</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Shares issued for cash, net of issue costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>15,570,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,666,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,666,500</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Shares issued as consideration for acquisition, net of issue
    costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>49,804,381</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>54,259,353</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>54,259,353</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(14,726,523</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(14,726,523</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Foreign currency translation adjustment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(350,287</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(350,287</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Option premium reserve adjustment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>292,828</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>292,828</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance, 30&nbsp;June 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>219,312,166</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>107,883,835</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(24,103,801</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20,761</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>79,987,614</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="center" style="font-size: 10pt; margin-top: 9pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
The consolidated statements of changes in stockholders equity
should be read in conjunction with the accompanying notes.
</DIV>

<P align="center" style="font-size: 10pt;">F-6

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>1.</B></TD>
    <TD>
    <B>Background and Summary of Significant Accounting Policies</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>Background</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida Limited, or pSivida, together with its subsidiaries,
referred to as the &#147;Company&#148;, is incorporated in
Perth, Australia and is committed to biomedical applications of
nano-technology and has as its core focus the development and
commercialization of a modified form of the silicon chip
(porosified or nano-structured silicon) known as
BioSilicon<SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant:SMALL-CAPS">tm</FONT></SUP>.
BioSilicon<SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant:SMALL-CAPS">tm</FONT></SUP>
offers multiple potential applications across the high growth
healthcare sector, including controlled slow release drug
delivery, brachytherapy, tissue engineering and orthopaedics.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On 18 May 2001, the Company re-listed on the Australian Stock
Exchange (ASX Code: PSD). pSivida&#146;s shares are also listed
in Germany on the Frankfurt Stock Exchange on the XETRA system
(German Symbol: PSI. Securities Code (WKN)&nbsp;358705), in the
United Kingdom on the OFEX International Market Service (IMS)
under the ticker symbol PSD and on the NASDAQ National Market
under the ticker symbol PSDV.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>Financial Reporting Framework</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The accompanying financial statements have been prepared in
accordance with Australian Accounting Standards and other
mandatory professional reporting requirements. These standards
and reporting requirements form part of generally accepted
accounting principles in Australia (A-GAAP).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A reconciliation of the major differences between these
principles and those applicable in the United States of America
(US GAAP) is included in Note&nbsp;27.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
These financial statements have been prepared on the basis of
historical cost and except where stated, do not take into
account changing money values or current valuations of
non-current assets. Cost is based on the fair values of the
consideration given in exchange for assets.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The preparation of consolidated financial statements in
conformity with GAAP requires management to make estimates and
assumptions that affect the amounts that are reporting in the
consolidated financial statements and accompanying disclosures.
Although these estimates are based on management&#146;s best
knowledge of current events and actions that the company may
undertake in the future, actual results may be different from
the estimates.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The consolidated financial statements are presented in
Australian dollars ($) unless otherwise stated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>Development Stage&nbsp;&#151; Risks and Uncertainties</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
As a development stage enterprise, the Company&#146;s prospects
are subject to the risks and uncertainties frequently
encountered by companies, which have not yet commercialized any
applications of their technology, particularly in new and
evolving markets. pSivida&#146;s operating results may fluctuate
significantly in the future as a result of a variety of factors,
including capital expenditure and other costs relating to
establishing, maintaining and expanding the operations, the
number and mix of potential customers, potential pricing of
future products by the Company and its competitors, new
technology introduced by the Company and its competitors, delays
or expense in obtaining necessary equipment, economic and social
conditions in the biotechnology industry and general economic
conditions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida will continue to review the need to seek additional
funding through public and private financing and/or through
collaboration or other arrangements with corporate partners. The
Company cannot be certain that they will be able to raise any
required funding or capital, on favourable terms or at
</DIV>

<P align="center" style="font-size: 10pt;">F-7

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
all, or that they will be able to establish corporate
collaborations on acceptable terms, if at all. If the Company is
unable to obtain such additional funding or capital, they may be
required to reduce the scope of their development plans.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida&#146;s experience in exploiting their technology is
limited. The Company cannot be certain that their operations
will be profitable in the short-term, or at all. If pSivida
fails in any of their efforts to establish or expand their
business, the results of operations, financial condition and
liquidity of the Company could be materially adversely affected.
The Company cannot be certain that they will be able to obtain
or retain any permits required by the Company to market, sell
and deliver its technology. Any of these factors could result in
cessation of pSivida&#146;s operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The date of inception of the development stage was
1&nbsp;December 2000, being the date that pSivida (formerly
Sumich Group Limited) was re-listed on the Australian Stock
Exchange following a recapitalization and restructure. It was
after this recapitalization and restructure that the Company
acquired an interest in pSiMedica Limited, or pSiMedica, and
commenced its research and development activities. Balances at
inception of the development stage represent the Company&#146;s
statement of financial position balances post-recapitalization
and restructure.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>Significant Accounting Policies</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Accounting policies are selected and applied in a manner which
ensures that the resulting financial information satisfies the
concepts of relevance and reliability, thereby ensuring that the
substance of the underlying transactions or other events is
reported.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following significant accounting policies have been adopted
in the preparation of the financial report:
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>(a)&nbsp;</B></TD>
    <TD>
    <B>Principles of consolidation</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The consolidated financial statements are those of the
consolidated entity, comprising pSivida (the parent entity) and
all entities that pSivida controlled from time to time during
the year and at the balance sheet date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Information from the financial statements of subsidiaries is
included from the date the parent company obtains control until
such time as control ceases. Where there is loss of control of a
subsidiary, the consolidated financial statements include the
results for the part of the reporting period during which the
parent company has control.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The financial statements of subsidiaries are prepared for the
same reporting period as the parent entity, using consistent
accounting policies. Adjustments are made to bring into line any
dissimilar accounting policies which may exist.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On 24&nbsp;August 2004, the Company incorporated AION
Diagnostics Limited, or AION Diagnostics, an Australian resident
wholly owned subsidiary of pSivida, to focus on developing the
diagnostic applications of BioSilicon. pSivida funded AION
Diagnostics through an investment of $1,200,000 and intends to
license diagnostic and sensor applications of the BioSilicon
platform technology to AION Diagnostics.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the year ended 30&nbsp;June 2005 the Company also
incorporated pSivida UK Limited in the United Kingdom
(&#147;UK&#148;) and pSivida Inc in the United States
(&#147;US&#148;). These companies were set up in order to gain
patent protection in the UK and US.
</DIV>

<P align="center" style="font-size: 10pt;">F-8

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
All intercompany balances and transactions, including unrealized
profits arising from intra-group transactions, have been
eliminated in full.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>(b)&nbsp;</B></TD>
    <TD>
    <B>Foreign currencies</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
    <TD>
    <I>Translation of Foreign Currency Transactions</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Transactions in foreign currencies of entities within the
consolidated entity are converted to local currency at the rate
of exchange ruling at the date of the transaction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Amounts payable to and by the entities within the consolidated
entity that are outstanding at the balance sheet date and are
denominated in foreign currencies have been converted to local
currency using rates of exchange ruling at the end of the
financial year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
All resulting exchange differences arising on settlement or
restatement are brought to account in determining the profit or
loss for the financial year, and transaction costs, premiums and
discounts on forward currency contracts are deferred and
amortized over the life of the contract.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
    <TD>
    <I>Translation of Accounts of Overseas Operations</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
All overseas operations are deemed to be self-sustaining as each
is financially and operationally independent of pSivida. The
financial reports of overseas operations are translated using
the current rate method and any exchange differences are taken
directly to the foreign currency translation reserve
(Note&nbsp;13a).
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>(c)&nbsp;</B></TD>
    <TD>
    <B>Cash assets</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Cash on hand and in banks and short-term deposits are stated at
nominal value.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For the purposes of the Statement of Cash Flows, cash assets
include cash on hand, in banks and money market investments
readily convertible to cash within two working days.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>(d)&nbsp;</B></TD>
    <TD>
    <B>Receivables</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Receivables are recognized and carried at original amount less a
provision for any uncollectible debts.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD><B>(f)&nbsp;</B></TD>
    <TD>
    <B>Recoverable amount</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Non-current assets, including intangible assets, are carried at
the lower of cost and recoverable amount. Non-current assets are
not written up if the recoverable amount exceeds the carrying
value. In determining recoverable amount, expected net cash
flows have not been discounted to their present value.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>(g)&nbsp;</B></TD>
    <TD>
    <B>Property, plant and equipment</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
    <TD>
    <I>Cost</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
All classes of property, plant and equipment are measured at
cost.
</DIV>

<P align="center" style="font-size: 10pt;">F-9

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
    <TD>
    <I>Depreciation</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Depreciation is provided on a straight-line basis on all
property, plant and equipment, over the following estimated
useful lives:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="63%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="16%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Lesser of the lease term and</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Leasehold improvements</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>the useful economic life</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Plant and equipment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" nowrap>3&nbsp;years</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Assets in the course of construction are not depreciated until
such assets are available for use.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>(h)&nbsp;</B></TD>
    <TD>
    <B>Operating leases</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The minimum lease payments of operating leases, where the lessor
effectively retains substantially all of the risks and benefits
of ownership of the leased item, are recognized as an expense on
a straight line basis.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The cost of improvements to or on leasehold property is
capitalized, disclosed as leasehold improvements, and amortized
over the unexpired period of the lease or the estimated useful
lives of the improvements, whichever is the shorter.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD><B>(i)&nbsp;</B></TD>
    <TD>
    <B>Intangibles</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
    <TD>
    <I>Intellectual Property</I></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Intellectual property represents acquired biotechnology
intellectual property owned by pSiMedica Limited, a subsidiary
of pSivida. pSiMedica owns the world-wide
BioSilicon<SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant:SMALL-CAPS">tm</FONT></SUP>
intellectual property rights royalty free. pSiMedica also owns
the patented rights to
BioSilicon<SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant:SMALL-CAPS">tm</FONT></SUP>,
a porous form of silicon and an enabling platform nanotechnology
in the biomedical industry.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Intellectual property is recorded at the cost of acquisition and
is carried forward as an asset on the expectation that it will
lead to commercialization. The carrying amount of intangibles is
reviewed by the Directors at each reporting date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The directors gave due consideration to the technical and
commercial life of the intellectual property (being patents and
licences) concluding that a 12&nbsp;year estimated useful
economic life, commencing on the date of acquisition, was
appropriate. Amortization will be calculated on a straight-line
basis so as to write off the cost of the asset over its
remaining estimated useful economic life, commencing with
commercial production of products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Costs associated with new patent applications have been expensed
as research and development.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Goodwill</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Goodwill, representing the excess of the cost of acquisition
over the fair value of the identifiable net assets acquired, is
amortized on a straight line basis over a period of nine years.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(j)</B></TD>
    <TD>
    <B>Research and development costs</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Research and development costs are expensed as incurred, except
where future benefits are expected, beyond any reasonable doubt,
to exceed those costs. Where research and development costs are
deferred such costs are amortized over future periods on a basis
related to expected future benefits. To date, no research and
development costs have been capitalized.
</DIV>

<P align="center" style="font-size: 10pt;">F-10

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD><B>(k)</B></TD>
    <TD>
    <B>Trade and other payables</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Liabilities for trade creditors and other amounts are carried at
cost which is the fair value of the consideration to be paid in
the future for goods and services received, whether or not
billed to the consolidated entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Payables to related parties are carried at the principal amount.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(l)</B></TD>
    <TD>
    <B>Provisions</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Provisions are recognized when the economic entity has a legal,
equitable or constructive obligation to make a future sacrifice
of economic benefits to other entities as a result of past
transactions or other past events, it is probable that a future
sacrifice of economic benefits will be required and a reliable
estimate can be made of the amount of the obligation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A provision for dividends is not recognized as a liability
unless the dividends are declared, determined or publicly
recommended on or before the reporting date.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD><B>(m)</B></TD>
    <TD>
    <B>Contributed equity</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Ordinary share capital is recognized at the fair value of the
consideration received by the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Any directly attributable transaction costs arising on the issue
of ordinary shares are recognized in equity as a reduction of
the share proceeds received.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(n)</B></TD>
    <TD>
    <B>Revenue recognition</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Revenue is recognized to the extent that it is probable that the
economic benefits will flow to the entity and the revenue can be
reliably measured.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Interest income is recognized as earned where collectibility is
reasonably assured.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(o)</B></TD>
    <TD>
    <B>Taxes</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income Tax</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Tax-effect accounting is applied using the liability method
whereby income tax is regarded as an expense and is calculated
on the accounting profit after allowing for permanent
differences. To the extent timing differences occur between the
time items are recognized in the financial statements and when
items are taken into account in determining taxable income or
loss, the net related taxation benefit or liability, calculated
at current rates, is disclosed as a future income tax benefit or
a provision for deferred income tax. The net future income tax
benefit relating to tax losses and timing differences is not
carried forward as an asset unless the benefit is virtually
certain of being realized
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goods and Services Tax
(GST)</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Revenues, expenses and assets are recognized net of the amount
of GST except:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    where the GST incurred on a purchase of goods and services is
    not recoverable from the taxation authority, in which case the
    GST is recognized as part of the cost of acquisition of the
    asset or as part of the expense item as applicable;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    receivables and payables are stated with the amount of GST
    included.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">F-11

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The net amount of GST recoverable from, or payable to, the
taxation authority is included as part of receivables or
payables in the Statement of Financial Position.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(p)</B></TD>
    <TD>
    <B>Employee entitlements</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Provision is made for employee entitlement benefits accumulated
as a result of employees rendering services up to the reporting
date. These benefits include wages and salaries, annual leave,
sick leave and long service leave.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Liabilities arising in respect of wages and salaries, annual
leave, sick leave and any other employee entitlements expected
to be settled within twelve months of the reporting date are
measured at their nominal amounts based on remuneration rates
which are expected to be paid when the liability is settled. All
other employee entitlement liabilities are measured at the
present value of the estimated future cash outflow to be made in
respect of services provided by employees up to the reporting
date. In determining the present value of future cash outflows,
the interest rates attaching to government guaranteed securities
which have terms to maturity approximating the terms of the
related liability are used.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Employee entitlements expenses arising in respect of the
following categories:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    wages and salaries, non-monetary benefits, annual leave, long
    service leave, sick leave and other leave entitlements;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    other types of employee entitlements;</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
are charged against profits in their respective categories.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The value of the employee share option plan described in
Note&nbsp;21 is not being charged as an employee entitlement
expense.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Any contributions made to the superannuation fund by entities
within the consolidated entity are charged against operations
when due.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(q)</B></TD>
    <TD>
    <B>Loss per share</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Basic loss per share is calculated as net loss, adjusted to
exclude costs of servicing equity (other than dividends) and
preference share dividends, divided by the weighted average
number of ordinary shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Diluted loss per share is calculated as net loss divided by the
weighted average number of ordinary shares and dilutive
potential ordinary shares.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(r)</B></TD>
    <TD>
    <B>Acquisitions</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Acquisitions are accounted for using the purchase method of
accounting. The consolidated financial statements include the
operating results of acquirees from the date of acquisition.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For acquisitions, including step acquisitions, completed from
1&nbsp;July 2004, the cost of acquisition includes all direct
acquisition costs.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>2.</B></TD>
    <TD>
    <B>Purchase price allocation</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On 4 August 2004, the Company acquired the remaining 55.28%
interest in pSiMedica Limited that it did not already own.
pSivida acquired the remaining interest in pSiMedica in order to
obtain 100% ownership of pSiMedica and therefore own 100% of the
BioSilicon technology. The consideration paid was $59,224,568
which comprised of $4,323,622 in cash, a total of 49,804,381
ordinary shares of pSivida issued
</DIV>

<P align="center" style="font-size: 10pt;">F-12

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
at a value of $1.09 for A-GAAP purposes, 638,537 pSivida options
with an estimated fair value of $292,828, (issued to employees
of pSiMedica in exchange for their rights being waived in
relation to options previously issued by pSiMedica) and direct
acquisition costs totalling $321,342.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The total acquisition price recognized for A-GAAP is an amount
equal to:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="83%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>4,323,622</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Fair value of shares issued</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>54,286,776</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Fair value of options issued</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>292,828</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Direct acquisition costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>321,342</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total cost of acquisition</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>59,224,568</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The results of the operations of pSiMedica were included for the
entire financial year as pSivida held more than 50% of the
voting rights of pSiMedica for the whole of this period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The balance sheet showing the purchase price allocation of net
assets acquired is listed as follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="56%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Acquired Interest</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2" align="left" nowrap><B>Item</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Total Fair Value</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>55.28%</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>520,173</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>287,552</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Receivables</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>198,239</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>109,587</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Property, plant and equipment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>600,640</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>332,034</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Creditors</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(1,462,721</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(808,592</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Intangible assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    License</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>64,400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>35,600,320</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Patents</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>25,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>13,820,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Total</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>49,340,901</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Consideration</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>59,224,568</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Initial goodwill arising under A-GAAP</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>9,883,667</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>3.</B></TD>
    <TD>
    <B>Revenue from ordinary activities</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="68%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>Years Ended 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Revenues from ordinary activities</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Interest income on bank deposits</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>667,310</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>325,479</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>110,675</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other revenue</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>161,666</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>56,200</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total revenue from ordinary activities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>828,976</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>381,679</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>110,675</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-13

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>4.</B></TD>
    <TD>
    <B>Expenses and (Losses)/ Gains</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(a)</B></TD>
    <TD>
    <B>Expenses</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="56%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>Years Ended 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>Depreciation and amortisation of non-current assets</I></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Borrowing costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,520</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,520</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,600</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Goodwill on acquisition</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>973,923</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Plant and equipment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>36,839</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>23,683</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>18,502</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Leasehold improvements</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,157</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,733</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2"><FONT style="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,029,384</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>39,360</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>37,835</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Included in research and development costs:</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Plant and equipment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>569,071</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>287,702</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>258,432</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Leasehold improvements</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>18,717</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other non-current assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>18,130</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>19,666</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>19,433</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total depreciation and amortisation of non-current assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,635,300</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>346,728</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>315,700</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Write off of borrowing costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,919</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Operating lease charges(i)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>97,738</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>95,772</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>36,569</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Research and development costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,287,930</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,011,666</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,586,182</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>(i)&nbsp;</TD>
    <TD align="left">
    Excludes operating lease charges classified as &#147;research
    and development.&#148;</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(b)</B></TD>
    <TD>
    <B>(Losses)/ Gains</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="59%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss on disposal of property, plant and equipment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,910</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Foreign currency (loss)/ gain, net</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,623,484</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,461,368</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,203</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-14

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>5.</B></TD>
    <TD>
    <B>Income tax</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The prima facie tax, using the tax rate applicable in Australia,
on operating loss differs from the income tax provided in the
accounts as follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="55%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>Years Ended 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Prima facie income tax benefit calculated at 30% on the loss
    from ordinary activities before income tax</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,537,716</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,255,693</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,606,899</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Tax effect of permanent differences</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Goodwill amortization</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>292,177</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other items (net)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,866</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,637</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>52,782</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Income tax benefit attributable to ordinary activities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,241,673</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,245,056</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,554,117</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Future income tax benefit not brought to account</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,241,673</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,245,056</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,554,117</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Income tax expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Future income tax benefit from tax losses not brought to account
    at balance date as realization of the benefit is not virtually
    certain (at 30%)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,291,377</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,049,704</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,892,095</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
This Company has future income tax benefits relating to tax
losses not recognized as assets because recovery is not
virtually certain. Such benefits will only be obtained if:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    (a)&nbsp;future assessable income is derived of a nature and of
    an amount sufficient to enable the benefit to be realized;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    (b)&nbsp;the conditions for deductibility imposed by tax
    legislation continue to be complied with;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    (c)&nbsp;no changes in tax legislation adversely affect the
    consolidated entity in realising the benefit.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company has elected not to consolidate under the tax regime.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company has no franking credits available at year end.
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>6.</B></TD>
    <TD>
    <B>Receivables</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 3pt; ">

<TR style="font-size: 1pt;">
    <TD width="77%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>As at 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B><I>Current</I></B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Indirect tax</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>709,418</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>340,482</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Indirect tax receivables relate to goods and services tax
(GST)&nbsp;and value added tax (VAT). These amounts are
non-interest bearing and have repayment terms applicable under
the relevant government authorities.
</DIV>

<P align="center" style="font-size: 10pt;">F-15

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>7.</B></TD>
    <TD>
    <B>Other assets</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="76%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>As at 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B><I>Current</I></B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Prepayments</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>322,933</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>38,958</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B><I>Non-current</I></B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Loan facility arrangement costs(i)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>34,559</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>34,559</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accumulated amortization</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(34,559</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(21,120</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13,439</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other non-current assets(ii)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>53,061</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>58,301</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accumulated amortization</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(53,061</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(39,099</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>19,202</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>32,641</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>(i)&nbsp;</TD>
    <TD align="left">
    Loan facility arrangement costs were incurred in connection with
    the September 2002 agreement with Global Emerging Markets
    (&#147;GEM&#148;), a New&nbsp;York based private equity group,
    for a fully underwritten US$7.5&nbsp;million equity line of
    credit facility. Such costs were being amortized on a
    straight-line basis over the three-year term of the facility. As
    part of the commitment fee, pSivida issued to GEM 2,000,000
    options to acquire shares in pSivida at 20&nbsp;cents each,
    expiring on 31&nbsp;December 2004. Additionally, a commitment
    fee equivalent to 1.67% of the total value of the facility was
    payable by the Company to GEM on the proceeds of any drawdowns.
    The facility was terminated during the year ended 30&nbsp;June
    2005 with no drawdowns having been made.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>(ii)&nbsp;</TD>
    <TD align="left">
    Other non-current assets comprises the fair value of non-cash
    consideration in pSiOncology made by minority shareholders. This
    amount has been amortized over three years on a straight line
    basis.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">F-16

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>8.</B></TD>
    <TD>
    <B>Property, plant and equipment, net</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="69%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>As at 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Plant and equipment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    At cost</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,439,455</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,360,533</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accumulated depreciation</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,119,916</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(699,938</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2"><FONT style="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,319,539</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>660,595</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Leasehold improvements</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    At cost</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>155,799</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>14,214</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accumulated depreciation</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(30,188</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,110</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2"><FONT style="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>125,611</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,104</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Construction in progress(i)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    At cost</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,828,513</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="10">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total property, plant and equipment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    At cost</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,423,767</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,374,747</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accumulated depreciation</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,150,104</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(705,048</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2"><FONT style="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,273,663</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>669,699</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>(i)&nbsp;</TD>
    <TD align="left">
    Construction in progress for 30&nbsp;June 2005 relates to the
    construction of a new production facility in Germany, which was
    completed subsequent to year end.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">F-17

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(a)</B></TD>
    <TD>
    <B>Reconciliations</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Reconciliations of the carrying amounts for each class of
property, plant and equipment are set out below:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="69%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>As at 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Plant and equipment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Carrying amount at beginning of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>660,595</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>400,549</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Additions</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,358,690</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>549,880</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Disposals</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,910</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Depreciation</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(605,910</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(311,385</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net foreign currency movements</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(86,926</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21,551</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Carrying amount at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,319,539</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>660,595</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Leasehold improvements</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Carrying amount at beginning of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,104</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,736</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Additions</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>146,977</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,525</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Depreciation</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(25,817</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,157</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net foreign currency movements</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,653</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Carrying amount at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>125,611</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,104</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Construction in progress</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Carrying amount at beginning of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Additions</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,904,551</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net foreign currency movements</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(76,038</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Carrying amount at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,828,513</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangibles</B>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Intellectual property&nbsp;&#151; at cost(i)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>55,927,494</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,934,622</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Goodwill on acquisition(ii)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,883,667</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accumulated amortization&nbsp;&#151; goodwill</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(973,923</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>64,837,238</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,934,622</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;(i)&nbsp;</TD>
    <TD align="left">
    The intellectual property comprises the licence to develop
    applications for
    BioSilicon<SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant:SMALL-CAPS">tm</FONT></SUP>
    and the related patents. As described in Note&nbsp;1(i),
    amortization of this asset will commence on commercial
    production of related products, which had not commenced at
    30&nbsp;June 2005.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>(ii)&nbsp;</TD>
    <TD align="left">
    Goodwill on acquisition relates to the acquisition of the
    remaining outside equity interest in pSiMedica in August 2004.
    Refer to Note&nbsp;2.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">F-18

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD><B>10.</B></TD>
    <TD>
    <B>Payables</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="73%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>As at 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B><I>Current</I></B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Trade creditors</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>806,047</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,162,281</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accruals</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>994,444</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>565,456</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Payroll taxes payable</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>167,227</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>117,223</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Amounts payable to directors and director-related entities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>38,253</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,910</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Amounts payable to other related parties</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,849</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,234</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,017,820</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,882,104</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisions</B>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; ">

<TR style="font-size: 1pt;">
    <TD width="73%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="center" nowrap><B><I>Current</I></B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Provision for employee entitlements</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,879</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>56,011</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="79%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Consolidated</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Number of employees at end of financial year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>36</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Superannuation
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under government regulations the Company is legally required to
contribute 9% of employees&#146; gross income to an approved
superannuation fund. Employees are entitled to contribute
additional amounts to the fund at their own discretion. The
Company makes the required contribution to each employee&#146;s
nominated Superannuation fund.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company does not provide employee benefits under defined
benefit arrangements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The United Kingdom subsidiary, pSiMedica Limited, operates a
defined contribution pension scheme. The pension cost charge for
the year under the defined contribution scheme was &#163;79,411
($195,863) (2004: &#163;30,660 ($75,149), 2003: &#163;28,672
($77,740)). An increase in employee numbers for pSiMedica has
caused the increase in the charge in the 2005&nbsp;year.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Employee share option plan (ESOP)</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
An employee share option plan has been established where
directors and employees of the consolidated entity Company are
issued with options over the ordinary shares of pSivida Limited.
Shareholders reapproved the plan at the annual general meeting
(&#147;AGM&#148;) held on 17&nbsp;November&nbsp;2004. The
options, issued for nil consideration, are issued in accordance
with performance guidelines established by the directors of
pSivida Limited.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Employee share options carry no rights to dividends and no
voting rights.
</DIV>

<P align="center" style="font-size: 10pt;">F-19

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>12.</B></TD>
    <TD>
    <B>Contributed equity</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(a)</B></TD>
    <TD>
    <B>Contributed equity</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="70%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>As at 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Ordinary shares, fully paid</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>107,883,835</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>49,957,982</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(b)</B></TD>
    <TD>
    <B>Movements in share capital</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="38%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="14" align="center" nowrap><B>Years ended 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="14" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance at beginning of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>153,937,785</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>103,916,213</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>49,957,982</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>15,602,183</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued during the year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Consideration for acquisition</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>49,804,381</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>54,286,776</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Share placements</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>38,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>33,946,640</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Share purchase plan</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,891,572</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>933,977</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Options exercised</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>15,570,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,130,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,666,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,626,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Share issue costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(27,423</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,150,818</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>219,312,166</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>153,937,785</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>107,883,835</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>49,957,982</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-20

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Details of share issuances are as follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="14%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Issue price</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Total</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Date</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap><B>Details</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    4&nbsp;Aug 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Share purchase plan, net of $1,679 issue costs</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,891,572</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.24</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>932,298</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    20 Aug 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>650,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>130,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    27 Aug 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>650,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>130,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    28 Aug 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,725,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>345,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    8 Sep 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    3 Oct 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    6 Oct 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Private placement, net of $338,400 issue costs</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.50</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,161,600</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    24 Dec 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>30,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    6 Jan 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>475,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>95,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    4 Feb 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>400,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    20 Apr 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Private placement, net of $1,523,865 issue costs</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>19,375,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">US$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>19,413,109</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    23 Apr 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Private placement, net of $286,875 issue costs</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,625,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">US$</TD>
    <TD align="right" valign="bottom" nowrap>0.85</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,222,791</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    3 May 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>300,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>60,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    19 May 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>300,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>60,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="3" align="left" valign="top">
    Year ended 30&nbsp;June 2004</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>50,021,572</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>34,355,798</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3"><FONT style="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    14 Jul 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>50,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    5 Aug 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Shares issued as consideration for acquisition, net of $27,422
    issue costs</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>49,804,381</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>54,259,353</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    6 Aug 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>50,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    13 Aug 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>40,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    17 Aug 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>150,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>30,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    20 Aug 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>300,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>60,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    27 Aug 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>100,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    8 Oct 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>450,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>90,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    27 Oct 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>100,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>40,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    11 Nov 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>450,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>90,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    14 Dec 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,650,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,730,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    14 Dec 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,550,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>620,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    14 Dec 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>150,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.50</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>75,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    14 Dec 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>150,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.65</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>97,500</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    31 Dec 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,470,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>494,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    31 Dec 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">
    Exercise of options</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>550,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>220,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="3" align="left" valign="top">
    Year ended 30&nbsp;June 2005</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>65,374,381</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>57,925,853</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3"><FONT style="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-21

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(c)</B></TD>
    <TD>
    <B>Share options</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 9pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="26%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>

<TR style="font-size: 7pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Balance at</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercised</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Forfeited</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 7pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>beginning of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Issued during</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>during the</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>during the</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Balance at</B></TD><TD></TD>
</TR>

<TR style="font-size: 7pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Expiry</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>year</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>the year</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>year</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>year</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>end of year</B></TD><TD></TD>
</TR>

<TR style="font-size: 7pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Unlisted options</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,570,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(12,570,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Unlisted options</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.50</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>150,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(150,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Unlisted options</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.65</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>150,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(150,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Unlisted options *</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,200,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Unlisted options *</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(500,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Unlisted options *</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,395,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(20,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,375,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Unlisted options **</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/08</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,050,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,050,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Unlisted options *</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,114,537</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(59,824</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,054,713</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Unlisted options *</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.02</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/08</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Unlisted options *</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/08</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>115,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>115,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Unlisted options *</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/3/10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,202,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(25,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,177,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>19,965,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>14,681,537</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,570,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(104,824</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>18,971,713</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top">
    <TD>*&nbsp;</TD>
    <TD align="left">
    Options issued pursuant to the Company&#146;s Employee Share
    Option Plan (ESOP).</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>**&nbsp;</TD>
    <TD align="left">
    2,050,000 options issued as payment of share issue costs to
    consultants not under the ESOP</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The options on issue at 30&nbsp;June 2005 have a weighted
average exercise price of $0.97 and a weighted average remaining
contractual life of 45&nbsp;months. The options on issue and
currently exercisable at 30&nbsp;June 2005 have a weighted
average exercise price of $1.01 and a weighted average remaining
contractual life of 43&nbsp;months.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The options on issue at 30&nbsp;June 2005 have the following
range of exercise prices:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="65%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted Average</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Range of Exercise Price</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Options</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise Price</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    $0.00 to $0.10</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    $0.10 to $0.25</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    $0.25 to $0.50</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    $0.50 to $0.70</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,375,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    $0.70 to $0.90</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,292,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    $0.90 to $1.10</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.08</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    $1.10 and above</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,054,713</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>18,971,713</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.97</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Employee share option plan (ESOP)</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
An employee share option plan has been established where
directors and employees of the Company are issued with options
over the ordinary shares of pSivida Limited. Shareholders
reapproved the plan at the AGM held on 17&nbsp;November 2004.
The options, issued for nil consideration, are issued in
accordance with performance guidelines established by the
directors of pSivida Limited.
</DIV>

<P align="center" style="font-size: 10pt;">F-22

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Employee share options carry no rights to dividends and no
voting rights.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The ESOP is designed to reward directors, executives and
employees of the Company and consultants for their contributions
to the Company. It is also proposed as a method of retaining
personnel that are key to the growth of the Company&#146;s
intellectual property rights.
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="57%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance at beginning of financial year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>i</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,095,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,700,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,200,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Granted during financial year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>ii</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,631,537</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,395,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>520,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exercised during financial year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>iii</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,050,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Transferred and exercised during financial year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>iv</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,650,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Forfeited during financial year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>v</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(104,824</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(20,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance at end of financial year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>vi</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>16,921,713</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,095,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,700,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<I>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance at beginning of
financial year</I>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="43%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Vesting</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Expiry</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Options&nbsp;&#151; Series 2005</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 31&nbsp;December 2001</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/01</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 1&nbsp;November 2002</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1/11/02</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1/11/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/7/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,345,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/4/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>350,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/1/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,095,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-23

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<I>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Granted during financial
year</I>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="43%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Vesting</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Expiry</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Options&nbsp;&#151; Series 2005</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 5 August 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>175,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 5 August 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>50,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 5 August 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,889,537</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 22 April 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.02</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 22 April 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>115,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/08</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 22 April 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>50,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/06</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/3/10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 22 April 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>450,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/3/10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 22 April 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,252,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/06</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/3/10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 22 April 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>450,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/3/10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,631,537</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="43%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Vesting</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Expiry</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Options&nbsp;&#151; Series 2004</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/7/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,345,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/4/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>350,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/1/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,395,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="46%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Vesting</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Expiry</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Options&nbsp;&#151; Series 2003</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 1&nbsp;November 2002</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>520,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1/11/02</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1/11/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>520,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<I>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercised during financial
year</I>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="42%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Vesting</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Expiry</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Options&nbsp;&#151; Series 2005</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 31&nbsp;December 2001</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(550,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/01</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 1&nbsp;November 2002</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(500,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1/11/02</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1/11/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,050,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-24

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<I>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transferred during
financial year</I>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="42%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Vesting</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Expiry</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Options&nbsp;&#151; Series 2005</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 31&nbsp;December 2001</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,650,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/01</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,650,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the 2005 financial year these options were transferred by
Directors to independent third parties for consideration of
$1.18&nbsp;per option less applicable option exercise price,
brokerage commission and fees. All transferred options were
exercised prior to 31&nbsp;December 2004.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<I>(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forfeited during financial
year</I>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Vesting</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Expiry</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Options&nbsp;&#151; Series 2005</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(20,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/4/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 5 August 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(59,824</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 22 April 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(25,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/06</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/3/10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(104,824</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="46%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Vesting</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Expiry</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Options&nbsp;&#151; Series 2003</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 1&nbsp;November 2002</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(20,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1/11/02</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1/11/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(20,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-25

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<I>(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Balance at end of financial
year</I>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="42%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Vesting</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Expiry</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Options&nbsp;&#151; Series 2005</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/7/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,325,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/4/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>350,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/1/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 5 August 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>175,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 5 August 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>50,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 5 August 2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,829,713</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5/8/09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 22 April 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.02</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 22 April 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>115,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/08</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 22 April 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>50,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/06</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/3/10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 22 April 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>450,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/3/10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 22 April 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,227,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/06</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/3/10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 22 April 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>450,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22/4/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/3/10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>16,921,713</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="43%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Vesting</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Expiry</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Options&nbsp;&#151; Series 2004</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 31&nbsp;December 2001</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/01</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 1&nbsp;November 2002</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1/11/02</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1/11/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/7/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,345,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/4/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>350,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/1/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 21 October 2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21/10/05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,095,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="43%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Vesting</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Expiry</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Options&nbsp;&#151; Series 2003</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 31&nbsp;December 2001</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/01</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13/10/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issued 1&nbsp;November 2002</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1/11/02</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1/11/03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31/12/04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,700,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-26

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<I>Year ended 30&nbsp;June 2005</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company issued 8,251,000 unquoted options to directors,
executives and employees and 225,000 unquoted options to
consultants of the Company under the ESOP in lieu of cash
bonuses and/ or increased fees and as a method of providing an
incentive to maximize shareholder value. The options were issued
for no consideration with an exercise price of $1.18, which was
representative of an 8% premium to the market price at the date
of issue. The various tranches of the options granted have
different vesting dates; however all the options expire on 5
August 2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company also issued 638,537 unquoted options to directors,
executives and employees of the Company under the ESOP in
consideration for the waiver of their rights under outstanding
options previously issued by pSiMedica. The options were issued
for no consideration with an exercise price of $1.18, which was
representative of an 8% premium to the market price at the date
of issue. The options vest immediately, and expire on 5 August
2009. The options were accounted for as part of the
consideration for the purchase of pSiMedica&nbsp;&#151; see
Note&nbsp;2.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company also issued 3,152,000 unquoted options to directors,
executives and employees and 365,000 unquoted options to
consultants of the Company under the ESOP in lieu of cash
bonuses and/ or increased fees and as a method of providing an
incentive to maximize shareholder value. The options were issued
for no consideration with an exercise price of $0.80, which was
representative of a 7% premium to the market price at the date
of issue. The various tranches of the options granted have
different vesting dates, however all the options expire on
31&nbsp;March 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<I>Year ended 30&nbsp;June 2004</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company granted 3,895,000 unquoted options to directors,
executives and employees and 500,000 unquoted options to
consultants of the Company under the ESOP in lieu of cash
bonuses and/ or increased fees and as a method of providing an
incentive to maximize shareholder value. The options were issued
for no consideration with an exercise price of $0.61, which was
representative of a 25% premium to the 60&nbsp;day volume
weighted average price up to the date of the meeting of
shareholders approving the grant. The various tranches of the
options granted have different vesting dates, however all the
options expire on 31&nbsp;December 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<I>Year ended 30&nbsp;June 2003</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company granted 520,000 unquoted options to employees under
the ESOP in lieu of cash bonuses and as a method of providing an
incentive to maximize shareholder value. The options were issued
for no consideration with an exercise price of $0.20, expiring
on 31&nbsp;December 2004.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(d)</B></TD>
    <TD>
    <B>Terms and conditions of contributed equity</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<I>Ordinary shares</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Ordinary shares have the right to receive dividends as declared
and, in the event of winding up the Company, to participate in
the proceeds from the sale of all surplus assets in proportion
to the number of and amounts paid up on shares held.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Ordinary shares entitle their holder to one vote, either in
person or by proxy, at a meeting of the Company. Option holders
do not have the right to receive dividends and are not entitled
to vote at a meeting of the Company.
</DIV>

<P align="center" style="font-size: 10pt;">F-27

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(e)</B></TD>
    <TD>
    <B>Shares and options issued after report date</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Details of share issuances are as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company issued 6,650,000 ordinary shares (in the form of
665,000 American Depositary Receipts, or ADRs at a price of
US$6.50&nbsp;per ADR ($8.61) in August 2005, pursuant to a
Private Investment in Public Equity, or PIPE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Details of option issuances are as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company issued 780,000 options expiring 5 August 2008 and
exercisable at US$1.25 each, pursuant to a PIPE.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>13.</B></TD>
    <TD>
    <B>Reserves</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="71%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Foreign currency translation</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(272,067</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>78,220</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Option premium</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>292,828</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20,761</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>78,220</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(a)</B></TD>
    <TD>
    <B>Foreign currency translation reserve</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The foreign currency translation reserve is used to record
exchange differences arising from the translation of the
financial statements of self-sustaining foreign operations.
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="71%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance at beginning of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>78,220</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>235</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    (Gain)/loss on translation of foreign controlled entities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(350,287</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>77,985</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(272,067</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>78,220</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(b)</B></TD>
    <TD>
    <B>Option premium reserve</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The option premium reserve is used to recognize the value of
options issued of a capital nature. The reserve arose during the
year ended 30&nbsp;June 2005 as a result of the issue of options
to replace pSiMedica options previously held by directors and
employees of pSiMedica as part of the acquisition of the
remaining interest in pSiMedica. The amount charged to the
reserve is the value of the options issued using the Black
Scholes Option Pricing Model.
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="71%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance at beginning of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Increase on issue of options</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>292,828</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>292,828</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>14.</B></TD>
    <TD>
    <B>Accumulated deficit</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(a)</B></TD>
    <TD>
    <B>Deficit accumulated prior to development stage</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="70%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,813,181</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-28

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(b)</B></TD>
    <TD>
    <B>Deficit accumulated during development stage</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="69%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance at beginning of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(9,377,278</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,694,073</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss attributable to members of the Company</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(14,726,523</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,683,205</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(24,103,801</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(9,377,278</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>15.</B></TD>
    <TD>
    <B>Outside equity interest</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Reconciliation of outside equity interest in controlled entities
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="70%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance at beginning of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,583,200</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>204,354</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Share of subsidiary acquisition</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,622,319</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Share of current period loss (through the acquisition date)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(399,196</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,835,771</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Share of foreign currency translation reserve</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>79,361</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>90,489</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Effect of change in shareholding</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,263,365</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,501,809</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,583,200</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>16.</B></TD>
    <TD>
    <B>Investments in controlled entities</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="62%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Ownership Interest</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Country of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>incorporation</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>%</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>%</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    pSiMedica Limited(i)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>UK</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>44.72</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    pSiOncology Pte Ltd (ii)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>Singapore</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>44.72</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    AION Diagnostics Limited (iii)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>Australia</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    pSivida UK Limited (iii)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>UK</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    pSivida Inc (iii)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>USA</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    (i)</TD>
    <TD></TD>
    <TD valign="top">
    Consolidation occurs due to the Company controlling more than
    50% of the voting rights in pSiMedica.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    (ii)</TD>
    <TD></TD>
    <TD valign="top">
    100% owned subsidiary of pSiMedica Limited.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    (iii)</TD>
    <TD></TD>
    <TD valign="top">
    These companies were incorporated during the year ended
    30&nbsp;June 2005 as wholly owned subsidiaries of pSivida.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">F-29

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>17.</B></TD>
    <TD>
    <B>Notes to the statement of cash flows</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(a)</B></TD>
    <TD>
    <B>Reconciliation of cash</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For the purposes of the statement of cash flows, cash includes
cash on hand and in banks and investments in money market
instruments. Cash at the end of the financial year comprises the
following:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="71%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash on hand</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,637,560</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>665,355</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deposits at call</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,254,501</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>30,685,301</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,892,061</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31,350,656</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(b)</B></TD>
    <TD>
    <B>Reconciliation of loss from ordinary activities after related
    income tax to net cash flows used in operating activities</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="54%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>Years ended 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Loss from ordinary activities after tax</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,125,719</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,518,976</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,356,328</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Non-cash items:</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Depreciation and amortization</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,635,300</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>346,728</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>315,700</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Write off of borrowing costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,919</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Loss on disposal of property, plant and equipment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,910</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Shares issued in lieu of cash</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>100,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Foreign exchange loss/ (gain)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,623,484</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,461,368</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,203</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Changes in net assets and liabilities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    (Increase)/decrease in assets:</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Trade and other receivables</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(408,904</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(238,081</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>23,511</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Prepayments</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(290,102</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(12,061</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,172</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deferred assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(34,559</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Increase/ (decrease) in liabilities:</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Trade and other creditors</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>222,635</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,062,292</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>401,778</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Provisions</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,879</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net cash flows used in operating activities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(12,304,598</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,821,466</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,554,867</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(c)</B></TD>
    <TD>
    <B>Non-cash financing and investing activities</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<I>Year ended 30&nbsp;June 2005</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In August 2004 pSivida issued 49,804,381&nbsp;shares at a value
of $1.09 each to former pSiMedica Limited shareholders as part
consideration for the acquisition of the remaining interest in
pSiMedica Limited.
</DIV>

<P align="center" style="font-size: 10pt;">F-30

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<I>Year ended 30&nbsp;June 2004</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On 24 May 2004, pSiMedica issued 56,954 ordinary shares to
acquire the remaining minority interest in pSiOncology.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<I>Year ended 30&nbsp;June 2003</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Acquisition of controlled entity:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In July 2002, pSiMedica subscribed for 90% of the issued share
capital of pSiOncology Pte Ltd., or pSiOncology, for
consideration of &#163;235,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The net assets of pSiOncology as of 30 July 2002 were comprised
as follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="85%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>623,664</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other non-current assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>63,615</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net assets acquired</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>687,279</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Less minority interests</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(64,623</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net assets acquired</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>622,656</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Goodwill arising</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net cash effect: Cash consideration paid</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(622,656</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash included in net assets acquired</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>623,664</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net cash received on purchase of subsidiary</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,008</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the years ended 30&nbsp;June 2005, 2004, and 2003, the
Company issued shares and options in consideration for services
rendered. See note&nbsp;12(b) and 12(c).
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>18.</B></TD>
    <TD>
    <B>Expenditure commitments</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="83%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Operating leases (non-cancellable)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Year ended 30&nbsp;June</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2006</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>325,509</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2007</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>119,424</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2008</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,946</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Thereafter</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2"><FONT style="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>447,879</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Operating leases relate primarily to the lease of office and
laboratory premises in Australia, the UK and Singapore, as well
as some office equipment. Rental payments for leased premises
are subject to annual or biannual rental reviews. The Company
has a three year renewal option on its Australian office
premises.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>19.</B></TD>
    <TD>
    <B>Subsequent events</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On 25&nbsp;July 2005, the Company announced that it had
appointed Dr David Mazzo as a non-executive director of the
Company.
</DIV>

<P align="center" style="font-size: 10pt;">F-31

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On 27&nbsp;July 2005, the Company announced that it had
appointed Mr Michael Rogers as a non-executive director of the
Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On 15&nbsp;August 2005, the Company announced that it was in
negotiations and undertaking due diligence to acquire a US based
specialized drug delivery company through the issue of ADRs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On 23&nbsp;August 2005, the Company announced that it had raised
US$4.2&nbsp;million ($5.6&nbsp;million) before costs via the
private placement of 665,000 ADRs to predominantly US investors
at US$6.50 each ($8.61) pursuant to a PIPE. Each ADR represents
ten ordinary shares. The ADRs have an attached one for ten,
three- year warrant (66,500 warrants) exercisable at
US$12.50&nbsp;per ADR. The Company also issued a further 66,500
warrants as part payment of placing fees in relation to this
transaction. The financial effects of this transaction are not
reflected in the accounts as at 30&nbsp;June 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On 4&nbsp;October 2005, the Company announced that it had
entered into a definitive merger agreement to acquire Control
Delivery Systems, Inc. (CDS), a private drug delivery company
located in the Boston, Massachusetts area. The acquisition is
subject to Australian regulatory and pSivida shareholder
approvals, as well as other customary closing conditions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The acquisition will be funded through the issue of
approximately 16,000,000 pSivida American Depositary Shares
(ADS) to CDS stockholders (representing 160,000,000 ordinary
shares in the Company). Based on a price of US$6.50 ($8.66) per
pSivida ADS, the transaction would represent a purchase price of
approximately US$250&nbsp;million ($333&nbsp;million) for the
combined company. The financial effects of this transaction are
not reflected in the accounts as at 30&nbsp;June 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On 6&nbsp;October 2005, the Company announced that it had signed
an agreement with a New York based institutional accredited
investor, pursuant to which the investor, subject to
satisfaction of closing conditions, agreed to purchase
US$15&nbsp;million of subordinated convertible debentures,
convertible into PSDV ADRs at an initial conversion price of
US$7.10 ($9.50). The proceeds of the issuance are expected to be
used for the expanded development of
BioSilicon<SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant:SMALL-CAPS">tm</FONT></SUP>.
The closing conditions were met and the convertible note was
issued on 16&nbsp;November 2005. The financial effects of this
transaction are not reflected in the accounts as at 30&nbsp;June
2005.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>20.</B></TD>
    <TD>
    <B>Loss per share</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following reflects the net loss and share information used
in the calculation of basic and diluted loss per share:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="52%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss before outside equity interest</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,125,719</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,518,976</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,356,328</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Adjustments:</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss attributable to outside equity interest</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>399,196</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,835,771</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,591,175</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Loss used in calculating basic and diluted loss per share</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(14,726,523</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,683,205</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,765,153</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-32

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 18pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="52%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Weighted average number of ordinary shares used in calculating
    basic loss per share</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>207,802,540</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>126,990,066</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>101,281,292</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Effect of dilutive securities:</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Share options</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Adjusted weighted average number of ordinary shares used in
    calculating basic and diluted loss per share</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>207,802,540</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>126,990,066</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>101,281,292</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following potential ordinary shares are not dilutive and are
therefore excluded from the weighted average number of ordinary
shares and potential ordinary shares used in the calculation of
diluted earnings per share:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="55%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Share options</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>18,971,713</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>19,965,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>23,700,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Since the end of the financial year the Company has issued
665,000 ADRs (representing 6,650,000 ordinary shares) at a price
of US$6.50&nbsp;per ADR and 78,000 warrants over ADRs
(representing 780,000 options over ordinary shares) expiring 5
August 2008, exercisable at US$12.50&nbsp;per warrant, pursuant
to a PIPE.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
There have been no other conversions to, calls of, or
subscriptions for ordinary shares or issues of potential
ordinary shares since the reporting date and before the
completion of this annual report.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>21.</B></TD>
    <TD>
    <B>Director and executive disclosures</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(a)</B></TD>
    <TD>
    <B>Details of specified directors and specified executives</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The specified directors of pSivida Limited during the year were:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Dr Roger Brimblecombe&nbsp;&#151; Non-Executive Chairman</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Mr Gavin Rezos&nbsp;&#151; Managing Director</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Dr Roger Aston&nbsp;&#151; Director, Strategy</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Mr Stephen Lake&nbsp;&#151; Non-Executive Director (appointed 30
    July 2004)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Ms Alison Ledger&nbsp;&#151; Non-Executive Director (appointed
    30 July 2004)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Mrs Nadine Donovan&nbsp;&#151; Former Finance Director (resigned
    30 July 2004)</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The specified executives of the consolidated entity during the
year were:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Prof Leigh Canham&nbsp;&#151; Chief Scientific Officer,
    pSiMedica Limited</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Mr Aaron Finlay&nbsp;&#151; Company Secretary, Chief Financial
    Officer</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Dr Anna Kluczewska&nbsp;&#151; Managing Director, AION
    Diagnostics Limited</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Mr Steve Connor&nbsp;&#151; Operations Director, pSiMedica
    Limited</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Dr Jill Ogden&nbsp;&#151; Commercialization Director, pSiMedica
    Limited</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">F-33

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(b)</B></TD>
    <TD>
    <B>Remuneration of specified directors and specified
    executives</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(i)</B></TD>
    <TD>
    <B>Remuneration policy</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Remuneration Committee of the Board of Directors of pSivida
Limited is responsible for determining and reviewing
compensation arrangements for the directors, the managing
director and the executive team. The Remuneration Committee
assesses the appropriateness of the nature and amount of the
emoluments of such officers on a periodic basis by reference to
relevant employment market conditions with the overall objective
of ensuring maximum stakeholder benefit from the retention of a
high quality Board and executive team.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>(ii)&nbsp;Remuneration of specified directors and specified
executives</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<I>Specified directors</I>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 9pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="29%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Post</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Primary</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Employment</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Equity</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Total</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Salary</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Super-</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Other</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Options*</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Cash-based</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>and Fees</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Bonus</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>annuation</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Benefits</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(ii)</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Total</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Remuneration</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>2005</I></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr R Brimblecombe</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>224,459</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>25,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>229,296</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>478,755</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>249,459</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr G Rezos</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>348,062</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>75,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,905</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,361,127</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,795,094</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>433,967</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr R Aston</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>315,683</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>25,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,438</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,189</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>558,592</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>908,902</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>350,310</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr S Lake</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22,917</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>91,718</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>114,635</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>22,917</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Ms A Ledger</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>27,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,475</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>91,718</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>121,693</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>29,975</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mrs N Donovan</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,083</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>188</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,271</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>2,271</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>940,704</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>125,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22,006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,189</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,332,451</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,421,350</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>1,088,899</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>2004</I></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr R Brimblecombe</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>152,992</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>145,200</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>298,192</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>152,992</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr G Rezos</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>363,881</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>27,320</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>435,600</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,076,801</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>641,201</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr R Aston</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>302,822</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>40,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>40,711</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>181,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>565,033</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>383,533</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mrs N Donovan</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>90,325</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,250</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>127,050</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>219,625</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>92,575</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>910,020</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>290,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>70,281</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>889,350</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,159,651</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>1,270,301</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="2%"></TD>
    <TD width="98%"></TD>
</TR>

<TR valign="top">
    <TD>*&nbsp;</TD>
    <TD align="left">
    These options had no taxable value at the date of issue.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">F-34

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<I>Specified executives</I>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 9pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="29%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Post</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Primary</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Employment</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Equity</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Total</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Salary</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Super-</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Other</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Options*</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Cash-based</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>and Fees</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Bonus</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>annuation</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Benefits</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(ii)</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Total</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Remuneration</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>2005</I></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Prof L Canham</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>193,780</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22,553</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,056</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>353,524</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>575,913</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>222,389</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr A Finlay</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>144,572</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>32,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13,135</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>370,396</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>560,603</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>190,207</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr A Kluczewska</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>208,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>299,808</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>518,141</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>218,333</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr S Connor</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>181,146</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21,738</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,612</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>143,751</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>357,247</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>213,496</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr J Ogden</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>169,816</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20,378</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,060</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>143,751</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>340,005</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>196,254</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>897,647</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>42,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>77,804</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22,728</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,311,230</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,351,909</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>1,040,679</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>2004</I></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr A Kluczewska</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>143,600</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>25,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>295,572</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>464,172</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>168,600</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Prof L Canham</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>180,537</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>35,410</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,832</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>219,779</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>219,779</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr S Connor</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>176,773</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>23,683</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,941</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>207,397</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>207,397</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr R Saffie</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>130,742</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>15,441</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,307</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>148,490</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>148,490</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr J Ogden</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>102,873</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,581</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,072</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>117,526</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>117,526</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>734,525</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>25,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>86,115</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>16,152</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>295,572</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,157,364</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap><B>861,792</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;&nbsp;*</TD>
    <TD></TD>
    <TD valign="top">
    These options had no taxable value at the date of issue.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    &nbsp;(i)</TD>
    <TD></TD>
    <TD valign="top">
    Bonuses were paid in cash on 17 March 2005 as part of an annual
    staff review. Bonuses were determined based on a review of staff
    performance conducted by the remuneration committee.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
    (ii)</TD>
    <TD></TD>
    <TD valign="top">
    During the year options were granted to directors and specified
    executives in August 2004 in respect of the pSiMedica
    acquisition and April 2005 in respect of annual performance
    reviews, pursuant to the Company&#146;s Employee Share Option
    Plan, which have been included as equity options remuneration
    above. These options have been valued using the Black Scholes
    Option Valuation Model, which takes into account time value and
    the volatility of the stock price.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="top">
    A total of 8,251,000 options were issued to directors and
    employees in August 2004. The options are exercisable at $1.18,
    being an 8% premium to the share price at the time of the grant,
    and may be exercised between the date of grant and expiry on 5
    August 2009.</TD>
</TR>

<TR>
    <TD style="font-size: 3pt">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="top">
    A total of 3,152,000 options were issued to employees in April
    2005. The options are exercisable at $0.80, being a 7% premium
    to the share price at the time of the grant. The options are
    subject to varying vesting and performance conditions and expire
    on 31&nbsp;March 2010.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following directors and executives were under contract at
30&nbsp;June 2005:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Mr Gavin Rezos has a contract dated December&nbsp;12, 2000,
amended in April 2005, which provides for directors fees of
$126,000 plus superannuation at a rate of 9% and bonus payments
and options to be awarded on a discretionary basis. The contract
will continue until termination by either party on one months
notice. Accrued entitlements are payable upon termination. In
addition Mr Gavin Rezos has a consultancy agreement which
provides for an annual fee of $204,750 which will similarly
continue until termination by either party.
</DIV>

<P align="center" style="font-size: 10pt;">F-35

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dr Roger Aston had a consultancy contract dated
December&nbsp;12, 2000, amended in April 2005, which provides
for an annual fee of $250,000 with bonus payments and options to
be awarded on a discretionary basis. The contract will continue
until termination by either party on one months notice. Accrued
entitlements are payable upon termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Mr A Finlay has a contract dated May&nbsp;17, 2004, amended in
April 2005, which provides for a base annual salary of $200,000
plus superannuation at a rate of 9% and bonus payments and
options to be awarded on a discretionary basis. The employment
contract will continue until termination by either party on one
months notice. Accrued entitlements are payable upon termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Prof L Canham has a contract dated December&nbsp;12, 2000,
amended in January 2005, which provides for a base annual salary
of &#163;77,327 (A$183,110) plus superannuation at a rate of 12%
and bonus payments and options to be awarded on a discretionary
basis. The employment contract will continue until termination
by either party on six months notice. Accrued entitlements are
payable upon termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dr A Kluczewska has a consultancy contract dated April&nbsp;7,
2004, amended in April 2005, which provides for an annual fee of
$250,000, 1.2&nbsp;million options vesting over a three year
period based on the achievement of performance milestones and
bonus payments and any additional options to be awarded on a
discretionary basis. The contract will continue until
termination by either party on one months notice.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Mr&nbsp;S&nbsp;Connor has a contract dated November&nbsp;1,
2001, amended in January 2005, which provides for a base annual
salary of &#163;74,884 (A$177,325) plus superannuation at a rate
of 12% and bonus payments and options to be awarded on a
discretionary basis. The employment contract will continue until
termination by either party on six months notice. Accrued
entitlements are payable upon termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dr&nbsp;J&nbsp;Ogden has a contract dated November&nbsp;17,
2003, amended in January 2005, which provides for a base annual
salary of &#163;70,200 (A$166,2334) plus superannuation at a
rate of 12% and bonus payments and options to be awarded on a
discretionary basis. The employment contract will continue until
termination by either party on six months notice. Accrued
entitlements are payable upon termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Dr&nbsp;M&nbsp;Parry-Billings has a contract dated
January&nbsp;6, 2005, which provides for a base annual salary of
&#163;125,000 (A$296,000) plus superannuation at a rate of 12%,
1.2&nbsp;million options vesting over a three year period based
on the achievement of performance milestones and bonus payments
and any additional options to be awarded on a discretionary
basis. The employment contract will continue until termination
by either party on six months notice. Accrued entitlements are
payable upon termination.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>(c)&nbsp;</B></TD>
    <TD>
    <B>Remuneration options granted and vested during the year</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the financial year options were granted as equity
compensation benefits to certain specified directors and
specified executives as disclosed below. The options were issued
free of charge. Each option entitles the holder to subscribe for
one fully paid ordinary share in the entity at the exercise
price stated below. The options may only be exercised after the
vesting date stated below, and expire on the dates shown below.
Vesting of the options is dependent on the achievement of
certain key performance criteria where indicated. The key
performance criteria to be met are in respect of certain
employee performance targets.
</DIV>

<P align="center" style="font-size: 10pt;">F-36

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
    <TD>
    <B><I>Share options issued by pSivida Limited</I></B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 9pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="21%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap><B>Terms and Conditions for Each Grant</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Value of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="11">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Value Per</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Underlying</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="7">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Option at</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Share at</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price Per</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="7">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Vested</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Granted</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant Date**</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Share</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Vesting</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Expiry Date</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Specified directors</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr R Brimblecombe</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 09</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr G Rezos</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,750,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,750,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 09</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr R Aston</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 09</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr S Lake</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 09</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Ms A Ledger</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 09</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,650,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,650,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Specified executives</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Prof L Canham</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>700,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>700,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 09</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>125,000</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22 Apr 05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.26</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.75</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22 Apr 06</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31 Mar 10</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr A Finlay</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>700,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>700,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 09</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22 Apr 05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.26</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.75</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22 Apr 06</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31 Mar 10</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr A Kluczewska</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>100,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>100,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 09</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">

    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>125,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22 Apr 05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.26</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.75</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22 Apr 06</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31 Mar 10</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr S Connor</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>300,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>300,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 09</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>125,000</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22 Apr 05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.26</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.75</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22 Apr 06</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31 Mar 10</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">

    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr J Ogden</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>300,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>300,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.09</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 04</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5 Aug 09</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>125,000</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22 Apr 05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.26</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.75</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.80</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22 Apr 06</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31 Mar 10</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,800,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
    <TD>
    <B><I>Share options issued by AION Diagnostics Limited</I></B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 9pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="32%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>Terms and Conditions for Each Grant</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Value of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Value Per</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Underlying</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Option at</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Share at</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price Per</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Vested</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Granted</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant Date**</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Share</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Expiry</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Grant Date</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Date</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Specified directors</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr G Rezos</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3 Feb 05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>Nil</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3 Feb 08</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr R Aston</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3 Feb 05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>Nil</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3 Feb 08</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Specified executives</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Prof L Canham</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>65,840</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3 Feb 05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>Nil</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3 Feb 08</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr A Finlay</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>98,760</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3 Feb 05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>Nil</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3 Feb 08</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr A Kluczewska</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>395,040</TD>
    <TD align="left" valign="bottom" nowrap>*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3 Feb 05</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>Nil</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3 Feb 08</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>559,640</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-37

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 3pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="1%"></TD>
    <TD width="2%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>*&nbsp;</TD>
    <TD align="left">
    Vesting of these options is subject to performance conditions.
    Performance conditions for executive staff and directors include
    specific criteria relating to the employee&#146;s role within
    the Company. Performance conditions for other staff require the
    satisfactory performance of their role.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>**&nbsp;</TD>
    <TD align="left">
    Options have been valued using the Black Scholes Option
    Valuation Model, which takes into account time value and the
    volatility of the stock price.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>(d)&nbsp;</B></TD>
    <TD>
    <B>Shares issued on exercise of remuneration options</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="51%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Amount Paid</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Amount Unpaid</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Shares Issued</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Per Share</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Per Share</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Specified directors</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mrs N Donovan</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>150,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">

    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>400,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(e)</B></TD>
    <TD>
    <B>Specified directors&#146; and specified executives&#146;
    equity holdings</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Fully paid ordinary shares of pSivida Limited</I></B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="46%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Balance at</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Granted as</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Net Other</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Balance at</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>1&nbsp;July 2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Remuneration</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Change</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>30&nbsp;Jun 2005</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Specified directors</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr R Brimblecombe</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>320,833</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>124,234</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>445,067</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr G Rezos</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,895,657</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>423,625</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,319,282</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr R Aston</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,090,833</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,002,753</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,093,586</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr S Lake*</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Ms A Ledger*</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(100,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,900,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mrs N Donovan**</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>54,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>54,333</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>16,361,656</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,450,612</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20,812,268</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Specified executives</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Prof L Canham</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,909,579</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,909,579</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr A Finlay</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr A Kluczewska</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr S Connor</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>189,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>189,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr J Ogden</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,098,579</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,098,579</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="1%"></TD>
    <TD width="2%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>*&nbsp;</TD>
    <TD align="left">
    Opening balance at date of appointment</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>**&nbsp;</TD>
    <TD align="left">
    Closing balance at date of resignation</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">F-38

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Share options issued by pSivida Limited</I></B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="43%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Balance at</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Granted As</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Net Other</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Balance at</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>1&nbsp;July 2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Remuneration</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Change</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>30 Jun 2005</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Specified directors</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr R Brimblecombe</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(550,889</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>949,111</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr G Rezos</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,450,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,750,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,228,970</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,971,030</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr R Aston</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,950,889</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,549,111</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr S Lake*</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>42,061</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>242,061</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Ms A Ledger*</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mrs N Donovan**</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>850,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>850,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,800,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,650,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(8,688,687</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,761,313</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Specified executives</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Prof L Canham</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>825,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>39,289</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>864,289</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr A Finlay</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>900,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>900,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr A Kluczewska</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>225,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,425,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr S Connor</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>425,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>19,645</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>444,645</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr J Ogden</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>425,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>129,708</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>554,708</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,800,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>188,642</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,188,642</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="1%"></TD>
    <TD width="2%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>*&nbsp;</TD>
    <TD align="left">
    Opening balance at date of appointment</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>**&nbsp;</TD>
    <TD align="left">
    Closing balance at date of resignation</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">F-39

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
    <TD>
    <B><I>Share options issued by AION Diagnostics Limited</I></B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Balance at</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Granted As</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Net Other</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Balance at</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>1&nbsp;July 2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Remuneration</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Change</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>30 Jun 2005</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Specified directors</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr R Brimblecombe</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr G Rezos</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr R Aston</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr S Lake*</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Ms A Ledger*</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mrs N Donovan**</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>500,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Specified executives</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Prof L Canham</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>65,840</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>65,840</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr A Finlay</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>98,760</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>98,760</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr A Kluczewska</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>395,040</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>395,040</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Mr S Connor</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Dr J Ogden</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>559,640</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>559,640</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 3pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<DIV style="width: 18%; border-top: 1.0pt solid black; font-size: 1pt">&nbsp;</DIV>
</DIV>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="1%"></TD>
    <TD width="2%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>*&nbsp;</TD>
    <TD align="left">
    Opening balance at date of appointment</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>**&nbsp;</TD>
    <TD align="left">
    Closing balance at date of resignation</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD><B>(f)&nbsp;</B></TD>
    <TD>
    <B>Other transactions with specified directors</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
All transactions with related parties are made on normal
commercial terms and conditions except where indicated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Consultancy fees and other payments of Nil (2004: $341,362;
2003: $173,333) were paid to Aymon Pacific Pty Ltd, a company
controlled by Mr G Rezos, and have been included in
directors&#146; remuneration above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Consultancy fees and other payments of $319,941 (2004: $44,000;
2003: Nil) were paid to Newtonmore Biosciences Pty Ltd, a
company controlled by Dr&nbsp;R&nbsp;Aston. The portion of this
amount relating to services performed by Dr&nbsp;Aston has been
included in directors&#146; remuneration above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Consultancy fees of $2,083 (2004: $71,858; 2003: $45,000) were
paid to Blackwood Pty Ltd, a company controlled by Mrs N
Donovan, and have been included in directors&#146; remuneration
above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
An amount of &#163;220,689 ($544,320) (2004 &#163;186,682
($457,567)) (2003: &#163;207,492 ($564,033)) was paid or payable
to QinetiQ Limited, a shareholder of pSivida Limited and former
shareholder of pSiMedica Limited, for the use of laboratory
facilities and for patent filing and administration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the year $114,732 (2004: $78,068; 2003: $22,622) was paid
to Blake Dawson Waldron (BDW)&nbsp;for various routine
arm&#146;s length legal services. BDW is a national Australian
firm with over 180 partners. One of those partners is a relative
of a pSivida director.
</DIV>

<P align="center" style="font-size: 10pt;">F-40

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
An amount of Nil (2004: $12,637; 2003: $52,187) was paid to
Viaticus Capital Ltd, a company controlled by Mr G Rezos, for
sublease of BGC Centre office space. A further amount of
$332,085 (2004: Nil; 2003: Nil) was paid to Viaticus Capital Ltd
for consultancy fees and other payments, and has been included
in directors&#146; remuneration above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
An amount of $125,982 (2004: $149,489; 2003: Nil) was paid to
Albion Capital Partners, of which Mr G Rezos is a partner, for
sublease of BGC Centre office space. A further amount of $63,360
(2004: Nil; 2003: Nil) was paid to Albion Capital Partners for
financial analyst services.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Amounts owing to directors, director-related parties and other
related parties at 30&nbsp;June 2005 were $50,102 (2004:
$37,144; 2003: $31,182).
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD><B>22.&nbsp;</B></TD>
    <TD>
    <B>Auditor&#146;s remuneration</B></TD>
</TR>

</TABLE>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="70%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>Amounts received or receivable for:</I></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    An audit or review of the statutory financial report of the
    Company</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>24,240</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>16,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>16,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other services in relation to the Company</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,020</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,628</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>25,260</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>22,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20,628</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>Amounts received or due and receivable by the auditors other
    than the statutory auditors of pSivida for:</I></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    An audit or review of the financial statements of subsidiary
    entities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>42,423</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>30,393</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>38,600</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Audit services in relation to US SEC and NASDAQ requirements on
    listing and annual lodgements</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>638,768</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other services in relation to the Company</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>14,432</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>695,623</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>30,393</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>38,600</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-41

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>23.</B></TD>
    <TD>
    <B>Segment information</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>(a)&nbsp;</B></TD>
    <TD>
    <B>Business segment&nbsp;&#151; primary segment</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company operates in only one business segment, being the
biotechnology sector.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>(b)&nbsp;</B></TD>
    <TD>
    <B>Geographic segment&nbsp;&#151; secondary segment</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Segment revenues are attributed to countries based on the
location of where the revenue is earned.
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 9pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="26%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>United</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Australia</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Kingdom</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Singapore</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Unallocated</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Eliminations</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Consolidated</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Segment revenues from external customers</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Year ended 30&nbsp;June</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>161,666</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>667,310</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>828,976</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>888</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>55,312</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>325,479</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>381,679</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2003</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>25,065</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>72,729</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,881</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>110,675</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Segment assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    As at 30&nbsp;June</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,429,117</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>68,660,341</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,934,243</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(21,135</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>82,002,566</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,733,723</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,145,493</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,299,932</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(812,090</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>40,367,058</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Acquisition of segment assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Year ended 30&nbsp;June</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>56,920</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>61,176,255</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20,836</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>61,254,011</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,901,489</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,696,463</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,501,723</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,096,229</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Goodwill, net</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    As at 30&nbsp;June</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,909,744</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,909,744</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Long lived assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    As at 30&nbsp;June</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>82,292</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,171,902</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>19,469</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,273,663</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2004</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>69,313</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>600,386</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>669,699</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>24.</B></TD>
    <TD>
    <B>Financial instruments</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(a)</B></TD>
    <TD>
    <B>Significant accounting policies</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Details of the significant accounting policies and methods
adopted, including criteria for recognition, the basis of
measurement and the basis on which revenues and expenses are
recognized, in respect of each class of financial asset,
financial liability, and equity instrument are disclosed in
Note&nbsp;1.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(b)</B></TD>
    <TD>
    <B>Interest rate risk</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Deposits or withdrawals from term deposits may be made at any
time without prior notice or penalty. Receivables and payables
are non-interest bearing.
</DIV>

<P align="center" style="font-size: 10pt;">F-42

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company&#146;s exposure to interest rates and the effective
weighted average interest rate for classes of financial assets
and liabilities is set out below:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="26%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Floating</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Fixed</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Average</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Interest</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Interest</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Non-Interest</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Interest</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Rate</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Rate</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Bearing</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Total</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Rate</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Notes</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>%</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>2005</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>Financial assets</I></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>17(a)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,528,926</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>163,135</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,892,061</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2.87</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Receivables</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>709,418</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>709,418</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>n/a</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,528,926</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>872,553</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13,601,479</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>Financial liabilities</I></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Payables</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,017,820</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,017,820</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>2004</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>Financial assets</I></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>17(a)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31,350,656</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31,350,656</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4.4</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Receivables</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>340,482</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>340,482</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>n/a</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31,350,656</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>340,482</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31,691,138</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>Financial liabilities</I></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Payables</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,882,104</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,882,104</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(c)</B></TD>
    <TD>
    <B>Fair values</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The fair values of the financial assets and liabilities at the
balance sheet date approximate the carrying amounts in the
financial statements, except where specifically stated and
determined in accordance with the accounting policies disclosed
in Note&nbsp;1.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(d)</B></TD>
    <TD>
    <B>Credit risk exposure</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company&#146;s maximum exposure to credit risk to each class
of recognized financial asset is the carrying amount, net of any
provisions for doubtful debts, of those assets as indicated in
the balance sheet. The directors believe the Company has no
significant concentration of credit risk.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>25.</B></TD>
    <TD>
    <B>Additional Company information</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida Limited is a listed public company, incorporated and
operating in Australia.
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    Level&nbsp;12, BGC Centre</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    28 The Esplanade</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    Perth WA 6000</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    Australia</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    Tel: 61 8 9226 5099</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">F-43

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>26.</B></TD>
    <TD>
    <B>Impacts of adopting Australian equivalents to International
    Financial Reporting Standards (unaudited)</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(a)</B></TD>
    <TD>
    <B>Management of the transition to AIFRS</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
pSivida Limited will be required to prepare financial statements
that comply with the Australian equivalents of International
Financial Reporting Standards (&#147;AIFRS&#148;) as adopted by
the Australian Accounting Standards Board (&#147;AASB&#148;) for
annual reporting periods beginning on or after 1&nbsp;January
2005. Accordingly, pSivida&#146;s first half-year report
prepared under AIFRS will be for the half-year reporting period
ending 31&nbsp;December 2005, and its first annual financial
report prepared under AIFRS will be for the year ending
30&nbsp;June 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The transitional rules for first time adoption of AIFRS require
that the Company restate its comparative financial statements
using AIFRS, except for AASB 132: &#147;Financial Instruments:
Disclosure and Presentation&#148; (&#147;AASB 132&#148;) and
AASB 139: &#147;Financial Instruments: Recognition and
Measurement&#148; (&#147;AASB 139&#148;) where comparative
information is not required to be restated. Currently, the
Company provides two years of comparative financial information
in its financial statements to comply with applicable US
Securities and Exchange Commission (&#147;SEC&#148;)
requirements. The SEC has granted a one-time relief from this
requirement for foreign registered companies preparing their
first set of financial statements in compliance with
International Financial Reporting Standards. The Company has
elected to apply this relief and will only provide one year of
comparative information in the 30&nbsp;June 2006 financial
statements. For reporting in the 2006 fiscal year, comparatives
will be remeasured and restated for the half-year ended
31&nbsp;December 2004 and the financial year ended 30&nbsp;June
2005. Most of the adjustments on transition are required to be
made to opening retained profits at the beginning of the first
comparative period (i.e. at 1&nbsp;July 2004).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In 2004 the Company commenced a review of accounting policies in
preparation for managing the transition to AIFRS. Priority has
been given to considering the preparation of an opening balance
sheet in accordance with AIFRS as at 1&nbsp;July 2004, the
Company&#146;s transition date to AIFRS. This will form the
basis of accounting for AIFRS in the future and is required when
the Company prepares its first fully AIFRS compliant financial
report for the year ended 30&nbsp;June 2006.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>(b)&nbsp;</B></TD>
    <TD>
    <B>The likely impacts of AIFRS on the results and financial
    position of the Company</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Set out below are the known key differences in accounting policy
and our known estimable transitional differences identified as
of 30&nbsp;June 2005, where accounting policies are expected to
change on adoption of AIFRS and the likely impacts on the
current year operating results and financial position of the
Company, had the financial statements been prepared using AIFRS,
based on the directors&#146; accounting policy decisions current
at the date of this financial report. The adjustments included
are based on the AIFRS standards released as at June&nbsp;30,
2005. These are subject to ongoing review and any amendments by
the AASB, or by interpretative guidance from the International
Accounting Standards Board or AASB, could change the adjustments
included. The AIFRS standards and interpretations that will
apply to the Company will be those released as at
December&nbsp;31, 2005 being the date of the first half year
financial statements that the Company has to publish under
AIFRS. The disclosures below represent the Company&#146;s
current best estimate of the quantitative impact of the AIFRS
implementation at the date of this report and accordingly they
remain subject to change.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
There are certain items that still require resolution and
additional differences in accounting policy that may be
identified. The directors may, at any time until the completion
of the Company&#146;s first AIFRS
</DIV>

<P align="center" style="font-size: 10pt;">F-44

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
compliant financial report, elect to revisit, and where
considered necessary, revise the accounting policies applied in
preparing the disclosures below.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>(c)&nbsp;</B></TD>
    <TD>
    <B>Adjustments to balance sheet items under AIFRS (net of
    tax)</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(i)&nbsp;Intangibles</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under AASB&nbsp;3, &#147;Business Combinations&#148; (&#147;AASB
3&#148;) goodwill would not be permitted to be amortized but
instead is subject to impairment testing on an annual basis or
upon triggers which may indicate a potential impairment. As a
result accumulated goodwill amortization of $973,923 (all
expensed during the year ended 30&nbsp;June 2005) would be added
back to the value of intangibles as at 30&nbsp;June 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ii)&nbsp;Share-based
payments</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under AASB 2: &#147;Share-Based Payment&#148; (&#147;AASB
2&#148;) equity-settled share-based payments in respect of
equity instruments issued after 7 November 2002 that were
unvested as at 1&nbsp;January 2005 are measured at fair value at
grant date. The fair value determined at grant date of
equity-settled share-based payments is expensed on a
straight-line basis over the vesting period, based on the
estimated number of equity instruments that will vest. As a
consequence, contributed equity will increase by $591,900 as at
30&nbsp;June 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(iii)&nbsp;Foreign currency
translation reserve</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The directors have elected to set the translation reserve to
zero as at AIFRS transition as permitted under AASB 1
&#147;First-Time Adoption of Australian Equivalents to
International Financial Reporting Standards&#148; (&#147;AASB
1&#148;). This results in the transfer of $78,220 from the
foreign currency translation reserve to retained earnings as at
AIFRS transition on 1&nbsp;July 2004.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(iv)&nbsp;Accumulated
losses</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
With limited exceptions, adjustments required on first-time
adoption of AIFRS are recognized directly in accumulated losses
at the date of transition to AIFRS. The cumulative effect of
these adjustments for the Company will be a decrease in opening
accumulated losses of $78,220 as of 1&nbsp;July 2004.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>(d)&nbsp;</B></TD>
    <TD>
    <B>Adjustments to current year loss under AIFRS (net of tax)</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 3pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(i)&nbsp;Intangibles</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under AASB&nbsp;3, goodwill would not be permitted to be
amortized but instead is subject to impairment testing on an
annual basis or upon triggers which may indicate a potential
impairment. As a result goodwill amortization expense of
$973,923 recorded in the year ended 30&nbsp;June 2005 would be
added back to the net loss for the year. There is no goodwill
amortization required to be added back to the net loss upon the
transition date of 1&nbsp;July 2004.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>(ii)&nbsp;Share-based
payments</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under AASB&nbsp;2, equity-settled share-based payments in
respect of equity instruments issued after 7 November 2002 that
were unvested as at 1&nbsp;January 2005 are measured at fair
value at grant date. The fair value determined at grant date of
equity-settled share-based payments is expensed on a
straight-line basis over the vesting period, based on the
estimated number of equity instruments that will vest. As a
</DIV>

<P align="center" style="font-size: 10pt;">F-45

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
consequence, an additional employee benefit expense of $508,613
and consultancy fees expense of $83,287 will be recognized in
the profit and loss for the year ended 30&nbsp;June 2005.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>(e)&nbsp;</B></TD>
    <TD>
    <B>Other impacts</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(i)&nbsp;Management has decided to apply the exemption provided
in AASB&nbsp;1, which permits entities not to restate business
combinations that occurred prior to the date of transition to
AIFRS. Business combinations occurring after the date of
transition (i.e., 1&nbsp;July 2004) will be subject to the
provisions of AASB 3<I>.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(ii)&nbsp;Management has decided to apply the exemption provided
in AASB 1 which permits entities not to apply the requirements
of AASB 132 and AASB 139<I>,</I>for the year ended 30&nbsp;June
2005. The standards will be applied from 1&nbsp;July 2005.
Management is in the process of determining the impact that
adopting the standards would have on the financial statements of
the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(iii)&nbsp;Under AASB 136: &#147;Impairment of Assets,&#148; the
Company&#146;s assets, including goodwill would be tested for
impairment as part of the cash generating unit to which they
belong, and any impairment losses recognized in the statement of
financial performance. At this stage in the Company&#146;s
review process the Company is not aware of any impairment issues
that would result in a material adjustment to the financial
statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
(iv)&nbsp;No material impacts are expected to the cash flows as
presented under current A-GAAP on adoption of AIFRS.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD><B>(f)&nbsp;</B></TD>
    <TD>
    <B>Acquisition of minority interest</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the year ended 30&nbsp;June 2005, the Company purchased
minority interests in controlled entity pSiMedica Limited. Under
current A-GAAP this acquisition has been accounted for
separately from other acquisitions (that is, as a step
acquisition, which involved the separate determination and
recognition of the fair values of the net assets of the
subsidiary and any goodwill arising on the acquisition).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
AASB 127: &#147;Consolidated and Separate Financial
Statements&#148; requires minority interests to be classified as
equity. Consequently, the acquisition by the Company of
additional ownership interests in pSiMedica Limited represents
an equity transaction. As such, accounting for the transaction
as a step acquisition may not be appropriate. The financial
effect of the adjustment required on the restatement of the
30&nbsp;June 2005 accounts is yet to be determined.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD><B>27.&nbsp;</B></TD>
    <TD>
    <B>Reconciliation to US GAAP</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The financial statements have been prepared in accordance with
A-GAAP, which differ in certain respects from US GAAP. The
following is a summary of the adjustments to net loss and total
equity required when reconciling such amounts recorded in the
financial statements to the corresponding amounts in accordance
with US GAAP, considering the differences between A-GAAP and US
GAAP.
</DIV>

<P align="center" style="font-size: 10pt;">F-46

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>Restatement of US&nbsp;GAAP amounts</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Subsequent to the issuance of the June&nbsp;30, 2004
consolidated financial statements, the Company changed the
amounts previously reported in the US&nbsp;GAAP reconciliation
for the accounting for deferred income taxes as follows:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Deferred tax liability for acquired intangible
    assets&nbsp;&#151; Previously, deferred taxes were not recorded
    on the intangible assets acquired in connection with the step
    acquisition of pSiMedica as the book to tax basis differences
    were deemed to be permanent as the amortization of the related
    intangibles is not deductible for income tax purposes. The
    Company has subsequently concluded that, although under tax law,
    it will not receive a tax deduction in the future for recovery
    of the intangible assets, recognition of a deferred tax
    liability on the acquired intangibles is nevertheless required
    under US&nbsp;GAAP because it is assumed for financial reporting
    purposes that the Company will generate future revenues at least
    equal to the recorded amount of the investment, and recovery
    will result in future taxable amounts.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Valuation allowance for deferred income tax assets&nbsp;&#151;
    Previously in establishing a valuation allowance, the Company
    fully reserved the total balance of the deferred income tax
    assets related to tax loss carryforwards as it was deemed more
    likely than not that the deferred tax assets would not be
    realized. As a result of the recognition of the US&nbsp;GAAP
    deferred tax liabilities in connection with the step acquisition
    of pSiMedica as per the above, the Company has reevaluated the
    recoverability of the deferred income tax assets, taking into
    consideration the reversal of taxable temporary differences
    under US&nbsp;GAAP.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Amortization of intangible assets&nbsp;&#151; Where the
    recognition of a deferred tax liability for acquired intangible
    assets as per the above resulted in additional basis of the
    related intangible, the additional basis is being amortized over
    the remaining estimated useful life of the intangible asset for
    US&nbsp;GAAP purposes.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The effect of the adjustments on previously reported
US&nbsp;GAAP net loss and total equity is as follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="70%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Years Ended 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    US&nbsp;GAAP net loss, as previously reported</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,059,011</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,288,418</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Correction to deferred income taxes, net</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,318,950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,216,235</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Correction to intangible amortization expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(279,913</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(196,420</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    US&nbsp;GAAP net loss, as restated</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,019,974</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,268,603</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    US&nbsp;GAAP basic and diluted loss per share, as previously
    reported</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(0.05</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(0.03</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    US&nbsp;GAAP basic and diluted loss per share, as restated</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(0.04</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(0.02</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

</TABLE>
</CENTER>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>30&nbsp;June</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>1&nbsp;July</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    US&nbsp;GAAP total equity, as previously reported</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>34,819,468</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,204,116</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Correction to deferred income taxes, net</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,674,230</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,355,280</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Correction to intangible amortization expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(698,993</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(419,080</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    US&nbsp;GAAP total equity, as restated</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>37,794,705</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,140,316</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-47

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>Reconciliation of net loss</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following is a reconciliation of net loss as reported in the
consolidated statements of financial performance under A-GAAP to
net loss as adjusted for the effects of the application of US
GAAP for the years ended 30&nbsp;June 2005, 2004 and 2003:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="43%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>Years Ended 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(As restated)</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(As restated)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss in accordance with A-GAAP</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(14,726,523</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,683,205</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,765,153</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>US GAAP adjustments:</I></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Share-based compensation expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(a)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Options issued to consultants</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(156,204</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(250,933</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(54,951</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Options issued to directors, executives and employees</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(125,018</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(448,920</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(10,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Intangible assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Fair value of shares issued as consideration&nbsp;&#151;
    amortization expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(b)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(18,198</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(18,198</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(18,198</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Direct acquisition costs&nbsp;&#151; amortization expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(c)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(9,357</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(9,357</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(9,357</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Amortization of intangible assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(d)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,749,870</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(650,140</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(451,606</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Sales of stock by subsidiaries&nbsp;&#151; amortization expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(f)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(39,232</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>15,840</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20,847</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    In-process research and development</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(g)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,035,018</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Gross-up attributable to deferred tax liability&nbsp;&#151;
    amortization expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(h)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(335,617</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(279,913</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(196,420</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Reversal of goodwill amortization</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(e)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>973,923</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deferred income taxes</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(h)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,645,504</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,318,950</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,216,235</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Outside equity interest&nbsp;&#151; US GAAP adjustments</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(i)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(20,920</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20,920</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss in accordance with US GAAP</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(16,561,512</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,019,974</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,268,603</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Loss per share in accordance with US GAAP:</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Basic and diluted</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>$(0.08</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>$(0.04</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>$(0.02</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Weighted average shares&nbsp;&#151; basic and diluted</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>207,802,540</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>126,990,066</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>101,281,292</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-48

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>Reconciliation of total equity</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following is a reconciliation of total equity as reported in
the consolidated statements of financial position under A-GAAP
to total equity as adjusted for the effects of the application
of US GAAP as of 30&nbsp;June 2005 and 2004:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="62%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(As</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>restated)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total equity in accordance with A-GAAP</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>79,987,614</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>38,428,943</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <I>US GAAP adjustments:</I></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Intangible assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Fair value of shares issued as consideration</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(b)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>142,546</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>160,744</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Direct acquisition costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(c)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>73,292</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>82,648</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Amortization of intangible assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(d)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,357,007</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,607,137</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Sales of stock by subsidiaries</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(f)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>312,335</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>351,568</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    In-process research and development</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(g)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,035,018</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,035,018</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Gross-up attributable to deferred tax liability</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(h)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,034,610</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(698,993</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Goodwill</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Fair value of shares issued as consideration</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(b)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,267,528</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Reversal of amortization</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(e)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>973,923</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deferred income taxes</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(h)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,319,734</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,674,230</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Outside equity interest</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(i)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Consolidated statement of financial position classification</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,583,200</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    US GAAP adjustments</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20,920</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total equity in accordance with US GAAP</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>87,650,337</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>37,794,705</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-49

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>Roll forward analysis of total equity under US GAAP</B>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="65%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Years Ended 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(As</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Restated)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance in accordance with US GAAP, beginning of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>37,794,705</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,140,316</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issuance of shares in connection with acquisition, net of issue
    costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>62,526,881</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issuance of shares in connection with private placements, net of
    issue costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31,797,500</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issuance of shares in connection with share purchase plan, net
    of issue costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>932,298</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issuance of shares in connection with exercise of options</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,666,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,626,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issuance of options in connection with acquisition</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>292,828</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issuance of options to consultants for services rendered</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">
    (a)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>156,204</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,933</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issuance of options to directors, executives and employees</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">
    (a)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>125,018</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>448,920</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Gain on sales of stock by subsidiaries</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="bottom">
    (f)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>540,727</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Foreign currency translation adjustment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(350,287</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>77,985</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss in accordance with US GAAP</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(16,561,512</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,019,974</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Balance in accordance with US GAAP, end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>87,650,337</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>37,794,705</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Note: The above rollforward does not include the
2,050,000&nbsp;options issued by pSivida in August 2004 as
settlement of share issue costs through the issuance of options
does not have an impact on net loss or total equity.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(a)</B></TD>
    <TD>
    <B>Share-based compensation</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Options issued to consultants</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under A-GAAP, the Company did not recognize any compensation
expense in connection with the issuance of share options to
consultants disclosed in Note&nbsp;12(c). Under US GAAP, such
options are accounted for under Statement of Financial
Accounting Standards (&#147;SFAS&#148;) No.&nbsp;123,
&#147;Accounting for Stock-Based Compensation&#148;
(&#147;SFAS&nbsp;123&#148;) and Emerging Issues Task Force Issue
No.&nbsp;96-18, &#147;Accounting for Equity Instruments that are
Issued to Other than Employees for Acquiring, or in Conjunction
with Selling, Goods or Services&#148;
(&#147;EITF&nbsp;96-18&#148;). Accordingly, the Company has
calculated compensation cost based on the estimated fair value
of the options measured on the date the services were completed
by the respective consultants (the &#147;measurement
date&#148;), using the Black-Scholes option pricing model. For
those options issued prior to reaching a measurement date,
interim measures of compensation cost are recorded based on the
estimated fair value of the options as of each reporting date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Following is a summary of the options issued to consultants
accounted for under SFAS&nbsp;123:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    The Company issued 2,640,000&nbsp;share options to outside
    consultants during the year ended 30&nbsp;June 2005, consisting
    of 2,275,000&nbsp;options in August 2004 and
    365,000&nbsp;options in April 2005. Of the options issued in
    August 2004, 2,050,000 were issued as payment of share issue
    costs, and therefore, have no impact on net loss or total equity
    as the fair value was accounted for as a reduction of the
    proceeds of the share issuance.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">F-50

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    The Company issued 500,000&nbsp;share options to an outside
    consultant during the year ended 30&nbsp;June 2004 as an
    incentive for future performance.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    The Company issued 2,000,000&nbsp;share options to GEM during
    the year ended 30&nbsp;June 2003, pursuant to an agreement for a
    fully underwritten $7.5&nbsp;million equity line of credit.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following weighted-average assumptions were used in
calculating the estimated fair value:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    risk-free interest rate of 5.36% for fiscal 2005, 5.55% for
    fiscal 2004 and 5.31% for fiscal 2003;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    no dividends;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    expected volatility of 57% for fiscal 2005 and 70% for fiscal
    2004 and 2003;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    expected life of 2&nbsp;years for 2005, 2.5&nbsp;years for 2004
    and 1.6&nbsp;years for 2003.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The resulting compensation cost is charged to earnings ratably
over the estimated vesting period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following table summarizes the activity of share options
issued to consultants during the years ended 30&nbsp;June 2005,
2004 and 2003:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="34%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="22" align="center" nowrap><B>Years Ended 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="22" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Average</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Average</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Average</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Options</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Options</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Options</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Outstanding at beginning of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Granted</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,640,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1.07</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exercised</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,000,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Forfeited</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(10,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1.18</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Expired</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Outstanding at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,130,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>500,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exercisable at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,055,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>250,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Weighted average grant date fair value</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>



<TR valign="bottom">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercise price exceeds market price</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>$0.38</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>$0.50</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>$0.03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>


<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>




<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercise price equals market price</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>$0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>


<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Options issued to directors, executives and
    employees</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under US GAAP, the Company has elected to account for the
issuance of share options to the directors, executives and
employees in accordance with Accounting Principles Board
(&#147;APB&#148;) Opinion No.&nbsp;25, &#147;Accounting for
Stock Issued to Employees&#148; and related interpretations
(collectively, &#147;APB&nbsp;25&#148;). Under APB&nbsp;25,
compensation cost is recognized to the extent that the fair
value of the stock exceeds the
</DIV>

<P align="center" style="font-size: 10pt;">F-51

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
exercise price of the options at the measurement date, and is
charged to earnings ratably over the vesting period. Following
is a summary of the share options accounted for under
APB&nbsp;25:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>pSivida</U>
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pSivida issued 12,041,537&nbsp;share options under the ESOP to
    directors, executives and employees during the year ended
    30&nbsp;June 2005, consisting of 8,889,537 options in August
    2004 and 3,152,000&nbsp;options in April 2005.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="1%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    Of the options issued in August 2004, 638,537&nbsp;options were
    issued to directors, executives and employees in consideration
    for the waiver of their rights under outstanding options
    previously issued by pSiMedica, and were accounted for as part
    consideration for the acquisition of pSiMedica.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    No compensation cost was recognized for the remaining
    8,251,000&nbsp;options issued in August 2004 because the
    exercise price exceeded the quoted market price on the
    measurement date, corresponding to the date of grant.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    The vesting of 2,032,000 of the options issued in April 2005 is
    conditional upon the achievement of performance conditions.
    Under US GAAP, these options are considered variable plan
    options as the number of shares the individuals are entitled to
    receive is not known at the date of grant. Compensation cost is
    computed on the date of grant based on management&#146;s
    estimate of the number of shares that will eventually be issued
    upon the achievement of the specific performance criteria and
    adjusted at each statement of financial position date (up to the
    vesting date) for changes in the estimate of the number of the
    shares and the quoted market price of the shares. No
    compensation cost was recognized for these options during the
    year because the exercise price exceeded the quoted market price
    as of 30&nbsp;June 2005.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    No compensation cost was recognized for the remaining 1,120,000
    options issued in April 2005 because the exercise price exceeded
    the quoted market price on the measurement date, corresponding
    to the date of grant</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pSivida issued 3,895,000&nbsp;share options under the ESOP to
    directors, executives and employees during the year ended
    30&nbsp;June 2004. No compensation cost was recognized for such
    options because the exercise price exceeded the quoted market
    price on the measurement date, corresponding to the date of
    grant.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pSivida issued 520,000&nbsp;share options under the ESOP to
    employees during the year ended 30&nbsp;June 2003. The share
    options vested one&nbsp;year from the date of grant subject to
    the option holders having satisfied defined performance
    criteria. Under US GAAP, these options are considered variable
    plan options as the number of shares the individuals are
    entitled to receive is not known at the date of grant.
    Compensation cost is computed on the date of grant based on
    management&#146;s estimate of the number of shares that will
    eventually be issued upon the achievement of the specific
    performance criteria and adjusted at each statement of financial
    position date (up to the vesting date) for changes in the
    estimate of the number of the shares and the quoted market price
    of the shares. 500,000 of the share options vested during the
    year ended 30&nbsp;June 2004.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pSivida issued 2,200,000&nbsp;share options under the ESOP to
    directors, executives and employees during the year ended
    30&nbsp;June 2002. The vesting of these share options is
    conditional upon a share performance measure. Under US GAAP,
    these options are considered variable plan options as the number
    of shares the individuals are entitled to receive are not known
    at the date of grant. As the share performance measure is beyond
    the control of the Company, any resulting compensation</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">F-52

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD></TD>
    <TD align="left">
    expense is recognized under APB&nbsp;25 when the target is
    achieved. During the year ended 30&nbsp;June 2004, all options
    vested as the share performance target was met, and accordingly,
    the Company recognized compensation expense under APB&nbsp;25
    based on the excess of the quoted market price on the vesting
    date over the exercise price of the share options.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following table summarizes the activity of share options
issued to directors, executives and employees of pSivida during
the years ended 30&nbsp;June 2005, 2004 and 2003:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="21%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="22" align="center" nowrap><B>Years Ended 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="22" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted Average</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted Average</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted Average</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise Price</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise Price</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise Price</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Options</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Options</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Options</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Outstanding at beginning of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,595,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.52</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,700,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.36</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Granted</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,041,537</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1.08</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,895,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.61</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>520,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exercised</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,050,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.30</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Transferred</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,650,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Forfeited</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(104,824</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.98</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(20,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.20</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Expired</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Outstanding at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>15,831,713</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.97</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,595,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.52</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,700,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.36</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exercisable at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,754,713</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1.01</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,795,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.49</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="70%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Weighted average grant date fair value</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exercise price exceeds market price</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.42</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.37</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exercise price less than market price</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.45</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>pSiMedica</B>
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pSiMedica issued 30,300 and 12,000&nbsp;share options to
    directors, executives and employees during the years ended
    30&nbsp;June 2004 and 2003, respectively. The Company recognized
    compensation expense for 3,375 options issued during the year
    ended 30&nbsp;June 2004 based on the excess of the estimated
    fair value of stock over the exercise price on the date of
    grant. No compensation cost was recognized for the remaining
    26,925 options issued during the year ended 30&nbsp;June 2004
    and all 12,000 options issued during the year ended 30&nbsp;June
    2003 because the exercise price exceeded the estimated fair
    value on the date of grant for these options.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    pSiMedica issued 29,900 and 26,600&nbsp;share options to
    directors, executives and employees during the years ended
    30&nbsp;June 2004 and 2003, respectively. The share options vest
    three years from the date of grant subject to the option holders
    having satisfied defined performance criteria. Under US GAAP,
    these options are considered variable plan options as the number
    of shares the individuals are entitled to receive are not known
    at the date of grant. Compensation cost is computed on the date
    of grant based on management&#146;s estimate of the number of
    shares that will eventually be</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">F-53

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD></TD>
    <TD align="left">
    issued upon the achievement of the specific performance criteria
    and adjusted at each statement of financial position date (up to
    the vesting date) for changes in the estimate of the number of
    the shares and the estimated fair value of the shares.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following table summarizes the activity of share options
issued to directors, executives and employees of pSiMedica
during the years ended 30&nbsp;June 2005, 2004 and 2003:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="34%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="22" align="center" nowrap><B>Years Ended 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="22" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Average</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Average</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Average</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Options</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>&#163;</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Options</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>&#163;</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Options</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>&#163;</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Outstanding at beginning of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>98,800</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9.66</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>38,600</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6.25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Granted</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>60,200</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11.84</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>38,600</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6.25</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exchanged for pSivida options</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(98,800</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9.66</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Outstanding at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>98,800</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9.66</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>38,600</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6.25</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exercisable at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="68%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Weighted average grant date fair value</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exercise price exceeds market price</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>9.79</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exercise price equals market price</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>10.32</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exercise price less than market price</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>13.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>AION Diagnostics</B>
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    AION Diagnostics issued 1,200,000&nbsp;share options to
    directors, executives and employees during the year ended
    30&nbsp;June 2005. The options vest subject to various
    milestone-based vesting conditions. Under US GAAP, these options
    are considered variable plan options as the number of shares the
    individuals are entitled to receive are not known at the date of
    grant. Compensation cost is computed on the date of grant based
    on management&#146;s estimate of the number of shares that will
    eventually be issued upon the achievement of the specific
    performance criteria and adjusted at each statement of financial
    position date (up to the vesting date) for changes in the
    estimate of the number of the shares and the estimated fair
    value of the shares. For those options with performance
    conditions beyond the control of AION Diagnostics, any resulting
    compensation expense is recognized under APB&nbsp;25 when the
    target is achieved.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">F-54

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following table summarizes the activity of share options
issued to directors, executives and employees of AION during the
year ended 30&nbsp;June 2005:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Year Ended</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>30&nbsp;June 2005</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Average</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number of</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Options</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Outstanding at beginning of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Granted</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.00</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Outstanding at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,200,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.00</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exercisable at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="90%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Weighted average grant date fair value</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exercise price less than market price</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.29</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>Fair value</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Had compensation cost related to the issuance of options to
directors and employees been recorded at fair value on the date
of grant in accordance with SFAS&nbsp;123, the Company&#146;s
net loss and loss per share amounts (calculated in accordance
with US GAAP) would have been increased to the pro forma amounts
indicated below:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>Year Ended 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(As restated)</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(As restated)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    US GAAP net loss, as reported</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(16,561,512</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,019,974</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,268,603</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Add: Stock-based employee compensation expense included in US
    GAAP reported net loss, net of related tax effects</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>125,018</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>448,920</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deduct: Total stock-based employee compensation expense
    determined under fair value based method for all awards, net of
    related tax effect</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,537,993</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(975,468</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(190,003</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    US GAAP pro forma net loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(20,974,487</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,546,522</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,448,606</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    US GAAP loss per share</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Basic and diluted&nbsp;&#151; as reported</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(0.08</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(0.04</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(0.02</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Basic and diluted&nbsp;&#151; pro forma</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(0.10</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(0.04</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(0.02</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following weighted-average assumptions were made in
calculating the estimated fair value:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    risk-free interest rate of 5.36% for fiscal 2005, 5.55% for
    fiscal 2004, and 5.31% for fiscal 2003 ;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    no dividends;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    expected volatility of 57% for fiscal 2005 and 70% for fiscal
    2004 and 2003;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">F-55

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    expected life of 2.5&nbsp;years for 2005, 2.5&nbsp;years for
    2004 and 1.6&nbsp;years for 2003.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>(b)&nbsp;</B></TD>
    <TD>
    <B>Fair value of shares issued as consideration</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On 10 May 2001, the Company acquired the controlling economic
interest in pSiMedica and issued shares for a portion of the
consideration. Under A-GAAP, the fair value of the share
consideration was calculated based on the price in the
shareholder&#146;s agreement (which was derived from an
independent valuation report). Under US GAAP, the fair value of
the shares issued to affect the acquisition is the average
quoted market price for a period of two days period before and
two days after the date the terms of the acquisition is agreed
to and announced. Accordingly, for US&nbsp;GAAP purposes, the
Company has recorded an increase to the value of identifiable
intangible assets equal to the difference. Such difference is
amortized over the estimated useful life of 12&nbsp;years.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(c)</B></TD>
    <TD>
    <B>Direct acquisition costs</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under A-GAAP until 30&nbsp;June 2004 the Company&#146;s
accounting policy was to expense direct acquisition costs as
incurred. Since 1&nbsp;July 2004 the Company&#146;s accounting
policy has been to capitalize direct acquisition costs as part
of the purchase price. Under US&nbsp;GAAP, the direct
acquisition costs are also capitalized as part of the purchase
price. Accordingly, for all acquisitions prior to 1&nbsp;July
2004, the Company has recorded an increase to the value of
identifiable intangible assets equal to the amount of the direct
acquisition costs for US&nbsp;GAAP purposes. The difference is
amortized from the date of acquisition over the estimated useful
life of 12&nbsp;years under US&nbsp;GAAP.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(d)</B></TD>
    <TD>
    <B>Amortization of intangible assets</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In connection with the acquisition of pSiMedica (acquired in
steps from 18 December 2000 to 4&nbsp;August 2004), the Company
acquired identifiable intangible assets classified as core
intellectual property under A-GAAP. Under A-GAAP, the core
intellectual property is currently not amortized. Rather,
amortization will commence on commercial production of related
products over the remaining estimated useful life. Under
US&nbsp;GAAP, the intangible assets are classified as licenses
and patents and amortized from the date of acquisition on a
straight-line basis over the estimated useful life of
12&nbsp;years. The aggregate US&nbsp;GAAP amortization expense
for the next five succeeding years is estimated to be
$6,274,253&nbsp;per year.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(e)</B></TD>
    <TD>
    <B>Goodwill</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under A-GAAP, the Company amortizes goodwill attributable to the
4&nbsp;August 2004 acquisition of the remaining 55.28% interest
in pSiMedica on a straight line basis over the estimated period
of benefit of nine years. Under US&nbsp;GAAP, goodwill is not
amortized but instead is tested for impairment at least annually
as further discussed below. Accordingly, goodwill amortization
under A-GAAP has been added back in the US&nbsp;GAAP
reconciliation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For US&nbsp;GAAP purposes, SFAS&nbsp;No.&nbsp;142,
&#147;Goodwill and Intangible Assets&#148; requires goodwill to
be tested for impairment at least annually at the reporting unit
level. Goodwill attributable to the August 2004 acquisition of
the minority interest in pSiMedica was tested for impairment at
the reporting unit level in May 2005 and no impairment of
goodwill was identified.
</DIV>

<P align="center" style="font-size: 10pt;">F-56

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(f)</B></TD>
    <TD>
    <B>Sales of stock by subsidiaries</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the years ended 30&nbsp;June 2004 and 2002, pSiMedica and
pSiOncology issued additional shares which resulted in a change
in pSivida&#146;s proportionate interest in the respective
subsidiaries. Details are as follows:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    On 7 March 2002, pSiMedica issued a total of
    400,000&nbsp;ordinary shares (as adjusted for a 100 to
    1&nbsp;share split) to pSivida and another shareholder at
    &#163;5 ($13.61) per share, resulting in a total of
    &#163;2,000,000 ($5,443,658) cash consideration. This issuance
    increased pSivida&#146;s direct ownership interest in pSiMedica
    from 40.05% to 42.85%.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    On 13 October 2003, pSiMedica issued a total of 237,342
    preference shares to pSivida and another shareholder at
    &#163;12.64 ($30.47) per share, resulting in a total of
    &#163;3,000,000 ($7,232,401) cash consideration. This issuance
    increased pSivida&#146;s direct ownership interest in pSiMedica
    from 42.85% to 46.25%.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    On 1&nbsp;March 2004, pSiOncology issued a total of
    2,769&nbsp;shares to pSiMedica and other minority shareholders
    at SGD$1,000 ($761.61) per share, resulting in a total of
    SGD$2,769,000 ($2,108,911). This issuance increased
    pSivida&#146;s direct ownership interest in pSiOncology from
    38.56% to 42.26%.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    On 24 May 2004, pSiMedica issued 56,954 ordinary shares to the
    minority shareholders of pSiOncology at &#163;12.64 ($32.29) per
    share in consideration for the minority interest in pSiOncology,
    resulting in a total of &#163;719,899 ($1,838,822) non-cash
    consideration. This issuance decreased pSivida&#146;s direct
    ownership interest in pSiMedica from 46.25% to 44.72%.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under A-GAAP, the change in pSivida&#146;s proportionate
interest in the respective subsidiaries due to the above share
issuances is eliminated on consolidation and therefore is not
recognized in the consolidated financial statements. Under
US&nbsp;GAAP, the issuance of ordinary shares by a subsidiary is
accounted for in accordance with Staff Accounting Bulletin
No.&nbsp;51, &#147;Accounting For Sales Of Stock By A
Subsidiary&#148; (&#147;SAB&nbsp;51&#148;) which requires the
difference between the carrying amount of the parent&#146;s
investment in a subsidiary and the underlying net book value of
the subsidiary after issuance of ordinary shares by the
subsidiary be reflected as either a gain or loss in the
statement of operations or reflected as an equity transaction.
The Company has elected to account for SAB&nbsp;51 gains and
losses resulting from the sale of a subsidiary&#146;s ordinary
shares as equity transactions. Accordingly, for US&nbsp;GAAP
purposes, the Company has recorded an adjustment to the value of
identifiable intangible assets and additional paid-in capital
for the resulting SAB&nbsp;51 gains and losses. Such difference
is amortized over the estimated useful life of 12&nbsp;years.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Deferred taxes have not been provided on the SAB&nbsp;51 gains
given that pSiMedica is a foreign subsidiary and pSivida intends
to permanently reinvest the undistributed earnings and thereby
take advantage of the exemption allowed under APB Opinion
No.&nbsp;23, &#147;Accounting for Income Taxes&nbsp;&#151;
Special Areas.&#148;
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(g)</B></TD>
    <TD>
    <B>In-process research and development</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In connection with the acquisition of the remaining minority
interest in pSiOncology during the year ended 30&nbsp;June 2004,
the Company acquired intangible assets classified as core
intellectual property under A-GAAP. Under A-GAAP, the core
intellectual property is currently not amortized. Rather,
amortization will commence on commercial production of related
products. For US&nbsp;GAAP purposes, the directors considered
the guidance contained in the AICPA Practice Aid &#147;Assets
Acquired in a Business Combination to be Used in Research and
Development Activities: A Focus on Software, Electronic
</DIV>

<P align="center" style="font-size: 10pt;">F-57

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
Devices, and Pharmaceutical Industries&#148; and determined that
the acquired intangible assets were in-process research and
development (&#147;IPR&#38;D&#148;) in nature and did not have
an alternative future use. Therefore, under US&nbsp;GAAP, the
IPR&#38;D is written off to earnings at the date of acquisition.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(h)</B></TD>
    <TD>
    <B>Deferred income taxes</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A-GAAP does not require the recognition of deferred taxes
arising from fair value adjustments attributable to a purchase
business combination. US&nbsp;GAAP requires deferred taxes to be
provided for the tax effects of differences between the fair
values and the tax bases of identifiable assets acquired and
liabilities assumed. Deferred taxes are only provided on
goodwill when the amortization of goodwill is deductible for tax
purposes in the respective tax jurisdiction. Accordingly, for
US&nbsp;GAAP purposes, the Company recorded a deferred tax
liability for the difference in the fair value and tax basis of
the acquired intangibles attributable to the step acquisition of
pSiMedica. Where the recognition of the deferred tax liability
resulted in additional basis of the related intangible asset,
such additional basis is being amortized over the remaining
estimated useful life of the related intangible asset for
US&nbsp;GAAP purposes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under US&nbsp;GAAP, the existence of sufficient taxable
temporary differences will enable utilization of the tax benefit
of operating loss carryforwards. Accordingly, for US&nbsp;GAAP
purposes, the Company recorded a deferred tax benefit
attributable to the pSiMedica operating loss carryforwards
expected to be utilized by the reversal of the deferred tax
liabilities recognized in connection with the step acquisition
of pSiMedica as per the above. Such deferred tax benefit was not
recognized under A-GAAP as sufficient taxable temporary
differences are not available under A-GAAP.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(i)</B></TD>
    <TD>
    <B>Outside equity interest</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Certain of the A-GAAP to US&nbsp;GAAP adjustments relate to
subsidiaries in which there exists an outside equity interest.
Such adjustments are attributed to the outside equity interest
accordingly.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under A-GAAP, the outside equity interest in controlled entities
is classified as a component of total equity. Under
US&nbsp;GAAP, the outside equity interest (also referred to as
&#147;minority interest&#148;) is classified between liabilities
and stockholders&#146; equity in the consolidated statements of
financial position. The effect of this adjustment has been
disclosed in the reconciliation of total equity to US&nbsp;GAAP.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(j)</B></TD>
    <TD>
    <B>Loss per share</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under A-GAAP, loss per share is calculated by dividing operating
profit (loss) after tax and minority shareholders interest by
the weighted average number of shares on issue for the year.
Methods of computing loss per share in accordance with
US&nbsp;GAAP are documented in SFAS&nbsp;No.&nbsp;128,
&#147;Earnings per Share&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For each of the years ended in the period ended 30&nbsp;June
2005, there were no differences in the calculation methodology
of loss per share under A-GAAP and US&nbsp;GAAP.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD><B>(k)</B></TD>
    <TD>
    <B>Consolidated statement of financial performance
    classification differences</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under A-GAAP, interest income is reported as a component of
revenue from ordinary activities. Under US&nbsp;GAAP, interest
income is reported as a component of non-operating income/(loss).
</DIV>

<P align="center" style="font-size: 10pt;">F-58

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under A-GAAP, proceeds from the disposal of property, plant and
equipment is reported as a component of revenue from ordinary
activities. Under US&nbsp;GAAP, only the net gain/(loss) is
reported in operating income/(loss).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under A-GAAP, interest expense is reported as a component of
loss from ordinary activities. Under US&nbsp;GAAP, interest
expense is reported as a component of non-operating
income/(loss).
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>(l)</B></TD>
    <TD>
    <B>Consolidated statement of comprehensive loss</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Set out below is an analysis of comprehensive income/(loss)
under A-GAAP for the years ended 30&nbsp;June 2005, 2004 and
2003:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="57%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>Years Ended 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss in accordance with A-GAAP</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(14,726,523</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,683,205</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,765,153</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other comprehensive (loss)/income:</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Foreign currency translation adjustment, net of tax of $0</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(350,287</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>77,985</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(31,765</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Comprehensive loss in accordance with A-GAAP</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,076,810</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,605,220</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,796,918</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="6%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top">
    <TD><B>(m)</B></TD>
    <TD>
    <B>Income tax</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The Company has adopted SFAS&nbsp;No.&nbsp;109 &#147;Accounting
for Income Taxes&#148; (&#147;SFAS&nbsp;109&#148;) for
US&nbsp;GAAP purposes. SFAS&nbsp;109 requires a &#147;liability
approach&#148; to accounting for income taxes, which as it
applies to the Company, is very similar to that adopted under
A-GAAP. Under A-GAAP, the deferred tax asset in respect of
income tax losses carried forward disclosed in Note&nbsp;5 is
not recognized unless the benefit is virtually certain of
realization. Under US&nbsp;GAAP, the benefit is not recognized
unless realization is more likely than not.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The components of A-GAAP loss from ordinary activities before
income tax expense consisted of the following for the years
ended 30&nbsp;June 2005, 2004 and 2003:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="57%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>Years Ended 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Australia</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,590,833</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(637,675</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(855,756</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    United Kingdom</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,076,779</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,736,347</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,054,871</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Singapore</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,458,107</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,144,954</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(445,701</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,125,719</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,518,976</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,356,328</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">F-59

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The components of deferred tax assets and liabilities in
accordance with A-GAAP as of 30&nbsp;June 2005 and 2004 are as
follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="70%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Years Ended 30&nbsp;June</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>$</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deferred tax assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net operating loss carryforwards</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,291,377</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,049,704</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Provision accruals</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,964</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,147</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,189</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total gross deferred tax assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,304,488</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,051,893</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deferred tax liabilities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Prepayments</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>96,880</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,687</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net deferred tax asset</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,207,608</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,043,206</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Valuation allowance</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(9,207,608</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,043,206</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net recorded deferred taxes</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
As at 30&nbsp;June 2005, the Company has operating loss carry
forwards of $31,945,180. Carryforwards of net operating losses
do not expire on a time basis in any of the jurisdictions in
which the Company incurs such losses. Expiration will depend on
the legislation of the countries in which losses are incurred,
and will generally be triggered by a change in control or
business activity.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>28.</B></TD>
    <TD>
    <B>Recently issued but not yet adopted US Pronouncements</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In December 2004, the Financial Accounting Standards Board
(&#147;FASB&#148;) issued SFAS&nbsp;No.&nbsp;123 (revised 2004):
&#147;Share-Based Payments&#148; (&#147;SFAS&nbsp;123R&#148;).
This statement eliminates the option to apply the intrinsic
value measurement provisions of APB&nbsp;25 to stock
compensation awards issued to directors and employees. Rather,
SFAS&nbsp;123R requires companies to measure the cost of
director, executive and employee services received in exchange
for an award of equity instruments based on the grant date fair
value of the award. That cost will be recognized over the period
during which the director, executive or employee is required to
provide services in exchange for the award&nbsp;&#151; the
requisite service period (usually the vesting period).
SFAS&nbsp;123R applies to all awards granted after the required
effective date (July&nbsp;1, 2005 for pSivida) and to awards
modified, repurchased, or cancelled after that date. As
permitted by SFAS&nbsp;123, the Company currently accounts for
share-based payments to directors, executives and employees
using APB&nbsp;25, the intrinsic value method. Accordingly, the
adoption of the SFAS&nbsp;123R fair value method may have a
significant impact on the Company&#146;s results of operations,
although it will have no impact on its overall financial
position. The full impact of the adoption of SFAS&nbsp;123R
cannot be predicted at this time, as it depends on levels of
share-based payments for future grants. However, had the Company
adopted SFAS&nbsp;123R for director, executive and employee
options in prior periods, the impact of that standard would have
approximated the pro forma impact of SFAS&nbsp;123, as disclosed
in Note&nbsp;27(a), Share-based compensation&nbsp;&#151;
<I>Options issued to directors, executives and employees.</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In December 2004, the FASB issued SFAS&nbsp;No.&nbsp;153:
&#147;Exchanges of Nonmonetary Assets&nbsp;&#151; an amendment
of APB Opinion No.&nbsp;29&#148; (&#147;SFAS&nbsp;153&#148;),
which amends APB Opinion No.&nbsp;29: &#147;Accounting for
Nonmonetary Transactions&#148; to eliminate the exception for
nonmonetary exchanges of similar productive assets and replaces
it with a general exception for exchanges of nonmonetary assets
that do not
</DIV>

<P align="center" style="font-size: 10pt;">F-60

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>PSIVIDA LIMITED AND SUBSIDIARIES</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(A Development Stage Enterprise)</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>In Australian Dollars (except as otherwise stated)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
have commercial substance. SFAS&nbsp;153 is effective for
nonmonetary assets exchanges occurring in fiscal periods
beginning after June&nbsp;15, 2005 (fiscal 2006 for pSivida). At
this time, management reasonably believes that the adoption of
SFAS&nbsp;153 will not have a material effect on the
consolidated entity&#146;s financial position or results of
operations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In May 2005, the FASB issued SFAS&nbsp;No.&nbsp;154:
&#147;Accounting Changes and Error Corrections&nbsp;&#151; a
replacement of APB Opinion No.&nbsp;20 and FASB Statement
No.&nbsp;3 (&#147;SFAS&nbsp;154&#148;), effective for fiscal
years beginning after December&nbsp;15, 2005 (fiscal 2007 for
pSivida). SFAS&nbsp;154 changes the requirements for the
accounting for and reporting of a voluntary change in accounting
principle as well as the changes required by an accounting
pronouncement which does not include specific transition
provisions. At this time management reasonably believes that the
adoption of SFAS&nbsp;154 will not have a material effect on the
Company&#146;s financial position or results of operations.
</DIV>

<P align="center" style="font-size: 10pt;">F-61

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV align="left" style="font-size: 10pt;">

</DIV>

<DIV align="left" style="font-size: 10pt;">
<!-- TOC -->
</DIV>

<DIV align="left" style="font-size: 10pt;">
<A name="tocpage"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</B>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="75%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Page</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    &nbsp;<A HREF='#300'>Report of Independent Auditors</A></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>G-2</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    &nbsp;<A HREF='#301'>Consolidated Balance Sheets as of
    December&nbsp;31, 2003 and 2004 and as of September&nbsp;30,
    2005 (unaudited)</A></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>G-3</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    &nbsp;<A HREF='#302'>Consolidated Statements of Operations for
    the years ended December&nbsp;31, 2002, 2003 and 2004 and for
    the nine months ended September&nbsp;30, 2004 and 2005
    (unaudited)</A></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>G-4</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    &nbsp;<A HREF='#303'>Consolidated Statements of
    Stockholders&#146; Deficit and Comprehensive Earnings (Loss) for
    the years ended December&nbsp;31, 2002, 2003 and 2004 and for
    the nine months ended September&nbsp;30, 2005 (unaudited)</A></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>G-5</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    &nbsp;<A HREF='#304'>Consolidated Statements of Cash Flows for
    the years ended December&nbsp;31, 2002, 2003 and 2004 and for
    the nine months ended September&nbsp;30, 2004 and 2005
    (unaudited)</A></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>G-6</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    &nbsp;<A HREF='#305'>Notes to Consolidated Financial
    Statements</A></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>G-7</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt;">
<!-- /TOC -->
</DIV>

<P align="center" style="font-size: 10pt;">G-1

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="left" style="font-size: 10pt;">
<A name='300'></A>
</DIV>

<!-- link1 "Report of Independent Auditors" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>Report of Independent Auditors</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
To the Board of Directors and Stockholders of
</DIV>

<DIV align="left" style="font-size: 10pt;">
Control Delivery Systems, Inc.:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In our opinion, the accompanying consolidated balance sheets and
the related consolidated statements of operations, of
stockholders&#146; deficit and comprehensive loss and of cash
flows present fairly, in all material respects, the financial
position of Control Delivery Systems, Inc. and its subsidiary,
or CDS, at December&nbsp;31, 2003 and 2004, and the results of
their operations and their cash flows for each of the three
years in the period ended December&nbsp;31, 2004 in conformity
with accounting principles generally accepted in the United
States of America. These financial statements are the
responsibility of CDS&#146; management. Our responsibility is to
express an opinion on these financial statements based on our
audits. We conducted our audits of these statements in
accordance with auditing standards generally accepted in the
United States of America. Those standards require that we plan
and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and
significant estimates made by management, and evaluating the
overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
As discussed in Note&nbsp;2, CDS changed its method for
accounting for stock options in 2003.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The accompanying financial statements have been prepared
assuming that CDS will continue as a going concern. As discussed
in Note&nbsp;1 in the financial statements, CDS has incurred
losses from operations and expects to continue to incur losses
from operations raising substantial doubt about its ability to
continue as a going concern. Management&#146;s plan in regard to
this matter is also described in Note&nbsp;1. The financial
statements do not include any adjustments that might result from
this uncertainty.
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="40%"></TD>
    <TD width="60%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    PricewaterhouseCoopers LLP</TD>
</TR>

<TR>
    <TD style="font-size: 12pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD align="left">
    December&nbsp;2, 2005</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt;">G-2

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>Control Delivery Systems, Inc.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<A name='301'></A>
</DIV>

<!-- link1 "Consolidated Balance Sheets" -->

<DIV align="center" style="font-size: 10pt;">
<B>Consolidated Balance Sheets</B>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="54%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>December&nbsp;31,</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>September&nbsp;30,</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(Unaudited)</B></TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>(In thousands, except share data)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="15" align="center" valign="top">
    <B>ASSETS</B></TD>
</TR>

<TR>
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Current assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash and cash equivalents</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>4,733</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1,015</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1,817</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Short-term investments</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,540</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accounts receivable&nbsp;&#151; related party</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>31</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>59</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Prepaid expenses and other current assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>248</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>76</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>190</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total current assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,546</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,122</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,066</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Property and equipment, net</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,461</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,312</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>559</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>12,007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>5,434</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>2,625</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="15">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="15" align="center" valign="top">
    <B>LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND<BR>
    STOCKHOLDERS&#146; DEFICIT</B></TD>
</TR>

<TR>
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Current liabilities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accounts payable</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>223</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>585</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>737</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accrued expenses and other liabilities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>987</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>897</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,792</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deferred revenue</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>750</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,351</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Current portion of long-term debt</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Advance from related party</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,795</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total current liabilities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,410</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,227</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,880</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Advance from related party, net of current portion</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,795</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Long-term debt, net of current portion</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,529</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,329</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total liabilities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,734</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,556</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,880</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Commitments and contingencies (Notes&nbsp;11, 12 and 14)&nbsp;</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Series&nbsp;A redeemable convertible preferred stock,
    $0.01&nbsp;par value; 2,000,000&nbsp;shares authorized;
    641,642&nbsp;shares issued and outstanding at December&nbsp;31,
    2003, December&nbsp;31, 2004 and September&nbsp;30, 2005,
    respectively (liquidation value at December&nbsp;31, 2004 and at
    September&nbsp;30, 2005 of $34,482)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>27,767</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>28,027</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,677</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Stockholders&#146; deficit</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Common stock, $0.01&nbsp;par value; 5,000,000&nbsp;shares
    authorized, 2,298,990, 2,373,847 and 2,393,847&nbsp;shares
    issued and outstanding at December&nbsp;31, 2003,
    December&nbsp;31, 2004 and September&nbsp;30, 2005, respectively</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>23</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>24</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>24</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Additional paid-in capital</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13,755</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13,056</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,805</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deferred stock-based compensation</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,469</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(692</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(820</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accumulated other comprehensive loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(311</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(169</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accumulated deficit</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(37,492</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(43,368</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(41,941</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total stockholders&#146; deficit</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(26,494</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(31,149</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(30,932</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total liabilities, redeemable convertible preferred stock and
    stockholders&#146; deficit</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>12,007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>5,434</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>2,625</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">G-3

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>Control Delivery Systems, Inc.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<A name='302'></A>
</DIV>

<!-- link1 "Consolidated Statements of Operations" -->

<DIV align="center" style="font-size: 10pt;">
<B>Consolidated Statements of Operations</B>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="11">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Nine Months Ended</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>Year Ended December&nbsp;31,</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>September&nbsp;30,</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2002</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>(Unaudited)</B></TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap><B>(In thousands)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Revenues</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Collaborative research and development&nbsp;&#151; related party</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>20,875</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>10,945</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>3,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>3,500</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Collaborative research and development&nbsp;&#151; other</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>176</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Royalties&nbsp;&#151; related party</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>168</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>132</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>120</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>89</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,074</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total revenues</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>21,043</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,077</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,120</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>89</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,750</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Operating expenses</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Research and development</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>17,983</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12,187</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,083</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,336</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,507</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Royalties</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>82</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>66</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>60</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>44</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>37</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    General and administrative</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11,022</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,571</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,646</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,539</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,741</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Charge for asset impairment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,575</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total operating expenses</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29,087</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>26,399</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,789</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,919</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,285</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Earnings (loss) from operations</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(8,044</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,322</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,669</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,830</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,465</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Interest expense</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(84</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(199</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(239</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(179</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(59</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Interest income</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>515</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>243</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>38</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>34</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other income(expense)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>64</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>24</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>18</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net earnings (loss)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,549</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,254</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,876</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,981</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,427</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accretion of redeemable convertible preferred stock</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(472</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(942</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,124</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,501</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,926</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss attributable to common stockholders</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(8,021</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(16,196</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(8,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(8,482</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(499</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 15pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<DIV align="center" style="font-size: 10pt;">
<B>See accompanying Notes to Consolidated Financial
Statements</B>
</DIV>

<P align="center" style="font-size: 10pt;">G-4

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>Control Delivery Systems, Inc.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<A name='303'></A>
</DIV>

<!-- link1 "Consolidated Statements of Stockholders&#146; Deficit and Comprehensive Loss" -->

<DIV align="center" style="font-size: 10pt;">
<B>Consolidated Statements of Stockholders&#146; Deficit and
Comprehensive Loss</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information for the nine months ended September&nbsp;30,
2005 is Condensed and Unaudited)</B>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 8pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>

<TR style="font-size: 7pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Accumulated</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 7pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Common Stock</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Additional</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Deferred</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Other</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Total</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 7pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Paid-In</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Stock</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Comprehensive</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Accumulated</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Stockholders&#146;</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Comprehensive</B></TD><TD></TD>
</TR>

<TR style="font-size: 7pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Shares</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Amount</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Capital</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Compensation</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Loss</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Deficit</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Deficit</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Loss</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 7pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="30" align="center" nowrap><B>(In thousands, except share data)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Balance at January&nbsp;1, 2002</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,925,583</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>19</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>6,282</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(236</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>32</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(14,689</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(8,592</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accretion of redeemable convertible preferred stock to
    redemption value</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(472</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(472</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exercise of employee stock options</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>27,435</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>206</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>207</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exercise of warrants</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>18,314</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Amortization of deferred stock compensation</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(84</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>135</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>51</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Gift of stock from shareholder to employee</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>595</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>595</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Change in unrealized loss on short-term investments</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(30</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(30</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(30</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Change in unrealized loss on interest rate swap</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(407</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(407</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(407</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,549</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,549</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,549</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Comprehensive loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(7,986</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Balance at December&nbsp;31, 2002</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,971,332</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>6,527</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(101</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(405</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(22,238</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(16,197</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accretion of redeemable convertible preferred stock to
    redemption value</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(942</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(942</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Beneficial conversion feature adjustment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,496</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,496</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issuance of restricted stock</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>327,658</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,674</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,677</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Amortization of deferred stock compensation</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>309</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>309</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Change in unrealized loss on short-term investments</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(1</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Change in unrealized loss on interest rate swap</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>95</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>95</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>95</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,254</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,254</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,254</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Comprehensive loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(15,160</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Balance at December&nbsp;31, 2003</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,298,990</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>23</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>13,755</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(2,469</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(311</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(37,492</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(26,494</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accretion of redeemable convertible preferred stock to
    redemption value</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,124</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,124</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Beneficial conversion feature adjustment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,864</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,864</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issuance of restricted stock</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>129,610</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>43</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(44</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cancellation of restricted stock</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(54,753</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(482</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>482</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Amortization of deferred stock compensation</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,339</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,339</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Change in unrealized loss on interest rate swap</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>142</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>142</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>142</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,876</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,876</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,876</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Comprehensive loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(5,734</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Balance at December&nbsp;31, 2004</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,373,847</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>24</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>13,056</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(692</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(169</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(43,368</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(31,149</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accretion of redeemable convertible preferred stock to
    redemption value</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,926</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,926</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Beneficial conversion feature adjustment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>276</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>276</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Issuance of restricted stock</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>399</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(399</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Amortization of deferred stock compensation</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>271</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>271</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Change in unrealized loss on interest rate swap</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>169</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>169</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>169</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net earnings</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,427</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,427</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,427</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Comprehensive earnings loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1,596</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Balance at September&nbsp;30, 2005 (unaudited)</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,393,847</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>24</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>11,805</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(820</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(41,941</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(30,932</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 15pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<DIV align="center" style="font-size: 10pt;">
<B>See accompanying Notes to Consolidated Financial
Statements</B>
</DIV>

<P align="center" style="font-size: 10pt;">G-5

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>Control Delivery Systems, Inc.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<A name='304'></A>
</DIV>

<!-- link1 "Consolidated Statements of Cash flows" -->

<DIV align="center" style="font-size: 10pt;">
<B>Consolidated Statements of Cash flows</B>
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 12pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="11">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Nine Months Ended</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>Year Ended December&nbsp;31,</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>September&nbsp;30,</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2002</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>(Unaudited)</B></TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="18" align="center" nowrap><B>(In thousands)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Cash flows from operating activities</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net earnings (loss)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(7,549</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(15,254</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(5,876</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(6,981</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1,427</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Adjustments to reconcile net (loss) to net cash provided by
    (used in) operating activities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    (Gain)/loss on sale of assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>62</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>147</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(62</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Non-cash charges for asset impairment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,575</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Depreciation</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,448</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,954</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,032</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>783</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>437</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Noncash charges for stock-based compensation</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>647</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>309</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,339</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,322</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>271</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Changes in operating assets and liabilities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accounts receivable&nbsp;&#151; related party</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>17</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(28</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Income tax receivable</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>454</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>297</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Prepaid expenses and other current assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>672</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,530</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>172</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>29</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(114</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accounts payable</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(660</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,174</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>362</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(55</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>152</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accrued expenses</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,091</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,244</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>52</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(8</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>690</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deferred revenue</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(7,322</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,140</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>750</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>601</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Advance from related party</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5,795</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,000</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2,795</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net cash provided by (used in) operating activities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(10,216</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(9,273</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,028</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(4,916</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>579</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Cash flows from investing activities</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Purchases of short-term investments</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(43,343</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(10,928</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,610</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,510</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Sales and maturities of short-term investments</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>50,477</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>18,425</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,150</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,050</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Proceeds from sale of assets</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>11</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,762</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Purchases of property and equipment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(6,266</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1,474</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(41</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(41</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(10</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net cash provided by investing activities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>868</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,031</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,510</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,509</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,752</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Cash flows from financing activities</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Proceeds from the issuance of long-term debt</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Repayments of long-term debt</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(66</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(205</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(200</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(150</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,529</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Proceeds from the sale of common stock</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>207</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net cash provided by (used in) financing activities</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,141</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(205</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(200</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(150</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,529</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net increase (decrease) in cash and cash equivalents</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(5,207</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,447</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,718</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,557</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>802</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash and cash equivalents at beginning of period</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13,387</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8,180</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,733</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,733</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,015</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash and cash equivalents at end of period</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>8,180</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>4,733</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1,015</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1,176</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1,817</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="4">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    <B>Supplemental disclosure of cash flow information</B></DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash paid for interest</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>80</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>251</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>239</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>181</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>80</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="4" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash paid for (refunds of) taxes</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(443</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(338</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 15pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<DIV align="center" style="font-size: 10pt;">
<B>See accompanying Notes to Consolidated Financial
Statements</B>
</DIV>

<P align="center" style="font-size: 10pt;">G-6

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<A name='305'></A>
</DIV>

<!-- link1 "NOTES TO CONSOLIDATED FINANCIAL STATEMENTS" -->

<DIV align="center" style="font-size: 10pt;">
<B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>1.</B></TD>
    <TD>
    <B>Description of CDS&#146; Business</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS designs and develops innovative sustained-release drug
delivery products. CDS&#146; two proprietary drug delivery
systems, AEON and CODRUG, deliver specific quantities of drugs
directly to a target site in the body at controlled rates for
predetermined periods of time ranging from days to years. These
systems are designed to address drawbacks of systemic drug
delivery for CDS&#146; target diseases such as the adverse side
effects characteristic of high dosing levels and reduced
treatment benefits due to variations in drug levels at the
target site.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS has two commercial products utilizing the AEON system
approved by the FDA for treatment of two sight-threatening eye
diseases. These two products, Vitrasert and Retisert, are the
only local sustained-release products approved by the FDA for
the back of the eye. Marketed by Bausch&nbsp;&#38; Lomb
Incorporated, or Bausch&nbsp;&#38; Lomb, and sold since 1996,
Vitrasert is a treatment for CMV retinitis, a disease that
afflicts late-stage AIDS patients. Approved by the FDA in April
2005 and also marketed by Bausch&nbsp;&#38; Lomb, Retisert
treats chronic noninfectious uveitis affecting the posterior
segment of the eye, or posterior uveitis, a leading cause of
vision loss. Medidur, an injectable AEON product, is also
designed to treat diabetic macular edema, or DME, and is
currently in Phase&nbsp;III clinical trials conducted by Alimera
Sciences Inc.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The accompanying financial statements have been prepared on a
basis which assumes that CDS will continue as a going concern,
which contemplates the realization of assets and the
satisfaction of liabilities and commitments in the normal course
of business. However, CDS&#146; recurring losses from operations
and expected future losses from operations raise substantial
doubt about CDS&#146; ability to continue as a going concern.
Management&#146;s plans with regard to these matters include
continued research and development in an effort to develop
commercial products and completing a merger of the Company as
described in Note&nbsp;19. If this merger proves unsuccessful,
CDS will seek additional financing. Management estimates that
these efforts together with potential royalties will provide
adequate resources to fund CDS&#146; operations. There can be no
assurance that CDS will be able to complete this merger or
obtain additional financing to provide the liquidity necessary
for CDS to continue its operations. The financial statements do
not include any adjustment that might result from the outcome of
this uncertainty.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
To date, CDS has focused its efforts primarily on research and
development of products based on its AEON system. In
Phase&nbsp;I studies, CDS has explored the use of its CODRUG
system for the treatment of post-surgical pain and two skin
diseases.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS is subject to risks common to companies in the
biopharmaceutical industry including, but not limited to, the
need for additional funding, uncertainties relating to the
successful development and commercialization of products,
clinical trial uncertainty, fluctuations in operating losses
results and financial risks, protection of proprietary
technology and patent risks, dependence on key personnel and
collaborative partners, competition, technological and medical
risks, customer demand, uncertain reimbursement from third-party
payers, compliance with the U.S.&nbsp;Food and Drug
Administration and other government regulations and potential
exposure to product liability claims.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
As discussed in Note&nbsp;15, Bausch&nbsp;&#38; Lomb informed
CDS in June 2003 that all future research and development
related to the ophthalmic technology, licensed by CDS to
Bausch&nbsp;&#38; Lomb under a license and development
agreement, would be undertaken directly by Bausch&nbsp;&#38;
Lomb and, as a result, in June 2003, CDS terminated 74 employees
most of whose costs were funded directly or indirectly by
Bausch&nbsp;&#38; Lomb.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
On October&nbsp;3, 2005, CDS entered into an Agreement and Plan
of Merger with pSivida Limited, an Australian corporation, and
pSivida Inc., its wholly owned subsidiary (Note&nbsp;19). The
accompanying
</DIV>

<P align="center" style="font-size: 10pt;">G-7

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
Consolidated Financial Statements have been prepared on the
assumption that CDS continues on a stand-alone basis and do not
reflect any adjustments or disclosures that may be required upon
consummation of the merger.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>2.</B></TD>
    <TD>
    <B>Summary of Significant Accounting Policies</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Basis of Presentation</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The accompanying consolidated financial statements reflect the
financial position and results of operations of CDS and CDS
Securities Corporation, its wholly owned subsidiary. All
significant inter-company balances and transactions have been
eliminated. CDS Securities Corporation was dissolved in May 2005.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Use of Estimates</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The preparation of financial statements in conformity with
accounting principles generally accepted in the United States
requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the
disclosure of contingent assets and liabilities at the dates of
the financial statements, and the reported amounts of revenues
and expenses during the reporting periods. Actual results could
differ from those estimates.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Cash and Cash Equivalents</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS considers all highly liquid investment instruments with an
original maturity of three months or less to be cash
equivalents. Cash equivalents, which consist of money market
funds, municipal notes and bonds, and commercial paper, are
recorded at cost plus accrued interest.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Investments</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Investments consist of marketable securities, which are
classified as available for sale. Investments are stated at fair
value with unrealized gains and losses included as a component
of accumulated other comprehensive income (loss), which is a
separate component of stockholders&#146; deficit, until
realized. The fair value of these securities is based on quoted
market prices. Realized gains and losses are determined on the
specific identification method and are included in investment
income.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concentration of Credit
Risk</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Financial instruments that potentially subject CDS to
concentrations of credit risk primarily consist of money market
funds, marketable securities and an interest rate swap. CDS
places these investments with financial institutions, which
management believes are of high credit quality.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
At December&nbsp;31, 2003 and 2004 and September&nbsp;30, 2005,
all of CDS&#146; accounts receivable-related party were due from
Bausch&nbsp;&#38; Lomb. Revenue from Bausch&nbsp;&#38; Lomb
represented 100% of total revenues during each of the years
ended December&nbsp;31, 2002, 2003 and 2004, respectively and
100% and 97% of total revenues for the nine months ended
September&nbsp;30, 2004 and 2005, respectively. (Note&nbsp;14)
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Fair Value of Financial Instruments</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The carrying value of CDS&#146; financial instruments, including
cash and cash equivalents, accounts receivable, accounts payable
and accrued expenses, at December&nbsp;31, 2003 and 2004 and
September&nbsp;30, 2005 approximated their fair value due to the
short-term nature of these items. The carrying value of
</DIV>

<P align="center" style="font-size: 10pt;">G-8

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
CDS&#146; variable rate long-term debt and related interest rate
swap approximated its fair value. The carrying value of
CDS&#146; payable to related party as of December&nbsp;31, 2004
approximated its fair value due to the short-term nature of this
item.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Derivative Instruments</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS recognizes all derivatives as either assets or liabilities,
with the instruments measured at fair value. The accounting for
changes in fair value, gains or losses, depends on the intended
use of the derivative and its resulting designation. Changes in
the fair value of CDS&#146; interest rate swap are included in
Other Comprehensive Income because the terms of the swap were
matched to the corresponding debt instruments at the inception
of the swap.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Property and Equipment</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Property and equipment are recorded at cost and depreciated
using the straight-line method over their estimated useful
lives. Leasehold improvements are amortized over the shorter of
the asset life or the lease term. Property and equipment held
under capital leases are initially recorded at the lower of the
fair market value of the related asset or the present value of
the minimum lease payments at the inception of the lease.
Repairs and maintenance that do not improve or extend the life
of the respective assets are charged to operations. On disposal,
the related accumulated depreciation or amortization is removed
from the accounts and any resulting gain or loss is included in
the results of operations.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Impairment or Disposal of Long-Lived Assets</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS evaluates the recoverability of its property and equipment
and other long-lived assets when circumstances indicate that an
event of impairment may have occurred in accordance with the
provisions of Statement of Financial Accounting Standards, or
SFAS&nbsp;No.&nbsp;144, <I>Accounting for the Impairment of
Long-Lived Assets or Disposal of Long-Lived Assets</I>. If an
indicator of impairment has occurred, SFAS&nbsp;144 requires
recognition of impairment of long-lived assets if the net book
value of such assets exceeds the future undiscounted cash flows
attributable to such assets or the business to which such assets
relate. Impairment is measured based on the difference between
the carrying value of the related assets or businesses and the
discounted future cash flows of such assets or businesses.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Revenue Recognition</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS&#146; business strategy includes entering into collaborative
license and development agreements with biotechnology and
pharmaceutical companies for the development and
commercialization of CDS&#146; product candidates. The terms of
the agreements typically include non-refundable license fees,
funding or co-funding of research and development, payments
based upon achievement of clinical development milestones and
either royalties on product sales or a share of profits on
product sales. CDS follows the provisions of the Securities and
Exchange Commission&#146;s Staff Accounting Bulletin&nbsp;104,
or SAB&nbsp;No.&nbsp;104, <I>Revenue Recognition,</I> Emerging
Issues Task Force, or EITF, Issue No.&nbsp;00-21, or
EITF&nbsp;00-21<I>, Accounting for Revenue Arrangements with
Multiple Deliverables, </I>EITF Issue No.&nbsp;99-19, or
EITF&nbsp;99-19, <I>Reporting Revenue Gross as a Principal
Versus Net as an Agent, </I>and EITF Issue No.&nbsp;01-9, or
EITF&nbsp;01-9, <I>Accounting for Consideration Given by a
Vendor to a Customer (Including a Reseller of the Vendor&#146;s
Products).</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Non-refundable license fees are recognized as revenue when CDS
has a contractual right to receive such payment, the contract
price is fixed or determinable, the collection of the resulting
receivable is reasonably assured and CDS has no further
performance obligations under the license agreement. Multiple
</DIV>

<P align="center" style="font-size: 10pt;">G-9

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
element arrangements, such as license and development
arrangements are analyzed to determine whether the license and
the performance obligations can be separated or whether they
must be accounted for as a single unit of accounting in
accordance with EITF&nbsp;00-21. CDS recognizes up-front license
payments as revenue upon delivery of the license only if the
license has standalone value and the fair value of the
undelivered performance obligations, typically including
research or steering committee services, can be determined. If
the fair value of the undelivered performance obligations can be
determined, such obligations would then be accounted for
separately as performed. If the license is considered to either
(i)&nbsp;not have stand-alone value or (ii)&nbsp;have
stand-alone value but the fair value of any of the undelivered
performance obligations cannot be determined, the arrangement
would then be accounted for as a single unit of accounting and
the license payments and payments for performance obligations
are recognized as revenue over the estimated period of when the
performance obligations are performed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Whenever CDS determines that an arrangement should be accounted
for as a single unit of accounting, it must determine the period
over which the performance obligations will be performed and
revenue will be recognized. Revenue will be recognized using
either a relative performance or straight-line method. CDS
recognizes revenue using the relative performance method
provided that CDS can reasonably estimate the level of effort
required to complete its performance obligations under an
arrangement and such performance obligations are provided on a
best-efforts basis. Direct labor hours or full-time equivalents
are typically used as the measure of performance.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Application of this policy requires that CDS make the following
calculations at the end of each reporting period to determine
CDS&#146; revenue from these agreements during that period.
First, CDS determines the actual costs it has incurred through
the end of the reporting period related to the agreement, and
adds to that amount the costs it expects to incur in the future
to complete the agreement, to arrive at the total cost CDS
expects to incur from inception to completion of the agreement.
CDS then divides the actual costs it has incurred through the
end of the reporting period by the total costs it expects to
incur from inception to completion to arrive at the percentage
of the agreement CDS has completed at the end of the reporting
period. CDS multiplies this percentage by the sum of total
license fees received, nonsubstantive milestone payments earned
and research and development payments received and expected to
be received under the agreement, and subtracts from that product
the revenue it has recognized under the agreement during
previous reporting periods, to arrive at the amount of revenue
related to the agreement it will recognize for the current
reporting period. CDS considers contingent payments, such as
milestone payments, to be earned only if CDS has satisfied all
the contingencies related to the payment and CDS&#146;
collaboration partner is obligated to make the payment to CDS.
Revisions in cost estimates and contractual payments, as
contracts progress, have the effect of increasing or decreasing
revenue recognized in the current and future periods. Revenue is
limited to the cumulative amount of payments received or the
cumulative amount of revenues earned, as determined using the
relative performance method, as of each reporting period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If CDS cannot reasonably estimate the level of effort required
to complete its performance obligations under an arrangement and
the performance obligations are provided on a best-efforts
basis, then the total payments under the arrangement, excluding
royalties and payments contingent upon achievement of
substantive milestones, would be recognized as revenue on a
straight-line basis over the period CDS expects to complete its
performance obligations. Revenue is limited to the lesser of the
cumulative amount of payments received or the cumulative amount
of revenue earned, as determined using the straight-line basis,
as of the period ending date.
</DIV>

<P align="center" style="font-size: 10pt;">G-10

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Significant management judgment is required in determining the
level of effort required under an arrangement and the period
over which CDS is expected to complete its performance
obligations under an arrangement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Collaboration agreements may also contain substantive
milestones. Substantive milestone payments are considered to be
performance bonuses that are recognized upon achievement of the
milestone only if all of the following conditions are met:
</DIV>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the milestone payments are non-refundable;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    achievement of the milestone involves a degree of risk and was
    not reasonably assured at the inception of the arrangement;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    substantive effort is involved in achieving the milestone;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    the amount of the milestone payment is reasonable in relation to
    the effort expended or the risk associated with achievement of
    the milestone;&nbsp;and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR valign="top">
    <TD>&nbsp;</TD>
    <TD>&#149;&nbsp;</TD>
    <TD align="left">
    a reasonable amount of time passes between the up-front license
    payment and the first milestone payment as well as between each
    subsequent milestone payment.</TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Determination as to whether a milestone meets the aforementioned
conditions involves management&#146;s judgment. If any of these
conditions are not met, the milestone payment would not be
considered a substantive milestone, and the resulting payment
would be recognized as revenue as such performance obligations
are performed under either the relative performance or
straight-line methods, as applicable, and in accordance with
these policies as described above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Reimbursement of costs is recognized as revenue provided the
provisions of EITF&nbsp;99-19 are met, the amounts are
determinable, and collection of the related receivable is
reasonably assured.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Royalty revenue is recognized upon the sale of the related
products, provided that the royalty amounts are fixed or
determinable, collection of the related receivable is reasonably
assured and CDS has no remaining performance obligations under
the arrangement. If royalties are received when CDS has
remaining performance obligations, the royalty payments would be
attributed to the services being provided under the arrangement
and therefore would be recognized as such performance
obligations are performed under either the relative performance
or straight line methods, as applicable, and in accordance with
these policies as described above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
For revenue generating arrangements where CDS, as a vendor,
provides consideration to a licensor or collaborator, as a
customer, CDS applies the provisions of EITF&nbsp;01-9.
EITF&nbsp;01-9 addresses the accounting for revenue arrangements
where the vendor gives consideration to the customer. Cash
consideration paid to a customer is presumed to be a reduction
of the selling price unless CDS receives an identifiable benefit
for the payment and CDS can reasonably estimate the fair value
of the benefit received. Payments to a customer that are deemed
a reduction of selling price are recorded first as a reduction
of revenue, to the extent of both cumulative revenue recorded to
date and of probable future revenues, which include any
unamortized deferred revenue balances, under all arrangements
with such customer and then as an expense. Payments that are not
deemed to be a reduction of selling price would be recorded as
an expense.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Amounts received prior to satisfying the above revenue
recognition criteria are recorded as deferred revenue in the
accompanying consolidated balance sheets.
</DIV>

<P align="center" style="font-size: 10pt;">G-11

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Research and Development</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
All costs associated with internal research and development,
research and development conducted for others and research and
development services for which CDS has externally contracted are
expensed as incurred. Costs allocated to research and
development expense include, but are not limited to, salaries
and benefits, clinical trial costs, outside consultants, cost to
manufacture clinical trial materials and facility related
expenses.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Patents</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
All costs to obtain and maintain patents are expensed as
incurred.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Stock-Based Compensation</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In December 2004, the FASB issued Statement of Financial
Accounting Standards, or SFAS, No.&nbsp;123 (revised 2004),
&#147;Share-Based Payments&#148; or SFAS&nbsp;123R. This
statement eliminates the option to apply the intrinsic value
measurement provisions of Accounting Principles Board, or APB,
Opinion No.&nbsp;25, &#147;Accounting for Stock Issued to
Employees&#148; to stock compensation awards issued to
employees. Rather, SFAS&nbsp;123R requires companies to measure
the cost of employee services received in exchange for an award
of equity instruments based on the grant-date fair value of the
award. That cost will be recognized over the period during which
an employee is required to provide services in exchange for the
award&nbsp;&#151; the requisite service period (usually the
vesting period). SFAS&nbsp;123R applies to all awards granted
after the required effective date and to awards modified,
repurchased, or cancelled after that date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS applied APB No.&nbsp;25, <I>Accounting for Stock Issued to
Employees</I>, and related interpretations, in accounting for
its stock-based compensation plans for fiscal year 2002. CDS had
adopted the disclosure-only provisions of
SFAS&nbsp;No.&nbsp;148, <I>Accounting for Stock-Based
Compensation&nbsp;&#151; Transition and Disclosure, an amendment
of FASB Statement No.&nbsp;123</I>; therefore, no compensation
expense was included in the statement of operations for fiscal
year 2002 related to employee options, for which the exercise
price was equal to or greater than the fair market value of
CDS&#146; common stock on the date of grant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Effective January&nbsp;1, 2003, CDS adopted SFAS&nbsp;148, on a
prospective basis. Accordingly, for fiscal years 2003 and 2004
and for the nine months ended September&nbsp;30, 2005,
compensation expense related to all stock options granted on and
after January&nbsp;1, 2003 is included in the statement of
operations, as calculated under the fair value method.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS has used the following assumptions in determining
compensation expense for the years ended December&nbsp;31, 2002,
2003 and 2004 related to stock options granted.
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="71%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>Year Ended December&nbsp;31,</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2002</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Expected option term (in years)</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5.00</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Risk-free interest rate</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4.39</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4.00</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4.07</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Expected dividend yield</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>none</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>none</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>none</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">G-12

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Had compensation cost for stock options in fiscal year 2002 been
determined based on the fair value at the grant date for all
options and awards under this plan, consistent with the
methodology prescribed in SFAS&nbsp;No.&nbsp;148, CDS&#146; pro
forma net loss would have been as follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="68%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Year Ended</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>December&nbsp;31,</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2002</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>(In thousands)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="3" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net loss attributable to common stockholders</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    As reported</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(8,021</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(16,196</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Add: Employee stock-based compensation expense recorded</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>51</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>309</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deduct: Pro forma stock-based compensation expense determined
    under fair-value method</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(632</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(579</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Pro forma net loss attributable to common stockholders</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(8,602</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(16,466</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The proforma net loss attributable to common stockholders in the
preceding chart includes compensation cost, as calculated under
the fair value method, for all options, including those granted
prior to January&nbsp;1, 2003.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Since options vest over several years and additional option
grants may be made in future years, the pro forma results are
not representative of the pro forma results for future years.
For purposes of the preceding analysis, the fair value of each
option grant is estimated on the date of grant using the minimum
value method.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Income Taxes</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS recognizes deferred tax liabilities and assets for the
expected future tax consequences of events that have been
included in the financial statements or tax returns. Under this
method, deferred tax liabilities and assets are determined based
on the difference between the financial statement and tax bases
of assets and liabilities, as well as net operating loss carry
forwards, or NOLs, and are measured using enacted tax rates in
effect for the year in which the differences are expected to
reverse. Deferred tax assets are reduced by a valuation
allowance unless their ultimate realization is considered more
likely than not.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Comprehensive Income (Loss)</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS accounts for comprehensive income (loss) under
SFAS&nbsp;No.&nbsp;130, <I>Reporting Comprehensive Income</I>.
SFAS&nbsp;130 establishes standards for reporting comprehensive
income and its components in the financial statements.
Comprehensive income, as defined, includes all changes in equity
during a period from non-owner sources. Accumulated other
comprehensive loss is comprised of accumulated unrealized losses
on the interest rate swap.
</DIV>

<P align="center" style="font-size: 10pt;">G-13

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>3.</B></TD>
    <TD>
    <B>Investments and Cash and Cash Equivalents</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Cash and cash equivalents consist of the following:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="63%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>December&nbsp;31,</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>September&nbsp;30,</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>(In thousands)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Cash and money market funds</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1,030</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>815</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1,817</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Municipal notes and bonds</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,703</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>4,733</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1,015</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1,817</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
There were no gross unrealized gains or losses on municipal
notes and bonds classified as cash equivalents at
December&nbsp;31, 2003 and 2004.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Short-term investments at amortized cost, including accrued
interest, and fair value at December&nbsp;31, 2003 were as
follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="52%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center" nowrap><B>Gross</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Gross</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Amortized</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center" nowrap><B>Unrealized</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Unrealized</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Fair</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Cost</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center" nowrap><B>Gains</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Losses</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Value</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="14" align="center" nowrap><B>(In thousands)</B></TD><TD></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Government agencies</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,541</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(1</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,540</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1,541</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>(1</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1,540</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
There were no gross realized gains or losses for the year ended
December&nbsp;31, 2003 and 2004 and for the nine months ended
September&nbsp;30, 2004 and 2005, respectively. All short-term
investments held at December&nbsp;31, 2003 mature within one
year.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>4.</B></TD>
    <TD>
    <B>Impairment of Long-Lived Assets</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In June 2003, Bausch&nbsp;&#38; Lomb informed CDS that all
future research and development related to the licensed
ophthalmic technology would be undertaken by Bausch&nbsp;&#38;
Lomb (Note&nbsp;15). In June 2003, CDS reduced its workforce by
terminating 74 employees most of whose costs were funded
directly or indirectly by Bausch&nbsp;&#38; Lomb. Due to these
events, there was a significant adverse change in the extent or
manner in which CDS&#146; long-lived assets, including CDS&#146;
equipment, land, building and building improvements were to be
used. As a result, CDS performed a test for recoverability and
CDS concluded that the book values of certain assets of CDS were
significantly higher than their expected future cash flows and
that an impairment had occurred. In 2003, CDS wrote down the
cost basis of these assets to their estimated fair values,
considering quotations received from third parties and recorded
impairment charges of $335,000 for CDS&#146; computer equipment,
manufacturing equipment and furniture and fixtures and
$6,240,000 for CDS&#146; land, building and building
improvements, resulting in a total impairment charge of
$6,575,000.
</DIV>

<P align="center" style="font-size: 10pt;">G-14

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>5.</B></TD>
    <TD>
    <B>Property and Equipment</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Property and equipment consist of the following:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="46%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Estimated</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>December&nbsp;31,</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Useful Life</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>September&nbsp;30,</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(Years)</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>(In thousands)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Computer equipment and software</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>724</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>584</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>571</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Equipment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>809</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>472</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>379</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Research and development equipment</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,177</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,048</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,980</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Leasehold improvement</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Land</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>N/A</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,055</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,055</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Building</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>533</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>533</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Building improvements</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,035</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,042</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2"><FONT style="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,333</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6,734</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,940</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Less: accumulated depreciation</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,871</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,422</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2,381</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Property and equipment, net</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>5,461</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>4,312</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>559</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Depreciation expense was $1,448,000, $1,954,000 and $1,032,000
for the years ended December&nbsp;31, 2002, 2003 and 2004,
respectively. Depreciation expense was $783,000 and $437,000 for
the nine months ended September&nbsp;30, 2004 and 2005
respectively.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>6.</B></TD>
    <TD>
    <B>Accrued Expenses and Other Liabilities</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Accrued expenses and other liabilities consist of the following:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="64%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>December&nbsp;31,</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>September&nbsp;30,</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2005</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>(In thousands)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Obligation under government grants</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>99</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>99</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>99</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accrued payroll and benefits</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>142</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>277</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>817</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Fair value of interest rate swap classified as a hedge</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>311</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>169</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accrued professional fees</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>226</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>243</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>115</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Deferred gain on sale of building</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>374</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accrued financing cost</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>335</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accrued clinical trial costs</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>169</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>55</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accrued other</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>54</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>52</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>987</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>897</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>1,792</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>7.</B></TD>
    <TD>
    <B>Preferred Stock</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In August 2000, CDS&#146; board of directors designated
641,642&nbsp;shares of preferred stock as Series&nbsp;A
convertible preferred stock, $0.01&nbsp;par value, and CDS sold
641,642&nbsp;shares of Series&nbsp;A preferred stock to
third-party investors at $53.74&nbsp;per share for total gross
proceeds of $34.5&nbsp;million. CDS recorded the Series&nbsp;A
preferred stock at $31.2&nbsp;million, which is net of
$2.2&nbsp;million of cash issuance costs and the
$1.1&nbsp;million fair value of warrants issued in conjunction
with the preferred stock offering. The carrying
</DIV>

<P align="center" style="font-size: 10pt;">G-15

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
value of the Series&nbsp;A preferred stock is being accreted to
the redemption value on straight-line basis through the first
redemption date of August&nbsp;7, 2007.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
After August&nbsp;7, 2007, holders of a majority of the
Series&nbsp;A Preferred Stock may require that CDS redeem all
then outstanding shares of Series&nbsp;A Preferred Stock at a
price per share of $53.74 plus all then accrued and unpaid
dividends.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Series&nbsp;A preferred stockholders vote together with the
common stockholders as a single class. Each share of
Series&nbsp;A preferred stock is convertible at the
holder&#146;s option into one share of common stock, subject to
adjustments, and is entitled to non-cumulative dividends when
and if declared, at the annual rate of $4.30&nbsp;per share.
Holders of a majority of the outstanding Series&nbsp;A preferred
stock may elect on and after August&nbsp;8, 2007 to have CDS
redeem all then outstanding Series&nbsp;A preferred stock at the
issue price plus any accrued and unpaid dividends. On
liquidation, the holders of the Series&nbsp;A preferred stock
are entitled to a liquidation preference equal to the issue
price plus all accrued and unpaid dividends. The Series&nbsp;A
preferred stock outstanding will automatically be converted into
shares of common stock upon the earliest of (1)&nbsp;the closing
by CDS of a public offering raising gross proceeds of
$20&nbsp;million or more at an offering price per share greater
than or equal to 200% of the then-applicable conversion price,
(2) following completion of a public offering not triggering
conversion under (1)&nbsp;above, the date on which the average
closing price of the common stock has exceeded 200% of the issue
price of the Series&nbsp;A preferred stock for any 20
consecutive trading days, or (3)&nbsp;the receipt by CDS of a
written consent of the holders of at least
66<FONT style="font-size: 70%"><SUP>2</SUP></FONT>/<FONT style="font-size: 60%">3</FONT>%
of the Series&nbsp;A preferred stock then outstanding or
conversion of at least
66<FONT style="font-size: 70%"><SUP>2</SUP></FONT>/<FONT style="font-size: 60%">3</FONT>%
of the Series&nbsp;A preferred stock originally issued.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Due to the issuance of restricted stock in May and October 2003
(Note&nbsp;9), the conversion price for the Series&nbsp;A
preferred stock was adjusted in accordance with the
Series&nbsp;A preferred stock agreement. The May 2003 issuance
of restricted stock resulted in a reduction of the conversion
price to $51.63&nbsp;per share with a resulting increase of
26,215&nbsp;shares of common stock that would be received by the
holders of the Series&nbsp;A preferred stock upon conversion.
The October 2003 issuance of restricted stock adjusted the
conversion price to $46.13&nbsp;per share with a resulting
increase of 79,628&nbsp;shares of common stock that would be
received by the Series&nbsp;A preferred stock holders. During
fiscal 2004, CDS issued restricted stock subject to vesting
requirements. These 2004 issuances adjusted the conversion price
of the Series&nbsp;A preferred stock to $43.68 with a resulting
increase of 41,838&nbsp;shares of common stock that would be
received by the holders of the Series&nbsp;A preferred stock
upon conversion. These adjustments represent contingent
conversion options as defined by EITF&nbsp;00-27, <I>Application
of Issue No.&nbsp;98-5 to Certain Convertible Instruments</I>.
Accordingly, CDS recorded a beneficial conversion feature of
$5,496,000 in 2003 and $1,864,000 in 2004 as an increase to
additional paid-in capital and a reduction in the carrying value
of the Series&nbsp;A preferred stock in the years ended
December&nbsp;31, 2003 and 2004, respectively. The carrying
value of the Series&nbsp;A preferred stock will be accreted to
its redemption value of $34.5&nbsp;million plus accrued and
unpaid dividends by August 2007 through charges to additional
paid-in capital or, if none, to accumulated deficit.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>8.</B></TD>
    <TD>
    <B>Warrants</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In connection with the issuance of the Series&nbsp;A preferred
stock, CDS issued warrants to a third party to purchase up to
37,402&nbsp;shares of CDS&#146; common stock at an exercise
price of $53.73&nbsp;per share. The fair value of the warrants
was determined using the Black-Scholes pricing model, and
$1.1&nbsp;million was recorded in equity as additional paid-in
capital and as a discount on the preferred stock. In April 2002,
CDS issued 18,314&nbsp;shares of its common stock upon the
cashless exercise of all of the warrants.
</DIV>

<P align="center" style="font-size: 10pt;">G-16

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV style="margin-top: 24pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD><B>9.</B></TD>
    <TD>
    <B>Common Stock</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In 2003 and 2004, CDS issued 327,658 and 129,610&nbsp;shares of
its common stock to certain employees that vest over periods
ranging from two to five years. These shares of common stock are
restricted based on the continuing employment of the employees
over the respective vesting periods. For the May 2003 issuance
of 59,613&nbsp;shares of restricted stock, CDS estimated the
fair value of CDS&#146; restricted stock at $16.42&nbsp;per
share and recorded deferred compensation of $979,000. CDS
estimated the fair value of the restricted common stock to be
$5.00&nbsp;per share for the October 2003 issuance of
268,045&nbsp;shares of restricted common stock. CDS recorded
deferred compensation equal to the fair value of the October
2003 restricted shares and that portion of compensation related
to the options which were simultaneously canceled that had not
been previously expensed, resulting in total deferred
compensation of $1,698,000, which is being amortized over the
remaining vesting period of the restricted stock. Due to
negative trends in CDS&#146; business, the fair value of
CDS&#146; common stock declined from $5.00 to $0.01&nbsp;per
share during 2004. For the 2004 issuance of 129,610&nbsp;shares
of restricted stock, CDS recorded deferred compensation of
$39,000 based on the estimated fair value of the shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In May 2005, CDS granted 20,000&nbsp;shares of restricted stock.
CDS estimated the fair value of CDS&#146; restricted stock at
$20.00&nbsp;per share and recorded deferred compensation of
$400,000.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The reductions in the estimated fair value of CDS&#146;
restricted stock during 2003 and 2004 reflect the significant
reductions in CDS&#146; workforce during that period as a result
of Bausch and Lomb&#146;s decision in June 2003 to cease funding
research and development undertaken by CDS under the 1999
license agreement (Note&nbsp;14). During 2003 and 2004, CDS did
not consummate a financing, a strategic collaboration or a
business combination and CDS&#146; cash resources continued to
diminish.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During the first quarter of 2005, CDS consummated a strategic
collaboration with Alimera Sciences. During the second quarter
of 2005, CDS earned all of the milestones under the Alimera
agreement, sold its real estate and repaid the outstanding term
loan agreement, the FDA approved the product for posterior
uveitis, CDS received $3,000,000 from Bausch &#38; Lomb as an
advance payment in lieu of future royalties and CDS began
discussions with pSivida about a potential acquisition of CDS by
pSivida. The merger agreement with pSivida was approved by the
CDS Board in the third quarter of 2005. The increase in
CDS&#146; estimate of the fair market of its restricted stock
from 2004 to 2005 reflects the significant improvement in its
business during 2005 and the prospective acquisition by pSivida
(Note&nbsp;19).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
After terminating approximately 70% of its workforce in June
2003, CDS further reduced its workforce in August 2004. In
connection with the 2004 layoff, CDS modified a majority of the
terminated employees&#146; restricted stock agreements. As a
result, the unvested restricted stock held by such employees was
not forfeited upon termination of employment, but instead will
be forfeited on August&nbsp;16, 2007 unless a sale or an initial
public offering of CDS or similar liquidity event occurs before
that date. If a liquidity event occurs before August&nbsp;16,
2007, all unvested shares held by affected terminated employees
will then vest. CDS has not amortized any of the deferred
compensation related to these shares of restricted stock since
the employees&#146; termination date. Also, in August 2004 CDS
vested certain shares of restricted stock held by two remaining
employees as part of the restructuring of their employment
arrangement. CDS expensed unamortized deferred compensation
related to these vested shares in 2004.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The deferred compensation is being amortized to compensation
expense over the vesting periods of the restricted stock. CDS
recorded compensation charges of $303,000 and $1,339,000 related
to the grants of restricted stock to employees for the year
ended December&nbsp;31, 2003 and December&nbsp;31, 2004,
</DIV>

<P align="center" style="font-size: 10pt;">G-17

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
respectively. CDS recorded compensation charges of $1,322,000
and $271,000 related to the grants of restricted stock to
employees for the nine months ended September&nbsp;30, 2004 and
2005, respectively.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>10.</B></TD>
    <TD>
    <B>Incentive Plans</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS adopted the 1997 Stock Option Plan under which up to
300,000&nbsp;shares of common stock may be issued, and the 2001
Incentive Plan, under which up to 300,000&nbsp;shares of common
stock may be issued. At December&nbsp;31, 2003 and
December&nbsp;31, 2004, CDS has reserved a total of
600,000&nbsp;shares of common stock for issuance under these
plans. CDS had 66,167&nbsp;shares available for future grant as
of December&nbsp;31, 2004. Both plans provide for the grant of
incentive stock options, or ISOs, to employees as well as
restricted stock and nonqualified stock options to employees,
directors and other individuals providing services to CDS. The
2001 Incentive Plan also provides for the issuance of other
incentives. The Board of Directors determines for each award,
the term, exercise price, if any, number of shares, whether
options are ISOs or nonqualified stock options, whether
restrictions will be imposed on the shares subject to awards and
the vesting period for each award. The exercise price for ISOs
cannot be less than the fair value per share of the underlying
common stock on the date granted and the term cannot exceed ten
years. The existing awards outstanding as of December&nbsp;31,
2004 primarily vest over the next one to three years.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
A summary of the status of options granted under CDS&#146;
incentive plans as of December&nbsp;31, 2002, 2003 and 2004 and
changes during the years then ended is presented below:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="39%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>2002</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Average</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Average</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Average</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Shares</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Shares</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Shares</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Price</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Outstanding at beginning of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>245,400</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>49.03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>309,467</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>77.03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>50,975</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>26.08</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Granted</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>151,592</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>105.30</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,900</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>105.30</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,650</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>0.01</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Exercised</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(27,435</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7.54</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Canceled</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(60,090</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>65.75</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(263,392</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>87.41</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(3,125</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>48.92</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Outstanding at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>309,467</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>77.03</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>50,975</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>26.08</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>49,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>23.77</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Outstanding and exercisable at end of year</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>121,833</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>46.90</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>46,912</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>19.96</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>47,184</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>23.45</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Weighted average grant date fair value</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Options granted at above
    fair value</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">

    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Options granted at fair value</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>105.30</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>105.30</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.01</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Options granted at less than fair value</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt;">G-18

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following table summarizes information about stock options
granted to employees and directors, which were outstanding at
December&nbsp;31, 2004:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="24%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap><B>Options Outstanding</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="7">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>Options Exercisable</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted Average</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Remaining Contractual</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted Average</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Number</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Weighted Average</B></TD><TD></TD>
</TR>

<TR style="font-size: 8pt;">
    <TD align="left" nowrap><B>Exercise Price per Share</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Outstanding</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Life (In Years)</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise Price</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercisable</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>Exercise Price</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.01</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,650</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4.37</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.01</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>0.01</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.25</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2.72</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6.25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>20,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6.25</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.00</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4.65</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8.00</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.00</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4.87</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>10,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>12.00</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;105.30</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,750</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>2.87</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>105.30</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>4,084</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>105.30</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;113.40</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1.47</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>113.40</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,100</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>113.40</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    $.01-$113.40</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>49,500</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3.53</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>23.77</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>47,184</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>23.45</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS granted 52,100 options in 1999 and 13,500 options in 2000 to
employees of CDS at a price it subsequently deemed to be less
than fair market value and recorded stock-based compensation
expense associated with employee stock option grants of $6,000
and $6,000 for the years ended December&nbsp;31, 2002 and 2003,
respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During 2002, a principal shareholder of CDS gave
30,000&nbsp;shares of common stock to a former employee of CDS.
In accordance with APB No.&nbsp;25, CDS has accounted for the
transaction as a contribution of capital by the stockholder and
as a transfer of shares to the former employee. For the year
ended December&nbsp;31, 2002, CDS recorded a non-cash expense
related to this transaction of $595,000.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>11.</B></TD>
    <TD>
    <B>Commitments</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS leased some of its facilities under non-cancelable operating
lease agreements that expired in November 2003. Rental expense
associated with operating leases was $638,000, $573,000 and $0
for the years ended December&nbsp;31, 2002, 2003 and 2004,
respectively, and $0 and $266,000 for the nine months ended
September&nbsp;30, 2004 and 2005, respectively. As of
December&nbsp;31, 2004, CDS had no future minimum lease payments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In April 2005, CDS sold its land, building and building
improvements for $4,000,000, and used the net proceeds from this
sale to repay CDS&#146; term loan agreement, which had been
collateralized by the land, building and building improvements.
In connection with this agreement, CDS signed a lease agreement
with the purchaser of the building to lease a portion of the
facilities for a period of 18&nbsp;months for $25,294 a month.
CDS has the right, and the owner has a separate right to require
CDS, to extend the lease for an additional 18&nbsp;months for
$26,444&nbsp;per month. Since CDS is leasing back more than a
minor part of the building, CDS has deferred the gain on the
sale of the building of $449,000. The gain is being amortized
over the 36&nbsp;month lease term in accordance with
SFAS&nbsp;No.&nbsp;28, <I>Accounting for Sales with
Leasebacks</I>.
</DIV>

<P align="center" style="font-size: 10pt;">G-19

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Assuming the lease renewal option is exercised, the future
minimum lease payments (net of security payment) under
non-cancelable operating leases as of September&nbsp;30, 2005
are as follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="3%">&nbsp;</TD>
    <TD width="83%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD colspan="2" align="left" nowrap><B>Period</B></TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3">&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Fourth quarter ending December&nbsp;31, 2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>136,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Fiscal year 2006</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>143,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Fiscal year 2007</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>317,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD colspan="2" align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Fiscal year 2008</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>79,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total minimum lease payments</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>675,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>12.</B></TD>
    <TD>
    <B>Long-Term Debt</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Long-term debt at December&nbsp;31, 2003 and 2004 consists of
the following:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="79%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>(In thousands)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Term loan agreement</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>3,729</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>3,529</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Less current portion</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(200</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(200</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Long-term debt, net of current portion</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>3,529</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>3,329</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
During July 2002, CDS entered into a term loan agreement with a
bank under which CDS borrowed $4.0&nbsp;million for finance
general corporate purposes, which is collateralized by CDS&#146;
land, building and building improvements. Interest on the
borrowings is measured at the bank&#146;s 30-day
&#147;Libor&#148; rate plus 100&nbsp;basis points (3.28% at
December&nbsp;31, 2004). CDS utilizes an interest rate swap to
fix the interest rate on its variable rate term loan in order to
minimize the impact of changes in interest rates on earnings and
cash flow. In 2002, CDS entered into a five-year interest rate
swap agreement on a declining notional amount, which matches
with the scheduled principal amounts outstanding of CDS&#146;
long-term debt. At December&nbsp;31, 2004, the notional amount
of the interest rate swap, and the remaining principal amount of
the bank term loan, was $3,529,000. Under the swap agreement,
CDS pays a fixed rate of 6.45% on the notional amount and
receives LIBOR plus one hundred basis points. The interest
differential payable or accruable on the swap agreement is
recognized on an accrual basis as an adjustment to interest
expense. The criteria used to apply hedge accounting for this
interest rate swap include management&#146;s designating the
swap as a hedge against the variable rate debt, combined with
the terms of the swap matching the terms of the underlying debt,
including the notional amount, the timing of the interest reset
dates, the indices used and the payment dates. At
December&nbsp;31, 2004, CDS had recorded a total unrealized loss
of $169,000 as a component of other comprehensive loss based on
the fair value of the interest rate swap. The fair value of this
interest rate swap represents the amount CDS would pay to
terminate the agreement, and is based on dealer quotes. The
variable interest rate received on the swap at December&nbsp;31,
2004 was 3.28%. Credit risk exposure from the swap is minimized
as the agreement is with a major financial institution. CDS
monitors the credit worthiness of this financial institution and
full performance is anticipated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The loan was payable in 60&nbsp;monthly principal installments
of $16,667 through June 2007, with remaining principal of
$3,000,000 payable in July 2007.
</DIV>

<P align="center" style="font-size: 10pt;">G-20

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
At December&nbsp;31, 2004, payments of principal on existing
debt were due as follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="78%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>(In thousands)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2005</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2006</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>200</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    2007</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,129</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total debt</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3,529</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Less current portion</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(200</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Long-term debt, net of current portion</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>3,329</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In April 2005, CDS sold its land, building and building
improvements for $4,000,000, and used the net proceeds from this
sale to repay CDS&#146; term loan agreement, which had been
collateralized by the land, building and building improvements,
and to settle the interest rate swap. Since CDS is leasing back
more than a minor part of the building, CDS has deferred the
gain on the sale of the building of $449,000. The gain is being
amortized over the 36&nbsp;month lease term in accordance with
SFAS&nbsp;No.&nbsp;28, <I>Accounting for Sales with
Leasebacks</I>.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>13.</B></TD>
    <TD>
    <B>Income Taxes</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
At December&nbsp;31, 2004, CDS had federal and state net
operating loss carry forwards, or NOLs, of approximately
$28.0&nbsp;million and $31.0&nbsp;million, respectively. The
federal and state NOLs begin to expire in 2023 and 2005,
respectively. In addition, CDS had federal and state research
and development credits of $248,000 and $158,000, respectively,
at December&nbsp;31, 2004. These federal and state credits begin
to expire in 2023 and 2018, respectively. NOLs and research and
development credits may be used to reduce future tax payments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS has provided a valuation allowance for the full amount of
its net deferred tax assets since realization of any future
benefit from temporary differences and NOL and tax credit carry
forwards, since it is more likely than not that some or all of
the deferred tax assets will not be realized.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under the provisions of the Internal Revenue Code, certain
substantial changes in CDS&#146; ownership may result in a
limitation on the amount of NOLs and research and development
credit carry forwards that can be used in future years.
</DIV>

<P align="center" style="font-size: 10pt;">G-21

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 18pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The components of CDS&#146; net deferred tax asset are as
follows:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="75%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>


<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="6" align="center" nowrap><B>(In thousands)</B></TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Depreciation, amortization and impairment charge</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>2,759</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>2,671</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Federal net operating loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>7,957</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>9,536</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    State net operating loss</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,664</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1,945</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Research and development credit</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>505</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>353</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Stock compensation</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>227</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>792</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Accrued expenses</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>90</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>59</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>180</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>298</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Total deferred tax asset</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>13,382</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>15,654</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Valuation allowance</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(13,382</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(15,654</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Net deferred tax asset</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">$</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The following is reconciliation between the United States
federal statutory rate and the effective tax rate, computed by
dividing each item by that year&#146;s pre-tax loss:
</DIV>

<CENTER>
<TABLE width="100%" align="center" cellspacing="0" cellpadding="0" border="0" style="font-size: 10pt; margin-top: 6pt; ">

<TR style="font-size: 1pt;">
    <TD width="72%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt;">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2002</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2003</B></TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap><B>2004</B></TD><TD></TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="center" nowrap style="border-top: 1pt solid #000000;">&nbsp;</TD><TD></TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Federal statutory rate</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>34.0</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>34.0</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>34.0</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    State taxes</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>8.0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6.2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>6.2</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Research and development credit</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>3.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>1.0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2.4</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Valuation allowance</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(42.0</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(41.3</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(38.0</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Gift of stock from shareholder to employee</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(2.7</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Other</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>(.4</TD>
    <TD align="left" valign="bottom" nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>.2</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 1pt solid #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

<TR valign="bottom" bgcolor="#CCEEFF">
    <TD align="left" valign="top">
    <DIV style="margin-left: 10px; text-indent: -10px">
    Effective tax rate</DIV>
    </TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="bottom">&nbsp;</TD>
    <TD align="right" valign="bottom" nowrap>&#151;</TD>
    <TD align="left" valign="bottom" nowrap>%</TD>
</TR>

<TR valign="bottom" style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left" style="border-top: 3pt double #000000;">&nbsp;</TD>
    <TD>&nbsp;</TD>

</TR>

</TABLE>
</CENTER>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>14.</B></TD>
    <TD>
    <B>Agreements</B></TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>University of Kentucky Research Foundation</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
University of Kentucky Research Foundation, or UKRF, has granted
CDS exclusive, worldwide rights to make, use, sell and
sublicense products using certain United States and related
foreign patents. CDS is required to pay royalties at various
percentages of net sales or net royalties it receives on sales
of products utilizing technology covered by patents licensed
from UKRF. Under these agreements, CDS recorded royalty expenses
totaling $82,000, $66,000 and $60,000 for the fiscal years ended
December&nbsp;31, 2002, 2003 and 2004, respectively, and $44,000
and $37,000 for the nine months ended September&nbsp;30, 2004
and 2005, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
An officer previously conducted research at the University of
Kentucky, and pursuant to agreements between him and UKRF, a
portion of the royalties paid to UKRF by CDS were paid to the
officer as subroyalties as follows: $7,000, $7,000 and $8,000
for the years ended December&nbsp;31, 2002, 2003 and 2004,
respectively, and $5,000 and $2,000 for the nine months ended
September&nbsp;30, 2004 and 2005, respectively.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Strategic Collaborations-related party</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In 1992, CDS entered into a license and development agreement
with Chiron Vision Corporation with respect to CDS&#146; first
commercialized product, <I>Vitrasert</I>. Bausch&nbsp;&#38; Lomb
acquired Chiron Vision in 1997.
</DIV>

<P align="center" style="font-size: 10pt;">G-22

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
Under the terms of the agreement, Bausch&nbsp;&#38; Lomb
acquired exclusive worldwide rights to make, use and sell
<I>Vitrasert </I>and other products utilizing certain licensed
patents for the treatment of conditions of the eye, for which
CDS receives royalty payments on worldwide net sales. Royalty
payments earned from Bausch&nbsp;&#38; Lomb were $168,000,
$132,000 and $120,000 for the years ended December&nbsp;31,
2002, 2003 and 2004, respectively, and $89,000 and $74,000 for
the nine months ended September&nbsp;30, 2004 and 2005,
respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In 1999, CDS and Bausch&nbsp;&#38; Lomb entered into a license
and development agreement with respect to treatment of
conditions of the eye. CDS granted Bausch&nbsp;&#38; Lomb an
exclusive, worldwide license to make, use and sell products for
treatment of the eye based on CDS&#146; patents and other
technology. Bausch&nbsp;&#38; Lomb agreed to fund the joint
development costs of CDS and Bausch&nbsp;&#38; Lomb related to
products for the treatment of DME, posterior uveitis and wet
age-related macular degeneration based on agreed-upon research
and development plans and budgets, and pay CDS license and
license maintenance fees and milestone payments and royalties
based on net sales of licensed products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The amounts of license fees and collaborative research and
development payments received and milestone payments earned from
Bausch&nbsp;&#38; Lomb under the agreement that have been
recognized as revenue, were $20.9&nbsp;million,
$10.9&nbsp;million and $3.0&nbsp;million for the years ended
December&nbsp;31, 2002, 2003 and 2004, respectively, and were
$0&nbsp;million and $6.5&nbsp;million for the nine months ended
September&nbsp;30, 2004 and 2005, respectively. Revenues
reflected through December 31, 2003 reflect the completion of
the contract. The costs incurred under the agreement with
Bausch&nbsp;&#38; Lomb were $15.6&nbsp;million and
$9.1&nbsp;million for the years ended December&nbsp;31, 2002 and
2003, respectively.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In June 2003, Bausch&nbsp;&#38; Lomb informed CDS that all
future research and development related to the licensed
ophthalmic technology would be undertaken directly by
Bausch&nbsp;&#38; Lomb. Bausch&nbsp;&#38; Lomb and CDS amended
the 1992 and 1999 agreements effective December&nbsp;9, 2003.
Under the amended agreement, CDS granted Bausch&nbsp;&#38; Lomb
a worldwide, exclusive license to certain of CDS technologies to
make and sell Vitrasert and CDS first generation products,
including the Retisert device, for the treatment, prevention and
diagnosis of any disease, disorder or condition of the human
eye. CDS also granted Bausch&nbsp;&#38; Lomb a non-exclusive
license to these technologies to make and sell certain other
products for the delivery of specified active ingredients, using
specified delivery systems, methods of delivery and anchoring
methods, to be used in specified locations for specified
indications. Bausch&nbsp;&#38; Lomb agreed to pay CDS royalties
based on net sales for licensed products and to make milestone
payments for certain events for certain licensed products.
Bausch&nbsp;&#38; Lomb may terminate this agreement without
cause, in its entirety or with respect to Vitrasert or any
non-exclusively licensed product, on 90&nbsp;days&#146; written
notice. In the event Bausch&nbsp;&#38; Lomb terminates the
agreement in its entirety, Bausch&nbsp;&#38; Lomb&#146;s license
to the CDS technologies will terminate. In the event
Bausch&nbsp;&#38; Lomb terminates the agreement with respect to
Vitrasert or a non-exclusively licensed product
Bausch&nbsp;&#38; Lomb will lose the right to rely upon
CDS&#146; intellectual property to make and sell the relevant
product. During the period from January to June 2003,
Bausch&nbsp;&#38; Lomb advanced CDS $9.8&nbsp;million of
research and development funding, which became subject to
repayment pursuant to the amended agreement. CDS&#146;
obligation to Bausch&nbsp;&#38; Lomb was settled as follows:
$4.0&nbsp;million was repaid in cash in 2003; $3.0&nbsp;million
in 2004 and $2.8&nbsp;million in the nine months ended
June&nbsp;30, 2005 were settled in lieu of
Bausch&nbsp;&#38;&nbsp;Lomb making milestone and royalty
payments due to CDS. The total milestones earned in the nine
months ended September&nbsp;30, 2005 were $3.5&nbsp;million, of
which $2.8&nbsp;million was used to settle remaining balance of
the advance and the remaining $700,000 was paid to CDS in cash.
Bausch&nbsp;&#38;&nbsp;Lomb also granted CDS an option on or
before September&nbsp;30, 2004 to acquire all of the
600,000&nbsp;shares of CDS stock owned by Bausch&nbsp;&#38;
Lomb, which was not exercised.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The sum of total license fees received, milestone payments
earned and research and development payments received and
expected to be received under the 1999 agreement at
December&nbsp;31, 2003 was
</DIV>

<P align="center" style="font-size: 10pt;">G-23

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
$53.3&nbsp;million which CDS recognized through
December&nbsp;31, 2003, reflecting its estimate that through
that date CDS had incurred 100% of the total costs it expected
to incur under the 1999 agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In June 2005, CDS received $3,000,000 from Bausch &#38; Lomb as
an advance payment in lieu of $6,250,000 of royalties that
otherwise would be payable to CDS. Under the terms of the
related agreement the royalty advance will be reduced as
follows: Bausch&nbsp;&#38; Lomb will retain 50% of the first
$3,000,000 of royalties or $1,500,000 and 100% of the next
$4,750,000 of royalties. Since this advance is non refundable,
other than as an offset to future royalties receivable by CDS
and there are no future performance obligations by CDS, the
$3.0&nbsp;million has been reflected as Royalty Revenue in the
nine months ended September&nbsp;30, 2005.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD></TD>
    <TD>
    <B><I>Strategic Collaborations-other</I></B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In February 2005, CDS granted Alimera Sciences a world-wide
exclusive right to use certain CDS technologies to make and
sell, for the treatment and prevention of eye diseases (except
uveitis) in humans, products that have a drug core within a
polymer layer and are approved or designed to be approved to
deliver only specified compounds by a direct delivery method to
the posterior portion of the eye. In addition, CDS granted to
Alimera Sciences a worldwide exclusive right to use certain CDS
technologies to treat DME by delivering a compound or
formulation by a direct delivery method other than through
specified incisions and which are not exclusively licensed to
Bausch&nbsp;&#38; Lomb. CDS and Alimera Sciences each pays
co-development costs, and will share in profits. Alimera
Sciences paid a licensing fee upon the signing of the agreement
and a milestone payment, which aggregate $1,500,000, $750,000 of
which was received in 2004 and the balance of which was received
in the nine months ended September&nbsp;30, 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Under the terms of the agreement, CDS is responsible for the pre
clinical work, the manufacturing of clinical trial material and
the technology transfer to the commercial scale manufacturer.
The license fee and milestones are being accounted for as a
single unit of accounting and are being recognized as revenues
over the period of CDS&#146; required performance under the
agreement. During the period ended September&nbsp;30, 2005, CDS
recognized $176,000 of revenue in connection with this agreement.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>15.</B></TD>
    <TD>
    <B>Government Research Grants</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Prior to fiscal 2002, CDS received federal government research
grants primarily to research and to evaluate certain ophthalmic
products. No grant revenues were reported for the years ended
December&nbsp;31, 2002, 2003 and 2004 or for the nine months
ended September&nbsp;30, 2005.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Reimbursement under government grants is available only for
approved costs, which must be substantiated in accordance with
government record-keeping requirements and are subject to
government review and audit. Government grant recipients are
also required to submit various reports and certifications. As a
result of an internal compliance review in fiscal year 2002, CDS
determined that it had some deficiencies in grant administration
including claims for expense reimbursements that did not satisfy
government requirements and overdue reports. CDS disclosed these
deficiencies to the government, repaid amounts owed and filed
the overdue reports. Grant recipients are subject to government
review and audit, which may result in refunds or penalties such
as restrictions or prohibitions on eligibility for future
grants. CDS does not believe that its deficiencies in grant
administration will have any material adverse effect on it or
its financial position.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>16.</B></TD>
    <TD>
    <B>Related Party</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS is a party to a 2003 license and development agreement with
Bausch&nbsp;&#38; Lomb described in Note&nbsp;14.
Bausch&nbsp;&#38; Lomb is a stockholder of CDS, and its Chief
Financial Officer is a member of CDS&#146;s Board of Directors.
CDS recognized total revenue from Bausch&nbsp;&#38; Lomb of
$21.0&nbsp;million, $11.1&nbsp;million
</DIV>

<P align="center" style="font-size: 10pt;">G-24

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV align="center" style="font-size: 10pt;">
<B>CONTROL DELIVERY SYSTEMS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
<B>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS&nbsp;&#151;&nbsp;(Continued)</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>(Information as of September&nbsp;30, 2005 and for the nine
months ended</B>
</DIV>

<DIV align="center" style="font-size: 10pt;">
<B>September&nbsp;30, 2004 and 2005 is Condensed and
Unaudited)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">
and $3.1&nbsp;million for the years ended December&nbsp;31,
2002, 2003 and 2004, respectively, and $89,000 and
$3.6&nbsp;million for the nine months ended September&nbsp;30,
2004 and 2005, respectively. CDS had accounts receivable due
from Bausch&nbsp;&#38; Lomb of $25,000, $31,000 and $59,000 at
December&nbsp;31, 2003 and 2004 and September&nbsp;30, 2005
respectively. As of December&nbsp;31, 2004, CDS had a payable to
Bausch&nbsp;&#38; Lomb of $2.8&nbsp;million (Note&nbsp;14).
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>17.</B></TD>
    <TD>
    <B>Employee Benefit Plans</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Effective January&nbsp;1, 2001, CDS established a savings plan
for its employees, designed to be qualified under
section&nbsp;401(k) of the Internal Revenue Code. Eligible
employees are permitted to contribute to the 401(k) plan through
payroll deduction, subject to statutory and plan limits. CDS
matches 100% of the employee contributions up to 5% of each
employee&#146;s qualified compensation. Contributions to the
plan provided by CDS were $276,000, $212,000 and $86,000 for
the years ended December&nbsp;31, 2002, 2003 and 2004,
respectively, and $77,000, and $41,000 for the nine months ended
September&nbsp;30, 2004 and 2005, respectively.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>18.</B></TD>
    <TD>
    <B>Restructuring</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In June 2003 Bausch &#38; Lomb informed CDS that all future
research and development related to the licensed ophthalmic
technology would be undertaken directly by Bausch and Lomb. As a
result of this decision CDS significantly reduced its workforce.
The reduction in the CDS workforce is considered an exit
activity and the costs of terminating these employees including
severance pay and payment of terminated employees&#146; medical
insurance premiums are considered one-time termination costs
under SFAS No.&nbsp;146 <I>Accounting for Costs Associated with
Exit or Disposal Activities.</I> These one-time termination
costs related to the 2003 restructuring aggregated $407,000 and
were all incurred in, and paid in 2003. $249,000 is included in
research and development expenses and $158,000 is included in
general and administrative expenses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
In August 2004 CDS further reduced its workforce as a result of
decreased cash resources. The costs of terminating these
employees including severance pay and payment of terminated
employees&#146; medical insurance premiums are considered
one-time termination premiums. These costs related to the 2004
restructuring aggregated $46,000 and were all incurred and paid
in 2004. $22,000 is included in research and development
expenses and $24,000 is included in general and administrative
expenses.
</DIV>

<DIV style="margin-top: 12pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;"></DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt;">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top">
    <TD><B>19.</B></TD>
    <TD>
    <B>Subsequent Event</B></TD>
</TR>

</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 0; margin-right: 0; margin-bottom: 0; color: #000000; background: #ffffff;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CDS entered into an Agreement and Plan of Merger as of
October&nbsp;3, 2005 with pSivida Limited, an Australian
corporation, and its wholly owned subsidiary, pursuant to which
pSivida will acquire CDS through a merger of its subsidiary into
CDS. Upon consummation of the merger, each share of CDS
preferred and common stock will be converted into the right to
receive an aggregate of approximately 16&nbsp;million pSivida
American Depositary Receipts, or ADSs. Based on the CDS
capitalization as of October&nbsp;31, 2005, each share of CDS
Series&nbsp;A preferred stock will be converted into the right
to receive 11.79&nbsp;ADSs and each share of CDS common stock
will be converted into the right to receive approximately
3.52&nbsp;ADSs. Consummation of the merger is subject to various
closing conditions. Until the proposed merger is closed or the
merger agreement is terminated, CDS has agreed to operate its
business generally in the ordinary course and to comply with
various covenants.
</DIV>

<P align="center" style="font-size: 10pt;">G-25
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>y15751y1497402.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y15751y1497402.gif
M1TE&.#EA&0)[`>8``!D9&>GIZ7EY>41$1'Q\?.[N[C4U-7Y^?B$A(8"`@#$Q
M,?+R\D)"0H*"@OGY^82$A/7U]8>'AXB(B(R,C):6EI"0D(J*BBTM+924E(Z.
MCD!`0)*2DIJ:FIV=G24E)9B8F/[^_BDI*3X^/IZ>GLS,S*BHJ*&AH:2DI,;&
MQM#0T,C(R,[.SJZNKK*RLJNKJZ*BHM34U,#`P+"PL,K*RJ:FIM;6UKZ^OKBX
MN+R\O,/#P\+"PK2TM-+2TK:VMCP\/*RLK-C8V!45%=O;V[JZNM[>WCHZ.MS<
MW.'AX>+BX@L+"QP<'.7EY?S\_#@X.!X>'N?GYQ$1$5Y>7F1D9%U=76)B8EQ<
M7&-C8V5E95I:6EM;6UE965A86%=75V=G9VAH:%965E5556EI:6IJ:E145%-3
M4U)24E%146MK:U!04$]/3VQL;$Y.3DQ,3$U-36UM;4M+2TI*2FYN;F]O;TE)
M24A(2'!P<$='1W%Q<7)R<D9&1G-S<W5U=5]?7V%A86!@8&9F9B'Y!```````
M+``````9`GL!``?_@&AK;&QM:8-OB6UH9&5HAVUM;&ED7V-I;&MH:&5F9F5K
MAFAF8U^F8)UD7%]@8)YEF&]KI&-E961H;7!T=+*;D&MC6EI<GF!?6UA96*B5
MIF.A95]:657655A:M62?7-FM7]Y87*66C5]8REJND&E@7%M?L(S(6LK+6ZMD
MJL-;6UK__`%D98H+&%59HE0!@ZE-&7ODP`T#B&7*E"UC2BFSI,4/%3Y;6IE)
M`X>--'M8XKW#$H5/RY?:RG"98N6*%#Y8PED"LZ5*RRI9B&W),H5/'S]3QG$K
MT]-/'X7*JO#IXH7*E&I1HDS)VN=/F#]]DE)+Z-**%S5JSISQ(D5*&#5>__SX
M],/'(A\_43"B2Y=E&4`M43SVL684:10J4L(.F^+'Z1\Q:,6<41.GCIHP7:Y8
M\?BG2Q?)?[R(<5,GCALQF;N\/9VXCY4P9[I8H4+;-94^7<ZX.=WE#Q6G4D)+
M=F,:[1G,HL^(\:*YK>JT76Y;><JGYA\I2+=2"4/<C1P\>_3<46-E2A4_7=2X
M.7/]3YP]`O#4^:ZGCAC,?;K"]A(FC!<OGD'F!ES3]2&%&'+L5D<=Q.FQ!QYJ
M2!;&%5=X,0@<<Y3$!H9S^%++(X@LXLQ(H]A"1D9II/%**:N,P8T9K614!ABU
MP#(+C1F-,1(;<V0X"8B&O,,%%YV,X8U/%XTAI/]!MR!S3S;9?-'(B?\,N8^2
M52KIXCECI62)(&BPR(HG1@H$93HA.3D.%V/]DPXK\;!"!AA85*$%&8,X!`\7
M5^[))C%:2"D,4"%I85Y.&9DQR!JJ*!/2,?;@DTXV1#+%!V)6Y!6.06R2Y=(X
M0P46A9<'F8%05D!)%=@?OKG4DDL6^2%%9G+E0TU6AWFAW'*)6?&9%WP`1%05
MC.&U#CJ!A84F%U50L5D4?5SAV4=.^1%43_EM=05FP8D1AQP$1GO=;%14".!;
M<L@1QUH5JO%='1-ZA587C3667V-2G+5;&-CY845GGIWQ[7S?PL7JK[I*.!J!
M5LQVE[0`9EK4%7'H8?'_'O`)H$<<4FC%QQ6CL>=KQ0+L$<=H>D"(V6]24'C%
M'Q3VYD4<>-R1X'K]J?>M'//1=\=N;OA'U1L8\D(T'7;0P4:8'T9"R"RJ;-%(
MB;8<4PN)I!STB"0I,L+3*E*.HF2,^^2"H2\@4M*(C8P,95%.K5@]C3_5A+0/
M-R?R%)2.D:R11BDT7ID1%T1=!90V=YMBB9']@`./.O?8N8H6V`Q3YU]2W^)-
M%E*GT<8:/`'D(D^V$E,.FUM-`1`\^803$BRFLDG.+:$;Y&*.MC#K[T=5Q`,V
M2T:U3`7G1+7$>4$&(3.L3WW\-H6!;?W&ATM`7?K;\4I2'AC$?S3,QWDM6Y$%
M_YS_$$57[Q55V`5VU'^,G8'>RA$&%5`9M,54?P3+6%@?AX':;V;!C%RF0(70
MP"PWD5F?O.JP,?7<(65GP$M1;G,O7XDF.OY*F,P$IBXYW,$^B=D.=^I0L[0,
M:$)M28RLS"6;`KI!#P+0&`QCJ`<UA#!?_F/.M@26,C&$)@[K`E"OI",%<H',
M@SR[@Q+!I1;B3$8YWEF0:6"S'*+!(1%$LX,=X-`&,UC"#&UX0R'6H`F9=.X0
MFIC%F,)8B%'$8@YT@`,<TE`&)>E$1_1H$8T4A<5%=*)K@M"%&-<PHSUUXA5S
MLA6EQI"+,KZ#&E)K@Q9+0HMM!(YRQ*H&-E9QD!;-J/].S'"$-%@7J6H0@TUV
M"L<]@D(D-(!!DZ$<!>&PD0\W66,<I>B)J[ZWIG]$*E"I>(>./%$)3M*($_O0
MG8&L=2TX/:\M_)%"4I"4*J#T91D^T8JLI/`1RI6K-_332CJ@A91QX(AP?MB6
M%ZYCD670Y";,,-+CI((7YL'F,C8YF&<VTP<Q?/`,'3O>-*A`G#]<I"+*^%BK
M<.,_>O6E#__Y"L0`=(7:0)0RW\I8'>AU&`H5T2G.\FAP!'8:MGCE,[HY&5AP
M`YGWX&%=:F&+%5KV%.!XYC/O*9EE2),R.<BF)J,)&L0"I)ROL.H_8O"A39JG
M3NQXQ7^C*4V"[A-4H?&'-''_B(Q_O*`++K*!:!D2$1D\MZ%,D)&,GE@#%LW*
M";/EP0YS^-Q7=T&'#OF-3*98BBK7\2(00<T16XM$&!.1"179(A2?,U4]5D<.
MS_F-CM/(`I'>H$59F*H4MC##(\8@D%48)&^!:U*=B)0B4OC#'^&PAR6FD9-$
M)H-SJ!@4DD*"I2YI[U53X!/JD'(>*O2N?$$9R$'JR(H<+8EU@QM*=6:*D[_`
M(R%."2!VM/*2:C5F>LV;CJQ859YW3.%`<0A#'_A2)ZWXQ1_>N%1ZU-"%\9XR
M"\L<'Y9\<I?\N*9"]SG@:,`5AO+PX0\"8TL?ZJ*5[\IA8U1(1U*RD$Y:5>=7
MY3G,_V/6=3"8<7,P6O@O6F@6PSW(X3KKS,R`HPNPEYUA/I?YS6VV%3+?.*M<
M9W@@N)+:O9=UCR[/VU9N[D!#,;0L-,>I:+E>N(<[W,>HGN$/<V[S!\JDA3D`
MQJ>Y`,0?=X'+RA#LC&0B=!_^!"Q%*2*C)!;1-$+($8L8NB*'ZFI96+#!#@/(
M0QSE^%4XBM$0(_&C(XRD#AV=]1!A0L4COCI&,3OML8/(A!>'U+HU%N(0D,4(
M)GK41=".0A"*]L36-$&*J9'B3_(@)AA4*SA/*PD6=?0&,6A$N.F91[@K8246
M[C*;O%1BUK]YU35O21!.VC$@_8#'0+!4)Z,,."6G]$96+/\2A8_B"C'.H@ZM
M-7,4"[+E(E^HPFN"U@??O;8:%K'&!"NDEC_@A7/)@-91`H6.<LWF7N*ZCFN\
MXAWV6NL\-OXQA68:AHK5X0\*N0I\J>(;K8",6P.V@C_CD!D;VV1XWL`-?Q#D
M(/N,YBL?H74*I4/NM5B!UKJB3&PTXZR9569=RSEJPQ-SJ7P!F69U\,)1$-,]
M<H5!#@(@0'P,%K/)^#`Q8;A#S2SCO_7(YBS%^19X],"SC!GY@#D48D3/<-G,
M>@[/N4@$AK28M#S(68X<ZA`=Q_H&K_="L*&PXB`Q41)&[`,=RV#'F.FHI$9<
M_7-H!X:F%S7*?`SI2V..1!K0@`S_1B)V[/L`)"+>(`DS3^(6FDU1)="[..5Q
MSA:VV+2F+TLZ5HR:6)*+DN;2<9!L^RLLE>("M&ZC%6(MFZ^<I<@PB%445R6%
M'!DYQI`HU\O=/X^W"8E"4+*@7GE/RBBWJ1Z+'=J3;][DE"AAB6VVV3#:T*8Q
M"RZ*:ZQ@I_2M<ZG:B?8$'[,R.R4DNUY12\Y,XT$Q7`$O6?%5]P8#7Z_<9S-4
MB#'#&_89_UQ!(<W6&=?1!=T15>RE8M*R/O2C?=%"4<XB+]^R'O>A&@=6'Q'B
M'["Q%F]!88^Q'%?@&A=T%`:R&9S1;WN@<S5$4>UB&FOQ!R_487AP&O^#&VJ`
M!Q<30QV6_S%[P!X4`C,`<T!4X05S8@YN5F@\`D=VX'5REC17-%=TYD=J!4=<
M=`N`-0APE"$=,@F5H"/2$"7<@`FS4$=[5%J8E@B:L`FW@`NYL#1S,B3J8!"!
M1$:<\">N0$:#%V9X9G>$-0N:14PZ`F:*A3S*@RI2LP^1-WA><PK/D$BTU`K^
MT`S)D!.FHDL*\06;,`8LP7JO`BOC@`RNYVJK-RLK@S@GXB**\C=L$CD3]!'+
M\`VJ4`71$AU5P`HS,3V_I6VC(0;ED8FTP0?HI@Q\X0>AD1JR41=0PA@$YAHM
M\WY9(2M*!A9;01?81RP%Q$W"UVH@!3+>`40VXQWBX0;^54`*&/\%Q#!P:>$;
M9A$T]".,W2%3""1E!-=D->-^LZ(>_^,2V:@:6\4?`@-$"_*/,Y2"TB)RN@(>
M'D8S+_5^]\4^+U875(!4=8`Q]M$?J0$9Z:(>#`0?.A>#/G0;4J`&#Y0Q'98R
M-0-0,]4;LS$K2<4<P5%'-0)&3Z@+O)"$;\5X%_(&L?"$G``*;Y`A[I`/)X(G
M;4`'<68'.%E,C/0).O$%>>9(J.!8F3=W,Y(/+SEWB01N=E*'*E()8S$[8`0)
MGQ,FI@!&G_,%^!`13VE8:4@[*]$25V$0S;`EJ?9WG7`+1D(4G4@V,@%*-3)J
M:-((=XDK7,$[?2$5TR,8KN*,<$$%4E/_"L/`E(.'#J='/=""$Z@%.[HS4U,@
M)=+`&,)G#P2D9)ER?@/VEFYC31#5&]?!<D%Q#+#X<"&U;[31,#96<-FT#'U1
M$2]&%Y137QFD!G7P07@@!Z,!'WK@!:MR'+*A*5L0!5>@'CHT4YE2)TW&@DGE
M'1_$&YE!&T&'!_$2!B04!S+7&(CQ,F^1%L?A/[I!'$OG("6C!V[P@2!S&9V!
M<P00'O"!!R/G/."C7=,3'%JF'$C%%J)(0J4!1'*P!P>@<U+D?@4T&96Q(%.U
MDD\1+5^!%\)HCS+S.2K"1R41"6\PDUS'16Y$"&C455U4"FAP-EX4#C0R#VS`
M"W$E#2$1>6'R_XA@H@E&(@\-<6F`UBA1(B./4%I`>DW%D"=[^6KP$&J:)38X
M0I9FH#W68@F.4%IIZ&FI5@WI,!&,]B?#X)6FTH7GP4O#]0B1E07#95J$H@\\
MH0S;`Q:I$AAU(157H0S:P1P@H3SF(5GH\$S@YR:!4@IX1`8L<5W:H"3,<A<*
MP3RST1C+(*>-$7!W(4'60QLOD10IT1-FX073,5,5)9T6%3Z+:DYMBF_Z^('7
ME6,;N"!J`&`G*`!AX(SIXJ#?(Q7/F2#X]"SF8:%`XQU`,T7]P4WDUQYB$)SQ
M"4!4(3/](1E)EE2P\4`UHRYW$%[X-U058H,6XR#UP1H')8P255/O%O\<F1$<
M-M$NP<D@:D$9,U0R1585'M&I^"4TS_)@;`%_`=1E8M`C<V!6=I@+<Z!%7P=7
MB/95=\A&B]`*>")&G*!IFQ"4C_`&A*<,8V6'9)`/8/`(8J,3L"!&E'`[CV0/
MZ]!YGE<+B&HY3+D&'1(F()L245)<<8,*H&"BHV8\Y+"%\U`.AC<+C$,Y%F$X
MM.=JQ3!X5-@3N)(4D!D)95`G63D23&$-=9.&=-(_[J<Z8[$Z%GL,I@`8M[<%
MS_,;3_$\OB(;=.$7CWEJGV0]Y<18AN)J9/$4=>,V@>&I#Y<=DPHKA7D-U?"0
M[Q<\*@1_WU,\XH0XCIE-;N$&\J&+BEH=;<'_'>S5!V%@G%41&L:!&2CY+Z11
M,R<C4X.Q%5:@%LMQ+D_T1.L3/8@!&P/"'"<Y&?S2%C#3J9WQ%3/S07!153<1
M&+.R/BQ&&22$!\.IBQ>A!?DW8V!Q*7<!H-KE+/6X(.MQ!NFR&S"D<QHC<X'A
M!PGU&AXW/<Y';?GQ+ZFA%EX'5X:`>69`64J8(;PP1NW0"8BELQF!!D13"%@D
M"WJ#$74T%,RPAEUT"DT:-:(#"I%`"SK1>:I0%*A2!<7P"(I%E6G`>"I"$*?E
M#\`H.MP0A?L:L2F1/,2@*##B2:%PHTI;&.'F$]>'!:=8BH#!MG<B"*%@!JJ&
MIJ4U2]9P)R[R!:L"_QK!`C89\2*91TR*:"B8DA^(\1\=`Q"A\BE#<@Q8D$X4
MLH"Y.23BUHK7\*7U`#Z_PDT#Y!33HQ4407M9`<(=]8%!D0W5T(IH(BCEE1]9
M\9$VR#%W41=UD6,5-05_8#''VC)!&*"HH2L1>C)=UC'6D)K](BZ>D8&HP4T/
M@YX2-9`#@D$&\A&!07.^X@9*M!QJ$1L=8Q[_A;HU\1G>T;SU6A1_X$%9Y7[5
MYRM?@1U207/]!A?<X2##B0<"L*`"X%,]Z,=1T+ENX*[6N[H6%AH4U6]G,`!P
MQ45;>0EPD(1U531)PP:F<C=3$T:$=`P)BT4]4E>@0SF!`FRL$+/A*Q(-V_^G
M!JPU)6%8B3,[V69LM[$%8/0TC$,D<EA')V(.MP9Z&*$H=$6BQ?0.`6&)A'3$
MIC@*9JD0T#4J\<!9ET*]-8*HQ'<;1NL)#DT[+JI9>YD-5SL3,[?$"A$HX,!(
MH\"T^R`D0T%\`]82-/=_?#(C#'8;=ELGT4(A7[L5Y)B*^)`,I12H45LNZU0@
M=('&1B%\Z7`-Y@$46W$I%$*]OB32;NLEZ'1?W7,>NG*]>VI-<_$4?\`@5^`2
MS1,<'R>,/M<;JH$:PN%#U/$OTV476?TRJJD9M*:/`)(9_08N'?/(OT&W6>$>
M2K0;"<(<(ZTM7S%@0$8<$0(S,<,=2I066]4;_3C_(7)1'5J6J^!I,20$'WM0
M!VNQQP[:9`;S&:RZ84&C&WE,,W(`5WU$1^XKH[*P(<CL$%A+(Z@01GK"#:Z]
M(44S!Z##.@6!6C+2!F+7OENI-]90SU^U"$.J6*[`PA71/'ZP!8VD(I'X.F+(
MVJ[POWI#*:6=!_M*"T/BF-G`2.Z@.%B;$5S;>K=4LY^@M05M1V8)PJUE7#BR
M$P>Q$MHP7&;I%%EQ3>`&C,OP66.3BD)M'KA2+_5BP."-;P5B%=3`!RV#'=7@
M$?13.1>L28QQ&_&D/>6R5``^8&U\?8OJ3O8R<X,!U#;E&V)17B&U/O;B+'3!
M2W4"7?6B<+G<!\M0J3`^_VOJ8\71)BNPT5[WA9*'B:$83IXLU^)VG%3J<1J#
MH;C1L^%5(`6Z\4$\PR#\(HW_\H'$XAX'RAY'`3(1.A_I>9V5H43BF9+/R:JH
M,7/K11KJDE3O@3%%%AMA+<DV""X\5C+R0=F:C3$]<D5WUG@*:RI9AS3,K"5D
M8@:$YD6X(-O)/&?,++XSLA-:@@9SD`=PT-&?0`KHL$DZH@A_UNACE:)J`@9<
M,R,H$2CQ?%I2`D:R0%RHA08\LD64L"<T4@^S,X3%A0P"D=^#PTE+P5E!,0VK
MQA/%HA`8D4NSXY*/^$A>0K(GK!"XQRQ#O6Q;VA/9M!4#)FZ$H>);P5?8F.)I
M._]KKC%>Q_UQK.0ZT&(=7Q$%JZ!+#REBF%P;3J%C82'5J]<PU]4712&=,X4=
MX1:-\R;$#I/BM<JWUG@8GT$OPG(8B4$\Y<E/ML$8,W,:RSJ!#6-$B3%-=>MJ
M:ST:HUP51#&;SY(J_O(<`S(9I_&!WV3BMNK9]9K&P*E$-5-2_P&<T1HTW)0>
M,T1TU/8O;:T:7G%@X8&YRY$S#\1T:'&""UIDXADM;A!#>3Y&LOTY,H&PGG,V
M*L)VC!=&8J=9NLUU6,C`FX"D+M*PQP0'<3:%I?()H_8Z"\ROY$QV-DDU8))+
M]Q"H=_DV4@)F9#0CK1"SU^V7<&E'L0XV<;.4G$3HT>S_HL;U)\3"5Z_HM'Z7
M#/4,T:=P)+14Z[.6%(R$B<0R/;"BJ,W3X,2;F[>"$],0&+EUEYP?QGXW#02,
M36U<.:_5;*JQ&_2")N>G&S*7$K!X%-/S&)P:U/3UKA?&.[<L8LW8Q=95'=["
M7KU11,Z3$`\)'1)S*=PE%@R6&.;'X"-6+E+@$UWP'4[.Q_X7,U,4%M/+^3N=
M3OZ#&=>A&5V,?/6"?`4$($DU'$$T@;Z!%`VV/K4*"'Y7:G5Z>G5U>'=Q:F)>
M9W**<6YQ9UUB<GL"`G5G9Y-G8F*-75=74G]A;G*59V&OKW%U<6)_77%[!`0"
M>G)J77U68GH"='1L:VEK;'-T_V]I9%]@8&-H;&_8:VUO='9SS<9P;6S,>=[?
M;VO)9>QK;VUD8V5I;VC2:&UV><=D7%]DRLQ\V3+&S+(V:1*:*6,FX1HXR-"8
M,8-O3;\L6+1HP;B%VA@N5:)$F8*%(!EK;-"0(0.&#$4V;01BR:+%W\HQT[AL
MX3)MX)<Q9,K@'),&F1DP6VIZS(EE"LDO%*,-U))T"Q8L/,NP;!GO8Y4I7ZM@
M@6J&2Q0^4[C$TZFE2LBS?OKT\4/%#T8^?M!BW5*%#Y^Q6.A&J;DE"Y^Z6+D`
M!<-%R\@L52`[%1F%+A4^5>0.JH5Y"M4L?2"%\3.6B^2K??[\H>)VBE^_=*5(
M,47%J?^54IU?T[7B9TJ4*W'PN.F2RLL?*7[$3I$BQHV;,%VD]*%B9?85*B.G
MT.TS)4N4N7E%6CD>V8J:.W+JW''C)8R8,%Z\=`F3R,T5N5*L\*D<3'681E:(
MY(<55%#!'7]6F'*%%0S^(5\89ZR"AR)WW*'&'P$ZQ<<577116Q;+X:+)'L_%
M80@>C*Q2!RN1X"''BW?H@8<8E]RQAXR&K!>&*5)0X>`K&,[G!2%R>#%=&'?@
ML<<>*ZJA!G12(*F''71`M`P<<,SQ!CD2L6/&.-=<,X<^YMBA3Y5PO#&'.<;,
MP48:$VD%T!I'G33.45]`]88W;93!A5K*]+/3G#`EDP8:^,#_N=`8>5:##$A1
M5*$%8SM!A<886N`%5A5;D/$0''0*-4U0:93Q!619=,J04`/Q--`6'2WD$IQ>
MFL%2GF6T02=C6H"EUD1!?:1%2:_RM!A%B`H4EE-:R`.&=Z2M-`VC&FF'UTAG
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M9CKS1IIIS@'1FPM]>0TV61ICIC<0;6/,EM?0&2>L7+54432P$H5-GZ:W@<;`
M[WZ!!CT0'3K[I6!\,5-&8RQ#1A8%1L'%0@,1Y3I2[S([1AN?N\[JM*?NKM:J
M.`4EU+!?:)7GEW0R"M2?8.`#4QI(9?23NM/T*FF>L$K#6!FST_G%1C,1--$6
MWTX!1C)QEL'8%'+)"V3<U9I(424SO5$,%L:5$2R$)&5@@=5,`$B=E#GL+'P0
M!BNZX)ERN?]E),3BPA0NX04KD"0I;M'"_/+GF[B@13M-DT*D,'*5JTVG#_OI
MSE6B\`=/W&<D>&&0I("W("EXP49WN%L7,..',R31"[WI`W&ZYB,,@:LC8`A,
M`/E@Q/2LR$(URYAL2H&==_'028Y8C8"FTX4SC.P4D'A.AQQQM"X0(DEQB,/;
MU-"PRES!B2C*6,HNIJ0]Q,$6>?1$<'HQ,EDLK@YAF-EQ;I&D6>3L%:(HH1%#
M<;*@X0TY5)C/>\BHL$>X,1)PZ`8Z=*6K9&BC2[DR1I7(H8YMU&YV66HE.=J@
M*VC0#RA!0<,:T)"[/,V)EVA@R#C*L!&W#"\-62J52Y*)*=_0)'S_,!E#%0RD
MA:`(BBCC@P9?.&4&9J1IF''*G4Y*8CZ@#*4,VCA4/"@RAJ2$3R6-H0I5?H*/
M+?FI57^21F-<,P63@$1@'0&*_ZR2$:I4XW?5J<*<)#(1KWQK)&YQ"PV_0[2W
M9*$EAL&A6(;UE7AIZEV'(9`?NK:M_82RA(.AB@1K^)D-+8@/A,E,P4"C']?D
M\%L)ND^J`M:LA>#O,ACYTP*I\!\Q7*%KD)'B'_C@G3Y(1V&?P)L8I,`I/\2!
M%UY`2]8\%(6L>4$*GOG3%GZCFAX=3CU)1%$D>W2T^^1P)E2PF=.Z4)U3]/!%
MC0B#'N5PLS-,51"C<-+65&,S&LG'"U";_Q`M,*2P,+"M#AG+6'7Z94FU`9:O
M<6'.S=PPLC`@YS!&A(XI'O&DDZ4".I?QD7P:BQRKTFQ(=;A<Z%1BO7@$A2*Q
MS$,>0"6G@JQC'N.`DSO`X28S%`8+U4`G1>6DC%K229AK\)-&=B(/=0A%H5KI
M51:@XHYTK,MJ+JDG1JH!IF=@:BP&,910INF_@'[!'Z-B5$NVH<MZY--]`PE)
M0S-"!OY&(W>PHDKZOC)>=H"$)CQIS$ZL8LT(KFM#4_U'Y<R`DX&`B"8.G`F(
MRWH9>WEF&MJ92Z2N\A;?$*B@F9*-@2BCG2A@Y"TK]L?`=H>1D*9L4O7T0P^=
M*A>DIKA`#"I0%?^HL0779($H95AKRDH2#=!((4).?0U31V:%O@250;+!H5ZX
MP`<U[`$/1NK/4ZO@!YI=P<:0B4*4W&C8/TZ"M&ZPA)B!2B"'38$*C\"D>UYA
M'`AA,D*S<.-S`L2'5'1(-=&16<W>@\GFH&=DKH!0>NYPA@49B*GI"76>7:$W
M#JW-%5A^JL&HDQ\'B7)'!')U==JXM4$_-2[3N8(;]*".=3#*)H="UBL?XB9B
M[B1W)Z%H&A#"DB^=27*OXQTTV8"LA"@#&ULRE.@6PBH)\P0,JUJ43G["AGW,
M(0U640NBGE70>4S$&I?BR4WD\3SXD2]/T@C63XHI.X0T)!U?<$M):)+_E/U\
M)C*R@\EW<?+@?Y#!*JG*9TW<UY;NQ'D_X<&+7*S`G4EI!2ELX4B":>I`'U7,
M@>_J"UY>^*T*^J8N0XW9<3#C0(ZFJC`9Q8J'SV(O![JE(P/[C1@J%`;]#%40
M?#M%UYHU!N"MIIME45D?/KJ6/__!$0<:1'KB<`7;=.@Z>0D+P<]X!KH&;X`+
M6\U*-5,S4E.'1[-9#6:&)44G1<=`1B2M?((F'S"CXC^`A4XI\F+$C"%9"H_^
MNLSJZH4\.OY%Z='#'LI.%P[M>DE[*-+,VJ,VYVRMC8SPF551<9SQ&.='QN&0
M:C$A'*;156*`QH,`8"*K^:D0#6F"R>H20HZ+_YR0"V4@!TQX^7""0#,<KIL?
M\-L`$8FL1)C,?]P[>@T-AG1I7>U4AC2W<I(US0$>#BU*&[*H0G;<5RT'9@BC
M?B*4C@1S*\C&IWTU;"N7/%PD-(%P4\22E)EH81[)Q`[1T!:<DEYLP6964Q!D
MT"LKU36;\A6[$4!Q41><@CSOXG\9L04#(6)1A1PF=C2UH5'>(5LP=1C@0G<T
M(T,JY!@K!1;>P2U)X10WA$-G$05`EQE7X!YY9"3-$@U\0&OR@1P1URNWX2$?
M918,P@<$\1&!D2"UH1U=@&>=QD2VT",TB!8Y-8%S(5(JQ!=9<S(8AQ='TU?(
MX10=*!U8P!A"1@F9%O\?=.8A"G-WK%8=N#59^8$T\7$<&Y,@Q-$C'-<N@A`A
MSD$)LB!Y>L!'`])XQ*`+`N`&V,%%?Z`X=3`R8B18A7-U;@`XLG$*X_$>[4$)
M[^%$F<=7''<8CS`*=P`V:4)1ZT<&Y68'XJ`KMD)O%JA"V&0FXL`&?J(8^(`E
M;_(\10$3E\)=UO`XR'`HZG`H[(`H<G)?X,8&S7<3+4$/[]`/&J$8"8$4+8$3
MPZ(1O-,0SF=_`34MO;4J()<GI9,[Z3).&3@-22%3_I<]B*(,*A$P)=$2O)(9
M/0)=$I$I1=8;8^%A*Z4;-T155A$9#00B)^1A-.%35M,43+55!L10RV$<O*'_
M<51E=4^55'SA&QI7%U8S+*YA&3(&,6F(/SGH"*7`&P2!%'+F'H_6!U=C,'Z#
M5FWA(RH(<=\Q8P-B"S)#5P-2"CB4%RX$76#`8`P&&1DX,!O"<2`6@]@RAC:F
M$3\828/A+;?A'CKC'*5E.-)A57SC(*.`-_J!=/&1AS/#B1PW'=11%ZEA,X\E
M"L&Q'L!`%UY0")K`"QPT$]_Q!VJ09Y'$&U&(-T\3(WH@!G715Y?@";MV"%NC
M!K[021BB:X:P)&#S#>>4$,($!\(%*K8R%2J4+BLQ$121#]Y0*-S6B[6S*OWT
M)@_'$06&3/)@.?SC32Z1#(Q28.,#+,^G#<YU<07U_Q$=H15J57%IN&SA%"@!
MI1C(,CMP(ISC]G&C8BJ5TA("N!B.\1=$X1!TPA<7Z`^P8A5R%C?_!R<@,9*8
M81*,(6)]81GN,F$35Q@7=7-7T7_O\B=58`5N%#>24C^9833Y`A[5@4,-61(:
M\1T)4H89]4!M21VJ\2]'>3BFA1;Y`RT&8E6V$#<@TH)``Q]/M2%]EW&4`50<
MLQ^5<33M,56M$1+=<5]*J92-`2*1P6;M,E3KY!N5840-@Q&_`1])<S`*<W5J
M@S,WLR-VV0@<,A]JLU6A!6GS\1^A4$)KMS%XAPH,,QWM`9<9TA^)DPAG<!DB
M!1FA]![W,07",#(V(PN$=?\?43()CH4)FH`'G19&1],<K\`VAF@(W<`F5:(F
M9E)LJ$,Z\D`/DH,0R_4-WS<.AL)\WU<YQ>@ZJ(,1&K90!"$^PY1,C%%@:;*+
MN0-NVG"IR[8&3;<QT3$8[1,4VQBC8V&IR.F:/@%,#+%LQ#0P^S2;['"KHODE
M<,**6C`=47!/X+B`^G)P8@&1'0<_];41$?<G-B&<H.%RS<(0T>`J63`@O7&!
M5Z%CBH$I0A9)R=$7.)1D*C89E;>1L((1&N$8&Z<?$)@<<-$U.7H<I+$N,:,?
MU1)$CI8<&;0@(Q$,I.%E3YHQQ)%D249SCC$;4_=!*W6F83!U(M84N#8Q"A,@
M;#;_%]315PP2IOHX1HT0-R)114[Z5#N)>.[A"<TQ"7\P(&[$5R@J"[_P>B:#
M"83%LODQ';PA9`W"(U<'"R;49.,A'73Q'ZN1=N#B&B!;6X\@'UEU!OK!'&U#
M+^-Q'GK`'I!@(1T"F92P(LX!"@/0M6;2M<9@#NFP**,R$?2@2N]@2YB)#<AP
M)<:@B[>I*\0$3,%D$<^"<-RC$%I1$-S`!EG48^.U!IB92G/P.IGR(SO:/HDR
M3*:R$=)@J]@%#<LY;M*@?J:!%;!Z%/*&$_"#FPKU<%:EA./F3?,C#;IS&.12
M&=VA0O&`%$HQ@`@W#_X3&*>`4^%S*/4T82'1@$ZQ*53!_YP"H3+L"B(?LS0<
M)Q*>T10R-W4,)1E^T;LBD3!`:V,[$72R8:]KE1U_<B\<X@@9HC)45;$S&C,=
M$A]\)8--(W?%2C$:YX!^`%E;!19`=!NND#%_=#>3"6F0=C-CTS4QDZ7-L2)%
MMX56=08"[(=ZHPJ5\`B^T",]9%K8T0>-MZ8&4C$KQ1POLE6V!79'@PH<YP=1
M<C;/X2`EU!<]%%9],1\]0D*<B!^WD7IAV1R68""1V#;#,1ON$1]?0P`'0`!G
MA@<K<C9R\!Y.X@6;LR5TL`]84B6\A$[594NY)[?+IB;?D!*QJB9PH!*F8VVD
M<CGI8"H?Q@7"I(R_Q;<`!QEA(?\[X/"G:\`8;#8;=J%@\-0YPR0L:D4ZP%)-
M8#&LV3H-(68LEGMLZ`B.`P%N]708\$H2UNDE['88,87&*503Z?(G`*%-B'$2
M`I$I!E)0GK(K[\B7(^&N*Q4I8O$/('$M_`<\YT$U/=6B>9*?,V>&VF&MB4%A
MY(LA:4&ZF3(>H)4=5?`3`_4MIX`=0X2N-1=$M.$7([$1;SDRT6$7L-(7J%`7
M+Q0E?+5&B)=)MG`&;>,(S7$A8\280YR8M`8=EN4BOU"*C:9'O\`AC1`?;#B6
MT-%)UY$R@O"71=<Q_P/"3?6A"J."VR1C-M9$DG<'-++*TM$%&Z09/E-6MJ`*
M+WLT8GG_5F!ZEWBS6HIS(YU`'*>`>')```GP`!'0`#Z<1(F`'G,SM<*7#.:D
M2UEB)=HP?&\R.\Q6$$7ABU&F0N7$!@.X!?!T#;H"C<W'#IB"<&/L/_16$*Z#
M*34H*<^8)9*3;1S&%Y'B*H-ZC)Y<$S&:*@S7A*@0ICJD0/R7;\)I/L4$7(VA
M%NOB'6<A%S8X#=;79)11$DDQ0/OAU!_!G&#P9_/:84UV+6,!/RIQ7W5]0M`;
M+U?D+;)!<P#31/B+&1>X;[U:,PV=HR\&%<0)HF0J/,ZB$?DI6(25LF)AG<^B
MS.]BB["C$4*V&AOC!Y,R%7\V)$]BD6^M!4Q5=B.*DYTQ(`F"_R$7?`9T0R.0
MP$=H854+XW:'LS41K,!KBC!GA"&W\9=.U;U00PNO@#(WY".C8'B_W`_:(3,#
M6R!C6`7BHE(D,05_(,2A,#<SLC#!40=.=3+^BPHG^R3A+`>F%:YJ8`A#'"%X
M.B'P/;"(APL'T``-D`"[D",K@@<@30!Z\&[5%4]"80VX>%U-3"=VTB?L5Q3O
MP&Z_+$Q%O06XITI8\L69>BG#LC_(H!7AAKM-YJM:'3[:T$MMH"74QBO6^7R\
MM1+S$Y`[5A/-I#(+4Z.2HA@702RY4W'=L80*N(&VV$P0R'&<HH&33(!:S3X^
M1M[]-V$H)U/7R!<WI"_HYTZV)Y)SQ_\71],;<D8<HOLGCE$<5`!B&.&.H-$>
M:%6MR>S3],@%?7"R[.':TN`8W?&#<\FTUP047R!G5)`8AMR1WZ$U,B0(5-"2
MXL(<4MK:6('>;P06=>6!5G%1(!R",;,*,YR#'L(I%?<QG*0*6T7>@?'0_*DA
MU6%C`#0;K.%`%X,>]5N"AM,>\0$=I$&$'*(:'$)G&4-5WK(@B<Q%DF;`+H(W
M$5(AH_8D?J4:$UT*8K`X5',RW+P)LY`>0.P<>%1:MD`)(T(,`G`CA&59!$#2
M>M"YZD`19`P09C)]RY!MO%<[ON4.67R>)%$0]=0L;Y`'7>LFNC*`D\*,JO,,
M#K'2\>8MKAW_GC7A$MSV$-WP#$A-$<AB*]2`\/_P7AMA0+VB,-<Z$^H6J-\V
M/PPV\;)"YLR*?0Y$%V@!0OY`V#KV\6Z\4N2-%*V1/RW1X^G*0W$S&4O>*-0B
MO.#"$VO5(Y$R'K4A#;HK<]#\+D!G&'7EL&6E']JY;&GP!7V0B8##!]+`ES3W
M@ZMP2#IWNA[\&!&V3:;0+X2S&E\]5'?A(#U[*B#4%W^$F"/YCV(AHT`3-P,2
M=QPL&T0S$WQPEVXSB$P[%BCDR]I11VN6<@EE*U5PE[Y`:8+?VTF3-6+`&\Q1
M6J=H(E/C(7YA5AC"<BO50S@#-8O@)(V0"$,,'\1Q>#DX-YEG'&JP_SC>_I=W
MTS<3[!R4!B&KP!Z-.6H00@PD8A#G%(`;QCSB8"A8G+;-P/"U-`[&IA%@T!#]
ML#\#/P!YX";*B!25ZA!8@A`)L0WOH)D?]P^N^YW;[Q+<$`Z7J@[)M!;RQAB_
MPA*F`0A145AC9%M1?%A;6UI;7V1E9)!D7%]@8%];7)5<8))D8Y&8FV.86U51
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MM*IH4HJ8.G?.!`2,I[`>.2JGH12C)HP5=X@<R@USIHX``7+"4/'CY<YA+W\N
MAHE))2R>RW4D6CE#LJH:D7?B]*G2YPK<N!!3>AEVQ0K*LEW4`,:8L\T;.G38
ME-E$!LV:-V_@M%F+A@UR.G.@T['S9DT;.&_8>$=3IHP9Y^%QD?$.1_H:ZFO+
MIYG_?`X;ZFCFIXG_9*;^'#AKX,+%+^]L00888ZS!!AS(W9=&&VV4`<:`UCQR
MX'K4@2%-+_F-84TA$XXQQC+&!,C%(IM4@LDEI;`X(8H('H@%,$!IL@48^:W!
M5BV0?"$-%;PT@E`SNQEDB#157)*%4GUDH84T3C*4A31^6/%8-%^4X2$W]511
MA1:<R'/7;GE5">0@FV3QDSU<+.E.']1X.<4\OH7A!1_77*.(%O/\X<6?4G`#
MVQUJ:*24GW#]R9@;$>T$&C7!6$'%.ZI0`R9M<?KQ!V5N8&3775?$Y,X45L2A
MAQYXJ&'%5GY<L9(K3RH4!4Y8>:&&&RIQ!-04?.3#4JMNR"&0'&?\L9,4_UF4
MTF:K7MC9!65=E-9L/0V%-(P:=V061AR%7:5&''5%H<L5PXAFUDM7-$N999C]
MX:05;L16EAA%Z22%%Y81((`:FWE!$EEA?*O'97>F"]H5Z<;51:A26"E%H*6=
M,;`;"'?1WG9L<-'*%VO`\1\<;)#7QG8DMS<''=T9)]YS`:+1!AMO_)>&).?=
M0F)_"L+\1AO>K?P>&N1A\B07:\R1QP`#O)&&&63X^`Z8M:1QG'WDW4++DZYD
M>6`9;+R\!B4(&;BTB.>5=\PO6Y2]!4).NG)C&4"/8>-6U532W'(*:57)%X64
MU_0B"&K1:JA!KLV03XG\8E,5OBCDI(V,)*20'_^KM#(E%^7]`Y(4XBXBXA8-
M;1J3'[TB/%$ENEC!RRMB4KY*%-Q<L:L?#;/2BB)M"A-&;F6%!NY875A!.A6.
M+NQH2L^,Z@H?#4^$1:]6KC0X*\QO6\=5T1(?:$<<=2$'JF$DLB2<KH^:BA0+
MCS.,\+79^^P5I/>Z4[J-@604-%L=>E1O"#=LFQIEN<ON0F*5.-B)7@1A#%GZ
ML!55;,0*]$)*/JA`#XN\!@][B(,5&L&';8TE76X`X&ZV=9D]9$9B`M`#`,_@
M&0$D(`%XH%^QX.278AV+'E8R6&<$4(>XJ&$.0)P#&KZ@B`3!P0YY2`Z$%`3$
MG:W!.SV+CGB,`S*FF>'_9?LQ`WW*H`U[](.)V=D/)-+P'N^8(1L)J4891F:'
M.4R':6.XAB8HQ`6I_4<YL0#:<J:T!?-@8HU`%(\9NO(*,W2-.EI$`Q<0@85^
M&.)V]VA%'Q>T!B)."153T$*6<!&K+#CB1`-:A"5&H04^_*8W4;@1$6W"*R#Y
M:FY3V@HL1#&@:RQ.E4_:0B$6>1*-*(,+A?!1E1Z#B(T03R^^*";CGN<;2;'$
ME(*A`I@:P@J$L&(359""&HRRFX?!!&'1"XI+HJ"5:$`E71+TY";X=!9$"*(/
M,%E%'_[0$T&8<B!J<!7Z9#<E5;SC"MNT"^6`0KL_>4%UO@'-O6YE$BMX82!'
M_X'+'Q)AC;RU"B8(9`<BB$>9LL#D89MBJ.SN\I&`W`$/F?D(2'97IEYMYA59
M\((>ZJ`9I01*"F%P3!?J@(<P"`*"X,K)[D#BJ3^8"E6$.56V!K:'/0B``'<8
MH1=<)2TQ/"LG5K(@KKI@JCILTPTO:T\:)H2C!=EA`,@!&<]<QC,SE,=E"\).
M>,(SLP/UXQ92@\X8%J=)0_Y':6VYT<NZ=I]2K.U+L5A0U]QZ($;L[1Y&!!E;
MFN.Q-6@)F&34TGI.9I\UT`(6SY$.><HPLU*>#D'(L(;0&EFT.:2!"]98)Q]!
M<0I(+H(AE*O&*$$W3YW@CV]@8`0C9O4PO9RH(=[PDO^!@-8T2V0#3"#*DW/E
M`:0J[,T1$\K;XGZ%,'$AY!USVN@P?*D-BW0A"LN04JQ8D1#)C,8=E(M?G*3A
M3BV$@K91Z$*G&F.%+^%V(@VQT@2%1SER:<1)S4B)E1Y:!R^0,Q7B2H7JF$<F
M"\JE"WX:JO>:&@>$G0$/>K@#K@*5A2_`EB4MJ8T;9OH'FU#N7E95Z4[$$,*4
MN&HC\$3)2$HBO%E]9#9\2%?P2HP%,5S&#4"Y0AB>0<\JR2&%KQD)N*9*SW15
M)5I_<`,&\8`K6\D!@U#VH&#^9#]NTBLS5MCI3*U*+Q%WZ@Q:9`,0=00T]@S`
M#G)M@Q7'4PKSO,$.>,[.S]S_^D?OC(P.<,C%*\8@->Q$*+B>+(/'0";:'36B
M$&E@`V'9DHE/:N(1WY&L?-)ZG_-@44MI8%`8W[I$/8J(/&U2)]\NJS439^D]
MAE`&T-!0"A"MK1&7F*Y"-!D*"6E#*UDXQS).M`@^_60V#"$7%:@T!5@<J!"T
M0(@F@QO;3Y]8&2*2AW4SP;:M1%LPPML(9`9ZEV@Q#G3.Z"\Z)(FU'VU*)<J@
M"8XI&*5=-.41I<`"%5A#$JS,)G7."W*T2)</RGT$?YN8@JT$(YP]W,$QD0J*
MEY*-$XC0!2GHRPFY"+@'/9P!)F&00U,O_IA&I(Z"Z2[5'O#@+JB,`RYSL6K`
MA#7"_[QP1!BZ4;`[T@R_)754)U/P0QP(0(#4A&4LC*G#4?#`]!2BBB#&&IT4
M3)41"`[GH$"ON![*LKO=762;<A`QC:D2$6QQ>:H?)I2PQ&">-MB!`7G8V2VJ
M@YRY!@ANQFD#*/CV!J3EH;/TT<_+8H8=-A@"%M\Y681.X4ECJ!HZT[FL*-<(
M'0:]@=/+6-LC2`NA-[ILK@":CW&^-@;TB(<Z3QQK)Y:AE@#U>D5N'=%NE1N*
M"9D!#D?+CAL53T7Q:+KTT%F0=#(-H#&<YQ.8(")'U,T1*]RJO[."AI<:*2&&
M!*41H@3EA!)BWS)\(1751F,F-R%P4QG0FRYQW5EJXP<M(/^C5T!Y=T*<=(E3
MX(2_55`(E)`*Z?('4;`L^F`34Y(041`:<I$2,>$*\]0D1(0^CX%C]R(8W@`U
M$E<',R40('9Q(R<[?.!)NN`G!C4;4^`GCT$%7H`1-E9!:J`',^<&FB$(N_`0
MC<$Y?>`&)7<&\N0,K($1C?$11`%UVY0K`X<5#A,HOK$PJ^""H$%C?W`%=Z`O
MA((M4[$'!)```H!!!'```D`56"<I"?@6P.,[R(,P0Q4&GI$9!@02W%('(U$5
M`T$<E5$4K_&"3D45N-(/;'`T`P`>(<-\#O(R/!,S=@`':!!<'$,'`Y!$G:4R
M,*-I,$.(0]0)F18>;4$YW]`/F0;_(6MA"+S""E_`1D#4>'!D"HZ`;<VQ:^_A
M5D"C1;&8#0:B('\W:[E0#5F`.=^A-!(R(5_@5FA4"7*4('T'!PP@`CZ@`0S`
M`)$HB$AS9T?TC-.(-`S@C"*PC7=V-$F$9])A?I'3$.1"$E?P4S<5$UJ`7V?Q
M)=A%;BXG+I8@#8E@">)F;E%!@PT&,7"2#T&Q#2L!)C6!8K!R#;TX(E70!2?E
M!=\P(B?&![:B!EV02:@@"'-".HC@)W:A/#."4U=0;5N`$YPS)SB1=G<B"-:$
M$G(`+K=2%;AA50^C#QOU$<\P")SA&*A0@`C3+!CV4'ZX9$"Q$=Z#4HZQ=0*0
M0>E#02CQ_QIG$#S"<"O;=(03Q1EB8!8-L1-5F"[ZU!L`(75NF$(C<2I.E0`6
M$`$$X%3ZHD+ITTZM-#^!DF4]5(5"B!$[](6ILC`,-A774Q6,TF:`47)I]U1Z
M$(>>(#7M@7GL`5AKY#%&$XEPD`:VA@9_AAQ)%!Y=0T7+-Q^:UHB=4!UMX"&^
M,05\(X"?D`VT(2GH57B'QY@HTP:\MDZ.L`Q\(POYT5P((H#(P"NI1%HS`UM;
MH3A>`DP=$R$FIB*00)OY(35GM8P:<&<G@T1Y(%K]P3.Q:&I.U`;/"8D#`(W7
M^(P:X(S0"(V+N`;A4"4'1B7S%!%\H`EJ0D&L`'Y=P1$VH0^*(/\Y-[(%P3`\
MI1$L<1`\/49.P"`N`.D.K=`()^(5V,0+]KA3=W`%]A5K%0E!*WD%_K40^\!Q
MO1$-F%,&^/F"0+@(4H`K)<@'^E44@7(2T?-1(_<G]`014]6$5'5O[>`7FJ$0
M[M`K84"#%.,1SG)P4_(6@'$&)Q$'8X@4TE9]#S->&X$^PS!Q"P<3CV&>]`0D
MO70L$(0'4J<&>&!`K`&&#R`!"6!Q-'@'#143O$)0>"$\ND`O0JHZPB`01/%4
M8"E!^L53PN*!IU(8G7('374J1]D8VZ0BYZ%%$!(S]B$+=H1$2(,R0Q0+J99$
M="")*_,=>/9H:A$>R^&+GI4%I6$0D:#_>PAB8O@@/%JP!D>#:(K('8VX"*PZ
M1WSCJ,N1)[)%.P>V27*CFZXP(UHQC.0A>H5P16>%-(`&:-+('8&%(ZNZ%:IT
M(M901+(I">5!"[^*"VG01!`R!\NXC=S8'89F(DMB&V)`+0XQ#`G8%*1B+#@T
M"&O3BS0!*N"T3S(9%)X4.5[B.E#*)FUB#HM`._6'"?D5KIZD#7/2"E-P!=\C
M!Q3Z)#-R%JY0!:4Q.FGS6M97%5ZP%=87!MZ@*1=A%VDF&EQYHSO!"ZU"3W`2
M#!J)/D;1&\Y@56R)$'V@!D^%!UXP?SO17RCB?P$3$?J5*H^AE?Z("$1G#V("
M$\WB*B6[I+MC_U6;4;,.-1">$1B4$1=V\I4)T`!-)Q)800VM$A,>Z4I:*0AA
ML8-`$G8H9'$V:!;SE+/H<QJH\2?84G(_6!IW(`",`#4E,@=(!"#L`40>@QW9
MP6LN4XUHA6C24:AG90?*T0E7Q`:X,(Q=PT6($(#O$4?V5VQ:(C@,5`9S<&?=
M\6=YUXA/`B:6,""6D$?F5V^N<)5ZH4FQ0(H:9Q.",`AW91X>`QUWYXS1"2!Z
MU#3V5`Y)9R4"YA!+]BP203I^(#%B`"=I-@P]48*H4VVG1P?/R)W9^)V#V(AJ
MTAON(`5QD2L<04Z:XEL[X0<PM7X"YR?!@PC4D+HHN3>P%60(-0PK8?\3P;`*
M"'%,:`(ZT]=*E7,-+UMRX;,V2B$[DS,_)]$'NI0%87`]6.$.+G@N=1(12JFE
M6-$PFW$7@3*?0,)>S,,;#V%V7@`7CE%=U\`9IX$'Q0)S&0PKR>:"28L;"[<I
MS]`\TW`2Z)4)M`%C$X463U(JJ%+!@.(7-&BV.6$1X&(L8G`:8A@'N_$87D(%
M.?41,'D65S`0*H$36T80_,,83:6'H[$9BF$H7N!4>Z`J3^D94J<14J`'!,"L
M"/$%F1:I=#`=W[$=A:LSI=9H@DBX9?0=2.-&;%$&4*1G_:%I7W,B@KPS@14*
MZ/&81*1+AV99U=%&DZ=:S&4)?:,ERG(/QJC_$,KP"6XU(#;JGDYB7W`PC<XX
MQX-E>ZM$)5Z`PKQ`!6K@5$>9A00@`0UP&02@!XRQ.P\P`@T0+[&A!P=P`+P\
M,&HP=#2I#ZU@#&1T'(9',I5D?XNTS.VH$!@,)V?R"KQ2#<Q3A2LA*QH'._9[
M(IE@2AI1):[2$7`B",FF"N&D#*!#.;:B$E_"J:R13ZF4!<LK!;Q27$]H@%A@
M!1[H!GD!O.>B9"EA)VQ(%!DA#!]!9F41&7"B%<PC*>/P,!]W=AXE3CE&8W*1
M%ZX$3S2$*()!%U5)#W[B*A!D@R(+/\*U)%E6$DWB)"=B!7.;0H)A%57)O3QG
M+]:#*WZB<D>9&?`#_SN#41?%!<]A`&)84<4"T`!6R\M^DB_[0G!'(1&PHQ';
MT%7LH!0!`4!R"=4.20JI=D=K,3)W=A^1=Q]U9KAXIC1NM;AX&R&0L"#7"AX\
MTVIP`S-I,"*MMW>GC+A:`FJ?=R)CH%B@1P;3H2/'*0JN*,C3T5RTR!8K\@50
ML0I<@`;/.0#.R+G'$-GXB1>5T51_4`5_T(434`$2<`![\!<30`$1T%1G*1CT
MU``G(`!40,Q[<``84`&7D0$<$`%JX`=A\%09Q"UZ$#Y(*BZ)G0?9.+AO4`;C
MP[#?Y1*[$@W6L*Y/'"BIA-D8O`HVU6/^-0WOT+MSX@[-RH`$J!-X(B8`E?\M
MIZTF`?->](L^7,T\0/(2>E$%,J4'Q``JHJ)-C+(;Y;*20IH/(U=2.0$DSF`H
MP9$K#`>EH8$4T2.%\YMF2EN"4_`0N_%QZH)S"$5/02'++*85L/.?5YHJ_IS9
M+NB!%@<2`U,'_KP-^J"4%S$6],1"ET$H(9UEE['<WC`C8[)B&409IU&UQBP0
M=;`'"?```E`9)313HS'6^$(H`A6V<CAW%[&*7X2W<Q`@4A-\]R%G]@%[,X,S
M+W,,GA!G(8,):0!H__%78EZ)Y*$@,_,(3,,WU5JIF6I('E(-M4<>QWF),U,>
MD2`?[`&.K-<<:_$BDX`Y1R2(0B3(K]4K[J`+)TK_``TP4P+P``F@06>0`!D0
M`0E``$P<!;>P.UIP1-ZQG=!H!E2P!@-0!@*:$UKP!P>`RPEP`)PNAFPL`1(@
M`#GU/\S;!_9'6FS01HCFFBL2.=.@"I-B#??`-YB]"_7H(]G\3/3P,!2E%6*2
M2J&J;9>0#N=#P+J:"O[B!E:0;`S:E*[T<][PSL";?]J0<AU&.\5.02F'*[WA
M&VZ7$>^P"T#"$J6A.NB+,,(!0!8<;]4`%?K`+-]RV@/-&/#C8O$"=<'3;B"!
M/#&AKE/0U'K@!N0K#AN_4,+"#C81HBL90DA1)4U>!U>0NE.2='@1*G[RMB87
M&G1H*CTNT%WA$&L78FG'_V6F8G$7<1I,5\9SJR\K9Q0YU69804$.01+/PH5G
MN9)D-!]`8QV"EA]'M(@[`S/V(2&M-R(KX@DBTC=YQ>9KL!W909VR^&?3W7K3
MX8B2("+-\8O+<8MMP4?WY:@PPZADXU:`UQYZ_4:)SC1P4S0H4WC0>$=<@#X<
MX0:Z_``SAZ4'\`(C<)1=6`?.YP51'@6)C30:4`1-L)U%8``&4`0^4`1%L(VP
MWP2MWYS?Z0--D`=LH065P2B<4P5B\``;\`"&(:>7(0!8P0ZZQ&C/.:QZ1A/"
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MU)$C@("`.W'T_?ISR%"8C5["Z"%P@,`>`6;6O('#)DT;.&_:K%G39B8=.C1U
MLC&C)0N7,5_&D`'3;`L9-&F@LJ$S)XT9-&W8Y$1#9DS_&3-ET+"!LZ;,&+%H
ML$3)0L;F&C)?VK8I<PKK7&;,OG#Y8B;-S#=KT)CM6^8+F)AMS.CE`H:,F:M0
MX>1A(&+`'#ASQRC=8N4.GCAZ$EAX@$$&!0+Y)I38X(F?F<I;M`S0H&'`@#QT
MYG[9<DU*EY1J]-214F7+&#-CCJ:QPV``Y2(#J+Z9[2-/GY9JQ`AH(*%"@P,'
M]*C!X^:*^3Y8N)B9XWP`G#1?6"GL8L4/0BI1M*CM\\XH%C\&5:$%4JE8004?
M4SR2117$]#'%7EQ$<44[4TRQB2YB7(%@@E4,PX>`7$`S$4'ZU!&+%K&!D\L@
M7?B!8A544)'%%U5($<8?46!Q_TV,Q9CG11<*:5A%)*M(@<N!`FH1CB<.UM.%
M&B&%(45^6OAQA1172F&C%\:`9J(N<N!1QSYN4&,?,;F(84X68VA11127`"E&
MAFZ>H8<`>OS")8)OXN*%&W6H(046:A%SS)R(>H%)'\0@<D\71JYUC2C;)//'
M%0;Z%L8A7IS1A8-::&$%:'=X)D<G9RPB)B%[M+2'&VJX<8:B?0P2AAH6P3K1
M2P(TUE,;:)C1!E!L%*L5'7:P`2Q87RQH7%A1P47&&F.],1:RF.T4+%W-'&93
M3F:0\50:9$Q!Q11ET)''&V1L\458:$#UQAQSE&76%X:502T;VJ*Q1AH`D^'F
M%F&!D?_*AU]@->]LM=F1QEY8R#+&%G_@(8``!TR@L0`/E-"!`*GLH<<7#.0Q
MEAUM;.$%+R\U8$$%,&/`P0@==/"""2>4X$())W"P0049:*RQ!`3PHL<9!D51
MQ1AYB.!#$]!--D`97(3Q`)X')-!`!`\08%$[75!11<)SV)$''%_4PQ^"4?P!
M9#]4=-&%-_KY8>`4Z,1F(=MP1E)%GXS&G8T8M_ASJ16,"C.%)GQD450Z87C&
MD*=BE./(@E$@9,R5^#'HX%&B=K.6?HS/0\4AUJ"S8!_X=(.?X^GT(<4??#S#
MQQ4IM;/A0VJ<(884\OBF97`:C4*.%_>H*:6?V8RTEA]=D*3_Y2'G&BS&'AXQ
MXO85/;KSAQP4Q>('2?708G2>H,SI8SOV%&YWJL#H<B/WLLMMA3`QXKU%%J/J
M<><>L,@':"YVAU1=K`Y>T,4OS'.&B-1!("(KQSCVL`<M\(4K^"H#3JJE%7J5
M12^[<<9AAH6;LH@%#G/(259V`C#D@.$+1=%"8X15$[@D92FKR$(:;C.4I'RE
M+VR8`QW>`*XR?"4KRA+,5_P%EN1D06E@,(N$Q&8&YC3'-N_A"A9JI88P^,$+
M+R%``RK0`0HT0`UVZP(9!M`&"V6!"GH`#W<J8((6[*`'-[!!#'*@@SV2``8K
M4`$*<K#'0<;`!C?``0YNT`(9]&`'_R7@0,TZL`$)2&`"#;@#E*R0!@WXP`=%
M,(`"FC"`RI#A#P)(P`0P(($()*`C>KB1%_H`AGW-Y&$ZLI(8NOB'V47O?N#P
M0XP`E*2B=*AOH?K/A%JACS-@*@K/()2.)J$TQB4('5/PPD;$X#HK`(DD_%%%
MQ.!AM^E)@1(AX@.6)M0/*]V"0Q5Z!(I2T05]B$%LD%B0/Q#!!TBP8FZ)4R>0
MRB2'%K$N;+)SPTOBL,LX]/*;C+*2&R8:$OI<`2!G.-R9JL"%+(0!>P*H0R]%
MX0K"&4.AK_*"&N[@A<RIY&(N"6!V[N&[&)FG/E;@R*L,U*FYV<=N5SC7-?[P
MHSY<(SAX(/_(*)+Z"X$@T#>^DT(NU#`F-<3J@18360%_<P8U6%!<T>0+3_Z"
MPC>@`0R$.LH/U\`>V]1DK&R(5[R0$I?DX"4]C9'+64-UE*6X:PWOT4Q8P!*6
M-K2!7$R\RAOL0(<UA$M<CTE.J-PD#/6@`IH[%$%EXHJ<+>QE"F>@H/\.T#4"
M1*`"$R!`&*(PAC14850$D``%3,`"&^0`!;A%`0^(`(0:`$$(0``"#%(``R$(
MH08\(,$@<XN"&`SAMCI@9")OP((2Z*P$.-L9!R1I1A-1@0MT\($"+A"""QA`
M`V\H@Q4P)AJ@1:`E"2"`&(H#!C8X!S.H&!\H_F`?>QBB<18Z73__LN#9<4H*
M'3#JI3$\884I8"$I2D'*%A%Q.LZI0DD7#0-^%B?,3BV/#TE97.82D4`C/<*?
M%YU&&+JP2T(4[F_QO,8X!"6@*OQTF/#01"+H\PY[W"H;256#V\30!02-#WSQ
M&X6:U-!@&_MR$);R0AP*B@M#O`-.M<+#'CY#DF/X+H&8^D,=-`*:/2C##V'0
M\L7VH(8$WB)NL?*$Z[Z(,0$H@W79.,.4WH0X>%!!#`/QPC`J9PXM*50/C9!"
M/OAK)>11X:)A(L^<<(4'D'@*IW^HBQE"I(6C]$4FZEH7&L8PPT_;!`YV<,^_
M]D6NJY`K5$D!PPQ)K10RE"$-5$-17-(0_YB^M$E`5R$LP`K3K<>882IL6,I7
MC-BF&,*P0EMXS%/LX$D&P*$,#,("6H?1!>RQY`$5D(!&")``.=C-#0>H``=<
M$`,>`.$(1R`"$8Q@!'G#FP@PX`$,@BN$X<(`!B28`0E(0$@=W!8%.&A!#X;0
M@Q;\@`8_:`$+:/""$[S`NB?(&0U.8`(3C(`#%7BE&V0$!C@PP``A\,`%?/"P
M.)P69C`G@(9(\H7%WB8-EJ#>(U9A!?)52!/\64LJ#)&?S''8J'K[T+.8LI<M
MF$L7OK/J+7(TA41<80KN2D4TZB"&/J!#,ZO(A!5`T;DA:2$*/=]%+5"E*D:<
MRVX'JA4W&A<%X?^]8TB9VX3<P/GH5V2G<IHDJNA6(3_NP7G*<N!O,?RPNB<1
M[J*"YD*-]FX@+V>C=_@IY^FD&C?$DX,^78A#+3"2ITU]Z';9"!,C&(B]/5R=
M"J((4]>'M`G.[P(/7NQ#&"HJ#XR>$\V^4$@S6]-`2X<B)$0V$C&DX"^>I$'6
MK@:89+`(K)N092=`%")@`&98JV`EKL]X%T]0F!BH6*4,[:K$<7;RKS(H*4?B
MDG49BA68W7!!7%[!=3/.TI4O0&)`9!`BT29$LR$"#/`&-&(N]<$'7G`G'-,2
M$3`!$;`'!R(&!#`!'<`".<`#->!;1Q``3Q``2P!O\?:!(F@$_Y9OO@7_2"F0
M`B2@`B3``RF``C:``X.T2#>02#C``A_P`C*`73GC`C;0`AY7`BQP`AUP`B[P
M`R:``4X8-!(@`']0!@S@`Z)T`0I0!&AP#'L0`1AP`A1P!U4@!IJT*6A@&^M"
M!I(@#XO#"K<`(/QA#T$%5%,R37VC;4:$5D8!!KP!)T!G#_F`*W+P.TJC=U=W
M?VGS/07%44IA,+*@=5."(I+H3EQ%"-&C4EIV![0S=L$`(W,C#/TC!\"3('4G
M-Z`P-X?P)+`"*8/0#O<P)5&`#X0SBNJ4$H5@#]5@&`RH$)<25%H0@..S2RLF
M-T8B.%2`(I.0(),`(+-#"`RD97HP418Q95TW_PG'X`4<(0#4L`L7HP9*(V9B
M$BC!4(NH"!`(5`QGP`MUD%'<DR#_,&9X@A%;MA%Z`B2]\PH,T3O=]`=1X1=F
MI3`JA&H#8`<X\0;(,@?*$AA8`0<%J1/^8E@]D1,!J"]3<1O6,A-QM13-H!Z"
MX1CZ]S?W!P86)"Q$%%?)@2^>Q07ZL06G@!<JR05?H1EO4&UY8`<(^063H'MU
MEFX4,`$6(`!4M66A00$E<`,J``-'4``+4``%$`!..8+UA@0C>`1+@`2\]6^!
MI`(K,'`NB`(P.'`QL`,MD(.,U`)ZQ`+>40$48`&R-0(G('$G0`,NP`(OT(,[
MTP$R0P,\,P(4$`':6/\-8$`'13!>!G!>:"`%$<`!$>`%=[`U"1!+4?`%]F4R
M:&`)LM`^1)4ALI,/II=C';(X%0*`$Y,@A%)W1(4\B),FV9`,084+V]-/^((%
M5N`*QP@)%0*:?\,?#^)_J\!.Y/1H/L4']=0(JP`*C%=UW6`/>$``>M!2PS`^
MO1,1SJ0EOX$[W@`@/U4?.O(',\4H#K8@PF0?B?!=B1A1%)8?]!01<M!FTC-D
M4K`X6-(X6>"&B(,X:(=2@Z@/7>0[B!,-TV`QVG@KO(`'8B`,Z5@+A!,CS,0-
M8,)E?^`&=T(`+C%RD!`-&;$'##&@#,%-]1$W0`(:Y,$.$Q(&R@8'N>$O)DK_
M+PQY&1<)%#K1?:>V08=U:RMZ&1EI?E.!&6-!%@'H6881%?;W%7PX()W%%X^1
M!EJA&$P7(D-R"OLS(/="!CV1!T]3&>Q2)9/P!W$@`$1Y`B/@,000![FP!P^P
M`300`S6`!$ZYID[)E$L@;W"Z!$]0E?$&7+U%`C%@@P*W`EY)<#4X!`S'`BW0
M`BX@`X=D`JV$6@EP6A1``1Q@`AN7<1W``3DS`D[(`27P`TA(`:@U`1+P``T@
M`%3`!E9(7B&@`',06@WDA1D0`>^5>%J0!G1@&>YW"5HB98.(.U"B88ZC'_H!
M#D:'!44Q#-?$"BK59O51#[-#5',#3O<PAWCC9/4Q_PPV\F$(4@QKD0YC1W9_
MHR1C9P7IL0KRR0=NXW55<`7KB3AD&`=3,@G$P)U!9@B'\`Z(D`F9<SHRDAQ?
M1!_R0&"$0@QX`SU_$+#>L"#44V$J52I<1Q)4(`W9`0JI,HB8P)U"YITVM@Z_
MLPD*$4X`\E("(%H@X0NQ`@M7D`^_8Q`(P6)Q0!"[=`<45`XKVQ&@*@!G()Z1
M,Q"P$A)=]7B,<B0/FA'[,"O'H`9,008F"BQB439V`!@\`2Q^41-]814Q"BY(
M@09V<+6,E1-6(2ZW%BP>^6OIH116P:2'85>W1EB%(4-9P17QUPPH\A6\H05E
M@$13P0`:(`*UX1YD0`5XT/\)`B`!&U`".6`#+O`"$Z!A=9`!)=!N1+"F2R"G
M((@$:EH`2R`$1H`$<_JXCWMOP04$,W`#.Z`#)-"5,Z`"B-0#-H!;.P"Z<\E(
M+_"H)L`!L[6I&-`!(U`!,C,S/,.I%'!Q/%-&&9`!%;`!C5H!!S`<4V`&#*``
M'N`!"L``;Z$'J[1=%L`2=K8%<!`=:X`*63IE['@IUE`)$,:;PE"^[T":6K!/
M3Z)AV6HNYC$[W-,H[C"M`28+FR!EFA0V5*`E5\(?<-9%5""L3G<Z'.5T.=(L
MCW8>M0(2;V8(\.EUEH"-;D`?P]0ACV8(,2)E8I`%R%%W4H4@D2!,6G)Z<I,)
M-O+_*7:C"A)":10QP0;A!PK5MZ)0!Y6V#Y3")9D03\.P%L\@3#E2%`P(CP)`
M$+S`4L<@$*<"P.4K3!!!09461O$8*ZW2`&%Z4]R()[]P(W]P*8MB(`BA!B_1
MPMT`),B!!D)$%KRFM$-A:\'R&((1$V41$RG:!C`4JWF`AD"!$X%!:K(FDL[0
M(8T3%Y`!%\;1%<Q`D<H"'^D!+\BQD<?A+V@`0]'&''D[`&Q0!G.`MW/P!5=P
M,0>``6X)<33`2J=5`BA0`T)`!%(I@JE<E5;96XT;`*O<E)I;@OA&7"1`73%`
M`BN0`H*D`SK07#'@E3$0`]15`C)`ESESA!E(71K'`1.@_VYN"89JV0%RN9<?
M@%JX*TD@)P%4K`=7,`8#8``74,X70`=^H`</\`!9XY-><P58(*4T809@\$6S
M4A\$%IMX<W^6,`6=IB,,(@P$%AMO(@6$H#25L$6J4'N9<";$=$QK82Z_054,
M=2D)Q&)RPV+2(`=6`#%VXW5N8A__>CJML)JY`BM"`CU78!1HUF:,LHP`TG.#
M,"%;J@??M47O.ST3`B12`B"0H@DL8@R?\C?BD"NSXF@&72J;XALI(3>(X@C5
MU#BQ40]M>+ZYM-,K&P<I$1+(4SGD(7J!%R-]I@8=<3%K1D'4\*!AK`9`@HTP
M-<1+;2`]>SH_Y;'BP;!4\)"HEO\;XY<':>@KB?%"?*$3Z"<L5/$P[K)#S6&3
M*81$H\:U(>(W#M9:34LN0OI"9W$3"$DNSF`82D$CT"06B3PQ7P`'3J,!N1%7
M6#`&#$`'\6&!%K`!-4,!#]`J7S@$*="XFBNY1P`#*)`"1]!O^R:5FAL`M*RY
M1)#*1,`#*#`#*,!(P_S;?(H"`S>X,6!P0U!=)F"$<RFH)U`!;[D#JRL#2#@"
M.&,"/;D!T[R$2`AR$=`=%(`!/Q,T$\#.>W`&49`NXH6%(L`&8`!'"9``X$$`
M;O">8[`&C%4NL^,@AT'/5><(^_,.J\V'S%`4O:H?:H$XZ!#2Y])1UBE@A]`X
M-L9X9W?_.KC0UE=R)8ZRQ7]"PUT@K'670)FP-HLS#^(`C8OP/P6NL:7`/]Q$
M$@O=<YE)"M$PQ`W6<WNGT<DP")XB"[.3=MTP(3>%"[OG3"<>).N049A`3LJ(
M)49E(0ZLDHJ&/%NL?+9:GVZ#"?_0.[+R(V"\9EH-Y-KA$1@*"X"B*[]`P3(M
M#0)!'D;RP=1*C"5Q:(/89WP@+`Q)$SQ!@.X1+F@P$VV0'&,P%HEA1'!<!K'Q
M!6UPQT`A1''UM!T$!Z/V0J'"D@N)&8]!%TF!I$0$&)UE08:!0[73!LG2R&`P
MDYNE&+;6(5_P41VA,0>@2=LQ`2Z0`RD`!)B+;S5P!$AP;_IF_P2])012*;E+
M8-RT3)6O+&\\<-W--01^U($NZ(*'U$?410,TX'&0*@-V1`/JY@(21P/F[=TW
M@P$90`%*6''853,8L,[":TD28`%"8P%<\TJB"`8#T`3DI0`B8`94P!$)8-^!
MPGRV\0;UC!_O(C#^<"XA;`W.($/(@>&^V@SYI"*88@I:8-!<4@Q;K`H(P7@V
MUCB08)I&8A"0`,B`J-7RX$T_LH`?LC>1T#9Q0$$,H;#4P--!Y4W<M//U4-)6
MY6*)4!X(L4N=<"5=0,,KEA(K;0DJ*P<W,C<>:@BO<$]6X@G\!9RN4&+`Y#EP
MB+'$$078F!VCL&)A]B,'LK\.X@>TX/\_<="?6VJ]?7LEW,AF<^A-XT`0LZ1C
MN",K4G53B.`@%O*L&(([GM%%*DX%9F"0J/[H9F,;0Q0O&!DN:T`5]F)$S(8O
MD][8040'0Y$&*)1JMH&0CL44^!)%-C%J^&(8`*D3Y`)#]R=M`J-M090&2H$5
M?CT4DO<@8SAF&\`!&=``>T`?8<"E+4`"R0X$T$X"-F`#N0UOM&R52U``3]!O
M1F#<3OD$S?[*-5!O,"!(O8Q;H\L#,U#,7CD$J3N$UN5P-&,"/X!'+@`('2<L
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M5LI1TY1*%'!/W9Q!)^6/134LU8CQZ(7EE3X4,>K4LV>/FW9\K)S90X#`GCH>
MNXA!VZ5/GRC":HZ5XH?*1[-JCE*QTL6F%3[.K,B3TD5.'3%B]`C0_U,0M!<T
M<P;,64,F#1PZ=`;(IM/&3)HV:VR_H4VFMQDTP,N407.;31LT;>:\`<X&#IPY
M=.S8>;ZZS+0Q7[!Q^9*E"K<Q9M:L22,^#9DQ8\HD9V/&C/76;=JPH9.'#IIL
M7[28_:/G@84*)M!`P0'U$'`""D(088000,#``P\KH'`#"S$`L002`1100`!+
M:!@`$"D($0"'"A)Q(1$UU``$$2C"8`01*9"@0@XWN#`(#C'@H$,.-MP@PPXQ
M3,C"#R[<T(,++K3@XPD95'#"#3'L8`(&&XS@PI`M3$+#"32,T"0%%'C2P`%D
M1O!`7PDDT,`AJLB1Q1H:O**`#W-D(8`%%/]4H@D>?+0Q`!Q<4-&%3W_TX0=E
M?'0SQ4-__!%%-=MP`48P?&11#3YJJ"%%%F!P44P4VB!CZ19;8''.37]88=@5
M;KA!17=]>&5-%GZD)(<<!77Q!V/\\.%82']42DP46=B#!1A?5"'%/ECP,1A'
M!YW$!1]Q%'5'&(=%D5(<7O"A119]\`$/,E*<H887YJJA$#Q_W%&4&E8D5045
M!)U1*!5GT*6''&%00>H51.E!EP"C<7N,/!7EPY$4?=24J44,=W$'8%>(<2M'
M5ZUT14-12!&'P'5PU<5D@J%SA125"J1JK(*E&H8:K89\1ASP?M5'1U[`[%D<
MU1(@0!PA19;&'/7_X=8<'//E,5UMZ9&!QAILL(%&IV,@%]\:;:3Q=-1MO`$'
M:V;(Q\8;QMVVVQQ9IV'&&&3D%U`56Y#A7GM/IT$>>;OE`4<:9:R]Q1=SB."#
M!G/T-ND88%PA0`0<=/`!!QMT(H$$)<P`@X,IS*`""C/B@,*#)(1X!!%'+,&A
MZ0$\L<012"#!.A*D/_'$$0RN"/L1`2!!0@LF<$#!"S(,84,,.72.`XY![G##
M$#?<T((+/["@O`R5E""##3BP,$('1>[`0@O/TX")"11L`&8%#SR0``$'I"(`
M'G>(=D`HJNPA1A5EL&&`!QXT`888#>#>#TRP@0BXH0QZ^\)+Q'`&7=F$_PK;
MX$/#D((9Q'!#"U7(`C>\086720$+YZE&-HKAARE8(QA0$0,[5.6'*^A*'8(R
MB'>J<(XSU`%^ZG(*-##CAS#0+%C\((:DOD4J</`!"]XX2`F?,86_12$,=X@#
M1*@@!<[,[`Q^^`(UG@$W+7@,#Q_30QW$,H\NH"6*?SA&,=2`!S5085%JB&(<
M]:"&*BA0-`*H2\$X<@QH5"8?Z,A(N!KFF'!Y(2IO^0/,+&*3DV'&&7`93!?*
M4I&3-2HG5U!5.!8BJ)UX`2X\.X,;Q``3,;S%,6JH`UV*$C*"8.4HG`D#&^9@
M!Z4I#6GS&8`=V#">,L@-#6886QH0)YS?.*<VNO^A`R[-\[3</,T,8###;NB`
M-N#8K0Q<R"88RL`W9(&!#&5@FVWF8P<ZO"$WW,E"&D10!`;<QY>TPH+B\&2)
M#!!`#PTX@0U0D`(8D&`(RA/>\'R$@AJPR$1(`,**GC`B#7EH"1<:$>Q8=`0C
M7$X(K4-1##)!`0[0`$HQ""D*2(`"D6X.>SHHJ8]:<#SL[4!YWK,!"7(@`Q?T
MP`8`!:B-3E`"&W6``Y!3WP'RV(`&C$8.=8D?^]9'&G65002OD(49]E"!%]@(
M`P=0`Q;@\*<O6"$.8S1EI::0D6>(*U8E+%86OF`X;%3A*5+0@MR0Y0UDJ*,8
MYX#?%:K@AU2)"QF"4MC_3X1!2"_(H8U7.`87MQ`%=#4EDU&P1S=\=8Q"4B$I
MAA$6%KI!#(V@K`H#$8E:KC"%[03#4#/I`EWND,<XB$0<7*D8'MQ0J%BYX0YN
MV%@++S(4N_3!5'H@TVC&6!*.7+9B;@!KR'!FA6$D@V4%85>KQG&8QF2D,7!1
M`T\.51&%+$2"5:2D13+9KCW$P3`)R>0@@=4P+[BA#KB:F!@8%JN3->8/L+&#
M;'QQSJXI4VM:&XY[WC`'7L8GG-*$PW&0`YW^'B?`<LL-&,"0AK&Q@6]R6YL6
ML=9+,)`J.Q/^9H7A<$XTE"$_9,B#"`:0AGMH@0HQDT"`.J`*`1"@`B5`4`IL
M_]"#'ECB1CE0Z0Q45`/<+4&A1,B00S?$.M-M"`E"J`%&B4""%0#!"#R(`0LZ
M4%66HF`%F\M!#F8@H^*1@*1B5L%,G3<$SNG@!CNP@0IBH"05J,!(P\/!$'"P
M`R)][WDG&,$+.B`!@OW%QGG<`\%8@I4[1!&I`O!":>'0A!!<0`-3$``DT&?4
M*J1F#K3HKA\D<IAZ:$."AH*&'[8P',2!`0M6^,D6?N/AMVFA5%&@B$B`V,&-
MV8,//@R#)AD6+V+AJPYG@&`P2@N&+$SF(1:)!A*G8):+_-$-:L"(JC)H#Q(^
MMX3X$,E1B%6%KWS%"HV2@QB#9A%TX<$H$UGM./[P,?^>-+%9$XG#;'\B!3GT
MQ2X5,9>CU9(I=2,Z9'6(@W>AL2S[=LPB28'&9%S8J(.<`8P?L4FF^N600=VD
M,O9ZB!Q&(X9P42%5RQ*4O9X!%Y0/Q@M>L8=`)EY._?K"G.0ICWN*Z<LU4/,U
M=EC.<+`6GS8<DS@6S@W;[(8&,DPC/&JCAJ2R209A`J=M7_BFT[/.3?D`LSBO
M><-PRL`'-[#O%B<`'P>$_8`?P(`(,$#!EM->@KJ[0*8Q4H&58:`"&"!A=B]2
M\H:6@"(CH([P##+\$580.A+<8-`!RD$-8!`C%,Q@!2O@00IF=&84>%[-),6!
M(G2@`ANTH`<Y6',/EH<C,>?_J`?@>^D.`&T"2DS`9Z/1P\3PN*];=4$C/KG#
M`7BB%BT,0`$A,,`<O-``"T3@$/;S`P+A,(9%1=8;XLI"-C'H*Q=.<M3=V(ZI
M&+8%X+@M"VOU,$UV-:Z\*&0FN<;V7K&0F9%505DC"18SAF':(/(A(1"!%^XU
M$B+Q7MPB!9DT$\[P#,>56.<V*!@A+A*T$&1%$%%T!=]"&8+!6C_S$'CD!F5!
M%'@0!EF`.%GP?\E%,QPA!G5P!^=B%N8B,'*D77O0`*!@%'%P!_`#@O)@&`CH
M!WEQ&1-!2HXQ&(O1;ZVD*ZRU!V$@$.^56U20#XQA!6Y`%WB@$#[T7G4P#B<3
M+Y.1_Q14E!`><1AYP13.,0=H^!Q2XQM:TQ["`4Y=,S;ZM4O`1#=K<$YKPP5C
M8'07-G3B@0;8\71M4`;50"K%,@9VTQ[E\8?61!Y9@QP#X`,^,`!OD'-I``94
ML`>D$`$80`,<X!<3<`,\``,KP",W0#X<\"1#T`([8&9G1@()D@(K(`2$9W@%
ML``+(%%$L"*K`P0)TB`&A00UH`(XT`(R(#TX8`,I4`.;9WE5!@,-<F8ID`(H
M,#R>YWDQ@#UR1B,WD%*<4XTYD`)&``0S-2,YPF>$4`@F\`(<4`&@<$^T=0:+
M]A$7=U[-$@9X,%SQ<P93@`8:H`#],P4$,`%@TC@3$`=@(/\;;]!LB'&"530%
MKY8,7?!:)\,P=W5__,!J9H`-U=`=[D`K;\0,S=`8?G!_#@$2CB(1,`%!-/$3
MSP"$[8`%Q(!^W?$5%%$8$_%:570&MT)*Z?"1Y28/![$0#\$1&&$H\/`0AO(0
MZ'(%)<@%W_!5`D`F>@`1MB``8F`,7G!#<K!7MR84C-1(*!E+DU1%CH46`K`F
M[J@'JM(N/R,.N85NA9$,+G0%Z/)[,+8'>.`%EK(1!N$8>N`SYR(&>+`'<G`9
M6]DO5P!I=,1&14$7AWD.N&(1J5)"+5<2L/5N>,!+4',;CP@<N%&'BV@<XA$;
M=,`&UH$>W&0=WZ(%%)8;W.0<O73_'F2P!D@#B&Q#!MKP!6\8FR26&[\A-N/!
M!G%B`!I@'%*#!1VT!P]@`C_P`4:5EB4`BS4P`S724Y7`4\VC",2C`BG``WV'
M!%@&!*-#!$^P9`50BT0@!#PP4KZH(@O2GC:P3Y<7(].(9O6I(A"".:6W3Z!'
M4CJ`4RU0`HU``8^#"3*0`YIG9S"0(I07):?G`HZ``1\0)D8E%H5Y%\V`+W&P
M5XLI%2/G%VJ@:'[``,AG`&P0!@E``2Z@907D!E]`'V;0+(;1%,0R$2$Q%E[1
M<JE"@?5@#]\`#5:P+(H%A$BD09#"#/S0+&W10/$B#Z.6!67A%2P7+X0T$^AG
M#7\@%7Z0_P51<%DE"5JF(0[S<%GP()1>>"@,%$CAX@Z'8J54Y`=:,`;E1D/X
M2#"1UE<3,S)#.I$JT1(E.1G@-J2<X11B$`?ZL`PG2!DCUP"H(`!G<!A],')Z
MP#-RX$`P%VN98FW!0@5U0#!B\#<=]!,M%##<DC-R<`8(^#%G,!"*1AH6485%
MD14O(P#KDW#J0BRQUA&B=!5X>F'(`1S`9)OT,0=J<X<DYC7`:G3+@1W@@1O4
MT!U?T![G809P4#1F`$ZN(1NX9!S0)"G@!$ZVN1R=\@]5,ZP#T`0&P`!MD!YH
M@`5[<``2`"8G\`(1@`<'P`%#H"(YD"4E<`DN(`/@8XP[@",Z0/]F/%`#*U`#
M%Z(BKP-1#*4A2V`$-3!3.4!ZT-B@-<`#)$4"*[*>#AHCTIBP0,",T%AY(54\
M*)`#V?,"'S`!1C6"ZN66G+`!&\`!)=`",;",_N1Y/6`"']`!+W`"'7![BI8`
M>D`/[E`%BL01J@2"8J!H7N`'!Y`!>C!K`V``%]`$9"``'3![,G`#)?``?,!?
M7W`H(X,,K))PPF8IR4!%4U1"S0*##"02)^$0X5(LWV$=W<`,3*J#KH4RPZ`%
M_V<0ZM!]%6%*5<`%7HI^]"9I,HE^,]$L@U(9:U%%&,$/B.$0"R$0H%%;&;$H
M510N&O%&A%LI#IDS=]`M5A`5:Z$/\##_%X#Q2/7P5FMQ$/F0*3*A030*1:)Q
M!R@'A%X`/X#K$Y%Q,B$!<X>",OA2%UY0*D^11H>2,SRC$/15$_"5*G'P/OJ`
M&.=`7"RX.#`[,9>:#%78JB[$@GH`/V0C'\?Q&V^0!P/```-@-+B4K,/D-%+#
M-FA`8)7H=-\T!MV0/_I58.ZQ!JE!OW,`=.S1&]ST=6.S!F/@I?"P5G(S!QHP
MB5+S!1,A!Q.`LRQ``0VP!W=0`2@@C#904Y1@`B-P`D62)>`C/.&XBPV*4:LC
M9:93GDA@.D<&`S,`4#&@=Z,XC=-(BA924<`X>0]R.=,(9M?(9^!#"#]0`AU@
M`0+P!]JP!=NT_Y&NV4Q14P;WT`=Q$$#70P(-2@(QL(I$<@(4$`'M$P%[4);\
MD#&%"48\B0=B\"U[D`!WH$9ML#\74`9410/*B`(E<`!;D!H#@`:HAAA7H!(-
M]"K-,@S$<'\9!%ILE'`%(06@`BY)L0S=H$6E\DW@4DHCX06<S`VFTC+#L%MR
M<(''<@_BLA%"&"[@T%P:\4<X^1#2,@U<T$*1I2QIE`Q5))1=.@52$&V7O%DG
MR)3S<`59T6ZO@@T]%'+#D@P^5'(MY!2Z<ER7<9)A,$I/6BE]\#+QDZJ'VI4.
MX17=<7(941,E%Q03>;<D\S`>,0Q\8$9=X"OZ5G+W5FXP418C%P$6</\`"3=&
MX<`7=X`R+109(Q,=T\%+Q$$TLI$'4=.'MO&'7X`%8_`&_;7`)+;`O*2;TC!+
MRI0VXG&MW$HTTU$>:,!+Y/$:J,FX,HD%9A`;](LT:[`%4A"8"5`!+:`#):`'
M?2`!-P`#0K`"./"OOM-1ES`"-%`"/P`E-I`#;[>>EX-0I`-11Y`BI(,BFQ,C
M,T!F9\8#478Y&]M/?(<#/3![J^<\A$"T8<(F/J.7Z#RU'@8J6*!N6I`&4^`N
M1D$%8(`&5R`!%9"6!DT1#Y!CT%BQ+-L"-,!E9E+7<O`,^9A'8^2K/T-6\6*6
M?4`&=N`#!B`+6]``+/##1?L`>O`%&B`"M(#_#M[K0A=1*4"H0=R0']5`!:FT
MR8N;=5M0#";4S.J`&'(S!>YUNQ^1#JK<<COZ&,FEJO5`6<^@*BK7*M-U$"]C
M+]J'!9QA!18,!F3EFIX"A"?G%(W2!:""S"+Q%MM`?\;0&)R!RA-4%BC#!62P
M!7E!7\/@#""Q,?-R&(YA1B$#$1]A,;FE6+&2$+<%/[BBJOP0*Y2Q<0%8DMXP
MD0H1I^#@7BVH*1K!0/$"&A#D#27TV],=!GJ@)@)0$'C@,_E(`''@%':Y$_L,
M!W/X!KB1'$IS3LTQB&QE&\>!'63P!K-Q<]#!7Q.,!640':L!A^P1'K3T&GD0
MY>9$FNZ1!F]03LN1_ZU[J`%%H`&G^8;\,9"-P\8"(`<?L`)'``0Z4`@=@`$3
M8`$WVXX5@+-*,F8A0K$7]=7F.3M1YHM``)[\U"":1U(SD+!IK0,_D`DP.UQ5
MR.*1+`P9Q`6_T1ZW\1QGV`<6,`(2(`@$(#$9L(X4`+,$$`$M@,8ZL`,<\``"
MH!::]@-#,`,*18TV8`*',`%F`JE5"$9AP`=;:0L9T`##0E8OH05E@'Y/=0$*
M0`=X0`&-0`,M\`%Z``;Z50;H5@6](:69LBFF)I*W]BV^HAEMNAU?4`V7C"]N
M\!.'D75]<*C]4@Q6:BFTPBO-4LPP\7V,DFI)F1+KJQ9DX4/)IL598)>,P?\Q
M6F`;U*`MR<41HG04]P4::6L-AR(N&>$8B=*2,[/KI3(NGL4.Y>T5)(FV))$I
MYG)#\%-RWS"1]D)%9J1[7,%;@^(&BO87V18NE_RE3#%?[M`';F!HFI(26Y@4
M\'!_CB&GV(<,7J!H1Z'S/B,PI)$JA$DPJYLW7_,T5SX`=*`V\0MJ8>/1YK0&
MQ!&_Y13EY90:>=`&;=,:,.U+K8$&&_T%;4!-]+%?"C9,U0`&:R`=>P-,>5`$
M7?XG:%`-47`'!+#I)U`!N)4!+%!D*@#9@?8!;IX!&$`!"2``.+8\-X`"C3UY
MT"@$"<(BL%.R)<O$H4-YFZ<",Y!2*S`#2ZT)U^+_!WJ('+'1!M/0!K6D3",=
M38YX-%R3!7I@`HM_`SFP`QA0`3^@9G3F`B5``2:@C)1W4AP@`)]!%)2C`T`@
MGCH@`__JC@3@+FU4*%K@;V$@`*&NAXO"!]DQ'L;M![V@M090!GI0`2R``X;P
M`'BP!@.P!I("3%NP[KD%"%5:7%I547Q34WQ64GQ9655^5'Y14U5;7%E6;GMZ
M<F%7?E534F%B5X)9AWZ64Y)165A:?7^U75=45F%J85:,5):T86%2?9155%Y2
M45A5?5=2DG]B8E1?:6E;6%9G=6I_5YQW:EY=8F>@5,"%?%%^5JQ1E7WF<75N
M77Y^?;!35F*@KOSQX@4<_Y4HSP`:^^-&CP`!>+JTHQ+&C1PU5J;,4R/GC+D[
M>'C%$7!@3YTXO:9@D;4E"Y4N9_#<N5+(BT,!<02JV9F/S\`KT/QDT9)EBI8M
M5O#HN0+KCTP]4.5<X;;GX9X];]ZT04.FS!HX`P;028.&#H,!60=H"&MG#IPW
M<-BL:0.7#9NW:\R8(4L&S*`R9;J6V6(4#1PX<_+8L4,'SAHRA52FB3N8"QL?
M!M#:84"F3Y@]$BATX!"A4X<:2VH,*=&A@XD.%#!@J!`!#YX*-U*LR)&#1(T:
M,(#_3I$""!`>P6L`J4&\!H\4*&S@P!&#!`\5,7K0B!`&"Y@T<N=BHY-GCIDR
M</_1E,'&18J;,U0NE6D#)\T7+&H2O,B!(L<*(#C<`$,!!2`!`W$]F%`""BH4
M)P00*.`@0P5[\&%&%`)T<$,,*,``0PXLO(#!`PD(4,<P70A`@!Q[3/#`%&!0
M<046Z\'1!A=B6-%7&3Z$<,$`8510P@DON/#!'W2LQ4897Q3BAQ0'"4)4%%5$
M(H5"@V3!AS%\\"&*%E-T$<<==YSDT1]=['+&'WUTV4X51?51S!2/5"&%&F>4
MDU$?<>CAQA]2X&(4%E'X@DB5+>V#2!^^4.)9'&[05,886?@QD#*2B*''26%X
MH<8XT"@C2#-6>!&*3VJX0<XM4D!I!16'>M8%/):>X8;_%T)%(04XODAATZ9=
MJ$2%&W?<RL\^<%Z!YQ5B7+6F&$KEV<4??@R"19Q2Z*+B'7Q@P4<8#KEA11]4
M2'%&F2SN@=)4W<+)!19=7,54%'_4H90>>,21IAP@R8&'`&N,\4499J#Q55AS
M8)/'`';`-8`(8LU!QV)SM*%7&UNM5P889!AL!F$J?4%&P5R!,09@!&>UQEQH
M@#&*(`:3P04790S@`P-OS!'6%'<<@`$++F"@1Q@3Y+`$$22T,`('&U1`P0<5
M2!"!`%*0@0$2$!0`Q`PI!.?A@2F00$+7NY$`!!%`P+`""2O,D$,++K300G4S
MX&#"`W%L,<<;,FO#!1D@&\6%_V%C[)K%&%/4T<#4>MQQ1C1B))#!!"7HX-_:
M)*"0`A(!'"T$$4:00!UT*1QA1-H'VB`#!PFX0<4S9TC0@@K\]7?#"1],30`!
M<8A!YD-A9`'M.F:T0488?;0Q!CQF:*"`#U@0P`$+.XQ`@!]P,,``&UQ46667
ML&@!YE'^%!0%%V!4VF8AC#(***/FI"J'O5&IBDXTHY3:QQ;W]7$&2NKH`R2@
MA9%7^4$66:#%0302/CN]JA)^F$H5^+"K_<W,)8S8E3JDT`6"7*$+<M!#'+QP
MKCIX@1]34):IO%"'/>#!"^KHEI9:!2M*[(-.6/!#&#IBA79,)`QKZH.GOD&E
M?_2."O_B\Y04JJ`+@OB+'![DQZO:I(]DJ.H69]@#`02@AC[,H@YW$$,T$-(L
M`AR@`27R$_*TQ(<)G@%XI;@#5,AACVYL*@YCVH-Z.K8&-*"A#1)C`UT6PX:]
MS,$.-OJ*6]RRAC+X,3!]^0(8"F8&,%SK*).D2QO`8[PJ@6%C7Q@#&+2!!2Z8
MH8]>4<M:WD"'O8'A#A&8``580`$O\*$"*C@"$(9``PY0@#:QC)H`J*`\`J0`
M!"`H``QF\+6OA6T&*^!!#427`^6L#3LX&`(.6D"]&VRS`P_PPA?6D`<-S*$*
M9W!('':E!@$\@`!>(`,;L`":!(3A6PF(V@,B(($,?,`%'6K_D!!@0((<!.@&
M-LA!#&[`@A;<P`6M.<$/7'`#%:R@:S"(4(=@8(,23"`.*_&"4C)0`AQ<5`4M
MX,`$#G"B4XSD#%CP7RW^4`7`6$$+=BB#%'9'A0$HX`)L(,`)6'`"#!R@"V80
M@0;6X(P^R`D>HWJ$%KP%):-H@0]7*`><DD&0/T1A#&/0@A^\((:&/$0`4-%#
M)^3@!C'F8@J2W,89,`(G.*40AHHPQKMT]8<V5D$6*T'&J_YJ!7*4$@L:*4H4
M9-2JBO2"%5WR`PC_Q)"J[`$?,!'C,^J`5F(4A!(O8=-BJ>0.<I7"#:"0@B46
MVX4N]&$*GI&C&&"Q"'@T0PUUJ`:K_\3P"2O\`4]>M!.@N!&'?^$$')]2JQ[$
M(,1-B0%011P)`1+P@'?J@:9:2`::Y'```J@!A"X,PSON@%:EU*$;G6!#5MZ"
MAE-B+`W%>P,;TA"8@@$F#1@#9&.PT8:5,>DO?B3+&%IB2E:VI95E0,@EIBH^
M+FPADVM(`QU\4(2U-&9)4W!#`SI0`@X<X`]RX``*IDE+"SAM`@1HP`0FD(`N
MJ&4/,2B``Q9P!-W`X#G(88X*4!!-X,R`!`?2@0YLP$T6W$";0]@!!PA@!?3H
MC&%HZ$(#*I"!!FRQA=7=0SZH(`9W$N`,8B#`!"I`9@J<P*'4V8$+:#`""DQ`
M`@\X0`(:0/^BJC3@`'+X0Q@X^X`*<(`#)CB!+Q=$4!7@X`03P,!H5FQE"W1`
M!ARRP0@2<`\JZ"$!:OC"%@XA$+AF5PMPX8(>"!`&,`S```J@PQXZ(&@7[4$+
M`V#`&OCPOS#`RGLKF5DD4,BH79WA5;X2@S*R0`:9W15:#\D7GHH+E1-QB4Z%
M@E(5N*#I*3"V7?I012ZBL(5";*$OZO,#(G+X/]7&HE"^,,<P_,5<+&BC4KNP
M@B'<4Y5DYR0+F;B"O_`@AXL\UW=RF!50G/H'6[WG#^JP`C-\8NLJ299?7IC"
M7A5!A6G(H7?/S:H8GW0.>5?!'*TE[P$.@).*0.4.5?'3O_"`VB[_`,-+5QA)
M=05P!ECXH81CVET<LD@`//2P"WCHA%K',6H!V$$Q<Y`+7=[02((1#`U\`8/)
MR"!*,[R!,78YC,4(\86]3&8.:."Z85IY=#JTP658D"0AM"!)-*A79T4P@`80
M`P<R+-8-*:8`!01P!0*P@#@X<`$%2&2!*A,@`F0^`!8,T(82+&$!!0@`$%*`
MG+"I@&LIV+$*K',@$F#'FSUP0=Q:L(,6O"`"5VC#`/*`,3J8(8(:IL#2*O"`
MF=CD(27Q0AP.$($$R/F,=,Z`WB5``!&BEA]:`,/,N#`%+X2A"F"0PA[.X(=K
M=&;4NR-`&._P@`U0@`,C6%H/5$`['-``_P,2.",&?J`#%/2``P_8!4Z8,4EO
MS4P=6#`,'*H@QJ&0H0@AH`%>8`&_)'L5(`9VH`%MX#\2X0K(QP5C\"Y\\#KO
MT$,IE"9@U@CXUA*+-17,<@_"YE5\P$+\UE=;LD'`T&W\PP6Z4@RP8`@3T4,0
M2"ALIPFWX$.$$@9X4`==P`PWYP6,L!/H0`Q5\`5?D`G:!5='2"^<57QA$`4=
M,P;.T`UR$((PP58%T5J-\"1`=`8"I`B5$`XY80E891"P``E:$`5B<`^ITE9_
MT"M0(B/@0"6[LBL]TUWJH@;_T@E5<0_V<@<CA"9+1!A2@`=;I`;=<G-IE59L
MY1#39P578'![R/]O*K('A$0P;#`'>Z,>>H$^X.$8@N$RW6(&AV$7\H4&`C-)
M<\%*<("*)W,76W$7;T%?IQ1A9&"$9)`&5\<`32!W@O0&9?`'`M``=Y8`>_!:
M&:`"-:`#,F`"'Y`!4M-[*H)X%2``:6``5A`#3]`Y`3!-8H,"*+!0.A`V"H4"
M/Q8A188#:D8])T`!$1`':+!ZYM$Q:&`%*H(O&^8")E"-5``&-I%/528!LR$!
M$M``CN,[`K`'-%4S.24RY[$QCV`%^-)7D8-XW+$%?3",<+9%86`4UB8C9R`'
M$2![+:`#/$`$,-`"&[`'<C`!,7`$*7D`GE*%?&`89I`%1S@56F`&9+#_%96B
M?%6`!@!H`%70``3(`CA``6$P!R)@!RY#)8O@1:)$%.\`%)/@'5'@!?/3'2.#
M.+E@*.A&+N"`;\VW<QGA#G)H!?@&">Y6*1*7AI5@)=0R"/*@"O]`#N(6!6"2
M3B_4+5EY0E%@#E>0"*PP,UN`#+?`;6JG"76@!UZ8=F"@:3DT+N*V$EXB#W(B
M;5+'1#F2"(D`8L4B1NW0)JL@;AK!#?Q6#NA`*Z&5"[7P<G]U<U>Q@V`V)B%D
M0F))5J=@+F+01LG0F'>`*SZA%!=G&\30+'H`0R#4$7%@6?C2673P!E*X!5Z1
M,?B5!E(G8=$986'G$WT`!O2Q2>?!%1W#!G3`_S":6#'88!<;8S)[D5]VT4>W
M.`;@83-%,`!;P15;H`8CP(P24`%4@`4C,#;5PP&S,0$1$`$$4&\)8`$2$`=J
M(0`QL`046@`U0#LQP"$ZL`,V(#8Q@`,VT'XHP%`N8&0W4'HG\&%<L`;SQ08/
MXY15<`5[P$\"@'<FT`(E\`!\,`9G0`".=@(TP`*T1'.AT'P.T06A-`97%VMP
M8`8,H9>:)@7VT$(1T`$Z0`(E\&'E4A$)P'X<X#JVDG$]^@!6-@$FL`,I(`0J
MT`%HM0,%(@,*N@=7``834P:"4`6_-05HL`7?UCUPH6EIX#P&P`6@,0(VL`,5
M$`9P`#$7X@B+<"AV%?\.?W(^7$`%Q45](N,7JQ!#^Q`+DD53[Y(,IX`(7'4%
MKU44;<0_(C,8BB(,0*@21Y&&](`KHP!76;!G7I@*7E(E<B(43-0'[D8HNO!K
MB5`EE3(-J*`EDV`(E9`(6>`53!*982DX:G@'GS`5A<A%%2<&^8`0K1(HX("!
MW.HJX``-YO(-C.!\7B5)UJ9G<:`&V>)89W`%D.`K)/0>,7$'"%<16B0`90)&
M.P@H?9(CFA('C$!>#[%%9_40<H`]:[`%CC`P7:&+6G$>;8!T\O483!0%:/`&
M:2!*8U`P$WL7$Y,'K<1T@0%639)\GQ@7:=!(H[0%:Z`!32`">3"+8%`O>\#_
M`<M1`7(@`"X0-BW@9A-@`6/V9L6G(@E0D%?@`R)P`"BP!-M8`"2@H0D5`SN`
M`V)C`]XT'5PK`PW5`NT8`7H`(VO`,.LA`C9+!A-T!0=``19P!A'04#=0`@U@
M$Q5P`B=@`K_4`&+@8%N0!EI`7E(P!H*T,64@2%_@!RDF!05#!0R+L`+P`3&@
M`CN`>FVT4R>P-CA`2P_011^$!R.78A)@`1OP`AM2`@_!`D>`!#%``01`!6-@
M//#`0%Z`!6R@:6AP2!K``'4'@7G0BVR@!A90`CO``AU``%M@!P.0!H3Y09U2
M#'=R%>+B#D"A<)C0;:@J;OL`#7#R#E20!=KP#*9@_ZIK"*]M-%5;P@S4YBU<
MPH6G(&[MD`B+\(96,"V5T`7W\`=3P*>%`"<36$.U0`EHF54$00VV!EOO$PY5
MV$/R0$%]Y6"!]0?ORB:YH"DF00ZM`F9M5"\C!&Q`T5@GX09M11!G,%>J4@Z@
M0*IDY0>80$%0DBV5(*JC&@4[!!!EA7+^B@Y=1J:7Y09!5P<*QT*_U@?<2BYW
M,%W==1)JM0=W8&O]%5:#4&R[FW0O2Q]E=QA:`3A*^@9@H!+?05\CPY,=VQ@8
M@P9?X'^@1`8LFA7SQ16$``8,8`#W"0>,<2$-P`$5L`$[L`,DL@-"@`(E@`$3
M@$8/T$\9H*`J0F?OE`5%(/\"!,`#`5``D!<=_9&AVS1^5;L#2?8##?4#>XL!
M?#<P96!*L08X;<!_?X`)8&`%!Q`U)\!0V30")6&4":`'75`%9PL'#I8&5Q`1
MJEA(FG"]TG<`;J`(`H"@*?8`UQ4&#7`""5(BKW('"4`!+F`#T3&T)J(&>[`X
M%F"TM#&,)C`A<F("2%``.K`!<<`/EGH%W3(8UV!(-/O(OML]6T`'3:```R`%
M#U`"'TK+?9`89L""'"0&O&`.+;0'WV`.?W`X5-<2AN!4;>03Y1"'43(*[N`%
MJ&4NWG`0XNLR`[%`'-1#D?5!T!#"`N0,'R0&D-)7?R!'$:$2D:`/]VLJNR)L
MQ=#_:]/`$54A!S$,#CJ(!VNB#B_A!A5<+EWP*2S)%'(2$^?5!='@)9"5U#L!
MA/H`E6MHT&JE%/Y*PJ@%#5%2/E(P%!3!OX@565>"1]^%<E6XAE$!B`2A!_ND
M9;HP/QX!1,^5F=FB*0E)?500$RR9*FN0%68@2>NA,W:`BFZ'&'E@LIJ82#G#
M/?P`!G.1%Q$X;6Z7GX4M"%X'=1BSBFS07B9S:D7@%F%1!E,@!R9@`RPP`LS\
M`"H@!#WP2Q5@`0E@1KMS`)LR:B2BVVMPGQ%`!!#@``5`!!$2`S80`P;ER3:`
M'=Q4`B8P`AWV``+0!6!@%Y#!!6^@`1J@!<]%`!\P`5?0_W5O@`7/S`(EX`([
M\`,80`!_\`5M0`>-8<=PH`J;1G/W(10;(Y%#0R54\+/32&8?,`(C@F+E\``<
MT`$5<`?#L@<P%`<3,#LQ8`(20!*]MZ`/`%`M(`'_0FEV4@)(@`1#,`$LQZWY
M,!_*`YX38S,^T+MSX#+7<(T7(`)4@`%)IN!'90;E`0;[("/3XBE'I$,Y@07%
M1@BP)1#AJPF=XBE#W27&T`SF<D+W2RUM1&UA0@[JT$&FZB:2`(EZP@R(%4'J
M!@_UXA"X/*MHPM(?;"[Z0BY9%0:WH"E7!M7F2L(JW%K$@J\LG58O-&W=%@7,
M`D-<?@6=`A0"@7!P)751`&8O0?\2"?M"'U317_D.P\`'LZ`,6B"%2%YQS;DI
M*4?"5:$&'#<,[502\'H(7B!'>>9;G=*%IC(0N2)2Y;4'A\1Z73'8S$L'D`&>
MA[$PC'$81]<6;""%^2??AY$&W5,&Y^D8<2$SUZ!><+$W_04'C4$PI]8$<[`&
MT0D&?:`'%5"2MW,`'V`$*E`"P(2@)8&;6?!)4=`G6J0&`]`$8W`"$%#O2S`#
M.O"A.X!0#Z7>.\8")I#@HR$`?Z.+](7&:+`8<-!E>'=F%>`&7R!?5B`!(_`"
MH[$!!.\6)!L76Q&!4]!E6I8M:ND'P^@&NY;J>Y``B'=F);`!#2`!)<`"$[!G
M9CH"$U#_H_["+RFF\F=*&B9&:BG"`4!6`@3@.A2$!11PSC@P-=5-$VVP,2&;
MN(ZD5&S!!@C!=F30(TT@!1L@>K4M`6I@!R(`!]O@"PH'Z#VH:>\@0&#""$`!
M*)<0F,K`0<3`O<N*6`(A0%H"#_A&+WE=<<O@#U!2"0@A$`HW"$?8;;AV51_$
M$6K0G"8!1&SESCXQKY1PKN[,962B*N>@#$`QD^00!H!XPC<1G+AP"48X"R?<
M0Y%(+'(P]Y/01N[V!?S7";"2166R*>:&57`.0G+4.+EL;7PP,WS2FS$:=/B@
M!E"A*DK1!461+8:@+(X/K%F@OU[H#NX1%;Q0$(S`".E4A6'0_Q9:L3)WL3!T
M4!GZ]]B"=!=[HS)CT)/!SC#8619GT1:/P3&382.1?1=A`0AT96P^(@-S`W!<
M77L3)S$W%1(G*"HG$0<-"0T'>W%]8&UO;&UD6U%_7F0&!F(Y3`L0`3DZ.#LM
M/3<_'28_-T,N'!04$P)F(FU?<%AB96]Y`W1I`L0$$B,O%0)R8G]29W5G851E
M#!IV:VMV`V]E9FAF7%8"!'%=>`=R:A44>U%]5/`0V)-@`H42.7)<BE`BAHL$
M>QY0P'"BQ8D&>PYTTB/&S0%^PB+(N>)%S!X**I"HX("G2QPP6C8(*9"#0X(P
M4KBT*:,ERY@U;;+P09,&#1QT??IP,?_5ILD%`UTHG*"PH4,%/QI\M)G2)8S2
M+U'\;$FS!DP5/U2L_''C1LP5/ES,_CGS-@H?/TGO\N$S90N7+&JC:.'3I8\6
M+E6NA+DB18R</UBT4/'2A3%`QE3X9*F")>X7+%6J9.'2$TL6/V($"-"CAK$W
M/UE._[GBY]^?+GRP1+GRQTJ?+F?4Q)'CM<^5+EU\6U%\AP#$,U2H])D2^^R5
M,V)@7QFNQHL4*U8T9YFR-PL5/0D.U.&M)HR8X6ZD\*'R1XT:.0(T#I0CQ<]K
M*G'L(49D5LCQR6YUZ!%'''AP!)Y\7VPQ1114N$?%%F`0UEL4YN'GR7UZW*&&
M&]U9X4<54_C_00<:8Y0!QQPO0H,.&5^0P08<<*SQ3CKPH+$&&VRD0889;-!!
MAQUYT&$&&"X.8$<I8(!!)!QLE$$&&FBT0<<`7`Y@3AMP,,#`&%X04,$(/[B`
M00(<Y&##!`\<0,"<!PAP1A5ET#$'&5K@==AH>30QP`-`@.``"`6@$,,.+.QP
M0P_94&!""2R4,%$%!WQA0!%3X`'&%G%\P<886YBQ1AT<G##!'GHT,$$&&V`0
MP1YA^*'%%G04PD`><R#"0!I81`G&&%S4H=H!Z<FAQP@L5""'%V=D1,`#&'!@
M`@I$H&#"!B/@$$,'#3PP001MUC`$IGLT5^<=>Q"PP0D<$*#'G'OL_U%!#$C4
MP$($>NAQ!141H(!$"B<0H(8?<8TQK!EC`$9;%D-N@<4718&A4Q,>:.#&!,)T
M`"X?&HB0AA1N7)&%%A-J448:8TQ1WQEGR-&6%%N@048487@1Q19:<$9A'U&@
MF,46$?+!6!2["<8%8E1($4:#840QQ7&\2=&''VA%Y\=>4@M%Q8FWFD::%WK4
MX86)HL6V&7E75\&'%%V<2"$?MT8AA1<,BC%%3V=9746?;M3;6A>4+7>&&V$@
M)\7?5HB1W&543$BUU8S(V9(54DA1GQQXU.&&.&((-V\""0B`AQC0B@'W'G9R
MZ$=7_568H&KIUA&.U7\D[H4;<83!QQ>#*?\6GDMX//N'0`/=\>P4+6)A!1QF
M$)T&'7D@F20;:Y2Q\AMSI+'R&FA8:<8[6&I!,1QOP%%]&5@$BZ49[J#!QAQT
MM#&&%IV5L08<`_A@@`]T8,,ZUO`'`E`$7OEI00IN@($&S$D`[2(`'OCPC`&D
M83GSDL-T1H.%+HQ@"2`(80%L8(L6M.`&+3!!!2KP@1?\H`05F$`Q!A"")O#A
M`%501#SJ0(`Z^&$*>\!`!?20!2S<P0*I<H%%).`O0NB*`8DPPQ2^\P<Q6.$+
M?:B#1!X@!BKLX00J*$&Z5K.'!EA@4B>8P1*$@`,:O&`(*FA!!3:QB1&08`DH
MZ(<8[J`:B=RA#A__V,$),`"G@A!``"-``0PB(2X"H,$+/R`"$5C0`#=0X0MO
ML*!NOE"%MEAA"NUKPQSL-[0U#$`!'A#!&9#X@515H`I-T`"9U/"'JT4A,EB8
M@A7<4(<XJ`%F7A`+%[90!:!QH0P-VTQ:Q*,V_(7%9WOC`O"B8(4PV"X,X-F0
M8/!7A;``A`^_P29X=L:S*?3A+HKYP]=NJ07\D8<S0IL:XJ;#!\Y$I@I4N()O
MAI9+*]CGDF#P@W?(XP4Y*&]>=KJ:9JI01:LU39U3M%URK'"&LIW!"G;!VA7$
M\)X[*,@+5SA.%WA8)SS$H2U7Z":[[H";*OB3I7L1P[1*IP?5%`\/JH$@_SUH
M-072D*PDG:/+=]P@@-+=`9MTD\P9I/&%8V[)23B:@QV@1Z1HM`%(5Z62E<A`
M*BZL(8`"%,06,(1,,*#A2%RR0Y6V4$1I$N)_7%I#&M(0!7*5P`42F,<.:G`#
M$V3@`8=DE8*TL`YHH`$Y`I#``P3@T?Q,H`1`<(!D)WE"1K6`!=NJ0*K<&,,(
M=,$I(C!#%\J0AS0LZ0P3L`H>J'D%+9@A"@1(50MRH((=#+$*`VA"$<1D0<E$
MS@L/^$`"VBF%5CD0#WB@``]:L`?;Q:%5$J!!#%"0`B(L006\*,$.''*`*\@A
M`14X@0Z(<(0;/,`+7*!"`C90#SPDH`0W4%4#(O\P@0;H80\=0`$)2F"!`^"A
MG1.H;@LF<(8TX"@-/8N0-=5@&"[D00-PB)(93#L'C"E@"A*H0`=L<8`V:&``
M6PA=+:GS-MYXX<1A<,\5J!.6VMPR2OAKWQ1$8Q>I;6$,P)/QWIKJMG^$@1M;
M2\K>R,`G/WPG.E;P`KOD4)BDH@QS?$'+;(`VA0EMK3,2:]]N_B"W&7?M9%P`
MS5GF<H<X_*$OJ*#"Q*H0AII"T`V?E-H4>7>%I&!-HW(826W^T#LJR)DP9_#.
M1KO#F,Q]XX\+<L/9J@`3,5QS.ERI0V'Z$(:B"L!V$(Q#'5A'NYP>M:=1"$Y&
M./(UM:#G`'$XSAGB1@7_,9B6-&08@`9*2R09M4%^`\C#&W;]ABUUCT9A_H(H
MV_"C=C`)'@HS,!MX#3XK`6\,##"`!M@P@"*,(9<"8`$*:C(%`=B`!RR@0&<E
M`!'E26$.!FB"#XJ`#"WLH2H5:("K^/$!!>8`A;A`(0M<4((12.H&-RB!"3C0
M@0E0000^@!'\^J"',S!C`B/X``4>T!JTX,$1.\A!"G+0`3Q480X^\,$`@(2&
MN$0F#7[H@`T^<!;CX,.!K;I!###`9#D<0`(3<$$-`B"$F<!@(B.@0:,XH`=4
M2(`#'+A!#8RP@A_(00N5?L!BZQ!>&M!@!!W@0#&*^JX6P/``;CC1'EP`!!YT
M_R`,C#8#&6+C/+:X)0M>:D,:@&0&BLU!!!=0`!?P$-T2?&`/8^#2%ZHXXK?U
MIXA3A-8XPG)DPE$!18*)$&GL`LHO:(]488E"7%"&!5+]9L6@04L?BMB8$N&%
MSPKR!FU0U(=/#I,/51P'7RB$T6/679H6`PW2(@/.OD1H;48NB3H!8A)_Q64*
M7NBESL8:F2FT60_!Y-!IK-!JNNRL"E(H])[;0\7*1"=S`.E"+=%"_?`4D0IG
M\&4MOY`%:*TZ=VT)0QSN@+I?QJQX>L"#&_)<F/HT)P&L<39&I@<:$2*JH0?)
M$0;C8S%H``UL``9D\`R\(G=7]09M('=S!R.W!A/!(O\*IK4&;]`C/>(.=?<%
MPC)AWO,%=O`_!J9;SK,'=@0#8D0`*%`#)3!?,O0`$1`!I;,\SB`"!J``!B`"
M7R``$Q!#1U@!&Y`!&$`#)F`!%<`"4N@"3HAU'<`"M2!P)U`"&+!4`P`_;0`&
M>K!"[4(!3OA"Q4``J=4",;`",!`#(Z`'9)`K0Y@'<J5V.P&!5]`!)/`#$-,R
M+L%#G)`!-U`3<7`&$?`!'2`#*;`$CE@`2-`#$T%P+6`#/V`!8>`&KC("+8`M
MY64!(X$L:C@G$%<")7`"_O8!$W!($R!$$L"#5\`&5G`"DN0"`D`W9C`8)S,%
M5'`??A`-9$`_R>!5:Z`%:"#_A&+(,2?0`0\P!D4P`%\@?RVU%\%"*G[P8VY0
M2W=!'VI0!ZUQ3D-S*_@CCAA"++MA-9VQ&3>F!7;!%Z;1!W/A!3\6(K1T(KQX
M!4%#4=Z13WWP!6@`!E'0!=TA'F[C9UNP,C0R!N/#)]31,WY09^!T3O#4,W=A
M%U)P!YN`!Z.'!7TP(ETP&I]Q%F%P!W?@!4EQ3JTW&7$@!J.W&U[@#4E!&9E1
M'R89%M*!-%]3';;A#7<!'+P3!EH04&YP5'XF4,-Q!IE3&=>A#^*P%G?0%LK"
M:7(@4;HT+X=T``]0.HIV!C\"/F\P54LR/78P!Q9H,S4"#Y]B>6D@=\3R!69P
M546Q_S]E262F93$\0TP]]0ZBM&Y3E15P,`\=H`(I($8/0`)"<`+T("[UE1_^
M)9#3(@"71`:#0`9]L'_.Y5XR]"[%8`%2(7!9)UO\=HJG2`$$\`4,@`93P`9H
M@%HCL`$5\`+[=HHCH%EL6`,UD`(V0`%Z$'@,4`3J=@C90P9@D")6H`<3$`,V
M(``:4`3%2&D"P(-W@!(S,`()\``<P`(V0%M"$`!/\`1$P$!(U`,P<`0\<`)[
MX`;6<(78L@0D\`)02"L-\)09D0$4P`LFP&]KXDMJN$(34'194`$PL`0](`!C
M$(95\`5KT#)>H`:I&8)ZPC(_,0=8$`9L,(11P"8N<`L"0/\'(O`&?/`Y&(4B
M?Y-+5``<8?`'?R`8Q90*E0$TE-<^-T8L8[4%L.<XX0%Y558>N<2+78$W]Y4N
MO?-)FY$%3=4'AW.BM'&07V`T7:!F;!4:%=D9TO0%5,HSIO$Z-JH8<2,:6+89
M=D%IK'-44O`/`2(':M83?0`WXI=/]V%%,5E3JN,8%]4TV2<?4]0-2,,;5Y,7
M[0A.O*%/P-$1G=,%=B%_7M`T5S"4;FH%R%%%OM1_[-(Y&:&5]Z$&8XI^["(`
MX7(`K!$Z67443S(DB!`-Z$,&H,$%Y3-C6&`C-O.6I%"!+Z(G;0`_%7.6\5!$
M9+`&O:D!1S)K9>`'^(4"0"`#>-#_`(U(`ZM!`#<G`3V$&^W4!1\Q`3B'`12@
M6/Y5!5_%#E&@J0U``1%PHK%EBB_``<S2`AM``2S@=?XV`5)@"%)@!G!0!7N`
M<TJ(`5EW`OC6`D.``D/P`A(0![C5!(8@(W3`!>=$48FC!B<1<%/P/QZJ+@+@
M!GB``3<01Q3``2U``B00`RH`!$9@742P`Q3P`C<``T\0`-]I`5U$`(^@2$``
M`RN@`QQP!\A'#ZJA"=9I`Y(HK9PJ![$%+Q%P!69`@P$@`U'`,*[%!ES!95H@
MEM@#%*-06AAU2CY`!0]@`CN``R50!V2Y!LAWHE@#'FGQ-5+V!TG%I6>Q%]%1
M9:(ACC%F_S==8#588Y/2H1D]0VG<T)&L0AQBL!A^L!R,\:>WT1]H41M-$SEK
M,V/@E#E^=J7_L!<N<5]=1!__0GXA-1W_L#6$DSFUM!OZP&5!\Y"KQQ4D"1W=
M]`>:RAKVD3BADS,XP0<MEJ;#46>*PQLFDJ:^X5UZ8"!X4"\EJ3G0\I1N(34E
M"C,I%C/>(0;]TB\"H(,"((\F.44FTHOT<$AF2U%ID#ZBI%;92SVYEB3LPSRC
M``9#0P9I,$IF\)5O`!3T,Y87N&L5F#YSD`=YH)I7,@"L,`<-^(7.]P$X4`,D
MD!\J0`0N`%@W*P'Q.05M,%5C(`5RD!$&D77#P`$-E!YU4`7`8O]-";"##Q`'
M$9"N)>`Q+L`"&_`!4T@#!2<&N\52PQ(0JV&$=S5;,0`)N_``<!8%;5`$"N`#
M%L@E:0!.?(`=X>$':D`-X08&%]"A?=`NRXM3&-`#*H`".B"8*="Q2X`$1T`$
M1D`"-\`"-T`"0!``,G@`BR$`'.`"-D!=DJ0O)$(ZSRFMX;4M%.`"/X`!]&(L
M%($!_G`%,7`$/Q`'2*,%9/"05:"0ZP`'1;$E:1`7__@%Z'8!39`%%E`",K`#
M&'!N&M`&?-`1CH,<?3"B6&`TH(LTU`%Y`"$U&8476/,U7H8TIYPVL3%CYI0Z
MUU$'Q*$6N.$\QJ(:G\`'4&8%=7`'*<K_J"?:!^GXM\CA&[";%GT;!NU2)S?\
MD)EC3>EB,J$<9.;C4O*Q&=T4'9'1!R]I9'T;'NW$!R.Y!W@`'48SE!;5&^>$
MDU741:P%'&J`.KGSDM]0+SB5'P)@9@+Y7.F,4:\CL?U"'"02'/O7(#:;:K54
M3-T`2E=P@`=#HV%0;&!B)#""/?QS"-<&,70'!FFP#J.TT7:0/CB2(UPE/S>R
M#ETR5<2&OPHP;>K3!F5B`7`T8`1@`T)0`JJ1``-!#W>0!73``&\0!A3@+2PP
M`D@G#!A0+1UPL1R@#5KP!F;`!T9(P7YP!S1@`RG4`:;8`;`IA5XW1%QRB`ZE
ML"'R`"V``S?`_]:8E0$$<`:P\04P701S,`@#4`I?$-%B4`5+<04\5`$MD`%I
MH``7P`!\4%-Q(@<5-0EP9`0!4`!$``1'@`22=,4P4%LRH`)+\)T?4$D!>0"<
MF;$Z``,P\`),&&\3\`'5PH45T-0NT`,NH`W*<@"IQ8SR]P-L1`"D<:!JYX]<
M,@KJPP9M909D.3XBX`$*T`76(H45T`>%L`9\L"#B@$W2ETOG9&7286?U=+<H
MFCG@(8\A&C19T&*:L32GX!LI`A#?`1"?'!:=X0=NX&9QX`=8X!_TP3IG\`]$
MM0<,MAM=<5)2D$_RZ&C(5;UX4"O]I#GSO1I=0&*98X]X`1Y\0#38-_^FY@$S
M<..WL6$T.5,?<*9+87`&[!(?:1J]8;%171`:)1H[N6,?APK8O7M("N(6%-4O
M^G>HY/$T-84'^I0[9ELAGW.H:?HP?3"[^&10W2$6['A5Q/:5N;8&81:,]8MC
M9@4D13$'4"1W=*`!4&0D;V!:XS-A1+%L\YMK5-(&^`O)=K`E;%`%$;`#*8`$
M-W!(/<`#/,U'/MTY4E`&=N`#&F`%'0`$DFW:/>!OU"I$$TP54CUR8M``2@B?
MVK5O+G`"6\@",L`"/<`"=@P&%C0&H=$G(Z*\%*#4XA8!=E(U6<`&&A"$SU@&
M"$K54^"S:&?<7:`@>\`!,H`!6F#8&C`%TQ+_+JA>41;P`CE`!)']!%<L!$8`
M!-M9`#P@<TA0`#5@`R9``!"S,V(P`2:``2,`</W6`:PM<:^-GP;!AKM0`190
M.L&UUAKD`DB``P0`-$-B,6:P)3FR/E@`KW:P*UGP!V-@`$Z@`7H0`9S8+&X`
M!\C0&(GC&ZH,2N&(H_A49\>$!=?!?4&33R<R'V"3!<;1N(@14ES*5D33,YV1
M8Q3"&X&V-]2D%O,''43,.O:`-[S#V`"A!D]Y'\X1(D'*(6?1-#_F"1CU#P/^
M#_*8&6WS%_\P:$TYXF<#3IAC-072SU^#(LY<!SBA9"ON4_V2@%'35'Y`XF9#
M?2.I&H^1.[AQD4`:_P=>,&.)JK#;0$6?!'M-:KCN`5)_D"!,YC0=D6J@5`58
M_@Z(D`=D,"$>K2,^LFSP^R)E,0:9%`WPJW9SU^9"HC#.L&M44F&0_&&)4`5Z
M\`)$@"@4(`![A9@$(&\.5))H(`(:D,D'@`,S\`,3P`)'@`/$T(I-?;$2_-0"
M\`8^8`9JT``9P(P7YP(Y@`(]@(HGD*Y3:,=;H,.Q!$6(7`;IK7B7&\N%G`<^
MH``*P/ILT#-@$`8#$0<##@9LP"YJ4%,F<`,=(`4:("A2$/S","<-H!K7T`,S
ML0`%8`0`#`@K1`4%0BI""Q!+,1EZ7E-H8&$"!'H''284'#0<&Q06#3$M'_\W
M%0TC0SDL'101`@<L2#%G6[$H#U=]5U%D:6ES;%QP<&:_&D4B=EE]8`,*(1I_
M$1PO,BQX&@QENGQ:6E-]?55:6%A5XV!E95-=5EIC6E9A9UY^6V-?6>535%=4
M6E^J6+ERQ8\6@5+X1-%"!IXY/UG&@*GBAT_%*%:L1+%HT8H4*7]R@;3B1YZ<
M./0@6HF#1\R?,`0DZ`G9A8K-<'RF6%%3APJ6+'SZ\,'R[8^8/N:J9-%'KHL>
M/'^DG*DC1XP5H5'"[1208,^?*6"V2(GCQHT8-7O$3.&B10PE`7KTR"D818J>
M2F&N2'%[8$^8/SS5*$2+QPW*D/.NW#EPX(X:-VK_YGF1XJ7.'3EW\#PM>V>/
MGC,L]^PY(\5*ESEOT#1,`X?-&+99OJ"!@[K-G`%V@)D)NX7,FC=OUJCSQ<9.
MGCQTVDR,LL77&C9S-!@PH,&'"#I8]&08LB3`CP0ED.QHP+7!@00)[D2QXT/#
M`"\E<D2((J!%#@X1)$S(4(%"AQ$GF,#!""-,0(4//F1Q@`45[+""#3<0$0`*
M-&!@0@LM[-!""17$,<`%%RB`#`.XS=%&&0%!1$X67)!AQFT#^*"``DT8,,`4
M8<B1P`0'N/'1%%MX@0<E9^@QP0DL1##&=&@<L`$!`F3PP00TG)!`&`\,$0`(
M$`0`0PLFY!!``37,`,0"_PY,>(($:G!A1QEUU&&)!2],6<$$_?G'0@M#H%"!
M``]DP`(,*7200`<8/&`"##)<@04%0L!0@11`50&&&73`P0L9540!AWNIL?$&
M&WG8\8P=<32`P0[?<<&`!F5$$1$7YQRDRQ]6=&-&&VMPT8<5XU0!4BY3`$D&
M&%E480X57^&3Q119^5&14AE-4<44?%CQ!W-80%M%'^U\I"T54?BAET==%'3/
M%XKI<8<70F7K13M^2($'`7*$,6]&5WCA!14EI7M/MUF`,<866B2KCSZ=E@:N
M'&=08:\>8MCD1Q5\N+%''47V%085.M%#11=BG-$2%?+H(0`E!!"P1V>4-)"`
M'O]_7<&7`&JP%(=5BAT@`,?ZAB3%R)WIL<=;`L3Q1QU0RB&G'FK\\8<;7+E<
MM1K:BC$''6R@,489:ZB6AG!CI$'''&F406JIO2[%Q:YMM$$&0*S1,4!R:9@Q
MQD98J&,&&PQ,)X((1<"AA1H;Q$!$#2[@\4(--D1PQAX^[P%E%&OXT,0`?]!P
M@P1B1'#""10\\,`$^U7@B2;_$?@!`604T48=J@(!P@)&++"`"J2/T,(-+G!R
M0!K3&="$".X-D`<P:3A$1B18;+&&W0-(IX`![:'QQQT"1'"G'AE1T8<`%D@@
M`#VTE[##"WJ(L#D:4>@X`08YV&"!6QF\(*8#!:2`80[_*5"!#%K``]TA`0@S
M8,$$OB""*9!/`@_@@"9H0($[=0`%`23!$5KP@`BPX@0W`)X))D`)%J1`!F+0
M0@52``,*\"$+5-@"&-A`AS2@@0M!X0(-X="&`0Q@:V5`@P@4P(`K1!!#$@`#
M`^:PA3Y8*RCEZ@)D:H(%-+Q!.>=0RA2ND*Z+8`$?49B"/J!5L"]H(0I4\`)*
M^,"%+%C!"V$`EK#44!,N4@&&.X-(N:0EA79([`JY2E8?[B(`J%@L*!XYU]"\
M((8PU*1>4H@"&L47E#^DJP]^$,>W+I8LC[CA#F?0"\"D8)@_E.0J9TB`!00@
ME94IC0J=48M%TMC'NU2B#BN#_XL<Y$"Y!+@L#I,)@^7V(`<\U,&179"B9S##
ML7GY`QQBP"5C]H"'.Z@L`0*0@QKPL(<X`,P+7('+*P20BS^<80YV&``<UL!.
M,Y2A#;E!0QMX*)%=P8$.:WC-%\J0!C;X$UE?*(X=WJ`W@Y%A"_=`PV\84"/D
M%>%&;FB`#)Y0@!;@`0,JL$%Z<D1,-\C!#W9@`#(>50,=-(`",;A!*R*`)_Y,
MH'P9P,"`_L,!"]0!<'UH4`I(<`,QB:<$)3"!"VY@`@P<(`ON(]S@E@B=-J1!
M;BU:`QF^P`4PP`$Y,3)`$9BJ!<#$!`,42$`NTEB!`GEF#VZP`@%.D%()5$%S
M:=!"'_^\0(`6Q,`$%B@=[7ZP@@)`X`@HB($*4""##IP`!R2H00`6<`025.`+
M:<"#ZB8@P1($E@,'J(#B%H?`#E2@!7^*``M4L(.:2D`"+"!!"P2PA0:0(`44
M4(O>R$`']_1*DF6P@VY_R(9U5H$+!@C!`,20@-3NX`!:R`,:WC@0+T2%D2+K
M6]ZPD!.24*0+DX%(%O:H+*9L-XQ]^$,<-B:%*9C+HUW(0A/%(`8OE!(<<1S8
M4M(XF:')J@]BB$-HZL!>-7B!#YWZ53NPD`]=$"0*&/-#L3)ISCK@03.>48/$
MU*`&*0A8"FJ0BT^`(H5YU+$+YJ2$',"ELG=)H3-A`#"TJ,#_AS_<9325\0PP
M428&;>Z2'CER3!?T=05+@G@><G!7(Z,;A;/$X0YW`+$>$F">2JC!FMZ$+UDP
M(X='X-<-<\B#\G0+!]449P[L')49R$`&L)W-GVP@#AO:<+`QO&%Y:6`+%[XF
MSWO&:$8:^)0&XD>`#J@@`"D@(1%BD,W/>$$.;O""%NP@`A\,@`QX8`$0>)`#
M$K"``QS`P`8J4($,9&`"$3C=!S@PZ@X@*@%4$,$6V,J!*7QA`BE`P0@&:`(3
MR*`$$IA"-MS7!`1I`,QP&%67R\8&]2H4-=%ISP`(^@8P6$L`E!V!!.(0CCIH
M0@)0@DL8<(F!5+P@`6[X`Q^N$`8W_XR@!R.(P`8><![R#8$(1$`"$HY`A!6P
M(`,1O`$0`H`$,GV@&WOH#PM>P`$=;%`""1`4$(B``Q24(`,2W`!+=P"$')C@
M!>OF``IL((`Y"``&0&AU#<GP!@:0J`U?[*V=NW8;-I"!#0:X@!WN0($6V*`$
M`K#;%/S%R#_8!"2FU`(7V.('+X#F*QB9%W.BX*\H<&$+SZ)(2(0RUSKXUU_E
MCD,7_%"N?I1;#;D(XQ?&@`469\$/R>RQ/;30!0'LX;_7\L.3'X$M!",X65#,
MHKD`Z0\KG,&:1SO:SZ1PA3@<4U\)N0)D7HB%NI!L,LS*Q5"BT&`\@%V*%0.D
MQ/H013>$(?^3&898'%_X+'FPA(ZX*E:'02PUDJG!)<PZBQ<PHDU,4D$@EO#9
MRN[@>4L:9`M5<$H=K%`.*[BA#CY,OO+>P$_CC(H.=F@#&H;36^?;<'IS0)':
M<B-5,!AL#6VPF_M`Y(,W^X`,+*6`#G@0`P)D0`@Z.``6CM^'+'RD"G9`Q@"Z
MX++/MJ!U(\`*F_9IGQ9J>((!8,4!IA96:Y`&!Q`&=K`%!8<#`2@#--`!+M`"
M+J`'KR("!D`C@^,>QH$:9%,,[[0U<K,&&B`"Z0`,;X!#6/`'"4`!!"<Y5K`'
M#5`!,J$R[:8R$^`Z'/`#-I`#,9`*-O`"#7!,#<(!#Y``'Q`#0$#_`BB`!$N0
M`C<P`@3P`(-R!$M0`$0@`U(P!GN`4BR0`!*``S"``A00!A7@`C90`T#@`A)`
M`12``3:'`7X&`ST@AWO``3A@`FJP!7N0`T+P`6D0'&M@!F;P!JAA!XIH!W"`
M&V\P`&BV!1^B`&,@`!5P`C+P`5Q0.%%P!FY`+WV`,@GQ#9CT1G$@83HA%6K0
M!UK`!W_A:F?D!R/C$@A6#LQ2&@2A%PN6$4;1!80725L0$!GF!>AB2M:U$GK@
M!EA@!FB0#U)C*6?G:F%A!8TD!5@`!E_`!U,!,?XU-1K3,F<`+I\7!?T"2!F1
M2'\P+YPG+:6(2>GR0MW($YX'8B9396+0_W?A$$7BU@=AL(]3XU]L!'540#5R
M(#7;8@5UX!>,]&-=,!19(%?%Y'-/%@9"<78U!C%#XDU:('=_L!17H`?L=@;G
MP`>5D4X^]"H,T&5IH&5T0#TFDC?LM`:12(DVZ4/,MRM7Q$YYPT\*E7_/8".]
M909RL`&^`P0JL!@H(`0)0'9Y@05/MXB:PP9N$`$6T#(5\`$-H`<2($&=!FHL
ME0'E8P&>E@&L,SH4H`?I0`9W<`(YT`.99@(ET`$OL`-RR`7MT00SHE4KB#QY
MYDY@4&9D$'X^E`9D``<(8EYK8`=?("W7H@=Y90(2X',X<P`30``)T$'L!F,"
M@`DRU0,H@`(ZH/\#*D`"-L"$%,`"K#D"%'`A*%`#\`8$M*E2"[(#*1``_',#
M;I`%%:`#*7`">'``)_!:)4`!!T`!/!``-5`"$_```G`"2*`#$\`"1[`"N$9-
M&'!K!S`%=Q`#2#`"54`'>^-FM$$,8\`&`X`\)N<(#%`J!H``%\`%!%`!-%`"
M$<`%R:`%'Z$7[0A'_D`0`#,R"=%BA'<%0\$'9K<%6U0:\V`%$SD&9.`'8A"1
MG3*1;50NVN(%N1`.V\@%7N`9?U$:5V%="DHN0P=\M*0L5'`&7;"-6("-I"%&
M,<I+`G`'Q[2+8F`T,81&"CHO7/<K`NIW%7,.Y?`LV>(/$#$%?8024L3_/0=0
M"?\B,5*@+/(0!@&I$751%@DQ-/BU!V!7;I71,CO32.,5!U+`=6?$2/U@3=N"
M8"TV7BTC`&%`%&H@`%TP!7^`@P@7!SF!!7T0!U:43BNH3FWP!L:Q6[REB,%6
M!HNH6]3S0XGX'&CP-V^0-E.E!6G@`R#R4'-`!E>0`"9@`S!``AS0!3AP!!C@
M!V/@!SZW!4&4!QXX`'NP)QB`'J?#)G<@`1OP:0_0`-ZS:1.@'Q8P/QQ@`@'2
M">8Q`CB0`Z"55P32`3_``A:`!>M9/!^(/;XF`G`PF%H`J[]!!W"&!G;0!$W0
M56/``%]@=.`B``TP`:W@1'L@!7L`:JC#'Q'0_S)9R`(G8#H$<`"G@P$N4&DQ
M8`,XD"$JD(8L8`(X4`.E2@)`0`@I@(4S>`,P(`1+4`(A>@,+@`04$`5A8`*#
MD`)_0@,D$`!'P`(-T`<-``,%L`,[4`,DT`$1T`#<TP$XT`,6P`5[0`)/4`$M
M8BDVN4Z8*E)%H`%KD`!U,*L,<`%*H`!^,(,E\#D#8"/\>09&=@8U(Q(:,2W?
M<A7!0B[?ZD;B-FX?`V#=`AAAX'3HD`_*HA.X4HI#(5>6,2_M!8P<^EM"]QJ9
M5!=8ZQ%WZA5*D1568!/?I`9RL#*.4"S9@J5:81%3@37]D!%BX'G[J"R9!&#;
M51)V%$97`!?C=30=A/\S!#$9RG(%B.L8%R,0^@5(+@J0Q!0&%'8%=<!D20-'
MN*0'<7`2?Y$K?"`'?<$'SA9[EA`!KA`&K70`KS<D_TH`[P(L5(`'6@`&C>E#
M/'2>;S`,6Y,<NW(W;68V/C0'K3%]\R0<E-H0"=,&31`BCI8&6]`%&3"%1S`"
M8L`"-2`#529)(5$%9?`&QZ`!:E`".,`"$B`'H/8`&"``!_D`IX4>\X,!G"8!
MH>8]`-(!'Z`)+?!:+2!!J+,!"C@")8`!4\``FB,B15`CQN,##)!.RG%0SZA;
MD!@W?]-H9)"G2Z08+@:L`2L`PF(7H78Z'$`Z\V.7/2`@*A4'4AD_#T`!-!#_
M`S4@LRP$`S`P!':5`@%T"`$``06@`XVP!W.X`RC0`530`A```C/@!G[0`#N`
M!$R@`M`Y`2C@`!#0`U!"`U)LQ3D@`Y_PG!+`5C?``9]KQ1%`4%7P!>*:9@UA
M!]4Q`)U2!C$R!W-0!!X```;@!Q%``SFP`P0`!T5`!U*@38^!C)@$+6<0,=!2
MC!3J!56P!7YG!0C%!T.S7<RR8XQ$1Q9V7^)P$-`"#N^(*^4B!J!$!6'@+E$Q
M%6=0HE'P&NB`(U&#C4=3!Y3"I`-A845'$$,B`&(@E570+P-!#^7B!H617VD5
M!51#,7[0>/-0H2PF,5T0&2P6HIX!%[CD2QS#7@B*_Q%=8#)W@*#&]Q1B,(P[
MT33_TE7NZC)7UTAB,"3$A(Q[2AY]L`6*YU%&LWOCY7:900FCD;B%%#%CH0]S
M!HTNXD^J`38T5"HTQ`#DN11?T)AY(&9D-C:^H!IC5P:^H0'/<`$:8`;GH`<M
M\`1'4`)W\``,=SZ1$1+M6`6!,P`-`#P$$`6]10`-H"H/<`9!40><R2`=K(._
M.@$6S!]H60(+VVDZ2%DG4`+21@4KR)<&,#@^4`1%8!W+)AQ?4&9F8),F!P=I
M,P9_PT-&L08#4`9IA`<-P&Y]W`%[\`58<&(W^I5X*""-30$_`'(RL`?R-`5R
M0`"AA@$X8`1(0`(Q$&LK4/^J1""%0-!O"U``1]`#`L`I!!`#[6>=3%``'"`%
M:\4".;`$,Y!-%$`"#N``.F`Z+9"&,6`$0G`#_U$!&#`")L0#(W`&'V<#?Q`,
M7'"(;6`&6\`%T2$"?WT;T(=.,>(!"%`$5[`!/P`$2W`"53``6;`SR<1B3O0%
MEBT'=Z2Y;H$'A]L%I2@UX6,4D!$'>M`3SU(1E(&@]2)*8F0N/A=>[)7/<E$:
MH)$S__VFKC8W-I,0JH@'?GIB=Z!U'R$.11877C"17P"R`7FY?N!1_E('WI38
MAE$/Z*A?QQ<'!)'/9"%NT/1@CH06-^H&])`+1%%DE$`S4_$T=>!<.4()U!9&
MI#3_T5`C-.#"3<WH+S6&X9^TX2J35@^S,J_8!;B$I\9G>2!3+&3`!=@B1M.+
M!I7ZTOT$R;V%3V%!8%:4*=('C95ZB&@`=5P`-C(2<PJ@WE)0!QQ0`P5``D>C
M`C$@`=J"7=M$3&:@`#X@!D!P!#^S!U/0!';@!<!:2-#,!WAP.JB3'UNY`>4#
MKQN`.JI3`:#@/7>"E"7P`Q1P!@/@UC/BZ+Y6/<BC7.Z4GL]G<G:`!K\%!MY`
M!EZ@'F\P!FZ@!UV`@TL,(!Q``&,P`%L@O0)``1/P`2=04QA``SW0`[:=`C'0
MKV?@J@=`'A-P`SQP!"G``B6@02@P`QA+!!=[!%E<`#E`_P!L$`454`+6_F<0
M0`(_LSHHL`0W8!D,JYLX@%HP,`,JL`1&\.VDMB<FT`-6W`%NP`'V=D-30`YH
M$%=94%O:C>;#\`O6*P+@K0%Z0`%'``),@`)Z\`;]`&(*9N94\!0Q=`5:RS1>
MH:`[AJ6K&)!<Y'E<M(]+48KETF,?(37_HHL[)D<M"DRY<BV%BXV6AZ4<V@T'
M`1(H8WIBD"V?U$AQ(FY%AQ(@4W\G#C4(ZD:94:5\H!"_PGG33!GE=C010V[8
MA:!;0,Z?84G^G6CI(DG,T8UA4#0X.HH9A@=:FRX[]GH)@1%3\13^A:4VHS)0
M,QF2=.QXH$UJA`>?AW;<@U;B,__,;]=B_\6@F$0,W^(3=(8&HM(&_N14"L4K
MP/XUNX).Z^23&\^(9J`/9!`=%]`$;3`C`\`%?U`!*'#:)I``+4"R=5`0I1&B
M!.`%)#\``G`#)1`')S`">D`&U.$'=?!),E,0>&`!&#"L\$HZQ:H?G&:6%9"O
M"1`!_-$?2$(#"1`[?#GK6J5L&I`\6[,\N`$(:6L#&G-59U%<4U-\8GIG:&A_
M<E-[%1\T%1,G)QE8(F]O<A,/%APC%!TX1#`E'#\H)$,E%75U#1$3)24Q,"0M
M+4,[.T(02[X\0D@!`2H17U$5P#`!!0$35@08-SLQ`2=[$BXW2T0W*T(P/#PQ
M+"\4)C?_*#@N*0$D'&$W1E=C7%E3QLQI,X8-ER]T[)0QPP;-&$)@TC1QXD%+
MA!L\8-C8PP!-%#%=IG#A@L5/%SU[O%3Y<^9,G#MNI$3Q(\6+&#%RXHCY$V4*
M%2E^IOCI4Z6/E#Y1KESI8^6/%"I_KOCQ(R:.G"M<P&CYXZ9+E2]<MF39\@4+
MU#!Q7NI18\4/VBY6FO[QDZ4*'ZE]7(I!*\>-&"I\?EX)4^</%BU^W`@0X"5*
M%BQ5NESA4R4*%3])'0G8$T8*RS!GO"#M@D=/URZVK%2Q$B:*%LA)PX3IXL66
M%S]4PNQU>@7H%2]6^/"9I*?.&:FYW>A97$>,Z,IBZN#9L[9+_Y?99_`(."#@
MSA\K5]3<"<-T*:.X<-#\PV(&3J@Y>0;(MY-FI)DW:[AH:6]G0!X[;[31QAIF
MD($&''.H1T8>/EP0P@!9&&``'7P0<$,!"ZC00`L\5*#&'UY$!=X9=T311`AE
M-+"'`".P8($<=Z`A(1LF$9#!`514H<<$&&Q`P0@G8!"!!+E,8&0&$1QP0`.X
M5%`!!RZT@$$512B@P`476*E`$1J(($*7`Z#1GWP:Y&%&&82L\0<>;OPQQ1=]
M"&!!`F*XY]0!/YZ@XB8W4!#%`#ZTT84<`F0P0@<FV/"$`T*<0$`#)=R@PPX4
M2,"=!!T8N<,1,.!P`@<EH$`$$2FLD/]"#40`0<03*1S`10-#X(#$$D`XT((;
M<G0`@PL4+(%$!PFP<(,-)!"QA`HSU!##"1V<0(,+.,``PPU$.$!$"V=4H(()
M4<"!Q5CWT2&H%'!H0`<;<ZS!1QL^H$$&'`HXT408#V`P0@56,*`!&H-5`<87
M6?1!G!J8\2&%<X!%41-(5M@T6598")=%%'\XY8==8?Q1A4]]+!*7%"3J(486
M)%WA5Q188#$2&6F08=8?U^E!``%U>.%P%)8!]17`663AQV#:W7&&&%*9M-,9
M?7RAQ17+[2''AU'P87,7WP5%51U[[!&'4E?\`1I(7LB!$AYA>.&&&YC%(8`8
M3(EQ1A=/Q>7_,&8-@R;''M[U0845??0QZ!VB)8*%%&+K\?09:G0QU"2/$G#'
M%74KMQW-4O3V&]Q0B2%3'U=$4L88:\Q!1T+R,<#``&]\404698A>8!L,^"#"
MN7"X1R`9#+G7AATB&!#"!7F088`(?3Q0`A$0D#!!!RFXH+1)!`\&8A]T$"\D
M!3I(X,8=>]11A@$*#)"&%!%4@$=8=4B`0;,?5&!!+A5(H/X&#1#P0`0/E(+!
M"S*4@(</(?@=EA0@(1]HH`@&],$`N,`&.R!(7&5@@^G0D)?-3&$.6K``#2B0
M@2S0X0S+20`%.$``0B5@`R4XP0/:8``(J2$"'Z#`!W;`@P)`0`4'_\""'BI`
M@0J$J@0$P`,!#O``5<#@""@X!0MPD`-BI8`$0(!!+)"@H3N<H`5"(,&%CC"!
M.Y2`!17`0`H<L((*C,`(*&`!#(A0`AK>``.ZB,$-8L"#%,0`>>:@0!TV@(0(
MI*$L6TC$`.S`!8'083YLR((9-,``@M@A!$[(@Q0>T+\&<$$$#-B"XK3`"#Y8
M`2=AJ()8J`"<*0"D"R"A"U,H0Q(JZ`TW8F`+9*S0!3Y\80M5J$)6BJ*W+OBE
M#U+#PQW^0H4<?8$,7.B)'_@0A3Z(H31NN,(4*H.%LE@!*%O03\Y`)`<\A$8R
ME_E-V8!BDCC4X6R/8.89W*`&-^"!:&$[I_\7@.*8+/RD"XB[`TH>$08WQ($E
M!$A`'-""-RED@0]P\PSD&L;...R!``*H@VS"4,S?\,0N4U"8;KP`FC@8+@Q7
M.,D!$K"'XW2-"N&13O=^LQ3+>(%J?^##%,)#H#*D`4&AR(/I!@#!B6FA#?*A
MPQOHH`$%LJ$-<*`#'`B4!D',H715RA+J#,`&`I2@5D3HP`-@,`,"3`4\?0!#
M(]2@!SW\`0U@2``.2'""`ZQH.V)X@P$NX(,M["$!>J""&<Q`A028@`4<F(`%
M)K`!#E@J`Z1@D@4>8#\H@9$-(?#`[[1D@"84X;)<RD-]V("@/&A!"V-(@^G:
M@(6H2$$+=B!#`T;_@`$*X($*F\%"%U(Q@034H0L":``'>@!$,LP!"WCZ0`<B
MA0)TH.`!<*A#!!I0@1D@`1^GW4,';J`"(0@A!S%D00M.X`(6R*`7-S`!#@)@
M`P),P`9+&,((CN``$\RV`1)@P0J8L(`=C&`)Y+T!#G#0@QW(P%(ET(@\2+`"
MY!6`!#BX@P`*<(,PI&<,64#(&\H`AC&8P0YT,$,;1@>'^%#8!PBX0!I8U((;
M3(!W:R@*'XQ"2UM(03]]`$U0IH`%HR0"#)#YK!9.\J'?.,<QA/,"Z\"PA<_Z
M3`K!:2:-I6`_`9R!EL?)Y6"L(!C:4`%G2/F6%G!GSV7V+6QQ\(+EI%"3_\`M
MPF^2>>DR:1F'6E(!5R_MCAJ>!A?,?"69%:O<7GYSG(/A2@`)(,`?J%`5,0]%
M*38;=!?:&=,U;::L<?C)7J2P8LBMF&]YL84>\%"';BY&#I2FI3012C0QW*'-
M?:B+%>+P3BR,@0]EPW!"[#`0-AQ2`Z@[4QE89H?3Y2$^_F%#&MHPASFPX=AP
M..I3N^0[!31A`&P8@!8JL`('@*`%<EC%""JG!O)@`0Q9^`/6(OHS#J!@!\M]
M`'<(L(<NE.%*&JC"'@[PVJAIH0X8B-\#"+L!MX[T`?6K'P$D8`(9=*`+OAL@
M`9M@61_([DMT^%P:[(#KC(Y!3/DI"<ZVL(8RW/_A?1/@S@0JL.7!)L`"$M@#
MV5AD@DI)0!,6>)(+3F""'>#`CA&(0ATRX$-[(&$'8B"#'N)!@B,$(`<4L$"^
M6UM8&Y3``B9(`1):D``4%"`&)E`!$W!`*#Q,@`4[(,+5/Z""`AAA!Y'JWP_D
MQR$<R``',;!!"A:P@!FHX`%BL($1)A`H`9%A"]$&`Q7(\`8VG&D-PAX$:=N@
M``08X`\6<($*6!`%$2P0-V&@\SQ[`A6;`46F4]FR&?PQDBFH00"/B*7F:.Q,
M*6S!'V/8`FYJ4DLM;`$,7*#"0^-`9A+%9"B8@4Q@_%#-+1A%IGQP-30VMN8P
M)&[-3NG\-0<S-)=880S_8,C,/*_IRO#01B<YRN8M:9+2#Z4Z8B;!&G6\B;&]
MU,$TUEEG&,`#3MD+(`*H5[G9J!-_\D2-F28Q&U0#0G?0;3&U"'P0%)[T!TS1
M$C)Q%]W$)E;@$U$Q`*9S.L:&5/&1!VV0!F^`81WF'W0P![2&!E]0!A\8"@@R
M$!H&*',5`@:@0&6@!7NP`PL``D80`1&`!"QP6Y^D,5\0&%P!(YMV`"<P`B25
M`!&0`(NQ(GO`!;ZC`5XP,P(01'J@6RSP`0_`0Q,@`.:D'2-U`/9#`9Q```R0
M)5IR`0:`0)9G@1;(@0T1'V;P+V`Q!D6!,Q<C%M!0!P(@1!;P(P(P!9RC7"-@
M_P(5(`#N)``;X`)#L"T3,$(LT'(_L`,HP`,YH`?DLP$5P`)'``(@8`-U@`9A
ML`$]``,0L``]H&X)P",\A`(R\(<<``1(<`(D4`!`4`(F<`0\$`%AL`?V\@%Z
M-P.G0`TJ4`(C,`(N(`,;@`'"P@)7%`-#H`/XA0(Y8`)W@`<!<`/0M@8$P@7E
MHB,,]`;))B!H4`9KX!!M4`0>@``#0``4$`,ZT`!V8`!P$`5AHP=WX!5$9@5G
M,']Q44RO)!)G(A8SI09IT8\ADB-@``8TT19$X18QM6+`M#H`068]<07O5P=7
MX!B+<(+@EDM"6#22T1-'84ID,3B;]S/2]&9SUFER0/\;89`%9<`%)M&/4J$%
M>-8'7,`'9R`%5:`%QV2'EZ-@>M`%.:(%"@-"*G<&WQ$8UG$%:H.)@2$&;@!2
M"A@P=U4'XH$'[21,9Y`3;N(S?7!H9=,U[A1*/A,4GZ62Q?03NC&!5+%IW40=
M'V(%8S)(R<8&;S`'2X4&;1`?QM9`/!4*;_!W90`'=H`N0L4&_F`&`_""SJ8!
M;R!;'=")!4`!$0`#.K`'?:`&5(`%-`8&@P$W5W`&=[5<B*@V5!A15W@`9)`E
M:1`G$C!8SH4"`=`"#\`!'5`!)<1.<G``$]``]6("+S`!6G`E6F(E:R@">8"8
MIX-A)(A48&`%B/D%RQ0%U\3_.3T1!GY`DW@P!7'PB$^2`(,D!@*``3W@`ASP
M`-O!(R-P`_="`R7072D$`S60`SI0`@EP!W@B7P7@B2@05UU0`3AP!`M`!"P0
M`01@`1]P141@`SQR`"R`!#R@`M7``@2P`S/P`7)``$Z2`5@D!+30`D0@!#W`
M0RU@`QSP)"8P`AS``BF0`CI0`ZP2=Q/`!M85!W-0!ED@00,B!7N0!0,R!PX7
M<>`V!A3G`P;@!"'@!0)0`CEP`EY@65S@!>ND!E>P!6;`!?Q(4:DF%%/A2EE0
M85C`&F'F![3T':Z$!7ZI!5X0!^S43]ZT'UH@!2#%-UBP!9"1!5V@3W'@&E&`
M2E-`_V11XS?&D7P4XQ1=$`=J(!-<0`;99S.N(37`A!J,VDXMA7L^\:8]:4HU
MICAE$`4$(Q;%-U,WD1;^U*A^X#77H0;SY`5J$!I4(!)9@!-^\`6"UQ?DP4L&
MXP4H94X[P129%Y/_(`5=,)9>H$_:X854@)-8$`6KTPA:.6BYT1<RL:I?*3-B
MZ&14,(+"E@9E4`9(]09I@`8>:`>TUG$3)RYM(&PVU1!H\(%P4`;9U`8BH`"2
M55EPH`5\$`<WX`!,,`,1P`(!4`%7L!-O,C$^0QDITYF`YE9I@1+;D37+P9Y;
M`#YFH`<1P`%:MP0[$``8R@'K686+484)0$1DR`%QH`&21?]`$B(A32`"16!9
M##!AN-,><X!,`R`"<W`06R$'7E`:>Y`_7:`%5A`P[L@!1Z@'&F`'4B``$A!'
MN.E/`R<!#Q!U*3!Y!+H$!3`J."`!>B`!'-`"2.")9)0!'9<!5E<`2;2%&]`!
MLX`!@_6(*5H"0@`"*@"U)T`!#7"R]F,#G-("'?`"*L`JN&@#K1`!?V@"+RH$
M-:`"0/`$CUL#+%`%Y'`"$I0'C%2N[=H07&"O^)$&_O(&N,8%>>`!'C``?R`.
M,;`#71`^6O`3$XA[?B,'8@"MV:0?17&K:*`%>J,W/XE241%^-S4&@>I/7[D'
M;J!+%.,%H$<64T!.I>D%6U8%..'_DU&S3%*P/5T0$0"3%&H0JUW@&)8Q33W3
MF?EH,+_A!LTA!;1:&0=35IK#%$<1,;<!!G\W,6$@OTK1BW5`:5Y&9H#!C[%J
M!5B`.WZ@$XY!!>UDE*P1:KYZ%[':-2]%46!@!EG0&U3&.60%45ZQ,;#A3!0K
M-,X43<;J3W]P>F((4;<E(.`*%F8P.FVP:V8@")PU86!@CJ.WD#:UI6/PEW,0
M>VV@`;[C`6KH`RDF!KD(`D1``#00`#B@!E4PJS\9$'``>X+P!:2D-OE7A?`5
M:(N1"PEPL08P!1BP5OZ%8!9``#&D@PJ:/Q!%`!&``5IH!A>`NBZKG)4%LSQ+
M860`.SPE_Q_B\P5M\`=#-%(Q-P$9(`#)ATMG($)1P@%4,`!@(#/AT$;`4`*+
M7!P)\$7#X`([\`0@``%,P&#:$0'8`P&>"`$U0`&*1``S@$0_D&^%U7*M1<>*
MO)LQX`!'L`$)$$83$`'=(P$G@"R1&`]&1P\J0`0N0`!AFZ).)'808`XI``/N
M8Y]<T"5%,``_251S@&-MT`0%8A"VAFN?.0`7@`!V<`42L%89\)ALH#"?)S"H
M!!=+L05D,`:^RP?_X@<<Y7KT6F;25&0JPTD"0VE7@`=X$,&+D+O_XA,)F*QR
M$`4S&!<'"QPR]4E>"'AI,`9E@1DSH3<VP0=U,5-8@S:%VA2],?^KYCO%+O$V
M5W!ED>$&3[8?9%`%!TLTS50YB\:`#NDUGTD%1-D%8[$%A$,P*<R49,82DY$;
MXRN(F4.5S4$9_>1.8F`7>B"&H,8YL=07N`(CBS%0;I,=36.0^"@Y7(EX2S4&
MH#."'8V_"S%LZ?(O:+"EA_$%'HW7O38'-:P!#F+$:\B!5H`!,``"]84')+`$
M`I`58/$8#P$*;+`&+E-D0D$H,Q-00W*R)]L`%I`!"?`%(<`&&\`"&_``/U!&
M&OL!&!"U$K"@E@)H/#(!:B`"J!L">4Q`7E)9LE-XXNB&A,`&@:1+[AC,&\L!
MW%%250"IN"6VW84!;L`%?6`XBK$!*6#_=C'P`Q3`GM0A`6TT`BO@B9Y(!(>8
M"R.0`DNP!$\0`$MP`EKP!AMR`]C-0Q^0`<N8"B.0`5N(`30`!`%0`AC0(TX2
M45$;*8Q[`L3@`"@0*C]'`&K0`#+`52V0`P'@B4CPG@&``OH``7KP!J9#!E=0
M!1N6.EM`!^*,$/X!!PS@M%0P!C[`I'!``"SP"V&@`'6U:&X#'!^S:+P'E,:7
M?)YD$S$)82&UD<_J&5<V%30V!E@`0K<5!1Z)UZH#K1^Q3V(P%41!!>O$E+[T
M4'@P@8MP&&\R>BMQ!]Y!&9E1-HJ#ATT!%SGC&M,T!2H-&/U*-I#C:BLA3:WD
MJUI@:K$*%`WS_QU>L!S<ZAFXPA,@%`:>M&=C^3-B%AQ54&8H$4T,K&F1]@>`
MEA*H@1(S4QR-:@43G!9W<]D1M6=83I=O(!_ITE0:M@;85P9UO1!K,"!K4'AE
M\`5XK1^$9SISD`8D'@((X`%;P@!L30`2#@(U4`&]P"WE2F0&P@"6I[EMX`5[
M0`5;T(M"Q)ZBOAQ]:S^=30"!\E8X4`,CP%@3T#[;(0$)8+5#-,?9G07XFB4O
MVP0*(`)ZZ0,(Q`!E4#T,D`=[.4A3@#!Z@$(C@`LM]Q?LVP=[=09+*`"ZX`+6
M2".2$P$VH`(Y0`U$@`,=$`'F)`$4`.,WZ(E7-UCY=@(W`$4PL`1"\/\"4[`&
MG?P!N>`C(S`!*&$O<#1"'%"++M`!'3!"?#MOF/(IZT.B($`"XA4`,S`!RO4!
M,9`#+G!'UB;>+'"@?O`"3-`!6T#)5/8%&A8\8$!4:2"D"G1(;W"KT:8``%`$
MP0(#*4`!;Z``>9#`PG0;8\G5IC&KH(FF5":[,M5,)/T/J!$&T_04-*8T5_`T
MLXM6CS'%R=<'TM&/!UDU!F-.RR&&0I,3&8-/_.P/^[O0HF07A^'I9S`4ZS1,
MZN29@C@%6O#H-#$TXV0RSIL4E)89?S$%>$#Y!JSDR6HX=R`';\-1['1E!R,:
M9G,;4ZRF:/$7?7,2K9%1>2$':(&/9"4'(++_'8LA-)XW$SWA46\%42*S-[TA
M[7OP!VP`;,FV5R-8CN6:S^9X;)R5;*'P1UMPF/S^.7E@`.M(5_+1!@)0#PX`
M"`4O!TLW?WY<7UA?<`,B/AH^;7@1>GQ2%3<F(QP'!P0">W5Z!`D)#PT1#U9C
M500H*!T/`@02%!5X>!(9$:&U'!0"#!X>%PK'QA<#8&\##,\#&@QS9F1I<VM>
M`GIJ'#$P.A($%!-_6*124=H$=6IW`A@L'01G:@05)BWZ*DM/1$`H2E20\($"
M"R(@$H((,"+"!@H<.K"X(0/'#!T<^MR9("#.'@$3:)00H*5.`PP</CR(@`)$
MBA$8()K@6&N$BQ,3_QYP@`$"!H<23PJP<+.G`8T8,6Z0@``"2(,?3!R(:1!`
M!9XOA[*`V0)F@!DN=HJ,"1,%#IMF`^PPR`-'@Q(/?C:TJ('DA(@0:<+HT>,E
M"A\M6_JHP1.G2Y\I5:3$B>/%BI\M6/PX1JPERY7&5;+\<>.ECQ\J4OIHP8(%
M#!DNI*MDQE+ESY4I6/AT26>%3YDR5/Z(D5/GC)0K869[P:,G3);*8O3$D4(Z
M"NPM?MSH.1-&CAPO?*9<$2-ZRA\\<JZ\CJ[FBI3?>/;($7/F"I4P=_3@.=-%
M3BD]5[B@`4-%C!LW8:C!&151^"'%'UWXH9T:Y4T!V1E[B)%%%'%,9X451/]1
MP44?7H11QQZY"'!'%VJ$<>%'>ZC7H1QZW'&'=;2`&`ICCH'VGBA^P$%'6F^T
MD48C=K1AAAE;?8'&''2PD08:9K1AQQQH?`%&&F^\D0887PR@``((**"!'7:P
M(0$)!8"`0P8HI-#`%V)$H047;$3C0Q$^L/$`"R_H8<4>!K&``@DO]+*''J[=
M40HH!"1JZ`A#E!!!`IY8P,$&!.QA"P%JR)%`!A180,66%X2*S`4&B#!`6G;D
MP8`&<*!QI6I?;"$&`0=$8`,1`:1@`24/2(%&'95TX9$;8NQQ@'JU2(!*!2?(
M$`,)*N20`A!(!&`$"3G@T((,-@@!`00.@.#`"AS_/"#!!ARD^\$()[CP0P1J
M2$%@975PD$(,%0APQ1T1]*)'#SWQ0@%*&#SZ``4E['!"`@3@P$0`'4Q``A-+
M;/"%'BV@P((+*"P``A$'E,`$""\(<$,!%,C[E1EEC/'&%VOX(,(64OC!AQG/
MO`$D''D8@(`!?TB00P$S;.&!"'Z4Z$<5V6E1Q15_1/W;%6?(X1L?6F$!W!]6
MF->'%0YJ$448<831GQQA3-$R%V)7L<47B6@!VR)D@%$99&'\L049DE'A1Q^`
M^Z'@%%WD(H;?5'0AAA=4<*A&%U%D444?8N`A`!Y2@`$&'U?T`<885+@!2ACN
M>>:9%%90@0<H>-Q1!W%W_^12MA>DX&'%%EDXQH<7<J#N11=9*!+%%7'\,84?
M57?Q5Q80JL$'%N]!7<<V4O"QV^)QW$'L%1=*(>SE[]3AWQZ)EB_`-G*(*$88
M853MAN(E>C%`'G/XV`8=>=@!1QMHE!'K%V:8`QO00`:X-<D,L2H#&]:@HS:T
M0007\$`(#*"!/*!!"Q4PPL,0Q@0,?"$*?S@.&.P@`A$4P0!S>``.;$"!,&!!
M#0?(P`E@L`!=Z6$/;N!#=,Y'G(\<X"0FR$`%<M*`!$B@`A9X0`(J,`)]`0L#
M&]##'#S0)0-8T0#'\$$3*)@'^N&O#%LHPX:L@!X!'(`",:@!$4@@@:E,H`MS
MF/]"*/Q0K/0E0!5M^H,>[C@!#KC@!CC8@0Q:<`,5&$$(*4A!#6"P`B`$8`$%
M*`!3(!"#7MBB`A7H``8R,(%.WF$,6V&9''&P!"3D(`($^MH4,&"$&,S"`A5(
MUP0@E8$7L(`%^:*`$2#0`@*4H$PHR((47K`#"IP`!65:@ALP$*XCJ`($)X@"
M,[Y`!@*2(0IO*,(;^*##,Z2A"`,8PQAXIBH&7``!`[A#"6``!`IHJ0QB>!P5
MJ'`%/V`A"U@XGA7^X"&^4*$*K*'"&>I0-O9UX0]5J-L4_!8Y*:A!#+<#`VHN
M-`4M6+0*4=#/&L`P!3<)LT07REL6:-:A/_R3CF[X`^#_]BDO>K(H%,%QCQ0^
MY(8IM($,5'`,%\`0!0CA@9_M(4WBEE8L/+!G%-<Y@XL>YPXU.$:I?1&H%4#H
MA2J(S4!G@*@?PN"&.)1'"KPY*!6X*1L]",`-J!-#8;[VAW1$8:R4HX4<_J"&
M>L1G+^<30!T(JH:]$%0,E2N.>ZZ@AK1L]`MM,*P97+6D,;!-<XDP#9/DAH4R
M.#`:&A"!`HA!01'800H'8($D7=`!&"PA#'3@IG.XD(<M&L`'?Q`D!AXP!A^@
M00\5*($0%G*`S?2!<W$(S]?V8($&'.".0RSB)VA%"P)@H`0'B(,`(M"I*/C,
M`P9H0A..D=TBT.D9="##%OCG_UC!1:$/9RB%!4[0`AR0@`03\(-SY="&-?BA
MJG$@@!XD\*@('""OB=HC#7IP@B%*``,_2,$2`#(#(1"A3.(*`!&0X(``[,`"
MGI@>!2(@`0E\1`!]@$,:QO`F+`B@!4N```Q>P`XJE.$./4#!!,)`W'15(`$"
MJ``-3(`2"DC@!$2K%0\6,H$T>($"QHS!$Q82!0$$``1,X,`>0""#+81)HEPQ
MPQ36$,[?_:$.91!!'IITJCR<R@>A\D,%<%"`%)SA`B*@POG.8(7&9.$Y6ZC"
M%*RPNMY-80I22,[E&&0=[E#3-*?!0A2DX(4KZ-!FEW%/X_I0!3,,,`LY!:%\
MU!`'//_4P85<(-OBN@":AVI%"Y\1SQ^D^Z)!?>0.7I#78<:PA3HWYFU2Z.H9
MNGH%U>API%;PS9[/T[CD**<>C1Z,]@ISH7EVP43>ZT*'XB`&JBE.#O^YPQFJ
MX(<NU$,,SQ;#'[CYG:_^]JWUY-PHI%"W/@07L&ZH@^OD4*(SF'4/:J!TG5/W
M&2D,8`Y@U$(:[/`&QU*3#?NSV]O&4`97L:$-7*BHI>V@@1,J(`0("$$34M6&
M$R,$`@FP00`X$(4R%*AZ65)`=K'`Q`8TH`)V0(`&ZC`!%CQY!G\P@Q9.<^?2
M9,$-'[B!!<BWDO\2X`[MBT-7W="`#C3`C+9H0!G.&0(%&./_&$WP@0'`:>8V
M+!2`K:B-(M30@!'T(`<W<$%[*X"%/_2B"F70PFY"H8<(8/)1&^C`"V@0#`%P
M8`8UL$$G)%""&2QA"49(P7N/$"XH$^$&,(!``880`0)@H0T02M19\>`%'>D<
M#&P8PQDRT`(A%.`(,SC!)VY`!`F,X0\$.`D',@"26UI@`B48006><(0)Z.&7
M($#!&M(P@0I@P`4U6,A>4@!E&VQ@"22(0Q.\HCDTL,$,:WB#&1I-QZX0?'YI
ML,99FJ"$`>CA!$=800,T<($\V#L,WDM=>18!-S]42`Q+ZP,_+1=<,QY=>7N#
M!F,0!634!5V0.F+@.IS15F,%&PAT_SQ]X#==\!&:MQRD<2!^\%9\T`>A80U@
M@$]=4`>\(0>&,1SG(P=6P`7^<U%T]1]2H`6*H0=HTQF*I@6.-3Q68%6?D8%^
M\`?4T07QQC6DH`?>]B)<PST&HE;6$1]UT"&_Y2%&%06.)08\U`5_EFINT!$(
M$AKOH08*HG]7L`7[,5,015?6\3H`4B%_Y5%]L!W_Q`<,,`"MD@9M\`9K0`9D
M4`8_,@=F@7!P``=(`HAP`$9D<#\59P`7@'$(<`':5`T$D`(.P`0P,`$P``-8
M4#<6-09D8`8:H`#YDP`]<`;KI0=VX`$*L`4-4`)'0`*%]6]I868#@`4F4`,%
M@`0;8#D,<_\^!,`'7-"#!W@%("$B!X!)!X`&5)0,5_=:16`JJ?(R;B)1FG@\
M<M!'-L!()'`"!U8!?D`&`I`!;L!1S65$#3`!&?`)N!<#*G`#\Q`'#>`"[R4#
M/\$/!;`$0E`#B$0"1,`4#@`$-]`M,#!(%J`%8'`&(<158>`'96`'45(&C4`'
M7.`&%1`#2U```<`#SX(">M`&?O`A$V`"'<!A)N`"&[`I)1`#X,("9R`!NQ4`
M8F`&$3!+&*`"%68!`A`#"6$$/]`#1+`!&C!B1_(D`V"'=!`%49"'9L$S<R!>
M7U`&U20"&:<%&)`#,'`"64`J8&"`TB8X655/^)0;5%`:6&`%?1#_&89Q!?;Q
M7WAP!18U&O?E-^=A!86S!W%@'E_Y.1&W&/;44>J@!YZ`'UC`!5F0'7%3&;"Q
M'P4"!AS"/295!:$#(&!#!FLP!GS@;'?P$6<0ENPQ;OO$3U/`!;OS&EP@7HN6
M#AW%--*A!E\6"@]U0PO(!ZJQ9W(`(M0&6'^6A9A2!5Q`!?%!D'RP!5PP.5Y`
M+(>A0]8#'E=P9^Q#1KNF5?LD(.SA'F3S&Z@)0L11!U=P7L_`%CK#A_7%!G.@
M/X!(!]``)JE"<&>Q(UJT65QBBDW`!EO@!2.P9$!@*RF``7"P%600)VS`!A4W
M`%<P`<'``B;P!G?A`7!P1B60`5]P#?O#_P"F,@86L`3B4C%F%0IR8#E2D`5;
M50?Q]@#YLE\8D`#RPR57EXS+>"IE%GI;\$]O@`:@X4N%!P0J(`0G0``<8`)J
M0`9XL`$18$^A0`DE`(\$`!_KU0,V@`.:$`%N\``EX"X[@(]($$E$4`,!,`-!
MB@,I$`!,0`0V8`,H$`,\<(T$8%-;\`YQ4`5HD`<ZLRH,$"1-H@<AB0*+M$BN
M9P:+U@`<4`$/H!,RP*,Z1D,@L`().`,@L``3@`4)0`'&<@,!$``F(``B`P(%
MT`,5L`0L@`98D`:GL@9ED`?7-P!?,`5F`(AM8&9:P`=@L`;8!P=WH00,<`<4
M``,D$`'F-`!58/^`*M5M!@@VI+$(N',96L`RL?(TTB$*7TE6N:&#?7`<8%5M
M\A)&9L`\'9$%)(9/R%,*`M`%7R"9(80:@+$%"T<X7<`TRYJ;[8%>CN8F>:@%
M@/,>`M``#Z`'&1@X&JH&KS9JCA$YFM$.F:$%7_`%[W$&C>$%*>(?!.4&?C`A
M`&49VB,X'C$;Y",`^6:6<UE17V`])D5/AY$[8@!6(Y)*]M8B+0)M?Q"<$'4%
MI)9/8[,'=[`O_W50!VAF;+$&;)`J<$"SW[E`_=,(0=D&<Y`_9@:46A=!"&"*
MRX@&F``#X;(#4[`$/8`%8[`(<<(`<,``/K`J!O$`*]`#8:!UI@@&!S#_2Z#@
M!961#M'Q`#NP!$20`BCP`"SB59<A'_0V/1^Q$J4P`1&`!V:@`$Y0#"IG#%8$
M3COB#&&2!EI@(K1&!7+P8RRP`FL+!!R@!Q*1`-I!`$TT!EWP(@1P`C'0`F\T
M!KAUHRY0`B<P`K0B`0?P`"^@`M5"D3S@7B@@DB"9`O/(MCF@`D2P!#D@`4J%
M0W\0!6A0<#BC`6.`6%Q6!O:D!R^`I0$@`P30!]4T*RZB!QR``ILT`B9@`T<`
M`DM``%;``N+B`GT@N:O3`D:P!#:@!P^@CS>@!T^@`M<Y!TV@`1R5AY#9BU/`
M6'/P!E;U!D$R!\[@`TZ`%P*@`D]P`U>@`$4`_P9M=2%=DX&(093W9`7PH08[
MQY2AFE-`"#D@!)>DPTU]X!P+54^"(S@=]1UWP`IQ-P6!26/ZI3>UAAU3\%N(
M@4^1`35^@+)8,U-.!2#/LP5.LUIMMP>F<%:ND3KS)%VTT!'U=%X7\@YR0*]9
M,"$(0AIJ(`#@%IR88P5U%0:]"4)8('>7H\0?ZX/CA@5FD!=/=Y`YI2!=P`W!
M(3A>$$_GHP<BN#AS7%=@TP><@1H$>X+O:@D>X@5T8`=TT"-L0`=TT`8M@WW"
MF@5PDB1HD'T_JZ9.X@-61T43E!9;8#),L00TD`$P4`%I((5L8&:KLG5I<0-(
M<`,@\`%%P'XA,`!R=O^C'U`!W+`Z#\`I(_`#"6,#'4""Q\EMU6$Y+8('714B
M+J<';D`'5%0,V06X32`"`H0_`W"':9`87H`=6=!T'`!Y2$`$*C`!48`'FA0'
M98`%'R`!OOEJ!)`!$Y$!WIF2,9$`'Z)4#X`!-"D!$LE[*'`"?5)\":"^+0`$
MO+<",;`"$TD$.S`!>Y`9?O`F\,$':-`88Z`=-_,D>V`"A=0"+L`!78`&:)!G
MH[$!-1#*$,$"*<`$"W`";J"2(!`#`CL!_-("*?`/`N`%3\8$+9`%0H`$!Z`%
M:*!%;###J3K!?K`&=_@Y`Y>=5/(&9'`!3J`!'@<#%B`"38"T9+2%%76J'N+_
M&]Y&+`E+&H$1&A3\N[NCA'D,?V2C!G7)45RU&(6145LPF9_A;<KS9Q$X!9Q#
MPK_A&)X1!560*<\6!GC<&WP0*_JW-/]J/>TP4'M1'G.\5UY0F;WSE^Q:V?/A
M&EZP:_5T'HA!8W705E=,',S5!>*4.DR3/3>D'+]+Q7W!E&X0`0V`!XK3)L+T
M.X!3LDSX$=QP4&N=()@&6%*@%RDR**F[!_6A'M]IR(6<)$2R4V6P6*V0!6:P
MG=VY/ZZ2!Y@<`L1P`4V0!V-@!;$:+BW``4)0`EW0!LP`!V\@G@H@`FA07R60
M*RY@74U@#!KI!HT;`P7&81E@7$=W`"X0`R90!Y?@_P=H,`"'6X`/E6O@<4/P
M^E,BX`09)RJB0D&'#(C8X$"!&6@YN`<<\`,HX&`IT`(2X&)Z,`(/4,CC*`9;
M<`:MLT<4H!088+5G4'E]43-B<``?P`(8\'(T(*%"L`%_,(T8T`(Q4`(-L`<U
M!Z5"``03EHX:DP#0.P:5?05PHS7DLP=_T!5P(`;'9P(LT`,4T`5V<,W48`$I
MT*<`>@,Y\&0IX&&NK"9R<`!WD`$E,`14:@%\0`*1R`)O,`0!@`%HD`5HL'5:
M\`=HH`$01P:.<"42%2>9I0%O4`:?HP``H`!2D`$X(`0ML`5-``<^B,?CAD^R
MP1G42C@=VZ[T]$_JX`6+L/]J!*47VW"=!L(<Q8M>UH$VSA%HU1;84U!_7-4%
ML2&61.EM7A`U;2489<,@AU$=?<$%=2T>_E&67M"9?"#CA<$U['->\M*96S`\
M`ILZ^R1=>B`O)F4%5/A?;2(%QWT`$B``7OPT!YC#8C`*>!`&GK%/OQ,:?$`)
M!%`8Z9.!'=N#TP,*)\@XB.%0UN$;7W,&$A]/[)$>>%`K.`8*>J`JKWC(#[<&
M4:(59\$D::#4UZ=`K3(&:\``V^7=5><#;S`%=W`"2Q8`%$`#!:`'::""5=((
M:-8$:?`%6D``'<`!;H`&).2)65`''8`"+5`!`#X!%J`LQG4P&/#08R`>S<`%
MU>/_!Q_40_)6"GU9!0;0MR$@*L>@`-/'ART*M=JWB=M^&0+0`3&0`O48`Q\0
M`7M`[7@[!K&8(CE,5R!!`3(@!#!``67@`P,H)8!S!2$#S,7W`".@8"J0`5B`
M!FK0`=/2`@]@KQG@`BH``S5`%T*@`CA0`ALS*;.$@M#S.J`@!EP0AU9P"B`A
M`S<P`5H@AZ9R`"2`XGAZ`SNP6P7``7@`ODA0`6Z`!WU``":0`RG6`7YP`OEX
M`UQ0J3>@JE_P#%H0G%,P`/XS`$6`0)@>O']H%DLR!YKN!#[@![%:`P=0!$VP
M!8_S&U%#('R0.G]QZ(I#:9<`"%)4455]86)57&X">V)=_W)W:E)98UA_5WQ1
M5%Y=5E=G5GQ><5=545%;7U]3:G@">*%34W]U>WAG?X=B8F%74F%A?5&Y?%N%
M?51_9W%>?I]>4UM^;GMU87Y6UUA;6+)35&=B5%554U9J=W%J;E)<?7<-#P)A
MY&$"!P0'<5)64EZ]?:[D<G.GCA<K?^[8.M-%#!X];L3\^2.GX:U?K@A4NX.K
M#Y]S<5SI\15'CYXX7?Y0Z?-'C1P!#1+H8>AE`(,!;."\8?/&S@`[9:J,H3,@
MSQPV:<R8^3+F#1TV:_(TN7`AA(<+3?)\<5/!!@0F)TS,N`&&S10T;>#8T6!`
M@0$Z5;!$B2/`"A8N;!A@"5,!AO^-"@),'DA`P,*$"14RS+MRQ8\<+VNX%/HC
M9@N7.@0$Q($G(<$>-6LN(*AZ08';)D5$Y'F#9DV:*&7@?$$#QI,5/0],H"`!
M(P4+`G@2Q!EC3PR8.58$W)$B2D`&"BY(U(`Q@HR!FWFX^.E3@4>+"!-&2/`B
MX,>*%1VN8.F"88<,"ODV=&!A`\5N'C%,4&@1HT>+$A@D\$`$AH$W00-QD,&%
M'`D($-`$+)300#$,-%$'"K\)0$$))JC`A`,FZ,$""`5PH(8:7/Q!00H0@%#"
M'Q7$4$`-#82Q`A%3,%`&%US(]<`#=*115I!@%*G*%EIL848:;VB@``(`.#''
M`3$<T0+_%Q=H,,4_5OCA3Q>,19$%'Z9X<48?JIPR112_B`&*%:[<844?=&83
M!B%=A-$)'W[PD4448GB!C%UC&*/%*FHPHL<=79#9AQR9W1'1&6>$<89`O%A!
MA1_):`%&'[A<H><5PG11!QY>\-&'&GK(\0<?4KAQ1A0]1N&'.6ITX<<ITJB!
MBQX"=,%%%/`\@$<8S/%Q1V!Q;.H/+V?4(<<5FIP1B156G+&''G],T46C5[@1
MS!6M[+'''9#@H48N=;CDQD#69A:H'/1Z8:L4MW9QAQ[;ME.%%V_,L<88:,`Q
MQQQ$Y=%&&6L,,``<;+311E)?Q$:'3TU8Y4$(I8G0AA\-#+$$_XD"5*G'&$F]
M$?``/IA6Q!I:K,$7!G)X^@475.CQ@Q`CO""#!`+(45(^@9FT+;`"2$'&%9NJ
ML4<76T0QBAO!Q;3'%"(@,!K';AG@@P@B#!`9&@K;(1L7E:XG0`0FX)!#"BB8
MT`46P$ZA!=525"'&`0=LMUD#%I2`0@L]K%!"&46X-8`64W!00`EZ-,`!8'U4
M08`*`:`P015?B+''`1G@\,01.;#P0PLL[&!###&,$%@$'U0P@0D_N.""#"78
M3D$C\%00AQ]W2/#""1+40481?=SP6QP1=$!!#P4P48(<)X```0L"J*$%%1*@
MX``(/W1!`0X%.+`#&BP4((`&;40Q1?]9N(%!AAUT<+$&&56D\L4661Q:<84A
M4(*4!'`"&`CA`8E[PTN@IK<ZJ`-?HN)#N*10,6Y$X0IQD,,A]`2,/FBA?\,`
M%J.D@(Q;V:I/SJ#"-K3`A2]H(1%^T(-&PF"%*10B#`^)0QA8U2XO2$$*+[F#
M,%25JBQDRTQW\`+3_&"F*UC!"V)0@SC6%(9%]0$+Y(B"7'S(J3Z`80J0D$(=
M@D9"-Q"``)**@QCX0`5+-2,;7LB%`!Y``"N001IS0@86K"`&/XRA'%5(E!Y.
MY`8Y($T`RHD"'\9(#3TPQQ-F/%<D^F"W+4A!(N?85J[\1)XRF`$,6B##&N9@
MASFTP2EYR,/_`.BP!CC8A)5@B`W]!O`D)2`@!*9A`!JR,`$8,`$$0#@`"F:`
M!C2D`0ZJ=%C6G)`E-@P@#@V`U)W<5`<*W,`&.M@!!0X@`&CP40`:V1<BQRD&
M+/!A38^0@A;\\*TP[*$!?*L#&IYT%:JXI0A-:((/-,"`.;Q!E7#`@A\MPX<#
M'(8#.T"!"K0I@#]X@5_"^B06^N`*6JDA`A3``$)CP`(6M*`"8%#`!8J0)&&6
MX!X4F,`].K.'%P#A"(:C0.Q>,(,"+``(.M!!"FJ0@AS$@`0QV$`<SKBL"AQ`
MG`*00&(H,`(*6$!V#WA:`T[P`PJX001LJ("$_O"`"+D`"`ZXP1TR_]`B(V#@
M"P,X`P6\!X(61.$!)/@E$,A``1#1@0$]6H,=+(D%+)CA#60@0QKNUY0YE&$*
M9,C"%/+``!^(1@%4F,`-D,`",R"@"%(0@!N0(0:.]"%;LN*#J@Y5*"O4H0YN
M<`,FLH"D*=RE?U7X@TE0HBDZ2>$/7<@;S+!%A3GU5A9^N)48XF"%5/@A#MNJ
M@PJO`"P]=*$/8@"G&_PTC23V00I24RYN&1.*A.SK3+BMA1KZ)!`_@.$+V?A#
ME[1XR63$(0X3$8,;ZC!(-T$16>.X0A>J8,0]$(8*9OBC%K8G!2Q<@1%_D()^
MQZBH.%!CG,JI@A3,U8>2="$9?OC#&7\4&/\QK(EJ#%F'(Z0P!4.$H0PH!@/*
MW@"Q-;AX#<8<[!Q>V08RE.&?:[F`$W8<@B:(``YEL(()`@`"))C@!BF@`!Q<
M/&,&:(`.<)C*58KP%CB`(08G6-8N3"`$(:0@1,":;C+`::XSGNL243##;JEP
M!7J=X2'@/("YKC``#R"@GJ4I@I/W:1/Z,8`U7.`#%[C!58V>H`4ZN`$-=B>J
M90E@"@,X"A^$YX8U3.$>!W@`!EQ@@A&4X`43X`+'TK`C/23@`+#C``8HP($)
MR/`#IQM!!53]@A;<(`<S.,\*8`"#&=@@!4=(00GZ]@4O'$`/='I)!2B@U*:V
MYP8[<`$&]'``3T__0`MVT,.BZ>+I#T#/!7](`!)`P`09_.0`&VA!`4`@`RP0
M0`??"P`!(G`$%'!!!&D@0\72D(8VJ.)@Y>#W%N:@@350\`IBR`,_?>`!)3#`
M"QU`0@KB@``%C.$,J:77NOJ@KSK4T'U?B$(?_%#%.EQ8*&90T*`5*UH,ZHJU
MY"C$IC*1!5%53A.7B,L6QD`&/EJ!8`8.@R'#@(4LG"$?>Q!$2<2181EZG`I4
M*(FF_C'R-M[A#GB0B!SH.Q(LCN(*-[MM%+0@%]=NXQL_3+`4NJ#&';JDCT*1
M,)LMM9D_?/`@?S"7?`D@#Y,K.`RIU5-)=`@,3,BA$540.A7XL`XO')X1_W+`
M@QR8LT.5^$*_5V#%'<(`%324@0QF..7!S-"-][6RQ6Q@0S%=.8`BB$9K%_`!
M&L;`!0'`&P0J:$`!4-`%,Z"!#1?+`QS,P(7Y&<!K"FBX"$@@@SC,Z@H44`$*
M3M!0EYQ!$%[80V#FF``Y_34G<]!"I:B`A\^`\]1Z.$05BJ"U$'#L`EZSB0;"
ME@>>`*65?\S[8,*S@QC8($(CL$9<QTU3``=ZT0$SP`%;P`"K(`;`8@'0X0*S
M]@"AT03S5P1IH`8)0`$_4`(?L`&L)@%Z<%H"8`$<4`*K,P0Q``-+0`0S\%,P
M0`(I8`0%@`0N$`'@9`$2D&D=8`(L(&T6$`$1P/\!.6`#.)`"*>`Z"<`!'+`'
M8/`')W!25Y``LO8!.K`!4Y@"OY0#K/0`6K5N+)`%$6`#"V`]);`'-T`$9\``
MJO<^:`$'Y$`'&O`%5/`%^-,&`S`&KY)@K3=_'A`$(=`&$9`"`?`"`W`!;S`*
MY9=^")$GP5`.O24T)+026"`_2J$@+J1((_<)B*446_")1?="":$'8I`%9:`%
MOY!YK,4-,L<YEC$&?K`+I`)$^;!&?<)F+4%F;K`9MI`WET0NZ^(+O9`-\N4&
M5``&7!!==Z!(/J0%A<(GAU(%4,=F4/<+9^!#;80L8E(%HN(%J=48?^`&S^4&
MZV`N,S%4<D9#H;`)C''_"',B)A?$+X)P!FJ@17=P5,DP"=R86I>`"19$$151
M"W@0)&,`!CO7!D1A950P"6M`!V_0!N<U2BY&%"WC`786`@8@`B%G!1-P!"``
M`CG@."7P!@7I2G:0!B^4"F9`!PO#``J@!!YP*7-@974@`0V`#;AU?5#'$L!"
M7P?0`'CP!1K@`W10!FC`!6Q'*M>%7)D1!KUE'7=&%:5A`/B43_K$`/XV!CY!
M!VC`1!(P`A&0`!B``T"``SO0`R>`!\S%+P9U`%M0!'8@`2I0`P>0)55P6G5P
M`!QP`SW@:HEA!@;@?FXA`E4@`2;``1F``1UP4":0`1_@`CL``RT"`@[@`$P`
M_P$25P-+$``PH`(LB`0P$`,M(`,<,`(>M0,1TFD5@`$GX`(ET`(H``1`<(.)
MT0"-\@$G]05[<`*@=A@"D``WT"(S``9Y0``<X!4@P`):,`%:2&XJ(`8;4``/
M('QI\`6NQ`9;X"IP$#9K\`6LQ09FP"G8%1L.4P0>$"5V0``_4`!`(`<>8`=C
M9(Z28`5BPDY8H`6W00!Q("9CX$FS)S^"509;\!%3P'AQX%=D,`9DQP5&9`6F
M,A/TR8T/(08(@2^G`"OB4@5M`!1;,`7ADF"+X`:W(HU@XDZ,`$YD-`@?<71Z
MX`=;``9%IU@71*'<P"`$$&)JT!ALA@I1X`;U=2;LI/\087`HFW(O_K4'G+4N
M5G!U_=`+A:`&?+`7Y6<+XN(T>Q`&CL(0;-99KF(FUP!&!.!(@S!H?4`-YS)>
M8V`&%8:BMK`';+`CGY@&"`-E=(@F_.9[/#=*;>!,B6.1(7!G!K`X9E0"99@"
M-)`#)+`^_7E7=H`4:'!'!.-);]!Z;7$5@7H%\#0(4W!<<P2"FB$1:A`'=2`&
M9+!/IO2H2N&@V:!]K2('9^`'=B`:[V=/1>`#J.$#N$IZ:$!*;:`%ZB4`%1`/
M[<$#.,`Z+A`LA]0`#>`%;,$')5``.[`&!I`'5/!<=5`!,M`"TZ8A)[`'(H"1
M"A`"/E`%E!('"5`!&B$!'=#_`2-``RP``PNP>S30`B1@!$1P!$@0`#7(:T!`
M`CB@`R1@`S(0(1^042#8@Y"Y`S-`!$:0`D#%`B=`1PU5@@+@!WM@:\Q6`9Y!
M`>.V`EN0!P]P`C'P/2,`!P*0`A\)`@$`+!!P`F!@!X!E$W#P1UN`AR+@`VM@
M7G1@=);Q!5A`02QS`0"@!`.@!Q50`T3P`*71!_`4IFIP$/=Y25CP!5V`2!+A
M!EY`"0795]SPB=RX'AHQ!=ZY#03EHPC&)W_`E,YU!=C89G5P!B/8!PR3!:R5
M!?SP4)HE$'.R*U7`3E2#!W%0!4&18%(3&-`P!O?#3E`D"7_267A0?AW6$'8W
M!ED0_UWO@@NV@ADCP6;>&'F9M@?!A5SJ0B]AT!)A,`5&A%A4RW<$D`NL>@WQ
MV"JY\D-=P`YLQ'&^HD1]0B=AL"\CV$=1L`<;)@&9D0!I8$QKP`9VD`=0U@8*
M"@9HD'($D[Q0UI`5Z:>W9`!PD%D9,+(@T`,O4(A8P`!P@!9IH"0^@9)?,$JL
M!#%FD`<MXWY%X`41L`=QD05NT`)$L`1(0`$41+4+:05H0`<)F0Q?D`9?@AG`
M$7ER``89XWZSJ@`B8`=A,ZDBH`&&E04M%"Z%M#8=4`([4(0]`+$'0"X/(`%G
MP`??H@9PX`-B4#@;,`!-\`998(=UT``?T`(=H*P8@`$3(/\<\\,`(B#$8R"\
M@2$Y)[`#.J`"LMD#454!.\`;2(`$1U``!=""0J`#KGD")\@!$:"L"2`!%,!J
M)1`A.1``$'`$,?`"+$`")H`8Q*L1T64"-)`!$8`!#9"7.0`"*T`&<R`!+>!+
M#E`!:X`!'OD](/(`0F`#)X.,`X#!9/`&94"<\X<&?8"',*,@Q40%8_#(!H``
M3M`$[C99+-`$",``9]`@JM4E=)L-?B(%P+(M>I<(,-I7N_*B4X"4\N(1,>>S
MVH)(/\0)82"0S:`2)?8MU=H8'W%R5<`'>4<`KL*V*=$'_3,LR2!%56`&6A!'
MPZ`.2A2EL?@2>-`%T*#"?4(>:)3_"8>`"F4Z#]Z2HV7*-X@DO`1@<F-$7$`4
M"9+W7K?5"0A!*A*T"$ES6PB'7-DSS`9!0M`E`&+`(Q<D*LZ'#:GBH+E@2.H`
M'.8*E'21!L!G!\M;2G"0%*.T9)_7;PG9,`8@&A9ID0I0!'#@HR,P,@Y0`B40
M``V@9E"1!GN$,GLZ!E_0!D:1$]W9)VC@`R'@!#Y`"&1`41D@!!_I`!W@!X/E
M/N[#;S(\`%9`"E'0$&K`8",H!U9`2VYQ`1MC&A),%*STR/QD!['5N1RA!H`<
M`SE0A"6PK@T`=0TP`6'P!6H&+'Z`!E?P`BX@!@;H3W,0$`E@ECU@`G-D`O^1
M`=R$I96+_U$F<`(LX%,D@*]'``,W4`'^Q0)(*`2RJ:\!,,5`D`(V,`(30`%T
M]`$?X(,[4`(G,`(;$!,N<`29PP$48`,Y<`-U+0%TY!+GN@$2,`'&<@<MP`0K
MT$(1T`+C%@`/H`4WL&Z6R00Y4`$]D`(54`5%,C%DD!>DQS(B`#/;^6,*ZDQ*
MX4HBH&,(,`#-O00DP`?N9P9XX`9S8D.R`"N8P`=FU`":L2YB6P8^JUA,TT);
M($AG0K<BQUHJ+*I"HPTL<1#;TP=<,,E<D"1_PD>5P@_+@$C]<+<TA+H3U24_
MY`>LA2UL<A`BEPV$Q`B[4*!_X`<2%F:*92VY=7C3-0551(I>X/\*B)0`$4``
M^T4NZN4%J4*N9C)(S-$'7H!U]6T7%2:.`>&C"9``7O`%C*<&E+35W"0%4>,F
MK2`&G_5&OG!;H<HJ8G`%]2V,#;E*/+$32)$6I+1DOK>A`]`&*&UG6G-+/C8'
M<7``-D"9*W`";D,%<&`9>&X,DA$S+F8P<``';?"H6_!96L``9(U+(A`%#>`"
M!5#:2U`!5J`%97"\/(?G(M`$`_`%OY`2)U)%>_`N!=@$"J!/@<DU+3V4J^1D
M:]`&&K`@@^1XN)``4<P#*Q`#/W"8$3`)N+$'9Y`%#Z,A!U`%70`<6)`'-SL`
M2]T`/P#:-5`"$?``\U$"'+"N%7"PIZ/_`D>P!*>=`C"`!%8,`XN6W20`!$8@
M!$9P!$1`!$C`OSS@VR:@4:.)`RI0A+[]`2H%(3<P!#(P`AS``TB``@!"`1LP
MT!-0QP]P('%P`WS<S!#BU$+P:---F1]Y!,XC!!W`,*JP*Q3,!F-0(0:@`3G!
MG6OP3P.0!ER`!CZA`$X0!`J0`"4P@S*0!TXP`-C`MJ%P*[/P*FS"=]TT=A<N
M"ZRE!7F""E.P+*"0!<AH3L7@0K$8&*$.2MN@"@6J!<3')U@DC942XW\0&-*"
M<[T[NZ_\!\)0#L*`$"NA*3:DPJ4["I*B1,A02*'*$9B2H[10!_F3#?Q2$9]`
MC_?0"$;>"VQ6_SG22')SULQ2X&AWD`6TD2WAD%IPVU`#NAE1``95L`@RL9"D
M>WW7E5L[]%R:P!CDZ$.9P">C-`"23`:_]^AMD'+(U*C*:P?WTP8,8``-IP2V
M),%V8`9J<`(>N0`B^P048`9V`*-I.EC=P$)DT/O,JWID(%`FOJ%.HC4:8`45
M$`!'H`,Q<`":@E8/L^M1,0?G-05OMA*]51)G``8BD-(*X`-4!@@&"H,*13X&
M/@,B&F589%9=5U92`@)>!"4J,#PY0RTE%7]D9Q(/!`)1!B(--Q]_:65P=`R"
M!F`-'"8W*3`_+S0C&`T'#0T1'QP/!RPP*"H]+R4U#B`@!40I*BE'2_]","DI
M-41".2TM0S<X.#<R+.T[.T/:*"T8!!4[,2T\!4<W+RY:4#@S18*)!`T^4""`
M`L0,+5,X[.`!8L4=/RT"@'!`#<2-`T=,K/GBAPP8+&GLV%$DPD"3/'3FF#&C
M2(,=DW`&V#'@(0B"+PEZ%(`@QT,1,%+.Q'%SQLJ4/F'Z3.$3I0Z!/5>J?`%#
MY0Y!+EKZ4/$S9<J?,WS(<OGR1<N7,F"X3`ES]4H6+5FJ<`&3)<J?,%;"W(GC
M)TJ5+@+4N)6B1\T5*E3ZJ*G$5,Z?OE*\_!GK)_.9,UW^B'$3YH\?*YH___'B
MID\4`03NA`E]QK05JGVJ@)GRV(L<-V+.W+G_XX6*&C=X#M11ZD5L\"M21L>1
M8N4/GRMW!-S1`E:+W^)5L/S!<\>-&S5BG"+6X_6*&CUUK$?Q6_L.'BMYQ5KI
M(UJ*X2A^K,'&&VN4,08:<.0!AQEKO3'``'0,D,=(7\#A@P(>**$$`B$HX(,9
M7NB!`S4%4(#"`@]LP0877J`TQX)IH#%&&6VPD48:;]#!!ABG1?%%&PR2P4`(
M3C2!!PU+I$!`%ZZ-,<`<:*`!1AEM?;$&&5WLX4<97%#A11QBE-'$!1=X>(@!
M`[#1DB`*-&%(&V-4<0469HS!AQP'))#`!";$``0,,<2``@X46`&'%!A@D$!L
M&H30Q@,48"``&4T4_W*(`@-$H4<&)NQ`0@U(&*'#"'NH&*48!,0A0`8<4,!!
M!0_P&0,,@-Z0`PQ$+`$#"40<88001&`SPPPHQ$!""CCT8,X-0^R``A`HR/`#
M"S0DP,$*0-000`$QO&`#"24T<,<!$>AQP`89$#`#"#F`X<8++<``0@IR2$$"
M!!MUA,,>2-P@Q19E#(B&&2K-DH<(16C``!UMP*&P#SX(J(%+!H0`@!(:A%$"
M$@5(T(0!9/31A1==="%%'U+\4<445/`1F,I5A"?9'WWX485A6D"$,F2%;3&&
MSV3X(708>A#&FQIJ>'&%%U:E*D8=A&G!!QX)Z"%%6E1,@<6=>NPA0!THB_]A
MG1]7G.%&<4)#I0<>7DR6:A=RZ`%86B7G?,<>>,3QQQ11\$&%'%YD`89W)5MQ
MAAYRB(%')6%PX<<?;C1`P'%U7.''&=I=-K4>;G3A!Q5N(*Z4&GUH085I41`N
MAAAA4!$%TX@SV8<8!SP@P+]^3":`&P+LH73*)4\AA1M2:&&X%V:@L<8:RK-!
M!\-E;(%%+'2\80<;<)4QP)@(=._!!:J4X44#%#%1`P<YU""!)558H44;=KR1
MQAHJH1$C%UN0`<<;<J4UQ1II`,,8V+`3`_1A!$!@P1RB8`7#"!`L7*B1&<H0
M0"O4P0U1X(L4I$"%,E0,?#ZHE`'RL(4!&."$AA#_01[(0`8M>&$+;P"#J@@P
M@1/LH`4W0`$*;&"#',3@!'O(PP`BP($&[.D,`VC3&"3`@45180UTN)"'T*`'
M"KS@!#`H0`&0H`,:5$`/6&`#&LB0AI0]3@UX\)H`(F""$G"@`S<0PA.(@((2
M4&`$.[B!.V[H@A_@@`4_^-0FA+"$&I"@&5ZD@`M<,((6Y&H!"U!!!W)P!!R,
M8`(5P,`#'I"`X>2`"3TP`QY,<`(5S`MJ0J@&!`I`C1P0`%![(`,;X,"&-<R!
M`3K1@")22*`VI,%A#-`"&XJ`0IX`X`)\P,`,"J`"/W@@#4^I&62B`YC]<`$+
M4K"<:[9PS2U`A0I9^,(8_[A0A;,T9S]OP0(6LC";*R@.+7P0`WS.H(8ZD$L`
MDO""%S;8!>3@00U^R!E$PJ#&/5R&"EZ[`H"NL)I(N(Z@>;-*`]8F`#WLS0]B
M\((?V.*EI$T!#%O@S=?V$X8ZU`L+(@N#&O"VG/:US#Q]N`(>W)`%/^QA25,0
MPV!F8P7#N>$.QA``?OX@ASLT9C1RD$-4KN.&"UZ!#WTX`S$$D!XQ"$!R;HC#
M&=SYAZ5ML&NW"0-PP$"&AM'!#G-@`Y"DE`6`S1(.4<K1A;H7`@]X0`$&L`,8
MNE`!)(`@`"[(QT$2$(<MS"0/N+3>&_X0@0;P@0U;J`(%V5*%K)GA16]X0\[,
MX/\'4M9A`&0X$#FY8]@!:$"7;0C:'0CPA^BYC@MYN,#WW*2`,A7!#BT1P0`8
MH$LT0#4M4>@#'HSX`#@6JP<W"%0Z4-`##$RA"%A8U!T2$($#<*&N<]##!.QH
M4"R\000B0$,<(I"!#4SD"$=(`0I(8`,*5.``9_B25N.PAP9D(%$<<`%R8[`"
M8)&`!0D``Q\D4`$!$%@9&1A!8V]``AZ`8PE'R!8*?D`!"4S@!CTH@0YJL``0
M"`$#+7A""DS``1GTH`,9V(,5XH""`I2@#'(809^8$`.J"8$)UD`"-80@D1A,
M`"];0,,`BE`$G>3!208P1![0X)TW,,`,5E"3#XK`@)W_`,`)?GA`"YC@@`@X
M@0%<2)D80J-2IG@A"FC@0A\F$16WE&$-6!@SP+Z`!3F=00I5H,H6HA"&*P@O
MFV)00Q>FLCKH".84:N!@%+)PNBOT`64*K?-U5E?/Q@"H#E;30A4V*(8XE$9M
M1I4#'@A`:NW@YPJ6:2O+4L:'P16&"FM#FAX$$(<L4(D+5D#<Z633'"[@SWBS
MYL,6K'H&P3@:;GJ+Q!\(T``\3"$+4EC<`2IJTJ+F+0QBB-OJQ!:&,ZS.VXO3
M0R3((HD^\&$*>H@``9#SA^"6@49VP"4<;B2@`(K30=6;A0@PY`0$>(!#B&B#
M'_3P`HT0`0,DT($`PN"',:S!_WHA7(0(NL""&JQ`#T4@`Q]T,X8OE(4,:\B#
M'6`Q!C]TP:I_8,L`(#:`.J&A87,8L@$TD(<HD+H*:6!@%-I@`'\70A!D(L1+
MG,R`/)BA#@(X0Y[O,8$)*+('\+B!#D@0`UL!Z@0-(`/(4CX&`9R``F/@21/\
ML,;J'L"@?K`GLSDP`C^M(`8RP,$,OH6#'WSB!"4H@0M8@`,2K!<&0!`"-])K
M`P[$Y@X2.,`5'B"!/>S!=@20@`4H<((3C,`%,:@!$';P`A:X8`,;2&X'?G`$
M$#RA`A40PH<QD,-Z4'4/*CC""*H@APZ4$@0MT$-?.;*``)#(DC,H@63"@(9*
M-2%-6?^H@P<_5@3.@B$/1O?N;IO`@#0,``%*H,(!3E"-#@B"#7_`=!Q^LQHQ
MS&D,6L`"%]BI4#YP04JHT4+T_L.'G$G/@@2HPU[*V9PJ:,$/X!$%T1$'!,@V
MT\-"6!`%/B,\DS`R5(`%&#5K7=!6Y$1.P5$'=R!HUV%M82`%TW4`=>$RK9-^
MT<$ZPK8:\R$<OV%47;`76C`&4F!068`8\1$%6#`&=K)2!*!T?6!26S45NE,<
M4W!-'(0%FN8%]E$'21-3`G!V>C!K>_`>>S!HZ2<R?,`'U#$)+>,'N=%"`I``
ME4``5C`&60`A,2<A;\`&9SAR4Q(A;'`P"',!&N)OWU,$:?7_!0)P`_@"`QO`
M`PI7+SCR!69P(1#S!2=P!#-P`W'@`W26!>$D0&60(PP36F2@9G]@!5A`5@Q0
M='20!F:P!G``!V6UB7E0!G=@`7K`'6<1!0R0(1U",82`5R?4!(E@!MBD4WC0
M!304`2-0`B_0BS0P!"FP`C>@`MZ``BQ0`7*P<N@W!W@H`02@!VB`5W;@)9=0
M"A;``1C`=A^``38`!#K``I9'`1\P`A1``>?0`RS``CU@`SI@`XO4`CT0`U-W
M!`%0`RW0`1VP/E*`!F7@!UCX-17P`PIQCAS``97'`BE0#RY``IA4`@F6`DQ0
M`/80`T)P2260`D!0`JP5!RV@`A0P_SM[H@.XIP<<4``@P&40@&,0D`,=``,L
M$#13T#!C8#UIL&=L8%H74`110`4,L`5?0`=<4`9T(`)-H`%MP``(``!IH`8C
MP`0+$`-[H``BP!M2<'+^L4$WV),;-093@85]``9@T).VA@9?`!;KE`58,`5>
ML`>=!`;\<W+6,06?XSI&B`5P4U1Q8`4`@P:5-91\\`?440=X0`6#(SQQ\#MN
M`5*$!B;6405^0#1R`!UBX#5Z<`:0<8E5X(A5$%/D%@;"Q@=?(@=)DS7M\P=(
MXP=(06L<)`4`*05Q4#DGQSL$P#:U\1?^,159$%I9,(2F(Q^0T`7O(0=6\#BB
M=C@5Y0:7X?\=7#!.67"%?K,9=Y$%5D`%5H`<S?$'*Z$P`[`_*[&)`P`G9*16
M*W<('@```.`](=`$:8!^"0`$(!"5I=0"IR`*9ID&8Y)D$F`L1\`!`W`!:Q!?
M<!,%9#`'&B`"::"6:T%G5*$%9@`G6@`&;1!S;T!&",(&5H(%BS-HE64%8.`#
M2QD"(LHF9>(2;@(Q<[`U5[E:L\9L)=`#+D!*)=!W*F`L,+`"]'!)?^`#&O`%
M9*`(9L"B6>`@<Q`TVF4!3%0!$V`!1E1#0X`".G`#+2".'/`".&`#52<#MJ(#
M+1`,&.!>&T`!-/`)GI("^E`"&.`[7-")7[`'2JJDK!(I%=!V.?#_`S80`"P`
M'Q4@$4O@`"7`5RKP`]F8`@ZP`A(P!5V``2R``;R3`140`R#P`G)@`AK!91T!
M`C!0`3"P`V2@47`P!UI`!QI`!V2`!F\`!RV!!E?`!2+P%@,`!O3#`"+```9Z
MGAY@!AQ`!`M`!!S0$F#09Y%A&.<6%V$@!V?@!X[8%STE--59.F-@A#W)!UBP
M!7S0!=WV!W2R!:@A!GX@/297!?;#!9!3&B;C"%_`'ZYQ!4_%!TPAK'0)-25S
M-=T:0`S4-L4I&.(V%:?1;1U('6DA%5)#':?C.K.356+P:+=14]U&!23(K3W9
M0*C1.E\0;750!WN`.).),GZPEIF!'UN@_P5[YH"(>D&D\1@NHQE;(`7,=G9=
M0`5^1@9?8`7049W[@85G@QI;U6EJX"`\RC#6\R`2`B=C8`9OJ`%%4"GG>67^
MMIYM$$\9@)(;67434`E2@`6"F`>UY2'Y,`(%(`!*8`!9MDE?J@9Y4`0*,`=B
MD1=6NP7(:@8Y9QT_*@)T``9H(')E\#Y@T%,VN$Y:L`9%@'UVQ2$B2B8NP0`Y
MZ0-'5@79MCB]8V`E("TLD`Z!(B@J0`)4]PDC<`#:4P93P`:UE0=\0%]8$1:S
M!H+,MCZ8HQT2D`,!$`!(0`0KL`,R$`/9H`(Z4`(V5'4M8'D=`"N+PAX80+LU
M\`TD@`,G(`%QH/\U:_$:DN>H<^H")]`#MW(-$@`4%[8$$(`"@&$"-(!)IE0`
M';!G"="[Z=8!%(`#()`!4G`"2[`1`=!AU2`$#9`".C`%:F`%*1%%Q_>)"2("
M/L"V9C`A]E,&N(0&9Z@!"N`$22`"$]`""[`$&+`&!K`&:J!4DK!Q58AI&0@:
MB]89;;-/?193U:%1=T$%$U@&U!D>-<4D.2.:6-`&93`[@A89KB$U5\A0K".S
MGE-9KMD5=<!!LZ%18/&Q?^,%\F09ZY1-T-$R,ML'*YR5@KE!5VA5XE880F.$
M4.$%4]`^EH-2M0&!3O&Q:G`*5]`%2W$&N?$7YR8%:"0&BX:%&:6N2)?_G%Y0
MG*+A!QBJ!YPD-V)E'=@A&]99'9,1`0FP!XF#FHFY6[KT!C626:<Z!R,Q!OIV
MM(*0(1?#(85`!U20`#]`#3I``4)0`@1XF0&%!HUR`2*P!C@0`Q1``F`0!&@0
M`7R2=T`P`8H0`EMW!I/)'67A%EP0!5,P0`^2![>$/0X"!R'U@E\0'F4@`AGB
M;]VSM$'W!EL00AJ0HLAY%33T`31``R80+]F0`^YX+"2@1R[0`0V@=!\;1I5B
M!WXY:PG`>%,;>0V@*'N0`1%0`?NP+430#"_P`K.2`B30`T5$`<FE`S&P7R5`
M8F!H+A3@1AN@822@`O`X`7<`!@PP!0E@`0D@_P&*M+L1G0)/``$X$`=8(`#W
M@EX$P`8'4`&R#*D04`+!+``4$`%4LP$/(`-,(`%]X`(:40!"$``X!@)$<``"
M[1]WX20^(`(RL09`B[CX,P=VXAJSR@4!_"`]!P4&<`<;`&$9\`4O\3>]$P=4
M$!Y'DS2'4P</6*V?T;)>4&Q&W!P`8G)N,`5H@)=\T%8)>)6NDS5[-AKGL54]
M115[,160,WZ`(172XR4=V%-K=AR8*!>K46Q9@'Y)P3MW(*U7.811T`7[H1DI
M`PG4T1@Q<XE6FU-><94GEQYR\#5DD07D]`<&E@!*<XEX-H,_#,P6!#@,=1M]
MXP6+HR<)(`=:0`9_</\'76"$5&P=)MQ/3Z@'#XAJ:;0G$F`UXR$'G@VT.M$&
M#O(@:@4G*:$(4S8F'M!OWC-S`_`',M!A#G`#(Q``%:`%:T1842`FWY,'!.!'
M.S`!38``;8`'>A!W'$`"!R`((>`#:+`'[&@"!#`%YUH2:TF41=D$NO4B$4+,
M,0<'7JF`:?"WZ?EO&N($%^`#%Q`":4`%E:(!8!`WA$EJ"8`!)<`"LKL+/N1#
MQI*(+B`#+E`!DI.\9!")$S-EM^4%%N#2&Y`+OL@!1<X",=YW/(",.``#I'(`
MN4`!D"<!Y4@!3N<"-J`"*Z`#+D`!>W`Z)9$%<9`<$]`!T@LH#Y`&)XTG'<#_
MY%9^`!+@`@40`!^`%!U0`TP``16P!@+`XP]P`US&`E*0!7JP`:B8SYBP`&*^
M`RB9)"A9#4<P`>!0!RAE!6N:!PKS2PIB0A$C2\5Y!A0PC3J"5G-0!!;C`6CP
M2@4@`UF@``SPG*.&!WQPEFLI,I8#D.&$!>[$L)LI,M:YL1"1.PLW3AMDFL'%
M4`P54)%U!:0!3I#Y@B%5!5O0%WYQ-K!-ACUUV*[Y!W&@!ED`"X%9UD#I'6LV
M'L01!HDI?YTI@)X=?I<IK5O,&X#1DR43[JC1EE5S!X?L&H%Y4U\3'77@!>E7
MF7?`028L:IUC?BZK!H,Q,E[3!65@!H=A,M=):LKI_]F/4QP8[QN@<1QCQNX%
M7QTP80=YT`83*D00$HH_:UJXA,#>L[0^,$M6@+Y_=0,[``,$P`6PH55\\)]W
M-08"(0U3@``7P`:5N5[;)04>$`(7P`!4\`(%,$<E\+%]@`5K``8$PP!3=D(+
MH_*,#$5(23+O9@8BL)30C)X>0(MU%9ZUY0-M8$'^/FO%Q0+G<*7.H$,H('4V
M8`*V9P+I$L][P`<X^`5IP%LMT01TX`<$0`$]H$,W4`$)4`$E8`,]<`(T\`,'
MT0#(10':$0:&807UU-)UT`7F4D/)%0,Y8+P2H`6T&"4Q0@5$I`.Z8@%<0`9/
M(0"8-P''H5V$F@/2V@"FY/\`'``&>+!)%=`0!>`"QBH`VCA<%4``'``$370#
MU'"/\&MZ)@`.!)`%K#.4,)0'5CU+B%5]AK467C`!TTBKX-D2&6(`<G`#"Y`"
M78`F^ZJ$PB:6;`$(4U1\6X5C9%%=?F1E97QA?555?%1^5G5[85E8?5=75%%3
M4WQ^H9Y?:%-6455<?%)88U-2I7U\6E-=75%;7YQ>>@)Q?%%R<GU<9%A6?GQ3
M55)R?UI@66<"`FYB4JU:6E56?WU_>GMQW&1976=N85=_8F=W:GY7?G<1`G=B
M:@)[;G_^G%%3!X^7/P7[=!&0@$"=.'(PU:$"+8P5/GCV>.'R18P;/UKZ2`GX
M2HW_'#S;^&2I%^]*%SEZU%3JLP61&SSM_EQI\R8/'31O[+QA,R>/G3EV!C#(
MPX#.&P87G'CP@,##!09DN%AI`<)!"ALP;FC,!H8+&@-6172I,8(&$3!*#&S9
M(X$'$`H1UG@(<2&/`!0@"A1H08;`%3AF&6@8T*1Q$Q$,RF`ADR8-FS96",1A
M@T;+``1!JB(`$,2#@0M[%2@($:)(GC9B"`B`F8`"BR%#4*0@D6)%CB$T?OR@
MP.$#A0H$&F"H(."**"QIL$@!8P"`!S9N,-P@$8/"A`P57G1X<(`#!0%A'I2X
MP:+"'2]JW`S2$\&-ESI>^F3^4`(%DB,VC*#'%VN8008<_WF8D888)WPE`!E_
MH+$&!D+L$%`$VBU`A`!:1%`#"!!PT(<`!$3P`@P@''$"-@1@,($<!%!@P08V
M4/#`$""`$(`1$#"1XV`JD%!!'VIXD<5*7YC!RQITT,'&`$J"D0<<?NBQQ0!"
M:="$#R(H,)H!=9RP!!(-^%#$%&J<(8885T0211]3</(''Y]L,<865EC!Q1I?
M7''&'U.$I$:1870A"1]6?.),%%D4`@899^`QA1E37&$%G&%,5`4577@A1AQG
M@*(?,U5DP8<8>ASSS:!^5!&%%5)$0<454IRQAQI9D*'%0@)(,84?7?R1Q1=5
M]$'%*`3%T844G/Y!11]>V/=''/][W$&K&7S(IH847>R1P&QM1B&&`&K\X49,
M<=P1S*UBW"&`'E;@,N<7U[BA!1;M=#)0D5SX,2<?^E%AA1?WZ=%%&'L(($8S
M48R!+1YZ$*P(&6L@E50>;*31!AQMH`''46T@Q0!:4E'E@0(,1">`#EW=$,,"
M*^ZAT1=T^("6`G3L40`,,<2`!@(#7"$`!RC4<(,<#*P60AX'K`#"$D*\,`4&
M?6C0!1DBB$"'EB)PG8X9(<_QQ1T$B#%&OW-X`(!H2@"@!`)54>4$W$6T8085
M"42@1S`6N-"S"D((L5L,)W3PP0<<='#<!`<\0,$'$N@QZ1AH_)'``V<,<`$"
M5^W!@@W_.+#0@8L)Z'''!A4\D$`<>GS`WG(;/%"'`!$T(!L!DM/1!A]J3'##
M#"L@D0(';I#!1D\B/(9%`B]0T,`#7/A@!0H05##%'AO0<,0"+F!Q`!&!;1!'
M!`<D<`+X)%!P@&S8P"@>!2ULL($*71E10X\Y+I!##BF4T,4580!%&!:!!2YL
MC`UT$`$;IK`%!MC!"@+P0K#8H($B9$T!2@A"$^I``1@4@`4#\,`;R/&N09T!
M(F(`V,'T4`<I$`-660"#%,+@A3CT(2NV\H(6O@"&97C!5]X(!1>X$`4^G$$.
M5`A),`)X!CW8XPIND(,:XA$&9OG!$GRH0CVH@(4M2.)7EVH&_Q]>08MZN*.(
MG@(B%>*@!D)D(4Y@`(,?`/(J/+2Q#&S(@AH"*`8\V-$*;/@"'C3E*CTT!#\"
M&U0<%ODG/F"!=WW`PK@:T*MF3"$*?R```0H5DRZX81UU",,6*N6'+V0!&"P\
M`PW_$`9U%<DY9`"#%<IQD2A@`0V480J6X)"&,E3F0$))`QPTH``/**%D56G"
M`/*P!1,$`$0[>-D$UE0%,I@!#CY8C0'0<(`E+.`&`FB"`F3A!A3\S0HB,$`(
M%)"&!Z0`!$BXP0;D8(5E^F$,79L#`T2@E,>400L*4DP9ND"%+YB2"F4P0%58
MXX2V.8$UHW';0QF`A@'$80(*.P`%.O]P@_V1``8J0`$.2G`""FR``Q5(0`(H
M*8`9/4`/OMH"'<:@APE@(`,<RJ8&[G`"';"``W[K`#;VE@`+7(X\!SB`!3(0
M`0FLYP3BJ8`$#C`%#1A`!&UP`P5P``0B$$%(<+AJ!1>3!S%4X`0<X,,%#/``
M(L#@`'!P0P/>^00KJ.%#,$C`'E*Z!QH4``0M>$`$R+.'.KA!`!08@0G:0X,E
MI"@%1RB``W+D`"+,(`4MV$8<KC`&`IS!#J8L`QK*0(<RC*$,6R@"'>+@AC4(
MH`)SX.<`!E`$#Y2F"@]`P<[(H`0?9$$`!]##">MP!DN]\0]JN(,QZB`&<6RJ
ML-VB`AFV(`7_,4PA#6C`@K_^4`4L7-(969AE-JBP"3]XZQQ]@!,6O%!8FE2J
M"Y',PK&P$`5:R`N(IL("#U?"K"[ZH8QB@,0H/,4++#3J$%^H+T6,6-PID$$9
M6:C"'[K@C$@0J0NB\,,4_D`B/>#A#%U00ZJ\$`:`:`$-??J#%`[[+6<5ZV![
MD,T=\(/<2-TA7GSPPA4F<1\Y$(Q@Y7J)'$@D!TET89&`TD(6"O2&9;ZA*&W8
M0BS@P``'SH&VFU/"VZ82`A'DX0UQB$'^>N"?/:`A#6^H3!LT<($+B(`/#>@!
M"P0P`!^DX0MI$$``4M`#'&S!`*J9@Q\X@`0'+,$$>(C#;+]1!IMI_\`.E6&`
M:[YPXHIJ8`VV)`.E&]:$J;1Y+U4QP&E&\S8$M.8":2B1(8ES`AN$=`8SR,$.
M3,"!#4P@`A!;7QWJT+B&'&`/4["#".:`MPZ,(`-ZM6:)EA,!&Y"@!`0`@QL&
M"QZI-J`",BK1!#A@@R48#05$0`$%Y,"%)ESE"@>0P1(<((03]$&98VA8U\[`
M@1%TX31H*($#<+"&`5@A!R"*@Q=0E(,Z$.`$$9`#"R;[@@0@#@.;[`=#3H`#
M#+C@F2$M`/ZZ@@08K*`$;!P&&=J8!S!$P6Y7^M,<R*#,*$1O`%MH<AO6P`!Q
M.L$)`]@##@I`!"H@P`!F\#"M2&QA+1YQ4/\/@:]^_N#'(?]!5I<TH!FBX08]
M5<$-=;!$I#09AV9(P0KG*I>#US`&8(3A"UY\59RJP$`NC,*_()X)'\Q2!E>-
M$0N<&(2L='*%-"9#"U>DA$G2*P4I$.Q3%.;"%HQ5A2WX85]UT,/"J)`?*H0A
M#IHDT0'N<'D]N(%6E1##'O00!H)HPE240.X=$DT%*IS+\\MZ![.ND%PU%)%;
M(&;E0LCW0S?(3!H`7`,<9@N',O0[#_\LPP`6HQ2KA@`!#JV*`D0`ARP0X)U,
M"'<*8G`%GP02#71H0@@,(&@!8$`.LS5#+3$`@0+<8`)L4,`%BI"%..Q`0TL8
M080U(((Q],$/<-#_!`:@`6Q@?'9P/'0P6QB#!EQP+W@W!6#@`W"S5JK19N)T
M&@T%-Z9V`4UP!=[Q`!_``B]P`BS0`C&0`BK@`K;V+:3'$)+'7@T1`;'C!VR@
M&#Y`!UG@!A)@`AB5=0-P`!,`!A-``D!``XU74R4P@C3P`8I#'K@6!QQP63VP
M`SQP!$]P!#GP`5IP`5UV`"P0`T3@?E0@`F7@+&Q@``.`!\CQ!:)&``6P`!)P
M`3Y0`H%!`%0@9C\0!1*0`R,@`#?`!`&P`4-34@<`$1%3!R.0`QS0`@&`!#*`
M`CZ2(_5#!"G0`;,C!\,R!@ZS,3`W!2*P!50`?EDS6^JD`%_V!61003X0_P).
M4`1NT`)(L`0$`&AP4$59$`51X`=4P"T"`2J=\G15H&0B`0]R<&-7U`M84"PP
ML@?($`:V@PMJX$=Z$`?.`B>Z6`I;@`9M,`6[1A$D1@Q3<"0:YB]^T("<\@D,
MPRB<D(LNT5R=$HZZF&-W,`RO@%Q8APV9$A-B(!*[I@8AA@?DM4:A-"YZQ4I.
M=`A1$`8,<0#DTDIX$!%U<`6G8@Y;P`6=8$M#1"<"81#*>`>*8"P31F*'!RBF
MTG<'H1]`6(A'IEQW,'IUD(!Y,`=L8$VZ]`9-9@<(H@%6Y0$-56JFX0.U.`'@
M`P$H8`1"@`%X=%IDT`:K&`(IPP5B(`%7\`:34/\K`F`"1@`#%-`';""`#.`'
M<^450/`!9[9/`Q!O9E`$"M`8&E`&8$!SC>$#=F!:9N`+A3`L#!`"2G`RHK:6
M5@5HT`<`)=-F;/``M\8!-^`"'(`!'"52+V`!V:`&K,-U7D`%HD<`&4`!$E`'
MK:!\-N,#6.!$#2`#&^`#9B`&`]`''X`")&!O4%B"-F`#+%`"%=``&S`"WL$?
M-T`##]``&3`$`0`!7A$!7#``V6$"*^``#F`#?\``;P`GBR8'^3`'(<`%@$$"
M=(``>U`#-?``6_`""U`!9$`!/.`">&`#($`"$716%%`ZH-(/)T`")Q`#-7`"
M)@`$DI@_@--N":,&C6?_!G%D!T4P`*4B`D6P!ER@`0PP`$XA`C[@0&E030HZ
M`%ZB`')0`BE0`"<`!PHP0N*PBT<62B)V8[F8!6.P";'$=I;P!QKF#%\P!2?4
M1'>`#'7P4@H"#>_0!ZP`!L3B#/^Y!I8C``(3!G.B1>D5!B4F<&+T"HX482-A
M>))@C]"R!R`!,%E`#G@0#CI1)"B$>03@8UH0!5/41`EP`!3F!?L@,)@7$QDA
M!J7""YAG0Y8IF7(`*K42#'&`!6"P!5'P";6B!N:0*;X"12X4"ED@!7&P:_91
M>/&")\M2*F$@`1$0!V+0!6PR!6CZD(LQ!W!0@&2`!OK$H'/P!FO09%JBEWN)
M_P`/=55P(`<R\%<+L`-/(`1Z8#=OV60*%0*Z4W8:,4-O=`:U,0('4`5E0`:S
M]05>8`)/P`0\DP"<@09C,`<#FC33IQIV`!T"J@!SL`9I``9C``9E8#>'D`<8
MI`0<:`"J-09VH$[0%P1!L)>LL4UX0``[2`,M4`*+50*U%@',0&(G@0><]W21
M:AP34)"OH"=-ID!QD`,+@`<*H%IK,`4W`@0M,`+CP0$QP`/<45(GT`+.9@0!
M``0Z\`/$208"<'%/TP(BUFHP4`,:9P-3P`!54$6DDAQ24`1%,`$:EP%-\`:(
M.:P?0`06$`44T!U3T`(.L`,.`3\=0`!%(GJ^`P0L</\#+9``-[``.1*)`=`"
M,+`$+$``'^$J7W!:;T`'<R`A!NHDD+$&FV*L<Z!XT+&@ZRH5>L!1!:`#4Z``
M:"`&<L`.>Y,J4G`%&7$%$::G`,,%9G"BN<@LXQ`&W?4.1\(*RR`&TM4&LG`+
M"C(&2E8K'N$%6/"<@F41(,&G??`IEZ<&`+19A5"HA6I7>M`'/"JV5)"EVG4&
M:N(%5M!X!_4J(,%T`E`'5K`,56<%9$,N?;>/M("I86"[ELHZ3E0'1<8%76!8
M@Z03>,"0FE1<5X2FC8,-$8F[U14&=.*/,^0&M@L1;&1=@,<-+WH'#;`'B/('
M.M9=6""X=``':[`&**8%B$O_!Z\1KCF93L;$-J:A`7!P!BP`JSL0`"30#%^@
M%$KA)1[`3VQ00%ID)Y07`2=`57;0%$"I!QG0;0YP!":@!I2Q)U7F,.G$)3Z`
M!EU`H6LE967`!5C`!E.R!K'4!DV@JN/7!,AG!G.`%J"1!%#PKIS3!`PP2[8Y
M`7V6."90`7NP)E%0K%=T!=0(#P<P`AQ0L+(1!RZG1`3@!UA2`4>@`@\@(4R1
M`"G``JPY`7;U`!W``O/)`S>``[I!!`X@&'=K`8/0`#K`,S3`>0D@`=C&`B10
M`RC0`&C`*;0@!NNS!UB@`%]``NF)-8BE!WY0`22P`7LP`C=``6J`L2/``C_`
MQA00_RHU*@$-D@(G@`$<<`(U$(F2&``E8`0%4`)1[`==!`=TD+]F0`<,X&C+
MIY,,P`;>ZD#S<DUS,`=-\#9G,`$EL`!"<`<7D)HT)`8D%BO%<BECE"<`PRQ5
M``9:,#"Y*U]/%Z:M@G=VDHQ:\*TY)@6YL@:.8`4A9A+,%8QA@"YX\`=\:@65
M(&&P<'5Q4`5?T`Q4P*+C3#M"JF2-,@O\VP>M=`:YJ\Y?P`?_LP5NZ0<FX8_R
ML"PB%GGODD3G."@!5'_^L#=GT`I2L"Z>5U\-,*F8AQ,;?3#M,'K'HHMB4`?P
M4"3YDHOP$`:?4BV1\"A1<%CT9"E7-`6FA"IMD`;?2D1P4O\39N!%:Y8U/A`5
MUL&33L"!13`'>L`"SP0!-[`$.(`&?%`&.DD'7V`'\J<`H@9H#TJ`6F`Y&!`!
M4?`3:[`[B`4$@O$$#Z`%;#"@>:"3:"#1_*<8=F`&-F,`30`&X<RC=O!H<#!:
M9J`Y5M$$&D##"")^5H$:;;.7"N`#X.`'<6`!-V`#-%`",D`!$]%Z(V$H?%`0
M(B8!+B(;#!D3?5`Q5U`!%2`&*T<`(X`!#7``7^#5'W`'&(#+PZ<%:I))$M``
M'2`#'24$1Y`"-W`"(X!1AE0<++(',*%)";`!.W`#%I`%J<MUW^(#`W`"$``!
M;F!1N',%$H`#M3D")U`!0/@!&&#_!$\@:P0P$G?`VS=0`[19`260`\^4GSJB
M;D?P(H1;"!ES)&V`0$5@``QP9<F#Q,<S`+M3HGG]P,;4!P[G31,0PX4'"F/4
M>+FHBU(`)Y<`L)I0+%>`S8/BSX,P"0:&D32\S:70*KXP+?,P"%#4MQ?1+7H5
M++0P+&^R">]`T'&D9"%10^\"U'+`#:2`!=\`=F=`"\'X1E2@!E/0!I:;",LK
M8"L-4WS@+A]1OP6A2E3`IZ/W!_1<!6:0!0GC8>4P$&6J)GA01:TDOJ;2!WTK
M"B+AI3`EIH4U80])T]A0+K8T(@UIOD1Z"\Q-`!R3%:9D2V.`=MT%!PXJP`"0
MU7.SED6`_P8-8`-86P`Y<`0ND`=HMDQID$2,H1JGT69MAK-OT("20P:&DL\<
M%``%(`0U@`<R25O+9$%]<`;]9B9%@-D^X20&@EJ_[!-BW@9V@!JA+6A],.$4
MVAJ2QH4+=0%JK3$)X`)VG`,M@`$:H4=EJ@>#<%@/02(.$0<GS4):P`!P0``N
M<`($D`5<X`42@%)[$`$<8`$2,`&UR0=PL`RZ`C!G`-X4<`+W30"&R3@S.@$4
M(`4LP`)E^BT`N05RL%B0R0ZR`4$2@&<-8`0@(`%DD-.;-31-=1RJ(P$T+P1;
M&P&ZT)(38`(Z,`3E@P$M<#^4)8GNMP0S@!(T$6&FY$)VL`92HO^@=E-G(I#K
M=I`@9J`%SX)G8\`&%Q`$::`'%?`A+P!H;!`PJ9>[_K(L\4(&?5`.'Z9A4P#1
M>\"0EAH&40!XFR('8C`LY@R!XUP)=WHK<S<%^4PNR0BHJ;+ESB#.KV(%#'1)
MC_)@6E!X??H.0W8&_Y=>*I$+!.7CI\0OEOM&6BH%6D`&5%`MN3B-*&X%'K&\
MXM`N7<"_4LT'U3)ALX,N,^:/5R`KV$Q>X658_KQBP/4`<N`-F60[1*8?Z;(W
M;B`M[R(.+_$/`#/7!#!;;/#+;Q"N>8##E'-E=8;5J2H5!@"46?``0@`""]"R
M-8`!LS5S;"#/8]!O_-?TM`5HS\=E-RC_"V*:$=$,"`4D.U(,6FYS`W0:345Y
M97`B11H#>79D46]T:6-\561L=&MK=CXA'A=-=%1=6EIH11XA%PI%(DT*(0@7
M9'QT7`<W1BH<!WA>4GH'`G)25']B<5)^>`1U77%G9VIB9U5C=S0X+AP<&"4<
M<A,D`41$)#<N%'M["0\6)38R%E-F4GAB$IP8D<#+%0$16)P08,2&'@("PB@[
M<^=*`Q4TW'P10^#*GP1JMNA1`6*$'S]G^$0Y(^#`!`P6("9(0.#&C0=_NIQ1
M-F&(C0QW"#0X\00$"`<%'!@-<*.&C3I4I%B)HH7+E"QM[,`IDX:!AC5:RK!9
M4Z6/'0UPVGPA_U/%"IL!`PP$$7&E0@HF+>!<\)$E##(Q8JY8D7*ESY0H6+A@
MX3/XSY\J?*[X<2-`SYDZ?[9H&1ST#A4N6J).P1)EL)4_8<Z$N2*EM!B=7KYI
M*=VEBY\J6<:`J7+%&Q<K9_[PP1(Z2A8^7I"=[F(XBA\K?*:LS@)ZR^0X5*;P
MZ1.%2Q2#VVM3Z1-F#P$\5JIT_^)'31T]S*2,SH(8BY\N?P;'N>,EBO0[85"!
M3!^]2<'%&'\00(`:40E`0!QR1/$%8VH0\,`!<4Q!QA1ZZ%&'&U+(48<578C1
MQQ=:>''-%']00<49B;Q1Q@"7C`'''&B0L08<=#!@P`5.`*`$`@@XX?^!`2*\
M\44"2X`0@`H%J+!''G/8\48;>:PQAEAV,,"`)7!HHH$M/B@@"RT#]$5`#$\L
M`,0&7.3QQAI4PC%`$09H8`<=>:#!11HWLH&E&5BL00<;9J2!QA9H,-#$+`HT
M,<!F''4Q0`@`..$$`K,@*8(!/L#!A@AHT'!$"PGLH8<4L\51QWUWJ*&&'FJ0
M)X``>.B!QQ]G-$"`&U18H0<&(YB3``LIM-#!"4.04$,,)0Q400<MN`!1"4`L
M88,`=G!1`0L4R+&?'@EP@$(,#S00A0&UA&H%'G58&`$0-T0!!@%[_$'/%%2T
M``(+<ECA119_8*9'!!4DT(4;YDU00@5]<''_$$05H+!#1.:=4(!13"S`!`A1
MHJ`""P3X44<87&@F!1\#,)`%%6\4P0`:64R!1A52S-&$I&LP,,`85911QAL&
M**&!'P?LL``,=82@P!=>G.%%8'[TX05S?DQ1115?H$'H%6I8007#EH4A1V5\
MC.&'``WHT<<67/#A1AUB6-%''UJ0@045B%7A1Q1]B)>%%ED<)T5MSWEQ&WU4
M#$Z%&&HH'H5D4G@A7<!;8+'%%UADT0=D`MR1!1@Y.=;'<53PH;H??&3QQ19]
M_('%%U+<\>$557TQQ1ERK-:%<F*+$49.75RQ<!QB1)'&&GZP)M\4?D15A55R
M)"#`%9$YZ,8VP5%Q_X7P?F@QAMHBBO%''W;SP7M@P)WQ>1=4--]5'F:\\089
M7)`RQQMLP`&'CR$(DI"&E`H1E"$,%%@`"(C0`R8,80IT>(,=]C<',WQA+7#0
M@`8LL08TM*&#7`!#7!1P@1!T:@HM$,81XL"%/IA!!!K,`QM\8`!;L$%H9NA?
M'A21ARE(H0V46`/^P&`'7-"B"`,@PXL@U`<B8BH(0=B4!Q1`(Y_IS``'@-8#
M!("=,F1!#);#P_6N<(<[Y$0`$HC`K1!2#@I40`!9.(,%.C"""7#`!C.0004>
MP`$<@,L$0\@!"UB`@@W(P0L$.`((8!"!`W2``F+`0A?J((`'/*`"#?A"$?\B
MI8`B3?$-5,#`"Q)`@Q2P8`J4K(8`_N"'$H"@!7'H`H;TL(<IB&$"&\!#%@10
M`0I\P`)GL.49\."&.)@@!R805X=&$("C%.!C($@!!XB@@@G$H0IJZ,(7QJ!$
M/\!E#%_(@P^2=,%>8*$(.V/`%]X"AS2880M@\($3#*"%8T&@`!4@(1>$%X8P
MR,</KPG<5::P!<U$89)RN,+8X!<55TFA"F)HP`/JX#JK_&%ED.&#&>"PH2J`
M`0OYJ9D7&J>;*Q3S#%8P:1SZH!)/@$8*_BR+&-P0G<9YX0YGZ((_87H%UU%A
M#P((3AQN%;8HU`=L5]A"&<"@!9R1*`R(X4/C4G;_A3K(P0^*.4UKA%61/SCH
M#MB@E1_TI0<YB*$*S_#$%`(''RF,(0H"2)5?Y*`JL+DA"F4@`^SBT"$Q;$=U
M8>!B%^Z`AS.$;S'!D@(8Z&"',HS!#&7X0AJJ5(D=ELD#05*"$X94"P9,@0`E
M@``(:D`#![A@1W.`PYZ$J!LS#,`'#'A#:N<P!R%R(7]T@(LIE`"`"^QA!#/8
M@=K44`8?%"%46_!1#=W9,E$Q-BNS^=\`VD`&,$3B1[0@E1?V\*HUI"%Z#$``
M`(1$I!`88+IF:%03OO``F`A`#%+8PA7DD)_*?($+7NC04"4@@99,H`,T*,$@
M*7"'.!#`CA2@R098L($P_ZP)!0/9`0HPD($4D*`%!!`!`50`!!N,@`!:@,,6
M^'"`#0B`#&3(VA7VD$8KY,$`1*+#`V3@`C4,`9_<K08!Y$"%%S"A!%&0`@8D
ML(S`4L`"?X@#"SS\`#R09XNG$\`+3+!%+HKA`T=8P!.::90<1"``**A#RIRS
MA36PP:@^:YF51#`S,X"&#4W04QK\@X8)+@H+`]C4&";``@<L@`*.VD(_9^H%
MPXR'#UU(3UETFIRY^2&R]KF-ZB+C!L*JX2J%F\(8VE"&[8`"$_![EQH0(P5G
M*-4+>(@E3-W0!>V4N@J$<Q$8V%"%.]#4;S"=Z1I5)8?1A*$.<=A/'!J0@#"8
M1O\]Q7Q>5&+'5R^0P0REB4(5?!@&YFA';+/C`]VRX`<"2$`/?`CL`12T#)SV
M)C99(!'8K`"&,E@D(AY1D1[(N(<K1`$U:@!J`O2@'3[HJP%NL`)A1X2%MFC#
M"G[`POC:#5DVS.E_&OB4+I0P)`\0Z0)?.8@)%%B#T')@`!)LV0`0E88VO"'B
M`Z"M_]C@\"HQUF?BI"$"FE""&+@!#E38PJ,4P(`6SA!)N=7`&\`P"C2D(>5T
MHH2BL+1)$BI``UJ`SQ70``<T1(]H"`@"`$+@,Q)J(`M2>`.;OP`?/;@A;(<K
M]1FHD(8R](%M>[B#',28@`ALX`7E,,$(W/A>,<:!#&W_V``%*`F#`N3@!11X
M@!L>0`(%%L`$33```3I`@#&XG`PGN($4?."%'^0`!NX0@@H@J8%=8($".ZB`
M"X1`@@\(8&I;C`(%`C`"]E```P\0"@<HL*O9PR`!?7C/'B(0@3[XH0(3P,,>
M+C0%*W#`PC50(`B8@,PCL(`*G&LJ%[12A2T<=PYTF(,(-:`6>,(!MF`P?EAD
M2R@\BY<-$C!!`9XP@?^5P0IUL&H<+`>W$0?(#P;!*_[T:'#P!7U`!7XS!6#0
M0GS`!6V1!>KA:6V@!7]P!5BP5'X`(?E&*Q&S&0\59'\3!FXP4E+!&H#C!Z.#
M!F@P!5W@;P,W@F$0!\H'$&Z`_QJZ@CU6(`:AHU16P`TBB()=$#J`D0T(V#FI
MD37;$3UB(`=J8(%+Y6\)5SNAPQIRH"#7D#4"@E)EX0Q_4SA4D&]4D"*#@1]2
M,$QQH`:W4DR5)`!64#-_H`QT`U\0<3@.4@>1806:U@;NU`8MLPEMD%NQP%M&
M0B2[,`!24`<-T`*B100R$``5,`!F,$$#H`%S4`8[8@<T\H=>0D$ZDG)8P@!V
M8`=L,`<B,`#;P"-9\$(&`"H#4'5T(`(^D`=M0%N0,`>*D@=T@`9C(%MCL`5V
MLDGLH@!LD"M>L`5FT`9@0`5A<$Y9!P`>,'*XD`=_H`9<P`"U4`67`51_D`69
M(QV/`?\V>'``"1!P.LA&+W``"6$#+/`"'W``?#`'/D,&#4`"*F`/''`"*A``
M#0`&!\`"-1``$+``+]`2!(`%N*A!:B`!>[`%=<`!-Y`#2%``$HD$/5`!4J``
M3N`#;C`!^_`!"\`"$D``=Y`N>[`!,<`!2_A((BD!-"`!:M``+@`#+>`9`D`!
M'9!\05@07M``$Z`'53`L%2`#33)]*_`#])@`XX,_6)`&CM!N<($&9=`&:$`)
M0Y,6<^`#`]!V8!`%?/`%FH`_>8`I%W`%)Q``2T`!_],&5L`,%"$`=>!1W.8]
MVA`L"!A"4$DBAO$W?/`W5=`YUS8<%T@SM?$VO1@]5L`PO6;_=%=P32U4:G<@
M`-RE:E(1!J]1&'S@#%]`!1:B![]#2^=S-SH%(2(B!9F)/,/A0_##-2#E(9`3
M2V*`4]HA&-%1%0#%A%T@(01S-;,B!W)08%*0'Z5!!8G1%@81(EU0.=!A?(B&
M&W]P&&(`5&ND:WBP,/1P#5>@2JI1-PR#!X]Y`'?@!U]`='#1=FR0!S#$!E]@
M!G00B$&P"T3B`1X@`FZ@!P\0`THA!#T`!!'P!KE19X^0!4>'B58"<2GW!ADT
M,V,PBFO0;E(I0C#$`&-0<%CP*4W``&OP!3H36[6%H1-T*&S@)T8'!F/@*#O#
M+AH0!14!!O;3!ER@C-[D`4&@!$=R_PL:<`88$`%V,`M-H!9<R2_.\#Z5=@"8
M(4920P`9P#8?0`$-0`%#@`(VX`(_\`($L`7[@P4$0`(00`(5`%6NM`-9L`:`
MT04?$``%T`*UQ%AOP``B,%AB<#`9(`$9D`-+$`!FF2P/T`:T``=2<),?4``V
MP`$3P#:^TEX5H"L4\&UR<``PT0`8<`+@4@=7@`$Q@&%N$`$9(`9:X&!WP`=H
MI`=1<`,0\#$0T`$94``N@#(JB%6W\`8>]4U@D`@TTB4:$'X^`%FMF%*IF"5C
M$):]104<P`.&AP@#$`5XT#A!>`#)<P66TP=RX`;&)P5XHP6'@06D@3X'R#=5
MDP6DH35E@?\^P;(-Z7$;8,`>7O`'B)$%0Q4&!#(U8K0'9_@[KQ$&L\*9N)$;
M<)4`BD4%M_(V!?<X+6B<NG,2WH,%S8<8BM$'[M%7VQ41X3D%5^`7D@:MDR,8
M$K$'8H0O;E!,K"`%W'914;`%93&->O`75_,Y5A`';B`\T.!MEI1[%4A+S#$Y
MO7,&0M%/B@.M4:.#X\@%=-`CD]`&B9(&=B!#:,`&UN@!O.6>""`+1=!\%@`#
M3,`$'38#W.(*7V`G9J`%<[!!++>@BZ4!/@.+=J""-Q1I999!L"@"7S`KA0`J
M^Y.@E#"T:8"A<Y`'&K`6;Y`C\$0'N+"*"F``;V`W6L"'H%@&!R7_!62@`$-B
M0JE`!PD0`S%P!284*6B1"";3A`('F0<0'/!%21&``0G0`!E0`2/``C<0`\'5
M`S<P`A8@`%$@CRZ``JQW`C>U`@%``9+``&80`3,@!!TP!5\066/`6%E``#$A
M!A!X!AV@`D*`!$N`!"EP`G7``!=@`&BP!QS0`RF@`B,P;A!1!WC0`)NK!HT$
MF=6`2[V$`0>P!QF``BE@`@?6`0^P5KWS,D3&@BV0`D(``DN0`1QPN_'U!F/@
M!7BF%NF1<I#U!M/5(WPR)WG0.B-7KJJC@JYU`0!@`'\@`2A0`$!@`4:+!5X`
M!FSQG&8E-<VC!JQ$'NX3!?'C6&AU-=!Q_YFM<Q@IXV_Y5ZYJ$'!K]3:1M86I
M<0<6ZT]1T0V-LQAF$QCE2`5EX&:P8U4).@6N8L)5\&N*!<*%IA+:X0?681NN
MLP540%<0X4^)-FWC85)W4#?/T!U^(`45TDAE18S14X92<QEQX`=@L!U1$0;J
MH0;]1%`J@@=FI09W<``6(%$2T`!T`[YU,SC.\88"(!T@$CD7]2X"$!*'L@AH
M00;CTXMFX!6/@@""B%F[`"H%R`$;$P!```,WT`4BL`9EP"AP8;="YPJ=P""-
MDB=O`"CA]UTN<0!7H%QYP@5E]0;&A95[0@=I49YS0`:Y"$1:<+5H0#AFH`$*
M\+=_:Z%P,VLBQ_\&4.P&5=`$1G(!XHQ$:B`#2(`#?9`+4\0`-W)O4\`%7E7)
M4\-%];0!C60!$^"_)[`#-V`#]#@#*$!C)G``?F!W]H`#`:"E_TL$&7`&%:`#
M1``#,B``:QPLW,$1+E`"7J#`8.`%"4`!+<`#1W`$0I`#'Y`%)$0':L`!)>`"
M-6`"#%.#4F!@9E0AYO%>"#$!%1`383`!1@`!0Q`!)7`#%-`2;1-D-%$U%E`!
M%8`#$,`"(P`#)-``6.!P029M/748C[4&9D!T$L11*EA=6$`&RVQMI&ERI+@+
M_)B/)!`!8P+"FT,:TX@\)]%/JOD'(Q@=51,=*@Q?>TFPOWDZ.,-=)9+_'>+S
M!6+3L"5R!AHX4G^#L"="!FG0HG&P!P$RGSG75%@`4WZ07O>67Z]2!57H!@1[
M&L:'<'##@FNG.6@U3&;W&#F$!82E&NX1(#IQ!;B1#`^@D/#SL'V@&[\3+'QU
M!L\\@L8QUG%D$+!F&'T`K>1!=PKB*\0T4E;0AEJ@U^J*AA9;/BSE!H4U!Z-H
M)610."GCBT6`)P'$6YFRM)'"`&4@!1H#`D#``P%@`EDP77,[!5I[WMW2@#>C
M!Q-``&8P3B#G3FLP!WRP`ST0+5=0)@J0)%FC`:M80TER=/8#<EF`!B(*B<^6
M,C.")T?4<US0!G"P!K,(%VS@!QZB!0J0*=7;_P0BD`?WT@,S8`%M4"9(DG)<
M,#1IL`5X+058(`=;=$LE8`(2L`$?P`&/)&$WH`,P(-4Z<`,[0&4-(`>1D0!W
MD="%%P`D301`@`,3\"$,XAV\Q`)F^0!Q,0=?$(/',@,JL`+)0@`Q0P=ZH'<8
ML`0MD!R>@!*SO1-^<#9A8`\24`$$H*\QX"0GP`%"@`(<\`-"L`-RL$L9(`=8
MH`:C*P$L0`0'H(@O<`:SQ@5JX`?CHP5@L`6(88Q",XDB0`=80'6(HJ9]L@7]
M,P9HL#]D@`:S,`9[<`-<7@$_,@;9]#F(UJROH59Y4P;M$3;+H=^E<1]053,$
M(BM401DC6P6C,&)^,/\\T-,;U58'>Z`&VMH\<7``;G`27##>57@'\.0B4Q.&
MT5-1SV`UK*(%74``;I-4CA4WK2,@^?$](_@-EREMK.,Y9T`8N4*O53,%:\57
ME@&!57.<@Q,[?*`%:XR'<E.!7>`YGX,^*24[6Z"M7[1_>A!+"U-6350&55`B
MMQEN:'@`\U8P7O`Z:*@'_3,G<[N7><,&C'`+Z3U>%5<+=B!?+[`Q*;`"!9`!
M"0I.LZ$%`[`S`]!"K],%<C`")G`%GS('M\4%;)`&>I!"+6`#)L`%?VL+4BD"
M)-0$.P0H(M!VTZ51#B<*%SH5D1!Y-30`9:`896`ERX.)O["$6V``0B+.3>#_
M/U\@`"/0`A.@!0X.XQK@0;:(!DG&E0Y"5XU^`AC0`2\P$*5;+3B0`C7``RAP
M`^A0`1+0:UAP!CE@%`Y`!!L#`D@@2"<0J+0"!FDP&V[0`DH1`PS@!+:P*&'P
M+2R@`XO^`5<`%W7P`S^P`05P`TFF!V+0;E+`78Z!3>/6`)54`6=@!A2P,2>)
M`T@0`SJ0%)!.`!P@`3A%`()'`26P`Q:0`T)``"HQ5EU0!:5`B5K`4H5C+R@.
M!OT`"`,#:6P:&FEO`PQS7&!5?FT>(6EN)P$%%$4A:W4"=UU49VIG;G)^8V-;
M55A:6JI45E%<6GU\8U.@?5YG8E=19%]>>@)R56UI_WYU>')455)]JUI==59L
M:5Q7`@ER5E)46%-G>WA46UQ<7LQD8WUG7GVN?*574WUA85148VUK;%M77OY8
MH1(EBAH]8;:8X1-+BAL!!.Y0^=)GCP`]5K9$`?/ECYXZ7?[\F<)EBQ\Q9WC]
M"=.E6Y\M64"%JD,EC)@^5VI^T@(&#)=V5[3\B7.&2I\X:JB0Y"-GCY0_:NKL
M27!`S!8^<<1,J>DN#1TZ;-B0T9+E"QHZ&GR(,.!!"0``2IPX\:"@"`-.0QR`
M($&BP(,Q7**4Y8)&A`(##(Z9N8-!`H4)7PSXL.)F3)HU6/18X+`#2`H]38H4
M\7$7C8(+&LJ000,G#YPR6O^F5/G"QDZ:+5K\G+D"IXD!!1H&^&N#A@R_-',8
M,*!CQH^:*$7<(D"@P,X`,@=*8!#PQ7<3!@-$T&GS!DX6J7'T'"!`X$$'#A,F
M=.CPP<2+#Q1*H(`AI$:,$12,,$(%#1!0AQXM+`$!$P5``$(`*+@P0@<54$4`
M(ES``88+"X!0``8*!!%"$W9HL4<%%-Q`!`PQ1`"'!E[<@,(+"]@@!AX"4*$(
M%F?H<<848@SSP`,"0.0&%BTP\<1C,N:P!`A(3-!`"RG$8`$>!%A0P8!UX"!$
M"7=8T4D<?FP!QW)MD+$%%FQJL<8`<Z3Q!1]Y-.'#`&C8H8$9:,PQP!M\^/&'
M'P/_(.`!'5UP<$0!'XC0!!I6[+%'&'YX844??33S!3!3\*%%&6;@HL\:7S0C
M)Q5^]'%C''V8`<=M7=QA51E50"6'%&OZH44::&B1#QASK$$&'P>JX8T?5[B1
M51A69(&%+I1N>M05?'#QA15W[*%''%U$84474WPQ!AAF1)&2'UA8(=`?7?21
M!1>!5G%%&'H0H(=2PL3Q!Q9@\$$&&6<<T`49X5CQQ192V'0'.7Y8,:\5SK#:
MQT!4I.?&-U:(X2\::2PDT!13>!%&%%C$<4<89X!RD!3I#%/DK6+(X8444;W3
MAG5S\+-&&F6D80<#:2F`@!)!`##=7`KXH($=#P`!`@@H_Z0``0&W>(I&&WD8
M<`%B:(2111PF8$!`%D4H0,9'8\"!QE%X-!##@Q$P4(2=/K!111$&V"'L&W38
M4<0`5%R!QA9?M%%&'UU(4<48`VBM0&)HN/I&&92OD4=P:9"1A1A4B."$$G&%
M<%@>=6R08QM%B&!'&VSTS><<?^!1+P%[$)`!!QQ((,`!&%1P.P<1<)"##3?$
M8`,+'9SPPPD5=*!=`AOLP,,1"BY00POS#7A``W^UX;`:(R#Q]`(4*."!!Q>(
MD$8V%,1@Q!(N;"'"%BW`L`,$-L3A!1]OB)`'%W[`D16*5(K:C8,`;FA!`'9`
M%0Z<``4%<``*)L""(^@E!PDX`_\!*H"!/:B!!RFP@`"PM(TLF,$,M,!"&N!`
M'-8((BT,,(-A#"`"-K1A#F/0`AK\(04KQ*(-(4"`!L+``2(LX`2*&`,6Y+";
M+H2!'HW``A_X@(4O9&%B/E0*(ARA!6!DX8M2B,/%+%.&:U&!#).#Q11^888L
M4"$+91@#%2RUJ2CPH0I\N,(?KM`'+EAA&'N0PQ7\$*LX2,&.50`9&JYH!5[0
MBP!QX`,5_E`2-D7!"V)HUD_<X`8K@$PP49A";+"0!999(0YXZ$4?2-F%LHA!
M8.6ZPQ6P$(4NI$QD6=A"/?+1!3',#%VYP=&/OO`%,&AABH%B61@49Q0SE.$,
M>`C('_+_6(<P[`)'=VB*1?;0+3$0@P]VR,/J=C@`.(QA#7)3BP*<\!:C>0!I
M&GA#&QK@-*BMH`!N@`/AQF`&.C3A`EMK@P!P0`#`22$+<_B;&"+"!S@,8`J>
M2``*/$2!-OC&`$7(`QM$$!S7)*=L/KC,(:*PJRG\X0MK,8#6)+.&,MBA#%G0
M`C^O1H?7J&E0#`BB$Z8CB8=>H1@:,$`3\B"(R15$CF>0`QZJZ88(F(`#&1C2
M!CA`@0IPH`(W,$(')%`!J^(@!R68Z@YZT($-8,`$/5!!#9ZP!!6P@`)GI4`#
MBH2J!&"@`0>P@0.8``((E&``[*2+",;P!PH8(0`QV(/2.$""_QLL8`=G`.=X
M4-B'.A!```](@!NX0`8U'"`!#=@#!5I`@02T!P,J(D(,8E"#"$+``3\X@P1>
M8-H8X(`#!?*$'NZ@!>($)@JTH8-'Y\"&)M1%=2+P@1E0X9,ME&$+F/S#4_B@
M`"4400Q%!$$,V&"`,ERA#D]9:C6A<<E.<@$+7<##':9P&3/,`C>S`0/(D.4%
M7>7&"E[8`IQRR`J.:*07?*B'&Z)9L:1$H19^L`47ND"`",PUFVH0@Q3J4:8R
MK($/-C&DN?;P#G3Q=PM]V"/$K-@%-UPA)WR0@AB6>8HWD($*7;@(?M5@$P&<
MP0]QH%TZ#$00*=3!"W;L@Q^DT`4_S/_Q)7R(PARE<(<Z9(H/99A#%B!"@`1<
MI"B5ND+/"!D%^#KD'F)`95;4D*T#Z($/?Y"5%@0Q!S2LP3IOV,=:0G,!T`%@
MIT,3K.'$8`.^YD`'1+B"!L90A7585'0A.$,*8$"!/#CA`G/80G(.<(,3:.$"
M"D##-P2@`@^]@%`^.`R<!$$',M1J"G.``QT8H!8RN*$.@MF"'52JTM"H#@YO
M^$-1L``J1*1Z#5IX!ATNL-,0&/L"=,#"3\B04EH780QJ<$,M[E`@,:B!`!*8
M``6JVCP6N(`"'#"!"Y#7`0!5X`0WN($+?E`"%_3@!BW800YF0((:I*`')X`K
M?"(@@0;<(0[_']B!7#D@-2$L8`D2T`#H$!`"'WQA`CD@`A)>H!P3U``'"XC!
M'<:0FC>2X0\3.$$)@+<'*MAM*A&80`8D8%H"'&"V+1@""8BPA`440&I'*$$'
M=H`!"A#!!::50Q_8T(<#R,%36OC)&\=0'##HD@$B4$29A#,Y,M#A#?TJL3ND
M@(4+`*`)8@@?"(R`!06\X20B>^(?5@RQ->5256Z@E!8>$;@^C*6+7XC"%;K0
M!2]4@0M?%.4L0-5<'Z98#TZI0A>TE9XF[W90^1#RXB^[AVHVJY16,/*ETA$&
M(4OAH!4#2;@<<85AQ"'SR;K#;G<3AR))80UPX((WS1P&I;KAV@)0_T:1J(S`
M*F1AD+A0_:#N0``\).[$ZA&`%[J@!CZX2T[JV<.K9_9$7Y+4CW%8ID@NI05S
M46N.>FP]`<(PA2Q4H37,N:$=WF`&-K#:N$.3SOFFT_`T5"$"*>!K"F:0@BDT
MP1]:@`5H4`3H8P`4P`0DT`%;4#1#I0%4L`,!<`-@\$XA(`)DT``D\"`G$`=H
MP&H#0#EU4@1H4#M7T`;")0)V\092$$A1\`8^0&MJ`1YV0`=K4`6U,!M](@@#
M4&K\,@!UACX`%0*Q]R=K\%&T)@)@(`4IP0?>5'D"@`$<H"4?0%7A=@)6R`(_
M("`M@#T;4`$L@`(Y$`/L=@-#$`,H@`(ZD/]N+?!4]*$E%/`!&!`!"<`!)2`!
M$5`!0U``1"`$0H`"!^`#0X,`%_`&$I`#K64#8#``%F!;!1`#`F`%8!`%50`&
M6/`'!_`!+S`!Q3<28;`'!Y`!FD@`\6%E+X<!/U`#`1``-@<#`>``!7`$-,`"
M//`?W-0'=%`$9U,'5U`%QQ0&;B`%6O`%UD(&&S4`-R02K$$'6[`%;1`'<?`%
MH7)B5Y`%7J<`?6`"1``"-1`%%\``CN`'?E`%6S`&SM%'59!Y6)!(>B<R8B`&
M?Q`0OC=WW4`RG>(L4_`L?1!*L2&.SM`25[!45,`'4<%)<N",]8('4]`OC3`%
M4B`[2)$X@8(R;F#_$?^F+U?@CFL4!CBB?.G8CJ*0."%A!6&P.Q=Q!Q#Q">5G
M!6K@!6H@?7TP!6%P6>XH!@.&!V[P;U)`2,N$.%EQ!:)P![+",K6#$%>@.'8$
M!F4P1^]8!VYP!LO$29C2#D429EX`#E^48%%`7VK0%(\(>%3@)QIU#&T`!VSP
M!C^C"4,#`$$P%R'@`8*H`600!AV0C2`@!"F@`E/``!WC+&M@``P'!S^P%QBP
M!2&@!)C&`!0`!`'``FC0!!X``![`!1.P`@\")F4@`@S`!N?``)A&![1#!GD0
M=3^C`=YX#UDP`$U@7$T0'&_P!M:`'-=@#E9G"`Q@&U[!`&PA":=Q`>5D_R=V
MT#H:X!LU1!9GD`!U,!0"L`?N\0(8$!\4T`%P90);&`,JT`(C$&\Q5P(R@`(J
MD`,M0`,T4`(X<#PL4`(G`"`8,"$2$&Y4!5<$0GP34`(IH(<J``,N$`<:,!T7
MD`<-D`,P<`0]\)4/,)X!T`+L<1.MX$D#)`&(5W)NL!X"D`$1T'HE(%=%D@`F
M@`)(D(H+X``V]S0%\`,\4`#0*0!@D`;^0ROM`BI4T)3?``:KD0>CH3=PH"9D
M0%PQQ04)<`>)``=S(A(&```74`4<``,+0`)3<`$^("SK0`8=0P5:H05BL`<:
M<X]58$W1E0\])%-,&!246`]7`#$L`PU#UG<#H?]K3_1W5"`'^\(0MZ>1>!`%
M:1`%JN%[RZ<N4E"4?>`0P^!R>I"37O!O7E`*-<8J4H`0OA<%II0%.+9;VR('
M14(`0G='8$`%LB(NE.$%D8<3!!$2$Y,M7L`%J9`.WY!><K!BUB0&3-E#SX`%
M@!$%<D!Y9Q!*9"82!G2<=:`&6<"$)M8-4W0&J/1C4B!)@A8<<$(&419.1.4#
M%X``:EDT.^4$(?`W8'`'$H`"?%4#9R@%8-!'8T`&<"`T"O`%+E``-1`WZW0!
M15`%/4`"0'`"UN&#'D`&%I`"'E("9^""<Y,'B:A2;_`CBL``9=0X`S`G7_`F
M>"-JPL(S)SH'<0(,"F'_!R(@`FICEG2`FKJY-:.A%LF57`K0!'10!ELA`!00
M`<3'H!%051N@B0]P`@ZTA3@`!$9@`RY0`BR0`@&0`CCP53W@`FSH;5,H<F$#
MA2.`.]PV`B8@`:?*8!_``@J"!#/P5F=079`F`+*8`ARP!61``T20`T?P`NI1
M7Z_F!S^A#7=@`1E@J19P`'>0`!(`K"<@)1'08#I0``60BA$$`GSU!"8`!$=Z
M503`!<J!&USP!Z<Y`%I`+39(&PZE','R!H9@!W$B+L-RHPZU!EG@!?CI!`HP
M!1-@KT#0!TGC#\A*!F9@J6[P"";S#GVW"_<(CN!H%&"`!E]0!5DY2='&+6L4
M_Q*I@@4QV4GI4%\6AF%^`"I+]*=9(!!?PW6M(!@VV"G04(EJX$0141+T@GC;
MX@TK]GEA$&#JHJE9$`4B08_T(BFYFGUWI*@C`PXP<09AH@LO20YD$`7+D!$L
M:I,Y<6V0Y'QNX#)XP"TD4S(34`$"(`:R$&Q-YEDF*R__Y@=3T+8$<!,Q!0U_
M4`=R`!+?PIIL$"=>H0$<I0CF0S1!4#1Q04,Q%`884`-/DP(Y@`*;50I@8()^
M:8T[4``P(`"_P;D#$`8WT)T5L'Y;X`-*,``3(`0/0@%9X(*GH0&VVP8^X`,]
M4U1F\`9X<W94<)D^@#<7L)IXHB9;P`9%)2YN-I9I0?^:#)`'_6``;5F`*I4Z
M>*/&`[!*`&,OD6I:''0`V4$!![`!(B=R*T`$56(#0U`"-X`$VCH$-^"=)?`#
M5&4")C"%)G`"+X`[5Y4!%K`!+U`")1`!^.4'$T"&*K`$K[@"+$``#$`=9K`'
M'[!H$P`'?5`"*Q`#),`!73`;5U!YYM<%)B,!-T`#6G``.U`"'*8'*WD``G"'
M=T@"$+`$-7`$'?(T`2`#%6"W;R5"M4P&Z4@8;2`(M&M%5B!#XI$<2T,>._@%
M;Y`&[[(&-W3&;/#`>,``2A`"7X"!8T==AR`H/32E>.6.[3*.QU0+T.B[$=8N
MC$H%730&XJN2@G1,UC8H`.3_!M(5!MEG!?R49K,Z=STR,LX7DZVB>+_P!;*Q
MJR2C$1"S"@:Q.V8V,>Y@NPXS$KC@!K5<1EYP$6&09A`A`'NZ!W'@>R+9!3S!
M$]>2,F?P!TKV8X^@2NZ">YSC'`<PM[W0!3XI*7H@!EE`!E=P`!.0``:LJ)$5
M#L.@!\HR#&K@)E;`'L9",W&`!5L0JW@`CG$@'CWCFFP0FJ*A%FSA%G`A'9(Q
M:'?0`4;L`"M@`SLP,%!A0G8@KG_0`TA``@+P@M0Q&=3)0([2.$H@`AF0C4]@
M`>3"`'61!J[0&P;@P7;Q)W9`&H$Q!J6=FH=!FAKP&ENA!;@&*JV3.6W`:EE,
M&E\1_U08E9K>\8)U$<==`&QZH`=7,`$;8"_:)D('X`(<\``<(`,M\`,[<`0I
M(",P4"4Y``0SH`(Q(`,V4`(FP`(?8-S-B0')PP(CT)PI1P$L\-T5L`<C>P(Q
M`&\Z``1/<`0Q\`!Y$`(&@`8"<`)]*`!V$`8[(`3>&0%3@%3;PI#_^P<EL`,-
MP`<5D`(D4`&7XDO)\G(1\`(J@`1+4'-/\S0W(``UG`(]EP"(=P=\`-7FP#@Q
M9`9J@@5O<L9I,)9J4P:1DXA5<`?;'&U0EP=?0),,(*U?(`$JP`1+X`8TY#UN
M,)/U,BF#$L-JXT8DD0J4P42VA`=J@$68D@^+(U]G`%[C*/^^L-N)1S<%+8D'
M4D!,C=02>>I-5SP%%NS`NU!B1Y)W5L`*+9I--ND'M<0L"B%?:&I-Y8`&7$!\
M`N`&*899`E`%5)"<`Q$&%IP%:#`&7Y`;[VAB#\H-?]#D`_%YL1H1H-`%@+0P
MG$,SIXH%;7"Z#S`!Q+TF7J#F66#FE^)#0SV[8]#F4O$1,M6)@Y0I/E!JJA'7
MX?'&:HS7AC(76S,`6=#7V;@`,'`#'<!>YT!2<R`T!E`%+K`$)'```U`$`*4`
M6*`#]B,`9?-/'H`&'"`^`1`!9I"(33``;T)4QC4W=F(GY30&E,YJ:W$8?S,`
MP<$(F>=?9I`'9]P:+Y2:'$6:`[#_.F]@\(;0[W;@37\P!C$C#"YP`A>Q;1<1
M/!1@`C9@`S@@RS5@`RV@`BF0`C6@K:LU!"S``E?%`1M@AW;(01U``Q\`BHYQ
M`Q0^`G&Z$"Q``H-LGBR`\OFM"2*0!0\PW4/@!7:P!SAP!##0`;.JJD4Y85NI
M!@-5`6U`!7Y-!"7`#,"ZI]?V`7QQ`WW!!'SU-!U@!0%P!"Z@)0<@*=*62=)@
M!5B3!6``&&/@FG`P!WG'!<OU+V70/U@1=9^US7G0!O)2*/(\`2@``05``*(!
M!S71+%LP%%X@&UK0?FD`!GYP#RW!![.^#"@!E%]MT-7"*Z5R>_QB$CGY#+=L
M8KIFP=R*_]!*D04JZ8P"$>L"D!1:ORU_,'>84BF2@BN2V*W3F`K6\@_U*XY7
MX4W)&0=E\0>7]10OHP9QH`S@$H`V"!#U50</X&1#06,B0_M,F4FI(A"Q2A-*
MEC@'"_K;XX[CV`=*-=31UKWG(!NZ!`A:6'U7`@)A7EE4<5=;?5)1#'9F6%%:
M6UQL#")%!@8A2@``'AY.(1<&<%E2)P4@$$<Q%%-H96A556P*"`QK&T@H>PP#
M!JA5+#4L80-P9`P&5#\!(`42;V8#&@8*!G-M(@8:;6T#(@I%8U%@`T5%/A<7
M34T,##X:&G1C7%IE9E]YG>;EJ6>@21$1`P8,8V,F#9P\Y7SXF/^SAP">/7?^
M>&G`8H2``QPP[-$S(<,+%#5PX""1P@:.'#%BH$PQ)$8+%RU*?)A@P4*#!Q4V
M=,`P`4.%"A0HN*CQ9`:&*YJZ'`&A@D*'D!U8["!P`8$//2=8"&D194"%%CF0
M4*CR1X`;*GRB1'$S10J''0<&;'EQQ`@-`7L.[+%4I8&*`%4[I*@!I``3$!SJ
M@"!!(8.$!@+.^)G"A0R6*W^F;.&SI<P8,G3RL"&CA0^99F/0S*$S8`T;'VF\
M6.%298R9*7_R>`A!YD$,"`$$M&LC)<P4,V"LW'&C9<R8,F6P^+%R1H^`.Y#.
M?*>R9<J=!@3.9-$WIE*5,''Z?(G21R[_'SEBHEB9TD>,E_]_4&&%%'R`D088
M;A"`2!QWR!'&?E2XX087<VC71Q]6J(%1;]KQH4456XPQA7]3\"$%%5F0@08?
M>A"@QQY[R'$&%V5$X848\.GAW1YGB*$''E=04>(?<8C!1Q5=Z'%'CQ+>`>,?
M44R1A15^:)%%'U.H<<`=46SAQQ4W6E&%&WNXX4<?7(S1QWD"5!'%'0(4J885
M]%$AA11_N*%'%U,$J88>5U2!188#Y)%&%KV-`08<`\QA1Q,A("#**)(B$((/
MS1QP@RL.,`%#!:1IL0898,RA@`<#E!%'4FJPL88(3?B`!@$4G#&`J[:D@84)
M3X"PP`9HL,',_S9SY*$!`VU$X4<54XRA$!A]K%'$/$6$$((!"-GSA@8BL`%&
M%6388<<F[6B@D`^>&'"0""*8*ZY"VWSQ!QQ7'+"E'"\2P`$%$6QP0@4/\$3K
M#3=\T$(-*MR0`P\JH*`"2R3$P((++&P@P001/)#`3Q/8,$1(&6!@@@PJ('$$
M#@]HT6@"TPAAP0053##!"".H<8$'!N`A0P\D?/"&'26T\,,1&%#1WP$1$.`@
M'\E*<$`8^IB`0@D7TV`"`7UDX<4(0.0D`PTGF$!!"P4L8`$!(-Q@`086"*`&
M>;%Q844??OC1Y1QSI&''`';H8T<;<V@`1QILT+'&%5SX,(`9Y-!!1O\6-NKQ
M!@(>E$$`"TLDUT0W473!!Q?]G?''B49'P8<5?W0AQAYJ5.$'GGUL`<86;AR@
MAA]Q"4K%'XA2(5>/D&Q1A19:7&%%AG=4Z<<?:ISA.19;=+&'%RBFB0867G2!
MA19MP&'%%6K4\<<9HHLANA]8C%%'9G+PV2$68'CFQ8]==.%[H&24\448=70A
MQ1DC$8,<ZN`&1/C/"R.10Q2^((",)4``+4K`]+SP(`)Q`0M=Z,\AKB"%*Q3P
M#'&H`P'NP(<I[,</9ZA#`_;0GCT8`C-QP,,=IH`%$ZE!#)OY#USX$"0KN$$2
M:/@"&(+UAC>,"@X&\$`H1($`22GA4G3X0@7_5+"`5Q1`!1.@`HBN\053(<``
M9;`;CC:3A6#)K0]Y:$*AVL`%/E"!!M,H0`7:0`<1S$$$LH(#/KZ@1SBD:0K5
MP<(`#&*."YRC#6PP5[CP808RE*91PF)70AC0B8*X8UH%41>Z[""`!DA!#@_`
MS`-<E(`)).``'2A!!B;`@0J(00`9B``'3K"#A*$`!C'8@0UR@((<].`$':``
M`2I"`$,4\P`D@,$-AM"!"I@@!D<00@\P4`<PB&`,+J@B$3A@@8M58`05T((A
M[2`&#O1@!WH0P1=8<`,6S$`"6###%O0P2M%A80U;D`,9*#&%#%!@#P]000TX
M$(<&-"`#5ZD`-"/&_X*9':$&`0,!#B1PF3KX)T5CX.$4.).&-.1A#G!@P!Q$
MQ(5-#*`-C$.(&P2`!0U<(W`BL(,6HB`%-=C!4F.0`P>.4``";&X`%Z2"'-QV
MA3"X049STT@8`D4E+"C""EA(PQBJX",I],D+4]`/%;Y0ABEUIPY8-8/^^!`&
M,7RO#J3Y`A>&6H<K6((*;\M"9P@7O3`830M<\,(?+L2'"TG/15@MPQ_TH`8W
MO*V&:I`#)/I@5-%!]0MN`N06F$>>NF#H#G@0@Q;AZAW"1K4/+7)1BPZ@HX\(
M0`QXM=/_Q("+*+1%#BLEP`0$X`>XNF&O<<@,Z,C4@`3\X3YZJ(X?U``D$_^>
M`0]UD`*2Q/`G.)2!#(4K5!JV\(4T:*`KH@@"`)H(`%.H$0P)L($#0!``(-Q`
M`E'(0A;6`)TY7.")6Q!`';Y`!3V`-7]4N$(6WN"-/'SA"DDB&S4D8(<\A$,#
M!YE#;;)P*@,P@`U7Z`,:WN`#>2C@`G:\%:/F`(8U\"U88_@"2CTLD7MP(EV9
M5,"%41%3*PB```=XP`$(8($'O`AC3CI*`BP`SBO<P0(9:,$(.*""',``"#@X
M@0MNT(*PA:T">Z@#<ET8)P*H0`@K2,$((F`"$A`A!Q00`!7,`(T:0,`!0#C!
M!`)6`0X(@`X.!BT'4&`",A3A#"^8@0I*(``ML&;_=\T:%)7\L(DOB.<`9Y``
M$6)``#=4H`0G(,`56'#F``2`!QTX`1)4($L0Z.`!,!+#%<[P%A-:50MV<*FC
MKN$(WJ4Z#9]+0Q$&<(`KT$.LC!*I\-PT`$O1;@-&@,`#T#6`]*HA`03P0G?T
M1!<MH"X,O(L"7+A0(AI5@0H4C!(5J,`%,,7S"R92MG_X,(8M4"$,8<B@&_E`
M&C*<X0YJ0!RTO$"(O0ZO.1HQK!OJ8`7L0*]/\*$W%E@C%[@VP@\NK,,93A0&
M/+A!N5F8PO`^E*<NJ'=X63"J%WI3A=P*P`N;B=]<]"!JMCH/#S)^$!7`(!XU
M].$Z]8UP'`X@S+K@83Q:_^7#&:P0!HQ8W`IRZ`,?XE!,/I2A"F2]`U:E(`8)
MD2H-V1`!'<JS!FV$P`D`"(+6E>`$KE]K`%\00PL@0%XA3'0+S@:#&<R0!U`4
M00`F@*<5'B"!*N3C2,\!PQ^X0(6+Z&$("W!``1(@N`&@RY`^$`$7\/",Q!]J
M40S8W(KAH(4WT*-1#2F4;]B`4KWAT0>5S.0V/*%B%3.`"^6Y0AT.D``X80`/
MH*R`!`$#T*1$P`T68`$+6K#[&*C`"$#(`0XF=@*++7D#!%#XZ@03A@3$0`@P
MF($+)D"#(ZR`!@T(0QK:A0$(9*X&%.")/R<PA7E0H8%#.(($!!<!"J3`"!,X
M`_^[V\T&6*<P#%5X1AKZ]\(61&!^!U`"'1`'>@`#("!X"R`$)R`#$)`#$7`"
M#B`#\B4'?X`%YQ<']2,%69`&FP`1&F`'4]`%>K4%`_`&N/`&PC(&#6`'J!)5
MQP(':T!MZZ$!EI(%>(`!0.``%F`.#"!`+Z8&4A`8`G0&Z1-QV/8'H.$'PD-&
M'60\6X`%4U!=9Z`&:D<(VW$DRF(Z8-(%VZ%<?N`_5BAQ:#`&RR,%=Z!TH],C
MC[!\>Y`%\^%4<I$%6Y`_7_"$5:!>2E@&5(`C]1,D7E`';\,LO--([X$'\7%M
M=M,%''0%RV(%#'(%IV,%-_(19Z`L_A,%9J`%!S`!!^#_!F6D!Q)``*@%!O0!
M(ET0`140!V.0!8/E%F70;<=E5U)`)HPH!CB"!\7D!V"0)A?D)GO8!5'`!A!A
M!T:4!K*!8`H0*9.B75SW1`I`!R)X`^-5`$B0`QE0&IO!!6@P`%<W!QSP`EY0
M5`D@`65@!V!0!K<R$%R@BU$`*#?`!-Z'!P8P!E*@`:>@+B)`!0WP*@G1484#
M#I+7!#'E4>9"!W:P!F_`1FJ7!@AI>*"W.0;1":7'#4UP#UE``%@P!V&0?#"2
M`!1@4!60`0F0-'_0`"4P`J%T`"=P`R;P3"D0`SB@`S'QDB]``1A``%GQ`&Y!
M)LB%7`>P`REP9#!0`BY`!#@P_P%>T`9-<`%\H`,0(`1"H`(;\`%)\0$"X%YP
MX$\?$`,D(`8B\`<<P`&^ET47E`G>D`4W)`5SDTB41X\-@`$9H`=4<`8-4`$1
M0'-(X`"9LP!/@`(I``)#(`$L4``=X!UW$`99\!D`U@55T!!O8'C9T`1K8(A8
M0`Y<$`5MX"Y^,`%T<`%K@&IVA`9K@`8?8@8^@``7T`=U0`%'``$6H`UY(`4Z
MX@5Q`2<"HH%:X`>0HP9WL!MJ)3URN6V;H04E`BY_8`5D8"-WX@:-4`9@$!=3
M4%LV`E9$P@B:Q05I,`=D\"5\T`5J\"!1<(=]X`;=D1[K*`=^0$%JR064("1;
M$'&S\_\%7U`?;N(Z_L-#5P!(C$AQ905R-31JT],%!)0UKO466!`&QB08:I`%
M;:`%AB6;WV%508@>5"(D0Z<G;;->9/`%RR,F?1`',"(`L*4'^&>!'/0'_A%"
MSA%B6;`\%E4%CC('1Q<%9%`.\()=6A<$S>B,`S!8*/`8`7`$51$%<+`%^J4W
M[T5K>Z!J,#AZ*K8YJ-`$W)`':/`"KB`$7M`$:%<$%S`1QX(%9V`&[K`&'99J
M3MJE]I`:YD)'TQ4E60`&=*1@!,$-[2"E\*!B13!28!"$$><=>(`'!]!-,#-;
M#?1Q'.`"-K8V%/`!(V`"*Q$#,V`#+N`",G`"9_,`=;!C)"?_`%:1`/@"6\B`
M!`&0`BQ0`CA@`@)@32+0@X<*`\F``1P@-@>P!5)J!F-#,!20!DW0!2<@DR6`
M`6*@#_=T+&LP'RAZ!6GPBG"P(AC0`@G0&@]P`KXE`"Q`!#5``@'@`!!0`&07
M`QUP`T30`J'X'5;P!6A`!H*R!MH)!H]B!^:`!A%P!V80&XW)+O.@!;9B`+?B
M&4.DC5Q`("(```J`!WHP`MR:`9MP="*HEAC2!]!S)[F97Z06!0A9!E<`(T"(
M/F3`=U=P!<RE1:,S/N3CL%#XGGU`G%Y0)'\@!^TCHE%U/1U;&E4@!09"!B/B
M!O6S<,U10(90!\G%!\Q#FZA7!0`6_P8*I#5G$"BDJ"-;52?X=B92('0()`![
M-4`Z(@<WA`5Y95$S-P%M"&X"H#$"@`>WTP>`$0=%HHAAH`</)`=>@%=?T!X7
M!QQ.$J(0Y%9(=R)%]0<])P!=T`^LV)O:\3-P0`EO*BR.\@Z2DG5!P%VF@"ED
M$`8_ZBM$0`(E(`5FP"PTT@8&@``*\!#<4`SP8$B&1'H71@H89@4RL`0G@`8B
M`'4*,`#QY`YIP`5M8`_6H0FB.[KKH@'HP@!@H`7Y!1I@X@?GJ@$*8*?)RPDK
M=BWXH"8,8@5P)0"G)#.=]#(:,P$KU`$F<`!Q$*VM9`([(!,JH`-#T`(=P!.8
MP3HN]"!X8/\!%>"W2M(%'[`"2V`$*L`"0Y$!+`1V+[('$]`#)0`S1"$`4C`;
M#.%\0,`"7N`#8;`3+RD!#X`'8E)=<\``&K`&6N4':?`E<Z`%.E4";L`&?R#!
MTCL!-P`#*9`"`?`8(/#".%`"M_0#$B"B4%(&="":LV$'<U`X#/`&:90&8?8;
M7\!VQR(/JI!J;,`;O;$&L1%&4A"P"F!?)P`!"R`!>)0&Q2,%7Z*;7*!6`%8%
M&")`X>@L;)`D<A`'RL5#7<`@<7`&V2,&=>`=@`%!FN6&Q),=7N`&11)`!Q`G
M^1&>>"4W?YL&A;`'4J`ZNA$'8<`'?^(&>QP&X3EJ5A`_.G<'+W+_5"2GBVJ"
M7%WP/=1#",/C0?;#=#B+)5O@!2^V)UF@<W,R7`G@B85``.@1!;F[!E50!G#0
M!F2P!LLZ%R/!)TR7;G)51E,`0LAU!XQ<6&H`<D"+MG1"!7:S.Z.S47\P+@-@
MC&PPAC]3#J>R1-LE*:;P8`R0!3LP7@DX-:21=V-@71?&#0AA>.IB+I-$#^BR
M.>K2!&K0`5@@D'F0![*B!<]0!`RA1P-0"W/`I?!PCYHD"7F@P5YP!YJ%A.0Y
M!5X`!DDTN@JP"?*01`ZF`6C@B&IPG$$8,Z8D!P?0`*CH3P##O5Y+`"=``]^(
M`PZ#`BY`E!5``!L#02LE9C2%"%XPBR[4_S$PD`,KP`*DM4)H0`<)(#3A1P`W
M9`BHY6'8PP</@`(D(`'9P!$5@`,NH#0-8@6K$*QP,+/^:@;<`09^@`</1#PP
MX@\)\`,ML`,H8`2.X0#C!0*-&GP3H".\LP5FT`Q`#`=Z]('UMRUTD'S.N2B%
M$E(^D`?/<2A"-P9KX,L'B5=-X`0&`$(F4#81``X#D`5F1;0E%)Y]13=18(&B
M@W^C(L=Z%07_BA'-XU;I*2$O9DQNX0?K&#OK>`9R<`=SW"`B&D._U<Y@H'I>
M`%F!<099H@=GP%@H0CV0\P=_L!G2QHA84`5>8(A=T$E^6S=2HA][C%D2^CH2
M0B")V1]24`9KP/\''Z$'NH$G>H6=>((ZR34%8$`/=+#-#F%$PC@,MX)!(_U*
M*]0EF+B.'N0&4!4%<K`'>"!_?!#1>O`'7U"L:C"V4,(\?S`,;\#>#/#0Y>"[
M.-I='N!$EY(04=`*($`$N%0!'39$FV<L]B!2X4D.>;#+;?`S_,4)C9(019H%
MR-L$>4`&'+@-32"C;!`X$[$%2#2ZAH3/>7H%&#@W]QF%I#(%>"`!75#BAJ0`
M$@%Z&3UK7C(\#!X&:B`P/_(3!$``$K`OCU8"%7``$C`"'9`5+B`3+G`"%#!*
MAJ`D$UX'=P`]O'D%!/LG$_"M*!`#/#`"?/L=[GH"-5"-<>`/Z06%7##_+ESP
M8S*@`Q]@!DU`('H0`Y9Z`+!U6VH02O)WG*@A5L,5.S.5F`BJ!F80!R/``I51
M`F;V"F0'`@+``0'@`J=EB'2R!82CPXQ2*"!%#VLP769@!VKU!G30$'.@P25"
M&BAB!A,F`FV`!79P`4Y0!$DR`D\``17``+%K([[3!<=I-$+B)FD"!ED086XD
MS7B"/NOX(%S`7E-2W5J0.FX")E10';PY-T:56&_1!R/-GFTD=`.7GEUR!>A9
M!GR`7'"!VB=K@7C"M`?ZX"AT!U?P!7+P0(88!U1@&I+8!?@"C!?N(E)`/%^0
MFY>8)*Q7!XB@A%H@'W-@T14(T(JCL#?W8O8B_Z+IA@6,8@=IX!EW$`$)L'&C
M1AI?V`7$7@53>)S4328_DA_O@1$^0G)2<`V^87EO\`5T<!`^H(Q;5^)!X`3G
M<"M9T`'3$*15405HX(9L``=TX+L?6"RN0AO0?BZW,F'<L@T):08E94@:\%'$
M<`$,@`9+34D^T`95P(VG$`*Q$BN=P``SQ=Y"E`:-M&%EP`H]$`>2@@KF@F"B
MBRW1J2C:(<9U$`?*]AT0U`4'L`$4P`$L@`,C,.>[UP,VL$LW,&3"%`9PHL8:
MF%4C`AAJ(%MN0P$E,`1#0`,D\-4;(SD^(`$Q<`,1()]R$`&FQ,'7M@<5X`(X
MP`%GT`P<4,,R\$]N,/\=.-+3;L`'E<"!^_U)EVX&F0K?R]('$G`"'``(!`D=
M)`X.$$P@#E<<$"9U8@)Z9U)=8E@##'::;WD^&@-I?%=^9&E:678B;61O9G)Q
M7G%J;`-H7&A-=E-T"AY%5FHF!0L1/@9T?GY45U15?%)74E92?F!D9%M2?59^
M7UM];FY37UE7=59?7U%7?%Q355I?8UQ555M?W6!565)W`F?X:`'#!4LE+6H$
MU(E23HH4/E&TC.&C1@H7/GZXC)F210N6*&H(G$%3):$`-Q"I1!&S1V$7/U+^
M:#FCITN4>'T(/"!0\UH5*E:J]/DG)DX"`7+.>.DS92@!.5L&B!B0Y<Z!!P__
M(DB08"%#!0P;)D1XD$!/GS4:BO@`@V=/'"M>(ISY(B7,E#5SN-QQTZ7.&7YG
M]NBIH\9+&#UJJ"0@<`?/%RQ;UN310"<-`P--%"!0`B"(9P0(`"!0L`KDBR4@
M%AS)P6$*F8QYX.01`>K-'`:@!@RP,T>JB#ETX)3)X[M*F0%EL#!04$2$)@T&
M!K!A8Z<(@SELUAA`X.&"@DS,FS098&;W%CH^?#`@/N!-&3(;A,R@$\3#]S9L
M9AOPK@&,EC1LC)'&&%5\@T48`O31A1Q=Z"$!!R[LT,('%;`PA`HDX)"##2YP
MT,`><HBA1F(_48&%%G_<(=@=>B3P0`8ET,"""QBX_U"!`!50\``8"I!QP![L
M>/&`"2-(T,!6%="P`PL84+&>'#;84$$$%A`0AAA>7&'2'FY,8U$:8+A7Q1IK
M1?!!`F&8@49(95$A0`DU%``!!"`PD8(;+!1`@1X"/*#''6%80@4:`VB@`1MP
MZ#9`&UG\<48?8Y#A42UM]`:&8'U0(46A9F@1!1Y2O,%&$1>(@(45+T!0``&9
M#="7&LWPX84;5_3QAQIB6($%&0=ZT<44;)Q"Q4M18"0%%5/P\<<?6="E5!5C
M8-$''TW%$0879>2C1A?49+$&&%EDJD4<`L31AZ=A)!9%L]#X,84546P!QA=D
ME*%%%RWY00===Q`@P!^9-O][Q6!NB"'&%5]0$<<58)QZF%)[;5$&'V%<<05-
M`G3AA21Q)`71'@_@8=D<4^PQ00<GO-`!!1M\10$''7#P`0448)!!`WKP\481
MXYGQKAL6U)%%&%YDH685>NQQAQH"6:$'3W]<T>\='WUX&+UHI/$&`[KQ;$`(
M3G3F&10`**$$`A?X@(84>HQ`1&HIW'""1'U\L889;[27QAKY*3I`'F^\`<?=
M=MC11GM?H(C%&UOL@85XZ0UPVWK3%6%'&7!H<($3"#0QE0@*A%Y$'G,404<5
M/EQ@``.)VH$&O0+PX$`%%P01@@9SF`%&HCYX;@NA?Y<!QAQH4''''03B(4"?
M'\C_V(()';1@`PPDE"`##1QP(``5#_]A!1]6B$$%%6[XI<8>!!Q0@0LE4##"
M"14T((<:#;QPPAT77#"'>W7$<<`$#SA`"5:`H10,(0)5R(06$M""&U3@#EL!
M%3_<<)262"(,?5!&+=!0AOX((`'HV$(6SC"%,HS!#V]"`0R60*<E1&`#)"#!
M!`1P@`/((41,B<(4WJ`>R0Q@"US0PA3B]84J^`$R\B@=`Q+F&C2880W1T@(5
M.I``R2G@`AH@0Q].L(`")"`S=J"@`*Z0I8YE80M\Z$(<\"`&/UAA?B_!1QG0
M``8__,$;9>!"%J80-2UL`4%[T-7%FN$%/+BA"J>00A1X_[6-+/`!"V880Q2\
M\(<A]N$*8O@#1*:`!6G$Q"8=><\6_*`&Q&0ACS\Y0QW\XH<RI&$*7>B"\M1`
M#BE:80L;VX.^S."%,_C!'&XXS![J$$RB`:5@59B"'KPP`!^800\3X(`)3'""
M$7"`95_AP`@Z,#.:8;,"$W"<"/CS!3$0H`Z6(&,?^E'(.,2+#W5(@`3^Q0<W
M/$`-Y10`K.Z0AK])R@RR$8$/2+49SQBT;`@(072^,`4)U``$$$!!#UB`A2]<
MX41C,"%!U-&*3+AN#62XARL!J@$XA*L/4;""`"9P!1&HI0CMH0/7VF"&J:3A
M<!<0C0A<RK,0I*V97!-!9@SPAO\IW(9177@`"4!``CHDP0,&\,$;L*61`1C`
M`*_S`6G:0(<!C&$/";`"'+8@``ED)0,9H$`*5E""%N``!BCXP`<F(($/2(`G
M?I$#'JX@1:#0!!8-F*8W)_`^";A!16KH0`PPL)R=,J"O??#"!&0`!!"`@`@4
M`,.APM``"TS@*.J+@![B<`TOU"0.$ZB`6?C`!S`,"")L>,,8U`$&TTJA#'8@
M`QY26X$2D(!.*IC#$(CP@GD&4QP5ZP,7TM!53=!A#5EP(Q_08`<X7"%!50C*
M9?(P/-R1H5,..='RMN`#[CCS#S3HX@&LHP4$E2L.?.#&WO9Q#@'<00P,LL(9
M[N"%+=C_)@I4``,=L<"%AL5+"UX00Q@`%H98^($/$DN#@0B\A9]XP0N[TL(R
MIJ`%*S##"U-(`QFF<(401:-BNTJ8%ZC@AY=(ZUCK2F,7H&6%/VQA"V>0PQ^H
M<$DK3,$/<6A``OR0AS5$H0]UJ<-@]#!:C?5A"UAHU!F"DH?5_>$!X'297&E6
M@0ILX`/7]":8:X8!#'RV"W900'2PP&1(6`%$0-E"%'[)K2X(P`+S]((5T!F&
M`^A!#'4@P!O0@(UH<2$/10`%095P4,XX(00*\,$<^I``%20B!RQHP3KK<`4!
MD6%>7-@",]#`!N&!H0U@J%L;UH`&.H9+"O?0`PM((("I,.#6_QIP#L\&8!TS
M1$4!9S-`Z!00@NXT9PYML(.A!#H`,$B!#G,X@#5M`(("J"$)3KA`$]BP7)B,
M@0$^H$T1#*`!5I>!"FK`@QS@``<Q)"`P+8M`#(3@@@-T``4Y&,$#_O&`/:@A
M#K%(ET6R@(T_-&`#*#M!!.09`0Z4(`-Q4#(>K/*"#Y@A=`S0AAE89X4(E*"R
M$&@!'YQSA02D=H9W.-(Y#\F%*-Q$$"WQ`FN+%8PXK"$-N.""&";Q!9I>]RH/
MF$`,#-&!.=0`!CJ1!"3JL`<NI<$';(B*&?[0A<=(80IYH$,;Z-(%IFRA#:PK
M\'0^P@8RW&0*&FF#"+BC@7MQ,0!Z$/^!)"?2DL2X"Z`2Q@(?Q7`L+;"M?U?@
M`ALXB`84$<T/8S!#/6Y,!54N[\_?V\(8LG`B1U*A#O:]0C+=%<0I2.$,RVMM
M'Q:L,:#P20QIK$:Q`!:,"UL$#:/`B!OBH$@_2.,>W*HCOA*DC&](843E`Y$5
MK.!(.2"%&E&`#AV"/`$\2V`"7J%9F<OLS9=EK_K8C$`<1M4$!KAI#UZ00AWN
MT(XJ7"%0DVB\`$#E!S'P%_1QX",!\O(%.^3A7<";S04V`X#^@P:AVH8&#4``
M+N``((!I-Q`&?"`&WL(*419JM@)E!0(&NL-)WT"!LP4&8W`Y#:`"!<`!;-`[
MF2`><Z`!XY'_"71`74T0&MSA`2%0;-Y!&CS5!`:@%G2P!VD@`F`U`3F0&A+`
M&=T!=6/0!;"""<)V544`7?[Q!103@EM``%,@!B?'`C\@$A70`DPB`%Z0;GSP
M!7W0,;[T#0Q3!GKP`!M0`CLP`<:W%=9D)00`*G'P`"-``7X@;'9P8W`@`EIP
M,CT`!`5``@>`!GT@`15`B!C0`$HF9""B8[]$(']F$'_@!GH0(J!'`'Y0!438
M+WMP!E=`1S01!WPR`3```D<@`7)`!"F@%3]"*X&6(&P@`F9P%L7#,,4R!G00
M()'$8E@097,`!G)0!WU0!3NV&V:0''F3!PS@`0@P`-YC`@X0`&K0_P1M8!EI
MP!)Z]F#Q4`]\X$@^AC=<T`71`(Y8(&%-@4%UD04%5@9ED`6-UW3+$P==T`R0
M@07)-`54$'Y:($1A,$Q-(P<MH0=_4`G<8BO2P"=R4$AMY$CX=5_1I7E;H$;+
M(@:<*!!_@`YI,"R>EU)A$`5N(`<.\7E[$3Y=D$9NU)%J$`6OV`1O4`>>%0$-
MT`!!YV5@=DW41S/:9$T4,)-DA@$2@`=F<%5S("O5L'-RX&/A8WP`B6Z_LF<!
M(34,>%UH$!F4\2Y<L`92\37\5S;*Z'_:-@84(``$,(HZP`(QX`5NE`;O\04"
M!F7YN$<590II$$D"U@:'0U,ER`450`)$</\#9W!%?^,<[&9_FP`*MQ$"G^$!
MW8$VZ2%L^5-L/J4!'T0%M1`&.`!1$X``0>`$+J@!?'`&LZ<&:)$9:F8'50D'
MT?(%;Q`=X2<'\K0!'$``5W``%+`R?K)C?6`&;8`%.Q=(9;`%?X`%?M``$1`!
M'>`"6KA2-8,5&9``,U8'']`^7C!N&I`':>!A>U`")8`#&4(!Z!,](P`6#8`K
M-"0`@N$&.X9VIT(%]!(8Y/F+8'D&7=`O`X@'=2`'66,%\1@8'X`:*2`!(X`$
M*T`!$R`2G!2)?#!XDL(0<(`&)W)$'%0OP=(4V&A2@N`&RI`%>3,`<*"!M5!>
MR[@-+@`"`8`'D0;_;6.@7V(0C]U`1F>PD5,P!1*3.SJD!7V@!C*A7RBUCH\2
M!1KA!^'G!9LX(M+@/?'%#U7P#EO`!G.PC@AR`%TP>3>T8-(0!?3(CE=0D>;8
MD50`#J9E%J^%GWB`!UY`I7M$>:9%0C`A!6(0C#`J!1VC!@JR!WA@87_@>D?*
M!V1`;&Q0!UDQ%EHQ`1B0DQTP`CCI33=I33`#/3G),G1U!@.@9@RPCM)"+G=P
M$U<`<''@!FI`&`U6!U(@+?,C"WO`!5S0!GFP!5J@CFD`'1?@`9SA&4JPE;&*
M&7-0%E;``0Z`:2K@#&Y`I?FX'%/P%ZSF:ZY!!^[1&SXP`%6)$?8B!1U0_P,H
M@`(6P#-SL`9OH&S&BAN4<S@&P&BQJHQ!H`#V\@9IL1^A`0`*X`4X\`+=!P82
MD`)'H`><\:T&,$D8\P=<8`?"YCLW5P4HR6NC<UT,YR\-4`$40A9UH`6LQ@9@
M4"R'82[D@`5G0`!U%2-CA`<2T`$6T``C(`,"<"!!1R1[L!SD%@49`$`<<#(G
M,`$4<`(RP`(;0`$F$`$9Y`9-]X\`,T0$9T=]D!-5UQ9R4#YOY)%U%Q2E9D<(
MPK%/<(`2D`,%$`,#V`59(&#&L2CW0BO#`P94H`5J@@8;T0:C,WI2,+5OX(L-
MD"!C(#%YD`?K6`5H<!EH0P=<<`8Z(*("H`!-H/]%1E1*PZ1)?]`28@"CB6,%
M!=$,%V&>6-`N6=`H#-AA:A!,,&&>R-(0?M`'>$`%010NU*`K1J0@60`'<_`,
MW%`%8``&\B(I=G1(&Z&F4W!"-1I_\^*C:J0&K509D44%=3JQUQ*%)*2.66`%
MZQ0%OW=?77`E0'&)]J`!'N`#8>`B69%:-3F3';`R@?H!@[I-V3,"1#*H'&`S
MGS5RS-$>071=>L`/9.1A@3&)Y:-N&00+?*('1::.6*!L<,`&=%`$8--_G@$`
MB-E_4.4#RX<'#5"9,W`#*H"O<?`79D`&!N`$?6`!>U`IM_`1G8(20A08LA`&
M=G0&+;``*)`"'4`<K@3_'5-AK'<S+V;`!IJS&4[@!)P1`JP36\2Q',J(``:P
M2N%;!000`6P0-J(!57>C!EC1`'@0%;I!&XFRH620%@R`!G\;=&21`!&``1WP
M65`X!W-`((^D!>#S!V&P8&K`(AG+`B4P"0W@/A$`J`<@!AQI`16"`Q,P!][A
M`V.@31]P`QP0LQ2@`D+0`S13)&M:I\M"`"(Q#5$0!G*P$MO0=)('(BY7,`O#
M!6]D!6/0L'H7!_V2`2T0``>X`4"`!"P@`&$@8+/%855@&&#I!=]V;F:@`9_`
M!EF0@WF01@R!"PBQ4C,TMEQ01#S&!7!07B%@!UH@`"D``DNP!\S!!5Z03&X`
M_Y8G(4M_LA>UT@6T8@]!T115F0_+(J2R$@<IR@?V\`5F`!E1>04^1D81007N
M-TS;\#T:11`ZM$?@TEH&1BTHU2@*."^\&PT7XY$2R0?]U#@`X9EE&'_.L&,%
M$64WIB51(P<903%7YR[):`!]<`##J15Z+#,<\`(OH-$4X&4P,[TB+=+4-(<G
M.T-8(%3.$8LBT@?8$"ZQ-#[B$#5/4TDV"E8"P`!M`$1@8`<#T%P&X`$N+#9!
M8#8(I6:FH@<<4,PD$`,IX`5EH`9RP`=MD)I.\`8G.UNV=S'T.`N`MCQJ$!@\
M(0`]2`1$X`+#TU5-<`$_O:!E8$3B/`9MH`&:,=0(U?\=5^4YXT9LL5IL!G`Y
M&C$'P*:5DL8`<4$`+RD'H?8&4Y$H1<`&83``XS$%`M``:74`#2!-@3J`#;#$
M2_HMD7)$50!H>H`'9>@"\',C>_`_9A8!"<(4*H4!#40!9>#763`C]\8A)9`#
M,/!P+[`!#S#5X.@'-W$\?D"C4M``&-!@:&<E_K,'FB=^T.('88!NRA5+^`F/
M>%`!0\#)*,`!0``$)T``T+T-'!0&A(P4GUJ,^7@<S@4<6O<.!":,0[D')E`"
M<2!%.U:YZ5`$:/,&6-``#R4$5T`:52"F@6':?L$G%0&.2(8ES)(MK"5Y9D`1
MP`=K]_@'/+H/6>"UER20$.;_=^&7(FI`#3%1W;QBSE^PRXMW(I_V#'?*8LI0
MN1'AH\T,(EWP!R)"!:[T!_XBI2F2J6I0!0U&=5.@SV3T2U3P:6J0`'$`$VAP
M`2'@(ULQ`58>J-;GLB6@T1\0LS"3/6!^?1U`)!0"?1%P!U_03,GJFR-I#^\B
M!K0"3[0;!?M5*[JR,0)`.J*R!M8J4T5P14)-U$'0?V<#:43%0*-(`CH``VI`
M!OA%!3>E`6CC<1;:S,M#2;3;#$!D"A*+(#M0`(;0`PE$&P.5*%-1!N]RH*A&
M*,?0JHCIPBW('6E#UZZJ!!<0J?.PX@/@`5II`%C,!Z7]-`D"!F5`EU\@V`,0
M!FV@_QY\D!7/UQ(<<`)><10$H`6:L`4<H29H%ZS_M@=GC,=M85_&EP`58`%Z
MH)ZO(0`4@-H68`5-`%54T`(M\`(Q4`,\0`(K\`'J?@*B?'4/D2R1U058@`99
M$`<FT`(>:09S8*/^20`7Y@9%DVJFG>-K1$9R4)`5T`.H000]0`(UT`(2D`!+
M<P4F%`F$'`5Y!`80409/-`9C@(QYP`:^QL5]H'=5$&5F$`$TH`;]`)_@\Z0*
MX`1%$&H'\%`PL`6WGA-)LWXV&A(+X4?^4:><E%%9<#`0V!;>S,:BQF-84':L
M=2K%ZX]V(7F>9P57X`:4_`4PD>-1YBY^A`KQ1:5?,&#O,O]G7<<//!L^Y5,1
MZBPB;$SD>Z$4EZ@L;>$H1",T:X`BA0'.->8HH+(-[UX$5\`5T'>R+@,S/[`#
M);"]U_3EV'=]-WE-768!!]#HX"8">7`@GND].5[=?D<*%640`&?.-%$HSO$&
M6B,513!N^T?44%#49],=39`'>7D$3)4#-2``0X/V[V$'KCH!.M``?]`B>H`2
MYLP`,A4ZPA9I=H`%=\`!`>``(J<!7'-K>1AI!>&CO6%"P8(&)4C^?[X>/A`"
M9;,ZH>,=#"!A9+`&*PX(:T4(2@`>#&1<55YQ<6I]:59G?%4#!@-:;1H#7'$$
M"01J>!$5$A,1`E)8`P-4`F)I:5K_4U)7?6H)%",F"6%Z=U=A=6X9%01U8&U=
M$ALT-*54(@9T#149+S$D0QQN$R4)5U)]6GQ74U%R77Y99&!Z)3<"7ZQ??`(6
M`E=^5W]=5%A7"/#3X\^+F#YB#FQP(80)""$]:NC(0,#+%"MJ_DAQLT<.&##C
MJDPA,P`-F#D:Z)CA,L4/EBA2MC"PL\4,FST3U$BQ\L=BE2QT+CAA8"5*!"`@
M:GQI\B;*`3UU!*3B(R<?F39E`,8YXR<9F2YQNF31<D8`'B]2^&C1X@>MEC%3
MO*`-U\>*&"M5L&R)$B7+%35GI$2Q,N6*G"E8QICA8X7/E#]XY(CYPT4+%Y`\
MPTB9\H7,_Y0P:L1<B0(&"Y6>;NZHKJ/&RQE_?+#XB5I'M!<Y4<Q,P2,@#F,]
M`L*4></2#@(/<.I(L&!APH0*&"APH-"AQ(\2)4Z8X,"APW0*X,%S[S["^X</
M&"8\$%!)@P@&:_JXD4.E2I]@4]:DJ>*'#!LL>#20@!Y4^*&&!IO,8088:%AB
M@`\^7(```$%06&$A3G@0@@%Y-!`#$2"D@((0"5STAQ]E@`%'"!YL<(,>9^BA
M1AL^&*"!#QYX<,$%(82@0!-%&%!$$6G0H`,'5LSTAAVL(`B'7HJ8\<:2`["A
M"!9@9/$%&UUTP44>(0"`P`4*&/#@`':DT88=<*PQ!AH&.!$$`O\^P#%&:;]8
MT5@=!]QA1A,:F$'2>WF0H9P$<N`A`043@!('%PW:P5(6:*0A11Q>Y*7'`Q2<
M4,$>4;EQA1A=V$,``1)<`<89IK@0PPTX=."%"`IH\,877A#P@!Y7,)/`'G%L
MQD468?RD!R560!K&!!PT0-(::+3Q12U;I,$'@66,8<4O5'"!11\[41&&`!.8
M,`,$("QQ`A$SH.*%'VX0(,9&<OR!AAE8F%%%LGDL">$:A=TU!AE99-&&@EN<
M\8`$>X311Q]1H-'F`"$@(`(5<8RP!`@D@/$&&%\0(`='>&SQ!3]45$N&%".K
M<0<?9I3!!Q]^<-9'&*-A`0<;%ZE!A1;_7:@AQQU>%.Q2&5MH444XIYVQAP!0
MB1'7L?5I:P460._QRQU_R-'''&Q8(2H67WQ1&<U^4!&%MWQD$719!QRPARI?
M:($%%U?4D6@<<M1QQ1FVX!'*16Y(X1\:?*Q1L0%5H'I*!!-@T%T''W!@P@F8
M8_Y">=]5/MX(H'/>00<49("*'RB),$`>9M2%12)BR*BE'U6@,<4=I@C0Q199
M>)'2&W.@@87.9OK0A`=.`&`A`$XXH803QUTBA[D@P*""$`+(P@<:5N;A@0$?
MN+!%@T4HL"&$&C"0!QMSY)&&Q&TDDL4>%4S@Q1MK@,'&3`PP@$875K`)'.@P
M``:\80M3\\<4_[3PARNHC0%*F),"RF2F(C"`#G/`7[;L<`'EA<!.4@"%UE3#
M&SRL`5!OR(,/BC``-_U!``EH@``:<`(62$`/4C`#Z]+@`S9\825Q$,`?L/"'
M.QP@<@?@TP2&IH<LE($*52$`%L[@'`[@``9$6((1;!`!-"A`0P\RPQXPD($'
M/"4.#JP"%Z*`P#VHP1]O\D.,#A`',*1A#&#[2!^`,Z_3"$X`5A@#%D`CAK(\
M#0,W0`((`N""`M3``G*;SQ[N\S0]5.%.;<C"B3JS!@R6X9-;R(O)P/"'+(RA
M#KI*P!VB0(4K;`$.=FC#`'+$`#ZX801/`,$-WM`&FP1'"L4:RQC2T/^Z>?G!
M#W9I(L'.,84ML`$.50`<&C3`ABNXP0M:(,/#^H`6,Z2A,F/@'1:<R`<\U$%K
M<IED'^XP!7!=:@HKZ8,?NO":(*KA)W_0"1C@`K&?I(UW4Y@"L>00!IS-)S=H
M*$,[PL&'/9PAH%;80\/$L`>+I(T=7ZB/!G0T@"L<P`(2".D$J.,=Z5S.!",X
M@0M*4)X/B&=TWND`2D?''=*I1XAI&,`F5,<'?W"!"W7`0Q>X^8<OC"%`$FB`
M'MQPMS\P``YO8,4:R@"'&Y5O0D'(:A"@YSSH(<``:Y`"!9!"!!3,8`*FS$\;
MMO`&!5R`"G6@@P90N`DVH($+*<I+%:JP!3#_1.$/;CB#%1Y@OY5,@8<%K)(?
MM#"E-3%@`&_XUA_.X`4J].$/83A#:,!P@2`HX0)FFF"9!E"&-0RPESBJD/^B
M\`N7G4I7!-@"@A+K`SM$X5:CR$`".(4!`<AM#0.PPA5Z"(8IB"&(P`KB)P8D
M@`@T('9[J`+!\*`'+;!!#A9(P`U@<`0(.,0!0BA!':;@-+71CP`"",45K)`6
M+J3!"WLH1V`J,Q8M7&$/5OC"'ZH`!B[XX1X/D$-9I-*``XAA'W*(PQ^L((?0
M/.`&1V`"!%(@!!5P`+UU>,T6_!"'/1S@#RGBPV3FJ04P*$T+:XC?^YX)!C>@
M"!<$$.P7HJ"S.:QA_PTBT)`=Y$.#`CC@!#>"K!XR%84IZ(U2UQ(J%6B!!SS<
MQ0MW`)P?HE6/*JS!?7\-`Q]8TI>TV7%IQZR9M\*@M3`(US5%E!>#]R"6+=QW
M:%!S@^`(L!5,L64T69`-%4RY!9-I(0O`Y$,8AOHNWOU%RWZH*!^BH(78-5!>
M50#F'ZA`A2[`X0(ZHL,?#A!2D58`/-&QG`F\H](24,YS)C#!"T;=G>EPYSSI
MB8`JL<"D`12A"6GHB12H8(4N%%(/XXB#*<R(AT>P+`\#%('J"D@'N2I@0E"`
M0E:5@(#D4?M[9IO`Q@HP@Q:40`]CX.\:[*8!T.;ARFUHRQ?B=XZ/9($/JO^8
MPP#(P`<O!*@"S<*"2-+``!]L8@!PF,,<4B3O_FVA*`A,FQ>`L]0H^"!Y&S*3
M`=SJ@S7(.WULL(2<0C`',*R!"GSH0WHE4($&6$&6_6+#>TI<!3T4P[F3Q,(G
MRI"&*UQAW%-0`P&ZL(?U<$2B!#Y`RL85AM+X30-S^,/34("$`(#@Z4\OP`Y*
MD`,2C``/BQZ5%\8Q!<=DP0R\80`;[).VOI38F!)-F1B6FX\$8$"&4-.(/N9Y
MAC/((0(Q.,("0.``6+THL%+P0R@O&X<HC/L.;'Y,7UJRMBQ4P0[N(>WKX``&
MJ/W06H9O!QN*X",X^`$/.W!``3)0A`LP@`NNZ9+_'@X0G"Z@MRB:48-9&N:%
M!AQCB*9L4Y[!L)<XB&$P4O@)Q!`B8)_1`O%ZF&06SA"'11"`]6*0@QX0&+M3
M'4#6HIFA'(;F,#%X80MDT.;5:%9B+K2!"WC1FMC>Z`L":+D?+CL#&8AX'_?[
M0?J1\0(?!J$C-H0!5<WA',]1`9_F.97S`MK!`973`2E%`R=0'MZA@.&!`?5C
M`1%``"=70#[P(UQP!G?0!6/`,FJ@!SQQ`+9W*GK00'=``&IB:PR04SXP!VD`
M!S@205I%;=:6(460<7J0`@X!`RHE`&0`?G"0!2?G/X[1#G<C,6D@&WU0!5$`
M&EEP/`9@!G_P`#'0*3B0_RG)``;])@*;0`??]`57Y@,BT`==$`5\504AMP<$
ML%140#'1,W%N128^H#XU\EB64`@,T`=;,&FV=``9,`&`]$HJ,0`U,@"REBL9
MP#!A0`5M4`5=@`560`:2<DVH9`7I%09NP!-Z\`D$X`;F9P7'P`8UEP4:\%X$
M,`$[(`1[!W6+U`(M@`(W8`%3@`9]]04"M1(_$06TLP;I0P>D)$^^)@6;X0=W
MD`]9(07)Z`9:(`$M0`%N`!Q]L`:"(@41@`H$P`$VD`)$X``@@`,K``,"(!EU
MP1]28$JQH`5>@#)N1@4@$P4AQP?[\P9E8`?]DP=MX'W`90=Q<`!G0&,G%`)-
MD/]N>W`##H`$>C!Q;"`.RB4W-I=>7<![M2`&=U`'\#@%>Y``<F`W-4%YCB`%
M^20'>/$N/V4?"=8U\75*D8$'>Z`/9R`&58!95W`'C\@'!*-9(K&"0^8M=5<'
M"K9KC1$+@W$%<5!LA,%[`:5T=;`O@45/(G$%6B!]:I,%?M`/^N<%`E`'=4`T
M8'`\WX,%>I``%@`=Z5$,%;`!X?%2-#4YNX`YWK$+J_8=%+`!@PA)7E`&>8`@
M!G`!>1`CZ^!]4]!A,M).<J`UG2@&0BAOO&1K19`'[5,$'E`(RG,ARJ,$U*8`
MJM,`0@".0G`"/4``=Y4&!S0/`S<LOC@%=M1+BD`S4B#_&GT`04XP`'U``$-`
M`2Z@`J]@!5N`!6RPET7@`VV@&%L@2RTT*FHS+%(0(UMI!7[0!J7W/7TY0602
MG#7R()O```J@!`KP!6H@46?@!A$`'@]0+&Q`!PTR5W3``B7P-`7F4&JH)S!A
M!G:`!6FX!?"&7DXC#`=0$?<G0PR&!Z8X,U50!\S2`3>02["X2#<0`SQP`P?@
M1%P0!E[0#Y7!AD.40FVP,U7@!A`C>,*3!5$P&5,P+/T0-&'0`!RP`6]X+`-`
M3'T@`7(3`:!)`D<`CB0@!$1``6_(&O/2$V,`!V;@D24Z`.$$!M>B!LDP!FM`
M,%P`!ZS``#]$!T1T!GU`!AFE_P4^\%5CT#4V\!!^0"9FX*%*TVMB0"I=<`59
M``>>ET]X$`9LT!14X`8P0P6B,0540%U;(6=AX`>!=UE>$`9X\%#PMD!=H'_C
M%#\@]P7_9(19P`;6.##LU@>+9F*^)EP'AJ>J\!%LT06^)0=6&42]<1"")(];
M]BW_(`EG$`9KT1A_)@?R\F=^8`=?Y`$^D&@)0'+@D0%H:9;100&>\VH<$#JI
MQATC\`(EP`(T0#HNM0'UDP!N,`;]8PDA4`1@L`Y9`!C7@EY%0U$=T6M>8`7Z
MLP9XQ0`I`7D#(`)"H3P64B$`@)D(H`!WB`<XX'1&\`(HD`!K4#/AQ`7R1@?Q
MXZ?2-?\&"H5`Y6<?5X`&G74!8W`&&6`".V`#'\`U79".:)`'K&"/O2E7`V`&
M\/((:L@R3T,T*#(`7T2=9$(FJJ,!TWF'#$`K'E`$?+""==`'#=`!)\`!`J`6
M4U`%<U`^#$`!+Z!4<?")^%6A55!B:=!B^;`&6[`IZ)4`4O&&7$`&$Y`"':`%
M9D`:W+1P&'`"R:H"KPAU3/`$)``#/$`#>%"U7P`:7>('7("?4:"7:S"WPB-X
M7Z`B`]`&35H4_)$W8E!I<G``#R`@83$%3](2&:9S%=`!+H`#0@`!!4`$*L`"
M[A>X5G"4D+BT7[`%9<"&<V!4:-`'P%(&;-`M51`&43`&;9#_!E^09Y&6+$NK
M;V4@F47`CGH``R"@`FMP`450!GKB#TH3!HY0!^+Z!G#P5PWD!V.@BUE0HF!P
M!3*R#VCT%^U8HHLF!7^$!R[&.V,1!7W`!6OP!>^39S'33E40%GP;51TK#G:#
M!0%U$0^C-N4@-&Y`:8$4+R0I!7M08&<P3K&1!IZ!GP6U9*=1%)UK!7U@GWCP
M!U?!!GW9(V?H823GK-:0EM!!@!N@EL!:4A\`4VW)@&!;`B@U`M.!`>DA#PB2
M!YPGKY%EE52P<+WA&I0U-'X*0`QBC6OP!F:P;DVRKEJ559>I!+;*"EA0`;J+
M!"R0`ETT67R17VB2!F7`KST\,.^6_PP9-#S3Q#P#\%\Z@`(NL`.3Y`9BP`=;
M,#!H<$$CD:XB`$U\))5N5@=Z\`M2``9TH``9LB,IJP`,,`>R=+)`(@)Y\$4^
M,`4"H`98(``8<!T'D%F2,0:TT@1;H"MWH)B_8A!7P`5TD`=@L'83@`?KQ&D)
M0+CIY7[#P@%,?+'".(V;@CDCT`(I,+9/YP!+@`1+H`(5(`9D8`:A!'*/4:*>
M2TQL,9Q34`9<P$ET<)YK(%R8A7]J$`PP]"MIL1.^I@_BDHS,P`$WX'0PP`(J
MD`!<,#.LA0=FT'%Y!BYI"K_#!`;BPE\Q,2Y9T)M48)/3Z`<"C!!>P`4,P".G
M=P41X'0RP/\`T_!-?T``<R,%<CR6:J`%=:-OG4$%7,$%7=!,@"8J51##6&!+
M5$`&;[`?ON@);B0:/S$\(F%4IR%0([%6_-`17_!)]Y)H='I,]YL&;M85%:T:
M`J`U8K`&>0,6WF=WF;(T5*"+&2$,<N`%-`83:I`%8)!@K^L&?;IY/!("IG<%
M,`0YSD&`T;'!!)B6*#RLG3,><<DYH',Y#R@>'W``,O$>34#5"M`*Z<B_([,3
M;L!??U`':6$8>KD);1(+I04'DFF#6O6NF,D\-D(&RY("(%``)%`#&1#.?W`?
M7<#0<9L%*6.-:(`&8_!GWO(%;9('=F`'D^D#,8H$*V`",=``P0#_M\)%!FF0
M/FF`L3<R!YKX*UU@!FL5!7)V!ON5!@9`;51-)F5R(V@0!7#@`0C@(QK@V3NR
M!:KA@1&`':PG(UZ`!6F`CPR0$"LH`?*"684''W7P*P+`$1=8N%+1!0]0`5ZC
ME7KP25\`L,(@`!OP`M/!`B3PBDSP70$0`$M@`PT0!D95#G^@%I(`CXH!A?1)
M!9:$M'I1!9WK:_AW!\FG&@&1`0YC%V[D&G%04'HPGB?P`BQ0`TQ``MO,`>(2
M9_WQO)6FB6&0!@9CC79`!KR--%S@!@+@!PB1?#:'1EC086)POQOE`0.`*Q10
M`$Q@`FT,I6Y3H5TP+NCU@;X(C^5<!AGF_]HD.2S"%0RO$7TNQCU<4!<T>4QJ
MF+1MD2R\#%_W^P]XA0;[LKK%Y1H&8056J95G`"V44`9^41M9T&&`$P4NZ3+`
M-@9Q``R6@1#IU0?21Z&OHXFIL"WV\@7S(05S,'$LXI>X\``+TQS0,1U=G9;@
MX3G2H8!B;0+8<0(Q=3G+*AX\J@5Y@+%-4(=VX#+?N2N%\[SA=`7M:!!>D*Y/
M-4#X`U5KL,]8-=@30MA?Q091D``IX``!L`(I8`%?\"V#IB<ITP;2,H,)-56.
M%\-\\`;]0P=P\-L&0%XX@`,,40$0HP6^^*31DD']TV\,X-P&[8?\015"A3-5
MH`&8F<?5N8%T\/]&3>`\,6LE`W`!;P"K;A`'',`"'$`1$N4&;:#N<)`&70`5
M4.,+$?"!R2@'$]`!##/H]W`"&!"05$``!"AK>#`%8S`&;*`,P+%;%3`".T`"
M3P".^0UU#@`!1/`"5V#=:>`'/Y[)Q:46K%L8,Y9\R"07*T@[&B$%C-!DGVA&
MKK<!]SLSMQ$'J:%@;B`!'U!&'(`""U`#'R(#!R`X,2D9@[[AZ]4&5$H&:/`&
M(F`'6M-+@J0G]R$`$B!8=Z!@C4"3LW0!=N`'>L`!"[``$U`$$L,`S3LL?LI\
M!]$2??"]\'8'B#P&^@"^X*MS<.<;]FP&UF3C@+1H;&0[1RD&[!`%`K#_*[ZL
MM<)SJ*U$"V&Q8([AYTUI-WZZ0`3[A_!8!E\@!@F`"G7@!PV5X@S]&5=0!C9N
M.%O@](IY!U*@#DP]!C!3/FY%U72@'!,04LP1.>C1Z9X.K.,1_KM``RUP`S+P
M@`Q8'I].`14@`%O0I/SVZC^2!J!2\:Q7W7R@$7TP8#H!""(B&@,#=G!O`PQS
M>0I.`$&104H(2I,('@8#8`<Y"P4H-Q5=7'Y>?WQ5?5\#&E]D<&UI;5]38%)J
M?FTB#&E?;QXA:5DF/3@U'&I65%MD;0-?;EYDB1H:#&1X!&)@7%168G)=5'5N
M?@,(``!.F"$*!A=-7%=O(4I.%QI454UT>PU=_P2,8%&"0X0#!.JLT9.`#)@P
M>N3(Z1.F@00!!"I4$)!@`@&&`LY0*/%!0!@!!R)TX)`AY)\H?NHDD"#!PH0*
M)7((@0"BI\^>3%0D`%.&#)<I5*1,(4-F2Q0M;,S`'&.ECARE5:;4B?#'3Y@L
M6<40V.-&3X0)<?9@2.#FRA0M?P2$O-)'3(,,'C$`*1``2(P<'/#L\7*&0`.3
M5[KTV34GBI4M;`@EB$#&#)@W<+1(\6-ECY4I7N+@B6.ECQ<_13PT8=/G0`LF
M1/`T&3#G#9>C?*BHH0)S2I0L7[)<^7-FC]Q<?1+S^>+%N(`Z:J3`_((ESEBY
MXZY<@?I'3YB75:J.O?]"A4H6+ENPA-F#1\PR*5VZA.DR94N=,V.J9.%C)<J:
M.5MX$0489JQ1AAH/'+#>'FKLL449A(&!!AA?;"'''E*@\<4?5I31Q1E59,5'
M%F2,H<$%(5QP03`#Q"&!1A5,(,$$&U"``8PP8E!C!QU00`$''8PP@@DNW!"#
M#2R,P`&0'&"``04;2.`&&6FDP88=`Q0!3Q%Z=)&&%GKL<44524W!AQX/)+"'
M'AJ(X,.;`\!A!P-%:."#/9!`$<DZE@2!CP$:F+''"0$XP$-!!&AAA1529/$&
M&%BDD0<?4[1AQQMH:($%&5=(H048=M@!AGD7()!''Q_$,$,,)21PAAII'-+_
M!A\')"`%-0.(8,<7>QQ`!1AIE('%&?3U<8<>7K1QP2/J(.#L!0K,5L8<(33K
M0SATT"&&`'%-P,(-(V#P@`!X<('F%5QT(<X=73"DAUD5)!!&'`?4VH!Q'W!@
MXUD//%"!!1$D*,<5!W"P00495&""##?H8(0#/X'`A,0%M"`'%EED@;'&9K#A
M%!]<9+8I&%%XT845?&CQ11_BD$?A%G\<($`X$U`@P!T:">`&%5KTL6866_BA
MA@#^3G#"$D\X$(`+*=#0;AQQ8+1'%5ST@84=&@"XCQFQ&`89E8^:Q]P7&ZJ!
MQQU_]$&*`@AH,$88$Z```@I81+O&%%9T(<89<4S$_\<?76TQAJ)4;/N<&VZ$
M<8<86VRA!P%Q[$.R>W[P<<6[:IQ"!6&*27&%%5=X(075X7AQA1^-1_'W'MML
M9LH58M3A116)<U%%%Z)+P446;IR!115=C2&&'GZ`<<<>?Z@1AA=WR+%%&F14
MH<:Q=52Q\JW"O74%T%.L4<2S(03C@Q3^5D!!!355H"/".-Z(`0<?/,F!D":4
M($,/,:B`PPL_OG#"^1IYP!_0``<1&,`'`_!!$]PA!C40Y0_N@4\?_+"M/1R/
M`(K(PQP(@25K)!!/DHC$/=2A!`\H0`-KD$($@`""`KQ@!!+`@AC"T"@VL,$/
M?2@#'_B`A@'0P4!CR((8HO_P!3]P80Q1N$(4%*`$'VRA`3FH`0MB0`$OJ($/
M;Z`#%Z)`@`BX`0QC@`,*P22`1;6!`6:P`H=P(0`]\($!'FB'BBZ@"3B,@0]D
M<,0ZFA`7+6@@#5WX0Q@B\*T3="`!TP.:%\AU'XCH02YAB`(>$H"'*]PA`QRH
M``$(8(&$F>`$%7A`!"30@$TVH`%A4MB---*!')`@!4O@2<28L``BE.`.G-F"
M&;(PA2F8`4!3P,(7RM`,,ZBB"TI9QE/*,`6K"4XS<4B<`'0D%YLT0`[640-=
MOL"',)3E``V@P`U(\#`DG(`(/^B#'N(`'3X\!0P2FH,=LO6&-)AA0FJ(`QCR
MP`;_-*P!#2'R`Q[(\(5R)$\,26%#^#2`!0%\0`4@:,$`HJ4%-[!3"F&H0Q^H
M<(8[A`$,6Z@"&)`"GS]P,PX044,4MJ6'*VP!#6F8@AC^0!\N\$$Q6?"#'[I0
M!SW<`9Y>6(\7RF`&*BA&I-2)@A3Z,+0S;,$;^^C,'G`8)BG<82SEB`@6M&#)
M.F3,%F!(CA^D(`<]["P*4Z@"'^(PM`/T80M,5>E\M"``/L!A#0Q@FQ)"P%<Z
M9N$`$TA8!FQ"HU6JST<?L)%&-O"D(-&@!2W8`0J`,`,:4*`#)W!!!V#4@`S!
MP1$AT%)JE#"&-:DK#B;KJ',:Z`8OV>ZE;\A#G-;PA388_Z`2D`B"GM0!@'L@
MX`(#2`,6&@`#$$!@(!3@0D_'407;$'$+*F-#(>B0!J&Y9:-_.$44;@O<,.``
M!AQ8P0FNL(<$]($-7$B#'!+@!2[$TY[)\\,?0`6A=2K.@E<@0Q,TT(8VS`$.
M\HP>'B80`3XT00D`0``:XC`%'Z`A#'Z0`P=N,`07?(``77#+%*2@E@@0P%56
M*`OC!&"!.QRO`6OY@`LF\`\6M$`"`:O7N.Z`D?F5$@,=(#`+8!"`!2P`8DR8
M&`@<4``8G``/P00#&;(P00*=AYB?&@,7L.`-^J`,:!,J`T"=TD`_7*Z-VXH1
M*B.P`P$HJBQWZ&@"&L"!%K`@!?\+6,(-CG"#-?%M@'=MPQO:4`9)#<``1="0
MA]R@!3.D`0X,&(`6*&6%,4SA#"G;J.4&$`P&?$$/-$C:!@P`*"JL,PY;Y1D5
MXG"&++0!B5>0@Q64C(7TA"AV;L"#'CHDW3EP00I[P\(8OI&5TGBA#F*H0AFB
MT(4JG"'84>@*4:>0-EYJP<M10$,0R\"%,(QE&403Y",%(R8R8(P/;E##%L`P
M(L6)`3AB+:L52C$\/41A"UGH3A5V.@4]2,$.3="K$\(7#`6800`3"'C`-4*!
MQ&KD28G%0`9F9+X?U>\'+-B!"H2@@O_-[W\)HP`!JK`&.]SVMQ=(31!\0`64
M(.0K?Q#_#$8$$`$\O($_52@0'0:0!UI\@0X&\,`C=`N%G@>AM_=0``/>@(4(
M"`$$"Z!!#%S033QXP6ISH,,6E-B'*-AS#9CB@QK.$+IWG>$S;&B"`=9P!1>H
MH`,P8,$D'R"&-&`]"V%PBX3>,(=-5($,5#!B%N2`APS+>@]A6(,/LL:&_QC"
M#&)X`)0$L`8/]%8$5=""HMM"@!'@(`<EN.;6L1#6.QP&)5&8`Q@8PH<]/.`,
M=6!=*2OP@@B(108L$$`IZR#KO6'$1QAY$HPY0`((..#W$OO]Q!9`@@WTP1EE
M(%MYY`LR++BS#UDH$$#-\RE(A6<IX_8"`696!P&H`15=Z(@`_Z20`!;HX0O6
MCL.QY%`!%M#`?#M(6@I(@`,.D"L.;B$#UM<`EEH;H!]O8`<0T6J5H61S,`=&
MD095<`7P]`4C104,X`YY8`9Z<`,@@`0"H`!%\'+A$`<Y%0?,E051,#BA46IM
MP`9CL`9L`#U)Y`<YI3%9D`9OX`=R40=8@`9)$04GX8)[<T1J9`98\`>\X0<]
M-`4"(`=/03:\1`;2A@9Y<&D?H3./4QI4\`=WX`:H`&]?,`]Q4`5;(`5_@#A4
M,`9C@`5;Q3Q4,&P]-3L8,P7QH1]6<(-TX`-LLP[!$#XA,`!N,",9D`'O,S]*
MPCY.<C`R0B,^P@$G4`**V`(Q$`,MH/\D2_(!!T<!>)""#+!`O_4.'A`$(8`&
M>Q`!$2`O4R90,E,'!*`&<X`Z:T`'#$`(<Y`&8_`,16`/(>1S0/=;1=`8`E`#
M+10#*/`#<0"&+U%`#/`0<?<464`46E`X9Q`&9[!.ZV8&>:`!=I!3K70"*1`#
M$Y```N`E`V`&6^0%7@`&;+!!&E`&YT%35:@'=9`\<B$`5%`$"C"/@%($L\$%
MY=4`%B``8U"'&F`R`S`&$H%B)=`"A[0'%O0K?>!]44`%.S,':-!]N5$'80`1
MX%1*D\$Z'#`!?A",?%`.<1`F>M``C$5P3K)C!3!+#C`Q$%!F]6&&\#8.5J`&
M;U$79W`&6B#_6PK(*%:0C%M`!<ZX:F`@1'+!CF<@2$`Y`0TP/!^P!WW@!B91
M!W>PD"SP`BQG`D<``@%P`SW0`A\1!I3"-6NP!6]A!R+0"C[`"QH@!P*`'JJP
M/&@P!]2&!C]9!03T!E(VBT4@"P1``B"@`E;0!'D`!PHX'&&`!W+Q&#I(!7RP
M5$`#DU^PBF^0%-T0!G(@E5>`!>3E'<%T'EHP-'Z`CGV@,LD3'&(@!D+##%=E
M!8LF.`MH-5Q`!G0@D'5@26<05,LG!5TR!6/E!9_A![?I3KT3@YI!!5BP4ZB@
M!6"B!ZHP;TKA!<!A4IAQ(H]00BCB+`:@!01P$^;S225@2.Q3B'@Q_W!.0@$C
M<`(T4`(N\`,E8`(F,`(KH7"Z)P55X@/PH``*I``A@`!.0`=>(`:]TP=D\@?=
MMP=B@`=G\`5Q*5L^1`=V5`99%(&YI2=[@F"4((%\(`80%0!'@`(FD`!7D*%6
MD`=GJ8#N\3>CB056((Y"2#5@H"D]1`>+9@4<@`(MD`,IP`('("9GQ$S@\%%E
ML`9G60H=V19_L`>H)7OC8@9QY`'!8`#O,`!84`<]=1%F('8>P`!N4`<,T`;=
MUP`U<S[]<@#$4C($0&AE`)S[09%1@`4E8VT/8!AMM$ER`6K1AP6/1`!XP%'3
M9%D3@(@G,`1$($M`P000`P)$0`%R<`KTH?\HD?1L#DA!,P4&A?`%L%-6YS:4
M6?`-90@&55!>M1D=8(9)"3"2#\`@Z\1U7Y@OK',"0/![0V`#.=``M:D%:5`(
MWC`&D`$GBC`("6`!0]D%:I`X?U`%9:@%1V$%:&`'<U".^SD`55<!1\`$+$`&
MP966CE8%M-=1HI-/98H&;9`%R+2`5;""SDAL<M%:P\H'8^""8Z5+0G0&5,`%
M:W!J7R@&EO-(=;"CX=`'-O4'6%`&M*,&8$$%7Y`?4T`V6K`%%:(H<G`'="$%
M7H`'&G447<"#`$LR?^`Y)A8%53`Z>EH&HW-3OA$BFS$&>7!;).0!UXD`>1A^
M-T$!+Z">)1`N3Y+_`1%`6.-Y6//S2>YI`OYC`DV"%PJG!US@7_`0#PP`#RGB
M!!H0F[ZA!5$@&O&!D'(@!EY`C7)B!I%I&V!0=QK@>)%`H5`P0NO@#AJ@!6<0
M?TA0`#$0+ETQ&N0(8&5@!6&`M=K1*5*`,K^0:'[@&?+%(0)P`J\4`S"0`W$J
M!F7P0\+Q!PG;!U,07&F%!7B`!U;@![/VJ3:Q!WG@!)X+<O/8!'.0!1P6IV,@
M`GE0!`Z6!0.`!NOU`&'J$1+P`*?#!V<@`&)B.]_G!7K0=Y#+,@MWI#OJC%<K
M'U.F.!CA)>TB`9ED/C2P`R_``T/V>RL99$AW`Q+0'MN1?`VI!6/`A,S$_P<C
M96IMD#P9)0?%.@9H@`8.$4114UX"H'Y70`"DM`$F,`$>I92A$083M$@G<`()
M0``]D`)"X``U(`0I@`'=N`5T-P?=9`8N&'5O4!1Q4G"E\"'RJ@8<IU-;!31N
MMPO.0@8>1@,%X``<D`<,X'%%`#,WM6Y!.*QQ`*!>8`9T(!PBI06\U`>+@FO!
M:"EKU5P=[`<-&50G,P4$)&55\!MQ(3.S]E1HX(;,X*E2D(:?*04W&$3@:FBA
MP@=W<+D5Z89#U''<I#I"@P=)O#FCD8YX\`!XL#)3,&4>FQQ\@`5M,(M.\',E
MQ&^8T`1E<`=G\3[G>0)"VP%">R,")W#FLR1`,O\DZ'D"F00P`;=Q'5<$*Q("
MG,9OX</'1XJ$6`"&X8$22[4'&@`'X,H&;V`&GT*B&I`:.^=S>`P)E'!"_)<`
M-A``3]`")?`#85`%QU*L5.*I'3539R`%05HB]?I4<1`!5*`VA4,`)G!T0E`#
M-I`@XV=/251UB[84XNB`M-<'?(`'5;>=:"$"E7`/3OH.@-(&5L`1!(`&11`9
M`^!?#&`?LA<!K'<"]=(`[/0XI2H&$W0'9X,2NV$%9^`O!R`%N/MTIG`?,$%C
M:-(`&JR;%K`2%?`!,K!T,^!COA=D3``!$$`$)R``?C`&A^8+C=-+$&I'7HC#
M)$TN?5";W1!Y4W`\4O#_!7=P$6.!4F$P$QUA`A50FS(#E",2%Q%``2QP`@\P
M62E0`#XF!*T22401/>P*;5I`!\QD!E*08V20')JR-RBK*-+Q"ZW+!=]C`'C@
M`A7P`TR=`!IHGVC0C,J47K=C,A+;!>[D9<<7+(\V7UP@!VZ`!730&']`'@Q(
M;GSP5NW**':)EU2P'=V!+,ZI:VJ44Y'D.#5=!?-BQ2K3R<4Z4G^0!5HP!5G0
MKJ%Y5XN4"QU9![8K!9XZ06KP$7+`,SJX;L!1"MWC`Z72)R7DI'&T;R)`*PSW
M(_`9)";0(WAA`301W/"S)"-``RY``YN5)@\@`>P%!].HGWS%5PB@`*5BR=K)
M_Q9@$*X9=A(")$E84AL,(`*B1XRYLBRYI5L_YP06B@\^0`>W0RA'L`,NY@54
M\&&5Q'%QXLW_1@!I4VRW$Y)=<``CT+MXL!E6\``W8`0!$``Y8`$'(`9<H&4J
MZLV#/4R!]`7:J0=`L[%BD``;,`%U0`<A4)U.FB+10@>82Q9S4(^)=I;#H@T$
MD`'0':?;QXT8$0:+XFFC%,`AT05[@$D/`(9W$`=](`6(N0<2D:X?%K^+A$DL
M40(HH`(HL`)&L`0!($N&^@0W(`!8L`8`]@9?D(0-^0MO\(570$.%@Z#9]05I
M8'U\('L3H0;(PFUQ$`6`E1(4D`%[(*S\#;!Q8`$6,/_=]8,!0T`"K]H32'`#
MM#LR4E8?J@`R>9`'^:%.4C`'6+`*6H!:)*T%<4<U;"!U7Z``'C``#[`#%6"!
M`6`%"`!H=G`%*I56B:$%!H(>.\4WJ!5(];$R>/`':?#6YT:78@`[;>2OWW8>
M^U$>"7MKJ$D88B-?(;)#JO,'Z?5(I-`',7RYGWX\R8XR9`DXIJ$\@UU6:M`'
M=0&"+T$E<&$<IS$&9M`N?T!M*L,?.*=SN44)O*T$%SH`)8[HZI,O\],C)QYP
MR'T3&)!8'\`CYUD"T4T`!_``^EP&@C"+P="R\*`$%_#;%2_B4D966W>JQ`%@
M,\>KUP`'D5&'8]MS?-);3F#_0G!@'!B@`D:@`C=0`F?0!X;1)5*P!O/HI@,@
M%XO$8GHP(PT0!A(@Z4YGK0,P!=8Q!#"P`_LX!;XP!V,`N1U)#PS`!MYV!A&P
M!Q(B/;URXGN0!6&[#IC@+!)89:S[#N^`0'AI;<91`1U`$Q'01MP8)DF180XU
M`AD@,W$0A@3P`1,@OMX4!<6AI-OW+@0@2J?:`!6P`0_?`EE.!#5``C6P!#]&
MO3"P`56`"/OWZ5E1'@&+CG_`EH'4`*?0=UM(92MUF;U;TV"`$H(A!Q:P`3.A
ME++C&%!#?IE$^4XRLS&P!$A7`$?0`@+P!896!G!`!J@C96`P<R)@WRIHW8ZF
M-KN1_Q70-F4@%07U<`%;4-01X)<HD`8(4`1Y\+%48`M](&M2T#%Z+:SYQ!Y2
M8#E33`H3#`A48E=35'==70($>WUD6%%25EI<?%1477U6?WQN5V!545-86%95
M6WQ38VM@B7I75%=^5EU94V)W9V)4M5Z*<5YZ!P1U77Y54WY_;G&34V!39W%7
M57Q:6VYW46UC6=13`PH>3DI!`$H("![H2NPA;VX-$A(6%1@8%!\8%?O\]_@4
M'$:,Z-"!PP8)#QXT.'"'RX`F10QX\!!"00AT'A1$',!'3P(\4JJ0X7/G3Y4$
M"=18L=,MCX8!<P8,L/,FCP^)`(($@<*S7$X`3A"$H#-A`O^!"BF0H#`A8(L5
M/6K^=-GB`P&?!%7`.-7S(,&#"0\(^$FP0P\;'PH4B!BPMLZ#"`GTQ!&3)<^S
M,E2L?,D#4</)!'+`I/&S1]$$"WN\5%'`+AW&"PS8F)E"1H2!M!<TE&%#YDX$
M`0GV%:UPH(N<>`+^X-ES)H()&B\VQ/DCZ4]7+%G&I,'BA>0#`1$.")C0H4(&
M#O$V;*`10P:-'$1@H(`18$&!ZTN&-+C"!4R;`73*:)DBI<N5*&#(C"&I9\H4
M`G+D"+ASA4\H,1(8"=#C)PT7"A)4@4<)+&200%%[1%+%%0((MP<!#U100@<9
ME'###$LX8$,,)&`PA1UH?+'&`&O_9+'9%V!H\!(;WI$!QAI?1/&'&F?T,04?
M?8S!111?B(<%`R'XH$8$GAFQP`3@,/!%5E*XL85'>/0A92A82'%%%F$TD(`4
M:PA211H,#%"&%'K4(84@5$011H-A?+)%%E%PP44?56#AQIE4C.&&%V7PX4<6
M6O#AA15;;.')&%9>X44=>X2A!19]`#J%,F%@P4H<!)0&!A]QQ-'%'UJL@@5Y
M=?!!BA1AA/$'%=2<(8>468WQ!19:M"%".`@X`8`Y&*F3JQ).*("&'A$D%($$
M$VQ@SSWY;``0!Q_@PP&T%&Q0P03(3I#`'3\:8$`3"J03P@4A!`6`!F$,D`<?
M=;AAA:5F__2A!A]9"..%']W-L19X-0T0I@8XY;033U"4$X02$_D`G!MZ``'!
M#"6,H$<84)WA1QD,*/%&5W%6\4<##;QU!Q@^:)"&BB"^V0<6;63!J"Y5F$+'
M`&^4889_9D3$0!5[Z$'%&G",H<8!$6PP@0!R6"$"`KRB4Y$&:VS!!1L`7X"`
M#UQL@49'>)Q!P`096&#!9YWHT0`!=V0ZUP$G%$A`)V+`DT`??ZQ!AQ]\5)&V
M'A5\-@$%%!AG`04L[-""=#?`($0.,1B!1`$!(+$$#R<0$(9>;]C!QAA;0%K%
M%UOT$88;==P1!RIB=(&'`&%,4<L5=>"!B`!X3//'!A'\<8`-)?\(,!QI84B!
MGA9JT!=&!"/8<(($/]QP!!(ON'##"75P@08<X,V!1AGJDO$%'=NDQP8=&L`1
MQQUA7''%&$]%P4857:!A!A]@&!""'7$(<(8)$`1P1IAIF%4?O!"W!R7("FI0
M0YRB$`4R3&$/#Y`#'4XQ!C.LH0Q^,)T6OM`'+M`!#EOXPQ[$H(7S:*4\7S`#
M%=PPAIJ!80]R0$,:P*"%/HBA"MVHX16DP`>I52$,<4##`#95)X^-<!1B((#/
MM)`&'_FA"\&K0AG&0(4XZ.$.>A!`'#11!SW\H1OTFD(?-DB&,MI!`;K:5=,F
MXBLG.,$#!B##'@X`LI#1`W!X5!;@,*#_'#Y>*P+'J@`%+!"'+0S@,MZRFE#(
MA8X@#&`/<YB#'\00A2NX@0I<"(,<NA`'"31`"F;@@AU\$!DXM`$,;Q!!$5XB
M$27L:F`]R<DYX(C`*.!!""!(P0EV(`$]O.V&97B#!RZ@AQ-$@0XEK$,'3V:`
M(CC3+DV*@Y6Z<*,Z,*,,7]`"&`:@`>W-P0Z?:(,IJ2``-60!#'!R`P&*9H%%
MU&$+%RC'+"]@`!_880TQT4`3+L,`=$K)"IJ$D`4RH*V>J2&)%,B`0A9R@`IP
M8!\)PL,ZXU*'<_90"@+8PQX"]P!\Y.-:%6!!#'9``A),)P4Q@(X1CK`$(J2@
M!1G0@QC\\(4Q_U30>V"HZ1A^B(<['-0*7CA#>=P0!E/QP31[.*@>"B,',0B@
M`0)(!`IHX*K"Q"$*QS!#&>)FB0:P0`4_X``.<$`##IA@""?`0VYP9`:9I($,
M<'C#&M+0A@L^*@TRV9KKJJ`%!_YA"RV3`ABXD`4Z7$`!<U#='6(`@AE0C0UY
M2*Q&NW8%-;CA$31"D15R5(LN;I`\7HA*%*BPLCZXP0^Z(8,?9#I8/]PHBS2%
MQ1>:N`5BD"$*6<#"%;H@*SX`](M@&.P4S-.&.61!"EG@Q![N,`7Q4.P/8R!#
MH%ZAVCBH`;F$!88;Q("'U*5-`%9`PTAB9B,>F0$,;#"`$W2B1G2DP_]7[H5C
M&J@0C`2$K"A%(>@\\"L!0`)RH0_PI!K,P`!$[O,B3@C!17(%``7`P0!OD(,>
MJF#:,PQ*#5<\GQ>TH"\1W',-TDV#*AG`@"*$P)6P9"\Y>&6`56AA#SIP``],
M<(,)^')B4]!:$Y3P!QSPP0XX*H,^T\(`]F&C#F+XPQ^X4(9)`=$+7#`#%OC@
MD`'(;PYLT.UFJW"&!L2A#Y7X0QV>VC=AL$8#K@0*113PK2;X0`0^*-D`2H:%
M+F#U#@VBXP0J(`$ELDX``[G6!TRP@09$@`(8.$`<]M``"_QF+EVH`A?VMH=K
M2>`#'/`'MCAP@A+T(`<S4($*2)""&@B!"$?_`,(-*/`V*T29AFF8@XL?-<`S
MO,(\C`J#&#;KA2YX03Y(6QUP6)>@/UQA#R1HP1ZZ@`4<:B$+5]#$'NI``&19
MJ`4_D$$'ZG``%<C@`%;@0Y/CX`=N9AFW:&##%^PP`#-D@0PA&H-+YO"%+P`J
MN&@8@S6J,`83&P`.5_"E$2`P@C<7.`^*\)T5HM`']/CA2B72Q9)VZ@8UB/%\
MK,MI%*P@ABSN@0I@T.2&RY"%+K@!#]U-TQ--4@4Q4-D54P@W%Z:LNBBD8:?D
MB8H?!GBO7NRA"F8(41_\@(4=Q2VC;V`?%?P@!2R,H0MG,(45`+K.!('!#.,)
M!1]"$ETZ&(!I/@&*_QN%PL;X7L`'8%!#@Q*2`#HJY``'\$H$&(J2MA.@G.(^
MY&&=&:Y9JH,=07$C&PI3B@7MP0IG8!T5K3OG5=(D#6;X#HE5>8$TZN3RP-()
MPMB,!@I7``8I<$$+,'"^!(0!W0-`P!50H`<I_($.(F!`U,18Q;N[00N(TJ84
MU!"\O(UBM&.PPRGI0(8KQ$$.7I!"_A+8'R[\00`24*B6\.`%.%C$E6\<UV%+
MUH0F,$`#&AE#%$P3NP##70('D<NO$S`X@@0N`H.;>U?8'P%7C&[IF<I%6*!O
M@3UC*P/6P@$L@`(FI0(P``0I``1(<`0DX`(34`=^T%=Y0")L`61UH!?#%?\&
M4+<:7>,&?_!$OF-9^Y$,#W(TL``C=;`!*/4`'.9\$B8<2R4`+Q`#)S`!NT0!
MIG,"$/,J=?`'8"!>=I,';!`%<1`&@'(%;>`#`Q!`W4$&>&4'6N`'3$<%9,`&
M:X`&FU(_'E`$T,`W"X`$`M!]:<$%6@14"10%AN)R:\`&EV`*6Z`%54`%83!&
M6/`'K;,%@Y`%6=`+^B,HU*`&7A`%9Y`@;T(%4J$&]7%R]4%)&U<)TX`%84`%
MA3)T7G`'$M8U7A`&2(8%G5<?7"`B:'`&=:!V!``&8R`E+J(C@#@%<7@F`D`:
M>\`'<V`&'A,26;`%7T`&&G`!**9B@$<1(0!?XF+_`&S@!V-V=PVB)<(!&@FQ
M4,)Q!Y34!GGP!G-@`(?E+0A6=HWQ=VV`![,A/%,@!WB@!WI`5&&@!G4`9ZNT
M#6M@!W`P!W!@!PQP*V!W>05C+D&0?0Y6!1B5`TA@`YC6`&E#!:-B/1Y@!BX@
M!V-0!FU0!F"`!8;X!Z@2!V=P!I)(!:YG8427BV3P7%,`!Z1$6"7G@;HE`%YP
MDO2RA^LD',-@!G2@;PJP*Q-Q`8?5!`"C`/ND``,@"X1W!AU0`GU6%`E`.W)P
M%'\S`OE``45!`7#W`'1D=]Q%.YDR#%<`=T>!:/N`+!S@`I\6`QR"`BL`!$`@
M!$90`S$P`@2`27+"!C,1_Q-C4"9\L!XP9$D:=5UA<`:KH@8$H$3=I0D213M1
M$095H`=#@`(G(`#HT9%?45#`40\;P`$R@`%D8`8[``,G(`=3-B@L(Q-L,0!]
MD!C)Q5O^@F7RPSDYQ71SD05L\%9?@'AC8!%K@(PM``(J\`5%X`.'Y3E3$`JC
M=09ZP&PUI0528(E3,'/V\05HP`6IDUQQP%>A("58]")JPG0-LC[<D&.F2`4'
M`!6%T06:8%KT@8MYPP4/)P!A$0$$(#QTP@53$`8/HE9IP`9H((A/)0!7H(E7
M(#\Q%RE8X`?XF43VI0>S0$"1ED)T<!,7(3`&<P[`HF#P-78(<'9I$(=_X)N^
M<_^A!.`582$7>I%N&K!*#+!/;M8$Y?)&$\$T0($`Y(`%#7`G[>('MN8'5``,
M/4@%^Z(!TSB!;6"%:6`'(E!YKZ03/,&@Y4`1%U`$:R`%>W`#2X`"%D!H>*!H
M%H9[MXD*#+D%F$!A2A8*$EEQSF`+FU@&=#4'KR@&#N%AR,D%"50K7]`%@W`+
M4\`&?!`/RR@%&D`'[@D&O"@4:<%F-T&3"L``9,`%72`<42`&([`\>V8!*$$!
MQ3("]_!0?R,!!P`V<9%%=R<7(?@@\.$%]L!^TV(M&,`!+8`".A!J!DAJ0``#
M)44"0S`!4^&0Z`$'<S4F"=(=4:`(5]0U>*!,258(<S3_0HHR9OJC9'V`F01@
M!#:P`0=0!V>`!1+``F#A.Q/0`!)6`BG0`;<E`T2P`VXP)Q9F!1]2!&LA:Z<0
M@5Q@"G-F2FM@!NIABB6T#'\P"EO@!WB@!F<D`B=1;20``C)03ZI$!U+P)E(`
M9H:'=Z[S!6&@1';6.1O7<:PS7._D(SPR0-KC'C4DCI$V!JX#$WW0(&Y@<AY(
M0+#05&"0!U+V;%GPB@]0*L]&#5T`B%[P(/B"#%/@!7C@!F`&4$4EB'J`EU+@
M>D8(!@Q"`-T5B;F%"F1@!T5@$?7X2@#P*^\EC+GR1D?*`&]`!EFP<XIR!I;5
M5'VP!65@$[>)2$6P3Z14!!Z0_Z+HD$:OE`1L0#M_(`=J<`E:H`6:<%!`-`!L
M``<B$'L,``<B<G->=Q&]**0'\Q-D!QE34`<CD`(J0`$E0`%1&A9A@)QY\+=;
M,`7B)9']J2H/N4FIP@<R!`UJ``9SD+5@$!IB``9T$#5QU0<3,YEHT`:^-2-9
ML`97(`]QIP=H4`1TX`8)L`=<$"[:=XV7H0`^4`9:<P=0Y05_D`#'`JF"PP(4
M\``<0`$=,`(9T&@-X$L?(`&7TP4:13$QJ`9,M0<C@!P-%2T4<`(R@`,YD`,Z
MH`(I``,SH#@I8`,Y@`(EL`<+60918P9PD`:"BV'&<`RO2!K2E$5]`(VF51BL
ML4/4)O\`%;=A64`%&``#!>*4#1`&(Q`#9V,!T;(?',`[8>`%.X`$+B``PC,+
M5P!F:>`#33``9%`&=)`'6+`%J3LB&H"%"VG`FI,%&)91JS)^B`DN<U`%OD,!
M2P`!&8``:I$&4@"!46`?K@:);M`)?*7%5S`(W=$'B6>TNK![7%!79,!O6)B<
MHU`%?D!`6V8%?@`'N7H`-5)T^O;&==MP+DD&8%9O:@!59#!!5I)%4#8&3\0%
MQH<(GIL&:/`&4R!37?!=Z&,,4[!!50"]L%"W56`%R%<&<``'36`U`A.D@1<4
M9>=>59L.]/02,I$'M+H&;_`&;'$3%J%].*E*3?"WO'@PZ_#_$V]K`&&PG=1W
M(YL2LE/GFVD`-)R9!V6`'EF3!YBA*Y>78N40%.G@`V.`!0D0`T)P`RXP`@VP
M!QD@`,X@A,%EI7@QK[8@!4WVFSA2"C?<;&3P!F;PQK[S"K@G1&8P(\(#<E#C
MG^8Q!0R2$&+1M!KP!]C2`%$0+HO$9FGA`P7LQW&W".69`2.`E1;0`4KYF#0P
MN0D!54?Q`&<`)W)0$K\I`!VPG8714!5P-G_3`6W3`BU@`S,0`S>04C>P`D*`
M`O/+`@_P8W/P'1\D$Q,D!C-5!\K4`":P/)<C!G0K'&Z@"'OI"J301?DC`+(0
M`2=P`I":$!5P!Q^PK!/P`BTP`A+0_P$LT`!PH`<J(`0<L"<60R]RHBIO8)-M
M4%QV$&5PQK=H()Q1@`;PV`96H`@+`171)HYP0$]#F%$CP`0DP`=2S`!3P'M\
M<,/)-9F?"`NID#7NRD"XD6.C90LF@1[+O`8-&5U;,%JX98SF5%E><`6J01]]
MI1Z#>EL3\R)E0`92<`91,`:J<2?6@P5G<')0]FQCT`9DH`:O$F[A=L-FD`@5
M^2"\1P7C<8Z8H(<,0B1K8I_MN@4B<&(^4<T`,!'C@,H/"GC#>!DT>5B8$8PG
MZEX:P0"9&Q&\N"N.@=^_0@X&X`9&D0#5,QY2$-N:@`EH4+MO0%=IH`6M/05S
M<+;A(C`$$_]+NX+-_];6-E``0%`"$\(5>(![GED'S58)9])#>&LC?*`HQH`C
M$<@&=H`;:K)9KO<'4S`B#+#7?R`&066;9>#)OF,*>H`L;K"+:<$&$((!!#`'
M5K-F$6$`&F`'SMS=!-``FP4<SF(TV3*J)L`"X6P0QQ(X":"S=D@;72`%!]`!
MOZ$0>E`4<3<!G.8".^`"(L4X+%`"+4!2,-`#*,!+<_Q]?VL',6'#?8!<51!W
M7O``)_`"VQ$%.!N#OE-'!_!75!`[YU,F$9!IR',"!I(2'4`"+/`!$H("X2P`
M=G``,[`")D``O!<\?K`%@RH'<<`%$PV'-C4'+X$&M!+)85"%:-#_!0V@4(V2
M/]"+!U;0!%N(!:7'6!7@3#)10CV"!EE0W+1`5Y5DVC/SDC54#`*\S??)![38
M'3D6;;-R?/RVVK0RU7H@849XPV60KE)`4WB;"I"W!3STD`^B"U:0'HCPV^)W
M3EI0YE1`+WB#&WR@B7&@3@^P!\?E:G^P"+QG0P3@:%U00U%0=+`P`/==C^SU
M1FGD&.[E1A`Z3.3"1A3A*VP$WR'@??-HC6M[S6T;!!ZPB\`R$70`0?(AXK+K
M!9LKVTJ&99F3G("B!7DQ!68P2A?@`>2P$T):,.S`*W`T!V5``"Z0`D8@`RW@
M`NTB!Z"2!U4\'DQ7#)^H,K$MH^]^MWV`_TF200K>*2>L`F9KD`=86Z]*QD1[
M"!P'D";`$0$-71%J$05WL)U9(`+J@+P^`(_SZ2IITP!G$`82-0\GX`+ZL)1M
MXP)=W0$8\`$GH)1X<,/9-!9*%`$3<``F\`.@80$P+;GU.P0XH`(H,`,[8`*B
M=^=#L`,4H`=D$";?9X5PGP?\:"5Q<P</LKW6.ES[T2!M9RP$8`7']51WT`<,
M4E`9\-$3(`?8L`$W<`.<E@)$(`&":@(IL`-&L5P]NW,;!$3UD04I)%U:D^";
M`D5BT'1C``;R,>6VUE/J$P;%&P(#X#5]``@;`0YQ"F]Y!G9596!<5&)]?%5;
M?&=J46UP:XQ:9?]7`EYC6E=345=2651G8E)485Y4KGQ?5E=:7%9B>GIJ7EU8
M9%JF75*2555@8&-E6I-<47AN6I1\?L5\97/"4G%[85MD?FYA?59=7E)^?GN@
M5WABHWH">%U6?W6\87QI<&A?455$*/````$`*$$2!@'@Q`F`APV=()A(<:*'
MBQY">$"042/&$!<N*&BB04.1"QX</@2@1,E*#P9"(%""X$*;,W'\B`E318R`
M/U7"B)G"QXV=`0P&L.'"!8P6+%NVC&'#P,`%E0JA0"FH9*$3#PH&?,%#`44`
M&R5&"(@C8$\4+GZH8)FTI0H7,EBT@)'2A<\6:U2TF!F3)<N8,92BK,G_,\;*
MF#YGL"R&,V:*%"M6O-32\X#`&2ENVJ8)`5)!$3A2SJ!K<P&!@M>GN<Q9(^9`
M'#4"".#!1R!"!!,N,$Q(<&#"B!(E7"A'SL($!@%<TI@!TX?"B0D/*!SXX*(M
M`0("(E1PH4+'$!PY2*2XP4('#A,<6HQX(`;-`*0#U@R8@V;-'S%W1$!`'W_H
M=D`#;:E1QQYW'/#``PTX*($`5_#QAP`/X.&'%P<(H(<$)3CW@!M6J$$`!2W\
MH-X#(K!Q@A$W""#&.V'\(<4?4\PU!157A*$/%V6004856911!A=$94$&&%EL
M@0886$!V2AA=G$(%&Q<T,48<#_3A`@@\<*$`_QHB>"!"%%!%(44?6X`1A1<X
M>9%%&F]\X0<?4Y0ACA]8V$,&%V*X8=D=;@#41S=UB$'&&V?4\8H;<<01!A4;
M\A','U[T06"F9,"!119LH%&795U,`=<]>IS!8Q5F?-I%'59@`<86?U3I!952
M5/$%%WC@T8<8<;"96J)1`!17GU)L848;;:#11A,#%11$$D%HE5!!#BVD1$,5
M683111>0!E)(KY%;A`A%*""32RP]="U+7QEP$D=S6-%'%%1F(06A;.DQQ11X
MT"&""+/12486<]C1QAP#T*%!:RM5JQ5-705!TP5%I$%%!#D$0`(%$F``X1X6
M%GO%%FNL8<9@1(+AA_\5@E51+!9CK/'G&%7\$484&HA`AA6M_M&'K%_L^(<5
M/&+!!8<$J,%''VY(H4%&(C7!P(Y4>`%&3`J(I`%>##!@Q0%7^+0+'KTU8`$&
M&SR8&P8FE,`""R[L0/<.-%C@(2154/%`6A%@T.$!\GS7@`04L!###3OT@`,)
M*^`P!`DHE(#!!QPTX`<;=FC``!MSB-#&C7'H49PW>X"GQHP"M-XZA`0<<$`"
M"0@@QYI>$-H%;F<(<$(/$Q#0``%N]"&`"3?8P,(>!H#1@A'+AQ%'IM7\X<86
M:6!Q112I2*$%856@\109:7#Q!;-OL,%(&P.T<0P?4?011B]:B'"!'7VH\2#_
M#`YDP$`3;3C)`-21A3Y0H4E<X$,]J"")+$2!"E;(4;&V4(8':H$,?-`#'K80
M!7M-`0Q3D(<7W.`'-*CC"FHHW1F4]`\L',F#77"#%[3`!C;4R@QO@(L4Q""7
M/MSA#JD3P!G\\)\IK($/:FA#'K0@!J'UX0I7H$)?!G,'4.3J"SUQ@QQ*50XJ
M1.$+6IA"7*I`AC*0R0`$Z8I6K)60KQ@$7BV1B$0NPA&,B"1<I2D72`R@+@0X
MH27L4@A+)D(3']BA"089`!35D*HJ9+`M\Y!"&`0P``W0@0SG@T,C*LD`='42
M)4I8XQJYLI*:&(`-(>0`"6"`@02XH`($B(,8JW"%_SIP@0UP8`,8P,@],"3M
M,%IPX%,^F`8Y-"!8RP)#J[IP!GM=P0^.L!0;&N8'`33`#560PB40>0$#>-,'
M98B2&+8&$I!HP`QDL`,#W@`.-QQ`#FXPT0/VT(`1="`!$4B`!.+6@ANT`#@G
MX(`+3-``>A+/#[0D0.T2T``]R"$!%J@`!3C0@=^A8`8HB$$.4I""&+#@!XSK
M@`0XD``RW$<$=%!6^JZ0@#/LX0!2B,(>?!,\##4`#^&90`0$4`<,"6!^=^B#
M*([6A3!@Y@X8*`%X)!`A+V1`!2LH`1HNL`<@J,`"!'"H&*S`IRUD`1EE*&"Q
M^*`%Z0AI#&1`ZQK2D`;JE/^U#2JK3*!DAA,!J`$.W42#-A,P!"8086L:@$,1
M!G`P*13#+FW859"T`,$H>(BL6^A"%U`FLRSD+E58\`>/PA@',;PA"G?PPA;H
M,(`Q>*%"9=C/D@X6)9Q8H0QT0$,M[Q"&+[A,#7(X0['.<`X!)$`.6/C#!@>0
M!3P(1A5]V(4?0+@]=/H!#WJX0A6FT`4YR.$[J[O=%[#`A[R$H0Y_\$,4YE"$
M$+A+E`A9"`(TLJV6/`20$:E(1KZ%D8JTA"+94H@<.>)'C3AA6B+H`AZ($RPO
M$&`/<@"O@`7`AC8(*0UHP&2;VO`&./0L71=00A(0LL8@3`0`'JZ)"/*@2P'8
M``;_':C`#C80RRA4J4=?\&H9TD`&^?4!#!:J0BY3\;+P+D/`H;$"'32AA3^H
M@4=7`(-2L#"%`NZ(`!;0`Q:Z<``K*$`)(6"`#^0E`CC4A@SA,H`/FC``9<`A
M#[&-0D_C4"$!'*!`B;O!!/;P`(#*;:(OX$`%YFRB!,3A4WS@PQ7H_(`$/,`"
M$;#`"%K`@AO$(`8S6!P*8)""(9R@`_VD008PH`<XB,`'&G#?]]Z0A00P:"@L
ME<!WY($@#`U'#T)YZ3N.;`;QT54.;W%#!VZ``0E88`]Z($`,B,`!$1B@`DBH
M006NNX=>1+`91<*"-4BQA2^,`0QE,`,U;FD'.J0A"WX8_\,7LF`&RKCX#G$X
MPQFJ*+40^$`+:FA0#4"@`OMIX)!VB-++_/"O+#`+C&F@+@>S,*LJU.,+VY7$
MS[H0A39%(0[TT$)H1'6G/ASB+V/@@E=#@8;ICH$*=Z@04_Z08#W<P0]G<.AN
M_(!.)(E!#GRR7A6D0P5XW@KBA=K"%8*U!2M\H8)4.(:FK'`'U?TA%D>O=A^@
M:8:4#>`"[DJ"U$5IL?GZD5TK`21-N"5?_$:L(!L!<4*P/!":S,1="4F""+S0
MTV9[00RKL(2-^M`D)>42G648@ZP8L8;_\?&_"1%EN[#E`9)H(`]B<(%Y9!"B
M*I\C#G*X0A;,QX\LG$.Z]RI#/_\V9(YTA'L,5R``!_9`VC4$UPWND`,7<DF%
M/>S!#6)X>RRGH(8$=,$``"A\UT3``#A\P@SJ(G,1EF@^]MG!L0?80Q<<@0<Z
M-X`%2YA`'^HP@117H`.'-D$'Q/.`.I1."K,:$FY,;<T(9(`");@!#E"0414L
M+@8DP,$-_/GH$DQ``%G(0\_6N5TG::'Y<5`KUR4`=T`[X!$>$M`AD"!<P,8@
M?O`K8?"`W:`&7"`'(]`#)R`<#8`!\&<!/I`')E``1K`!;+<WOI`:<B!:4Q`&
M<C`4-;,&'70,DK4%<#`'#A9&X!93LV(*<N`A<7`'<D!.&M`'7B`')[``3'`"
M31`"&J#_'Y]5(U80!5/0!U(P!N73!V;`!W$`!@V&,P02;F4P0O[V%&Y22WH@
M!GR@5WN@++D4:-6F<1#T!WO`0&H@-#TE!6^'*?9B#VRQ!Z?5!50P!G;08"ZS
M!5,`17ZA;;YU![V#![D%19(5!I_A0/K09&M`*W)`*&Z@&F^7*5&@!?IQ'W.@
M``L!!5)WBANF7N.R$>[U7O"E=11!1WXD2#7A`15C,2(1`BKA$N]R$`I0!7H0
M*5[P,F=`"G&A)&2`)M.T!K@$5WF'<"95!#Z@`#,A,1*#$`SQ1U]Q+G/@5"[0
M41G0`A+`!W?`#7KP!]@P!R06%Q82"Z!8/E8`A4QQ)0P0!77&_V!KP`6IT`5_
M`"')$EP'$`'EX`58P$-3T`U>(`(TH1$A(`(J\P]K$!,&,`!6LTM:@`9APP8"
M4`%^^(EB8`$94`<5D`(-4"(;F4\[10`3\`$=,`(40`!0U%5CX`:U4P<WH@<-
M0`$TP`([D`,K$&DJD`-#8`,HT),U`#DQ0%!5<!0#D`=Y,`=I(&X%5%0IU'8O
M-P$4\`"^]6H"@'HSTGS@T5,$4`==`"R]\@<-`!\8(%$GT`(J\``&,`<X``)$
MD`%2M`=UP(BUTCMC:04*%`==H"O,2`6I\D!_@`4T-@V(D0Z?D@5@E`N]4@=J
M,`4/$Q8(M0="0)<"<!(B("H6`GE^2?^%KP`,7Y0_IC(K?(`T4U`S<J`':.)%
M6P`:O+`%;+`&!00&9$!:5<!FLV(.4Q";_]%,NB`'N9`H?C`^8Y!"D!!,?MD?
M=I`&?")&`($%4>(&#N4&#,(.N(9!4;,+C<)OK#(%]O!VT'5DV)DH9Y"&2D0'
MN'<0J#AU7N$!(:$19Y=U6K<2\85?+J$$,(%&(,828&&+%8-V'Q8$'C`&RO<'
M<[(.82!MT#0*3C(`SYD'#&`';_`&.,8%#N,Y2^@2Z+5A@\>?&/-9OD,"+9``
M+3!ZH%`+$?0%:S"(&6<9?L%D9=!S5\!P;\``=-!);>`%#7`&7\`7NL)!$X`!
M85`^6?`A2D/_!=/')EZP!W%`!RG1$1/9#V!@!U;1!#MZ;W"%!FA`!T4@!Q,0
M4Y%R!@K%2!6`!P%Y(A5P`.`!3Q70`YEC.S=:#W7@I@&X<RJY:;^3`C6``C>`
M`C:P`SK``RG``S60`CJ0H@2@!9S4,&U`)Z`'F,2H!PF051BR`17@:Q#2(1KD
M>KV2.J96#UZ@!W50(7IP`C+0&1;``C9``6#@!%IP!$R@`A/0`%12![KJ!N'5
M!S'$9E!$!5,08UR0A7>@!U7HCFC"!6@P!^"0!_>Q3@[T<F+@!WD0$J+S%!50
M`"`0`UM0!$U`$EAP!XYXJI"G!L!V!6,P&,^@!KI%"8&Q)$R1"U,`_RGB5538
MD`;"<#XY8@:!$H5#LRB4\2DUDP60]05$6#:BU09U087<,X4Y$B52<)I<4`5:
M8`5N,`NTQ"/=(`?[T`9@T#=XB(9:P`=>,(P[5!C=`$'Q)CP"T`5$M`891A!3
M9XKP^17B8HLK89]8M[.N2!,9T033"'C\J;,242T+\1`;L1`&4`7%`P90&1IJ
M@!OD4*IHD`=C)@(EX3D-0R>>4X-%0!!BMT8@VA4LP9\:T"9<P`'*PP$8D#DH
MEV!G0'=C\`8@^RDRHW%1P`A4T`M8D*,ET091`$TX)@9J0)L1)@]D)05R\`[Z
M>%T)X`85"VQED&&D@3&?9DDG90!:FQ1)0?\'N#0`FN15Y(HIQ#!"4D``'6`"
M%>"V[,!#G#%/8A![UN4%K>.N/F*[&(`!$;`!.\!^C$8".<"3)"`$0)`"D,,"
M$:`'?``'8_8YTP$&T"F9W*!0`H)3Q7&KQJ$=:'.&FZ@'P#8[W=D60\0')X`#
MX9%^$U`$02`&0N``./!;;J<&L'<T?:`KU(49?_`'5Q`KLY(%F+*:YF,DHC@`
MPF`&]P$'6:!N/"(%9?`P!K`&=B(`+'`$**`'9(9&32N)1=<Z8UD%)_L%;&`&
M!50,PY`%3Q%H</`%83`%5;!T69!"X1:RUAD%<D@R:;`&:(!.XA8%J\,'C>`'
MN.4&O1(&H%$'?D#_"_5@*EQ`G4CB(U/P/2^,0>Z:Q(V`!KI4&$0B'6+P*6IP
MHU$4=&A00;)2!>B*(]SP6%6P!UJ0808A2J>(C75T=@KQ+M=2Q^DU=CA[1P:A
M+83D7FRD+=,"!0P`<>C(6#\E!N`1!6<P.^SC`^>BM?=120,C`@-0866"=F0+
M!=NRLTK0!/R0!P]P`C\@`ZK[`5H@!58)Q.GC9-29!:40#M8%LT[R!I>$)G0P
M!CH3!68PPHRE#J'Q4X[4MP10`1%@"^CJ![@'%IS+1P;`I0/P36B6P'!@!V:P
M99JD*36CR[=3*P0`'#10`3QU)WQQ!T=&<J:J"U&S;I!R`'L6`12P`T/@_T\W
MD`(HT$\\<`1$<+PHT`'*][<,8$EIM5UM`&_T*P`28,P58,P4,`&S8QP8`!X[
MU;\SL@L'H#<Q%&POVP4L,`,8\`,M<``*``!N<`00\`-J8,:K<QN7P54YTIMP
MEXDIB'!RH32#48.<<RYO,`=?@)U_,!@@1P\5D@9\!`=\D`5Q\`-`T`)Z,(WL
M"1.P[&*04H1=0`>2U+"4XF];4(=H@`4-1T:,96T*5")[<`5LL`6*G`!J$`:[
M\)L_=S`Z4Y8U<@7WFS]H<W(U5P<,5`>:$4&!-A=^$$7%&IL5X@8D$D$NC`9O
MP,/64`IX`#_6U0MR,0:E5T`]$@?=520H;`93</\':&!>O*@5[XD00-O'Z)7'
M@7>-[[(M_,6+@W1U($9U0?!?'*8!7O#%.-466!`&6KF";9$P#6,'D$P';2#<
M0AO0$JH!"I!?$D,M%/.?0>!NAW<%?W,#BG8"%.(3NB$%7-`LFC*X<"%=H!<-
MXV`J+C3&F/2`13(K6'`&-5(ZGE$%=U(%6*`&]B0`$?0."ND$"K!EYO(&T<QE
M>6#+@W@D)F5(%;:C#$`&^&`A4I&J%-`Z#8H%J;$3K="X*:1N9^`&YHS0$M"[
MZ3=_&V7/,:`"0'`$2X`$*?`#"6`%<[(&US88N^28?/`*13<!'+!/)U`!++!]
M6"D@!/``MZH&5F!8=_#_`/#\`,3@?'H0`8':`O$;`DI0!P50`!O`51#W=FY0
M*G_-7;"L39G(B&RB)E;8+%\`!PY6W',0)%OMIG_@"+GEB'Q@!QY0!'S0"@T`
M!`[P`6B@`(D`R6VP=%%!<&N@!>%V*U$PNW1'0V0@%VUP)Z)B6';A8NY=JEW0
M!DB-;C5",^YP!X;;@W$P">&@6UC<&'_PU<001D$EQ$?S@%I4(=7@!4<7!K8P
M)/@"#]F$A\WT*YV%*6QV#(&M>7\Q(VJ@-&BB%"IC(PK9+LV-BNFU+5B!7G6,
MM-,N=KWX$'64+=+.$!-1!&C@`Z)3!58P8-=D>28G*:TP8FTP309`9CG:!`2C
M_P%BIG]6T<>!!Z)^])\`$`+R\CEGX`(PT`(5\`%*)0<-*`UF4`M:T`PX9@5M
M`D+6>07D0P9MHB]X,@;N,[L"UGQ[(`:P0GEIL,8G,`(_:@:0QP`-$0)=(Y^O
ML65^'C9->4F7>`=80`?\80>?9LE;W04#W<2F`"G;(VVWT4Q3X'W?Y06ETPMA
M0$\2,`$FT`+S;`,SP`/JD:@I0`1/<`0J4`)Z8`;9-@6GWA\XQH^9."/%\0$8
MT-`1(#?V-`($T(,'(`$)H`?7PP5[L&<F,`'8*3P-T``<,/(<\`!-X`$1L`1'
M4`&`(CS$(P<1&`M-P0=4\`PQ90\3.PQ&!`=M=4'_\/]!?P++3\1(?Q!LJBP'
M8Q`N5@TU'+`$#D`!:>#G>=`$<[!N?_`4@9$&>A)>P!(%0F(^6T"="$?7IW+4
M126LB;XZDX*;4Z`9R\*QK4/W]RL%*A,8J!ENXT8&:)`&!2T'X=4*YD.8Q*&K
M"5`'W26(2=$&4Q:!18ZNQ;,C<D#D3F);7W!=5/)Z+9T%O@E"]G!D/@!B!0H(
M05"#A(1!`$I*`$&"286,D)&-C@"5``@>"(J14(R7"`!P'"T-;")?:E=>>V%4
M45I2!P)>?W9M:VQK<W9O:70,<&0:"D5V/D4*H)R=EI5*""$&#&UR+40K$Q@H
M$6=_5W5B8V9J5F5I96!845/_ZE9]?%-::6M]95T4:F-;5VH"=59B[L21LV?/
M%3!HZ(")TP!#A01NH@@@L$7!LPL&%#1!AK%($0TBC@T@L(<,F3->R`Q@H*&(
M"#IOP&@APP7,%RQ<^$BA(D6,'`(/],B)H^8!`35R_KC1HR;.Q(D63K1HL2,&
M"1(J5@@1`H/(D1HZ:-19\R4+E3]4MI3A<F7H'@%X!$28(,'$B`@/1I0PT0&#
M@#!N"#0X4-"-G`02(G"P(&""'CP/*+3`\(=,"`TCELR(T*5.@@.?\=RITTT*
MEBU3HF3I0P5+GS]=_JAQXZ5/'S]:QGQ)LZ5UE2I8M&QQLZ>.GCV?_8C18L"#
M@3*V_P_@6,##2A.,=C2@J4/`#Q<K5+[0Q$(>#P$I9>BTZ6V%S^\M6Z)(Z9*E
MS!0I?KY\^?/'*7HR5,0AQA9OC)&%%&?$(<467P381Q:J82&%0&"`X4<66H#!
M111^1%%%%%=P4484;@@@0!Q>B$$&`P.\,0<=:Y#Q115=G%$%'&#\D<5J5W1Q
M!1];L`$&&6/T0X``=[C1115;:/&3`&XX)8L:##@!0`@A*"-((5P>LLF6ADC2
M"22#>`F`$P@X0:8EAZ"9Y@4E+)!"!&PP,`4>=:AQQGQ>!/9``@00L`888[1!
MABYLL)$',&F$Q*(&/B2S2)EA'H*($\Z)D,<]-Z1P0PDL</^@AQ98^(&%&61,
M8<46=M@Q11952)&%'ZUQH04?6JQGAAP=R,&%%`+HX<<859QA+%!Z2%$%&<&$
M<4`&$Q"`QUM'V0'*92(88$!(/C!@QP!%9-1$'_^`D84:51A0Q``#V($&''"L
MQ4=P?O"IRAT'-"``<@GL\8"^`JAQG%.)$7!`!2?\X,(0*JB0`PDI`($$$4C4
MD$,+%7CQA195L!;A%&((<(88>P2:F``8C##!`QQPL$$%$^@[K6#Z[M%`!18T
ML$$"=300A@`?F%`"'@HX8<</`<2@AA9N''`D:'J$$88?:)BAA6VW_F&%%E_X
M(4>P74S!1QA_8/%%DZEQ/-,4`AS_H(<;=Q3GA11]#!""`@QH<98)2Q0P@@@8
M,3#'`&1XYH4ZP?7A15I\&,<''V/`P05:I,Z$QAA:>.$'JAMKP45P67BA1S=J
MX*''%6QH,(9J?`S)A:IQ_/'YZUVTHHH55USQAQ\FC<&%=U_PT05];;#+(AMF
ME%&&[V.0L047OY`11HIB6!&%?%?<A^L5>``JAAAG\,[%&?[T,<4J>O111"(>
M7."!(HN`66802=1O:?R2L"F))THXX;\B8_($`M($C4L0H``@J$$71+`&'W4A
M;G%I0`..%*@]C(@+O,@#'=)0IP$D2@2"LX,(D*$)1G#)$8<X!#0TX@,PR,$"
M*"#"$"I0_X(#R.@+:#C'0J0P!S;\H0]:>%46V*&%*(QL#&S00F/.@`4U2.``
M91!!%8)UAP0T``]J*!L<&)`&-V3C3Q+8EP#\8`!$*,``&!G`X%ID!S1>X(QY
M$`X#:%*$)C#@#3DA0QK,U:'[>"%!>C"1+`@F`8,EX#,E(TQC<):!$;!@*E8A
M@0YF`(,C!&`)2TA!#TY``"]TP0M6:$]\KM`',732#W$PF"P.0X$*'&`"'X#9
M!B(`*#WH(0$1"%AC(@"4H]1!`!RX00OTX#XIZ*``,7`#`_S@#R_<X4AA<`\8
M\@`'+'@C"E2P`CMDU(4]N`%(6_##XWS2!=4P*1UUD$"R]`0E/O^D!(T:8`,5
M?D8"$`BA#@:PXTK*8`7NJ,%L(!I9'[!0A2LL"#^_$T,4QH"%+/A."V;@R1;6
M`(<IQ,$*N-!"%Y@2A]&=H0M?$`$;N'`@/[RC)J0$@UI0`Z#CN$4.?+A)%ERC
MA:M9(0MPJ*,/\+@%,IA!-UL01QKLP``ZK(XG4]C8%_H0ABA886Y_^!HK?/2*
M*>AI"BKM0Q>D8`:+*,$#F4@$_KI4/_OMSQ/-8),E$N&$+T%B$9?(Q`"#H`$4
M@(`)+*"#`<`@AB$*3`\$`)0<G/E-<Z%!`WFPQ1C0T(:?ID&#;*`#2*ZCI4+4
M#Q$J#,$;BP`=/+``"#,X@0LB`"0<7H[_#WJ@PAJJH#EQ8"$U./G#'NY@A1PA
M*2UGF,`$J/`&*IB(7P30P^'RL*TJ/``#$XA`!09C@00PQTI?W=:W-``I!5P`
M(V<L`@-$H('UU(D.K!61.OKP5#F<X6L'B,!@`O6`"$1``O"U@'LE8($'2&`#
M%*!`!TI0%1W$8`4PF`$)@/"$`BSA""N0`0>".Q$]=`$G8HA#'X!5ARL$)KA1
M$L`#'O"6"D"+`A.41<D$(`>#PBT.=YA(`E[``AI40`$>2,`2%M""/=2$9`I2
M`RO:D`8_N&%/?GC5%%A#A2!_3FONJ((5>M*V,,!*>&'XFA3(8(4[7"%07>##
M`,Y(N&YV`($W_V"``E:B``7T(6IJ2`L6/FD:Y6$..!V3S1D>Q`<_@($/8OB0
M^<!@ABX(0`QT8$,8[N"*,Z0/%F?`H!DF'.4KE`$-8*A"%M#P!G>R`0M]>LN)
MI'"%"*>9:UB8EQEVT0;EK:$-YN*0YWJZAC?D@;IVF`,<<!@%,7"A:V&(@QOJ
MX`8J\`%"?Q!#%C$$V&]^P0=6TNS[X"<(^5G6$95":UH1<::VXB^%9W*&FP!P
M`0(<`00Q:$,^S6`%)<LJ"WQ0A1BB/+4WT$&-:(ALH,<`!C;880U<,$4:S#"`
MYFR"2U!X!EPQ$8TRG$4".3B""CK@RJ2:(9PZZ2D5PG:V(KZB"M/;Z/]'M3``
MS`$K`4T-0Q^N7($*S*(/6Z"#"$0PAE?^R;T/J``&"#`%'[P/4PK00$;*?-TR
M$X-%+&D#3_)M!BSX-"==(,Z)])"O0TKP`72!.GXYD%\*?$`O+^A`PEAP@QC$
M``4\$`(0@"`$(BR!"##0P0ER.>+3F64/<9C"%4P$MP0<AR1JB/`=X@*4F+6W
MEWF2`A^>VH6?8*`$/Y``&LK\`28L8`1=&#E@"2"'TNUA"DUH@A<X<(()I$0]
M40"*&MXQ!1KQ6G1XZ((5IC8%*HC!`A+X1Z+\P,X]6`$-3<@Y&[(0A@;H``0!
M2`!&\M"$]FGA#%3(ICBMIY9S,(@,GG-JG07_SX4MD$<^VAS;%?Q@JCDT:,AA
M4,."L!"&M[V6"LXK,1S2P!8KY&$`&*_"%`I%A;?](0SK+H@9UK!O\FXA#?'&
M+G,04:#T0\E7!5Q@!N[V!FT`+VA0!K+U!^Q`!7>0%'V@&EOP!T*1%F2`!@0@
M`6XP9`.@"1?@`P:0)F(E)@!G69;"/\[0#&(5/\[`5HG`5IC"!2P``RAP!@!P
M1G:@!>CF!UO0!JOC!W\0*'I0!P/@`QHP*(TB`ART7=.`!64P`&70!CH7`DI`
M)H7P#%L8!,^@60Q0='C@`IZ2`",P`E<0!23E!U5`!5E0=&KP"GU0$VCC!1PB
M"V'`!7F0!F0@!8$B_P9_P%5>(`$50`#6(P6WQR)9H`<%<P`YTP`9<`!WX`?9
M$0)G@@E@I8E8PD),J`$#P#17@"%H\(!D@`6F,QL"8R(3(1BZU0`20'4<T`$?
M0`$CX`(]T`(N<`(L\'7^A0)=801E1P1$8`0\8`,N,'-/(3!X<`;FH0:TMR^I
MM`'',4$?=0=,84H50`$QDR^%9#IXX`9Z0CX?8`,Y\``&$`0,T`(.4``RL`>K
M$"@)\&=>L"]3P``>(`4W4`,I4`%<X`,B$`4FT`,)D&=<4`6_I#EB$'FWP05H
M$`;Y10#A82!^(#HDE@5;9@!P4%!U0`%$X``_L`88`3@(4`19L'W.%`=;1?\%
MI3=37&,37W"%?@@A6;`%OZ8/0#(&?0"-R5,&6%!><S@/'%(%@:0'?Q!.83`%
MJ1(%GH0\@U<%7V`K5:`4J3`%Y.,&YD`&*L4U:[`2&L``;&!$8C!/8B`%I8<%
MA%)$6)`&#%`$>1`%V&@%?A`&D3=QY4`&]4AB"Y(&$T=0?2`"F'`!N3=`5G)M
M)K2"7<(,B3!``#`FU`8__=-6_5.#BZD`4:!?4N`!`.`!"O`%8_0[5\`Q@V@%
M@/49<P"*"?@&*S<'(1$2U,0&;9`'(X0,:M()A&`_:0)7:"*8VJ$&%,`"):!<
M'!`!?Z!269`.*+$%0*0%V\<D6Q`KI2)!;L`%;0#_FV)0`1QV!C=E,W7`!T47
M!W4`!BU2?Q($%!GP`":B:W<P&F:0$9IU`5EB;5^%$0;@`TR8!]"1)#BDE5I0
M,G>P.,[4-O)H%!J&7#)7<A1``S>``RW`=2B``C&``RI`C$!@=@%P!#"0`R4`
M8G+0`!$`CPW6-G(@!K:T!X;741*`GBEV(FJ0`!L`+;#W1!I&`1$P.G(@`2X0
M`T.0`0H`!5J``_9$`<$E&+(07)YT!PIE&5$0`PL@!!(`!QAQ`"E@!!S@!<0R
M3VH04SPA3E60!E@@`.H49'YP!6%@!7^P+V%`!LC``.>"!Q40`P&@`F=09OFD
M66B@"OUQ''!'!5R0$W;V_SK*^05T4`;0]VLDM0X--5-3D&4R(G=(X08Z8@9I
M,%-@T`4&0UNN!YYY,A%BX`7X)W@U4B-W<`93P`5>$`=7@`55PR!@4#R@^`9E
M8),)$B5X(&$$=1I1``]?T&\,,`97L`<\(3*$\E2IL10HLE5,TH$(T1S7I2WN
M\S_ZLS_SXVR0@"F@,`C4]IB229EGX@&=.`"MB@!0L)M;<`!YIE7K,&'M@2^"
MTB)9D`;P`BX&,`"R.0`@I)KUJ7,(<)BW"079Z@QW8P!V8*FC8`*",0)R4"%C
MT`LD2@7+8JIRX&1?H&I^\($"4`6Y8`9A4%]'<AP"\`>,M096L"]#F"KF$5@2
MH/];!U`ZYB%S*WLXN,`&`Z`!3:"%%Z$M37`,G&485;`&9E`6/T,`8?!:<7``
M$C!!1P*>Z=5>L#<!&4`!+H`#4OMU-H`#5E&,0H`$3_`5,_`I&$`8*R,')5(<
M@5('4L5@%3`MNH6>%018LA`!&(!<3H,P$K`'>F`!/<`#-R`')Q@&*0`"*W``
M?/!,^F(<3*$[[3%Q36`&+S`#'1`%#.`#:&`"E]0!R[(X0011%=D'OR$]>Q`%
M/]MIL^$%_>`&6$!\/J"Q<;$#"V`$!U`$=P,I\UID@X<[<2$'4X`J?$`%1<2[
MLF(&N/(A>F0?6C-DPV,]'^*,O=8A'@(?N<J<>D!H4_#_,_0H``T`=VJ`%&)[
M7GLPAP<Y<JW1/&4Q!BO1!ES`5`OI%$>2GA-V<1Q3!?PV`*O55U&P!WC@D"`3
M!U(C!OE!!7"'<F30!GKU1F?4!"<X0)I@;7#5;"9T5K;IKR74)I")")2))HL9
ML.ZSKUZ"``:@!=CX(W!X$_.!!53@!FZP$CCR!<W31G;$"W"P$BO!(B*0#%M(
M*5U"P?W#F0R0$Q6``B?P+X?X!Q"5!P]8!7'`1%RP45[P.=JD!:B$2VZ0!C<Q
M!7]@'E#W`&<P!G1@!V"`!PV@!ULP4VT@!273`+B$,P10<A9@B_G5`1\:2`WV
M!2=X)@1<GUO,!EL`!O!RBI5Z_P=UR`?F(4$F0@`_1@"PYUYK/(LET`(QD`,J
MH(,HD`(U``1&@`1(``0D@`(X(`,MP`$2@`$9P`IV"Q@D<08"$R@"8`$C\`!&
M&S.!<B3V*P=W"S/TI5[S2``<8`,D<`-X,$`34``.@`/I@XU.0QI(R@=.Q7TZ
M]FI^UK-?<`898`+$*`!E4`7A4`;"409FH8B^M@[`T1.X`T@$T`5VH%UTH`5(
M(0`S`&YHX*T&@(6JTP=F8"B3*C5!-GA70`5>H#E@4`9KH),U\07V1A8[$DK\
M0#>/\Q;UT"3/Z1ZO40619BIN"`^],'*_@\SGM3M=D*5F``;D13>ID@5E(<`&
M1Q`%$?\H3=>Q=5`'NS-0J<$@[5)]'2T%XN<'3W4&OP8>8'`&=0LD5\@%@)-/
MX>(^FXB",=ALDQ)`_!HF_EJ8E-D_*`@-!-<^"J"%,.@!=/!``C"*=`,AX9?/
MM\$+[J8\;V"O,^L#`_`N=E`&\)`&65A9MXE":S5`(=`$:[`&<3`"K20M0BK2
M8!`/)-(%8WK$7J"4Y*$/)7(`OI(:Z&9*%G"(7\``32`"?1!8;A!I\'NJ_I(`
M5TP`&8`!]66+HJ77%1`!!V!?!(`Z)WC!.3>SH!@2DC,`Y$8%8`"7$T$M>/`]
MNS0!,F<"+S`")[`#F1Q)6($"-<`5*9`"/)`".#`"5$<!GBS_("01)7=09_U`
MB4`C`^C97K+`BL&R:P1`2]-2`1RP812@`@6P`UL0!`;P`PM0`"WP``,Q6V+`
M#_:[SQ]EIG6`!^*6!U\`!VC0!S?:`DN@`GA(-F9`!]\!9Q,6PGI#"Z_"!XH3
MCEF@<W``O/OLD4OP`%5=G^\7+^PG(LN3Q_OF.UDPLG=`A1L2!4T2'"25NW.0
M(Z-X*J78!IDC!KF[!JZQ#R92!V%@+%=@!?26XP=Y:[Z#'S.B!F'P&WQP:SNB
M@&NQ!FQ=>$\A`$['RL&B8=<+#G/Y!_*W&VUP.<O3&0X[!6BP!>X0QGL0`7?`
M!1WX!FC@`YH5$CL7`ILX@Y6`5@S,_X72B@AI`JUL]><#Y*U88N>2^>?.X4/'
M$0656JN"1X%SHP9P0%0:`.!L`.!E``>PMM9*P5O94M6%22EEY:^*X#\XQUUH
MH`<5,`(/80(80&A54%-G(39=L&YBP`<`R"!;`!BTD51EX0>62A=Z$`5H8`=F
MX!GIX[]RX)-6:3`>^AF&^$05H'4N4`(=P(T20`%\@9UJ$.<AT%8(()@9H2T*
ML%,M\CIC,`4E8G>B804;;3.GG0'D?0(E0.]>I\L0DP(K$#%```-`4`,P$`,<
MP-L.4:0$D"2VY`JF%$8$D`W[XC2#?`"@$5QQ87<"/@&MM#`Q8`)HH`0#T`),
M4``N@`<_,?^/"J*!;J/90R'+>%`&8_8VJ;P!'3`$-U`!M2,'74`&=/`%7>`*
MZ9:J?(;.<B`%I!(</<%Q&[$&6=`%7IP#,$`!=G`!+E%FLFT2$U8O8?`C1N<[
MKC$Z-550.O(%5B`:23GI53"JS^-3:(!OY+50WR$%7[`*=BLR6I46>E-N)F4K
M8S`&3I8&Q3)A>Z(\Q1-HI3(&(SO(WJUIO/9,[C5!0H&F-1(%@]/16Y`BI0H&
MYTPV3E4'>]`%'%-N90"[8P:[=V-=N5EMFY!6SS!`BL"MF_!5FRB?4(TI/4?4
M'G#H51WN/K`?7G`%S6-*`F`]):(D=2!"'Z%&/^OF:#`'D1M'RH+_!I)-[IDP
M*5MB/_UC";2O$7G3`%)1`ASP`A@0!\!#HC5U&VZPY.)0<8JS;GS`6,P9,NZ5
MA*T0$,(U!7N0`02`^6@@!;<$"!$-"0D1%141&!\=-"4<&!PG)3(N(R<<$P1^
M#`HA'AXA%Z$7"AIS<&UH:6-\=PU[9U-H7GM[>@($#1$3(RXF'2XW,2LI,$1"
M*#!+1$0P.2TC&X>9A01W=;E[7EX$$P\$>G5U>P0$`N02#PW@>@<$<G_M&2PH
M.WLA2EPD($(C=V$"'B3`(Z?.+0%X_J@1P)"A'C0*M+AH04G2"`)7XHAQHZ;*
MF"Q2K/"1<L;*F#%HML0)8T6*E"A3J$1A_V-``0,S5NY,&(*DQ1=2`XH@0#"`
M"Q:%=?#L8;A'CA\_4OQ,F5(EBA4K5#9^Z7-."I<T8/[<$9-%2Y4L6**$W%(&
M"Q\K?KZ,O'+F3A\N?+)4J2K&Y9\I4OA$D1.%#)4P4]S@Z0.F"ID!;ZS4<K,G
MP3H]<=1H[/+G2I\^80SB.N`NP8$]=_"$(:/!#A@I=;Q$.8OEL)<K4_M`O2-`
MSA8?%PS0''JAB8*A3A!X0.!$B7,ER8>"$C64N9/KUQ&$\)0=>?40"@P8")']
M.8+Q3D(8X'-FRQ8N6<+L">,VJ9HN708P8##`AX@T6[QAQP`$#H#&%VWPEX</
MXBEP`0)!1`A%$O\4)A%$<@`$`8`3TQG@PQQ\=)`#"Q:\4$("X7"%015;P/5'
M'U5,L849:Z3D!69^5-$&&6>H(0<!#V#6!1576'6%%0<T@`<?:Y31!QX66#!(
M(11PD$$%59KXP@LL[,"""R[08&()(U"0@!A;&%"=<AX4)X(//FBP'QQ9%"0&
M&0S$(8$`5Y"3P`02*$*!B3O$H`(,1M1`0@XI"`$##"BXP`$'58Z`00(,659.
M!`3@X88>IKDAA@!BG''`!`?H08`$F*YTBQYX"*"J"T?$X$8("-PAA`,YH!CK
M(&Y(<<L>>-QQ!A]A),D0`6[0T<09*#Q!`@>RKJ39&>(<V9(?6X`4%Q?_7V`1
MF!5N_!-8&4$5D<<65PA`0P!';)`'>!HHD!X:?O"QD#L"N!'''FKX<4485&3!
MQAI1A!&'%'\(T,<89VT%UTM58%%&&5],,3$6:V!A!AE8L)%&'QK]<<89CHUA
M1AE3<3&%IVJ,%:,8<G3AKQ]:-*P''P)4,$$#[K@3BUE1S';6%$7W<<6HZY3#
MT!UJ6,$&`VU(P9`7?\@AAAA=]&%%&F^`D84;Y9R!1A'!F>'#4`84H<!RZ3FX
MW%`;-F?W)\LID2$`T('B@=Y*M"G*=,IMA^MS`/"M7',(7!!%'5I@T9)N&'^5
MQ151R2E"$TWX8$<:`\[1!AL'JT*'Z&WT][82_Q)"X3J%4"B!@-Z):Q?<`&5H
M\<`E%%A000D_5%"S&RQ.P4?!R/)1ALA8>"&'UFI@H84;=<2A:AW76($%%GYT
M\2,!=5#!!NYG/'!(!`DHXC,%&&!9`@LMW'`#"R64X(+].]P@@R,3X*'%^"(P
MP'+P%AP1\(<.;=#"%.#``#=4P`(]<@6E,$"!7K1@"#'003%20`(2`($(*7B&
M"3``B8F8X!T"&$0Y"$`.?NFA"W%(P!V\@(<#0$U5J9(#'O3@IT+\`%)6<(((
M.A"`!0Q!#U4@5P(R((`I8.%3YXB#%PZSE"KV001C.$$!`N`"`H2A"R'!G!?N
M@!DQ8"T*8)C"D49B!?\9;6$*?7")]N8`)P:@`30/B`$(4#`%4!A``P_20!G$
MUH4&?`-\65A9&;@P,([9H0W'>X\5EK<R1K[$#Y^)`A?@TY)N:0$,?<`"N.S`
MAB]4821Z.$,:V+"C+\"!"VM@@T%JM@6UB$$/>@@8&=8P@1N<``\/P,#/SH&'
M,_1!"V^4HQ6NL,:IJ*4.N##-'JRGARF<[G%W@"$[-$*`+H"-#.12`Q_>L#D&
M<*$(T`E/)P88BD]X@F_-<<YUH-.<#&E(=M-AYP4NX,[JU-,YB8,.<C84`I*9
M@0]_"$P66F02,$0AH1J(J`8(Q``1%$$#;"`#&N`043J\(0]Y^"B#CI,AU[W_
M+@E0T%#B-*2=4#`@7%800`=:@#Z*/,`+5NA#%K+`!Z_U@0I4P((<U#`&+(@A
M5N:0#4#D<(9SX(*H6`",JA*P!S^,`0YD\,(!JA0!53U``A6@U`0J8`(6W,`&
M^G,!_%@@`QP\HP4M*($)>H<I-XQ!!&^33GC$8P`&O*&B7$B`!,ZPD:UV@(0G
MB)\-8L"H#A;#"""T`0M.,`(32.($%)`5`0Z0E(80P#0L=![ZW)"1.."A#G(X
MP%<?<`"P8FD(0+"!&HC"`@=`X`8"B(]7(W`'*SB/'/T2@V8,@H<X7.$+10`#
M!XIQ(G@X,0M1Z`(9Z\"U*_!!"W[`RA6VX0<RA.LM_U2H0AHT(((!I.%R#V!!
M"HX@`7LI0`0:*,(`LJ"*+51!8=@2PQ@&8`<T9"$.!(@#%MXPAS68(0UM*`,:
M5%$&@45!"WS@#!6F@$F3?2$-9.""%+H0A3&480Q<>.,?ZO"'-30)"UO(PQS,
M("XU$,0/4<@"%?"`ARYP84`3D`$%"!`!"73J/G`13!2RTB,UJ.$,7[R-'Z)Z
M(]+L03']0@,#TD`2+U#O4V,1@!JT8(8Q?($+5XVONOB@`>G@S6_5\=MS`#?/
MQ.UMS>D1#S\)R$_9S2Z@\TS.)YP`@,:=@0#<ZP+7^*`O+W"A"MUS@PC*RP8X
M_%4!-J$#',;G@\YIP`=%\/^/`3IW`3X'P:0FC9"H@Z`=Y30!#@H^PPANL.,-
M<&`/4;!RN/I`89%PH0\2.``9QC!&`1`"#]E]LAARH=K<NB<*9'N``*0`(RJ`
M"A+]DP(>*G`"$U#*U<%8[`Y:D+\;X"`&**!("UC`UB^5X`45(`#*!L!/PWTB
M.#4I0A8"]@<K),L"EAG!#O*W6!BLX%`U$((0>(""&]S/%QVP4@.`]L(X,.0`
MYU#M`:@W@0F02@ZJ>O)6/P"HA'?`!D2X01\NH`4<."``)6"6'AHP`2EUJHJX
MV`/7GO<O/7AA"ER@PQ<(8((8M"`#>+@"BHM&!1]Y00I`[0.AC7<%*N0T<J`Y
M%AK_^H/1)'JA!$<PP@G8T+@F1#0-7A!#&<RP!32LX2,YJL(G^7"%E0N@NV1(
ML)?-,@6]Z&8OGQ%,%I0N!3EHX4!:@"X70'D6T(@A#'WX<A3RPH4Y@"$,G@F#
M'L00A2WPX391*(,=YM`%AE2<64WG0ZVO8C.#8,8-;I##'58"HRI(X0Z;%4`<
M>O0%!MAA"MB*3<*,U06<<T$+*.%H36SRAP%X`G!]RQN;UI2<Z#`'<-KYFT!#
MX(.WP6V?S!D*0/L,-SWSN7%ZF,`?Q!`'.5S!]5*,0M/%<M$\$&A\'IK#`":J
M`14SP#]OLF@1`OBW3Z?4_Z`6(;(C.PH@7V70+B/0`0)P_P<?0`%[<`56A059
M0`805A4,<06K5!52L`<-(``X=072I5HL%P''0FCMXE3FYPH-4`$CP`$2H!04
M(`,G<`(=$%8NT`.+90->L@,ZD`,Q8`,XT`/<MF]G-00WX"6_,`%UP#'R5WW[
M-#@V`0=V4%[LP@=B4`$3`5<W``,DD`P!YR@D<`/U<PDF0`.']3/8<POED!0)
MP%J^]D"GD676T`T5<"4=8`(V@`0]@`9*D`5```(U\`*]`2H5ARD+N!0&,4T%
M,S!G\#POPAEZ$"@<L`%>A#F$Y414X`6B)S"=P2+J%P5I005=<&1],%YQ,@!?
ML%UWD`,@``-=(`J8UCEC,'M;H/]`9M<&8!`7]\49M20';F!59N`R3/<'74!8
MU]4'9^`%63!V1;5XU^4'?U$&:T`&ZL<'W%,0?Z`%7``51!(&59`[?Z!V@F$R
M4H`69C`'HI,&5B`!-%`!+T0%3Q%'Q'@&MY`DZ]`0"^@&9]`%US48@H4'6=!&
M9?`&7R`'N.!W&X@'V@,&6@"*7V`&`V``HB`"?<``R+%F:S(WGH!]<\,F>!,>
M^(`<'E`3V]$=;090`J5]=9,X%R``%B`L#T@&91`&)Y-*`Z,'(F`'=%!_8Y`&
M_+63$^4#:<`%;/`&:<!1`\!*$<E/)952)Y52>J-2T6<`:;1S&V`!ON8(<N`2
MB,<%5'#_!V[0>5(0.=.(!F,@!G7E!1(X*KEP"!U83%YP#@10`3X&)!)``29@
M*>N0`33``270`0>P`<&``T.`5H5"`BJ``S>@`RH0`S<P!#B``HV9`R@@63T0
M`SY7)A1@<:2U!7:`-J3@"6TR46DP;2?P`RR``R$4`S``!#"0`BLP!/7S`S28
M<!2$`1G`6K;`$.)0"[[&6G>@>E[@!S]B"SRV`9:@`T"``V"``%Y@!("864.U
M<EBI!AM!DVH0=F+P!UB00$VG0'"$/4N!2^'0!59`?C>'-%#A!8VH!X21,5(@
M(U/@!1I1!6B@`4T@`FB`+(TH`4#P!!30!"%@0!+9!&C@=%3P_P=_4'D8PRU@
MP'9;D`9K4`5N0`5MD`>L`'SG^8%A,&0T1@5C8&!*@P5C,`4O$GA^X`4$4Q9F
M07EM<#E8T04LD05?L`51-1)R$`=6-09OX%&EI`<88`(2X`96L'A6,(H8]R=C
M14%U6'%O"99"QP56T`Y+$A):\`9H<`NBDBP'\`>U:#/Q^4EPT`3[5`1I8`#1
M$4]P)AT;V6G8T2:C$*=F!@K;X0%\LWWW5!UK]F9\HP`\M@4;%B`?@5T%\2\)
MD&!@\$U3`P=`.7])V64D^@8J0R,B4&>C=E(6`E`L-3LAP`9:,`=:D``<8`$$
MT`$G4)=BT)!Z4`$/(%UGP"UH``88$_\'Z*,';E`T7C`.P21,K&*KN"`!E84J
M&5!M)C!7$]"&D/"7*W@"/:`_.)@#)/":*$"9'229K9D"*)`"0,`#/T@"1B`$
ML)D",S`_DO(`#[@%9$`'U0<>I``';C`!)E`H*(`#-O`HBZ(#-A!7OU`EFUDI
M(Q`!M;`'=9",-.D&*90`UNF>3?4-]&@^)Y`,+Y`&(2``2``")#`!JV>=V'``
M"DD%;K`-'!9C9@`':]`M7&`&B.9;82`&5"`7J4%8''$%.Z4%$.8%:C`.+T1H
MNC%^Q=@%(8-I;=!4LI(`)P`$+""Q"F`'=O`V#%`5R)9*,/)&81`&6?"@1CI^
M8?!WLV$&87/_&$A'>5/0!4>2(UD@MI'C!UR0$GS@<-DTLC52=V,`83Q5;WP0
M(UC@M%00!]FX!6"P,F90-?#*`0G`CU&@-&?@)QG``0FGN`U(`11`EQ`'->6H
M?K;@!>9YI6FPLE%U!Q80`5[@'KF:%S%!9@YB`.P6'<^!';0C4'3Z"<H1FJZ[
M)M(Q.WK*-VZ6.!R2-[>+D0:0`!:`%U60,6HP!6:0!1O1#A$@,F``!G/``.)!
M!^,#&0-@0`D6.2?!J&R0!VZ#`"L%:K`C.VYV'7Q3!&TP:7O0/A%P`!_0C@3`
MG7_0#02`+'70!5OP$7BQ!Z0A`'4PM=2S<A6P`8!"5;^"`2?@`A60_P!D90E]
MV7(5UP%L56TWV`/P$P,DP`/BB@(SH`(DP$$ID`(Q4`(GD)K16@Q`('!$D"BO
MV9A'Z`B/JVY2@`;`,:!=,`$NH)@[@`,;W)C@9@.5,"DN<`(/@)Q@PBF8T@68
M9`4)M0??<`VX<`@2T(&JU0$H(`0<$)$"L`2`:`%;8[D^$BLR%P:\UV$D2B"K
M()-C`,9`)@7B-3VHL8_U1F&Z@32'X09AP&Q5P`51H!G;=7-L,%%:H,2YL&HM
MT`6?8`!YP`"@D`=N83.I])!^D!E$.GA8`!!U<#E=<TQ@A@:WUA)4:Q1D8'E5
M@+)(1VL]>2!GD!!90`=)F0H*A$S>Y37(1/\5>U<PW]@Q8/#):8L')[`#"B@5
M4"%Y![`+'U"L>9F`D\(!#<BJ^BL&,!(%_Z*/V=AH\)%&!UL'W>(2F!1'?3``
MI<MN`I6ZXJM2M3.G[;1FSJ&G*$D[MPM/RG%GYH$KB>,!12`!&X`%,LL%?[`8
MMR8&4&$0Y04'IU!]3<`&7/L&:Z#*_/4&BP0&;#`@_-$?(="4)E4A`XB[?!8X
M/L`&3D(`CRL'"?"7>A`&?Z!5>]`'M83$1:*-Q(EQ#A$.<E`9$[`!TO`-5"()
M)D"7%7"'DO`"%/`!E))8^C,)^F-6E*F#-`@\-C`#(R*X/:('#S!3.5`#)RP$
M*$P$1X"M(SP#TTK_KIE5!4W@`7GR`?`3/QK$05UH<)+P`_D*5AQ0K#2]!W`A
M7,SF:W5!8PU0`A306F,U`C%0`R,PO1]0`$PP+?I[#3RDCU54/:\JD[2&!F_`
M2E\P&VK0QF;T$FKQ/%90%3]U!F[P(B&677R0+U_@7Z-(DWV`!GE@!V.0,+E0
M`BN``W5P`8'C=<>1DW:@!:_J=&U@!U])%6@D,E-0QR"F&PYE73UI!L6MC7_'
M8C>&!1J!KL:C0&#T!0>SO`1&!D@S@:!D!7Q[LO'1$7,@`NNB,LB$!A%@A!BP
M93%Q(X*5`15$`S1P`B]@`O.=EQUPWQM`5?"0%U\IL+$`!P/0!EO@!W5`_U69
M`1A!U0='!V-T\#9])=O086=\YF:K2^'.]V;R5!T4KLZ*`WT7B4^OR[U]U@04
MT`&`FB-'"H_XH07>I07R10=Y4`9'V09C4'9VD-H$XGYYT`8'UJ.';!SXX'\`
M2"%!$)4:TAT*H-!5$U8(:P$E8$-_P`</X#][QW:D=<N6Q]()8`YXL!`-D+@F
M@@F*,!$T0`$R_0(^5\`L0`,M"`PG($P4X`)>T@+@U@(4P$3E5P<;,`0[<`>'
MX5L`IF42@`(!<`PUP`,P@`1+4`,J<"@"!P,J@`+3ZG,*&)%@$`%E)0,MH)HU
MT,'A-M]FI3]GZ#O*5BQ&MEEG(`6F-=ED%`$?P/\I,2W%-=`!<G("#L`$,6`!
MZK`IRK:/#B<`J=Y&1D$75_`59:#J74,73=44`TL%<<0'1N$UD'<69-`8F/1%
M=1<?E3M>`[`&/S4V%"`$!4`#;,`A%Q!?(=`$5*`%>?`%+=L6]5N+:8`Q!Z8%
M,JY`Q_T%)U.U9E#=(5:X[G&D:RL`72`Z6A"7W42SH5UO9O?);X%H]^$19)`&
ML09Y=I#16O!EP?L&%!`#)H!$R53@&;`!>"D))1#?,SB&Q/P!/O9DX7A?Q10'
M?3`^;4`%E?$`]-$%)`9\8_`9:J`'<+`=;4,>V>>Z&4)/BF.[1:[.LA-/UB&^
M=9/A;")0S9<<=?I\S3'_DB-0`B9Z>-CR15Q#!<L3=V;W!FF;"FN0!FA@!PP`
M0`/@?K:G8##.`&[C`9X&@!,".ZZC4GIF$VO@[CV#`>!@`1R`\V&0`.VAZN'E
M[#CW$=`D@BS$&\'$)7!UT]76"RYP6)$PUN,V5YL)<>GS`CL@Z2C0`QP@".='
M$'+P.U7`!@3P`AS01@&Q!R.0`I#UFA]$!$#0A2M@P1U$#%T8`SC``A&PDW@`
M#/9S`Y*9`T#8`B_0`>_SEYL)-$##+_I;+OQ\!4G!&RLH*2SWL"H0`3[``",`
M`0N0`Q2P<(;H#M-TRK(2ED62%LO^%UF0-6=P!>-7X.`3CE\&"'QA8F)_?E-<
M_UM355M<B51Z`F%>>P1Q6`,B`VE69U9X.`4D9P8>"DUV&@8#?%1;6E195'BT
M?65;65E@:VUS:7U76FUF?FY>6,A<8V-;551>9W]Z!W?54F\#66=Q>']:66)N
M87QE8'Y_5GQ2D6&X?&1^5'Q6;PQF65M1P709-`)^6[#X\2)@`H4/'4Z46&C"
MA$(6+DZ,Z$!QPP,"=[SP$1A.3A<R><K42=`@01@L?,Z<X6.&S9@H?_@P\.#!
M@`(/"#PHR8E3R4X$3GP"]0G`IY*@1HL:13#4"5(G3',"1?J39D^H2CP,V&#"
MS9\S=\1($5,GCI@P7]!4@</+)1@SV.:@Z37&SH`V#/\&9'IC1X0&O44N>'`"
M(`B4PX>3)$$,H+'0$`;H5.'S)P(%"W'N<"@Q0<X=/E7DZ#DSA8^;.E*F].ER
M1\"!!@TP1A*0H$*&&"HJ''!=P08.#'H(O,BAXD:+#P+V2)!#Q@H%%$>6P'!1
M\L.#M7P>2)B`0<H``22$</!C94*%""60'`%2@\AZ$BI(I$"!PT8*&/!5J$"!
MXD:<(F1,X-`)+."``PLGG/!#"PB:0($$$32@W0,E/3"!!'A<X8475EAQQP%[
M"&`!!S^,8,$())!P0!%FL+!``#]$0``!`@B@QQUUX+%''%V(X84:>+AQ!1=@
M]!$&'G'P\047671"BQQ[)"#_@#=^J"&&%93L(1879HRA11]2])$%%U&(]M6-
M?<#!0!YK5"%&<!C`)X`!%QC0A`$BT($&%UATT4444FCAQS0-N,&%%E%0X0<7
M:&3111A]*#E&'W[D(D4<;D3!!15=^`$301>EYHH9?(X!ABQ_2)%.%9I^Z0<?
M7GC%!Q=&SOH%%ENLR2J9+,VQQP%\9($%3'581M$("I7PP@@CE,`""S^48`('
M'2Q;00)XB$%%%8C^<8<;9OB`A@`2-"#)/''L(0<?8(PA[!N!U7D!`D9!A1-3
M4#E%5;U2*>&8OT5!!51400D\%<`"TT3O3D%IA<$)>%"!91]:O%E'%U5\H04?
M(JQI_\<:6WQ!!P-PI&%R&72`_!<=&N0Q0!%%L,F`#SY<X(1AB"&F&!1%-=88
M`A=H0$855A0T`8T/[-#"`6(,%&0<4E`1(H]7@!D';1(\8*,8:*0AF@I+3``'
M%R&RD,,$;X2!(A$H[)!`%'OT0$$9:4A@!`@%H""`%A/,X,(!9F@@0`\W<-!`
M&F>HL,`2%'SQ!PL<O/#$$D<8040`1.200PTP](=##BCD$(-\,Z!@0P5KB"`'
M!R[04,(-/9Q`004FU'<"!A-$^$`&&%0P`6P92$#`'G60Y89R4DK0P40CV`!#
M!@QD$8,#1E20ZAEJB*9''7?LZ,<W6DA1Q\6Y_/%''U^DH?]%&%<X@T=R`A!P
MAA971,!!`HO0IH<:?F#QB$I2((\5IH`%*7C!#V"PPQN^4(6K/:!V-DA`$YR@
M@"(HX`(7F(.?4J(&/O!A#&2@@FBN\(4O1,%/E5*#`.0P!3]4@0Q;,$,9L.`%
M/<BA?U3XPQ;84(99U(A+41`$%N#`!CB`X0]BF,(78-@',^@)"U?XPQ?6P(<H
M6(%]9"##%."@@`%$;4EEL$,;K"`%1<Q##03``+,ZP($!O<`A)?A!M&@P@LB5
M0'8-V(,:J!"%D$U!#F>`@P'8$(<&'"`.?_"":/:P(RGP`1%YH),!BJ`3G]5K
M,$?!5\">$A5_$>5?1[%73WYRE*7_1(4F2!F*!YHP@A:<00I9J((?^G`&0%*!
M"ZW(@LLTD*<TK`$.<RCB&[!!!U/!02]S:$,:&"""-7`!#@L<P`4*$P2<)48Q
M1`G"SRZ@@#Q400IN2,`$QGF`#[3@!`?`PVBL\*J!$*(+5D`')<19`0D<0`V\
M)``'.$<`$6A!`A#B@``&4`<:I``)*?A!'Z:P@P"00`)_B`,-8"`$%C0'!0[(
MVP'F0(<2/$$%/[""'E"`A`"@8`]K<`$*5&"$)1"A/0%80@I(P)Z9HJ`%.P!=
M"H#`@QR<LPX,V$('>@"1'>R@!!_`0`=<P((.F*>>V\$`[K)&@`-$0&NS(0"$
M+$2!$K0`_P4DH,``_L"#!>!@#V8@0Q3`5(<0$:`D5F@#&J*0!<J<9@]ZB(,:
MHC`',$B`!ACXPQ@@,:,]<.L!+9"!`.;PA0=0(`)X4(,7_O`H=DJA"U6+@C-<
MP88T?#,,`K"?#4@P`C``Q0"E`-H<$G4%.;@A4F3JPA2T8+(H6"D*2]S"U:R@
MBS*0`0ROJ.L2M;",-<R!&&(X0QB(RZ2+?0$,7XH"%JQPRV&T`0YSO4(4R("%
MR*9J$528`@-"X`,PC<$,:8!#&:C+!5F*+P((X<`'VIB@A=AW(2^@%@TB\B!)
MO`H?)^0#-MI0A1])(0PA:IH4)!N&,$QA``J`C`\6EA3'.&8HF?]$@&."HA2B
ME)+#0L&73QHV,*GH*\0#*\()=J"&.-#5"W600QAFR0T=,M,'+<L#'=(P!C3,
M02\#*,,7WM"&`>1%QPRP`Q?6,`"7E&'"U,R98I*P$W]ITPDTZ>86^I"C`^".
M`!M@`04(<`4L`..=:JB#,2A[-0)$H`(8R,`>&&```=P`H0<0`1L2D('8J*$/
M!W@!"0*0`@J\X0HU``$22D"[`NF@`AK0`Q)```$8=*`/39C`$P*@`CD<@*9+
MJ,$$R,""`+QH"4)HSQ&.`(,4U$`%]_'I$/83@QG`H#@WZ(`?Z-"`$M`@(2>@
M@>PH0($-5(`#)^"`\!HP@>`EX`"OD8#_LQ-`(W&.<P0[0,$0"*`!,:1@`2>X
M@AF^F<@[S.@U#3C#`*I0@0\8]DMGP,/%H@`''W0!!T)P`1]\,(9I8"0+;EAQ
M!_[0A#F\``4G$`"F6D,`/5R!#U>P$@K+P)8I=`BT&!@"#%H0!@5D99+S:@(9
M^F`(*DRBC-"-`@BG$(8X^,$,,->&&K*PAC&X\`Q[\,(]L$`&C<G#454P4A3*
ML`8P1&&R?5BH%F39!]ZN@0UK*,,4U/"'*<`P#E[0`AK*D(7M^L`#/I@'&=#P
M!C9E00M:'(@`CCT1#B#[OBYP@7WK&_<3F&`#`NA"I'#5"BRD@0UM*`,7K%`)
M`=3!"FEHPZ'T_V&%<(6@3CBA2H<!AC`,DW+R!0.*)8?"E!&76&!&V8G"LN(#
M%PSA#TRZ`A6D$#\W2"&B/!)!$9I`,CO8`0UO&1D#UH"%,N3E#73HF)'GX'N_
MK(F2A<G9-8.0S2LC(`1=],.ZNL"="-1F!!,X0Y/"P+TPR$'>B#Q2_![0;@H<
M@(MW^'8*&J`!!A#DJ@=(@`0X0(("S"`!=$@<$8A@`V(;9`<=,``$(`1$8`1"
MT`-[X`,14``@4`-JT``U0%,S8`%A$`,@``(9101"8(`&R%,QH#E&E0,DT!^C
M,P.^<0,18`9NL`$=4`'M=@(N\"#CM`'[Q0$1H!P<8`$7X684LAWV-/\C"1`!
M;\8"*,`"8=`$?$`"(+`#;)!_>10K!"`E`O``>T`'"A`!1Y`"&,`%`_`E7>`%
M5"!(&O``-;`$)5`&(3``<O``]]0'>U!L!%`&"E`&*+``0R``7M!R;65X?4`%
MV>,)93``=C!N?.`'9S`!/2`$*S`G.Z$`/M`$(1`"<+`%W,5:4A`%4P!"E`(K
M>'`'?\!S46=Q?*`%6+`(<6`)I/)=?N@&8C!S?"`&FA40?0`&8(`E?-`U**$J
ME*@%5G`%K^)(65!F:X`&4&0%7_!U!@`&[Y`&/]8H:=%"8@!F(V`":Z00<A=W
M<K<0+O`#,@`1"\$!!*!W4]`(FO4%=&,&6$#_-)6@!U8P1#L&!B:G$6]@$P9`
M89Y$83X#`/ER8?3R+Y,7>IX4,/V889_4&*+4CPA@`*R3!6RP/E?`>K&!&GYP
M!6Z0!QI0!/909';`!F7W%V1`6Q?Y!FOP%\`W`'-PD4UP)PJ@><H'!5-63=JD
M34?A`2'0!%-0!U5`-A/P`A6@!Q,P`A60+6'@!G%P!MR#(]"0(_('9Q3P`&A0
M9Y,&`PW@`V]0(P<`9Q60$/6'`H!S!B7@`BFP`A(0/A,P!#'P!7@0`S%@`SR`
M`P+P!B=P@4#0!PG`-CI0`B21`@X``DRP.`7(.03(`_3!(#BP4BB@EOR!`SN`
M`R;`/@20._/G:TWY_V84,!$5D$<5,`)7%86Y\VP2$G\6$#P-L`$MT`)UH`!;
ML`),@`)A(`)W$&P$$#[:82,"P`>3=`),(`04P`9-\`54$`Y7(`(A8`8EH(@8
MT`;DY06YXWJB<7@OXP9```$WD'>18D5R4`>^.)128`9ZX1)?T"1[4`(P``,<
MH`%,<0%-H`$1I@'<,@<A%`924`6R-`59``QDQ"->T`5:1P=M,`5_,&-<P$"*
M@@MQH`=ADDBJEP6JX0=A8`5K-0=P,%UEU@9KT"3M^`5]\&>!1P57T"%<4`95
MX'WS4P1.$`)O,`5@P(QP\"5;@`:JH097:0)O9`++DRS8*&QQQ`*)E8T<</\`
M7M`'W((+7S`&Z?4%$><%5_`MFA*@M"('/")@,-,$E'=A^L))_:B/F@=*A>%A
M3@$P/1-Z^^BE`-!)FJ<$"I"5)71";B`'V8-764<_S+B193`'#-!^`Z`!/J`)
M:^!$FI`'##`'2S8`P&<'#%`$(M`$\Q)E4W9-AU%-%V8*>8!V:>`'>_`"):`U
M'?`#$[`'2,)]=1`)^W,'G:A5&9`!OV,&(C`!#$@$$M`$%6@#\/1`)#`$@S8#
M%5`D)C`!.[`"%&`&!/!5,8`/)4`"!%("=V`%-G"!,(`%`B`=)J"#%&`#3\`$
M&74$&J@",9`"1F!30_!5OC&"Q#$#-^!5)4``Z2C_!G@@(,GV`;^C'>-4+O&S
M&[#1`+[S.ZYA`=PA$1@0.6%`4"3@`"AP'53``2K@EAI@!AC@`A*@!UT@37!0
M`B:5`.J)!G<0&U=0"E:@`P&@`Z-6)UVP`11@H$`B!ES@`P-@`>/Y`@)`&EQP
M#AR2"SV2*X+8D'45!@\P:Q@`!Q[`34T@>PK``&J0*5A`!1*3=%XP!5,018A0
MBF_`!KC`"&A`!E5T!1@#!EL'<'KP6@(Q)@B$!J82++3R6\]EE'YP"TM&!V\@
M*)K"!D,C!6?0!?[3!2M!!Q>0%0,0!6C'D5&P*$-#!6=0$-/8$!Q``6\W=P_Q
M+*WS`LG6`$U3!;@2H&$T_P!<`'M%(P"1`I^P`$]*(@(*@%J:Q(].$16=MTE)
MP3#Y:)!7RC"E9$F>EZ4^<TH*4`([$'3Y^9^X507_*0]4D`9=TP9L8`?\:1<#
M0`=]\:<_AK9ST%=@P%%HP"XMHPHV8TT[XY(OV1@R29,*H`$*-#0-L+@/,`(_
MT%]U,#R5@!'<$QP1H(/F\@8^<`")=@03X`,$L&D)8`=4<`(I@`-@PP,L$`5T
ML#NVD0!]@`&CHP("(`)Z4`,^10$UT@,%4``LT)`X0`1RLQL?``,9)5.ETP+9
MJ@*C50/BZAN?0P(KH`(Y8`.(BP%BX%M2X&7G,0%L"&TED1RCT05R\%83(B/!
M`?]0%``1/\`!85`$%E``3)`#;],'!$`!'?``?*``41`#`=`""6";"B`%.(`$
M+8`'@6$'!-`!&!`'I>`',;`$+1"'"J``?-`!+1`!/1('53`R]UL#-A`!#$M<
ML&(%C(`%AE!D=,`&D]M:$4`@$9`'":D!3="Y35`$:8"'K_`69#!#;J`(>H`'
MN!)>9$"A&%IF9:`%4T"T6S`&?+(%450%8'`KEPQX9K`%$YD.M#0DO,LK5;`&
M=L!1:Y#)71</:@`I?`!/92"<.\&>6#`&OYO*P^4'8A!:'[!&Q48!)L!4S_(#
M3,4@B5M'&'``70`:6@`&9#`&8>1-?Q!%#89#Z(`%8"#_9`24!]Q4CQRF%)NW
M,%2!%5ZZNJ7D21P&>E<ZIH1A+S?3,V/*%)!Q`BV`*(K"=Z_W!]LR$'20!QOY
M!M"T!FE0!FCP='KQ!FE@9$?V!F7P!MJ+#PJM`>WG<2U)O8K!?$K@J$QA"D4P
M`&H1!AD0@T%X`CWP`@>@!Q(R/#:2([1!(;LA!B^#!PUE!!F@`1,``0L0P?+;
M`CA``D0``SF@!SY@!@>@-0)P!QB``@&`!";`!@,@`=$B`3C2`3!`!!V`!@-P
M!Q20`0U'`#]0`S%U!"1P`W+D:BB@`R10`RMP`S<0`W,-'S9@`VNY`P@B`4.'
M8`GP`&SH&L,S(S5BH%5P!7A0_]A2"-D1,`$?X`([P`%2P``)$``@D`($$$1=
M$")W$`5O<`$-L`!,8`,'P`6G`!Y(<`)Z()P,\``WP`("\'5@<`(K\`)WD`8V
M804ML`(<\$I_D`9"(P%)_0+%XPK<14;R(%UKD`=S8`=C@'-@AM060`=,,0"1
M9`IX4@9J``9P<,G2+1=2D`9?(`=RH`Q(.RMC`'%N@'@5&LP\MP7L$J!=8P9M
MD$4,T`9Z?`?C,`]_<G9T\`5G05NFPD.\*`=-LP5;(`57X'U",@8,H`!0T03N
MLF0*=%[.5&`",)K4,KA*++LWH#2E>>*M(Q&7L0>7."9C5\X?HP9G0')AP`5L
M8*3?0_\&<*!>Z;@&]$@8K.NH6!I*IG1B^?@37=JEH+3.52:0]TAA6*8`&U`"
ML;`D8P<.68M;4]"P=9H')D,'`P`'Z:-`9I#?;6#(?RI7]=9+%9T';<"^(5#2
MUG1-BU%*CKH3&&0`;T!=>\`!(T`!S\8",B!G!)`!!^`&W7,C41(;->(%=I`'
M!'`"0B`$&Z`!%("!,!`'0=,`8",=*M`XBFR4E+4'/Q``!1`#"=`&>7#,<B`%
M>V!0*6#;08?HRL$"0'`$DRX$*H`@-P`#@#F>*F"6\J$"*Q`#BZF6QH$@>[`%
MW/<K5(@'-'(\M'&#\3EU544`#S#9?38B+6`#)V`%=+#9(##_`Q`%X52K7%N@
M%RR`-R<02"%0!`>0`D=@`GHP$R*0`2E`[L+)!AE@`R,@!_.H`'N0`D10`FZ0
M!5]@DG%P`D78``:M65J0#S\"AFN0%UW#!],0K3S0`E&@$Q[@%X*1O=1]B;3X
M7&1@!F`P!1CM(VE10(@0!83005''6V9P!93X%J0R6W.AH!]3-`?0!VDP76:P
M!N9%$'4@#V24CN?@!E0`0D'GMS<2WT_)%`HP!]R"!FS0)70Z0^M0&VZ'$";@
M5?5A'"=>FMEH`AB0`*_%+>7<<TQF!FQ*5\^T!E5BC(_,)/Y#!CZ`6B7]I7V?
M85,1%)V724#^,Y:G>7=^%*S+NJ4T__@&&0(),`)U,";^TRXPCWJJ?`5A/@`^
M0*%VP0`LXP-Y$-%TT%<CPY%HX$1Y`0<R%&1D4*<W4=(M.65C*N?:]'P[.P#0
M104"T$86H`</L!`20"X'T%8A4B,TH@?34`=LP`8"L`$D@-6"0P004``?,``A
M@`8M4`"$E@,[4`%78!=I$$)RT.^OQ@(5L"-#20`EL`*">5/(T@(W4)A`0`3L
MP3DWX`(W`%9U#0A+2#`Y."@D*C$Q-RT]+2<=(R8C#5%?87@"!`)[>FI7<0(-
M"7)2IFYX<@0G)Q4)!!4[*S$"41T0!3($8EY=5V%R`E<#/@]`$"D)7`,A!@0D
M0!UQ#"%%&_]'1!0B'F\2-R9Z;P8*$@$!+&YE`R)2%"TM"5=]55%25E%]8G%7
M7'`,>5FZJ!$P80<,6@J"**DFXH*'(EBZ>,%S0(Z6@%WXX!OC1T\8+%C"[-G2
M!HN5C&;`B+EC1<N?/EO*C`$C18X5+GR\^$&#1LZ$!EG@<.&RQN6\,P(.$#AS
M18P:*<#\K$G3YPR5*7RD_#ESADL3#P@\-"&CA8P9,FM$-$D#AH^<`Q,V4.!P
MHL2/1C<8L?C!0H:,'R4@91#0)8H6+6#*<"$Y`(T?*V#HL$%#)947+W&Z_,D(
MAHR((CZ<``#@I+22T6$].#FM!(%KT4I,KXZ-0(EMUJM'`XA]6K?_;]*U=Z_.
MC>""&@MRHF"6XF=*%2Q<L/Q1XV4`@R(&&`RP,X?.&PT&FF@8,&`.&_+^Z,S1
MP`!.FC9PUMC1,+Y)"`0`@D#9#R6)?_]*!"&@@$IX<($"/@R0!A]X/$`!!1$(
M\,`()VP0X1X"X)%`!1+L$89`!.#QA@A:W+&#$2ZLD<<$*A#!PAY9D"%`"R3$
ML$,/.YP0X0$18'#"#C',H$(A+;A`0PFRP$#"##SP0,(A,`A!Q!$ID`"#$37D
M<(,.A=R``@^S[-#"#2R\T,$'%'(@@0!ZZ+$'`0_HH853:A`0P0%U6#'%0`+$
M$8=3>N`1QA4"<$#!*Q&8D,,/;@B``P0.__S0Q19945&3``)HX4,;."P`@PE=
ME#&'`@:(,00,)^PQQP5-8"!(!P-<0$8&+70@`!@^6%-``#^<04<3>1P@9@)9
MF)&%%W>(P4<??_SAQQAPT)%'&EWH(8`$+*BPPQX&[.:!`6HA$`(8<B1PIP!^
MF.&2'%=LD44?>.R!A1;,_D&&>^ZFP484?_J!Q18`3Q&&%5Z<,0464M1QAA91
M[-&``'UP408<(?'Q1:,$*$4%%S75L4<=9.1!AA0Z5;$%&&!@D449V]CF@0]E
M9#'&&W9@]P8:6URA!X\5=%"7"S_(L,,.+`16@@M&FM#!!@WDF<5A9:2!115?
MD.$N/7Q8@90`@_\2,`$!F?$QQ@`**-`$?L#EUIIKM^EVFQ.NQ1WW:+:EW79O
MN_W66FYTSQ;6'PE<IHD;:H3!1T28GM$'`]<9X(,/X[%11AL#:."#>&RD`8<=
MQ&PWQQSD_8.%'>+988`'JNG'WW_^\1=$?D$X<4$1(O@`QQ1=B-$`!1A$V$`)
M-U#`)B=V1G!'[GH04,<7<-`T@0O@]'%'!32<8.@$%G#0`@Z,M##T]S?$@`*3
M0,"P`@F('"($ED"4G\(**0A1`PH]]("#"E&2T,((''10/09QZ8":W$"%.E&@
M`G+H@Q2TL(8K6.`1>!`#%:B@APCLX@]A4`.&SG"','@!0W+0H%($$('_$[1`
M`EE00PY`4(`2B&$,4_/#=)(2AG\T0`5(L$$$O$"%*FA``5$8`A%*0(`U*(`!
M)2@`$3B0!@7`X0%%FL`4BC``$RQ@"260@@@4@(8(N``#?%@#'*10`01RH1Y8
M:,/GVD`&"NYL!(L0@`'"<B`?,.`"%UB#'A[P@#U8@0QEV(+*4-$',O@A%3B)
M`AA24@8T5,$+6Q@#%;K@A^<`<@Q5$(,>SF`%K5!!#&?(PA]"V(4^9"$-`]A"
M%=[0AC]<1@UNT$))ZN`G,50-"UBY0A=*"<@TO"$/'EA;"!@`AIFQ@0%-&``<
MR!"%:B5@`G0I@319\`X7G&`2(^B``#<0)R\<_VY>:&!#%OB0A:EQ@0Q\H(XF
M]7`%/]3A``)00Q<&U@:'7*`VMBG-:EXS&[S=)C9P2XUKW"8<VO23;K\IC6_6
M=AJX'4`:(L$#%:P0!BF<X0`'D"@6M&,Y$7B4<0-@@QG>@$P1M,$,8K3.'-*`
MAC<0@XK%'$`1\O"5V@QH/ZQC'11.`X78*>`S#$"#%J9PAP?T;$T3:`$+-K`)
M3&5L#V]J`#SE@`HW-6`#&["`4B8P@A*PX`8X^`M8\X(#\:$O!S9`00I@H*3Q
MG8\$:\U!-;-9`AR9($(1J``%7F"#%EA@("9HP02B,`42CL0*&-H`#DI`!7))
MA`,W(`(/*B`%,%3!"O]R*(45:(FA.^"A<'L880(ZD0`.T(``;`A##AP0@!8(
MH`KT$.49/":'-6A@#S,X`@E&0``Y?(@,!B@#"X1`@P.LH0E<0($#4D`!/SQ.
M#=)\`!=\P(<?4*D"FC(`%PB0`#<L<@T$0$$+")`%?ZD(#F;X@A3VD(`&T$`%
M.HB`"&37!`.$IPD*8,/."*"&*LSL"U9HCA<\@84U!*2\!7X#%[0`8);T00U_
MH$(4_E6&,FB!#V?X`SZHEC`K$-!8?O##TZSPA3RTX3!5X,,4UL`&+4@!EWW0
M@B6_<(541($M9J`#,YR`.@0HP`YFT8(9+#>`-E@V#->BP`A>P`H7L(`%+GC_
M@:$V4,:?[$$,\U`9&-K`!H1-V`\6"T@4J,"5+F`A97X@K"G2X!`%(,`T^8Q;
M/_T)M[?)^32ORZ=MY,PWUK"-;Z\+"]I(TX$8U"$+5F@)'YJEH3I@2@S:R0,#
M-)`'-M3,`(U!`^@&0`=I;8<.BD%EY2#7AANO)5;!R<_J<IH$**Q&/TE0@@&*
MT`01J$L*>)``)![@-2=3X`$).$`"'B#L"!`;H\-^&`$D0($-2""`-/CJ(G8P
MA+*JX$DHR($C;)`(&9R@JS9(0?ER4((,2'4/&J0`#1H`RCA800QRP,,$'C"I
M/>!@!AG8PA^P%P4X3"`'.U!!`&`P`0&\P@38"``0_T[@A?2.@0M6N,(GXW`'
M/<C!8Y@:=@0DT(`'8``#>R##,PHP@PXT`&Q>,$4JW!"&+RB`"SM8P!%*(``Q
M`*/FC'N`#"J@!QT+@`<+0$$%Z@`&$:"A`3M$PQ<>@`,2N$``_4C#0/0@AEUV
M`0,UN`$!^%`%,:YA#$.M`[-+D((:=&`-K1%/$R[0C`%8`9Y]6`,:II"%*5!!
M'E3(H!26^0<L?&$+7[@9&*9P&1D2D`J'0\P6"!OB+'1F#'_PB"WG$!`QP/L.
M?###&`+F!RW`H0P6^SIB5#8&=>DA'7/7PGE.]QJQS,%86J"#X^S`QDQ>:P-H
M,D%=`F,H#DF5`!Z1,$@*//\'-!PK#'V0H8BSL(4I)/_%;P"UNR9L!SS.L6Z[
M6=N;L4\WVMPF;GCKF]]>PWT`B*O'K$$-6-SV@Q2H8?.$W0S)E/5,`8C@#6E@
M@`]:;(8\E"<-I:<YZ^!1&C`'9(`%8T.`"H(%J%0%:>`#"@`63J`Z_:%3K:90
M09`$0?`MI#(`:[`G!Z!7'_`U$E`",L`!%1`!$3`!K[`);T(`&:,4/#(!-%A&
M2G9-<[$#3Q(#.0!7*&`"UY(#*L`!!X`A&&`#0A``-=`K/D&#$C`"*(`"H_4"
M,A`H$?`*=Z`&:M``,<`#'!`'#]`#/Y!`'/`^1!``0A`#+=``>]`"$+``1!`#
M+T#_`%&`4I)$.%[@07G8*`>0/!.0`1*P`1S``;5%`0$``57H!4FQ!W$P6QER
M!GX`!R'0!2@@!"6@!_[2!QE@`@1`!CY`!IY0!0SP!1Q``D2``PG@$?DW!G@G
M`"=@/AL@`'^`6'J%`1*@<10@`QL@!HOT>5$0!8AV`"^P`SKP@UH0`@`0`K7F
M9AY@!V40!7)P!UC@'3(&!B[!!55P!@-#!7'@!EG0!HL'!WF`!@_V8H0U!E\`
M6ZHT41X6!E,0!6$0!IO1!XND!5?@!F[P$E=@,5J`@"YV!>EH9M"Q>5QP!5<0
M-7'@1WT0!>1T'@H@&G14!&]`!F"P!MBA`:Q$!J*T!WDU_Q?]PP$?T&PL*`!W
M$`=A('SSP@5V0`>4H@:"H@7-MP7IM047405^L`5I,"><8`5H<#K!A%`&I4^]
MT39YLQN"%GYUPQO_-)1[ACKWD4^H$0*JL6<L0`)G`(S,X@7R,`61]`=N(`4,
M8`=K`!]@EP9S4`;G`8YH4#D,(`(>^`8I809SD"L:0`=F()=T,`5C4P1@D3H"
MTA\5^!]KHVH`<"".,P`TIAEZ,`$4L"8'P`%E,F\6\``GAR%-10`-@'3&]FQZ
M10$-0!UWL`I*0@,5<`(I@`,G-P1+L`/78@(5\`))6`"6:`8#\`<-P`)<H@(W
MH`<24`,+P)JNB`."10`F4`,U,/\"`C`"Z-,!8E!"7(4#.A`#J.@&);`$`8`"
M0,,!9V`>7]`'>5@M6?B">U`N'T<]'=`%6F`"!0`"-[!B5H`I>A`'L(0AF#@`
M!O`'*%@',<$%$T`".M``4Z`!(O",4V`%!#`"UW8">.`&<D`%%-D%=T`0,0`$
M.\!K&2(A$R`!?:@)PJ8&9:`>"S(HF40!0K@#$L!F<',!X^`!`-",I<<%SL(%
M8,`%:9`';S!.&.0%;O`*5Q`%V!@%%29C6!`%S?$%`$A1Q?(%?M`'8>`G?\('
M)Y,&:^!.OC`%7X!+55"@5!!.?X=H5V`R8`!X-TI)XW0'&64%=W=.S+!GR@@'
M;$`&7V#_GT7@'6U0!M*Q!P\P`664`328H0^C,%UP#_/"?"Y5!E[))CK1!^_(
M'(.R>%=P!I04!\\F!SU)*D,94$/)-L*1?6C3&NLW&GG64*FF&SRV?;0!%MSG
M!"'PE#QV`CJ@!B(6!;]@D\A'=U80!P,P+=%AI3JV!BJ2!V.C`5*#!MPQD6/0
M!G;`.6))!FHT%9L#'O:%`!2X:OZA$+VQ'PM1-@9@!T.!!F1P!A*0@MSU`=!C
M`4C'<=R5`.K:7I2IKDB7/12P!W3@`W[@13;"`1W7`VIB`Q```1]`!2R@6S%0
M`]9Y!#D0`7Q0!EV@`@OP!"E@`G^P`4A`<IBR`A"`!"<P`3AP_P0PT`%ZP`$H
M0`0I(`#K=0>AB0'O(`!><`)$(`0],`)/U@!;P`9*VJ0#05KSI@=FRI@C0`%W
M0`4GL``!0',$T`$3H`9UT"99&`=M,@4BH`%1@`>^4$E>X`(!P`,/(!5GZ0=A
M4%HT@`(FZ@G64I)VD@$<$%8-<`9J<`=0A0=9F$&$HV%KZ8Q:TXUU$`$W``-#
MT`!VT)<J&H&O8P!C4"QE0`594`4&66!F0`5NX`5<,`;5<@5M@8W[V'Q7P0=<
M!P;&UZ1=@'A/4P59$`5Z\@5UQQ%N(`93T!PS`790X2]?\+J39`5\H'A:P`5^
M<!GVX@>;8))7H`7'Z@/!Y`1.1`9ID/\&:.D#X,)I;[`&'!,*&`6#FL`F)LD<
M57`8Y90&(D`'%+0)OM6(4G`%LR@&?S`%).,FWXLI5S`&]24"@\90='-G<+:4
MIK%0^R2!HA%H/:9/`35G/,9VJ^$!U,,'S<$'`M$')R$%<>`%?3`,DE,&*',>
ME<,=N=H$/J`%<>`'>5"`,H&L:&`&;"!W\;&7&L`&;3`B%W"_.!68U;H?-Y4:
MRC@M*+4%<1`!<_$3'5`"(]"G$=``$F`!3IB9KZ`4F/D@";`%35`&&'`#-$`!
M)L`!&W(`)^``+"0!41`#:(@".@`$2_`$1\`#)=`%8*`##N``2S0%$D`_([`'
M%1``(+`$)^#_#4"0`M(P`3<PL27P62$B/2-``U+[`C"0`OOC54"H+@^6(7*0
M/!&0`1;$77F%`7W"`A"P!!7P!E>@`T30`?Q"GV>@#W+`!VU0!0GY)J^0`">P
M`C;0`(&J%6Y``!MP`DZ&`=S+7B?7`!;0F70H2%+@!G5PDN3KME[`@'-@!XM;
M!U0E`!O@`HO`MR&`1P>"7P'B`0/@!U<ANH#'N#WJ![G3!_K"!UQ@+#=1!90$
M=E<@!5!:3!P1!G506@]@&&"P.6:P8%[Y06)@-2<Q!6CP=7[P8A-$OLWR!SVJ
M,@^VR^!+DUX`;V&0!5\0IFAP-@B@`=5;!F_@I@.POKDZ`!-)*?,4_X\V%ZC"
MMP6+<1AK*0)CT"A]LA5XH(W.0@5I)KI>H`9B(`59,!18\4.G,QO9]S9P`Q9R
MUC>7>JFED;]\(S=R]AK\%!NK^F8>(`$<$!VBI`=U(`8]R@=WX(V:9@9MP!ZY
MHAV7(P)M&1YP(&(\86FT5Z,131XCK`5Y8``:4'=K6001"`#\H<*MUCJ[(2#F
MIP"T4V1;<+LD-`(_0`D<(`,EP`$9JJ<84`$38&P;9T&!LB$`)`!LT`1J\#^#
M^`!7R`)2'``3\`<R<`,OP`(IL,6"<`0Q<`!<\`)&4`!',`);(``EL`%[<`<T
M$`!DS`%X8)HP0`-R0`$HL`0%\`2H^`><</\'&6`K87"$.L`"NF>"$U`%4C!F
MGU4M#R`!'&<N%;`!"1`&X;4`-4`!M'D'**@&6%`G`G`&WVLMT<ALB!T7S48!
M2P-/GH`4&W`T''`A(80',.@FFK"[7'?`4"&/9Z"S7<`%K&0&6W`9$U&"-_!T
MU<<JXV!?]Z2,=G`1!"-#6V!@1@:D95`%5."56G$'FUP%,O%P,!D3:V!ABT:<
M)%`"`W-FF&0%6=H4=^`'93#.4D"/I1=(G8$&7,`4WGF5?/`A8M"X=R<15Q"Z
M_M@%>9('93,`,L,&WL$&<"`"X<'5[$$':V`UL$6DH#LO"?VZKYM_(I`&_')Z
MLON]R=?2'E0%&JG_P%\`C%N`67VP109P'V\&JD899T1-E)KJ-OTTO]BG-G!3
M&F]VE'ZFTR'@#E[0!FN@!JGXO6>0<D8*I[[T.?3A?Y+V#\30!$$5-?X0:9L3
MT=YA1S+Z#V1`'J%S`0$2UZS6:K$!.PNA'47``#%#!1%:FIRHQBY0*WI*%R\`
M0!E0`8!X)YC)PQBPBYQ^`-8T;WK%`3$@Q4<P`7W0`4,@`S&P!`M0`$NPQ9,5
M!1^@`T9PR5NP!R7`B0_``BL`!"J``7HP`C>R`6<@`T]P1370`Q%`!7=+`=)4
M"PU`C'WU`R?``A00!?<LU9F5"3R<F>Z]%!20`@&`;P'JY#8G!@*0`1:`_XD8
M!KTA>$`:REU2Y51Z0$DZDU<6`#:\,%%=H(U+>@:I@'AWYUN;U8>6)P4F@P9M
MD`9;P"Q6H`8/8$(OH`<^X!H(4N<A0"I<S0`L60]B@T']0`<7!N7&I]*U>TM?
M,`9,JH55UP=C@#,$0P`E``,N`*D='F^H6Q7RV,UH>@9N@$M4@`5GH9&YLV`P
MCH[EY09Z\`=<P(UN8`6X!)-:<04K9I^CV%)P``=O,`<,,`ZD`CG:80<W@P8R
M46%FP!,I(:-LX%%D'N!W\`?5^RXA)@5=0,Y?8`98P!28M!4LQP5%<""J,5!Z
MPQI)R><_N91$21ISEA]&.7[D)[\>4`(J@`=ARO_R<G`&H55S:=8':&#X/,$Y
M:S!2W6'6XS@'_E<[VF$=C*,=;]`$1]P<IRX><R!&$;CJU,HZYG>_K:'614!%
M.",27N.9<5`'$U`"+4`#@\A['$!E992"EGT`#0`(%10-;!=M$Q@$>A85-P$.
M(#4/61TU,"E+`4N;`4`=?`0<*$8G4VXL,Q0'&"TG-!4"'!P6<6$Y3)$C$P]W
M>B<U2S`/90(Y,#`Z,B<E&%4:>7Z]>W5Q!!$3@@=Z'$<+,0)C8UE2?F18#S<I
M+0]J9WH'`GH$#1$-!&Y]5&YQ:KU>65_XN-N#)\R?+E?XY*-2A<R8*%W^?*DB
M)DP=,5X$/!`@)@J:-FO_S*!!4T7*E3L27K"@(*:($B4(#!11X`&!@C14J'`A
MHR6+EC)O^KB),L!,'RQOVH#Y$F[+EC4#UH`!@T5*&"]2IIAA4V:+E"X)=M0X
M<06A%SD$N[@+L\4,EC!6O)R)TL>/EC%;N/P1L.</GRA?OH`9@^6*FRM^SIP1
M\P<+EBA\^'S14F4-@R8,QJ2!8R>/G3EY1!BX<,&`#PT:!JBV0P=.4C9LUI0Q
MLR:TCS=\_NQ1U&=+F2_DHDC!Z*>/E#YGNE0I^\<*EC1-+M!$0!T``"4`@EA_
MB=WZ]>X`G"!P`I.\=_``$'BH21[\R_#4J;\43UY[B!$Q]/2)8L5*'SD"$""`
M_Q=>^,7``':\,8=J9GR11QYTJ,;`&E6$)D)J=K`V@`A%%"'"``QHT,9R8SR3
M!QMDT#&:!]E!X6(2,,:81!#B>9=>:09\.,<6;M0A@`092"``2BS8P(()'7#0
MP0D48(-!!1-8L$L"#4@0`14&&&"%``DD((``*H``@@,I$+!%!S#4P(,E0B`1
M0`!"=*#%'Q'8@$0+?EC10@`Z""#'"!)0\,$!#VS`SAX]%`"!#M-$0,`>)SP!
MP@(<F"%`"@4<$4,))IQ0`1]122&''M/HT4`&%%20P!X<U%#`#!%H@085>CRP
MQQAD8(`$$ZD<0-`><9Q5!ZEX_+$3'W*U<T456TQQA?\7==0AA10$7G$%%5%H
M`09E4_"AA6%_J%'''7M,PP<;><!1!A>"9=&%'A.4(`,%?30Q'@+2*7`!=2*(
M>D9"5;"[5194/,<'%6"0L84?6:"AUUQK?(%%&4I-4<48>1B@P1;\7?&`,1WX
M\<<54[RE"*E7I,'&<GT<C"VN6&0QQ1D!)B"'8^Q^P0476/@A1AU_=:&0%5&0
MP<8650R@@`(,.+1@'G/``<<`/N@KG8<,''@@@G1T/0<=H351Q!Q5=2%``P(4
M;897PLFAAA?(Z2'%'U3P$88?@7%11A&DU53==^]]9R-,[L7G'GKX7L#>>(4[
M(1YWZGF@A'874,#"&7C+#`;_M'?<T9]D"VX]@+IM'!AU&IV](9H(2;7!1AII
MT*&!#Q].10?L8(O$QAL;&L!B$"]"(6.,06`7Q/'%>U":#QY^8848`F3``09>
M9O!##T=R,$()3$XP008?=/#!!-IP><<`!FAQ0"M=N+$""$PL@((`7SQ@`@LQ
MS(`"#YD48,0':`A#!U80@!A$`0PN@(`#7/`'/52@!3%X01TB0($'-.`#*;@3
M7QI0AS`<(`>3:L$>'C"#`A!!!K)XP0:\@(:J4.L,(Q2$!?8@@!;`@`0[H$`"
MXE"%+.Q!527#0`V0(`,)W",??(A92<X0!BJ080U<,`ZU_K"?;O&A+'FZPA^P
M@H4Q_X"A"@B9@K/<(`8KN.%+>@C#%-HP@#FT@0M4\,+!!/"!&^"@`W_P'74\
MD*40("`('F@#0\"PA9Y0H1QM*&1A_I"%+(AA/U@`0Q34H`;`\*$*7Z2"&/#!
M!@,,P#A7"(,$5*""#4@A.5M`0Q<>@`<\[($+:P`)&K;`A[E-@9!\\)D>XM"'
M1Z5R#FP0B1G*(`X_H"$-?'`#'J00CC(8K0GK:<*Z\A`5H'Q-`P900`A"4!H/
M:>!"(1*!"'S@@R9DR0=MP((5PA4@/?!A#%^80A2F0,,J?($,?G"#%!C2LSYH
M86%9\('?L$-0)=#'1M8AST&WX[C`74=P04@<>\R3G?0@X/\Z[8$)>V!R@1?L
MP`^#V<(7S)`%F@E`#42+`A?08(<VPF%W=`#-T<!@F0X5@0%S2)`XJF"&/)2S
M"&3(0H1.`\4LE"%"#.`;`B;G(N&]2$9-U4YVE.`!;BYM`.:0@JDL$($$'"`"
M'&`!"[A7@A^,H`*H.H$+3#`(&MHC"TW(PP12L(,I4&$&8^(3`=`@AP<\0`(8
M.`$,(%"`3'%@`%MPP1+D5P416"``("!"!,J0@!0X@`@9<(,:KH"'$P`!"3;@
MP*KD0(`1I&`!P4"!"M(T`Q;(@@,3<,.V)N:N`TR@`:ZD@`V`@`(.-.``!!##
M,#&`@B%4``,X(,$/$G`'/'2!"V__>$,:ND*%+I!C"V3X0LNRD"<JU"5@$O.#
M%*QPA3+"$@U9\`)<D!.'Q<2A#IOE0AO:@`8SC,$/[Q#7!TBP!!S4P0!4)8T"
MBN"[ZQ2!D&8@@][0,,\$5T$+6/C#@_M`-ROP@0M\F()3D,8%,%BA'6?PPA<8
M@(8S_.$/8AAE#";0!3&(P2Y[\0)Y=7:7-VS!.%3X0AJJ(`=RJ6$+:>A#&#R2
MAS>0P0QFF&X9V!"5#X=!"E'`%1G>X#LG&*`-:4!-&G1,AY8F=6GY6IJ824,:
M`XA-`VCX@V+N("`Y2*&'"J$"N'26A=QHUI^1&8,9_,`'$83``T[P3O'B0]'N
M.&X\@^/._^'>8U##B6>I#%VJ0<U3'H5>H`,MN$(4JNN'+1A&#G7H@ER\P`:P
MP:$-"Q)G:V9I!C:24P-SF`,#X("7I]A!`T7PP=%2),X\K($,<TA-&QF@`$@W
M-0G"&QZ,:-2=1BM/!'9(`QG00$\)3"`!!$A`!5QP`QF4P`4G^``%ML<IV-+#
M>WM`7P-X$`/AGF`!$%A"#`XP.DVJ(0$L0((#WG2$$Z1A`!L@`@12L`<[U"$&
M\!["`23@B`+8P%`/V.\2CH",$G2`!C>``1&$L`(>(($(,6!!"UK1`0I8X`X4
M@T,>MA`';?BALS`P0@Y&4#XU<"$/7&@!!)!0@A;8H`0$L`(5PO]PA3'8@0U:
MB()P$/.7+%2!6<WZB]*SH!DM;%;I)J&"%A0V!?&&H5S1*B/5T["&,6A!"WP0
M`P$F$($*_``%*)"`!L2C`',J()M_%D$5G`@&,8*A#$^?#!>FT(<L;`$+6Q@#
M%>30!_0")!P[TX(5XM"%*6B!#@SX@ABTZ`4)Y``'%D"Q&\(0!CF<H5O+(H."
MJ^`'/TRAPV.@"!DO?&0N*-T,;C0#%ZK0!RY\QBNU#'$5?C,&'_C1`'1X`SGI
MT&IJSN$->6"`",R933"363JLF^[+R\4E/5AA"U]<Y\B.D\OB_`'478A"%K;B
MX2GXF3WGF32B#3H?^<0?/?>?#WTFW>S_0U.GH=;Q?R_A`1/``GO0/G5P8G<@
M!@>33_%`8"+`!B,!!R'21F_@90.0!QJ@+FCP.FOP@6UD!R)`!VU0!F#0!E.C
M`0DB@A\R7R*P+Y,#/#!R;%#U.`FE'J6!&;ES!7H0(`_`=H$E5C]P`AW0`9U"
MA"6W`12PA!,0!4W@!R?0`PU0!@1``@%P!#F0`6/``&TP!5Z0`#?@)DB`!$:`
M`Q$0!AL``P4`!"?0`(U`!,$0<BTP`T10`RJ0`RBP`D=`<23P><9@!#70AS$0
M`R2``]HC<A;W`16@!W!P(7F`!6*@&`3``D=`!#O0`1-``'&@!W)P!5K@!3?@
M`$N@/1QP`'^@_P5^@!5;YRY>4#=1T"S^@04.L06-='95((OIY`9V$3-?5P>]
M03!G(2"M]'UDD`;#%%1B<`<"$`$?H%8F,`%BH`%+=0'C=`';)!T;HP9B(#,Y
MD2U:,`4^<6/,]`59$$E^H`9]L"Z"009MX!:&5Q9;H#0^\`7CUP42$`,]\`!7
M<`;M=09RH!SO<@4GB`5WP!8AD0_E"!GK1`7.U`=>L`5O,$LW9@7:`A%],!&A
MU`?-]((7H&O!Y@,#H""J$9$BL08MA1JH,4ZGT49?,$]1<`5QL!OP<'I@L#9]
M<`564`4O*09=P&=4\`<&X2WU507?5P3K41,(I6@8U6@"R!T(E1W:T?]0^N<X
M[5%1ZK%-&X4=CT90'D``+R``%/8'4Z`65M!UDU<NV>0#+50W-$5-WS0[.&4'
M:!`87X`N<#`'T#8`13``8/,@"L(`"4*!WA0B34`3QM-4R095Z1%HUX$`6*D\
M/D`':X`&0>5!%,`!#W``&T`#/\`]16@"(\`!)W`"+V`"3X(!!R"+`I`D`2(#
M0@`$*L`"$[`'Y$(`#Z1QKRD$0H!#.4`$2%`#<)<"0,`#*9`"QP`#0"`$-5`#
MK[F<*9`#.\`",F`#,S`#.]!S-Q"='?!`.^`"+I`DI:@B(C(%82``)K`"-;`"
M+N!7#:`'7;`'WI-M/U`#.5`/)Y635K%/42#_,MXU!<4H>0B3!F!0CH+A%/=4
M!EK0>UP`?E(@``<0!U-P?N\U#4ST%&@P&\;H!P$B`1W0<QUP!W/@`=H1$Z(Q
M'A[`-'A12PSC!XCQ!<1T=L;AGV40H<[QC9<D767@1KPG#EU`!0-P`1I0&"81
M!A.``BQ@BF>`![SD,FJ01E&6!7'P!VA0%!%Q%V"0&&H@!5_@%5>`!0%1,.`'
M!HLG!Q29!EQP'%JAE])A!V2@&JN!5'3`%>N(*VL@;=,6&(418M/28GA```2`
M4JE$;:_H!P>D%V[0DWRP3G8Q#L=!,B*P'I!F'5*5E/5G?TDIJ8UY48#CE,UV
ME7[4;(W&:"%P!]"X_S-<8';QI!9NL`__I0`#<#"6MQ.E,X)M0$U2`P<.8P;B
ME(+EU`1-P#R804U;@VM%@&MWEVO%QE1/I6PT$FC'0U5^Y`0G2CLD)C%B\`!-
M(B#86@+98X0F("\LP"05\`$8T``),`$CX`(T,`(L0`(W]'DCUP(XH`(IL)R6
M``1$8`0\@*]"<`F?100K0*]`8`1'(`0\L"9`<$,HD`,VT`(BAP,Z@`,TL"0E
M0`,4@`$E@`(WP)D<0`';.04:0`>;4P$Q8`0PT`,ZU(-[0$FVN0&H\@(<$`$"
M4`=>4!9>0$96`&5GEW0\]09CT"U&U9(:)ABS`8LY9@93`8E[T(F4)!?_DO\%
M)RAM2#9X)R$`%?!M':`&CYI0(7!W%Q!H(8!8(D49-<FBS!)+7,!=WN)%6?"*
M6K"@=&%X[#@&IP1E7S$&!O`&)T8M:E`!*<`"`O`';E`N5L`%?A`&[>4'L%>3
M:8`&/QL%6*`WXA@P'%,7Y7A%4S`1HE8@230%7\&0:GH!`P`&.,5D"!)]66,'
M]%4&6*!A/5$%5W1B8B`';K`8/5('K70%6?!O;*`&5,`&)_$%=(`%VAB)_&@%
M5"$&;W,'<?`&^B(Y"#6I@C,?-8$\W[%_]<<B#T6I!N4W%!4>"M50^!(&"="3
M=(8&<(`%;G`'=;"J<N`A<+![:P`'K=92JD&"4Z/_&G"0!G@)DM3$/!J05*;A
MIA6X(:>Q->.D1TRE;#*B'2ZB'3`1'UVK`")0!E%0!5-P!]>0F<`%5MS3*2X@
MA$0X`B6'`1Y[`C(P!#(@`^Z:`BH0L2A``L8)`SR0)C4`!,/IKOF:L#:\`C(\
ML$<`!#-``LGYKBI07#M@1T-P`]_)`9PB""RP`T-8`A2P`=_:`']!`">``D+P
MMQ7@5P?@*W*`!USR5[MP!TT:I>-E'!%!!8GW&%]P3%)!>+V!84<A3XTD9XB!
M>(@W!GR`%KW@!LUQ84D&>`?TLW%AM:.9`6+@`WO$37VDE2+PC?$$&&WP!E2`
M!YLU4DG',T5S.U@`8<]R_TE6L'XM&4IR($?7(@)DL%DL>@850`(GL`=>("YQ
M$&5I=P9]D+1;]P;`T6D*HP5(FP]:,!G=TFEFH`41T;8A9BU?L;[;B+XB<'>^
M+$XAXK^X]JO5U'58<(M1H&::Y6*@AKL%J5[.@09NU`<!TZ??ETM]H!;#\@^U
ME`^X6P:%";WT=SSW%VG@$96AVI@UT1W2^U#\MQW]IY7W$@)2L`<8W+I6X`=5
M\`=U(`=Q@`<7$8*`>73%J!K85`1=XP,AP@#)MP:RAB!<LR%-\"$=.'TAF5.J
MX494LR*!AIB)&2/!,SCB456E,0`C\04T0R5M=[$5X,0N\&W?)E8EX)F?>0(L
M</\#)?`".$"<,7`#-Z`")`!W.;!:KWD,*4`"-6`$^6H)7+T",*";0)`",8RO
MZ2G#)-"P+=`#.^"P-/`"G/(!+^`"+P">&S#4-&":&U`"5FT#GD(`#U`!4`(/
M7Y)M7@(7LXL5%X9AHE8P!)..T[5Z?N!=;<L'63!Y<K!)M8L584`J:D%#?*&+
M7)!D:.L&>H`85Z`&5BL#+M``6F``XB$=TI$E+!(32,<NTQ))9G`%?"$%6P=/
M<]!"L+$N4:2,7A![8[`&M91AB!LP65`$;.`%76`<:K`!*-`!-)L<KA<7:C!D
MZY(%%!:Y?S$&:-!W^?#0D!O*8'!)#;*?$K,'<C,.ZR3_!E*01&,`!^64!EF@
M`0H0F=3Z3:]&OW5F5WVP3H@[T16MI,I2%CF&H'&A19N$$433$WW0#Y2GLUA0
M%TJC34O%.-O[E-=K?_1'?^GAO8'#:/BW'8D&'QJ5!=ZGSFE'LP32'Q%Q!0OB
M`S)Q-&UQ:T4@-M<,(A^"H,#V&6F@9U,S3HCU!=C$`+'Q!I@G;`1&8-![/,E6
MTPV\XA*\-&;V!J*"!W>0`"Y0`S-0BA5`UTDM<G$]<IW)/6K%`GG=KM;)`D.P
ML#9@`SB0`_5Z"<=PP[JIFT:@G#3,G#=$`C*,G#"P`L6I`C@@5CN``R,7UWC=
M<^&JB!F`5MA@`B,G5DPB`=A&_T&*V%5^>@!H(V-B4`O?116GU$3[N4^W6,P2
M0Q==8&'RI!L$T&.DH@<^`B38I@B=#5*P\8%MP`<'8`'QH!$;L"0/P`8A<!TA
M8$[6:-L=*8$)IA?.P0<<$V*G:@9O,#6DXP==`+7_L0=G4`:;L0::5`5MD`5N
M4`4*XJJ&8=UU\`$JP`%N(!>['`43C=^8E!=\<`==D!<[`8OMRQ!]<!1D4`8)
M+C.1.TN$JTX^L6GZE#!O0-U60`<!3@:-F&LJ.`"IX;-8D!O6;1)J@`=ZL$L]
M:5>AQ$BPH:&/HLOEE1"2T144YF(6!G5F8`#<M"__A[T.92/2^F?<(941_#@G
M#CF(9O_0#E7TC*,>8\`7F",4`M^?;UL2&7,!'HVT^\T`Y&0'9J"7&1@A`P`[
M"0(4K$MX9?!-HXL%4,$&8\`&WW0AWY1KJD$3SJKER@8%$4Q0Y,%-UZ@!^"1T
M!(`#:]@!`H`'"=`!8N4"/Q#%.!`#-G`#8Q7"+!#"-X`"(8>=-K"P-V`#5DW6
MR?F:.)R<;K)QEM#5B:XF*1"PFA\#DKX#-A`#0Q#Y-_`#+I#$L'U6J+(+UW"Q
M;&<EV%;83\)V7A(@BA`&R8@'9T`%A*=>:A`'#'B+SB(&8$J.U#)Z0C<WKD1)
M*KL'A&*NCX(/PMR.K38'9D"JJJ)M+W`"&"`'#`!I-L'C-5'_5470!IKA,&?7
M&&L`"%AD96!@9(=F:VED7%5A<F%997UB?5QP<%Q4>GP#8&)^;R(7<'%Z<5YZ
M'20=<6)N?65<4G]655];4UI:5%1_7GY15VJ545586GU98WY2?E9A?(985UUB
M8E+"=7)W4V]C6AIM86@*"FQ;<$5-&G1Y#`QT;&-15E92751><I!17V9EIG0)
M,R6-!@9CSNR1<T8/`3E^LGP!,Q$,EBE1HDCI@_&+CQ`A/"!00M()@I-*3"H!
M`(!D20\B5[)T29*ES91.G)`\J;-FS9DZG<#,"1.,`#UAK+DA1DO,E"V4##9A
M,$A>&09%&,!Y@U4$FS98-=@9P&#-_Y@R:<!<H?+&!YTQ6\"@^8+ERYH\=-*@
ML9/'#ITY#)I<<!(D")0DB!,K3@(`I4T`0D&&,,#`#)@Q<4Z@D&'A``$""2J<
M8+%C1XL;0W;(:&&Z18\6+8:T,-%A-`X5*W+@B)%#!0\80(@@(0($B)#@2)`L
M(0*#!(D4,&H(X4%"A8H<,6S8V'%#!PKM-FZP8"%#!HL?+RI$F#!!P@,"`@3L
MF1__P`0,ZCT?)1#A@7P!G^UQ!1]AS(>'*UY(<=$U<:@A1156J'$'!1G<T447
M5_RQEA5QQ.?A'D=U4449)**1QAMVO,%'!!QDD$`&)]!0@1@B(-"2$B$H8(`!
M(:04@@AME/^A"!IKL&%&&T:^T<888PQBQA=39,$%&%QDH5`798RACQ5-6G$'
M'E1\P<<94GRA@0=C'"6'&'N8`,0(88111R5]9+,%'WPPN<8<9/C"!Q:_9&,&
M&V`88XP?=>AQAA=BV-+(&5VH<0886?1QA1QJ9-'&&F0,L(88?!C@@09^^($&
M`R(P,,"J<[SQ)!80=F&H+F.@,5<55/"!A@@^V`$&%55HT84`#0APAQI61$%%
M+(MH8447?_3Q!1L,*#!42BDA(%)..67+4[9./.:2N#A]J\2W/;4TTTDCF722
M2&;HH<<=>^@AQA_1^.&&%5,T4X89>G&QQ@!OE*%!$1H,D,<`/A3_\48:>8@@
M`AQHO#%/&@/,\4448^1UUB)9Q,6%&62`<20N:XRE`8\C&;;88E"H6UAAD,$4
MP@4&>+H&%G40H`<>"4P0P5$-4%#"::^-AT,..MB@VPTXN,`!!Z,-81T.2Z.0
MPPK`"7?$<<4)(81PS#FW@G,P4#?##"K$@/4./<2`PMPQM."""R6<H+<)&#S0
MP'H1)""`&UV<D>@>!#R0P02"@\@?>PU\!M\>V82!AQYU>&&%&%Y$,44U>.SA
M115]=!%'!QO<(08D?E0Q11\*P3?OL5%<5L8A9(Q1)!A_6,#!!A*TMP<8HKJ;
M(X\>Z!0"`XN<3,:F<+0Q*!QKW#Y&&F9(_Z%'%U%RP<87_&KQ!814<-$''G7$
M&4<8"48Q``)\/,#0&0*<(,0'5X1QAQM>G.&&%%/P112PP`8Z;"$+9&`#&K:`
M!=V9@1EA"!86E.6%/TC!"A+9PA_V<(8K3&$-7,`"%OH`AB&580YF*)P(E.`!
M-E00#1KP`0/R,(>O//`+6GA&%HYDAA!^X0M9V*$=1)`SRW`L#5E0`S?FXX92
M#6@*5<A"E**0!32P(0^B"L%(7*(M!/3$7>SJB1<?HRZ@>,N+*SE73AQ#KFZ=
MRXLG*0.F0*2&*]2A#E4`0Q_P5*IY9$$+9E!8&NB`JH31@2P#L(,BYI`Q(!;I
MD'A1H!G04`8X#/\@#5NHY,,&-0`X:"$*9*!##(M0!%$!``JH1.7+DJ!*5@8!
M`*\\EP=NUH2,T8$.;^""&.SCHCMT*`(?($UIXH8"%<Q@!2B(00QZP`(7D`9J
M-]A!#&9`@KFEH`;!`1LV:P"#Z`"!!VQC&PJ>XQP2K*!M.(#-TE1`@ARPP`0O
M>,$(IC;/P#W``A&00`/JH`\]R`=$#9!``C[3``NP1VCPR=P?^$"Z_'6A=5?P
MPA7\,(4_7`X4?B@=?+R@!@'4P8(1C0,>XL,0IY0!#50:!"_X,`4.-:`"&YB`
M'-!@@)'DZ`(7T)$"E/!*#XC@"[W``ABLX`<L^($+7!B#J\BP!K/,(PS_>KA"
M'X"U!HNUH1Y92*D7\(`1:USA@GW(@P?$8`$O>"$,!"@!#S8`#<+UP0MUZ&"I
M_M"%(+IA"FR8`R-16H8QZ4$.NH@+DT*H!3*@80IW\.@4VB"]*H#2#G9``U(5
M804]M,$#``@!&DAH!PTDS`Z;>E((LU`%+K0!A?4([!CLT`0#:(!2XYL"%W#(
MA3'%H0M?X,(5XK`_*NB.DEO0`AT4@(`+>*`DV:))&$U"E)B0\29;=)=,6F(2
MD<#RN=!=B5"X@"S,\:$/QMK"&M`PABQ0P0HI.FD,-9"'=]`A$8S,"QW08(8\
M^,``/G@#&N!PD%N2156`\<$<3FI?#3!2`VPX_VD;!BDQKA#WE*E<Y6)N9)/J
M>D`!39#A'*H@!P$DH#\'*-:7(G""&[@-!S:(`0E@D`+L9*<'/4CQ:VS@''8Z
MYYI"2,$UN:GCM*6@FBMN#CE5,,YJIC-NX+'!;#I`&PI\P`0<>,`#0/R`!.PA
M#OP8*8#^]F$)2*`_^=2G`,*`C#]BP0I_`)8?PA"'.8TI/GC`@R_=D*@ZN($?
M6*[#'?PIGR[4I61?$-+WNA!7RQW`H`V(`QTN,!($&*`("L"I`D(0+I_JEW1^
MN,(5[)$/+;2!#K@HPZ;*@(5ED.&32(VB^;!1B"G\J;QE>`L^_+!H/4S`%W\X
M``M(L(%?=*Y*?>A#%?_B4@8J/.(``E`#%O+P!BE`PHYZ4,-"<W&&IV0R"\_J
ML!ZBD`=Q_.$,`'M@7!;FAP/PH0C'O<``&%&&B+$7ERC]X1<,BU+/;2&!?I&8
MLH+!A2W0@@MS^8,8IA6%:,OY#UKXE[_[\`9KB0JY/Z$N',4XRW#=)(WB"J-C
MWCB2,JHQC=UJ3`BT$(<_R*L+S\I"&IK:!C+PH0N='0`;[BN"5@U@2>,=8E;@
M,,2&B4!A`Q"!!K:"%XR)H`@^R%A>.PD'(O*%#H8@"R,AK458'D;"BFE)QX'R
M+IP-H`^%C@,!)K"!!NSAC@0PVFELX!VM%1D%.+A!#I(9@Q7P`)DHT+'>XS[_
MM[E9IYA$)@$/J%--IL5`!2F80=U.PQH4RP#*'>!`>RJ0@08$=`)5AH]\L`R@
M^,`GQ`T8*`$\0X`]_($+:2#1%C;-!RE<0P\#K0/B/G,`9"]$]@N1@[R6B)0_
M8,%Z6[CWD[PD'PF,X`08$,`6?'#<EES8`,:=)4P,P(9=@"$-;.@3J,;`!0OM
MB0S_6(,9JL"':9%A"[4J0Q9*104,!4M$:*C"+>C+AP'900%N>(#`PY"`%O``
M`P.!<#B4!7R05"&$9FXP4'?@>U@@!GC`/\[0!W^P!5S@!7O@9TG54J42!J`$
M$-JC!EK0>G\P@0S@`UN0`&$P<R,Q*EM0!?NU%7!P_TL+1DEP08%@P`9!UP1-
M('180`%W@`5>H`R>PP9OH$=1\`9D4`<)$#K)%C*&4%@#,&E-T",X$7$WLG'5
M%5U8F$8EP2YH%'(1]W'4U1,75@:,<@=?%0=24"NY@`Q\8`6BE#"\0@>5Q`!&
MDF!K(`(*D'0+8P>6I"I8D14U-#YT('2=M#!S0"E@,`!9X0.],@>X-`>E9`"1
MECR&T4JL]#(Q$W(TDRT7)@+TH`5<$`5W\`!"$WH$,%(O-0(RD&+:@0+=U$XY
M0$WLQ$VRN`(I<!TD$`,WD&(QT';C=#8ZAHLS8`-90T[+=!X_(`,W<`,EP`$8
M,#43`!I>]@`2D`$14"_U$O\?>V8L9R`&9Z!E`B`'(B4O2+$,6F!49Y`4W_@'
M<7``[_$9"6!Y">`9?^5//X,'9X!F72`%4G(9EP$A^.`&`A!B%5`".V`"!+`&
M%P!R'H!3(;$3"J`!I(9^AD4]57`&IE(&:A`&#/0%8U`(X)=49!!$)S0/Y$>`
M%\('&5$ZOG`%%D$%?C`'!B`%`F`%2]$`,K`"%3`07C`%4W!!?B`^5?!540`[
M=$4,+'E>`W(94-0'2G1Z9.`ZK@8LY\<1<;`'R-(%9W4&51!T6G``4J`(#-`C
M'E`$G00^5%`7UU<&4+)'@&1?E*@C2=<'%*`&W!5M5*`%8]`'85`+E``B<C8O
M2='_!^B7,J(B&#WA$CIQ(S@A+ML"+C)A+F^T1NPB$SZQ$V[$7$*A`&@0!MCP
M.7+@!<MR!6+0!2S5!XDT`!KP<XJP*@]C0W,@0]'S!E6U*@/C<W9@!KLP!W8P
M!T$R1'DP!D_!%4&W(YYP%4AW=*W5(X5Q=9GX,J\$2S3#$I&!,ZE",%60E:"Q
M'AGP'O)"`!5``SNP&S/`8GK'8L]1`S60B\X!=S<P`RF03'ZG=RGP&^@YGRB&
M`BMP-M>!`RQ0`C\P'L](`1C0`1V0`:,W`17@99VA!DKD!GL@.%^B!GODCE]2
M!]50!P=R!QS(!^`H!G66(&BF!_9(+('C&<BF!R!R%!S(_T!:$'P_E%1F8"5[
M$&+!DP$C0`,8$`=S0&GN<F&3YD5!H`3J-HICP%CH@'Y4L"\X]%U2<`4A@R=,
M=6I8P%*A-`=\Q09<P&944&QUT`R0$$)01)-7@`=:P"@-P`(YD`'XTBA4<`U_
MD@51`"VY,FQ](`=WE26N-@7_L#%W:@5UD2M1X#];`%1_4`7?!BT80@O+E@=^
M(`!:\`;_P'Q$07U_``NE0U$2>`5<P!5-L`[X-4-Y8`9QP`=9X`:?$0?/`"(L
M:BS0<@8="57U<@98*BK0YT5?1!-66!@LM'5DQ%QIM"T6MG4^$13"BBWG$@)R
MU`5<\"P<@@<=Z09A\`QQ0!8'`?^((I`';3`6<[`(.%@].+@PGH(&>4`]FR0D
M>+%@5]07*6))"#8'GD5J!O%S=L``K4E<X0*=6-=*18J9VI)3=+D%Y8@X]_1E
MQ<*BH?$".^`=[!0=Q\$#T"%DS1$>*M8<O_@<W71W0_8<,X`=LZ@UV($#.^`"
M)V`"\X0!&$`!(]`!$@`:&8`![N$?W[@-=^`9]2)M7<`-=H8A'3:.<C!1:A!G
MNB<`>!`&$=4%$RH`(OIA?C-0'B(?U<8D\B:C9Q%P`A`!,8L!$]``=U`&Q,5"
MYD!+I@0%07`!;P`K&;*7#]1#B4(%N0,5MC!"I%D(S>!8M9-7*-4&P_D+1=4+
MQ08,N97_21J@`*DP"UX0`3N@`A6`+W+0!5/5!Z46!6L69UX`*]^&+!2A#!21
MCB92,G%"!5+P<A92*UFP:0N5!5W@!G'`/UP`G%2`!UE@)(PD`H+A11=@AW,`
M!_00%X$TEPJ0!VN`"49"0UVP"VH@+Q&DNKCG!EN`!EC@>E-`!B9W%&X@!EE0
M4[?KA2L12^)"G=C"$M-Y$XVI=>PB$ELT+I#A1FS$$MIB!G7@('\0$6(0!Z:I
M!U9`!0(@`:/T661A!VQP,`,`#FU0KH#!*XKDK;*0!GRA7VD`/;^Y!FV0,`LC
M:K#Y:7F05Z,$?2!A(Q'&KZL$!>?"4UH'$P]I`&]0#\K0!QWR_S?NH1^@40$O
MP`)R9T[08<-U@P/G-$[#J'A.(Y\_]IZ\04[)Y#0ZD!TW`!LN$'E3@Q\4T`$8
M4"SV`3RA9V62,E+(1HY+Y#/;X#\WBFQ&BP>?H2:)\H"LFS@$L&?PB(H/R*%N
MD*@3`9(DLC&<6UMB0`!;^P!J8`8U99T70'7/YP%%J@!I(`7LXS^=HPN2Y0K.
M<!;]ID=N<`5C\"2N=@PLY99'247&=@7B0UZT<%23/"58$05>X&^)NP.\%BEZ
M,+\#5`\LV2$"T`7?"@U64'X;$WQ\$!%!\@QG<`86)`6^/`9LD`8A>`PA&92]
M'`7U-0?@Q19Y@2)C82TF/$L7T%J5^/^0.=4&6H`&AV1%<!`%).(E"J(%8#`%
M>H9!17)^4?"\6\#+]L(%-:6'7FAQ%_<81?HMSQ6^("==F5D315J^Q[H3'K`%
M'I(IX$!:8O"U6P![Y,JM1B+,YJH!13@P"C,6J'));S``M^2'GV8':3`M=(`D
M>&%%/B`6H&4&\BHQ$AU(/M!:/A!IN>HRF"AA(CQ&,Y$M.55+;[`57V`I';;&
M]/A/#V`"/;`;Q;0;,)`#<I<V/,!C?:=,Y'1C,X`"0*QX4.-BZ32@/T`;+T`#
M(T`!3E8!@B,`IA@X?S,X'14X=^`%IN!/5L:$\CAE$=``M8>S#5*09R?&F0<@
M]3B.?Q`%N7S_#/T6%^1%6FB6/QX&CQN@H%'```TY$T+*:-I":1[@`V80!1K2
M!U1D,O,&!VG`DC%Z&412!GX@*T2R"%?Z0U)B6Q=2OQZ9I&/@!2RE"Y3[!7J8
M!IH=40_0`B1``:NS!Q'$0*U#.E*P#V$PO(I:%[B`?EM`N7R0.Z[G9@0X!>9J
M%B%#).`P)?U2!F/1!G]``&)00L.K,-S,FI)MF=I2V7-`1`.P7XET%B`T7E0`
M"1S1SG>$(9JM"W@2?%M@!05I!7#`:(+!A9AI1AF7/(X)L(NIF6&HOF042UV4
M+6$@LP0`D[*`)X4S!AF)EU]0,0OV0WKEEJ*F*N:**H[8!B#-!600_T-H`9QK
M$$-T<*^`6-*XA.)L@##X2A:\L@XE6`1$A%FI!,*K],_Y;,(".P#-+44F-WKS
M*#C^5`%#L!FC(1XX0!S7=`1$(#9&``.`-\1G@XO1D3;5$1Z[D0/@41HM$*`G
M4`(F&WD4T+4$]641@$^E1]9=FSX.(2]/^V%S'6):RSB.4WJS=P=R@#A0&Q]G
M]P=3@`S(T&](=3UI,`7?&"E9"U,2X!E[;"U!$;`7$!)B]",+A`N%U09PL+LF
M$B0_E`;$+,RNH@5`Z6E^X7)DD!95@@]5``X75"M/X@\@Z@=F13P7T`9?%:46
M8`,K@`%R0@!U(`@46`:Y8`A4@"S]MLUIP?^7J=?<@CJ*B.(%YLH&.`@'(F0(
M:3#858`]6!!([6V!<+PJ!U%#8'`5]Q5IDA:J`30`30`'H52JA0`&6P`09R9G
M>UDZR6NTI&D%:V'(5U"*!!`%P^5H@W'3":X2,V&^O+J8W<(M*J&L_=RKYMLN
M""``+B`!RUY;P"P&$E)!MO!'$:TS6!'I:$`6:8`%=-`PI$0'@U`&I<47@(1+
M<'!?!]&:)9T'].4J+^\65G0P\"`Q2?<&>5`$C&9Q+H-UB&&VE_A*L=2%C@8'
MA``ECW`'H`$?%<#;1)`"(W``$?#$+7!-T>$U1X`$0``=\\E.6K-BQ?'VW[$;
M[.1BO#@$2=Q,>2/_3QQ`(5ZV.(-?`?@4/.SA'Q/J'_N;`150`9@'QD$SC2-%
M``V0>8_;4?#Q@'%P!FM9"(W`4()U4J16(/)1-!\@`4S+!8P8`C5C,Q#9O4&`
M``HP`+=S)+:)!J0^S(!:!8,`%WQ07R'-[R+T/"%M@R%T(F9@!NS%!9X&G!OC
M+-56*5_0!`J0$)!+!1A`9!:0\`>`!WDT$0R5)60P!8QB"5:T0"RU_"/$4("=
MIGU0B#)G!M&[!0KTK'DDI4:U!1D-"&Q19UEC7P,:&@P,=%M;:%EM`P.+`W9K
M9U0B(EA]9G1O<&!^45E<6WQB:GY<?*YA<G%245U]4G)Z<GL$=WYD12%%_PH(
M2@!*"$[$2LO(R4[+T,O&Q0#5R\D(RMA*S\9.W='%W-_)'@0N$FY];@)W76*Q
M<E=86WEK:P,&179I;)1TDMA\22/"@`\&D^!\.42G#!@M9M)L&3/`AX8\D_+0
M^1*%S``ZD^SD28.&#D`XDP:4^6+'1Q,#"D(X"1($2I*;.'/J3!)$&H`@TY1X
M4.!C3ADL4:ID<9-`0@86,V;<X)`@CILZ`BR8V!$#10H@0L+6J`$6"!`8*(:@
M6`&C!HP9.KJ22)&"!`D5,6[LV,OBQP\7)SAPZ,`!`P;"%B1,V%"A@N$*%AXT
MB#!APH,$#R(TCD"@LX`#$1X0$""`P`,)"?:X^?^C9L\>-5?\^)GRA8P6/J6T
M<"EC9@R8+;3T$(A@80.%"7+*,!CFQ%B(F`A"A+C@`0`4*$H,V&FH94R9.0/8
ME&DS!XV6+G\>E=E298H9\/:XC!G3IT\6+%5FYY\C`DX:.F:X`L8:8/`QFQ16
MK$$'&FSHPX4:7?AA104V[)#`'UC504464TBAQQF.<!A%'U%@P<477%`A1QU^
M?,'''U@LA(4??V1!QA</47$%'V6D\4465O3!QQEUZ*&&%FO8,0<687RQQG>5
MT`&&%5&`0047:?R'R`!CQ$$%0&14L84=&@Q`1A]6^,&'%QIRP4464E3Q4!5]
M7/''CE[@(<45>!"PAQ7_OUP`DP?-.4---=]D0\TUXA0#E$_'>*!--]48@XPX
MS8VC*0!.A*"'"16,AMD>?F!A*A54U/<1(@S8$1(=&O@P0!YLX&.``2+,"AXE
M!C3!"!=DF*'%%G`HPD@:8SBRQ8!SO&%&22")H`$<;S"@P1LWFE&1#\(0$\1.
MX.:$73;-`>4-`AX8H`$=:Z31AA4'5/#!"2=@X"=I>GC116L-5&!""S&DX!8,
M0!!QQ,%$I("""BND``,,)"S<\,,IX(7##3CTT$(+/[`@@PLFO%#""81U<%P$
M$E3``044;#"!!)15,$%D#31PP`,S1X`RS`F0=F\"#?A9QXINQ.GF%L-6D>H6
M_V24P<6P6?AQQAZ@*39!!`?$D88!'A!:#0*"*D`HN@@`%4(3/HA0Q!Q\2,''
M&&N@T8]X6/"QQ7KY_2$%&0SX<!"!6NPI!2M]8('&&&V@0<8;:UCAQ=U9J*%A
MD%R\`9(/"H@P"(E_8&###0]X(<<=:EC1A1YU="$F'UB`4<886;37!Q5U\"(F
M%8"ZSH9X4M3A1112B$'%L%&4&GL55IR12Q1F*(*%&&TP``<=#.2*QA1]3*&%
M%C$6NZYM8ER!8YA5M`''&`SR<<6>862!QAIF9.%Z;63,2,H5XDM]E1=M#*/`
M!<3`AC4.!8!L_(13BK*&-2@5#@(BRB?3J-0X+A6=3_]MH`%Z<$,8_M`'[LT.
M'G&`@ZO:H`66,.`-:)B#!D2`D46(X"#56X1+>F61)Y5!;G/(`T;0``8R^,8[
M*2Q#%K20AC=0P@[^"189TD`&+N1AA45H0DR44!.;),&*X;H)`AU5*6N`S2`(
MT<(=!%`S`:C!"W<@P`$(8"0WR,$-:M##`S!`@Q8,00<S8$O!B""$L9!%"$!(
MP0KL0H*VK``%,8B!#E10(8VUX`8W:,$.6@`8$Y@,`U>;P`<H@`&93<`QD+&`
M*"50LT]N``,MFT!J=C$:TM1!#%WPPA^BL`4<?0$+6<A"\;`0$3-@X0]A@`<!
M%E,!SLB!#V9@``"QX00/7.#_`O]#0`01T(233`(-KL@>G:K@IO9HP8B]`1*@
MZ"!"6G%A"@:Z@A4Z0<LMX/(+9?C#`00PFS^LQITFBH(3?8`K(<WA"UW@``IR
M,(&KU"$.8:C#'L+0GBMT(0ICX`(IHB`&`>Q!#WBXPABHX`5N5N$+C$-#1:TP
M!2K4XD;8BX(7Q!"D*$1A"EMH0YFRT`6UI4$#11#!&W"YA2E,@0Q9X-$+X2`?
M/G30.US`@A;\H(9#J'-[-J+6C=;`!C*``:E_Z$*$S!"%((7!"V`P`-B4D0UI
M]H126[24H@CH$W,%I8L#[*(T'H6,9D1'#1R80#O2<TX^N($`L#S#&=(P!X6T
MC@P]_\T"2#\B@B9H8'>NBB(C**&(2:3A$Y:@0Q[@@`9HP1,.;$#BC=[P!C8(
M:R5I(L,<UC`&'0Z@"(DP`'4<A<4L7K$:4*"),7Y"5V<V000"^8V!_"`'GS4@
M`9U![ADDU)H#6(`#]&)!#%0PEQ0(P0A&`"0,Z**"/*Y@!H2<"PIP8(,A#"$&
M.4@D#F1`@Q.,8`0FJPS+.%F!#7R``\7\9&.N9@&99:`"&4"-`/"P!P'H00Q>
MR)ZIMN`F+7!(*>C\Z$.P0(4QDB8!E4F`&+B0CQ`0(SHAZ)H"Q.8!*DX#`44P
MQ"U+2(\VS,@*>M"#%:K`ARI@80T(\0\7Q-15F,Z'/51PV_\4K*"*/\S810>0
M``'BT(7AC8$,\//#'<Z@!3;TS3U%`"@'[I(!-]RA#G>(A1ADXP8],!0,45!#
M%:*P!\G(@:18B$,<4NK@+ES!"U=X4]W\\"PN],$+I;F#%Z;0CS+X@PU#5L06
M-O$&I,5M"EA(PR_Y`(=%@`*7\RE#N[3@!3=L80UNX`,:5I(&4?AA"R39L9RV
M8!4C`\D^]<&"!J23J01Z0QP#Y$8S'`A7W4(C@H]JH#2.$<!K>*`/J+G"'?`P
M!3!PX0_#\9*!W$4]#9B!R&'P@VZ@K`%]#*`-6;(#(]!`'D1(ZPUMH(.K5I@1
M.)2A"OYH`YD8D`>_#0`-,2I#CT#_D@=THT01+W3);&M[$X(7W(JYA2"BG*FN
MOA4A#X:@Z!@QL\8$1$``;H"E&,204#V0D0(G8,$C54`7AVTW!3RH&'H=)L@4
MS""]B<S!PG)@`QF,K`0E,(%@!F."$5#`,138I-7T^X`#V.QF16?C&;P0!BE,
MP<;;P\]+326_+4@A#%>@<2S/0,8UCN8.4<B#;*5YC+!)YP(RL4YN$:``!I#A
MI;'#`MQ("Z<P&)C09EB/%GJ8]R],H0MGD$(?_)"%&T[!"WRX!W'=D"HU_2'&
ML($(OO=6!CZ$`0]RF`*9NF,'CFX9!1(0W>CP[`4K6#X.?G`7&,!@'N7=`75_
M\$(<(/0'_S!\X?+YLC%,M2"G+-AS='$X@QNN$"Q]#@`.;?N"W`90H)@R@`VH
M'L`OJ<"'0_B@#4+Z`M+20"MX\FZ=Z"N#%JP@!?GX`?%?T`(5PL`Z*:@AU*\#
M0QN`(:D`@B.!#)2KH]SZ5K@>@X'DL"B1@@Q!@2Y5T`!U4`9A<`=BD@6U8R1B
M\`>G%FG\E`;Z4C[LXCHJ5"8(P09%A$)FP`8@00EPL`9OD`?5DP<#$2L#H"!V
M<(*+$"M%P`!'`0<ND38?@4+@02TQU%@`]!,&9UL\06SE0A.1`DW_TP1Y8#X.
MF`M4DP!`TP`"4`=J(&==('A]\`?%)0`8-@(E\`,`@P(H,`,HA_\7.=!=X.5R
M`Y5(`Y5>G\,Q+,`"@/$"[V5)&_!?CK$!H0$TBB$:!%`'6#&%7D!XCF`JVU-+
MYS1XN+$Z:H`'>G`'!;8'>,"%&20%VF(`'G9_ST0=9343/(%BYZ,46>`(<M)$
M2U$T8>`&6M`&M4$G3\<%/00&"((%Z`0&Y#0%J[%W;5`&Q4,%(Z(&9_`'5(`%
MNU,@P]A3?[8W"#$%45`&)H4!8AAZ<J`&'$0*6N",<1`)7U`X[.$*73`T8I!Q
M)-('301X:H!U4Z!O62`&J+-TZ)$J3K=C@&()4=`^;[`=>2>"(P%2&D`&=F)D
M8+!3ZQ0W/>(JU382S,A.7=6,9=`A?_?_.R74!0)P!F&0/5?0!V50!%TC*=&P
M0,]@:]4`%-_`6\&6#+QV#+^65EVT#2OI`5,PD5EP!6$`4\\6!ROE!@_E'7#0
M6`PP:FA`@A$!!\TR*R8Q!^(V$K!2)J#0!B=H"<*R!K&B`9=P0Y8#"N)F!\F2
M#_J0*W#0!E9V+:7F*@6!=EY3$T(H+FE%$V[53%US`;"E`670!5;@-&)``#:3
M`/-$&@(@![409%)PA5)P!I-H=/+BA2W@2'NQ`S=@`SF@`S:``SB02#'PF)`9
M22W``CGW7AU@,IXD`9Z)7!BEEQ]2'UG505=E>]Q3!6+R$#+Y5;'4:1YG=!$@
MA;-'?"VQ3.10_PXAME9PA0`&0`>7Y4-/HSZTV&F,YSJCF`4)-@6YU%5;@$*N
M@")?X`]FL"]](!^)X",X<G@D%05$E`9@T!Y\0),T9@:Y@AY?0`6=HP(H,`%B
M\$J#1XA?0"/;0V1^8&.Z9`N79T:T-`5/0TM^4`=XP`=-)`5C)`\UMGJT&#5_
M,`6O10=](`9DD`AV(&Y2:09@X"Y\<!Q;8`8]A3V'()4\A&.5H$-5$"?7F08[
MIGT28@4VJ07`HU"9X&QAT`5<4`2=N%MRU8F\-I(#]`PI*5=`"@[/H%NYEI+-
M-`<Z<@9-9HW8$Y@2Z`?F5CU-T`3?=@_O@Q%P8`9VP$-T$'#AH0%H,_\`C&."
MEG`XE68)>6`4\F$&;Y`&4555R700VS$K1L1NM7*/&C!BM^)AM!6$!)=;0"BH
M!U2`@E($;8`E"$$&:K!&>EDS;"0'<N"(>K`'<B!+5@!,=Z8&$Z<8]85*'#`"
M)U`"[54"DK07&R.'+@`8^&5*,A,:>6E@J[$G?R",)<0]IO(TS)F<^`-I4A`'
M>$`Z:E`:%L6%-;,'4H`%RB$V0(HNN^E,(8!K*WDV1$D'<S`?-/4'^;%T96"M
M=M`&6_"-7O`%9O`%5>`%65!544`%W,0%<N-74C`&<)"F:=`C:'!.O1<;8^`C
MLH$%38,%4K`%!X$_4^(%%/!R$]"(=^`&7B#_!;@C>$.$*A]%!F\7!OI$.^V0
MK+'#!UF0!GW0#AQ"9&K@L%8PC"CD!U2`LH#"3VQ@9#:H`7/0-S#+'G"P!290
M`$.PDURB5/QQ0EN@;?,*;FVP!L'3;)2`!FOVE[%D!2>B/+\SD]8:-5^`H]P@
MK96R#1#4D=-@DB;V#=``I)O2D?R'*`D4'0HP!U?@!L%8LGXP.]_(KE(`6Y/`
M;J7E@9(@`M)C@ML!'HDP!W,`6_-Z;TS3@>4VM\?"&VTP!J6@:6R0"(Q0!F3P
M1"DQ*R&8!ZYB$:XB6QQ913L!J`@7%-0@DLXD`B(Q*W#@@'C@!G%`1I?1&0<`
MA:_;#A<58W50D<QH_PMW=@9J@`NQ"86:$708L`&,D0'!&QF.:F"S1XU&15*\
MEQ3W44NW-$3HA#]54`8[56"K46:HHPH8]@"D8:F66!',R@S.VC7H@G94=!U0
M```>,!T^8+GL(C=0YDM#9&-K\$)+R$-_I@7R"Z.E<DO,J057X(M2X'2/H!&2
MQ@=6@&K!LA'3*'^3YCIXTP8.XI]7(`84$`-#\`"M00`)@`=9M2-*L6,_.:]H
MX`=NT&Q;D`5]@'6Y%#S#N")RXF>Q=$9682,T%2&N<U,^X+%80#UST+@SF`82
M,@=JL`1,P`)8@()S0!YG<@7H)$OM@04G.`9=X`9,2S<15:OKBFI@H$[^*O_!
M?A>P3;!KT="L7O-66AN`(4F$B7(I6>M_BX(-R.!,%T`'$9**;N,'?]D:<2`D
MOV6X']$&X-:XW-(JE+!:B-`&MM@J;(`2"N$^;U!8:S`]X&$1=."!]>ILH_BW
MY0%NE1RX]`:>_@`0$0$>^H`Y7A.H9\D3AA*2OL9PN4*F6J"((EM<56,UEW$9
M%B<!$QDDY%>R_LE[-&8@@R<%7B!+=M(%J0@A"*(F:L*,)<)[BO6S5+(])Z(%
MTFP@3%<E9C`%!98+QLI&[-`S75!]<^`#`&3&Z+*1A*)K)78=/:&$?D-O>=`*
M8J)\ZCH%24(&;:!#X/8&8V`%W?$TUZ@X7."A<N?_!QPG>,LR!KZDGEF%)/I&
M*UUP!QVDFJ:0?G<S``K0!,#!!7<V`3L@`QH6B7Q)&QQ"#XO3$%M`!5?1!860
M(N=H4G&"-"4[+,,"'+&'8"7R9T9V(EG`'W#0'20Q'M4S`,@"!@.@!P&`!!PP
MEY,0LVUP!@2@BK]J>E60SF]0)TJC([70.K^A!27X(E'@+A2[$E709`.00,/V
MM<005V\M07!E*,2F#'#]SN$05XDR'1>0!U*PC6(@>"G[!W<PDRLL*ZZ"$)/`
M!F_Z'5%I!WBK68L@$?>00SGT;2?RSTBD$2C!V"U(!BG4I9]&NI+0MTA#"1\Q
M!T6YI4(,1D6@N;R%<*V<_P0HR5NP;(1FJP_V$!$^2094$`<>AV&-X1B540$4
M(`'SI`=QH`I,=I_MH4^W!(M7I6^&@#2FLF#N5,R0ML)/9PM4\G3W83JQ,07G
M%XSJU`544W&?Y,L76;T,(`P<:0SM*RGMZZ<F%D$%I`!%0`9^(&]3?05MHGS.
M0ANS8E18PD..C1168'I<P)1K(&]"!%2J2WC:%P6I,+(_U40GLL(<];^7A0J%
M`P9Y`$UAL@5V(@$_0`,'P(Y%,\!I,`!FL&8[[4[GQW%A8#A_%TLUNHKXIAO=
M9'N.TT':K'T/.YY;[5BWM*\*,LB.;41>8`,CX`:%IV[^X`-D<%&&T")Y]UH#
M,/\%>J.V*P4CH^9@O\%17I"RK)!^*G4%=C#?<@Q7<M5_1KHI7@2V"&2^("G'
M(*8`:*`&OU&K[G>.:1X[?O!\;[!"CKL=N_@)>&LY`_!"'4BQ)!I:`V`4UDL)
M.*AN*+@)GQSI++23>.L2#Y=4(!'?LO+9B!!%.45O#-`$G#C;M<T3@[J^/BJD
M0Y%3TJ+:C/PF@&9QAX%)E?%)$T``TVAA1L)TPJ/`)"+>[5&_(X([]XGAJ%)C
M;Q)D#4M^^&,Z!28'ON@%E1J)9$1*:H27`M`%:?#JG/AK90<=T#H3-:&6]-T$
M;SHCCW!91-P%/V4&>0?13!DFI7`BVE8K7+!2=O,0WR3_$"_E!QNT&^-7HPG&
M>GE@!M'L?NP7$5#&!EA`);38!L^AN%9W!1$`&(!5NVL6!6M@#W63!=3''B^U
MPLD:KHAW!6K`!QE*'U90"(&#/1KD)-OH'7RL-WS0'6D#YF4P*Y/0!EQ:5670
M!P00!5NJ.+I!!Q>@`7=P`,0H"9>."';`!T4B#W5"!3\KC%?0W!?M&F:&%&%P
M!I=*!WXJYX?"#7+N#=T0;$'*#$!*MG;E+6,[02*V!7I0"'4B90(@"X/3PDM(
M!VE362)A$I%U?1XA*V_@$'!3;S)>:7F@;Y+@$A?1+'U3I0B!1(G>!#E564"I
MMQ7!0D8Y";FBCW`0^5&TSC,1_X3A4EM!\,IJ21/KV\[0]%METM@_"VB6L48W
M4QF\0$:S>;P'\!H9=R=9A6`D$DMW`DOQN2=MNR?*@P>[.QJHLP<H8T85U0"7
M<5Q&=]4DY<^WR9'C\`RZF8GMG+ZY!11LIU,^]#HXX@C/XA"L-P8E!`AI8%E9
M8V1?7%M=5F!H;%A\6E51?U=8?E)2?WU19'-E5517?UEI;&MH6E)7?J%B?FF@
M6UM\?&5D6&P*/G]=7%=2#S\N!%=R;GU\?5E<5E)3?)UFM5IC6W]A9W5JF9M]
M55I^87Q@?5U^77)66UI]87U35&)>4GU29P,,7FII/@P#=-B\T0#GBQ\_90`F
MNH*,S?\%-A$D3($#9X`(.W#FK.DCYXX;+[VH1#F#QTV=/7I.WA'3I8^J.W?D
MX`%SP8D2`#B5Z+R)TXF3G#@![.0I%,%/)39U^C1J,R<"!$)U!D7*4\E3)T\-
MC#E#90P7/EG$Z-%S1TT\/'3:5%Q39LV;-PS^,=`@8L";.1KL<,'"%TM"$0S0
MD!DP8`UAPG3<VIF39X`&?QC9@&'SSS&#.7#:C`$#5T,^'R+>?&$C0D0;+FOF
MYIF;SX#K"S>#0(&2I+;MV[AK0P'@$T"0WSAE_PXBU(F'"\@O&/"7!PX8*U0P
MB5$SUHV<!Q0P1&B0(($$[0(("""K9\^>.V'4"!#@)@S*.G+_Y.B1(Z8.@3T"
M(CP8?T!\>0()B"?``0T0D-(94D21D`\&7.`!`D19]10"'G@0@@<^5?63;%`H
MH9P!`U3!2A5PP6$&&F^PD0898'Q1QHEKF%'%%%^DD886T2R3!1]DK-$&&ESX
M0<\6480AAA15<.'(&+?LM049L9#!QQ]^:&'&&%-$,4664?31!Q8M5D&&9UUX
MH<4H#[C0`@%4Q(''D52((L`>5#`SR"M3]"%/&-BX<0:5[OPQQ8QCF)%E%E[L
M$9\;730:71=2*!-&&(#].8`!&K!1!ER`.6=&$4T,4,88F;@XP!D4"("&'6Q8
ME-@:7U@QJ39R_$%%&-"=P9(5M4S!_\656_BQ3!1N:*&`!S?I9-10.^64+%53
M">44LTI5%514536+U%$(%/$%%5/LV`<Z=Y1WP#8"<#$&&WF\4489;=BA`0-T
MP,&682(4,4"+9&R1A1EST8%&&AJ!89D=9-`88QMMO`%'&6C004>36^`E0AXN
MIO'&`)!9I$$;+MZ%&<=%`&8''0PT(8(/%T"(TVRSY2:S;L'!'%50Q/E6'%+'
M*="$RH3EH:DU6&S1AP`32$``@!%LP,$$WD5P0'@$&IA?`R@=D$`##4P]UAX&
M[B&!!0*X:1Y]>(B'4DD(O9&'!@8H$,*R/!%G585&4?A@<,/Y!D403BA`+P-V
M3#&.P2+`T?\C0%Y]T4@^=K3A(QJ.1R&%%FFTT4X9;-`QAU=<E)&9%E1$TB(7
M7PB&.B);&(+%%%N(7C`?4L0I!H)\^,&'&3[XD,4F8OS1@`L[-""%&WC4<444
MDY3;AQDWAE%'+6J(<4456/312QA==-F%FU%@]@465?PAQTEZX+''&=!%L047
M[F"AKQ5:B&```PQ;Y)@&<PQP@>"I`,<6?"6`"JC!#'.@@QT&<(HUE&,>?+@"
M*Z0@ABF0(0M:`L.5$N$53ICA#6/H`QD:!)7B^&0I+G/6MI8%E*!D*"<_P5:$
M=@(A&M:P*@C00!;BI(;DG6$4?SA#V>)4"+4,0&AM:`P<TH`&,&C_@0QVZ!T#
M&O,&,`S&'VWPA!W,D(N@H2$:A?(*E+:0!L*TP5!2*(,=1$"'+!B&,"IKS$4D
M888U5$0#>&15_QC0*0U<X$(0&HYL9B:SF,4,<"S$F2"=4J$0_,\`<:0#8=XP
MA2Y<@0I><,,>M#:>I:UG/?TI#W?60P"M%6@^'7'#'[RPGC.$2QDTZH/UJM"(
M*,H-;T3!2@V-@\N>&`4`,/O;WYQP`1^DA0V2&T,6OM`&,Z+!#"^J1AL@EH=V
MR8N!7]@A*UZ4A2UDAF'J6L,<YH`&:S!C#%T:&!A"H04P<&%+56A=Z]@UAV9T
M`1M>N$*C_``'!2C@"V((@QNDT(`6V"`"_U<X@QS"X(=NTN)+8!B#']I#B#)5
M851:L-P9NN#$*(CA`%>0)!JPH`E-J.&D9_`"N+B`BU&0001LL$(9-*"RSJU,
MDIX1`7**\`B6CB&;`GC`%<@`ESPX$2^45,,9"*&%+\C2"TKJ@Q6XP$0G7D(,
M5"##!?M0AB(X2`DY0\J$?CF5H33E9L]R(53L)A5G%2596$E*4Y#"`#Y0P0IG
M&(L7NED^/;@2"V]0(!S>1B\%LF&P;1"$%JI9D="8@6-U>4,S[;(&%:U!@678
MPAKRD%DSP`%%<X$#"/NP!338BYGM:H,/FN`9#6R$#V\0@6>"QL4RI$P$MX#;
MSVX9PR`0\K<T<_\9</B6L[[YDD(*@&3<EB/;`6!D19OQ5Q8P806I1D=6*?4"
M2*SP!RLT5$1]`$,9OD"&>,6%+D7X!]QN>4.^"<5"&*+0A38$G-@<LBA-4)P9
MV#`',FB!<VAHBVCS@`9P<($-=DC#^[;PA;>Q2C-9.!XG>$1.,!#)2BOB@Z_4
M-84_J9,*;K`"&<R@)XA&$`O]^X(4&A4%KSAC"G3XGQ;<((:/2&`(.9#`%4Y:
M)RUD@1-@`(,?K*!=6H+!KF!(@QG`,`4K7&$*9=C2%.30!Q29(0I>L,*,G($Y
M+4R!24[UTQ<T@(8P<.%2/+5890@#-TR)U@Y3K$)YHD`PN]1N``H80!;_PG"]
M>!I*#750D)%:O`86!>L/"?+#*,!0!$!>:R=)(<JU)IV4:]GMA9-N(5K;JLN;
M("`/&M9"]JR`A3&0%`\%:L^\Z/*8(GAF+J!IEQ;^4(TQH*%=>,D+NTH#AU9]
M=G&$0YEG#-LJ'SCW#0&VHC5"]R(Z/.9B8QA#,XN@KXH,0'%:L$.HM,"&6-OA
M;0:8FWUIHYN9D?LV?_-;$G:#:=\(,F?'U5N%_I=<UQB@+I8AC!T6Z-PYI*BR
M<#Z,9T:5AR+8VY_(>1#>GA(ALHJU0D>!.#!G,QR8$0<!RO&'9.$0$#.D;@Y+
M%C"!49.'@*2A"D.>2!X$D09681F#5$ARBW!$_Z-G9F$*6-A+'/:PUR]4H0MA
MD,*ZR/`N1+2CQ>7P0J.PD!$BP?9_6V#)22?0@AU$0`QRB`-67W<^*/OA=GVP
M]1:J*UZ?2R$+9`B2K,)`HT2,'4G^XG)ET\XB*N`G"CZ8@Q>V,(`F\%1>*Z/7
M&\R@!338S^\_HP->.Y&1-62A"UO@HVC`889#;($*:K@"ZISL!^;AW%]1J(4Y
MJ("&(E0(66W-M*15?]:PMCO3-\/6HRD$%24H@`Q^X$(5OG"B(X?A#@>H@`0$
M4`<^%L$'J\9C:4K3F"VV06)Y`(USTV*8X\N%B94E#!EV#X?'S%8NS8&5>-?@
MP"`WE0[(9QA&VH#'-O^``66`V=0`_`NW`?"^V-1NF;LY!#/@VJ;_M5$433%<
MEO9NDR96$V(AR1$"(9!<"I`<_A2!R?%'%O(:#X)"`S@59R4A-F$<%U(W;\4A
MNC%(08``]\8`3/06S2<0:+`&"?8^F6,C-D(82X0)?D!&9N`OC7`F?$`8XU5J
MB04EDG-!D0`DD#)`/[07658H#D0%SS`%4L`K(H%Y5<8J(<0%#P@&[9%)!S`!
M$\`>\1$\3G@'!.`&6!`%HM`'5-4,8($]?A`'"F(XZ2$&7W!Y>E(]K3`%5_`.
M8[`&X6!%1[,'8&``<_`':*`!Q[<R`Z`6<[`B\#,&`P`JA/-9?-&'C9@%8A+_
M6&P0;76X!2(2!RO!!:=U>6=P!KE'4JL4=*2E6J<70["7>K&G+!IB5C-4BV7E
M+!,"5@C`!D#G#BX1+'JP-`2@'^+A&+(%&(YQ?,ZUC(3#+OG@=Y]31ICA`^GE
M7&3`+HF!.E]1!710,O_@,$<$0DG23`Q@+Y+S7YE17GD`*TCU7VLD`FN@9%-@
M,*)2!7W8=VSD/TPQ@(/D?^7V?SA#&QUR%;%17.]VD&'%:73#+">4>D1!@/L7
M!"N$0BQD%7,S<>FF;N06'!YB&GUH"$U$,/XV!VR`3%_@/BS8>Z8P3=-U46?D
M8RY2/CW(`)KR*Y]E)>3'!B>)!>2G07`P!G_`!ROB_T'Q&&$)4@6R8@51X&-.
MR`=;<&3LXT=PD![.H$]G$`=Q@"#WT!X]5$&O@W.B9@7ST`5'X@=J$`5<(`7T
MT0N-HI3&0`^(QF)E4`Z7DSWO@&=L<`:#01>@P05AH"!?\%\U(DEV,)=M@&!Y
M<$:5%SHTF`I3X`>B\`?4L0=A\"^HP`68]`?8HY9RH`9\IF60J'`EI'JPZ)`*
MF4C2PALI-$-`@8!D=0%5X`5&H@<#%051(`!*HP;E4AY!DP?-A8AY,4Z+H2(L
MY1:$03G]D`<(I`&#QP:K,B]FD`5T(`)ID`5E(#%V0#EMT2[3I04NF`>LLAK]
MXC@M<EDNZ`]IAT")809<D/\%`Z-[I34'<\$`#E,$<N-(#O(3,?-__J@;`)@$
MB&03PI&:($A<"&F0!@A[!IJ:91576`%?]B61`AI,OV%QO(&?1:!@RW18V5DZ
M7^`6;^%^T``&,<(6&O0%7\`D:+`%6!`QBA,Z[J(,6L`%3\0PJ7`%D9`&#.!X
M?A$C"+8&AN!S:,>"9X@%HJ9H2AD%_Z(%3M8%:A`'5C``(=`$T2F$*VI7?.!S
M7I!=5``F:<DC>]:906=),X(%OX,,6-`%ZZ&&MQ(-P'`%:B@(T)`G"N,#"I"7
M6;`Q=-`<4K`'?@`D4V!:`N$N3[)`H#$'`S0&;[!O$J,Y8="9/_0'UJ%45,`.
M<"K_7D<F!N7B!>(0!U[P/`;P%"$0&P>X>J\(:6>U,\T2>[&H%`U9@CH4#>8C
M!Y!G!FZ0`'C@!RGE)7"P&/)Y1/]P6/7R!J903[$#/1R7(@,`<O`2;>-DC(3C
M?0R4=HUP>08S!UE@I$8J:J%C!I5G"@91!JM5,@Q46>.TB4_"+@7!!7/`6C[6
M!G'!(,G%("'0%.>VG_VY;K>1,^0VD"P$D:NJ,P5(@/!67Y*F+"5T-RGT7@\B
M@KM1,\%$<>\%27DW"%$(,`JT!BN6"[VV1$VU&1Z5.K?&!D3W%F``A!K1(X69
M!6"`95U0"D"J!5K`#FB`@D]4!G?E64])!E@6="T:G6BY_TX29)M6,`6=@P:4
M$`5^X0,/TH`^XW>KM:-DL!E\<)57\$1:T)E(26/NR18,5@;A$!U!=@5X(`!A
MD#W+0'180`6D52,Y2$M*U@;V.0#S2*QF0`=O<(:400:"(A`QLD%CL$;TB9E3
MD`:9T3EK,!+'P`U2$`?K(0=7("MX(`4)Q+-64`<"<`Y[@`=6T+EI4!/BIFF/
M9BVD>;"Y6%:F.KI!`04A4`92X`>O<P6?*FU1H`:08K9!9@>HT"ILEF"#A1E]
M*`+D]$Q@8&U\-`#E1!%OLZQOT2K+1Q@G5R-'MBK"N:*S(+,WAP5W2P<*]EAX
MQ$!IX((`,3%@()]Y,;5V4`1YH/\@DD08*]-:3?"`R%*A_YFOZ+:??[,3]"N1
M3+%_V[)ZU4*JV](;./$4#U*02E`A8"5,$CEN_FE($CLA%U`$=O`&A49>Y94/
M:(`&(*-E+4@82W8*/E>XO7H1)8D*V\<'J.%OY<076R`%0:<%;O-96Y!/?2@Y
M)$L/9-!$[_-S:L"IJ4,Z8$)>0,H7JY*8U(H&>$8WNF3`]^.<8S`EL%LH6Q`'
M>H"5*U$%`78)T-$]-K<ETQ$%2Y8G@^$<5<`'5L"R[5F'VNL8!*:8XLL&WJNQ
M5``7WSA>9@!G4_0&NC<&F"$0)V<DM3-DCFL6?$`=:I`+=(`E?8"Y=>`&X[$%
MAE(%3?#_H#%$NCL3+92VFARXL/]KFFX5%$6@#>.`B4H:;7]`%GB0`&J048#A
M.0L4%PFV7]6T,<:V&&R1#Y)U1!QG$=3&`(3W*SBE`1(S>+V:!BN\J,MJ"@#1
MLA?E&`!A697%,.37OI3%`,A'8*BU!NQ:<GD@GW%$%W'1(`^R5OQW;O:;&Q5G
M&Y>FD1SH;D7!</!,>Q'*2T[`?[RAGQ1:H?>[;I>&``VX7'E13C1*5*'E.#YB
MI.\26#EX(NVI)(#G;R1K&&G`/,PT!EY@C^_T)5!"F"?WR!;4.<[!MH57$#,;
M+E!(6D@)98;+0$^I%M@7DGV77"W32([$6H6Q!5=0!UUP"^*U_P5RL`=^H@:"
M$F%A()M/&@7(!L-*ZI0KLB.MP[+]0@TM\@5\0`_<!D)<,!G?C&R<XR[58*@^
ML([0LZC5-`#5R6W@Z2X1EL;L\'45=)(D\0>VR1<RF\IU4&.&6$]18`?(<I&J
M2YJIFLGYG"'6$L`PA)H\X0%H`"!XL`R3@#U4<`<H81[T(`;C>D355'(C93!O
M@V__8"-T49W2IC_'N\A8X`GQN$"1LS&`@<R>I6"K`F<JHSEC@,VSE9@<[*W]
MHWY\5')X]`^:DSHVPG%X2QF0Q#$^@$R/T01Q$[K$T8_ZFLX/C&Z"M)\2ZC>S
M`0`4<A,"R;_W;$B\L<#_%]WW^I\4RO_=#>C<RZ%\@.%^*/=?>XH+->)`98#,
M_Q)"A<`%7;(%&[..@K$%I*$!:3`&3=4'>X`%"K:4(IT62V8YS_`N3"1JI6-:
MXV5%RID)]1`=(V8&#-,O6RU>90`)7]`_GY6^)>,9;!%@2$F&=<`B6)!-Z6,/
M3]:R;K`2]5`[DR`%G!IE3CDCF!@&`I!&5W)S,XH+8J$&G#,2BX76[^07@5D&
M"=18%2P8'HY,<LP7E_7-/`L/.SL%FV!7J\`2C\H^OZ(%MAL%53*U_M(&"O#.
MJ%NZJ:NJ@QW8$M)65:$`6A!4>@`[F2D/=W`&80"EBJ8&<+9\WEQH?.'AK'&\
MAP`'K]V'5%3_:"R59(T!I/`B$);!!BRZ,07&KGS$'"NRIPDT%Q4,0N6+/TDT
M2<[&9GE@".+5/]G9(\[F:O1R(I(TG_(*2!ARSM1-2/5;&^<LL>HV@MH]@OS\
M?\$$['9CP,5$3DDD-(L!+(30"!_4!J$0!4GV?&D@+/YR/1!CX,PPET3W3K$S
M6'3@+S2:46S;%C"R9)Y(5#\Y"<+R3GY@15-+=(4!A;7C9%1`2RCB0&>\WUX0
M!U101^^TE(NJNTGB5!ME!=8AF"SJ!MQP!UZ0.E@PZ'^96>G`=N_#14JJ:'`*
M\<%3M)**5=F:!5>@!WRPCE1",(`*Y8[3AR@RR^,#8(7BK7;$O4RT_R7JLAEK
MJYM=(`I\("(IP5"86%U^8"M+B0AH8``W$5=P-8!S7IJ0-A2*A+H.&4,>H`&*
MH`=G63Z=298((@IYT@L;X]PPY1;DYZWL<EZO+#F7I8@:,T7(S*WP^HUV=!=X
M"RMCX)MU@4R]F@]U44ZK<6V#]0_;Y]^:#<+%NXA7HL0#8`UI@`@:),>K`A!+
MYEGCY#FYWFHDQ#?+_NNX@<Z_-?H/W*_]AZ_K9OK[S-V/I#+$S"+D20:>HTR[
M]RZ6EU%=8`N'Y7B?^F-2``9M,`>G005_8"LNHE4O?._E$`7C`PSN0UX;3'3E
M%`4N6)T\;BN3H*0SNQ=50@L9O4Y*B3HWA_]!P`"[40`?4F"F3GCO>UJ=10L)
MF\`%[5EXN#`CF!0'70`(6&-?6%E<:VUE5G)745MD:61?8%->77Y15EYN9U9_
M8F)_5%=]?GI>=CYT551:9%I98&5C9+5I;79V8UQ;6F5O;VAK>0-V<WFU;V5:
M8&:[6E)Z<IYN?UYA87%J7E)]4E1]UE1<7WQ:`Q=.2@CJ`$KO`$%!`/3U]O3R
M\^[O2OOW]OSHO6,'P$D1,H7$R`G3A\^5+G_"_.D3A0^?/E?^F'DCH@@#-&;@
MP)GS9LZ`DQT9O('#0.6:`2(TK#%S[`V;/&B^H+%SDLU+#0/2;`%S2(0/#0Q$
M,)C3!LZ`(G;(M-'_(&+`&ED#-*"9@N6E4CMPMFQ)P\;,EBE?\N1A$RD*%C1O
M\JR1FH?.&C1IYM`A1N>8'3IT!C#PH2`$`H'Q@D!)DF1Q8\:.&4N>3+FRY<N0
M,5>&XAC*/'Y.$'A04"0F@SQITJR9688H&;UFOFPL2R:+'RUFHDP)B=-/'S)C
MINQV2J<,EDV_E]E6\X>/%S54^(1Q0X46ES(BX9@1YHM,%"J:Q%C)@F6*E3Y3
MHD@)(X6/'RE8P&3:L@RC%2MASHBR<H6*%"E^=!%''VSP]$475TQ!'B]<`%>%
M%EKTX44F;DATGA]5@($(&%]D$9TCVYFA11591)'%%/]U\8U_771!A7I___RQ
MQQU8/#4`%WYDT0<56)"!UVILQ#4'&%H,5<8Q<SAUTDEKQ`4&AF5DD445?\3!
MWQU[X(%')W\@Z,4?I(AUA1=^^.&&%&4P8``"ZSCQCS[PW--//`(IH4X_<^Z3
MIS_[.-&.!P-,P0<64H2B6Q5^A"$'@!']884479!A!AU`E90''&K-H5<>#&@`
M!QHLG517'L:P<1-/(MCA3$B)>#6`&5A,\M))?=$!QQN!:;5%@76Q010=1>2Q
M115E<,K&&,Z4D08:;:`A:1IEV,$`&U]$BQ0;97BE`5AMY"&""&S,P<!)23$@
M;1.%>1""87[&PYD\G'&FV;STUDM9O/'*HT0(%__TJX`!4.E$S*=F!$G6&ZO-
M84<;><VQAFI8^)'F&UR`$1@<M0P`QQ=:7!<N6U%T4<477%SD'A9:8.->'&=,
M44:U:RBI;%CJ`1C>'X9$L<D?4EPAQ100DL,%%0P)&D4494JA1AC<#/MBRG=8
M8889:4QQQL]5'#+&@V#HZ,W58N#AA16CJ#$-R>=5\5T6)&N!A3=15!PR?E1X
M6*@869`!1A5>["&`&%S84:FOD.9]2[-$;3%E%5N,\;`DY*#AK0A-:!!@%F/L
MB-$55L0A@`!XN"&&BO?YS,<6:*!AA1YUJ"&`'G]40<8%!1'T3T!Y!J0G/W$*
MU(X[?H(&SSH&I''%%57_"$J>>XL($$87>NQQB3>YB$I,'B:9R\:M:Y11!K,E
MQ0083Z>1*E@>;XSQEDTFG:0,+6\,<#$77+QA!S%V+$,R)&6!`8<&OF*&3TX4
MKO&-ZU9M^`(<CH(7#1A@`&@80QJ>4H1MI2$5#%A#^S10!`-HP'Y484`1?"`"
M`QA``1<X3)L2DP_%1,9>]HJ,#/'E&3O=R1T(N$`1=DC"`>2A#%?`@KCLH!J;
M#`-]\:,5'=B"B*V100-:`0-)[C<'H&R-#W$#290:4@4L<&$C<&C#T%Q6!HQD
MZ`N(P!4:#M&&*[2N"E7CAH(*<07672$+N'&&C\Q0A3.(@3F"LDB9=L0'5NR&
M_PS>P$(9MA"%/I2"(H_@PLA@5<@O?"$*<;@#'\!`"=?)03=G",/QQK,%/E"!
M"E.@@AI(80XN=&%"CSK#&;Z0&C+PP0UW"`,?;),&`^BP#.9@EDB"\Z**R>)A
M6B@3.+B0AR:8<`!6@*,9^*`&-5#D#'B0ABC&1+;S\&$*0\%"'?40!P(00`!U
MN,(`/!`:@NBC('>RTYQXMP[=]8Y/.%3'#>F!``6P`9-QV"4LL.@?,>12#@+0
M)!=L`Y,/BB0NGF*#8*R"A6\ZK@UT.$U3<D&'-(P!#0/PP;BFJ4!:L40#3!$7
M4HKA+)5690!S<,87>N'%U)%,65/CPACR0!4?E&9);/\XA`^:4)>DR&\D]^N4
M'=@0&/.9:PXQ,95:<F&3[3T%A?RZ@`<\P";>N8N&-(1,O"8SUAG**U^Z<X<'
M^F4`=*VU<C`Q2A%$PH98O&%<N\`+LYI5AL`(1@27"L;+R$`'(GYA%P43%P0-
MR<E=9L)EL6G0PW!$!8N%!6B@LHE0&I>%,^A!#&-@`!Q.A!<RE/(,<J#"+.["
M!7`.(F+;\`,W*$*R79"B06`8PQ:NHP5N:`%I9!-.UJ`!QR5*80]J^`)3L-`%
M.9S!$?:)FUBJT(>122&AXU&6-]1&A3C480J\&)849(D@ZK"D*H)3RDGLP#X*
MAI`-M=A("3WEG3^\IHQZP(/_%:(0AFU8`8OIV27*I@`F3-C-"EW(QAWB0(4W
M*$"?>XI3\("'@*ZFU4X`V5,[?P>`'`X@"G44@#6!&X4N3J$4V6@%&L#`A_;Q
M!'UM($G\OO4J/*8!#E:]%$G6\(4I@,$.2CF@&<@04L#>]2BYZDB0->#3"JK)
M!T-N@Z]TDHAJZ0414DXO4$0BOR]0P0]I$.U*`M,2BHXA&,+T:TPGN+'_K3DO
M2QR`,TDHPG^Y=:MX9A,+\^$9Q;007RUTX;L"W>&L<G6K%W"FI^@P5*!<"A<B
MF-H:QB#1:?7A$K(9EB`X-`9<P*%[>$3$4,;@AVT8C@YMT-MN2\8S+W@!"U(^
MCA]F_SH%1&TR2`CA`K2V(!N,40%,X_C+R[9WE50FB`PO&\,8,#>UW*CA#%>`
M]J#&`*$J="$+:3!#MC*!*#$TH@N<L`)X$R6%+!0(QU&0@QJR\+V]720+#"/2
M(QZ!!BR<4@Q["`/;:-'(+<0F0)9XT8F]T07\>*&0CI.H=K*U+#@8`WV#&,10
M7D+"VH1!#[.TY7UBD87[:"$2@QB1</A@A3-TP2W)\PTK7(=.*9B!=O9X)SU^
MY]5_X%#/[I!3/`5R`0V8(5&?$X,C[Z/3;*&!;W_`PB/&P(<;)V6ED8@?>UL2
MT_B-RR10M,I,P,"&3I&D0.,J(5PYZ`,?=DJDM^)45=K0!O\2*DLP;`G7&U1#
MA[DKC,M6D8H/E?%K6(/$1X`!AAFBDRTX`";PL0E)!&'R!@@ED<R=TEA(@>)`
M!5B^7R'@:H4WCZ?@M0L@6V4'[YP0^M"$`&!`\<$%_H44H"SR?Q@C2V[M`!*/
MXF(.QN%#-WI<\,.J9S?-2F89-(8A/M0A`0((XC>U\-&I;0$\,?)#I]_@9:#U
M(0L;XQP8-*:%03G'#VT80!OXT)P3?=RCB9TT(78KEFQQ_59IH(+HOA&?,O"Q
M%%;@0@2/9.UOAL,:;C`A7^0'>`!:;<`A;;`&?7`'I@82NM5ILP`&DL(%1=('
M9Z`&H#`%@_`@6*`;M&`&7"`&<7#_;5^@-IZP2R="!8^06US@2%CP(*E#'E7`
M']!G!6\!!VD@@7\@`(S`'U'@.$<'#F#0!KJ%(F/B**-0<!5A2M$$8G&`<6?@
M!700`G6R)WPR/%:()YO'8;=38:%1!$Q'!9XE!L,R2-_T!7,7#6XP*.QW8UGQ
M5P,0)+2G!072%UGQ+9170281$QIS#,[P!F3W+>,25SXD&!E442[#%)9D$@K3
M$L'0:4J4"%3D%&($!@.34;'!+#ZA&AOC!V/!(1(50F#A49-`-:$8%5_`7J#B
M,'#P+:AF/VJA`4W@`R>T>I9G>0!#B[AX0EB55:MG0K5HBZ110B;D$7.0!KI&
M0FA`AXCP_WIYH`52,RUCH"ELL0OVMQ%S4!L1`R!<<"Q^@`4*IVR=L@:\9@H'
M0`!A0`5R$`=^P$EGA@;D80AX(661``;V!@;@DAYD\!>O8&UQ<`4ZL8Q_@!:$
M`@9HP&OAIS'J=Q82U#42=)#1ATHQ@P;&`4Y?\`JG\P9D`#34-@I89`C.=X)]
MD(YI\`95<`=:0@60@RS,U0B/4`5NH`=J@"`0`32-5`6[L"-1D%M^(`J"P`6:
MT!R'=2)EL(EF<"*$H'_DV#&\UH&"Q'R4)BR9M`<#0E/=]RB8,`HBZ`9RT`7I
MH4IRT!R>@!Z\E@7ND0U30`=K8D,<9H7^@#MXL@XX9W.DMU4*L/\&C^(?4O`%
M;?""'E('`75)<G".85!K_O8XKV$4ZE4&CI!15P=10$%F/36+MJ(29,`&5#$`
MCU@MCT=F:5`DO]`7(I%1&I!15;$58*`F`*.9N9`DMK(2M-%U2R1EQ!!Y0)D%
M)@$8Y'(:&A,<BJ0I;^`#/I!2BU24U^,P]M<D\3-"3-8$X]*<FKEB73<N#*!H
M'>$1(H2=1D%GV$,,0S4`@X!&VT)@'6,&B*`QPL$I8113S4<_0[:/I5E]34(&
M^G<,Q1!^IPD7:-`'HF,1VW`1*J@6J\(&B0`2'(,%;^,':U!W9%%89>%*8H`)
M"J(%?*D,4\(513D2<)!LNO4*/?,-5J#_$)CS!V>PH)(T%*"R!MW'?%N`,N0!
M(11:+3GX/:44HEX`"^OA,R4&(!!"!75`3I<0!@20`&&P!59P!UTPDF&`"==1
M#N#`%5IP8M[W9>=!HM?W"Y?R@(LT!@X7,?1C#FPQ!7X`-)`P!HL@#=TP$4Z3
M$?WA![_V$.@A!5X@!B9G@=:$1X70?7,J!5%0!CZ@0J$13VZ)&#I781$V3Z:G
M``,0(#T2I0TR7%V`!]:4*'=@3G'0#8)@$\F61,J0/%+Q%V_`=FT`FS'VAL2P
M+<?P,.TS+JF6.DUB#*\Z1:<!#`Y'/N'B0WPT!I57.?C#,(#A$]Y3DCQ!>V00
MJO\C?I)"#'-@_S#=(D*1IAN*!U*:.9%<]X9@,1))8I]9<2EVL:`<Q`!TL(Q<
M8!)D(8M5\2T/0QAE1XBCJC&*A!/H,0>E00:GY`NNFB39IG`EN1JI)D&?)CE6
M40Y3$&:AFE%TL#7TT8\]HC<"]',NHS=K\!=SL1$\5@@-8DG#,J[8\VGTJ#Y^
ML%_58H^[110FPB'`@0;44F+TTZ)24A%48%#CT05GT%?`=$J[TAJQ46)$T1`E
MT@<A^P7_,5T5Q4I9,!1Z@P4(Y@540%T)QJ=>\#FJ105XH"(SF4H%AZ=X9&M7
M,)-+.P6X=`=N\%^,(S?2USVRP0;=1R(6P6LAZ@<E$RO0Z$?HT4@1H?\;IQ0%
M%PF-I"2S7:`078"!;D$4M:8)_]4?9:`!"L`F[.`G.)<[-L>6$P8\[51A'F``
MJ*%[N)%,&9(M&G<?D+()<B`&X'`?4)0'4F82>6`6C?.J2Q*JN$(2?A4,-R:'
MMTJ=Y@*+<_<PNH4&N;(MX7(]=;%((/4&5",X35`5@Z@I5T>@]G,22+&>($%$
M:1`8QJ`PI2(N3=`$<U`QN,)V)8F#-M&N\E-826$:<M%I!]DQF.)P(L$4_Y,'
M\5%%,5$5CU!"'D$<Y!!^;.!(0T$_`V``/L`QPC`7ETEF;>`*L\"[<Z`^9M!0
M$_47Q]+`"RQ%:V`>8YHC1,%\[5H543H,28+_%Q[5,9)`H61!;13(;L<`!U%:
M"'Q9!CF2.F?Q',VQ2V*Q+'K3!^)AENR6:DUB!GT@!U[P(%R!+&`@%O2#%CP6
M-\$W@[($3B@C(`-9:RA#'\[0.%1R2GT0'UR`-$BS"5=#)8NB>\<3!WNP!T)G
M(B-"$=)A<N[QHV';10'R#6[@!EE`D2O\L?_%!PGF$&)@#C&B&X_23=Z`@6)*
M"CZV8L(A&]U'!2UR-)BC$QM)<OV!$75#'P.@`%SE)X):#_8D//1D)Z*A>:>W
MO=1V'HR$Q4/1(0$B$3E2'HX0,5:P0T!1&N-"O`>3%1WD`\8P&$"A,=P#PC%&
M/EMF*C'C0VDP"1U2_P:CFB19UA)U00=DD"/7PQ9W%4:#F!0B93Y+0A50Y'6I
M,5,O01)Q!5AYD12IVRT^M%19@3"&)V7:MJ"#D;TBL,`KJQXUP@#.T"!.(9QM
M`$XQ0P<Q<70-G'44::1:$#/4X@=\L`;;0BDR$3\.(RE8A\]E,B5:0!(5161%
M,(M4@8=ML%M>=@7*0B05\P4W08Z3$ABZ_!W%ZA-<$!_R@;=2D<+RP3CE80:T
M)QT%!VO4PI=D0"*>Q0@6D<6W4C)7P!!4`H[+2(E1L$JOT09FR048)7X>$A_D
M@2Q4LP55PA[558+]45&HU&D8XZ9^$#96@$;'W(&U)J=IVB7EMC==<`=Z\/\Y
M=^!MUS<L)((T71(1HHLZN1$*S;5NRM9]B1*ZT;$>_O&-*"(&SV--!!8';N`B
MA=2WC^068M$,.6@1S4`UW3,3C(01V,`CJMP'9N!+A[$[.:<G%-8.<0+*HE%A
M%^`#:Z#6_`4=X/&W*K(C3[@068PRUZ%;6T`,6>&</L$P&O17&PT552120.&&
M2W0,=L&(9+%&T#HP]*DARSHU>+$=0(82<V"61!:'WML@X[(7,9&Z7"H_\>-H
M(;7`*%L&UW'<@@%`$*)P]$&-_P,P=$`U(E&/CA,81C&M.;%0?<`%@1&J1(A&
M5O%%"`V(`]`UQFD5]M@CVQ$NJ39\SOEB!)J#@K/_%B4A%`#&'SC]F;N1%;Z[
M+--438[<%'A!#`QS?^-JO6/`IQ`B"X0B?;GE(P]%?7Q0K%^0Q0C1!_^%%K6@
MS!J0!QVBHZE4)HWP6]_(E+(#!K^VUEW"!S2!+0<:D-=MI%;PL8V`$=>G/):D
M(=37HE'`#%&0=%707SA))!9M&]]@"&JC?PEH-2-8!^E48LE3)&+J10@V"C_#
M=64P@P7'(]VS'0CA!7@@!P4>'&"2:<]W@5X)8A?X,^1A(D`)F-\T8#2(!=MQ
M6!&$+%L3;7'`CF!`%K7Q!1GU8/<@#_\PN>]P)YI\)_T$![HA3K@D#<=S#5ZP
M(W(JUW@P@A>(/%UC(NO5_U!E]KNF8N*G0;U-X3YR*"KM@X,S`8U!9!)SIRS2
M(A=-HA;=PU2=`G&Q\D6D`BT%XE&2@QI%PE0[!A@*(]SK92L$RMU(H0S8^.&6
MA)E%,`#V-P:R8)ZL<4'1>4'@DL*C>&.J(J:-I`5[L9L;<P@Q@SU$V,"H@;(O
MO0:TJ`&)X%%%G`6#T5$Y^(+@Q0I5<."IQE1QL0;4A9,$*`>#<M!AQ!)YL#5"
M'@5IL!;=@P4\\R(^8FU[&3-7404X"8);@%'UIG0.@4JE,`JJA1IN:CBU\1VC
M$PY!O!U%M(SVIB(J.Y^C_B*6=#3,,`F*\QWM<6)L<TRCBD#04.!3$$3,Y0;]
M$?\=4E+$X'`ZZJ,%F44MIB0&%?*-8A&E0;,:Y5%1770=NO<>+U*6MB%NSE$-
M@W(Y;,%;7N!<7O`05V`HAG"9:U#65V!*4O`H7[*T70,.;S%3K.8%V%0'9YT3
MC8-L;2`"EI=Y3A!HK@X:^K1SIB<"0!NZ?V`VVJ"TZG&!UL#83(,@?P"VUX=)
M,FDN?F7BFJD6.3&])/%0.0@&\8-CTI+-W8EJ!%H;F!,8.[:@7Q%Y:Z%LPY#L
MNK63@F$_*N&>0>(L+V$KRRJ'2P%53?`73$916.`42@$(<'9S<'D#;&!?:WEV
M:5MF8%QM`PQY:V-H`P-H96L#(G8,14TB;VEP<W1K6U'_?U=@`QJ:(@-O96!H
M:69M>99M&D66;U]59)1T9%E;6UI87YJZ7%-:9FMPD&^:<'1V=FMD8\116VA1
M<6)5G6R09&QO:UQ\55AF[YQ<?E117VUK5:Y8TJ0!H^7*E2I;L#"C-D::ER[3
M_/3Q8Z7/ER]\'FY9@T8+'S%NQ/C)(I%+KC9LQD2A@B4+%C!EN)!#9":+E"D*
MJW01<R5+&CIHOF"Q4@7,%BM1RG!*LZ9,F6U@K%C!HB4+&#!]U'CY(\5/%9PD
MJVC1TN=/%#!D3G6T4N?,'RM3HF3Y(E/L&C9!6XX9X['+%8E4^D3))^6,&Z1]
MO$BYTH=/%$Q\LT2YXD;/GCI=__I<D3+WRY@W;[;TD:HXWQ4K?*;X"1/F#Q\N
M5:A8D2VE2QT]9_ADF5*%2R(^?,JTV:9!`0(G3@!`@1*D.0`ET*$[0>`A1!%N
M6+QX$>-J:Q0LX*OXZ:)&C'DO?7A/X8-ZRQ0O`@2X\09'UH`\;9X.8J.4#1PV
M[A`"SAISA"*+#PS0L<X;=M"1!QUMI,%&'@PP8$<;9IC!AB9V:"#"''N90889
M=(A0Q`!MI+*&&7!HPH`&R*28!AE/O6C'&W,0LH8=)Z+!A@9H</$&+6U4444V
M`]PH"QLIOB%B&A=^`8898ZP!#"USF($&':JP00@;7#+@PR$=-O@.&["1P8`(
M=+P!(_]HNJ!A1AH,MI&)`3XT.$<:4GJ9AA95[`4&F.^84446F8B@03=)MKGA
M&U<IY..*4X314XMO2#,%%QO:@1<S(_:#!AGDS.'D45[P06H?+?71E1]\_-'%
M/%I$<8854XY1!H`B8A&7%'QLD<458MQQQQ]8<*%%.S."D847>^S1!1AV$E24
MG6V0X8Q,45@1QAE2E)&'&5'T0049;8Q111^/)-M0%EJ@H5(448@U(A94Z!8>
M<`C16(48<;"4195I8'&&'F%HQQX57,"S6!1<E%%I'V44W$47B_VA&'!267%:
M8!,1%4X5L[7R1UE["(!'9O),R<4X9/QS!FM4Q,6>'WZH@9O_'ZJQUT6^?%Q1
M'K!Q99:(%&)(49'299AHP`4('!<==%%[<($!;%811A1QK9>%>'SD6BL?5'3Q
M1V`5X00H3%A0%H=9WV2B@09YW&+'`(3<IPDC:[*YQAL45N(.'7#<8L8<E.11
MX)H(SB$G''`XR<48IG[QR(@#%%$$`W-0J,&>=OB@J"P,#(`5%G/(@B.D9GR1
M1NG:EI'%:R+&1`XW;Z!A""&0(O0&`ZN,<56GL6@`QZA:;-%&[F0`1<8<&"*Y
M:!NJ3+X['0-T4F$JFKQ!QQQ>:L``'&G$PL87;(C`0!E;H-NB)@/`0>.$%3[8
M)C?^M5Z&ACE&&,\4_&!#4ZX"AC1T_XX.ND@#&LCQAO_4`T1:``.^_%"&F)%C
M"F=`#T*&Q9DOX,1]>1!?&IPB$++`*FA>H$(62!(%,GR#9.312A^4!2N%C(@+
M./2(%-+#L2ALJ`T>X100Q\.'MEE!&7P(0V.F8)2O3&$+4B(#.,@0"2WP8T\D
M\X,SI%04,'3A#EXXS18HHH4V8.4/":-"'`0@AF6)1@INN(,;Y/"'9M0,"_2B
ME12B@`8X<$$-`JB#1*)0*S>X00UGN,*FC)(/*_Q!#&H(0Q>LX(8PP(L/B1'`
M'O[`A61H05DN\<@?7+.,G(6!-U=@S<K88Q'A@6$,OVB"#YJ@@`O($D9EH(L?
MO."'Y*D&//]>(8,)"1F%249P"K)11J#(D$0W%$,+X,L&W>SD"1$H2E&EXU+Q
MXL>D!D+.&GG(E$O`D*,6F4A]#UK3`/Z$DS&`"0YW>=]_!'&W^(5P`'1XT><2
MP:(V*:4F".DCBL0C&++U(0OM>(.=JE&()+VA5F984Q[84#`M6*,-];3#-:!X
MGUR\@8JH4&`(QS><:Y2!&X,PXY`6]3["4>)N;Q#>'$!!AM^M<X%HR-(7R""(
M;Z2E$'F`0S\*=`T-1>YXGA%>6OBDA4ZL@4[@&T@5^I@&A#:P#=4BB6]VHXPI
M\4<\?OB"DW@V.5W12$M"M5RYZ/$%5\5FAC%)C1:F,!HJ:#%#8^/_&D(BL1L_
M_$$-6AG)5\#`I340!!-;N,(9Q-`8-<1AJO'(%Q9HE$O=[#077,B";[8`RS_5
M<%EH(,C^IG`%0BJK7CQ%DV9V*(8ZL`10)(F#'L20&;H()GE:H,A*JG`7#.)!
M#;H9S&BF\`<]Z.$@?@#)%;KP-IX-1I)3"$<4PH"',TRU#9FUHJY>-DAEP?%6
M..M#&`1PAH1(A6QGD$,7MB"[@`QC#,+$Y`H'&87:Z*.(6>A"(F]"D(-P0;P]
M:08.J2"'.CRQ"Y28&S??`"91;"Y!9NA$*A3')1&1`0UWFYL=DE$%?HS0&N!#
MR4S'=+XM&*4>,\(P'!)1!B3MS:'42U(:_\9@P'0)$XI5.`N`WO$%0H8#F5WP
M@PLK.*%8J(\.1OE%_`CA&2;]9**%$EZ+[*=0[/TG%C?ZGBKF!+DR'&I+;<K%
MW3RA`>\Y"1.*$PXUV="^JN:K#'ORS2FPMV$?L2$99-`HE;B0+#3<Y485-`4X
MTI!5B(&C@)SXVXRV\!H)SG4<8$)$N11A!BY(J6(9`L,4K."5H%62"Z:J`K!N
MTD<SM*2^-[$T1M%DP\QR-B%8D$(<)HD:H2R+?>!Q6;>N\!HNU&8,\HN'']I7
MAC%D03`N$4O/[`H>1X:5#*Y;Q1<R%.N#'CM8/E*HICN9"*,`9PO_2%JP^$(1
MN)`%+G.1%T4VX_\Q5]AU-7C0`QXDB8<]J,%L5/&502KRM2FL9R07F6`G5X06
M4IDXW.W)[VS'(@4EDC8D6@R,0LJ%1HQ-8W;KX3>W=!8'PTCA"UIPR]>D\);T
M),0+>E"#%-1`@/H@J'3QRP4=Q-<B.W@T1QK=!D4C[";1V;Q&AXAPL?=74P7;
M042CHF+RQ%K5*65#47.XBYS`]"#^H"%W'=ZINJ;`T_\HL#\*;:MK(M$.Q.ES
MHEHRA7`NA!)K:())D1#6%Q"'N%IP@GJ,,&`E(A<4,KPL7U_(!1JN+F,P36*B
MVH+O3G_JB+*^DBF=Q!&7YF:G4<&&"P+I\;!/\1\<<2A(R[C*1?BLB.__]3B"
M?XL;,5[V%T^@P:`O@:^ON/`?O/SK5I2Y0Q<H)S_P!,M+8_CW2*JA"`P-'JM4
MHE$X8F8%.[X6AYCD`V@]@MI4:,N%8T#5%%I'!=:@9SV8]%8=4I45B'"!2@W1
M355:<1HI**V(GRP#%KJ`!3O+KC9P3!45`@6&E6B,)5N`0U]004/Q%SEV&O[F
M+4GS!WC@!N*E!YBA#U:@-'%0'CS!&66@!6$0$HJ$,1<1=V,`";!D!E/0%9NB
M$QW',ZWU<8G%:YN&!=GG!Y51!V'@%5_C&*ZR!80V!E<0'R'A!BED!>7Q&%M0
M&)DA&5Y@77UP!P(P!OED9):@)7=#/@/@`U8(_W/WP1'8@T!%AD\^`@P)8@B,
M@'BAD"3>@`;+XV05$TXN%&&(,RY0%(!7AS@(Y&=FT#ZA@&3[@`H3!B$[4CIP
MD'WA8&F=P"![LP[R\CQ)DBYC$`M=$A22X4[YT3F%$RBI4#B3D"1XTT3R`#$"
M`4O:T$WW=(=4H$*3@V%S\`4KU#SB0P=E$`7E`R#5M`DXQ%=84&Q^<`5;X#C[
M`XIYH`M^IP7PY13P]3YH4AA6@#ZF@E3,E$)P]@5:-!:=)#NNL0U"9096`!%3
MT`5R$`=2``9K\#W94@]`9%<!6%:;0F-<0E3?\$I5DDO4B#$(48+!0D`2U!B4
MHPKN(8Q?0`7@@A5B</\&9]!Q[((%9>%873`77E$V?=4'C3$:?A`%P$$O5N`%
MK-$57G`'5L!>09(1;H`'!R`'<Z4,63"!=E4OOD$7(Y.+2<$?EL8%93-L[R$%
M6"!J&(,T;2&$;A`'<:`8U%`%>$``>L!+W"$LXR$&8;1]=E(K58!)J:0&=?`'
M?G`;5B!=*^0M(^&/>B`'BJ$0LU,;@)449J`%8@"!C$$%5\`5:.D',-$'%<@8
M4A%=6H"6Z*-/#&!&UF`'O3`+!G!+I<,`ME`BM=`Y`A0Y7A).;!`*V-0&]0<:
M:8@2#G(?^:0Z3N(9N0!M4A1A:"$BT_8?[B0*/D`'.#0<<*8ZX>@AI6,JK_3_
M-^YP-_OA#C2V)MX`;9=Y.(<@+,(!"3^1)&O@=M.3!U:(((.W!NG",THQ)2OB
M"9Y"9QW!$A6#55%G0Q.B8:US%\4&$U[""DUI,P/3$#QU"[E$6:W3$B:Q/-[$
M8!BB$F)`!05$G'3F.#4)CKK@#G[7"6``'.`0@&0@D>U@,+/F!VM0.I<P(?DQ
M#:"!$>X'+%>D"7/0?W)A1:]TA\(%*U3@"DC15.DB5\S`9Q.Q4\-R,5RY'F=P
M&4RDBJ48-A&R!6(@!U)@5_Y&$8WA&)S%9T*XGNOR!U-@%8[@*IHQ6\+R%=ZB
MB\G@,<$2>F.`1P&!'U"D$C?!"A(1*$*!3,7B!8#2_P<74Q94,!9^D$%E(08;
M*1[<:%SK%6'K45])N%A:\0=U(`=48&)3`@85*@=R<!Y<T4M\@4D9R:9&005[
M=%J'`A[X<D1'T8TG8Q#^MD)9`#A7DB")B9IXDT]%(`(^%PH3M0W+$TZ)&&%V
M&`KU$S^#QB2]N0U.D@V&$'/4$W665P;UU`9"X9"/@`H;X@.1V@CP12798`O4
M(IL,UG@;`D_>PR7?@PC\4`L410R*`"9`017#&"&I@%6Z4`V&%5&RX"D=0@OX
MX&]5$&'NE#WNY9E6P2"*PU3UX""7Z!30ZD'+HFGEPDN\40:4@$^@L0X),0^)
M8%948@956`M8Y1XY]AU\5O]&FM`F1QI!&X)/^N,?'.9([&EA:X`%)U.3#1-U
M&J(@*I&M8^D8Y3(;65`-(F(37.%^?;`L9+!I\K!IVS%)P]84F-0'O=%$>81'
MMH$'4C!70K,U\,)H&G,%],`%5^`%O0%RFV8N%]-+EJ,N)S,7BL=I?D>OP4<.
M).,Q29-38.`%*H>M(:A\(]*4EO97I148;[$76(!)?+HI89N662$'S>=!%>$J
M`.0K=$6UMT(505,L85"A`%,'=[`'=]`3@[(&&.$'/-FBX^&S$>01$X%&@3(%
M6O$2ZW*+E89,K!()99$:4A!&7%$O%@(':T(W^22IGS,<5T(+[F`(LI`A!>(D
M5T'_)T<E"P7B=HW@):U3#Y7I"?@4(>OPA-E2):!I!^Q#$;IA!AFV.9'I)%1%
M(^"`8;7P5-X90D(%&KGP5)"0+"NB0/B`!;R`(IZ1>=22AF""!G2E!4Q!($#1
M1]3C(7D0)/`""6"`(QYT8<3)%-XS"!"R%W1B"`HU*A5T"G^R/\H@&F'0?*_C
M`^*CKP.DDG,B:!W!!7EP'0PE&L70$&'++G(B1?&@&W`&/4^U(_$C.RMZ!;3'
MJOC204'#6TPA=+4"*[QA$EX6ET?:IUE0-D$FC+O08U!$5W(5MNEPGQ4!@\:6
M8ZR2@?KU![W!&U0Q5SF6D6[0!8WV-:]D%%\S5Q<#0!?Q_RX!J!`B,AN9Y3J.
M,(!@0!AGH`9]H"M3P!V.L7\)L2S9!VXN82MW<`;OMAF[X2I$`2B=MA,5FD(N
M\<(T"2\5'$$O_"VT5I9[4(,K!UAY>P=2T!OR`B@D:SE_YQ+,H%=4D#0DXP:N
MP:-6X7>345I[@4P<TP5A$$E=(0+8=5))4G?B@Q)/)[H@5H4B`"9)`I@L$@M_
M>9<8UF"/.@?:0E6=8"";L",C@CCP1)R:2S<<$12E*%:*&53OVB8V%WB"%HZ$
M`R`8I6#V*Q0#B#P1Y(Z1\!(=$G6[PSX%I!1Y4`IQ(3<)XHK-@Q;+8R/WBT,_
M80K$F2$;4CH18@B>PA2I8"K'K/\4.7(7CJ`E-J&+;XC!:?`5F+`\(Z1MYV=I
M8((1RC,0_-`F=\@'SC4.K-!KRV)`W\,(H)J-3S1X&'$:]$(>26$YGW2.G@R^
M>T(15O%?LX)9$P&\ZP`@,4%7Z2`A0>$9F64D8O'"%9&M:_`L-'D1@3<CPO,R
MZ345N69LR,0SDS5CXM%4`I%+"Z$:5B$E^-`P8U"#D\$24M"`\D`L2IQC`D-R
MZ4%(,U),!Q,'Z5&E:&W17",;(/=7!S46Q$6AS#!RPY99N<@:7.$%:WIO.R$5
M`[F>DB$8RR"1V^PLYD)(OE(5#(@;%S,8IV'17C%7?Y!()+%#HZ$T#7<R?%`*
M-;DE\,/_`*0`(-G'(OS18I%I9!6"(!2B-Q5R"#95(0VB(!(B)H#9N>JS0!>F
M/2AR8275.:>[%WM!N_`3F>O`%&A8G["*.+)0JH1S#32F"1)C5S"1=KE$NQ[B
MBKK2.OZ&KS!2(A:"4OU@/X@`9PUR(TTAK1S"K(8`(;Q0VZ8R8PU5"W,"/A5$
M15Z2W>G(%"#'!7XA5OA!7.U#%\1`#F60$;B""@RBES;G*Q5)!5<G$RG!!W-7
M.O=["G4S@/LC$-+`,R6HLP#I!\+C%,U`(YTSM76D!1KC$RMR?V*%!H%R9U3;
MIE(2#E`T)S/2E,V60E9D$RFT4Q'#W[EPI$UIUBA.X+<A!G(U_R*J&"@X4A,1
MR0SY@`5_<SK]=V\DEQHZ@QY\H%\4MQ6;8@Y`^`=9``=?(#1!J0?[]V-2$2\J
MP1C4`@:II`\YR@=JD*7@,1C?(26U8E<^[1%QE$BH0065X8WY\`>'`7T3P1M2
MP(1Z<).W-95[0$=>,1CK%D86G8V*$48O48`2N4BU,""QD&!+<GS>DTM0A0K=
M("::(SH#3`G9U#F[P]$4586;XP[;-`;YTCI"H@I.<17)\ZQTDA+4`AJQ$'60
MLPO]T`\$!ZTS-P`B4@AYXR!@"`;NY[A@M@XA:`?69`O48T;KL04MHD]LS@_R
M$J#O"D2XD!;6\`X&0G/PFR.!@S<;4O]FOJ+EG',5*,$47I(CX.X1O40C?V-I
MJKL%9I$-0`$;*[3GO?048A@_$I0=>"`&"/5*<6;:K$H@'BWPE:=`?B=%8X$6
M+U,,T%I!/C)1?>`&4L!HED(.')%+*.D>)K$%<7`'D91!XS`65[<.5>$99SRO
M?N!^.9JCY<X4,1&V-L,;N6@VA(005)$(L*)U'\%8"5&A]?=?NL$'"<H2!HD:
ML++9(",1"I$57E`1L)`&K1!'ZJ5"<Z4/F/>*FS$1%1H&P#(/0R&58'H08=L5
M<2Q]-(8%EN(,Z]$%#]$%ZTI;+U&2``1N<7``!^#6,8J6J824K%*":I#$?T$V
MW*BW4EE$JNC_*CRC68350-H>/\>@0.6#3J.R(>H#*5C`!D5@`!XB.M8T-Z,#
MK_]Q=9%3S8HR"-OTB@@U5X\@S"*"0Y5VBXI#G&J'/:"1(S/WEZB`0)>6F!75
MK'TD[DUP(J:&/DZ2!O9#.'IWOI[`.>L`$_--"6BB"$$B+KY,*KZ"/MV3F(H#
M&J]]-Y4`"&M?7W0:=%%J85EL;&1<7&-E;P-V<&UI:Y9?6F!M=@P,;V]P:VE1
M75P#&G9H7%%^?7UD95M:8VAMC&]I8V!?5%Y]5E5@OE]F;VQI6%F9;6!1G&5L
M:V-<96EH;W1H7V3*O)%EUEI;9695:GMN5E=]55A87UM96%M3?%7F_V1575YJ
M=^JXZ:(%#9DUHBZ96=-F31DL4J1DN6>E3Y0I?JZE:6-FS)<J?K*`(?.KSY8M
MWL!H^8)1WA0K4O[TN5)'3QV9?^2<\</GSQ6>4:SXC+*%"[T^7<Z<D6(E"QDM
M6J*$$<-GRY@V=&A5Z</'CQ4J?LK5*YKESY\N;O2H7<?G2QDT6+S\X7/ES!6H
MP/J`V2+%2ULS4[PL>L-E2K0J4J+PZ7+E"QLP5ZYP00,&RQD!=:(4XX*%#U-A
M5J9HZ:-&#QXI5:+^42/@P)ZV6?A<Q'<EC!<J4^S0&0!JP)PW>0:\.9>G2!$&
M=.;,R>/#0)$W5,)P82#"S@`1/GR(T"!BN_^&56S@#*"32SDR$45$J%)/)TV:
M-VW(Q$.C(?V`/'#HT#%3!H[N.73``<=&O]TW0!%--&%`$\CE,<<\9+2Q"QAH
MC)<&%UF@09UO#<WAVQH(_9:'!@W.@4P>=BPGH@\#O`?*''#\-@X::=`!BAT/
M:9'&`)2$]T8W7*S!0!/'\3C</"M1XT<7&4U331:IM6%B&VV4089X>03'XWAF
MT$B&&5E<$04:W6B1!5?QE%%&.6MT,\88$?XV!DID1&,&%U3P$:$@51P#AA]B
M='$1%C1^M(49:;"QWZ%SI$&&1UA$H=@[('DAQQY[U-&%59&^-!>&4W!A!AME
M0*F%9U=TL>EO#4G_20<;5*;QA11RB!$%%U'EHP5(896!H1;Q!-G&+U60Y$L\
MFU!!1121>A&'%U*<41,>9X3AAAS0BO''%%E$49<:@NV5A1]GJ"&%'^=^@>%,
M75"A8WQ3I!8-&%RH"^<6@_)QAK:7"4#``7A0<>@:_20VDTE[Q<N2/^^$&8<?
M:*S!3!EK3/$'6#^U`4<5<4C!!1DG\6$%41YE$>I>?,C%DQ1BG"$H%U58T45I
M>XBQ!1@@B?9%%EVH%48?DY`(X'75=6D'=AID>9U]`[!QRA1P,)`'>JO8H9L=
M:[!QM2J^[3;'&&]HD!V)617U!@,:L.$6==^Q-T>*1L(*'`._62+@@3X@_UB$
M#Z&`40\;O>FVBQFC?;$<J3-:K1L<9I"AS7B\S<'&;V@L9*,AN`3W!D,;K;'7
M'!KP&-\:E8R3"<A6IC&B;]<-`.>%MXX1%NCJF3$2)&2.@>4VP6UG1QO=8+'2
M('V$004S54Q!115L#``'7!:5T5`U9$QBA]_"%_2\6Q';888W7/`!%C&^=`1G
M+VZUJAP97&UAA1I^1.*H'UZX\\?/8ZP!<LRHW9-AHU]`UACZ$08_H.0+(QE5
MFPP",RITX2M$R4)$>.)`*70E3VY1UQ;``A4_Q,LB'OE#'<[@$RE<(0L[RP=&
MIB",6(QL&@/\@\OX8`N0=05*=7F@`=$1ASI80?\>9TK*%%['$8BXX0]0\H?,
M]'`'EZU&#!:Q@A7RL87.]&$E4XC)OGZX*S$(0`]5X$)%'M&3,*A!#5;X0A3$
MX(8K\`$29JH"'V+A!3W$80N.\-8?K`"+6/`!2LS"PLS^L))N'<IV$I0#'KJ`
MA;>1!U98(5&,Q*8>Y?"&1-0)120FYZ'0P2H\WL,&,D8!(T79@0W!,5$:8%0&
M=9WM=R-IG98J`8=1.*1+P'%>?N;0JEHJQY2-L-)")H$<H[4!"V.PSARJP8G=
M;.D<GXP:WP"4!S9DKFF8>(,=WD`2.(W#+96XRB6LR9DO8&(,9H##GZJP#1J=
M<C+D*<8L[!`Z6![*/^W_^<:KW(.-X#P#"\G+PL?(X(<_B`H3?^+"B/+P!C!,
M88B5&X<DLC*/Y&&!8N,821OR@`9@B>]6*)%?&F@AFSY@04++](@?HB&R*KP%
M#0.4#1F@H85';4&.4:@"E#+""'M4J8I].(,5M,"9+!!U'A-!0QE>(;PLFA0+
M8(D"R^I0AS!(`3=6T0(^FN(16U3A#%[`HQ_BX`8WG,%=72))Q,81CT@E!H\>
M49X';_8E^<3+"FX0",38@`4YW"$,;R1#%JQ%!6'HB`LYV8,<KD"%<BGE616A
M@AK.V@<QQ"$,42!)'_R2A?>!50J$4J,;!"``,5C!JL)#"AN[``\QW$$,]1.-
M__B$$H8S*#(.^HC-%>3RQ\YX`0\"D$,6RF"%R]H#*K>KQQ3"P"0MB`X,9K`=
M&*PW@+&ER#H&XLYWA),U#XU'0-Z='ADP@0GPHH@4\JE>F^BPN1^Y9T??_433
M?+62;E3/:M1D;T.L5`:<<4%KBQ/L%NC`T>DRP'G>#9#GR,#>7&KL/OY!CPBR
MM$VL4,(CI,M#&ZP!IP!N81)KP".]=M8G3!QDFU70R1>JA$YKJ`X.CD!#'J3V
M$*.N^,!PZ&]T,90:,-S"FAZIES<-TSQ*K$&@<&`H+XJAIE[X&%&^J,47G/PH
MC(#!FKNZH;J0R8N=W6^.6<C&0Z)!5SCA:EQ\$%X5$/^E+LY@@3.2@H<^YM0'
M+L!X*V<1*%0:V`7FNE1V5#"G&D63!3W710YR",/(U`RE/DA!"XT#PU+CH(9F
MF"$*?Q"#:;5PCEO0J$WTVH(?;",FZ/J-A7T:R1>\0@^601$E6?2@0,>0!2I$
M1`UX\,)6XJ"'/9#V#GF]PV5_4@7%3.04;C!75YS%E#`4L`IA[(:^=/('IDS!
M%U&P]0^[<04QQ,2`J^ZS9?$P$`L6N@]NB,,5N'6F."1``@?P`E1C:]%[^$&G
MMA9H%L0S`)C2B&)#$X'41J&*T!EI$MR0Q-1"X2&T.<\Z\*EEHNA@-3:,"])V
MR,,XN/,&,TA(%)782,8;A;W_,LQAO!3?DM220Z5<C"'-:^#1;Y;,AC?T@M\'
M9JBK=#&2&(U"2V@[L(7&.V,ZW(,,5FM3*7#E#6UVG"5$0>`:V'NE`9B!#V'X
M0Q@E;9!#O>HDS6,%%U;:"<F-X:AWVFP71&(/;0*O2P9Y2!724.%GK'@.94AS
MIT=BI9LQY$ZZPSLDJG"_,8UT+_;PL:@NG>FE&*70&`&+CRMW$/E(00UK#Z"D
M<:;3,;#ATE<L1A64%04$1L&/J3$*%Z!1FCK`CUYS+(A@WSR1G;7C+!5AUIF8
M11=F%?LE8;@"%A(E.]!H1DUIV$M=.W,%-<0!B1YO!>&I\+$O(*4/D;C'8KH0
M6%#C_TS6Q;V#&OH@V3OH@0`-$$`/\:`3X8^C*/@2V<SLZ%<O=&%;?9\RS+YB
M5"A]0:E5!&T14BJQ`%ID<@IGP6MJX`[$\`570``"P%J&02X$D``$<`<_(1I8
M(#-_5%@QLX#HI`4Q1S:*4W#CD0LU)QZA`PJD@@G88"-\TQ!!XQN?4$]S0!GW
MA08SD05FP",.41\#D`F?1S&5DPV/\AYRHS12HQQB$SK/8P;!T5&1L!#54"/6
M%%&/PP`IHARZ$2""Q6##4133D!SA,1YJ)`F-`BQH`$MHD&-4L&_(\2/R(1+O
MP3LF,BIH4$5;L!A\@$X/\0TCM0:\=';UM1MOD`5>8`57\O\&EO$L^4"'(Q5=
MC(!(4P!_5P('DP,'UE=3)N,4^_4>`.((F;`&>$)6)E&$GX=`;^$>7]`376"`
M:6`Q4<4%)'<2"/%R/D$,K?0F\:(/#.$1UE`8%<$)$"$H'O<FUB!J7@!;:D!]
M-R4;._5'AI$JN"$R[W`1HT=#M38S2\$3?G!OP*)3`8@%7])?%_$(\_:*?Z`9
M-#)2[E-J?_)#%.,0B&4K:*`?U5`&6R$:]",3S"`44A`&:J$&<J`6/G0,8A0H
MWR@&=8`'>B`'R988R/085J$2\5`/<20J3P%0S%(OHV$M?8@%9B%%]S,5)Y1\
M8G``"5`'%G01--%$>\18Q78&ZB;_55=@!<XB;Y61<A+&(V+#(IB(7=8A=#Z@
M`;L`*U&S'5+C$#72-&'3!-L1A%;B"?K#$$6A#4/I/&9PE=AU<B)A2@Y7""*@
MB4B''1]2!L$1("UHAF!3#0CD"W27(B,B-0TA*W4&9.BB!>&!B:+T$F`#'ZBT
M'<."#4]A!AI@`!HP(&^"#;F@'P."!:&R!OP!!GV`!]*Q$13S&&,P4K$!<P7W
M!E500&]0'5IP,:MG!A37"E\@B,LT#_1@&**1/S'2"-=0#=#6"34''[F@1GA4
M!E-0!WO0!=S3AMS@"QIE358R+EM@E6&!**C4!KAR%=OD*["`!=_C#1XA@,Y@
M*(-0#/RA_QAD<!__AA)RY`=4P%ARY0=7\`<KU14L(P<=<Q(/]5"<X!9W,@5)
MX053@$!95(G1H1ED,%.<@1$6`6WC<E7%ME+(,@Z(<!/,P"V<L!!H<`IOF!(H
M<2I<L2P(9";V@"&V]A)^I0:A0BY,M"U]4`?J=V_?:`X(P0;W8"9\I%/Q`&V]
M,"[D!T''Y@5V`0P+V`<K$P;FQTA5P)`-J0=GT`<846W3V#+KJ18D9$*[E6P_
MP0>44%T&P"+4D3?]I@V;(QY"]Y,\HH2]@7<3-0NM@S:\E#5V\QV$`S:4D!S<
M9!5VH!VADWSWF!RJP`I'DP>-(XBG-#G:U(2L`Y4C16"-@$#P)/\Y,Q8XC-.'
MK](*6[`CIY2'%XH%S?-(#)`>'!4A/$)/1:(;PB%1%-<(?-"'NP`BD$$0DW`?
M'3<+<P(5GI>I8XDA/5@TG2`XZP-M:*EQOY<:]U!8_Q<>N2DY(',E^A$@:6`[
M>Z8%7;`.'Z8,-,(?C7,2&J--0;@2")&L[Y$-K2(*-9<<$XH:MO-_;V`B4P8&
M^J,L7+`1'==I$3(@TL,1K8"1`%59%A0+*(0A6'`%O78%B#*@`E4,2]<M\;(2
MT$!($_HL3K$7F'964#%':88/)M-MMR$2=W(&1OJ(#V6=M61]?988,BI!7O"-
M%X4&,7-O+$1#6X!N9\`'R6H%=2`'`H/_!97UD*&%!=`%(F`B151P,3D%$C14
M&7,4$U-TCC<5%%-Q&XJAGEYP!P)P!Z_X0#"K?E0@,S_T$:L!5F*@!P-A&]66
M*NRY63%R(`FB'=WA`W8`)?5B8`<&"O51!-N59-T1.@YB">9P8*L4.A)"'N?P
M"<\CB#.&(L*!!H!C'YLS.4`W`!LF)*$C.:UD!F\#(#[0!"22)=G!.%'C/)C0
M!JV3K!'#`-HA'$%R'[\Q.=_!!N&C&:;$(Y^G3<O!.&S@A!YB2=\!8]X0'*0H
M4,`Q.>-!"U4WJ?SA.-[J(52CB;IS@D&#'(Y243S((WF74R@T/]@G"MJ4'-4@
M99D`(\KAN0A!_P8R$S^*PCB&@2B4<2BY('&#,"H"\B.NP`=@L#HV)SVE$BJ[
M&"+060_R\1/0A15I`"720SC,@@S4<)U.!A'N\B93AH1:<`9W`#&>,Q9.Y18J
M02%U0GY,<3-\H`9U\(:OL"3R!E75EF:1(C)I40=NM+`LTP<302\/!0;N`3/J
M&1%-$3[E`HW%X`=JX`9>X&R:<2;5II<$`Q-3`%"&T6=A!!*I82;H$A.P-45S
MU"[,T!4B,Q>0&0UOH@6GY48G46OV)P:))D6J\@>\9G\*R"ST`U;W(P9^L(%N
M8!LD%`6TI@;2LS0+,F&J0`?EE`;B$969U,>4`+I-0*=T<R>Q.P`4XO^#DV!S
M!P$?[U%PH%`=65-=8^D-2<8C:&,',T5WSN,@<S('RHLE(#(.G,M-![$;6:(!
M"N(#<U`87&`C^-&NBJ)@:\`=>,PM8U`(=X-W9$(A,[<+Z$0JZ40)[@4X#*"/
MUR`>SI0'`;(Y,U44QE`A6;(;ZO$[T(8&RW3(26,0\K$2TV"&E0@IJ_0]S4,*
MKR)8GT$4;P$GL().(\(-@F`.DS,&8*%47>(+LU`9)G-O^3,*:;`%W58%G-LB
MNU(.Y,@1Q^`0`41^E2IE>CP&PI!5YOE&:N(X':$2(6B=RT14P+%A$GN1;T29
M)$2.'P%IOLDRP>`9?^`L8J(8<[2?=20'H!7_1SU1D,TX1ZDQ1P>U)E[Q#I#Y
M?VK$%/I`!3J</$,<'9-U?PB[*[!)T/?0!=Z6:F8"#/6SGF'00_<'+BM5M5=P
M+EW!+8YVT^^@+OW`6H[S%%(0!Z85$IO`C>6R&GH@`'NP@&>A*GUV!>90!<DF
M!YBA%U-P!BY,<6)#N1%CEJ`J-<HL"EO"79YL''MS8(ZI"[ZI!1IS#OFA-<X#
M/&=C",YTA7!0.ZM'.N-AS7!0FY*9/S=8!G=\CZ,]&SBK,:20A9?DMFH#7X"9
M(_QA%&D`"HRSF=E`#:Y[$'AW90Y"#5\"8RZ\.1\7''#0"_4R=>4Z2S\5#R*&
M$B!"*EOP:9<V!;LZ_T!@("-?XA;P824[(Q+=X`=?("!9,QRZ4R=]%@RVL"9]
M$0W1(!Z2H[B80";S$`E<MQ<^QA(S81L&M`8HT@HE6SD[@P]#?(]5$C'0D"=9
M8`W(I!*`6!G,P!,KH7I1\68^5@\(-$IWXL)`LL4R9#R0<+0K04`9H1(I_0K5
M%BU4L)F`]E"E`;6V@"^PT`[NN[*X<7K+F0;](!=7%2H2(FKPP$)FY#$H<Q;+
M4R]X-"QGDB<1`6E;T`7/DEFRPC^G!9'_8*2I$BKW($=5^T>.<RK)X^#A*.;9
MX#=AL`<86!4PI9Y;';6E\44%I#QA0%57,%Y]S6MPK<;-I\?*P+G:40HB0/^Y
MV@$*<)JLJ'1@N<`V:*,!=\A)ED`OJ-DTE2/@!V8'O-"&RX05_R$A>>`0#,%O
M:2""OT-*-S@(%&,=^%$ZNQ(-VI"6;Z,E89ID@B!C--@T)Y%1'I<EL.(ARXV:
M[5$9DF`0&X4UJ5,E/I91FZD)$T':2B7@`U"8T(J".,.#C;`%GKX,=[<QIG4Z
MMH`HFW,/\C`/D7(7R5I15'0%;>QH?1@CZ+!;4L`8!;$-F.PD8S#$]%)3^F-4
MUE#6L1$-G`MCV`!31C%>^:Z+,]6A:R09IX,K/FI.^*S$(D&8WG)_*EQ%DC8.
M"Y]XQ>`W445^;Q1=$-$66R!#Z_8QXR)'/DHK2"3_::])%W)1+)0A/&]1#)L`
M;4$A)O?`D$IA54ZA#/3#!UFD*FY4#L664S<#)_7ESXK&8VZ!(29C;A=1:(TE
M!LNS)$PQ5-]$Q))RW1VE#U-PDQ/(0J4W4IN`;FZ@:>L(%3#Q]NB2%GH@!J&B
M+WN@!W]`/):%:'(P0JIB-55B!D<#Z?0D-=@1E2D"K9Y<3=7%`)*Y'+)B3OAE
M"<E[2AMQ(]R$#)3?J9<C'!1RR6:WFIW:270`,I`;'"@BE/$1E_>!7;X$'`Q%
MF_<8')?<$+]N"6^3#-;Q>6%'"U;Q*)!+"8Z"#8R0#=G0"WKLY/4"Z)^WAIB\
M!8"3V-.^4JA)"I6\'[G0_Q&RV(:EV0?F1`IG`E&^@@7W5@P@;$%8)QCSR@6>
M\#M0Y6C#("H&(3SCQ06UE0]],@X"M1&H#PAM9F-D;7-@6F5M8%E54V1S;5M<
M8%Q865&-5W%6:'-V:V5:?5-@9%]3?5%56%M:65Q95%==?U)\4UQK<&994UA3
M?E-?9&-;77%2B6-?7Y9]5U-EO7Q^5E*M65N36WYB?U1\6\U:6.9:7UM849EH
M;61@6.A?55)7?E%\4F%>7;=:9,QLD7+&5I@NI*8HY,-'6Q8_?JIHX;*ECYLS
M4]"`B=(GXI@U7ZZ(#',EBY8H5/I(U,)J"A\M8,9PX4,%WY1Q6EQBHA)ERT,J
M_/^BI-.BQ9L;.7H$Q'EIQ985552\>/ESI><H,6*L\.DCI0M)/WW.Q/G#9\"<
M-6G>,!`Q((\(!F_6#!#AHPB#/`,&O$DS9P`=.AI$S.&BQ4R;-<SDFIU#9P`#
M!F;9L*'#0`.=,I`@-_8A(D\;!D5$P"'#ANX<,V3(H&%CQVP;.QKTIFDS(#8=
M.'@U^+B;-X^=.7-\PUG3IDUC.V\PMX'3]W';/-#UFFD<Z0T;-&G@^$VSFLQ$
M,ZWMI$ECQM/OX'2LT\'+)N"8,K@'V,&=YXVAWGGM;,1B!F\D-GFQ$4DZA&WA
M#A]UG%%%&G:P445*7!A'!TA3`,0%%?ZP$D6$=+#QA4G^:/SFW3:4@+'%%%&4
M4\476.`A@!=55&%2.F50%AL<DJ'%G3EEH+%%-7Q$^,X8)IF(!456>!&%.]:E
M44P9F)%1Q5,5GF3/%2I5XP<N7[Q!!QGXI',+&&9PX4<<>G21A1EIE&&F%U>L
MR&9J6$CAAA4R?M%C&5AL6<T4,XXQ!A@F]A'&&5U$4XX\IG`Q!14\94'HHPV-
M8TP42?;311<:+M11/6Z(T0<E4W@11Q=;E)'%&7C$004Q6M1TA1MJ2%$%1:DT
MA$4Z$FV3Q15B(!2%.1Q=$4XI:)!19QQG",-'C&'H@8>+!.A!1192.-71%7](
3!-:M\4!*RZ;WE".%&%)D$0@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>y15751y1497403.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y15751y1497403.gif
M1TE&.#EA>`$``>8``,;&QNSL[.3DY.;FYDA(2,3$Q.GIZ>KJZD!`0.+BXCT]
M/>[N[HR,C+R\O,#`P#0T-+*RLKBXN*2DI+:VMK2TM,+"PJBHJ%965C$Q,:ZN
MKOS\_*RLK+JZNBPL+"DI*9Z>GHF)B20D)*JJJFAH:*"@H("`@)"0D'Y^?J:F
MIIJ:FH*"@O#P\**BHO+R\O3T]&9F9I>7EX:&AFQL;$Q,3`X.#HZ.CB`@(')R
M<GM[>Y24E):6EIR<G/?W]VYN;HB(B#HZ.G!P<!T='79V=OKZ^GIZ>OCX^!45
M%1D9&1$1$9*2DF1D9'1T=&IJ:GAX>`0$!$9&1EQ<7`D)"6)B8EA86%]?7V!@
M8%I:6E-34U%144I*2D]/3TY.3@$!`41$1#<W-]34U-/3T]75U=+2TO___X6%
MA=;6UMC8V+&QL=?7U]'1T=G9V=#0T+"PL-K:VMW=W>#@X,_/S[^_O\S,S-[>
MWMS<W,G)R>'AX<[.SLO+R\K*RM_?W\W-S82$A-O;V[Z^O@```"'Y!```````
M+`````!X`0`!``?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:FYR=GI^@
MH:*CI*6FI$Y.IZNLK:ZOL+&A7*F#4;>XN;J[O+V^O\#!PL/$Q<;'R,4T45RR
MSL^3-$<V(0@S,P39VMO<W=[?X.'BX^3EYN?HZ>KC,Q<$'39!--#T]8914!8-
M'R`J*C%D`@;D(["@P8,"^1!$.)!A0X0+'3Z4:%`AQ8L8#UJ$Z'!CQH\0(Y*)
M$8/!C@@0E"!I9J^E+"<(&,!(D>3&E6S7<NK<R;.GSY]`@PH=2K2HT:-(DQ(E
M@$6&B10I=$B)XK)J*R17..RQ0M6JUZ^FKC@`<,,&V+.>HHP`L`,#,Y9H_^/*
MK10EA(PW9.;-W1O)B8(")$+\X4)X$4M:JC01IL4R,:'#B1@;DEQH,5^7-)3X
M*='ULF=#3IJ%:``CB*#0?T*C%A2%AN-4CB>O+C3[D.K8MN&>+DR[EBW<EC]#
M8U'`AF[AGE4YN=+&RN##M9S80#`"1XDE5W[80!U%P9870*1DZ3"/-VTN0;`]
MT8:`_.!41J9<Z))M?1</A.L2N/`@"FHD3USQ1`A<^/='%#]<\((0/62W76K,
M(!<+2S\DH0(2$@I'RP\P"&':;(5AD,0;+01@P`('0/"$*IG!<6(`)D:`!6Z/
M.4%%``<(((`!!K21P05O<?&#&P'8,<``!N3X@?\'?Q@AA!T'H&"6(#_($8`;
M-QAH!!5Y++"``3"V80(&M$28H2N,.3$"'8*=F1P4?CS0#%PL94$!B0/$80$:
M8WQP1&HES/%&$6MP@(8+!MQQ`E7F#>($%`$,,,<<`6BP@@!BF%">%V[PT,8<
M`@R!:!\18.#$#7.,(8%I@G@!APME]$#5$26\D8`+"30@APMCN"$##8VZN0I+
M5]2!@;"7.2'#&FU69@0,+@A0P`@=8$!`#PH4V$,>&N@A@Q</8)'"'!K@L06C
MN#EQP0`"-"`$`E!L0$<184`![`-F%#'!$@1D88(8!KA0!0TCA*'!!ZS^\4`=
M"]PQ`E5`4)I`"5XH@,#_%"G`0":RLBA`PA48<BR7LG),64@4,NQ1Q!U0!%F8
M#044R<9*M&`0@08#;"`8+;1=D.0&V3KA!0J7.N"%PF9H(,$/H?U`@@`:X!""
M$F4<G/`#7<*A!!<=1#!&&CO@MY@-'70F,BNJ>*!"#\V>#9832C20,"%&<*!C
M'!@ZX5\S45RPQQ``3'4@%TBD`&,91Q^7FL\I=C'($F_,L0`6"K>A@04K_A%"
M#`,,<8('2AB,\"!8+[`&%$Z4($<+<AS]GF/!N4T*SR'@L$3;LEOEQ`M^F$R(
M#74$8(8$&`9WQ`EB:!"!`JHT0\,)9BSPAA9S#M*,N@,$,('C@D!1@!T\C/`'
M_P9H7([`+4H4$.H(2(Q0]>B"E)[&%%&@$/T>?^K-"XVY?]*,!R>X`>[ZUY+=
MQ<%W@\#`'5:P!DVEYG<U2!X$.N`8&N`@#`%(@!2`!9M4T&)=!MC>(.PD`!<T
M@6MA:$$=V)`"$A3``"W8`_-D\+ZK,6P-0(K`&P(@!R/\`0$H^`!4+,``TRB.
M@)\`H`"1J+L7'/`0"L##`M+@0-W8@`%IT``$/%#!"P9@#E`P`@9&((4JC,!>
M7&`<!;CWAR>P00`M($(4.O"%`*B!5V,(0!H^,`4:T``(-20=P^!PA2CH\`!X
M,`(7F#"&1FI@#'3HP'.8*`HE#I"2SS`@`@6!`3P$`/\,*2A>]8(`@BQ2@(*#
ML&`85D"')QB!`8[,HVE`N,9!S&`")03"'SI0AA;$80)W0$/.)-FD'@0R?@Q+
M`Y`H0*D><@$!%`#`'@#6@)WQ#Y.9L"0V[:')0QSA#@&@P\Q2$YIF(.$&R>,`
M`AR#!!`D8`%J^`$-FJ`&/;C!#@!0Y!3`1`$$#,(*ZBN"%,9GN1U@X01@T$`<
M"*`*(_2@?"GX$S*G2#\4M&$!<OA3:X+`AU4Z0#"^V28GM"E2:'33$$A@@QX,
M`(`VT4D!>>"!');0&1J@@`<#,);FNH``!3R!>>I*TAG\*0@<2$H`65"8&I36
M@2"<H04#F(!@'`I1B8YO#2O_`(,2E`4`'JQA!EV)@A#0L`(_@/2:):4$2=/Z
M$B=N\D!0V(,&X`""*3E!.TW:P)$F0$PGS```8Q!`#*S:LR-18`9<,,(,-E"$
M`\!`,/C20`9^\`<J`$`#`3B!$9P@A3FT(`)*F$<09-"&`,#A!4X(P@;&``8+
M*.`T)U!#`,PZ2;9F,X"7M.TJ3EH9&C!@!2UH00V>@``J3.`##W#"%AHPA@68
M8`L(>`$`7,"#"6Q,-]>SP@("L(<<C(`!95C!$`K`-"YX00\:.`,!_D`#$[@@
M``*@PA^\@(8A#```/;@``Q8H62^H0@J'XH$$+A`@$1A``V)@DFXUL=8%MX*W
MUA.-_PE@9``!&&F[*O`/$\0P@!PE('O:VP):'_4E.^S(``-800/.-9@?V&$,
M$)B!*K;@AP",(0-E`P$:X)ND`QS``&6@0CDSL](<Z2@!"3``!-[J8$DTN,FG
M@+`@$/.'(UP@!5]@%QW.``14(@$!,7"`D=H0`2&X)1&I($`#.$"!!L0A`]XM
M6_-L]@43K).]4VB``PH@@RI?80<`>(,`S.``$"A@'K5`$`XB$`8UE"$"#+""
M!_R#5B@SXLF61H5;;9,8)V!@!EC`P@R\D#=&54,+HE:`1!?3P0X&`0$]5<`/
M'N`><CKARS-XP&:;8018;T%.!^H`4["PA2X0B)P&^D,0?O^@#05,^CU'S/2E
M<2OM*&^:$8N)G:,Z6"/^(2;;1Z1,A$/Z.@\>@C"MCG:U'8'I=7]"RK75GQ^7
MH1S])=M1N;A>:_RXMW*W^M\`]R"Z88/=#EZO'L%ZC+K!TFYW=P+>/&L2%7P@
M1`90ZT!=@((4KF`J6SSA!5*@0OY^L`0=?*`&1)@!AJ+@A1G`^N4O)P#S.@!=
MF'=A!FXAW`^VD`T?#N+5Z_E!_A:.MMI8S^AR:;C#-P%Q0<S``@48U!`,D`8*
M,.`'':"`&.K``KTXX0$6<`,`&&`$&RQZ#0$8P@+FX``)*"$*)DB``QR`$@IP
MH```2(,%HM"$,D"@`0"H`P#D\(;_&X3F`3O``P?BH`5"2*$"'&B`!-:;<%AX
ML)R)^38AR#TA<R-"Z4O/!+Q3XP7F&F`-&9"`#L=0`0JRP,8"R%:5#3<&,V`!
M"2=8`$X;P((,U&$(*S@!#3Z@`32T`4R1,H,;$H""*'P@CPD``QS`H`8#C"`5
M5TA#<WF0@S8Y00>6:H$=^CP8>O#&/.*NRL)!'_I+C!X)$G"#`.1P`WEX@0\`
M@$)J?K"!%9C!`I*$`7W@`G00`US0!0[@`F:``EU0%U9``2:`!$Z`!3@`!3T0
M!W,0!AG`!"/P`@K@?%^#`E!``%<P!5!`(%$@!04P`&*@!Q&05$[P!!D@`&%@
M?#?P'J>1_VZN0`-!@`2W@`3RL!NL801'`"R.@!C<I@E18`3RH&[LUWZ5,'I&
MD`<&\`8-X'-Z8P1F4@(&T`<&@``T0`90LP$4U`1Y`"N4-1A1@`3`4B#S8`09
M<`!]D`1'4""W)@&L54008B!1<`-X(`!@X`9H\`('<@-UX`9E$`8"<`*;%P08
M\(@/@`%!P`R85PGJ%E(V,G9&8`0QD`?Z1V7FE0(;4$B%D7Z$4!>1B`&TMFNW
M42-$)P@=``,.H`5F4PA/"(63((5I$`!M@`=*,(E&AP$D$``K(`12@`?LT@/L
MQ0=I8`!F``((X(/\8P0;L`!]4`,A\P?P]S4G4(>UP#=DD`8)$/\&1%("A/,!
M;Z`&:/`%"^`#4Z:-/=``8E`&?;`&>2`$;7A^=.)Y4[8:IC@9NV0!C80`#W``
M8W"#[Z@68"(KOO&/?V`#)Y`'=_`%:@`'$``DZ-88:M@\2#<(/U``8U`"/G<(
MMXB+?7%MA8`$'V`D99`''W`#5$``(RD(Z^(&#>`'2*(#3.($6A`'UC@'$T`&
M,C`%J$0W&;``;I`$V;B-8B`!4/`$5G`!-D`5-``#;I`&$Z`&*Y`"FP@!K#,!
M:<`#-7`:39(#CQ0&!;``@=4RAE%IJ?&*FG,#$1`!(=`%*S`&4U`(-"`#.,($
M9K(('B"08U`&8#`$8[`&5X`(G)<('@#_`1H``G-CB]1FDIPP>D[0!6P`7P'`
M`SP0`&3A4@%)!P+0!V]`!TDE"#2@`DD&0SRP`'20`F#XCM083A$X"/"G`6O0
M!@E@!]'21^PE`@?``3Y@)1!``%[``6,0`4T@!QJ0`]6#!"7``WB@`$:P)F-0
M!W]B!`H@()/&-03`1>SE`5Y@&MVA!4^``3[$!2'P`!Z``1PW/E<`!5=`G9K#
M!/Z$`'=9`C\P`_*4&E:P(R]`%=H)71B@%X5@`\_G``B@-KRR`X(@1EV@!0J0
M-T%`:\N&`.C)$DA0,590`4-0`H0EF4M$F4R'DH9``!LP!SQ281W6?6FB`&AP
M`&U0!CE@%H41_P1"<`<"@"0&D&0-T#(\`X=7HI2V*0&XZ84&<"F^B01QX`)L
M``02T(MK4P$:L`,*`%@?8*!($`-#X`>2=`04,`9?L(D@$%Q%(`=70`-LH"H8
ML@5U,`=*<`0]H'L\0`>+X@0,8`=XD"I+(@9Y-`0!<`%.L`0#0`%&\`-J.00M
MP`,&L`02:`5(LE4T$`,!T`(N@`8CH#@VP`(P]@!_@*@\P(@T4`)N,`0:L`!\
MH(5"D(@BL)EA4`)O>`(EU`(:X`(@RIB32:*B9Z(1%@4>D'$JT``FM@!ZL`2(
M=B`L<'P.`&R2@03[.0(DD`8K%0!+5GY"FI1+B8=A``%20`!2<((""O\'&K`!
M4``$@38!$/`%?=`#'@!8$F!52,`'+K"N,Y`$G<,"7'`#EBH$$-"I.3`$:O!:
M/C`&+N`!A.H"/L`"/)``,_`')M!(`;`!.D"E9&$">$``<#<&8F`#B#H&`S`6
M'CM0("2H*O`E)F`!/``&#%5^@A`"Q&<'$L``#<`#"$,#+S``&C`!*>`"+7`#
M7-`$!D"P$3``8^``?P($-M8`<$"PM_IYN:JK[L>K.&@]-D``/D".+D`"/D05
M45`":?!9JU8;-#!&#M`&!P`'GOJ@&T";V3H&:@`_[X@$VI<!6?`#$[`"<E`&
M`M!/[3H&&X`?@@"=-C8'?NJWX\E<%:!8[]3_`UYP,PS@!#`P!@`0!0)Y!S:`
M`2`I`5%P`J<J`T@@`V.@`6SPG6[17F-0`$?0L3%@`UE@8\YY!4@R`S10!F,P
M`:^F?1)PK()@`S#``Z';2$/@`U$0!(!%ET<0![5[!%/0!BV0`AZ`APZ`!"'@
M`)+[`%<0!A\:HH10DE"["!"'=!C@(D-@`5O+7B?PM1%@,DB'!"Q`!Z:3AGG%
MMD7JMBFP24&0/!OP`T9@`;CI6=@8`A70J8D!G=M%M*?[6EL`!E^3`Q:@EA:`
M!"HP!G>0!0T0`$`0`F&J!SF0`@D@ID=`!&.0`&:!`&L0NF*0`S-`IJ>[;&JI
M?S;0P3N`!%CP85AP_P0*7`8)JY9C^D`MFP+V10$P$`%#8`=0T`&I`@+L]7QU
ML!]T,`==P`4/&P$T`"D\$`-U<08:H`+:.PC<V[UH)K485S;T%@5/P(X!$($\
ML[EB\%DF,T=>8`/TIIXSN```0$Q5MK9]4)N!BX=H0`)BC`1:*#0)A0)EDP,K
MD`:>U6<AX`<:P`&9HXUD4`1G<`,*W`"2A`5^"E]NX`9?P`!1\`(\,`01X`(.
M8`0A@+PM\`9NT`?_AWN!91;=T0`#0%UT(`0`I`$`P,)C,%!!T`=CL`,T@`4"
MD`!:8`-A,`8KH`8)H`9B@`)Y,P@A@(<9,*$88&,I,`,",`8QP%XY(,%8L/^\
M=H!8-9"<GUL$+=`$=>&834N23^O%N<@[;Q4$#;`',-`@%,A,/%`!(O9`FXM5
M$V`RHUH'$:`"5;`%2I`"=W``"<"5#V0$P*D&>JR-1KH&%0`##&`"##P"-J``
M6?0!(>`$3``'3:Q,33+*<<`5@<L'0V!=PMP"*C`^<G!C&!`"1V`$*X$!;#`$
M13`&+-`DU"L'#Q`"06#37#"P`@#0(3`#:RH'6W`#19#+7J"6B4D#'<P`7(`%
M57AH9C`&%!`"-(T$$AA2-D`"8V`!?W($02L!,Z`'8V`"@B"0'-`!%S`'"7`%
M7##.$1`%5P`U.5!ECJE9N#JB[DP)<-,`F\23+3#_!D/0!W60!]D\!GN@$CA(
M`SF@EF'0+#:`G&-@`%N'!HE]`#4@-JI`O*$K`B.)!/UJJ=3E`H_D6E:0V!#P
M)PB`O$-P!I1E!%^PV3&@%T;PL'=`'A.01_B8`6/0!TKP!$)@:*GP`FHY`#U`
M"P)I`#V``$[1L#$P!@=@%EW0``Q``%2@?1/P!#B`8--QEP"0`WBH`<IX`:$"
MJP(Y!_8I!"9`BH[A`2QPJA```Q/P2!_0VQH@`"4`!&R]=U*`8JB3`JRWB6N:
M`#5@`2TP!'J(""%`!$*06X/=""!=!YL4!6`F`A6P!F;0!GNP#Q?@<VE\`Q"`
M!R20,$=P`Q(P`77P!6T`_P8%``$E<%W-<`0Z4`<-4`+9Z%MA,`$1T`!KY@!R
M0#%8,`%?H`)OV`1I,"U_HI)Y``%`H!?0>0!&\P=J5GM'0``%T`(+8`<M8`9:
MH`H(X,LIL#-9``&Z9P<K$`#BLP2U9QI8\$BJC&`7$`0G$``-<`0*P"YWZ;$U
M(!@8X`?7^0-/(`'B509#,`<RP"C0;`+`99A#(``R\@>!::HXX@"(905J$`98
MP`4@,`9R\P=30+MC$%P"8`(6KC8R8*-P>>&;)P-P,$!E8@1>``4RP`0<YQIT
MDAHA@`%>4#;6<PLV8-`RH`1=H(6_[@3B&=2OX0$_\(C4+NPAP(08H!W-D[I>
MH/](J2&>,YT844``#"!`M'`%$C`F3M`!29`&9D`"M/B@2J`#7=!I'E`"`$`'
M%"#93]`A&&($%_`!:*`&:GT+6&`"#Q,"#-`$0)`"[A($?',!0TX_$%D'9I`!
M6/"7@7L%#,`'*N`#9,`VRA$"0C`6(&`JGJ8")=`!7$``.=`#/G17*```-2`$
M,2`%6RP("B`!:?J6L@X)G-5ZBJ`W_#9BL'%NN="12'@<`?>-1]^/LY&$K,&&
MXF[3RH$$1S#49E(@/KAYTJ#U?,.&<[*$0:#U4\]!;$@#@&R$:KB)C/+U6HCT
M;`C6TN@H-$"$$O@>5'\@8G\:>*_V]V8(5[`'7E`]/___"%]G`D0P):Q63N#V
M;0/G^-EV>8\_<(TO^:Q6^9IO^9,O^0+7^.#V^9L?^8^/^://^9TO^J-/<)K/
M^IT?^J9?^K<!.U+0!R!U^'UQ!7>0F*B)`%5P`<`?_,`_!<0O_/)A_,)_`<>?
M_,RO_,W__-`__-$?_<L__<]?_,E/_-4?_/*Q_=9__=[/_<M__.$?_M\__%00
MC8.``"EP(3R,^X_@`0[@`R&#!"^0`@R0__J___P/"`R"@X2%AH>(B8J+C(V.
MCY"1DI.$)CI51W]_-!L.2)J@H:*CI*6FIZBIJJNLK:A.FEY@'T9<7%%(2#2[
MO+V^O\#!PL/$Q<;'R,G*R\S,_TA13EPV*APC47].L*[;W-W>W^":MG]1%W$[
M(=KAZ^SM[N_PX2%)`#(TXESQ^OO\VQ<-*60\R->OH,&#"-=U@)(#@HQ,"2-*
MA-<!0H485[H@^,&QH\>/($.*'$FRI,F3*%.J7,FR94H%"+K,..$``@)-T2;J
MW-G-29`'-R`4B)`APQDV;,XH1:JT:5*G2)]&;;KTZ=&D4Z%FO4K5:56H79=V
MM4I5*E:F8L..M2H5[->T;-&BY>KUJ-N[=N&2C8H40AP`$'`@.!)M',_#B%<=
M03#CR1,"60A(GDRYLN7+F#-KWLRYL^?/H$.+'LWY\0P$-@@:3LRZ-2@NZES+
MGNT:-O]!VKAUPHZ=N[?O>(:SW?Y-G-_PXLB3;[M]7+GSY]"C2Y].O;KUZ]BS
M:]_.O;OW[^##BQ]/OKSY\^C3JU_/OKW[]_#CRY]/O[[]^_CSZ]_/O[___P`&
M*."`!!9HX($()JC@@@PVZ."#$$8HX8045LA@%$%TT($''';8H88AT-"<A21>
M%X00%H@@P8HLLBC"!C%@,&*)-$H7@@YFS%$&&F:@X:,99I2AAQT9*`!;C4A2
M%P(,>@C@!AUSS.&&&U'2,8`!$!@Y8Y)<_A:""5^T(888:91IYAIJN&'!#UMV
MZ29N2ZKQAAEJ`&EGCV\DD`&;;_8)3IOMA+"#'0;8\<:AB!K_:@"61I8"J)\3
M9I.*;:`4QMRCJ01!Q!D3%.7IIQ-$4(.,I*PF#J0D2HK*;KOE])IPWW!!0P<Q
M(6#KK;=V\<0#GX0"JR8T!'$-JL3BY`0T.`41Q#W8N,K-D:NLQNH?1A!P0PD]
M=-%KL>)AN@\71H2@[!'DEEMN$$>(*!P706"A0@Q2=!"-JK&NNILHMH10`AT!
MS!&`&3<$X2VWTR&KBBWY3/L:PM[24,(=#33`P<0<1$`Q!W6DX`4L^6!@08]F
M?!''!:?^V2;#"Y/3@P$!V#&'``L((`7'`Q.LW"T#YQ2<!_(:RPH-'XP10``'
M#&VTT6-,X`$H1Z10M)0"\&"!![PA_V2+$P]8X$(;<(@!!QT\Y)":LS9?9YL3
M'LQ`@*Z.M=UV%@H,"^P/-^@`0Q,*T%#8*C28<$`87P0NN.!@"#"!$@0\@<`-
M+Z?Q!1AI#"`&$<Q*=/45?@B`AAA?H&G`!@C\6K;9L-`0PP('1*F''G.LWKH=
M"_AA!"A16%%`"P,DP$,=4%Q3=2E]!P`X&,077WP;>)QAP?(-O-&&XX^W8<8.
MVT9T]0\;!/`\Y'0LL(,'"(^.W3@TJ-""`&:TH?[ZZO=Q0`25!Q%!`'T`J<8!
M`(30"@TU'/"%&&L(H``%.``1("`(1J#!#.PP@#4\3@Q]`$,.JC<1AXU!`&E8
M`Q@&H`$90/^#;.*;#OE*$``W<&YPA.M#'8@@@R74S0QV$`/QX"``.DA!;JE`
M@@3&L((>MN"'0&S!"L;@@(UIH@,1X,$``->',0!``;\S"*LZ4`,[:(`'13"#
M"D*@L!!29X0!H$,:C&<\,;1AA3*XP0D@`"3.`5`/8<`!1%01A1M$@`4MRB,+
M(!`C;41A!B)`@P`&T`8`2($GTS)"#W20`Q,HX1-=]*((-Z&"%=AA1T#RT8_:
M,`#XB0,+>QA`X&1H@"]<`8>K,H(-T'6$<9VKE>E*F"8P4`(.^$%CB:%4J40G
M2>K0@`$\6($`!CF`81IS`#PHP.PT<80,K"`!0-+#`@J0B2B6BF'_V,SFI7"A
M"VM:[V2]_&(T:+`%$)2`"#@@`CIQP$YV\H$)E<,:`\JP@@6X(0<_F->W:A;.
M!.TF"C0P@A%R0=""(F&@Q[&!$DIP`ADL#1O\;,4XLF&I?DI(E^PP53\T:M$'
M17125NNH2$>*((Z>PE1&Z$`Z\&%2VAPGDKZ)(KWP1=*#(8P&7E`<KG`%DR=X
M(`JWB<(33J`#$[S@`4#E96\H&HJ6KB,*&%"``KP@L'#<(@0(<,P#9C=3:A'@
M`?=PJD<30JDC3"`!9?A"&<*05K4^#@UV(,,<D?`"-`1`#P800`-N@E'?R,H&
M(3`"-$8D+6^$H`%F&(H),+`.(Y3`#6%H_T,<;@#)IA*`#C`(0LDHU%<IYN,(
M#CC?&^Q`VM(:2@`N($/EM&"&EO6!#@)800[TUU6<?+0?45"`#*2PA1^$"%_K
M$BLJ.A"`%D"``KO+0CB"0((Q1*`!`1!`#Y89BBP4@0(/)=&]IM79IH)0HG\P
MZQ)E^+CB_4\,;MB`$&3`!!F(P`#;2T,8!E"'*?R!H\+5B1,0<`(A,$$*4SB-
M%SP@6)K>RQ7$O4-&\#`&N=X@!A+P`0)\8`4D>,`$/_B##4S@!PDP(`<2((`V
M@F"!%GC!"#$80P..L"0_;"##"C"N#9P@@PDTH`G7F,$'.&`!(7!Q"S6`P`1J
M(+`+;*`!*NA`=__O$QMUJ"J_KOCL!`0`.1F.Z<II0"\$5"`$(9"A`0((@^,X
MI[X;;/9544BSFM=\K&RL^<UL=G.:CP4-.,M9S72N\^*8,`(9].`&0N@!%6;P
M@P[8X`C/>`TW.K""!OR4""X@01;4@$487,``*0C!%8IP`2-LH`AIN$,1A@"`
M)Q`D"!(8PA26-(848"`'!J@`#SB@H15,K0M4ED,`<("$)<`!S"YH`@WJ,`0P
M;&"V!,!#8MN0`Q'Y!UP;ND9*T^&3#AB!-TZ@@<&6$]X(&"!(.RJ#N-$@[C8L
M(`;"PL4)[LHY,)1!``ZXPIDK%00,V/O>^,ZWOO?-[W[[6PLR&,$+1D#_<((S
MX<\W8,(%NM"!=.EMT0L`P`/^<.D,8$$-8S@!5`.0V0N,809=&$,9.N#Q.4`Q
M)T%(P1@6L``-```#.!C"!FSP`0W,5K98B(`+L."%83X@"R,X0@G&8($C+"`!
M)%/E!Q8@@Q!$0`U&[(\3LE``/##V!D,(@[(DT(>;B*(#,"!":K@!BR"L@8<L
M3[O:6S`&'6CVOE<0PPKH$$`[C($!D)R1%_PL@[[[_>^`#[S@!T_XP?/Y!8@G
M>.(+SF<9`.$&-Z`"6+?1@8A/_-(6($`:[$"R!RQ`!T>X@@:P$(0]N(`-?AA#
M')8FJ2#L8`QB<,$>?A"%YFK`!6,8PPYLL`(3_U#!#!H8`@_&\`9:@6$(N4]!
M%/0P!@U\H00(4/D5Q^`&*Z#R/D<*P1E<,`(DF&`,`PA"%@RP`H&%@``8`"H4
M%C"!&8@H!`K@HJR,<(0.;+54?T""#&)P@G;ZOYUD<`74I4`9<`#!!P8,T`'-
M,B,8\`(!5W`0&($2.($46($6J'@#MWA]!@1"H$XR``5:@``><`37EPJ,1@%!
M@`09T&`>L`9S,`-_\`,NP`?[I0$74'L:$`8P(`-O=VH2X`($L((,0`,P,`9[
MH`4/<`4=X`4\@`,SX`9#0`:TX@5=T```<`$EH`$0@#8/0`1J(`!"\`$\P``S
M,`,*$`3>)!]'X@1#)_\!5[`!8V``M%1L&$`%9Q`!&W`%'A`#0R``2_``5"`!
M#0`#5\`%,Y`")!`!8K=+V58,NH!#N44$)N!(RZ14XF`$//,A/+,A&L(AG>@A
MH.B)&K(AH?@AG_B)'[(%/2!P!.=G-]`#+T`%5Y`%"/``-O!P4"8*&'```@`"
M*J`!;]`%'H!:5O`'&#```'`"%C`&2A`%34`T&5`"!%`Y&I8!`6`$"M`&`2`#
M4_`%?7`!3W`!(4!<<C`"1#"&7J`%71!W<(`%#*`!!4!R3W`#?;``5-`$"Y`#
M!#`%!%""^>$$-Y"#)M``&K`"-^``"Y`$5H"0<#`&=\`$)=!#4O`"&B!R*]#_
M`D>@`KDW!SU`0<;R41QEB>(`5+/!!5X0:'TG<$H@!0MG;9=R8*W@`0!07"Y@
M!EA@C'>`!C!X!!#0`D-P``,@!1A`#16`!F/``P00"C8``V&@`']`!0&P!AYP
M!0>0>T5@#7[0`BK`!7%0!,TG!U[0`P%0!$-S!CW`02L0`!,0!![0`#S@DQ'P
M=O[A!#,`!D4`!B*P!BT@`@,P!U,0!5.)`V1Y&@%`/2,P!&Q`!2S@`E"P!`/@
M!@KX.[F(?S1E"N$##^-P"VF6,+4E"E'0!?W5`TJ`!;Z%!!1U6Z2`-O=&&.3`
M,Y`4!02P!1E"8ZUF`Q@@:U!@6U$PCO=``P_@!??0_P%5<`'R(@T\EW]:\`)/
M,#M&,`-"V06T%P1;H`0(,#O@@@!*H"TBB7TAD`/(9P$J4`<&X%R+`0,;P`(\
M8`<;,0`Q0`,RL#L64`%W(`4]H`9E()?%@0O$D`LD>210]0)`<`6I`9/`\P!;
MX`7B(EC?I0_XI1HST`<&X``.8``-,'&GB0^CX&0X(0Z\@4JU19+DD(;T$04O
ML`"Z1P!)@'L?\`=PZ``OX`)OP!$!(`$T,`5#H$5"``(AP`0!4`8V<%_(\00,
M``)\H`)&6J1&:J0F<`(/H`U.@`10L`%Y\`4.P`!=D`_>=`L"%1LPE5%7\Z7W
M-2)(0``-D0$,$#K-`BL51?\VT+*AE7(<7)HPJ@%1`$(`)@H"1C`"0Y0#7&`!
M&I`!=JH!4]`!?;D%5R!?5'`!)N`$55`$:/"C(EH0K-(F.#`&0U!/+-=#/;0`
M0T0'RH4359`&&B`E`]`"?J!D(!6F"\@/,V4;E-*9P-4LK\(JWZ5+!&JK.E,8
MD6H?'3"A(_`'#Y`'94`%,<@!0U`&#3`'-Q`%*1!Q4$``:Q`S;&`$71`!$F"=
MB!$%+MDF-Q```T`'X$H'4S(E?>`&*X`'6D`N2-"K!D`'/S(`>B!7SR*IE3FG
M!V.9<DJ9&-I4_)H@4?``!*!94?`#)Y8/'3`%5Q!5^F,#D*%9/V`%%^`%N+`A
M>W/_&$@P!1B0AC+P!FJ095A6)G"`)G!@`4F0!`Q``E+2-60"0Q'`6#7%9`LJ
M13EA`S(`1:@@`WI@!B$K0'#0LSU+!W6@`E(@!5=P`VU@!W<@0VF`!G,``2[[
MLN=QF:,P4:BY#O/B!4OP!/X("H+I`D?SM2T'!J:6#T8P`0LP`.36!K@C!!X)
MM>.Q)9/Y+9I@!%BP!!=05:9P`[FS/G6B!GYK!GT0``"0!7X$!7[0+^5J`!.@
M/U7KM@TR#D&@!#=P5-YT?AJQ4[E"`&>H#E$0?4)2`#X&&UOKN.Q!`R$06+O:
M#K#@`7XF!$]045-K*=J$,O<%"]HZ`QGQ=K`:'FN(!$<@_U#`&[S!F[K$$@)6
M``7`V;C;0`,*T`-,<`)70%'$:YGJ0+OK(2E.,`4FH`(ET+W>^[TZ(`-M&T(=
M`&A/@`3*&RWYT"X!)P108`,?U!RP$5#T=VVI)%"_N[5B%;<QA:4?,`0!L"@&
M<``$+,`&H`%QV5$=\&<(@+X',0X=,`),\`*B27M`2@I!P`<"4)$"\+2E8`1U
MP`,NX`)J,`4STJ:Q&[/.D9E)T`)H$`8P+&YK%0;$HP%L,$?AY`$,[,!60S<R
M,'`R<`74Z)E"8`!K4`(XD`1'H*6W"*;A]08J%@,\$``OL!OTJY^W\`RW@"['
M8@.UH!U<8`(+$`97)D-@8&5KP/\#&X##O:3#-]#`Z?LS,[`$`?<"DTM=HX`%
M`C`$)+,)?^`!0L`"T:B`H7`$"3`$Q9@"6A@"6(`#*<`'5T`$38`!1T`&4Q`N
M,L`")-!?.[`%<5P;8DS&5T8\9@P':LS&DK3`;\S#5J6JI>`$(7`!JXAX-]!T
M4:21;Z`_.%&$*S``8T"CQV*:ANP"+_`''4`\/=!$&B`!2K``GOH#8U`#'L``
M<8AQ%U2(&V4Y.N`"AH(H>G`HJ^,&&D`!J.Q%;@S'Z^"J-).A7N"`BK>*/Q!6
MHP`"8X`&N@S+:9``61`"%1``/8``+P`"7H`$;\`#OQH"<)``0@`!&I`"X45W
M"(`!/"#_!%U@!BX0L7W0`O+VR8P(4,4`HMTP44DP2,94TL9D`")0SB%TSJS\
M#;_277^4<`7'7E.0"<VAD0+P4+`I`'4@6!#``RE0`V(P!NVI!\1LS.Y&!2*@
M`3CP!R%`!V#I`3.H*2[@!Q"P`!#`N!S=5+9@!%FP7A681KT3*^.``5>@&>%H
MP1:ERNAL,G,;6,!S`4(0@7VGRZ-@!0=<!9K@`1@`5QD[`2V``U?0!!]```1]
ME5$@Q1F@?1EGC#S]`%+M`U"*>P>``EJRU5SMU%4$!WD@!Y[]V9X-!VJ0`>.[
M"NO""IAM(6S=TN`25;_Y`+_I!5X`V[)-56$*&S8PQS%P`T_`_RP$`<M2L`2L
MB'@R(`0>'`HHM@!]H$X6$`(?T`(6L`1E4`<9QC3C&0$@H`$&``4TD'IDX-2M
ME0/4;`*LVP9J\`%.6`LJ[-8AD`(\4$.MTSJL\SH!T`"EG=FQNV2BT&9P"[N0
MPM+#$058T`!N4`=UD`=Y@`=X<.`)#@=W4,SC8`,ZH`<#8`?#9`]T2@-=\&>*
M)\$]0`336`I!X`.EJ@$)(-MPR`,`8,+(#68!L`!M\`)18`0LX`8RL`D,8-1I
M208_``46,*1E,`=4``OK[0T$T9TKT`=J16X^,FY?&`'W_::.@MH+FIG6ZR>K
M'>!0@`8:,$P#\.7%%.9$`P2@@`0]H/\'S]0DR@WAL(`$%R#3K"C!-P`%V34*
MV#@#6`#'(3`#6I!^^]T!"O`82-6:/[#$&/(#9=@%-@`%`J`&5Z``>3`&)2#/
MP*$)7W(`90`'9K+I8A`&31OE![&[6+[#`7X!,TE>A/,X7]`CA#@%4X`##7!)
M75,F&D`"UV`+NZE2#V`%/2`%(J@A7XPOC^(J*&Q;E7)]#T`!+9`'$_`&?H"F
M^^34,,`#"5"N4Q*N5*('!^`';<L<]NO*\6`#6_`"4A`WQ)+EH1`%5P``!J#I
M93PF:R!?9?`!4K!>.^`&:G!"8G`',K=,KHJ<2V`%\B>UE5*]54,OQ=ZFK3(<
ML*P"$1`!.:#_M?T@*4O2`AS[6GV0\1D/)13JD01A!$\@`R=P`UH`/ORK"ECC
M`Q50!L:F!`)S\@^RP$#0UII0#GDPQCNB29F$!J\E!#20"U?@``G0!J3\!3SP
M`5S:YE@PYURT*OUZ4DX_(C2@KM/[+&4G`Q:P`W8#`US?]3"0`A(PZ:8@`]TC
M`-'U`2HM#QQP/GWP!L54`H/5)P">[E!`!V-0-%\[-)S:`D0`"H[E`@=P!W*P
M00,@!+7+H=2R]%#0]*QAKQM%4;XKO)+_N]\5!4I0`?#:!GT@2B6`G^EL!$K`
M+^55!B[0LE4/(7-/.PC``!*0`SF@`[#/2*[_]2FP!:_A`3F0`!4Y_P1J(`0V
MK1JP8`1%N_@1Q04>`.W>M=^\0:UC!RNF$@)>0!@*ORY$7OR3^5U&(`$#T+&0
M8P9T\$3O8/PFD"<:!$`'(`=C+?>DWE1($`(><+KP'__N3V!-%0(WL`,6H`,C
MX/F'#PA&5S=0(5Q_B(F*05<](R,7&'\=)`T>BHA<3IA.FXDT(P`7GIV91PHA
M?R]P#$9_AYF>L;"8M;:WMERTBD<1"V)I8,)F=@2XQ\=<'B8"`G=?8&LK<%=1
MR-?8V=K;W-W>VAXR0`A(N]^ZV)I_1EA+5(;',W!C/!IC$4=/<`E/?TXT2*(<
MXA(%"0U2-`[^";%A#)!.4:)TZB1E#@PC3?\TR+'A+^%`B!%E?1NYCH2`-E^@
MH6E31P')6TB@H`D0IHS-(A""F'O)LZ?/G]\Z]+A!;F>W3KI@H<.DCATA>+@0
MF''QHT.&(4F./#B!Q`F&&R>T&.%BA(H**2$Z>1BQI(.3(!_&R'#284H0)P\0
M>&`PIL$,!%*N'.P@1$G:*!B\_)@"12?0;5%&R`F@)@R8`0)B!'F,R(:%!0'<
M"%B!1H9$HYQ3JUZ]32C1<CR3REZJJ"F6IZ@1*2CCHL,?*1H2S)`R@0:4+V+B
MF)EA`X*:`A4L1+ERQT""/#-HF!A#Q8B$-PHZR,D`!<:8-R-*Q%$19<H=`0$*
M$$#"IK*!/GR@LH;_.:*.BQ9%],%`*KF-1-<-*'`000Y7N$+;?A!&**$'0Q4E
MX2N;.%5(@0J`P0,"?\R@`0]"I)"`=V,DD(,)'A#`PQ@0E'"#$1/<8T(`$73!
MUQ0>M#'&$PB,H<<,)=SC10IC3(!!!"LP,($&$H30QQAY1#"&&C.(="$B@I!A
M@@DO$*AE;(?0@,$6!-A0X)9LMOD-A:^M"5135[BCGRT*?,&#%R$.L<((-=AA
M!`X'"*""!U%TD48`(CQAQ`,U;<:&"R"`H`$5-D2@`0(/+`!`$$J,T<,?9/!`
M0@DN;/`'#7O@0<`$"1`0Q`!T$""G:F/Z(]%CFN3JYJ_`OEDA;"0]F(FQ_W3B
M=LQN+F#`Q0MC]`&%"08$00,1`/#0@@Q(7"&!'D/@L04`7X1`PP0NU,"`!E#8
M4,"F#ZR01P@CC"'$'S'P($$)+43@A!%[[#&#'P)$<A\!ON[7ZU)).7'K-DC5
M%NS$%&,#IX4DE5+;1$QE.,B&QR"0QA`]3`'`$#?\(($`02@`Q0](2J#%"!CT
M8$`+/["A00]>`'!'%3F,844(=8PQQ05CA!%"J"DX4>0&,^P!AP(]+(!"$`"X
M8`4&!^B11<(*)W6L:K3)5O'9:"=R,;$2'J+AG;4@4$'2`2SPP1$A1##`7F+D
M$,$;,D@A1@H6F)&!$54D8``>9N!P1+T<8$'$&/]I%-!"&2VZ$(`0(D!YQ!)]
M?&$`&%C0X,`*%W1@0*U@I^WZZ["3M/;#&$:4$$!((&%$[KGO;E!"$9WV!Q):
M*(M+"#VPL`$$.'!TA!`YA$"%`VC4<8(1(4BP!Q@?_$"0$A74D=]"*30PA1$Y
MY$&!"B4$840,#:0`@@E41!'$"0#$`8432-S```9!8,"A:!>[`AKP@'^8'2YZ
MY82"&,$&'NC``WZ@``0\@0!9((`&-P@D!7CA`1T(@0V.$(6W%>@?1@B"M1#!
M/R/\`X+F\@?>0N!"1$3!!B&`S;]L0(-UA,!:7>$"$E2X.QH<`@DVL($U_M$5
M_G4%@5",HA03."RC<('_!GB3X`\0@(`N9&$&5[@`8Z1`1B4\0@E5D$(5H#"%
M*UP!35U`@!=<!@0H8,`:BM#8%/?(QSZB38&9P&((/)`8!&3A`E!(HQ)>,`(F
M/&($,NA!#X!P@QL`09(RD,$C1_""%Z`1"E*0`100T`$/V,`(>/2C*E?)2M8L
M!4X*Z"$3@]`!!<R`,5"@@A1>((,;$.$$)5"!,/E`3#+$X)C()`,QA<F^$I2`
M"$(('!.DP)@+S.`''BABZUK)S6YZDQ.>N!@-HA""'V0!"UBX0!5D((03G``'
M."@!'WS``!/D``8[(,$']LG/#Y!`G_[\0`I@L"(&Q``$)^CD"WH@A!%0X0)8
M_[@"`;P0!($X[)L8S:@WU9'`2&9!`0KHPBU',)0;"`$',6!`$F#`TA2D8)\2
ML(`(-I"!#-"TICC=@`A$@`()D&`'.T@!"4S`!$;>H`1",.D-(#$#('E!B1J-
MJE15B9=,HI,*3,BD$$I`SR_E0*@QO6D&S@`!"DP@`@U(:P/\X`>U-B`"$9@`
M!,[`AII&@`0R,.,)8&`"@Y[@!C)P9!5FH(`'9'.;4TVL8MMV48(<P0,S:"0H
MCQJ#KJ8@ICO=`!LH$`$_%````*A#'?*`!SG(X0ZH3>T=Y+`'.>`!#W4`+0`J
M((<S`$$*(V``!"Q`@APPH%)D.`$0E*#&*R@@FP)9K/]RE\O83A@!`S.P`A24
MX$@B'#0)'Y!`6"'0V3@X`+1YN`,8:H*&\IK!#&BP27K5BP;TEA<::=A#'QP@
M!*RFH``4V(`%M/L!$\3`F2?HP4.G,`,/'`2QS$VP@K.A"20\0(,7F"0C90""
M#^S@`Q8XPUDY$`<`R&$-8"B#9:`!AB^$(0PF/K&*5WQB$9\X)6`00!V$``49
ML&`-<8!K!-@@@7VF(`DJ($(3&GH!`CRA`T]<L)*7?`R':4(72.C`#[90!28<
MM3`CN$$.,@`!"$S`#P#``QS$4.*:V`3%PD@)--3,YC:3N,3"&$`>:"P#"[Q!
M#*LM``?DR@81?$`'.:A!"9;_``119@&;1F2RHA7]9$30(`A>T$(5>(D#$.B@
M!+LD`@L:\-TZR"$8[2T#-,A<8C>7VLUL%H:JQ2`&`0"@OC(0@0#4@(8OP`&V
M!6@`!#:P`12DH*\QP,$(E$"%&3R@HF-;M+*9R[\.$`"1,CB!,+=,/RF4``)R
MJ,,:S*SJ-+^YVZ@.=YO)+./Z]L`">BA#B<M@AB_LH0X5B`,',B`!%`Q5F$08
M@16F\`1S.?D5RPZX5`EB`P3<4@8XL"X,+KL@79(A#FYPL8A)+.Z*6WS$KC:W
MG=5M8A*?>`\`>.L$++!/(`N9"5?X2T4/@6"!N_R`2WGN$ZZ092*0X9XDV$`$
MZK`#_RI4`00`>(.Z3PQNBQO=S9:)\8RI<.XWC-CC9P8#'.J08PADX`-\Y8,0
M@/"""W2A`SUD8<M?3G:TL1S2,Z!"EDM03PQG@`(`H(,%?`Z"`LRAV]Z&<:KQ
M?O1QM_K53+?STRD^7A&+80]Y<(#5+;`#$X!`1@XEP`..(/:R6UZ*]D/`%6H,
M3`9<U@(4<$`!UC"`#-#=[C`^]9O[KF8TAUL8Y0Z\T$^=9E63]PMX<$`<=BL!
M^:D`!Z*\`@+N<OGB%Q`6-'`VS=L)`AA@>`(-*(`<P-`'`X@`E`Q`/:KSWN87
MKYK5P$B#N&&_]*9SW-1LK@D8ZN``#D"@QS`(=A.4(%%$&?___FB[*!)^,(,(
M;]4$+Y4!:%4'XO<%;3``%I!(=:<'%3=Q\+4&<(!:IW4'K<5:=Y`'<K!Z;,9J
M&2=[YX=^:_9BE0-7&4`"?(4#T61-#Q!VQH)_+B@A_^(%6T`%[$0&-4`X&3`!
MM#5>T&`&`[`!N;2`2/=BK+8&1M@JHB5;22A;8:9ZJ?8%'7AN=O"!*8%BVW=B
M:Y![%)`!%O!K6C<"4#`#&.`*+UB&$+(43G`*5U`%0%`",9`#)&`!$`!F<)!>
MH^:#0$@%0KB!T1"!>)`'>;"$T%$!!>``;>5=#F"(`"`&:D9[Y`9XYJ=W5?AZ
MPI!><A!RN]5;9`!\5*`%7C`69AC_BJEQ47\0!%TP!56P53%P83H7!W4`!FA0
M:F`@!GBH@`7`@(V8!G<`6X*8B+HG>J#5`!PPC&DU`7&`=[*8!FG0@3*``FZP
M9DZX?6Q6!F)0!V^U7RD0`W\5AEU`AJ+XC3_!!3:@`%>@!.WD>220@PX`!T27
MC&@@``GX<Q7@!F26$L!@A'"P!F*0>''P5IW%CBBV!A4P`68U`1G0`!T'9Z7&
M@8!G8V6P!]O6=ZK6>G?P5CR6`@P@7%)P390'CAZ9,4&@>2.P53<H`1#0``"P
M!M^&'&Y@`"MP#XF4!&A0!(5B!L&`=V4``!.PDP<9##7Q!>KF!S5U!A8P`6;0
M!WW0!FV@_P9,J09FH`8'(`=-0(,?`')X$`9VF&*R2'N-V'%P4``[UGL,("-*
M@`5><`0$])%JR05'@``7\`)"X"4D(`)G\%UI$(MI0&IAT`8`H(XY0$8E8`'N
M-P%[H`9NA@8`H&,34`"APVHEQA(;$%,2L`$.4`&628A,"`!HT``W0(,P``"B
M-WT+N971^&9EH`9W$')$N0.")@2!@0"@J):R>0OH0!8*<`'F*)<B8(P`D`:N
MYVWP&$964`6<A$:(A`,.(`#=1F9H(`<5X(M7N68]*`<08&$DP`+\=)W:90'<
M:0$18`$]4&4YX`!IU6%Y$(&GQ8B-6&;K66IJD`8`X`>[U7A_)?\%6*``L3F;
M^ID)KX`$7K!Y_Q>'QE@'KB>=*6$'$R!@N_0(G60%+R`!:T`'58AB[`8`<[4\
M=5`9HV:`X^%2%I8"%_9/_\0"VB4!$R`!/8!;29!C:.4'B?A9&*B2W-=Z25=F
MU:AK72AHPZ4%&(`$KY"6^WEY9>(%P_%_S^<`<E`3K*9W+^8&`)`$+T"<#*IO
M,H`';Y!>Y95>:J`'#L`"V)D"$:`'[38,;U`!,)`$.@`#:<I2+06B^Y2.'Q`X
M(V`"$=!E9X56H@>C$+F>--IM-K%^\MF%&7D#5:`%';!$0!JD`4<;B)%V/5`"
M)K`#H.<'5UEKZ@EG5:@&90`!8/A(G03_!4*0!G0@-:H%!V`P`2UE`A]0`6:@
M!W.@!TY*`B!03U]2JU^2!/>T<"F``C"05[FU:YKE92T*C``@-9<*@B46B];X
M?A@I7%"0!1[P;XH:BHWF!#8`1C+@ACM@DM\%E$O*GGI7!G10`:*T24J@!"4`
M9@H25P3991*P(@6E`PU`J@X``RK`!\Z4K\%D3`?%`/YJ`KWEJRJP7R2Z/#O9
M79T67CR89B^6>NNV!@`P;Q(``R`@;%/0!8XQK:*(#BUS!3*P!#'@3Q#084`Y
MB^K9L&LF!GQ97YS42:%4`S7E4_J4`H!F3TG@KR"@3"G55R6``^\D!$+0!$1`
M!/`$3,YTKP<%_P,U,&PO<`+:U5,QQ65GQ6D%4`!U(&9E5J-[EQ)E4#D<(`(F
M^'OT1PZ)D*@:JV1)X6#E*`1\`(=G@))B(&J,2'NE%@:'!Y\,P+2=1`5$()D"
M15`%Y0,^``(Q0`8`-F1`>P-+P+8D(+,B>ITD&E,6D`0U$`/#I@39AP?OQ@'U
M1E/<A:>?Y6D`:7M6.&HH%@9>6X+V>@,OL`4KB"%F>[8)QG(=D`50<`,X`+""
M.7IF4'OM>6+QE8020*B/!`4G<`8H(%`ID`-)8`+J$@/-5`(_FU259$E,P`#/
M0%I_*%J`"(ABL`8PD'#G*@,DH`=TT`9FL`8.8`$L(`)2BU;>9;4?UO]Q$]J5
MA7<'#I!?'S"60#`%6Y`6/RJ[]_<676`%(T`$GE>4?G`'HE9T'O<%:9!MLY68
M30`%G#0"55`"&T`"R]N\#.`#9"!,)R!D0W8#/9!)GOISHH$&3=G"3/D&=)`"
M\$1<-[`!`A"+0-D&%/`!*&`![\L!G!9:6.MZI4MQ7U`]#4`!8MD$,G`!PQ>[
M`IQ@-*``6/`"*'59!YD'(7:L3YB%L46>SUD"4*!03!`#)K@B(.`#T#O".-`$
M)IQ)CN1):L1&%Z`"9O`&=3MQ*M8&:/"N-3!-0&`!4[AF;1`'/3:7-656:%4!
MH"4'<-"5;99FHE8'[O>N/C"54.`%8Q?%2D;_3C.@!(_J?`=9`4?,?1,)P1)<
M`6_U5C&P2)WD/[_V6]`KO41@22<\;%60RU0`!59P`1`U`T00!G-`9HXYBR9[
M7O26`CV@!#(@`79@MV1F!@706]DE`>Y[!ISEHJ$E-4")'*4)E&N0:[QE`M`D
M!5T0K9S\<AQEBHU0:1A&`14@?D5LC^-EMW<06[D65Q0``2;`=>=:`CH`;.PS
MPDM@PL-&1KQ\`6[D1EB@!4TE!'0P`$_IPDJI!G8P!SI025``!27``1(*#&$@
M``N2!"]5;SZL86G%R'6PITDGB=(9!G<0!R,'`QG9=62;S@*G#E'0`6^Y!,UG
MD@V0![WKA+-H8F#P_VZSY0=Q55<E>`+G*@5D(#\A?`*)*P,N2\=NA"8<%$<_
M``1S8`!M@)1)J93F)0!O<`(SI]`J```#\`9N\*IKL`-\8$\O1:(6L`$:UEDJ
M_6F8:J!P5A-YX`<7B50C,`.'FFPXK6A.T")3T$XF(`$"^(JI-Z'"8+?O5H@B
MEP$BP)T;X`-2L$B0R@<CG%2:1&S[]LL:!"0(\`,_X`4?5!=TV<,[Q9V;S9W[
MW`//=C1,(`%.^91Y\`'.-#_WE$_U)@)L,+6$>+6/+)W1>&)@>0;[&P-`X-`=
M28J)S611\`.ZU`0F``,2P`'K&(O?_`59"``%X`=[5E<B\+1DL$@]H`+!AO\#
M;_P"NVP%;[0%3052K/T#&-`!I10"`)Y$.`3@'A!!#_``BE%!6:`%6Q!&4-`#
M-;"_0$L$)4`&]'1/*6#78\59T;?-JO?AZ^:<[_<!/K!45X`!+'C=3.8$(?`$
M+[`$)>#=!SE]\]QZY(UKY#D!9\"%$H"='T`&C]`$TDO:]`T%$(4%,T``7.1!
M_5W@'B!"07`$1X!*P7,[1G#E1Q`$$#1'%N30!(`%D]9)609,*M!5"_<!+.##
MPMH`C)P'>\#%2(<&>#!O+&`"*B`$198**JYH-."6Z7&#`E@!(59Q:P!RF"U7
M/#ZS.@`"2^5.6S=L5-!&*1='7O#?-N`^XQ0\FG[_.P8A$0WT+X,401CP`!7T
M!#.`!5N`!0[*!#VP!!0.WRJE`R6MYG`%C'@@7@;J9F8@!HG98R;0!-3T`)N\
MY]_T%I%U`RJ`Q17P##6>9H>7!Z#Y5E87F?I$4#4``@U%M$`P;'2<Y$]06!B`
M`1X0Y5.>Z9J>2HD0!4>01$>0.U(>!"'0`>'^`UU``/W'&&;$2R:%`_!M`BN%
MYFH.?:(W6KYIRI@*TPW`A3D@9%2`"L-.[-RT?S/PJ*MXW!6`LI`L==`>;W&E
MV2C``CN@`S>;QOE&22_`1E>`Y`2@`/S=`5A`7+NLT`OM1A?0\#V4%&6!`GD0
M!Q9```*!12H4[Q.D`/:._P6,H4NX!02N#NMT'58<CIERH)X@V+6YM@$860)*
M<$WH#O'*Q0A3<`,@`(<3X`!Y(&JF)@RW%NUUJMD]MKSJDK//!`1,``5('D=+
M[@5C:`,PD`:!"%J?%5JQ59@@T)%_<`0G4`<&$``#,`![\`*'$!$IA$,=H!@(
M0`!;H`4OD`.[-E9>MI/E6;4)SUV<E@?Z^'JG&P9[X`#T!@,E(`-4X"A0S/5[
M1!<7P`1"P`!QN'/C%8TE]NQ)#5=GH%]MOR+_A8*NWP,Q4+DR<,[ACBA&L`%#
M$``&D/@!$``'4/T!T`)C0`*;L0D$\`8!H`?"X`9](>PL1`,I%.^%=$$C,`$!
M,/\'9J"4Z-M>O5T]W'E6!9`&(O;-:`8(96(5$QDI?#@C!!U1?UQ_D)&2DY25
MEI>8F9J;G)V>GZ"AHJ!!"!<W*B82%`UX:&%?L;*Q86MW=WAX=0`%%7$-#1,1
M$2@E2T(O5$097W1T#D(/(4%!44@P>K!IVV)I8MUE=BA7"%T(,09F8E]@8G-R
M.#22UD<V'A@_"@A2;`-M7V$"O@I3AE:>#!DF-*CSI4P8,+,BLH,%P`&$%";X
M,-G2!<D?)X]&B1Q)LJ3)DRA3_NEP!8H0!C`D-`"PIJ#$6&#NI+$IBV"85VJ>
M(9,QY08`.V[:M!FPAH\1:W^,I$CP"B).,.W*S.$0`X?_UPP#T'AKI^>+#X^0
MN*B-<B1("`Q>O$#)($#-.JRP(N[YY8!FP+Q8)4(,N`8`!1(??/2H<N6((Y`J
M(TN>3+FRRBA>J,@@DD."B`9W;EH%`T=.35H$RZA&8Z8-G0I$1B@90:+/FS!B
MP/0)`*##QZ@?!)AQ^/?O%S4&4DCS$&)$BS9KOJ4Q``!*H\>/N$0QXK8#A@L6
MA*=IEQNKU2]YV$"(X`?.W_/G<0($""!"!@D@FO2XXJ%12,L`!BC@@)-Q<80"
M53110@XB4.#'&GE%!!$8>^0!(3OF96@5`!*DD`,)>0#VA1@"K(%`)$=DH,$"
M`;3H8HL'M##&!VC]$<(&+;@@_\``/*Q@@A$A<>&$)$X884,((5P!@0L&O*''
M''JX(24=?;C11QTDD+#!&0"@@096N;$CVA=HY.''!!*8H,(-5RC@&(%PQBGG
MG)DX@0$!2I0``@P;-%#`3C>QDX8N[@$&1G&'H@$`1C`!0(=8[<!Q0!L/1$+#
M""DD8<*FG'*:PP<O>.3$J%Y\D$<:<-21A!=I65(D-5F@8`<:<$C'S5AB.+!#
M"A9L$`$<:*@F2V`2-B1&?1TR<`,4,X1`Y[/01@M@%*:,H,*'&?B!!T#QB9G&
M'KL`ZY!JJP6+AAIN-%#%##-HP4`8;SAT[@`-O"DD#4CDJ^^^^D8QZK]%$B!$
M#T\8`?\29)9L9\0#3)C```,YP`##!Q^08($(&9RQ`0P[6-!K`WL82NQ-9L#!
MP7TF"#'"%!A<)^W+,,?,B9"/&/&$%*CL(`($#HCQD&!?I)$'+W>8809K2IFA
MAAJMO2%`'%1L<<4/6)QA0``[C@'`#$-^0O-'H_YA#1)1"!DV)31K9V0'7BA`
M`!974#$"$S?@4((/)N2@PP<22+"!,'$`4`<>:UR%FBRT!F.!"3@(`<4#0,HL
M^>23J_51"$^,0(0**;`100$!=6O5&G7T4H$#'$0PP1D9B"`!8AZ:4`(55US0
MA1=7G&!!`V?40$#9H%C^6->2J/5?)&:'Y$0]-L#E=NU5C`#_A!`EQ`#"WB3X
M?<9Z%10`P!ZCW51&&A4T($(./IP`!0(A$$_Y^_`_2\,#,S"A`@,[3.!`'01)
M>&@:<BB='^R#`@E\(`<U`$$)B#`P*5S@`E"XP@P(X`6W(``+78@<P@`D/"<T
MP@E(",$#?H"`&5QA"DJ0P0V(4#T0Y"`%._!;!M83!^\1;D(W>4@>'+`!#YV`
M"C-X@/OB1\0B`@@)7<""#&(``Q),``!PF,]HL%*&.^2A#N6+``0V8`$4'#`'
M#%`!#HC0@V1,809/0(`7/%`-Y(WJ>)U0VQ&,0,<ZVG&.90L2#4+0A2MXX0@T
M.(((W::%*5#A!3T0@MU`8`*.L0`%_QM83P/ZDH<[!"10`%D##TD``QR\8`H_
M<)D11TG*E!AA"U;H@0_X!@$`7')8@PG#'@``@`IP@`)LV(`$6'#`&OB@!$VX
M`1.J<`$LS$"-&+#!4QSQF#S^RWB:B((64D"!#8C`8QX3P34CR8(+Y/$/-+A!
M!1+0!SVP@6M&P`<"MG"!*4BA!S=0D`\8D(049&]GPNA+'>30K5D<"@P6L4`*
M2B`#*B"@1J5,J$)%88,+*.$&(""!""*0AZH,"R`!F64!XJ#%7!K00R!0`1&`
M,`(JG-$<:PP"V0`6MBA@H`I2>$(0A&>)1T1A!'D(@!WTP-,Y0.E)"0B`&&1`
M`[70@`IU8/_1U0R0@2W0(`@/4$`6L'"!*LA`!M0C`R-AR`*,K<</!1B<SWXF
MH8(4(`(])(,0E-"%(`QQH7"-:R6<X($KR*`)#)#`&5IA4?GD1:,-T&(&+-"A
M'&0D!?>!G6$9$%(BL%`*'GCF$4:0`0#(80)D\,);B22V%P#`'TH)[=+4T(<$
MK"$&#\!`""[0@`'T`0]P@(,=!O"!IW3@!UW(0DM>,((EG.!N2=!!$T6PI0A,
M$@!X&&L__PD`/QB"`2=X`0'Z(]?J6M=2'<#"#4I0`PE,(`YX*$A\K`+`6@96
M8RA@@8>@&P$#&&``!CB`BQ:P@OJ.X0L(Z%H49"``#;@A`0<8@P7_;)`=./XF
M"E)PP&V^P6"L>`,-=R#!#=9J`CL(HAWL&,`$JN&!MCWA"E:(W@I/X(,:)*&)
M%_/<<2TTGV(Y!`\.R,`.9/>"&;0,$\;+\?%R[`@>ZYBF:8&F)GA\W2)+8F%7
M6$(,DB"!S^W!(1%9QQ<J5!$.%,)U)``I#LY`!Z:Q9K2NZ8,:>.`'!01AC@]8
M0PN.5@8S+*`,/1#56X<4!2440`!M,)J>C58&-+PA#7P8H0V4X`Q!`$0-`3C#
M4T)PVR=0%0HCF#`.R,"`1F;/`AF(``=J6(<[X%!"A*E`!CX``Q6\``L_D$=-
MPV:V#0K)7VH!2:M9>K8@R[K'EXCU!HU<_^127&`)>T(!!^J0AA;+(C=B".!&
M!4O8#WC(!\LPPXBDPV`QK&$-;JC#!QP&@@\,(`'@2\,:Z"``%`0!UY.@\PCP
ML``!).#=";"#O.T@@`"4X0;^^H,'2!#OG2S%#"J(0A3LX84NF!#2*CR!"D!0
M`QWL@`68%H8?!+>'NXA)3(,!`P#.(($=\&%E'<EU@6/]'P\"3TAI&16L/[)R
M[+AQL[R..25L0``H`)M7$=C639"M;(ZRS@+JS109FI`!-8"I&]*Y-AP$```^
M]$`&UDJ``.0@J#;800+G-C`SHS"%#=0A#GX(N]C#OK\)6`<23E"`!>8@@#*`
M"P0>X,)30T!"1_]#@;<W^&T,&FY/3$-`(3;TV13E0Q\(6.`#9)"!%`C@$9JB
MG`M&\`(!$-`!@_78;)CY@1&00``%`&E4-,!`1W9M("^HL1K909[EY,[H#MC@
M.K+^L>JA^34@RUQ.(9B!S1GP`0M$X,G]C,6@>.'SP689!DE0P1(H,(!Y2WU'
M\'VOUC`0DB/<00-S@`4:7#`'HO[&52RI`A2F0/XI0.'\YZ==!TI^@0W(@0(=
M(@`D:&"$$+0MB5"00J1Q<`(RU"!B)`!)9T`!'*!/:Y`AWT`>N1$&AK$!'^!T
M-68$V-%J?Q`$5Z`@)7`#"B!*\R<$9``Y*@`$-A`)3D`%.N`8T.0$(0#_!0IR
M`T^@:B_W"$[0`4K0`TSP`EF`@FC3-2BW@[9W>W`2`E@@!4N@"KZR!U\2*,/G
M`(&52T`'`SF0?#>0`6Z@!GUV-*_09E88`!SP`UT33F40`'TP!V[0`B@P@K4V
M5P*WAFS(AG1&?S;@!3,`!"KP6R#0!6E!`S;0`0^``(5D!2\03S@0`WF3`A"7
M`13`'H)#=4J#A5[RB*2%!Q%P!BP0`S<P`C-@+VA'9U>0`D#P`P3`!`C0"-9`
M`XV`!$+@`UY``V<D@4Z`+R\``Q+X>!ZP!`S`+!>P@7)G!#2@<EWC!#]0`T1P
M!3>@`U0@@320C*9HBB;G+Z_(BU%@B@*G=4`X_R!),@)"H`J9!@?2IH1X4!'!
MT#H6P$F:$@-$0(B_Q$"7:%)70``$<`5M-21"8@1S409O```G$'=O1!)(T`$S
M@#,G<`)$T`1$8#<,@(=HMS:@6#LUJ$B,]$)^`P$<`%:$\P5]8`?Q-F\:*75?
M4`'$P``J4S"4,"23]0'>%!5%=4I"(`3Y10,]4`)>@`1`Y"\8H'\Q$`-H85-7
MD`,O4`U((`\V0`6)L'ZW!HPY``4A=`(FT`4T,'Y34`5>8`5>0"U0T#X/\`)$
M<&H]D`4&\X/5*"`><`'8:`(HD`$<L`9HL`X1@A-K\(U,6`A=1(XU$`,E(`2*
M-P5:,'G2H%+&LX^6@_\$N&,%67!NEY<)-+./X-0\"'`%[W0">^<P/J`"):`"
M"Z<$7O`#))0%!S<;*B0$!:D"/@`"E18Q.T`"+"`!*(!I"+&:K(D0;"`"++`#
M.<`'#+1XF*D/"D!@X#0%)``"4C`#'O`1%^!)/8`#7B@#)8`!1D`$2.D!0M`$
M+T`&9%`C!C(")I!?*/(".'`!9.0;DO`#)G`!HP(%.F`%1G"30+0%,?""5<`'
M(6`#."`#-><#32!$Z/:5<-(!5L`$39`$%L`&#0`LM"`A<(`'&Q6.(H`"G.0P
M="D$3*`$>$D`7;"7154\D]!J0C9D/#AP/V`%2\`'C01&,2"9DTFB),I(G%+_
M`PD$`C[@`S$@G7Q`HB40D&,T1HXUD"N9HSJJHP3)?R50`GPP3RJ:-PQ``#03
M`E)P`DF0`S>``1W0%4;0`0Q`5$QP`LJI`E1@`U!PG2'`!`PPBR`1`C?``$)$
M9S,``R\@328`!32```2@G%YPB_ZB!3EPC"!`!!Z`!.Z"`#2@!"H0!!B0`E9@
M@1)P`3"(GW+2`5"P&?X)`0&*!H%"&@;Z"W#Y.C#`H"=@ER\006BT1LI$C201
M:^#T`R^@)P]SDR,:HS^ZJJNJ`C'@HJA*!C%*F;2JJJPZHP&YJ@&YJS^:J[W*
MJ[1*:8Q%3S[P!-H!$E$0!`H`!";0!%B@&-:0J3;`_P1$H)PEP#*H,%-3D`.N
M."1!T`,FH`#Z]0(I<`5_\``Q\`(>``,9T*0/X`-3X$%0D`,78`0,0`4"AP4U
MP*=)>B09>`%+I%F(2B<>``7%Z9\3\""0*AJE`8Z5NJ`,$`.9*@.;>@59<#L>
M8`-(`*HCP07V-XMP2#_6DC<,>JM:A07X8@3UX`%]^`0'%XAV0P;S!#%\4S&0
M-$,3D+,Y2P$4H+,YRP;CF`,2NRQ/X`48\`!Q,5/:D6]_$(PJ,`,$!4)U&018
M57DE<`$=T`,Q<&X78`*-1V=0D`)2H&I.$+93<*X,,`)1P#8A0`-Q.@-B(P0Y
M,(H@H`3YR@`;"`4X$`)&(/\#?&`%R01S`QL@BMH#1&`"%J`0:!FII)-%6_11
M)@`",<`'$_L"N9A:-D!_EN<J#\!`0'`#H!NZ-_"Y1"`#&#`D78,`.;`!"&&E
MOX@$>^@%66"P?)`#41BQ9*`"37!5\.29=U,#>4,".8`#37`_()`$K80'<O"-
M<;`_.H&`R!8F9@(!)`!=/0"<O>B+:N$!2B`$Q:2D6&`$+U`#8ID$5H`$-Y`"
M6.`!.3`"1T``.K`$4%`#'^`L)-@!<BL#+>%')#8#COD$EY=V.A`#5'`#,$`%
M>L@"0-"+"*`#.#`%O(<!?9I`-W`!D76?@TNX!GNXB?NHC.N6?F!E3IAE24"Y
M#EK_!06L`K1Y!2%`<G/U`@M@`%+B4VY`PVY`!_9V!;_X!!$P!"X0`"LB`=Z9
M;E%J"E3`!-3C`S@@`6\P!TNC%*-U-`)0`&2P0O=S!F:@!\[0!V8@!P#@:6VV
M9WM&6G#@D=5;`M=+7;,7`E2P0(V#!1[!O:!K!3;@!%W`)AA08]L!!40P82-`
M72&QMB_0!(1LJ%YP54+`>$1"@Q/6!%/@&$%P`RC[!T=`!4W`!"/0`R'@`3*P
M!00@`R8@`UG'L1FL$H7+P0J1!NK0+=H@;G"P!WAP1;M0``5@`3.Z!"\POG*P
M`B[@`G*@!$65AB0H!0<@'&/,-$8C`'``!=`8`A00`.KP_RT"(``G8"_/-`]!
M\`-B60(0T,1>YF6J`2\%P`";$P,?``9N@'1B,#Z[$!J8]!-[<1@,@,8ST`'R
MX'B0T(^5URI1\)[^X01N04=D(S9GA@2;UW)H%P0><`1=@P0+C;J0\8QT1+9%
MLDS@-`UK2`![.X,GT`3.0LJEG!**RJ@6X*AKL,K^$RBI@080()!0!P)A(``$
MT08"<`=$Y95.(`4"D`T8XD]@0`=@D`*CVP-DD`8"X"U]0`=L@`$Q>#S_$@4^
MH`?!`@L:(A!U<`:81@$.$"SD,2&I$AK!!Q%E(`=Q(,\GD,;R`!EIHVO9H=:R
M=C!OE#QL76NS1GMQ;39!EH*QM_]ZK+82UJ,GQ?K/(!W2):&?)"V1:V`7HF,5
M?Q'.86P&$?`P30`"#6`'<[`-NC$$&9!U<U4%.\T."6@>WW#9*F!,,R`#TS$B
M[+`T#<`JLZ=U-)`#*Q`8&F(>;<`A$V,!')!G=W%)I+,'%U<L:"`'?B#/.-`#
M6Q`"_A%D&%R8LW>A6O<?&<I,JM?<S]TJ%[JV3\`1'J!J7DG8*A&68XEI')`&
M1A=\P=W3EQ0'?<,@93!%<,`##F"_<Z4$*W``//4&3L)3_!T`:("4_A("$!``
M=-`-:R``;\`'A&F8<I<"V-=39'C#H<5T)L!">24&_["`@G!%P!VI9)('#4"]
M=RH#S2+_N'&U68,-WB:1)"^0C649`2<M&I^&40'19V'@`+O4&7@P'-[@#470
M`"/H*E0@`.E<V^:A!WF`!>-:``%@`#L2`''@VD,&3B80`!@")D<G!F[@`"#I
MF#G0`%\P''WV!=]X0^^,!G4PB2S@`PXZ`W4L<W3]+RH>($FB!$4H`=O8C5$6
M)NV0&JJA9Q0PHRLD`6YP&^?R!@'`K37%!5Y0`CAP##N:HYEJGV@'!7&`%`*0
M`;\31U&`!;J[DBPDFB:@`S!D`1Z'`RI@8A_0`&(0+%\@![2<7)@$$&90'QE`
M`C&P!)CH5M1=9([WW7.N$KE7P#4@4;_'$SX](N*V!K%U!WOP_^QWD`%>T021
MU@#3_`8'L``D\`#`,Y)J8T?@;D>]F'I(('I9,%V(:9@@$4AU=`0>@%LS<`%R
M(P.^Y:JCWD09T`"_<%QX``;('A$$T8"X7D8$`*8I7DK3'>R507-0,*:]%P%4
M-R8Y(0=#\PLBG`$.>),AJ`0G\`';DP$F\`0&C>*[5B?RZ"HFCCS=CG:!Q#9N
M&C=2(`..R7`I0#%:`@&.&E;)]>^S$/"&1P)\(`-5H,BWIO!&+Q*E,`5"$&S#
ME@:7]$I2!BX%<":/ZVP(Q%BZ*P/G]P):KUIL='(E!S!]R5)L+=W$(SP_AO:Z
M%M?+<P\+^9293#TQ4&D3(P$1IXAU4/]Q:RD1#,AQ#S@"4!!R)7_TA#]D-8,[
M0A`#G3$3=P!EKV05=^#%3!@!0)M>L:-`?;PRQH0`#_``'1`$O>AR:[UZ:=_<
M0*8\"(/V'K37:V$$+(M;6&!(=$,$CEEI>V/W*E9#>1!%@2)E:U``9\!)*C`"
MN9C6!U_XA(]R-)!=VZ4*^B,'XG43W\(+#B!8KD-J)D"71*#K5'`!6M`%"N`%
MGX\$\JC6D2',ML:!D;`=;U%P6S`%6*5P<Y\W=H]IQE4!EE5LD?H0!@H(;#LY
M*B,S#U%_BHN,C8Z/D)&2DY25EI>8F9J;G)%<7'].'E<R.#42%`UX:&%@7Z^N
M7ZYW``45'!#_&1L2'RDY##$E0C(C4E-:,P@/'2%&3G^?BAU0(U,=H%Q.H']1
M04%'X.'B1T$TBMG07B-+(S_8VD=/5!=75Q=02DPW."=\(&0R;I0@4R('FS@`
M`%2(,,%/`0!R8KV:*.M+F2]U'&1(P:#$"P(>$G4:2;*DR9,H4X[,!BK(%25+
M&$C(P*$.*S"Q<H:Y4T<A+C:[2*1(D0'"!@L26/3*D<.$#P8,9HC\0X-`BCMH
M\J28@03:-ALJ3/`9.Y9,63(^<B!0I`V)%@MJ$O2Q<`7)-B\IOA1PX.!APCIU
M\NS)PT8&DWX@)I2AXZ:-&3Q^_`"H(^=+&(H3<9H)4Z#!QAA"E#P)__),I>G3
MJ%.K5LGRCY$95GJ`^&!A`@!8$F%]@9.G3H4&##,@32'!3`(W<_2\>6/'3@(!
M`E8,46%.T8PV!NRHL;/@RY32BAXD&")@@/D!!LRG#S!$QB(G%]X$T(-&3X`!
M4$HKR+#"#O(Y=`381QMMN*%&!$((!,(&9>CQ2AAE[(30'I5=AEE%:(CAP`0B
MI*!"#U0@8,1J))9HXHFK1>/:$Z2`D`()MMUAV86OB+%''7LU,($N*!"7AAH6
M08A&&66@P8H=`?10FA$^K.!&+/*9$`0C&*`1P!=HF*'EEF:@,4<+4"QR!`,K
MS"%&*W0$H(,'H/Q@@0%J@!'&G`]>9D89!?\,]8$$>0!YIBQEB/'0'G"XDALL
M$,+A`!L2P'#""%;\,!6*E%9JZ:63T.!%%C+$D,0'%%10QYR'3@1'3[]-<$8&
M*.Q@P1J!XB2KK&*@X08;,:B`0PIUO/&%&%^D848`$"``'@9@&`"'&+/.&H8>
M%O!#Q`YXS!$&L&F@8<`9QO[Q`PH#E+$&L^3B="9G'^R9P1=J,$OJ93WM@1.-
M@(:11QP;?)##"55H\0!XF`8L\,"K11'"$R_@$,,.$#0``*DT@@$''KX!EXL%
M'VP`*[.RY/2*EQ"`(`P#?MC1RA=K#+O!#\>*,4"AS9I;AAT?]-"$$#XT,``:
M:8"QAAH!H.#%,PK_;+"`&V:TH889:JAAI!E]F.$`5#J0X("6\];8VQVME"I+
MAIU9H`,(.%B!0`@`$ZSVVFQO8D074MR@`E$3.""GG!92E,8=>>SEQXZ[B""&
M&A!RR?32"2QP@C.A$.&DD6@D$``?72V"@1H+J!'@YINW(4`15RS"Q0T+"#"D
M&0($L+@B;H9K$46RJE%&`R7@`(()(MS1QD2!RE'''L#2^XH9:P!G01+"3.&%
M$=NT[?SST#<2!0)3C*`"##,Y`$>$%\J:!AZUQ*%J!C.!T4>6!+;1!V-NT#'`
M"B!@P`P77=2!WAL&+-#`$Y]L\T`;`8".``=H!P,$8`3GX,(#+'"``,B'_U@*
MB$8'B&`!%K!``B@0P08R4!0V1(`#&XB!#Y*0@QU$X$=="H,<"E`'.%2D>SA1
MPQTBP(;C#6,*&)A4]';(PX$YX0%9D$()3)""#?BA#F"X"&9B(0;?Y6@"0-F`
M")`B%!C\`@2ZNAD0IM`%!?P@"$;X`0XVP($,G$!2_5,$$IZPA2>XD0`$<*,<
M"8"%$+"%"U'H0`\R]@$98(`&GW""$3SP``0\8097@((41B"#)1#A!#%@P.WT
M5!N$U(*%=5C#R;IG&3#4(0(88\`2J*`%#YRCAZA,):6<8`,%4*$)*LB!"!H"
MAZ[-BF,2RP,`'."'")RAAKY@`!]P(`0@%&,*6/\@@`(*20`$_,`+1^!"*PGP
M@Q&%HGF;<,(S\HB`#I3&"5%`@A'&:0-"_J`+6;C"%*@@@QX(H00,2$(*]B0!
M"V1@`@UH@`/PL(<T=*Q98NB9O<0G@1S$X`974,"45*3*ACK4-'CT@A2`<`*Z
M5:`,<W"#1C?:/N30(5"GJD`<&@"!5:&`!(.H@3!/0`0@O$`)5KA",A#@A0Y$
MDQ':Q&8FLA&%M(4B"D<H9R&[L(4+3&&1,A`"#E1P.R+N@`0BR,`9(A`'!U!&
MDWW@*$?9AYPU.`"4R$/H'Q]*UK*FI`-'W14*,@"`-/3!#F]0SG+FNAPZH.$+
M/`%`'!@"%`L(I2G_.$'_@D:@!"A<(9G.[``8D:`-;?KT$HTM3?^<@(0@A*`#
M7C"D%NZQR!LH504^J$$.YIG!>W)`,K\#0Y:80]>YZD$/<.W#&N)00Q,(X057
ML(%.S<K;WDXB&D?(;/7VP0`BDH`$Z4IN<I&;`ACH(`DF`(8*2L#2!/5@!"^0
M`A6@<`$LS*"9SGP`!C#@`1L<P0@]9:@FMH&-0!J!')?%P`-^H(`N$&`&6%`G
M%:3P`D;>P)'\X,-31)L#&*1@!Q]`KG*5R]P<^(`(2W@!%IQI#FWX]L(8=L0G
MPFF$(-@@!![H0`?D^X`2F_C$)1[O>$4L8@^XV`,AB'$(;&`#;X1CG.-$`A*B
MA1`%&D1AMR7!HX_#J6,<A\,;'OZPC$'L8A:/F,0HCK*)5PQC\QJ!L>K-L)9]
MJR+V)K!_8`YS-,3<7C&+KA%99HV%*P%FKS2ORV0FL^C>?,<MV_G."<3SFM.(
M"15I\Q+HT+!7\$SH0F<8R)Q(LR00;>A&._K1D(ZTI"=-Z4I;^M*8SK26`P$`
!.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>y15751y1497404.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y15751y1497404.gif
M1TE&.#EAGP&Y`.8``,G)R;^_OWIZ>L7%Q</#P\'!P?CX^)V=G7U]?8*"@G)R
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M<%Y>7FYN;FQL;%]?7VIJ:FEI:6%A865E96]O;VMK:V9F9@```"'Y!```````
M+`````"?`;D```?_@$I`@DJ%A(:$@XB'B$"*C8N/BX6.E9:7F$!.F9Q.GI^?
MFJ"CGDBF3DBHIJNJJ*JKJ;&OJ4Q(3+6WN+BVND2^1+G!P$S#O[X_R,C&1,G(
M1LW0S\U&.M76UD;4V=74U3W>/>$ZW^'DY47G1>KKZ.T]0?#P-37Q\?3R\TGS
M^_S[^DDT`-(82+`@0(`\$BKD06-APH8->>R8.&3(1(H[+&;$2*>CQX\@.]X9
M2;*DR9(^].A)Z0/)FB,PCS22-`D2346#'NF<=).3SY^=2`D%Q0J6JU.E9K$Z
MRA15+ENF@NF:2NR6+ZE8DS%3]N-7UVC0G/V0EJP;MFLZM&FS)HXMN7'F_]#U
M4%<N';MP]>;5"W*O;PU]_?P%%BBPH&&"#!$KC,AP8<:*&RU"CGQQ1\C+'T]J
M/KFRLTH]+F,>R3F3$B.:IGE*NFD()]#7KT>)&IK4E=*BJ68=11HKUM-5NJ!&
MO0KL%[%AQZLRZ<ILJS*OSL.*#9MM[36S:-.6`U>W;35VX.>NFQNN"#V]]_+Z
MS0<X\-]^`PL?)HAP8./%]QGSF%Q1(T7(&@V!V8";%3B22CZDM)*"H<4$B6FN
M[503(Q1.&"%LG0`5"FV>:.((+"`:=5MO(Y["2U2W`+>+<LH55Y6+Q377'',R
M?E766&3E.$UVW/!X35UPO27D.>615YX[ZJ2W5_]>]KC7WF"&'120?(HE]M!B
M$=GWV)8!7B391`."=$=F!FK668*>L=0#!VJXX>8AJ$W86FJM24AG3D`)@J&&
MLG$HHBP@MF)BB":^DF(M4.VBHHNY$"?5,<O(N(R-TMU8UC8^HH5=6]Z)TQ9=
M1KI3)%U!F+=77_@TZ=Y@^P04'WT&N<J8?8K-NH-$_@4X667]A1E2F2/1@=*9
MGWFVH!Y]A/#'LG_`>6<D=)Z6""6H[6GM)9O,MLF&VQ(E:*"O[#8H;B:FR`NB
MP9R(U57'(4><I/!&"A:.TSB#G:;WHL7I-]Z,$V1X<HD':A'R\+6DP>J]M^I?
M_S!,Y:OQ'73?E;,ZMI__?Y7Q&EE%OHKD$;`D">O#'<8>6VR"/LBA++,4KE:A
MG75&F\BUCF2+(8>@:"O+M[R%6,J?@SXE]-`H6A4C<HT:_=6,QRS=-%F5CH4C
M-_>NE6]WY@3)W:CCB6>77J<BK*I@_`#V3Q(/0RRK??A9R;:5^VWDY:Y<=OPK
MR,$*^QE++!&;D@UZV&#'RLNF1IJSCLQ9R8-X4FN)GC1CTJ&V-9.B[6[B%KI4
M;^.*J,J**AYJ-(SM)F?,<LS1J/J,43_CNC0Z_)!I6K33CK4Y0L)%EZC@=4TP
MDP:CB@_:K#HY']J'%=98Q0_I]QA_`/:G$1T"8I:WQR&7*3*:".Y]YM\J`6Z#
M_\K,_M&XG(E3J_[AJED[>8:5]+GM;![^W+.@MOF<%&X_.X6NZ%@97=)*9Y6E
M<85U3Y-:U.R%(^PXL'8_V@Y;_/66=MRE:W5!AST0AAZ^K(<]95.8/UQ%F,*8
ML$J)@0BM%#(WZ?4'(W*KGMV$=1(:%FAD:%)0#K\7N,^(CWPLXXG,Y*2G.3DN
M<C?+F?R(PCF?%:45^&OB)Q)%173!HD6-8A?2;I$Z&C4-4M%1X`+'TJ/9N45K
M0<*:#L+C-20%#!]^*5C"0K@PA\DJ;89IGD.N])",86QCO.)8QX*%-Y0HR&2'
M[)X/;""^1NIA<.6+5OHL5)K&1<YF2:P9_6B3F_QIKO\VXM*-4:A81:JLRVBG
MK)$Q#/@+J+4N&OF:W78\U2]^<2U@`2//[GYWL/1\L(Z#H1+RUB:0%+Y-C\VC
M@=R6N248"M)N!;+AF*3)O6(I<D$*`ES@M+E-(!9.?44,9TTF.3,DPJ9;D\.9
M_30GQ<X5*ER^09&Z%&4*XRRC1>PBQG/BM4]+S4M'V8FEOG`W2[A\QX+CP>4%
M-RB\\_RR'PV##V&F1-%8M2V9#HF(QNCF1QE.TV.7*21)4&9-'GK&D3WT8>"\
M:;XA5FLUI.$$Y/;T/DNH4RB;(Q?_!B5*0"'J7"<J&NE(]R)[RHMI-?(GO:1C
MEGPU-8(4I.760J50N>Q2CAS_7!(P0<B/.[Y*2J_28\6RU+QF?LF/<Q.3KP@)
MK.VEB6_&2A`CY\K(;18+<)!D5IP(L9RDKHX(KZM.=1HHV,(:]K"8<JJ/.M4=
MK4F0H&\QJ,`FJPY3QBB`5BEJZIKV'*=92AJ@=675J%;&TE(PJIS2'4)U:=5U
M'`RK#B7>5D>8O"C)9X^S@DAB_N.EYYT53#,425LYT[>367.1*>UA(\5GUSH0
MKEGD-(0.GEN^ZEKWNMC-KG:WR]WN>I>[,S`"<(ZF1>.8;BN24AVEI)8CT2;#
MC-=Q"T%K>8W=Z;*-HYI+P1SJ0:TZ:6$G3![:BKF0%>:6A;T%)`PS$J:/3M,D
MTBR0_W%1QKU$VK6N&&9N7>&0`^=&THC2_4,`O""&$EOA#6;``A26((46D]@*
M4##`$I:`!2H8P`!O@,**=6R&-]QX"5G(PA:\0`8U````:AC#&,YP!C"X(0`H
M2`$'`("&-)0A"F!``QJZ$`4R`*`-8T!R&]C`!B6?(0U@*$,7L#"%)KBY"F7X
MPA.F0`8WI>$)48C"$\9@`3`PN0U/#H"@W:"&`#2@`7\0KRV&RJ+,0FJSZ%5O
MZ[)!'?CRR%-`2B-J!88D(XD'JQL\U:J>!*4I26F8$)O8,0O"PNB],'HQM)[U
M(/S@S1RW9(<$7_AV35<,!RX''.;#<R&4&AW\@0-0L((6Q/]`!2M@P0I4@((4
MJ("%+5AA"3&6PHIGW.-MSUC'4A!#N+<`A3D_`0Q?(,,`!!T`-Q0@!2UH`0C<
M4(9SI\$-8RB#&X[,[R.[R<@-```8GM"%,%BAS5%00QO`@&Z"EWG?:-#S&-C0
M!#20`0UN.'0!"N"&`1QZ`'_0P:,<C<5V(14ZJ:.T>YEJZ>QXIU\33`=E[SLP
M\YRG26(;VVQI.Y^UL7IYR$2,,O_X)>@Q.+C"%2G)KJG#DRW2U]S4<$IS`&P.
MP\'#+-/)(XP-@F:7N-G.ID*TG;T%*K18QMN&0K=GO`084P'(0.8"%=S\A#A[
M>>/MAO(!#C!O,D3A"VS`M[[]W6__0ANY``)_0A6X</`F5$$-9R@#&;X0A2X\
M'`!IJ$(4R-P$,I#AWH<F``$`X/$&@-P(YF61N_3)%2^BW#FNM%?LRI*I;@@T
M:]P!QUU8:U].)PSG<\S'5@?L\^/5AV+(Y"-OI?>\WLH0FC4$%EPGC"!=IU2;
MCF0N'+:__:IC?5E[!4(1CFT%+ZA8[%0(@Q>T\(4J/`$+4O"Q&6:,!16K>,=;
MF,(4M*!C:2_A"F%P!>NW?V=``.MF`3#0`@>P``60;VOP9%^&!@#P@/?F)NVF
M9&06<?HW!5WP!$]0:`1P!FQ@>66F!@-0`&HP9U=P!6Y69@10``00`*0'``40
M`&P0<JK7_VCZ-"F>90RQ)T;6X`-#`%BR@PT"13M&@&D3E$895"1V857E`6JO
MY4%U)%M==6K%=Q!H`S?,PT<)858<M4Q(%V%XPS=]HT.)A%S9IV'<I!(<5G56
M1W7?URPQHR<]\`<H``9I$`4U]FQA@`:!UP;\AVU4\`;8%@9A4&-0\&Q;P(=:
M$`50H`52\&UYI@54D`5-4`9G8&0=L'<@,`)C`(@!T`$K``"?AV]D4&]/@`8*
MUV93P()/0'=ZF`8`T``$0&AK4`8`$`"WR`97T&9S1F<&^'$#4(PRZ`9KD&A%
ME1RC`VGI%49B]%[?0`<),H1E9!WPA3O^$E7CT#NL=21RH2I3*/\/$;5SME5"
M/N>%!:9"$D$#70)K:/5,,Z1T!U)2/%1-=657N[9-=,5]W`>'P#:'>$(3QG8`
MI+>'6]!^3Y`&9+`&77`%6(!M4)!^"5D%7F!P8;<%6Y`%EB@%8:!C6>"!39!G
M"SEQ9]``'-`!!GAD#0`"(-`!:L!P9*"'7^!F5S!G6M!FO]B06<:*9U",F)=Y
M3L8&:'`%6N`%>!8%30`&8S``!&`!!5",9P``!D@`R8AZF:5ZJW14K0<-S&`$
MI5($0Y`@=R`1H[4-MY<UD)5!O(-?-0<VL"5J(41J92,?J(9J/X=\N*40`#(W
M@?0?8TB&94)AN197*L6/X8-]S*4'_FC_==T'A]LWA^@S?BP0@VK0!5^096[`
M!E%P!7(W;2MF!7A6!F#0!%K`!5<0B>N'!69@!5;`AUB@E&Y6>67`!DPV!AR`
M`DB6<0#0`2*@DB-8<5%091H9!ETP!6;@!1:I!6`&>6>`@<CX=W`6!5;0!%8@
M!E,`!F0P!4]P!D_`BPU@`4=F9%59!LI8##&B7EMI(Y36#,Q`#S2P$G<P!'K@
M!SL`0;-C'8T%#OK".PC5:>\@-DJB)#H'8.RA-E%"0NR(4>LH$0K&?,ST?/.H
M=-7T5M84=6R(F+U&=0`);)#)?<+V80-9"92Y;F?P!8#(!FK`!E.0!6%`!5Z0
M!3J&E%VP!FQ`_P9/(`97L`7+!I%20&Y/L`5<D`57D`5_EVYML`9?X`8<4(K[
M)I[L]F5QU@9DL(GZ%P95T`3K]P5$:F2$9GAMD&1IAIE-(`9E>@514`7'V9U>
M5HL=`(/D&8-I$')(@T#]Q$JA]0M\D00C0P<[H`=[``=RX`?\8GMGT512-218
M8U\)A4M1^#LW-XY4:(6CIJ!@-5$10U9LPXYLXUNZDC$;H5:#%$TG,3+>4YC5
MAYC*U6MSM4UP8`-OZ)A4)ZL>F@-S\%PX<43CMP#[EJ3[AF110`5FD&)-\`19
MP`4IR@9K0`99.I)5(&=BL`5!Z@5NM@5%2G!5`&@6.`*\Z)2V.```X/\&6S8&
M^Y8&:X`&:GH%:CH&=U9W'?>KHN<&3?9W;(!FP?BL3:!_3U!D^U8`IO>E_':5
M!00OE.(5TP$I?$$#/M`18QD'.9`'=L`'>X"?\15!CY5[;/F?&.1[P7-S!'HV
M="D89H..MA4QJB96^C$0O/4??5DWOS)K-"28M382U=1T%99-&;I<V!<XW1>'
MC>FSW;<'>W"KY?,3XW<"_F9G,78$!B`&J-D%-;H&#*D&7W"<P%@%6.!C-W9C
M3+NU.(9B'/F`;@`&60`&70"NX$IF:;`%9K"(VJD%5:!Y45`&:9`&:&"C<0:(
M;H"1;U`!-Z9^5A!_*&9C7-NT=OL%::!P.%K_9F,0!73Z:$[#@PH$#$40'PL[
M)G'@!WYP`W)@!WU0!Q.;6(>%A*:%C5`56:<568LZ5>(`*CV0#2'K#YB*H`:!
M'[HU,0B6*WWY0L`57'B3='=08=A$+"9#5ZMZ89_QJCWKH8[9F!R:`WL`O42K
M5SXQ?@>P;FY`!F_0!"4P`2K@`$>P!62`F650;Q5'9E#K@4M``21@`N[KOA/P
MONZK`B:@`B1``AN0O_>K`B[0!%U@95QZ!`X0`R8@`VI@`(Y7!1/'HKJH!G<V
M!7H6!440O_*K`A9\P2;0OO";P?@;`QJ@!6=PKE]0M5SP!SW`2EW)6<K`!#W`
M`TDP!-.T`W$PPW90_\.>^[DY$#NC>XUHV<.%A2^UHQ9I(5A44QU#3+I'K!9$
MD`1Y8'.RBY<(>EL9M4<.,1%QPU&Y`IB^2Z&$6:&Y%G6)F9@Z.U?^.*O-V[S0
M*[1J/+2X6KU_4)D!H`9H$`,Q4`)V7`(R0`%BT`5@H'FQ"`9)-L*Q^`8Y@`%U
M?,>(G,AV3,>''`,S@`69&*0'P`"('`,R,`9Q2VAG<`5>MIFR6:88H,BB/,HQ
MD`%)@`5CI@95\(IA8,(\F%[[I`-#L!\+:Q&;>P,UW`>ZO,MUD`-$?,2D:ZA"
MG,3`3,P_7,1$W%2BJQ;:\`-%(``XH`-G\Q<]5\T%!C=8TA@KZUO+)!GR"/]]
M!A)AQT)A$Y9-=Q7&O,9(/WO&__B/:RRT5,?&1>O&+-`F9&`&?Z`"2*`)+C`#
M`O`&BC=D89"=3$9F7R`&1[`'$$`$,;4G2#`#7*!X5?`&$?`'+K#/3&`"?_"+
M3=!Q(0QH;2!G^?H$5X`!0H!$1,``.C`%I$=O;M;*.A`I!JL5`#*?%I$#>)`'
MNZS+-\S3-I">701&KJ?"T%'40WW4DU+42<T<.B``%\`'/7"@)T1\J*:7^H&[
M#HI6GJK%6PPRU(1KU)>A_+BSVO2S9KR\[9S&:OW.TPM^;GP`:KH%$#`!0"`$
M=JT$0A`"!W`$%0`3!D`%8I"30>IC1\`'$(`$=IW_V(J]V(P-!!`-!E/`!0<0
M`D*`UW8-!!.0`379!F>`!MCI!2WV!F\P;4>``2[`V*B-VDZ@TE$P>FLP9TV`
M!8\KU&)$!#(TECF=!WBPT[S-TWV`!S<0W,(]W,1=W,9]W,B=W,I]W'GP``B`
M`'4@S5Y5?`J:'Q=UNT.G,2L;/6-(C\'K/=T#WN"SF-?7:XP9JVG=SG'XSNRM
MQB%*O9Q`F6JPHB&WV#K``'\P`_J]W_S-WW]0`HB=V@)^V3.P!'D6!1&``46P
MV$6PW\S2W_UMT0,^X$C``#^0!52;N)H'TT@U'4;`!`("P[^]V[U=XCU=XKM\
MPR?>VRJ.XB[^XC".XG*`_P`"@`!\4`2S2]U5DB4I>R48470*]AC=74C"0HUI
M`M8^U*KYJ%RKJLYHK-[.V]YKG,9"BP-M'-]_$`&&UI*)5M=*8`0A\``5<&[H
MMIENXB9L``80.02'/>$"[MA;T`;Z9P4)D`$Z@-=*<(=QK`95JF^$1II3L)%<
M4`&F[>:I7>$]0`41]XO:*=LG/-/.``P"$N.4[MN5?NF8W@<K_N*;/N,U/@>5
MFZDEJT+'!'1]U,V4\6J2,>0E84/`.U*W]CTZM.10I^1E_8^U^J$`*>54OL::
M:^7SC.5:?F@BD-\98`0QL"P)<`0AF:]M4`9*-G%ET`1<8`9Z``%`X`+:ONW<
MWO_MW2X$,Y`%;9"O4.``RU("/;`R`T!F4?#:;3!F>F9M*E;:WE[O]@X$#%`$
MBK[*V4D&'!Y&SX`$>[#IF5[P!J_I"'_PES[C"#`'/8!'>73-?,3C%Z.[6<P1
M2$?D(9.&?D-2YYQA3-Y([/R8Z%VK4G[RFNL'P`[?F3!^#C`"+PD`82`%!?`'
M/,#7KSF2DL>4:88&^=:!4#`'?X`!1%_T1G_T2(\!(8`%$S<%8K`$!G`$<?`'
M'6"(::"L;>"32H8&04H%5T`%1\``23_V2?\'=O`&;9:)GK<%)OQ9T@`I>1#W
M)L[B"E_W=E_I,^[PU8P\>XG55K+-H+HQ$KI6]%@R8+W_0V*\LTS>0[%JQLQ;
MQMMW\E*>\D*K\E?>\F\\!JI<!6B.8R_:!&V29&?@?F$*>6.`;E6P!:(M?RTV
MD5L@!5'/UP;@MP:@;5O;!"M8K)WYBEX``"(HDO,-@5I0K'CF!=@F&A5`;6$P
M^W[=U\EF!D>@M5%O`%M0<5-Y9.9YPM&H0)1V"SJ0!W%P`SQ-\"SNN3:LZ3.<
M_C-\`^$?_NSO_NT?_^&?!\N-W/1?_\.-!SC0`[$""#2"@CR#A#2%B(B%/#Q#
M0SN1.X^2D923DW2:FYR=FG>@H:*CH3YZIZBFJ:AZ-JVNK*^O-K2T<'`YN;>X
MN#F\NSE[PL/!P\;"?LG*R3@A_W_/?T#2T]1%?RMK8VIJ35Q;65!@9``B`VU?
M75%13UU?[F1@34]1XF5N``!E8%UB5_-:4,0\:3(E7A>"3:(T61BERYHS;:Q,
M0;/-38`!;MRP*1-%RQ0K2\PL&0F%'IDT6Z1P>8)E2IJ,:JYHF;F%BQ@O5[*4
M47/F3)8_/7X(_6'$R-"C1G0H_<&DQ@T_>_+8L=.GJM6K=OCPJ:-5*XXD1(D6
MU9$T*=FR:,_J*%*DA]NV/>#&G<NVKEVV0>KF+1(D2`V_?VO4*&*(1I+#@QHU
M6J18L2)+DB!AH@2)LJ?+G>[0(<5Y\QU5>GR(#@T:]*Q6IVC-<J5ZEVO7NGKI
M.D:;]O\RJ'N4-8,6C9IO:QW2G'&SYHH5+U6XL%$#H(":)U,8JF/W\,P7-&G*
MD$'3)@T;=P!;+MRBY<D3+?+B+9PRK\KR,6?:]80_```;^&RZ;%E"!8J4-TM(
M(044\D3QQ1906$'%$EJ,D5$;4'BQ1!A;/'&%%UQ,>`48:$`!E%!&@1@B460I
MI5111!"!Q`Y[P(''5'U0=56,7'6UE0([Z!!76SRR]19=;_'E5U]]!49DD8(E
MJ>222B)FV)-."N)D$H8PLEACA/`PB6271.;E(YB%R=F8H/CPV2JEG6***K"D
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M]X+GG7O>I@PR>_CY#*!`.-%R$'^<,)P;4;C7AGWX`.!&&4U4<5#-:*#!QCTY
M3UH&.EADH7066WB1-'E5F+?%%O),_\W>&I6VP<8:9(R1'1E@H['&V&5,$0:O
M;_R7-A=9#'13I_UM,04Z6C!-1=,"97%AKM0"952(96W+[8F"AV4*''7(,:Y5
M6=7!%;IZL/NCCT$.*1B]\QYY;Y/Z!EP8E*`;[)B5X=H`QQT\V#";9'3HHL=D
M0SB<V2=CTBZ*F6J2%MKN:XKF0RUOHA8\QK_HXDML(0M3S,C&[,GG,L_[H7)O
MTSAAO<O61$!I&5>,0<#W;A#0@'U@//$%&%&WD1$`]=6'CZND]D<%%K]:L848
M59311155R-W$%?V(`@`:T`!SK`$-\$%#&5!U!?Y-@0M8$)`4>&6`-Y3$"UX(
M@QFLP#8M0/^05U#0@D@FB,$$60$*`9)"M7HPHFR9Q2R$(YQ;=,0N$(4&7'Q8
M7!_D\#BMS$$/.JI+D'I`)'E9SG*;$TR^DL@O@!G"<XE)Q.@6@0@B,*`$)9"!
M">)``AE@D0%)B$00&!`#&9#`!@W+S!W\$+M-D$D4$1M%[F*1)C?!*4YX/$6X
MCG>\CM%)-G=:WC"@1\B3*2,.<5``!'A3O>M)PPDP.\!)M%`&][EA.``X@\_$
MQH:AL6\`];DD&+*CCOYA(6E90(\7T$,/[33J"T^H`AFT\P6BX6-2&)E4&]I0
M'"J$(8(3E.`2:F(3+C0AE>8#@P<5M`0H.-,*9D!A?Y;`S"Q004#_*Q216K(U
MN!A*K@<T!&=1C%"$.PS!#XFS@^.V@H,[_.!=<<D+8(Q4I,S-<TE+Q!<^/4>E
M?ODS8(UA1)88HZ4>+/(/&7#!'B:`@6?(0$L[J`$#_H"!"=A`3$DH00[<^$;.
MB.8.L2#-FG;7)EFLAC6H,9WI_!BR7P!#D,2(*3(*J:>:0@^1B3SH,Z['T^O!
M[`0+0</W(,(&C+2!>V``P/<*T(``.+4`^!A#%[2#OE]]1!T/;."SCN:LJ7Z!
M#&QHPP#8L(\NJ*$#%P$`I<#`UB]P08,#\@])LM"$=C1!#&"@%`&<H\&13-."
M!DC0*N6W!"\L:`G5*@(WMS66%YH(G#.$_VPX9WB6)-!A!S?@@P(V>P=R\FA'
MFKN<:.G)Q"3E4XE0#!ABG!10QQ0L$8B(Q&5E\`<9Y($'>W!"0VMPV2'<@0A_
M<((?'*:9&=Q@,[;KZ&=&PXK>A71C=S2I\%KA,6#<(F0?R\7R@I$+8RS/D":C
M:1R2@4@_*)(W/&V9]:1AC1=<X0IM:``!V)`&,@0@DV70R0`(R%^G7F0`:@A:
M&M`PJG9801W&F0=;RU"%Z.A#.Y0*@!NFT(\V@`"MEWS.0JZ`A29$LS]F"#&#
M"D*&*5RA#/AH@`@`$(:X@@2QU!)6VYP9!BB`V`R)%5R)8"@X=O48LM_TD0YH
ML*4AK*5=\-)<:/^15-I['6:U3XQREJ0X144L@F%ZF$!M]P`)/#A#87=0`@;D
ML(DAY"`/-[A!'C2QAPQDX`-L9',?\-`'/=RN#W'0@QW\4,>1\BZEJ8$%QE!J
MBY7*QG@>XR/SCD'(Z('7#^.%='D3Z8P_.?+2,$L!.]30U/J<`2,;(8,:`F`!
M`EI`!$TEJ_HXN<#^A<$?3>AP%<8`'^^@`7WBV-\7UI`%L"['6#H#PQ<P&(8F
M*$@*G5()`)O`!C(LI`L6,74#TM#,M`W+/V_(=K#>>TJ02$%O;_A#$`;G0ACZ
M.+*3C:R/A+@C'9GHLT60U^7JI>0FZVL0_^1G8@@Z.BM=J1*5&0(-&,#_@#Y,
MX@XZP``&>$L''Q0!`\<=`AP44((98,#-&YW!,S#`@./:004*Q\`0['P'//@`
M`R6HP1\V$`<_ZRX5<#I-Q@!MW>Q>]^;=732C2Q;>\.(TTD`_+S1ZVE.8<2`-
MZKM(`0H0@`X4T`U=(UH`Y*NS9-$5'?PX5!A8$H97<P$-9#B?^;Y@J%@6^PE@
MF`*EMK&&=41-4PIBR16:B4$O6`@,49C"&I9S2S5$(0MGLP*`;+P@`U20/]X(
MPPG%0(4K&%O<,=2Q4B0[>7<#>2U"S/RZ*1=O)-7+B$5L\FGQ)3#003&*5Y)B
ME1:CL,I@8@=Z(,'*T<@#/F3@#Y:E0P\RD`0?_[1N`RMG0@\:BH$[N("BW=+#
M'F0?@R1D8`8?G8'&_\"`#3`@#W-L+J$!K3%!:[=.?X2#SIM'TT+F:0_C_3EY
MRROTG1)=O3^]3_@&0(``C(`#'"@@&+S0!7C<%^S<\TM0T#1W%2I1@`5/("Q>
MD!":DA#?$1T)N!`+L2K;@`8+\01A@!X$<072=$)0D`534`5M]03&0F!1$`82
M8@9O@&/_@6PVAFTHA`6&%1!Y9QYA`'DF`D-F`60\"$Z6AV2<UR-`6$]&%!CT
M=$^H-7JC]SE1(F7\UEK^5@FMQR6Q]P<Q$`<L<E"^IRXSL&9TX`<E\`<JD`-F
MTE"H@U`F1P=XD$6T</]R?\`#>E`$0(!0<$`'21!2:Y)')24+>/1'?`0RN+`'
M,.5=Y*<GCN9S."5IZ;=^TE-I[D=T3H`$*I<"PG%);D!_3F=4%O(%^A,`:\!@
M58`&4Y!*$Q(J7.`%6W!*SR1+L%0%:Z`&V3$0L98>[!%+7<`V=R>!4R`25@`=
MFN(>M)8H3M,$TS1!4!!B4)!MRDAC%F1C(R$%'O014(`%.+@MWW2-DA-.=A$D
M0KB-2H8Y]&9O2I0D_E)ZY0@E_4)EC$%%_X8P1189D.`#,?`'))`#-X`!/]!0
MFA`$QJ4)8"B&.7`'=F"&-(!0>7`'RT>/>``'<G![L*<',!,"?6`:S"4\T"7_
M:#)G73@W)]DE4\S#<[=QB#\WDB29#.T77$2'!)$XB=G@!@ZR5VAE5%%P!>?S
M!9X(BF@`0%I0BJ;H!<$B3?D#2UW`!F>0'0C184]0-JERBW0U-[(X!1-$!0I!
M$.YQ!MI0!:?$*1-$$LBHC-G6*6'P!OWA3"%Q!5Q@'%)`C>-FC>?F8^$T69PG
M.?`&%YTG;_066OK"1$[T.5'F;ZGW6HHA&0#W"%Q2&38`?!N0`W&``</W!W;8
MA9SP.W0P!'%P>W]P!P69`0>Y!\#'&\^P`Z80D7:0?8%V1Q<Y:.&77=_'"^,W
M2"9SB(:4B).VB(FH9A^@4RAY/4BPFRLI*#T35F*%_P]KH$R:\@5C<&L%X`8#
ME@:PQ&$0I"`R6%AIV6%UI04R40:B*!/081ST(P\;]E[6:9P'Z&UVMQ"N2&LE
M)A,<>$TJ:'C99@#M:7@CT6(5A$()\FI.@P56\`=%D(.4]9:415F;]R,[,D1L
M`7KUE#E&Z&1-<EI\^:!/$E#L&$57!G`+\R680`<W(`,R8`>+5`.W%P0TT(^?
MX`-[,%%_,`0$:9`("7PD(`?IUW*A(9ISM'W`$V@X:G.`B'.^0(B+UG.&:%/D
MI8@D*9MQD`=H=IOHI5Z1N)N[.8D:&!UGP`$P(`)K8`!;``9M0"B3TB@?04UO
ME09%0S0%\#WUETM*M5?L<_]?!.`/S]($6_`&7Z`S!!`?\O`$-F9,K](%,F&=
M6&`&;<`<DS(VG<1WZE,I.J,SD^(J9@"-.!$=:CEY;9F--#1Y/7*IF[=NX/B-
M]#)ZFW-:_10EIQ>AB_%:AS!07>*.K]<EG/"/+I`!2J!G&D<$&;`'GB$:$P4$
M?9`'*ZJ9+4J/-Q`:<-`#HQ&1=992P#-H-VH+L:&1.[I=.B>DKVDR11JCZA<'
M:99F2*JDT."DD=BD3_H'(R!+8_`$("`!T#`!WU.!:U<%5]!U6&!C8B`%<>"9
M]GJOGCD#5I`&\7`%1?4#T"`!*=`%T5$SHY)WP-*HC7H$EHFO#LL;<7`$U"0%
M8H#_!9WR!S7@@^C6@TJ!J?#$+D(D6G<9>DC(.>-H6OIVCJLU,*UU"'XIF.YX
M"0G31IR0`[)'`ADP`2:J<3/`!Q$3!_,X`<?5!V8X!`;I`WD`?#)@HGZ0!'_P
MD,;Z.]&5,82V4LWJ1RYU/*WIFGR2&S-%K259K=BJK=J:!]SZ#$[JK2HIB7_0
M`8=2!3>(`3Q@!$$PCQ\P!6-`E,\!31ED!6%P-P:@!PQ0`T4A%N-TN(@[3CTP
M`\K18`9``7]0`DE@!#MP>SP32P\&MP$28M)R!!A`!(D;NJ$[1GIP!#;VMYU2
M+4F@L>Z6;D!(%W=1H$)"A)N*E^+8A'SY9(4A.E`H"#M`_V07*K/"2[.=,`1R
M$(88@`3@LD@SL`>B`+2UI:%.H'%PH`((]15(X`(:5P)"P`07-W)[4)`A@`-[
M$%)OHJS5U5(=8SPY-XBUX3S3.JVS*6GK-YM(2K9JEF9G^P=KN[;?RK8%(#=3
M<``9$`1"<,`_4`(NP`9FL`6=<@1'4`$2;``5D#9'P`<0@`0'O,$<W,$>#`0S
ML`1NTP5T(`,ZL,%!D`$.H)\UD2!O`,$5`,$RG%`>7,,UC`0,0`>F*\)G@UBX
M]TVN"V]R";+<F"2?-T^V:[).%JI.B&^H-Z%84@@,HS!2Z'J$Z4:7D0/6ZP(;
M10=U0'T!&0HY8`(-I44'A;,0,/\#$Y!%'Z"]T%"KIT`"P(<!)B`$?M`F,R<G
M+P4;JBDRQ^"^KBFD*`.D1%JDBEBV^4NV9HN;WJJ;O1D`82`&^SD$'.P"2<``
M)B``"N`!'H``"7`!GRP`"2``#^``UJ?!-IS*!PS"2Z`09M`"<MO!=_`'"O``
MF_4`'O``GPS*&@#*#C`#+J#*JHS#.KP@L39!U9*QC\6#0BR$!1I/0C)O"EI$
M)8M/^U0#3NS$HUJJ+=M:5'RAKX<PFB$[D]D')"`$)*<',M`'<:2&$\``$)`!
M<)!%$%`'.0`!(;`!<R"0[RP##*`'<-`*(0`!_IS/P6I'J!`NLE%=J9ES@ABM
M("FM-67_K9%6R#B%R(B,I/=[DM:3MOVK<@T036]@!S)0!$0@!$#0`R3@`K_U
M3GWQ`S6`!$20!(#A`PP@`Z@LS#4,PG>3!580`"JP`47@!-U;!#*`!W]!`_PB
M+X91!#S`6W\0S#I]PPQP!T?0'S;A'U*`L4#,S$"8>:`U;_(FS?:R1)[:.5(B
MJDV8!.H(6_V6>C$+CU*8">3<"7<L"C<P"LAU9GF`!WI`9W5F`U1Q`VOB!U81
M+J<0(S)RT!M#7:I3<^F+7>[+7<JS<T$:T<TSDO6[B'Z`OVBFT9Z=9@_`R!W=
MT6NK<@$`(/^!4!"P`R2@<1IP!&]@`#(,P[4-P7S``$%P+;Q]_RTCH@,S0`62
M7`45P`)_,`,;0`<0T%!8<-O.7=L9P`0CTMO4_4X,,`02>TT.'!(86WG<^%ER
M"6_R-%I$:"2!D2]FS41KK<VEEX[^1D4$!;R.$-<P6YC$*SO*I1F@L!D5F3NE
MT3M4V]C;IT<LU4=[#$@ZEP/Q2\A`%[9`!VEEJ]&?G:V)G+\>P,C]:]J0]`<!
M4$%<<`9S(``^8(4LH`$$8``6&R`!PBSZ.8U68`!X<-S2-^,S'G(V'G(T#@5=
MH`6@$@`7$`&REP<:H`'@T!]8\$L+,B#_,1(,2^-._N10_@=^(+'#),G^@8.7
M.D3/O'E,1LV@)X[[=(Y.Y$_[!L53M/\#$!5P5KPP5^P)XZQ&'15'I>`[_]U]
M&%E2@B9H-T<G?V@G'OG0#UT,0/H\7FO1BDB_Y74#V(IF^3OA&"WA>'#AO)&V
M_QNN`5`!!M`$PS$.&M``$:S:O!(@2R,%]A,L`1`!+)#J$1`!#M#J#H``%X``
MLIX`0ZX!`J`!$A`!+8`_/L,&4?#"#>``.[DKI[0$6<`%5/!B`A(2*G@"+7``
MT`[M+3#MTMX""W#MU$[M"S``%B0%5]`%5O!MN`?6'DLY\02."%K>2ZW$#1IE
MI^?>_.:R!>.[\.AZL".8]XW?H2#G;U0Q>.ARIKF'L5`\>WY=-J==E/WGE@T]
ML+G9LVFD8WO_OVK&Z!-_OXP.Z7D@Z=W*F^!JZ0`R!?@`2^Y902$68BMH!5K0
M-`/"!59@;`*2[%2P:>N##U;)-4&#=UGP!AW&!5WP!&(0'5Z`8V_PM\XD30B8
M!2+Q5BKQ\X8GP9@^\C%,P3$,P897]9B>@0+18%,0;C1`[K`[%SN"H.;]Y2<K
M>JD%H4]H9>RH&&B^Y@A#F&^?1N2<WZ30WZ3I.WPHX`&>&EG+ON"WM80<7GDB
MMIL-X1?_V11/X=J*!TC*^(R?\:2MF_X+,R#0*>8#[@LB]!UFG6RE*!OQ!4K#
MX_65!E%0!FN`=`#@7S#!/^Z!!NXP$)MR'!@$0<Y$!;.=C,T4@Q:;_X'L,"KL
MT1]U<RLI[PVSK>(CL4'%AAU;PSW-5DK5TO5TN8UVD:!B?41,!N:"\:"C.E"N
MU;O`.]?@;^^<\.9B0B;\#@J[HSLC5><8@]!X_";.>N`&#\@D$_B(>*T6?=&)
M+^&.#@AY>3>"@GB%A1X0?XQ_2$Y(D9*107\!4E9A2U!+9@9+6%-?``0#'1T+
M!R@-`6P`;&H#`VYK;&MH;6<`;FIM3U988DUK9V-EQV1-35165E#,4-'1;YN<
M4E!85EM=;,5C9T]76E=C!&=M6UMBUTM+5)Q144^[`!8!LP!E3?%>?TE%``/V
M*-*C8)$@-8(H5%@C(<.%"!M*E)@DR<2)-/\R)LG(L:/')#Q"\AARI^0=D2(S
M\MBQ8TC+ERY9LAQ"LR6=FSASZJ1CLJ?/GCQ+^M#CHZB>HTB1#O5APX8>IT^?
M0HWJM&D..#FRPMG*%2O6JUMS[-DC=JS9LV?]J%V[QT_;M7#]Q(DCMZ[<N7CO
M$KJQ5Q#?07OY[L5SJ!!A0WD4-7(TZ9&D&I:V/&DGI5VG,%?.6`!PI@,'$!Q6
MK(#1P<(I$0$`J!Z0ALVW,6RT1&,FI@JR*D^RA;&RA/<F,V_>&(`2/#B4+9JP
M8<&B)4H3,&6@MP'0YDN7*4^R;+H2A<N4)D^^6'"S:TV7*EVX9'D2#XN_@03A
M#^P!L?["A`XOZM__7X/&QO\`^B?@1C2DQ`,-0P1U1U!TA$0#3#&Y%--+,MFT
MTX4W_:3A3W0,15121AWEH51-E2C544V1:$-66H4%%EAA;876C#2J]=9;;,6E
M%ET\SG577G()1@A@?OT5V)"(%'9(88DMT@@DDC@!"21)6))%$Y551ID74ZBQ
MV1B>C1"::"!8,`(((A2@&@"L=3,&;%D\\TP657Q1!AFX-0/,,YM0X8EP2Q3W
M!A5>)+><%5=.`1UTNK"!WA11;+%=%5Z`]T07X^V"1CR49A'/+W_00!!`\Q6!
MWT,.0=101/RU6I%&'WFD4H$.KL3@@A?"1*%,-$6((4ZX`KLA4`L*E92(_R.*
MB!14S$:%HHHVQ.@55U=I]2*-8Y6%EHTZXNB6MW3]Z&->>`569)&"#:(N8HBT
MFXB3C$`Y"1-,(`%9`^Y,QLD2F$DA111J=)&%:J4U0$`!(EA@CVINL$'&,=VP
MP8885&C1&Q947'E%%T\HLR\4ONUKA:#%!<K),\PI`YXRD'ZG!149?_$%%E=D
M\<X34#S!WA-HL)&&&V3$$T45!O@S:D'VU3<10ZTV+>O3'J$TZPXF\:1@L#A)
MV)*$$>[P*X8E7<UA3TN%.&*R0U7U+%4I3D7MM&][U2*V9FE+%K?>Y@C7'GB1
M&V[?0?9%Y+KG\K5D'DP:=MB2#\#KR)1(T!NYO?]_@*!%QU@\044855QA!162
MA9%%:P.\0D_I:MCY\!-3'!/`%;";88873VP!A1A<\'9%-I91!H44!@3?R1L@
M6\$%%4L80`T46M@LC!573$%%94U`"L88:401AA;H==%%%%94\>D78+#W*=&A
M!H10TJ?FQVK3^L$*M7\$%CBK_0[J84<=.82MX*T9TII,<H(UL`W+)PI"VX>.
MQ4"UE6@J#WS*BUH$(VG)B&XSRH&.-KBWM9!+7.1:5U]&")AT+4YQ24(<X@C3
MN,4XIEZ1D-R]LC"%*RBC8T\`PW<Z]H4QK($,;OB"T-*@&C7<B0Q9Z`(::@$`
M96A!"ML[3L>\X`PHAF'_.=(P@.QD)QPI4&$XV("&-):PGC!@(AKM"$43)!:]
M*'CA"KB9PAG`,[0JX(8]76!./++P'OJD:GT/41K\]$.@^KVJ(O6[GX$.A)(D
M^*`/=K"#'*!BM:KYKU@)^MJ%#J@A$(&(*7!H"E=69"TXK(UM3HE1!5M$K:Q@
MD"PSXJ!;9-DWP-52+R,TDKH$AR05LBMQA`DF"QU7+\E)HEZ0L9SFOE,]E>T#
M#&U0PQG4,(4I%,H+9>C"&HQ8ABTT@0Q@&,`8P%`]+&"&"O'@@ABV@(4E2`$[
MAVI'-/X4G.`))WB?^]PFL/`[9_2N-YL##W*^LX1E=,(=WQO:I[J`F7ALX0\\
M_TB51.MSD*195%6(I$@-*M(0BV24HX@,J4B3$(0[0!*2D9Q*L?S'($T2D),K
M-4D.A.`'I7C(!W!`@@MVRM.>[C0);3.15%;9RJ^T$H-VRYLLQP*7O_UH1R`<
M7.%V23C%+2EQBNL#8;2*AQ8V@EY@G5SDJM0!+FB!"RNKWN6F4`4PM*86->2"
M%[B`'C:TX4YBR,(2`3!.9<CUK#K+:QB*QYYFH-$,[B19/8-#!2QPH9TH\P(_
M+8.-9H1!#&(H5!:NL(670>&:N%$H;I`(J4A!M'WKRT\-BJ"#'QC!M:_5@1%>
M^X,?Z*"UKJTM;'/[VM[6=K;`G6UN=?O;W@+7M4C8P?])^X!2._0A6GI(4+#"
MQM)-6O*Z/O'!'?3@!Q5@0`DW4,J'\)`!#)CWO.C%P!]44%,3605&%&115[[R
M2E@RU5LWZN"W;EG+_J9+2$0:4KJ2=,)@&D*86TUP5XE9S&).[EZ(O9P8.I8%
M+D2O"V#(PEQSYX4MS#4,7(`.&;ZP!2YT0YQBP$X9/A6.*6`,"TVP$QBXL`7>
M2.$-6[PG<8*G1=%UX0I0V,WV(-N.]2!/"F9`LCN%`>(M5,%G7T@#&3IVA2>D
MP3SI_,,.6!410*[6"+*=;9AO&UPR!U?,8$ZS;,<,YC6'N<UICG.9=8`$'BR7
MN<R-9!Y6Y`.:5/>EM]J0V(S_,A059(`)&1#"'A98E#Y@P`5G#BX/0D`"/S!K
M14;MR@1;F52Z?6N6<<%1WOI[%W'II80E'#`B_J)"`QMFA2O$`U>%R56O,B*L
MDBLF9`+PAFNL4\.7#<4QK&"&:?B+"YKP@A:^`#OO6`<`V=/9&MJP!LZ:]4I5
M4,87<@B&+LB.V/4,'G%P;`;'8B$+60A#.D!'A<>ZL\+60++QPK`,+V`V"M"V
M:_;F^N,Y@J<?6[X/(!72`R(8G`BU17C"B6MPXB8<X1#_`<05+O&)Z[;A"I]X
MPR7^`R?0(`]X#GF>Y1`'..PA:Y<L5H9BBMT[:'>[1/'!'OY0!"5,(`,?,%<>
M/H`!_Q,(X>=`!SH1*!T'4<I-E7*#D7WI)A9MR7*I0!K7COJFZG.AJ^HH].55
M%4SK!/?!UG\`JS&+20-+]+K7%39KG="`AF68(1,&0/(6I8!N*VA!#)GK0O:J
MH(7+H>$*7LC"%N+:82FHIPM?\*R@DHQCX/GK#1A+1Q;RZ@7)SI4RB)4K%RSL
MG"T(OL1I2(,:V"`.=7"'#+'91Q.T/'")E!0./]&N[%U>%*$4I?8OG[U0;$][
MD^C^]V23O0]V`'*1BSR2)(=E)BN)J^8CT/<?&M',G:`$%?Q!!MC/O@Q*\(<)
M!/W[/R!ZM.1KK6I]I5J=?N6G.0BNO_FHU""\01P*@20!T_^?JDI"\.*"R5S]
M:W766@5V#@96!L<$5<)K@>)Y35`%:T`,;/`%-O,.[N!.Q18&H$-C7#`TY/-W
MDC=Y9(1N-,8;Z2""Z?`[P$%NGO`)*8A85H`[A8(%A0)XOG%LSJ%05X`[E^,]
MFP(`74!Y-M0$99`&VU8]$*4J$E$$<2`'2KB$3-B$3OB$4!B%4BB%QE>%>19)
M=F`C7O,_8I-=(:(L>I`#-&=S?[`!,7"&)1`#);`!W?=]01=^)'`#+$)4YX<5
M2U=?3Z<W'M0C=C$N>:%+?A%@1S(DAZ%UAZ-UL?9_7B=K_+=@+B1V1$`OD5AV
M#4`-2Q!8!L`%9M`$:&!'P-`)8A#_/)5G5IBE!>2&8UA@`$>PBD=0`4>@BA40
MBZY8`:JXBF$0!<5&!?7$BL/Q1</Q&YL3'!G8!$#&BJO(8\$SBZ^(C%_$BF_P
M'5/0!N34!`#'-!-1!'L@!U:XC=S8C=Z(9\[UC2$72=M(CG.1`UY#$AMR>]%W
M-D]A:(@&!'8P)''`%PKP:)$&7),6AW#S(M/B2G=X%DZG7]VR-Z3&7WHQ?[K$
M2^BB)`<6:UH'@(K(B!39=5_'8)%X<$P0B0?8:_Q2`4_``!L@`PEP!,RA3A66
M!:F(.Y=E@6]``6NX`3))`C1)`BI0DS>9DS=IDRK@`F_P!(A%'$?``C%@`C)0
M!D=P8SCF_PZPHP5O]`1B,&4&8`0J4)4U>95869,;4),QX`!O0(QK\`75PP5:
M=A$<A8WA*(Y6F)9JV99NR8WD>`-XD`-=N$`,Y$G=A0%`L&=5415V4%[IE5[K
ME0>;%C?IET%*M3>BUA9MT2/]16I&0D+FTDNOAH@/J6!<-6OZ)VM7>)&+08"2
MF)%DA6-?R0`R0`(R60(A(`%2@'K3U#P;1GFIZ`<9@)HR>9NXF9NZ.0,58`5>
M9`8'$`(Q20(R``%8@EB=Y1Q5X`8$H`97U@18@`&Z.9W420(9,`1FT`95@`NL
M`W#\$01^P);B*)YO69[F>7QVD`=1X1/(4C9@6#9.D0-`$`?/TO\V<$`$0)"?
M2B`E_,F?0[`'%B0W];5TH?9T3(60CUF/@B-"K$9_A(A5A7A5$ZF9G(F9>29R
M`EB`&DHO59("?;=-W0<$2@`$0H`!"6``T:0&;J`%M2`Q:(!96V``<``!3*`$
M-GJC-BH$2J"C.(JC3L";U3"4?R`$(NH$$_`'D[=.Z$%M:A```4``!(`]7H`!
M/)JC/7JE.(H$#)`$!B`/;(!A97`%9:E1#8&$=2`'6)BF:JJ$DL2F:OJF<!JG
M<CJG;TF.2Y%RGK04[2@B[A5!T!(MYR>0;8%^+G*8&)2'W`)J">J'IR95`495
M[')@A[AUF,EU%FE\SN5<&1J)&[F1'/G_!R>`>`#P:#L*=$"0`1'P!EY@`!4`
M>3HS!2DH!4>0!Q"`!&YXJ[<*!+RI/&]P`!D@HM^'`36FB^_`!<P&!L5P!E]P
M!(^&J\X*=%K*`P;P!,W3!61`!ETPIAMEEA6!$MZ:$O93(!52(2M1KN-*$W30
M*^JZKNF*KK$W!)S9C6FJ>^RYI^V)+*CDIWWY+!2D:?,U+76#+7:3J$PU2XPY
M:HOJF'-1?P"6:H)Q.!#;:H;8=9M)D9@*CIKJ.!G9J9)H@*!*/@/P!T3P?4;`
M`(MQLBC[!R5@J\_JK+I*B\$3`3.@`R0[`RE[LW_@`BWKK-%J`,2X!5]PK=FZ
M`QUE$1?!$88D_ROU\ZW>2BLH,1.[4A/JNBL8,@3%UXV3U(7%HD#OJ:?YZD`1
M5!7_.K::9JAH419+I9@>!$+\176YU*#_]1<.B1@06J$4RHC_IU5L29YX!G8;
MR[$;678C(`97X`8-X`@Z*P1.@',F*0;`L1Q:L!Q^,GA>L`.UNK.X^K+MH(L.
M@`$L*P1,\`<`X'GHYGE3@`:Z0![540'-BKENZ`1;^@9\IP5@(#%5H*T344A*
MJ[OT(S6^Z[0'@B`"M"L4,B$[T7Q#<`/R2I<'E"QW*5Y,T9?2VS;.@FFJQ$KR
M):`"VVD;Q)@<=)#OQR.!$[>#\U^$@U6P!FO\EYEWN[[RVK<8J:$'1_^)O7$%
M9#`#&!`"2A`#-GL!!J`%^R`^4;!#"U@&:O`$21`"+C`!#-S`#OS`$,R;%>.X
M%/`',U`"0``!ZC4`W[$&6;`&:8"Z`=`!NW`I8M!S$)S"*>P"$*`#8=!VV]"`
M:H"[#0$UB20_^-.TM?*TO%(3Q3LA%G*\-Y&\?"MK?B!=!Q1]=NF\RQ*VU-O$
M@$I^1?4V=M-I`XNHH+:'?K/%:A&(D<EJ@^B03'*(=%N1BJB9_1>OX-B-&2J)
M'&=PE.A-[["*8_`'>G`$5X`&M-`QV/$$;O#'$C,&:J`%]Q@"AGS(B)S(BAP"
M#`!CZ(9WJL@'?]``HHB!74(*#4`==H(&9.#_!:IIR!`0RJ&\R(:<`:9LRAC`
M!UA0!HXB>!V&NX;$N[*RPXPT*]\*M5%[KKSB4G1P`VQ9"'&02=B5(3;%:`KT
M0)?FQ&U3?A54J%"Q%2LRH'JSF`5I2VU;+@`F8),I56.<?Y+:B!5KQN1XH?)J
M!WZ+<1;'`Y/L1;TA!5ZP!$?P!MWPQV`@#TW@*7;%!MK6!F.0!;0H'&$0'$AF
M3_*F!2G(8\%1!5,P>4D:!JKX!NK$!?["H@_X,VYP5]=*!FO`JL;(BA5`1EI4
MBU!`!AT@`B+0`$@$!FM'!C7S!F,J($\34AT1O#3MNP;2*U"+TS\<Q)KDR\Q5
M""\U+%Y[+.X)Q=7;_RPHDDKF]Z_F5RT\@`0&AP0]8`-X2)!Z.'51QX<]HLU3
M)8@-^FHG1&``&,Y;=;'>F*E^^W`11P3JW`"8,('^M`5DD`NI,P5BX)11T#-I
M`![;B09EH#/R@`;U',+?\05V-4W3V`0`+#1Y)7@T%@UA8`:;`VY:@`9IX%9J
M,'I'1`9I4$->H(O`H3QAD`9M`"F9Y05=,``+<`(OL`(#<!Y!BR?H9@9_0`>[
M2S_TL[0[;,OWD]-:([5;T\,Z44#`<@-UH"X^L'+K6!(Q=S:$IBS16Y]"1;U&
M5U3-K$H[0`2S100Z\`#\XVD&ND$*:\V!<W5@;'6_-+=750CM6Z&7VIEF/?^.
M:@IV#U=Q"5=V(F")$[@)SH8>E"([,#8.-F374Z!-EXT;PQ`%(/P$93`=!```
M:E`%C7T<GP<%C^5%?A(<H:U%;Z`%^M!6/P0&#W,G&`8&#BUXD8T%8+`&96#0
M85!Y6$``!]`"!W`"H]L$:5`&5:!Y+FW;&A$@NAN)"Y=P18`21D`$3ALA/@S$
MO@TV.;$#.E`#.3`(>J#<U"44&3$4HG)3XA5SRD+=R(Q*<>,B_7A^.?#4M<4$
M1:``"=`'39<66"S>C@E_Y3)_4@6(@^-J$-IJE(I@[0W??#N.S37?&GMP"X=P
M9=<!229/*7G/U%IWE9=BS<,]VK9$WR!$@#T.VW3_!CZ3/8-U4)4A.]/C3@`%
M,\V`9.G@354@>@.`!C*#>$_`!8B7BNZD9$'[!8Y[!9M7N*S=``T`!I42!3`H
M*<#Q!T,@T[!"(!'%`LS>[,Q^`'7P`P>B`Q30`C.QY#[,*]?.RPLR!'9P`AI0
M`T@LU$'P`!JP`TG@`"?0!U^H%$$UO2>2(GH02J0TMDV==$SU(%1C`SAP`0C@
MYDZG5(G95`@J+E^,YPY+8,#TD+%6D62MQG"YMW)ZSD/><&5G`8YU4/'0@`L]
M6.Z<#NI!N-A1P$';!FW`,2,?!5U01&R@TKZ)1IN[;GX2T.$6/&:@;AZVG*10
M`-D&!C)C0S)#;,!A!L8:_X1&U`5-X&'?!`(!P.)0L#'+8#Q(UN,=D4B,Q`,Z
MT-'&R`9[(.U```5'H"O7CLM;(UV\?!,[4)(#X`1:ZQ,\H`!-(`(ZX`1G<`0"
M0`?-;9=/#$%K$TIE"U^E%*AFL81VP.8((`#_KD$#OWZ)"D)0]53E\JB!B&IY
M7H@-GT(.;ZEES9EI&8Z=+_&9&J?T77&&[EH[\`<<$'@@#RF.@C&<4"DE)G@J
MLS&PH*(JZC,-.-=MX*0-`P:=B`7^LKE+(%=>1`U**1Q#'PQ9L.)L4CI(WVV(
MQ\_&,`5HU05J```/XP9C0&)A$-ELU5E68`!70JV:MP6T[>-(NQ%2HP/*<P`O
M\/_^+W``=;\&.3`0![`"7`/$.+U\&0((=(*#=X-T=XAW/`E'!4B)AXF(/I1)
M+4<H.DD1'')W>GJ4H#:DHWJE-J:I>G"MKCFOL*]P.3E[M[A[?;MX.`@"`@AV
M>WY^Q,7&Q[?&R'YQ<<[/T,[1SS?7>7DWVMO=W-PW>-O9V7CDYN9Y>.OL[7UX
M[^OQ\G9]]?;X^;OV=OW^_P#[/(#PI^`?(D1^*%RHD,<?$$N6/'G2Y,H3,%F@
M4)$B1<O$*&:J1(GR1,L7-6K:`'`#`(`:-V[8P`Q0``";+FS6<%EBAB<6*69Z
M\C1@1LI0+`:P>-F2Y0P9``,&C*G2I<N7+E58MHSBI0S_&@`$R#PYLT:+F#!<
M#'BQ8H"+E#=;N&3)PL6+72E_Z"1)0H-&$AY]>0`6W,.`E`E,$#(1<B/-D2YS
MADPP,63(CATU7"@1PCG($$)`0CM1\L/'(!\_E#AQ`B31#D:.]/00DD22#R0_
M;$B6<.2%"3I()@P!-8I.8B),DL"QD:,(DSMP$!+ID<,&+5JR6LFJY8I6KENV
M=/'R!4S8L6;-B!V3QKX]M&=^L'G#I@U<_7/HR*G;7X[=O'G^^;?//?@0N,^`
M`"7XCQQV"$"003\DI)`1$QKA4`=RA3'%16!TH0455G"AQ15--#&%&".-],07
M``0@@@46-!#5`"ZAM%(57X#!_P89:(E!A1A8:!&1&084:0865B#I!15(BH2&
M&FND,<883;2Q1A4BQ213&5I4048`%J0Q11ID:,$%%UNT]085<IUEUQ-BV.6%
M&7GY1<-@@N')0V%2('&G8#O\X`<:1RB@1`!J7+9#$(.V!``:`OP@R!TN..K2
M"1.8YL,$)ZC1DAI.^*`((P$@T<,!55S`PR<^Z'%&`3T(L,871S3!A@`G@*'`
M)Z#0D<-3;JPA`1-P%#$"&G(H`9,;(@BQ!RS;17M=+<]^%]XM^_3R2S##H(?>
M>NU%4\Q[T%P3QS?97"-??=>L@]]^^97#BSSR``B/@`4:F.^!_O"3H+]V,-C@
M@P4QM/\0A3_L\,<+5471Q41-,&F%%5DT444:;(SQQ1,I1O'%&`&LP`$*#1`0
M@!M?1('&&F<TT>48;8P1!8E3_&2%%%!L04504'C!!9%6;!'%4RZA\3`9;J3A
MT1=.H?'$%$_5M%))6XB115QOO&&`UER\(46<883!U!9>A*%%G7GJ&=B>AC$!
MZ`Z6]0`'&%#X@,41ER7A@Q5']-WW&PH4L:D;%?A]A`$'N&"#"P<88#@;0OCP
MVA&E,F'!$1+P$`HH1U#AA`9'5&!`X0X`<(0`=Y1"AQ>&OZ$!A64<08,;?ALP
M@A!^3-M==]]9>VVVY'&;@[?HD?M>->UU0U^Z^LW''[SIE*/_G[WMW.O.@=AG
MC[V"W/<CL!S@#V30'P8S9.'":XQQQAEL3*$%%F)H5/$4:PQ0P!DICS1%%RBY
M,0"8-"%`S"ABE2D\"25D4-$5IL`1HRR!(U80`]G"D`4L@($,44G#&<H`DP$T
MP"7!.H,:0,"!`("%#6C8PA*(`H46ND4*83!`#+>V!"I<;2Y=>=(?%*&GM`F&
M!D8P3,(499D=5.H(><@"WH:0AR4<`0TW>,`#\J"&(UP`"6IP'`ZDJ(`%'($#
M*FC<$5C@@3J,+@TN&`)LD$"$#F!N!YO3PQ&X(*@'K.`(%E``#4PG@%;9@`9\
MFX(=%#""PR5@`HZ)PND$X(##B4!N_]SI#BQZ1TEJB6<7"MB6>8@W+FD@[WC2
M4-XXE$<.=8U#/ZA\7CK<83WJX4L?`^+7+OX%,(`P"'P!8Y"#QH>P"3'$(2A@
M61D2Z#**6<%$4ZA"_0)PAC:LJ`HE*H,:SC"&%A&@``500Q2F,(4P?`$-;"@#
M&VA4A2EXP2)6F,(5M."%)83AG"4RT1?(0(8TI.$K`XA1"A;``1JEP0T-0`$*
M+`"`)I1-"E:@@M;,D+4B>>T-80L;FTQT!3+DA`!Y2=N?-@J8($IAB$6TC!),
M=P,E7D8.1UB#VRY#@S@HP`9(",,1X*"H'=A``7180.%:`+<=W.!P:$`";)A@
M!#=*8`>M"O_%'(W@@R)$`!-&8`+M^D@**%3`"X6XPPXN5X$'9/%TI[!!(]WP
M`^Q`:Y*43.LR@*?);B&#&.Z!C_&J89]O+"]=IUSE\_A3O>K9:U[:JT>_`MN]
MP7KOEH@%WRXA5#X*&4%A*4B#&L``AA)I(8)6H$@RQQD`]37A*@L$@QI@UB)L
M(JI$W>P"QKY0/P"4$PL6P0)JO2"%,RT0M1>D)QG0$)4.6``%!^```1X%@-^B
M0`0`T$(8;(8%K;VE2$5:PAOJ8A<J>.%I5UA#3@JPPSMQ5$\[*((0+U.9GH[T
M""7%&QWX$#H"N"`)0>#!()``!2$FH08T$)414'"$`]!`$G&8HQ/_AOH#HR(U
MJ4O50Q)8@(D>$(&//B#%$;R@.5+XH`8-L.(93I<=!!S!#4;0W;72:LEE'(.M
MY1G&,JAA//9T\AEV99<I[QH.=^$G7JOL*ROK!0_MQ3*P_*BE@L!'Y"(367R,
M-9@1**2P$[!!FTTX9CQ-5(6,J>&:!7`#-6%&AI>0E@`F<P,9FL"Q*41A#&B8
M4@-`X`8U9&$)QXQ"%=IP(C-`P2SOM()DT4!/?'IP!2L@*%32\"AZ7B$,#DQ2
M1*#@W(C@+"X^6\H6Q*(%C+DAHS_T[I^**-XE$*&F<!N"$$P7!R4*8@</.%R1
MCK``'0S""%*`;@78X(0[_("_$0B").X@_V!&$"`A!@Y%JXZP!2/H@08,1H&#
MIYHZ.7)!!V&U00]$H.%":<<&'@;Q*\"CUA)["\7<4D^+Y?IB:YB2>3/&ZSC<
M%;WJZ:>5UMLQOO0UR^P5=LA%SB61`Q8P)!>LEP<SPA`6QH;U(?,B7Y"L&FAD
M/].VQ`TP<T,`:`+Q#L439E\H0\:KH`8++&`$`6"#B43H!A"(00Q&,0,5M&"B
M@J.!FT]:R0`Z<+*6K&&8%'EG&'I"I#<L@=%%^7E<*&*B)EB-(A($9Q4P[5W`
MA)J\03#,IWMJ7M,E\0B#H($`CC"4PD6`!H>`-5!6#0`7X#H(D4#$')D`&R(4
M%7.:(\X<=?#'9/\O^W0(W@+=KS-M*U91`=W)=HA'K%9<$(\8X$9`'_805T_*
MU=SR61=]1HE*')]#'7Z5=X!Z7&\?\ZL?M008/P3&;WWG6[$$(U^%?F`$';1^
MX!Q(\QC*8"(Q<($*71@#&SX5%3"[H0`$<$,;_#>`8'UAG2/2@IQ-]+3]L:3-
MZSL#30+0`33\#(97N((8UL#G)]BE"2M!`QBDOQ(1D@$,9DGH&X+2$ZUM+2AB
M<!\8Q*"%Y#>!)%$P^D2ZP/0[/9V\X64`GA9JEF$903`&1^`'2E0(=+`#-/`#
M+A`!!I`%9G`$"4!>.J`#<&``6\`W''``1Y!KB:`'O,8%;'<$OU9@;T3_'"4(
M;3R0;$7P`\R6"DO%'3G0`VYT`1NF`+*@!UL'8L]B"X1'29R$>+PP!YHD!\CS
M272E+J4D8_:Q#='3']*#>?TA;W]5+S\&9`C"/4*V;T86AKFT6`53(1EXA@-W
M`E4Q!F#`!590`/\#`%!P$CBQ,1ES!FT6,U.R!M37`'[HAS&R9@*%`H!V7".S
M``=P`!1P`";T0EC`!6H@`@'5!=)$9DVP<"O!!M/7`2#`!E=@*2WQ/\`7%6!1
M`(!XB@U@`0,P?&(1!6S0!OS'0W=27D6D*.(E!5/W=$(P`$?@`4*P!5A'!SZ(
M`[51`TB@`I>3`$G@`0*P`X6P&!=P!#``@BM0_QFA,`1;AP5"A8+`=@0.0`.@
M@(US=VPP2`13-0I'@`5VX"LY<`J\F`!_)PLV\(,]4'C?D0R<Y`>SI"TI-B[5
M\(]PX`?@8$K$X(3VP6[2@PXW$!^K-"]]13UQ<`.>%V3;,TO]8`Y")EBXM)&F
M%X9R4`=DJ'H_<(8D.7`O<$%J0`;`91`3("-@<`51H`5;H'%@D(?:-09>``?C
MLY,\V9-_,`,ND056\`9KT`%(8!`.L```<#5<P$$`,`9K`'P6,#)N8``9X)-8
MR9,T(`9J4`95\`080P8[Y'2T&%*7<8M"$`1!4`,U4`1R\`!L\`8/``1<$(SL
MI05QT`-)4`1[4$4)`/\$4&"!^%4#='!''.``CH,"/N`7'F8``&`$L*$0E[,"
M/@`8C?EL>O""F(`$2,!'T`$'M&(%=4`#.[`'O&@&"K"#VI$#V5:/E90+S)"/
MQ9!X2MAX<;`''B`!#Q`?,X8'$J`!.>`\JI1*?B``$O`!X?`.ROD?KN2;#B"1
M$_EY_6('>9``%*``@N4/I^>18&@'=?"=<A"2KD>2)?D'"\`&.3$%?X`!/&`$
M-1`#?\`$$2`!$5"?#D`!$6`17:!.5W`$>L``-;!D`CJ@!%J@/3`#;)`%,S-&
M?U`"`;H#5^D&$D"?$I``'O``+U`&`S`"',`!580!;E>@(EJ@02`#1N`%5V+_
M3R($`'^@![0(:@4X!.+U!@G@`#;J``G`BU8@!\Y1EX*0!U7P&!=0H;23!0]@
M!`U`.A+@`"=P!&_``B9``6]P!"?@`!K@.`/@`G=`*DQ0!"PPI2M@I150E5Q@
M;):`@@Z@!WRD![!0`[&3!34:`$<`!0+@`H[!@[<`!ZU9>-_R5L1#FXP75S=P
M!W>T`G102MLP!T>0!35`'WK5;OHQ!)?3`CF0>3J&/3_U!G?`A?FB(#M010Z`
M!QJYD49V6$8&GN`IGB39>N.9AEYQ!1(0`D'`&4+P`RKP!PQ@`BI``KRZ`26@
M`1?@`7UPH0'@!Q"`!+2:K,JZK)P!!#/@$70!`#I@_Z*T&@0A(`$F8`(;L*TD
M$`-"P`=PL$47(`!8@`$NP*SHJJQ(`*!O8!%M,'$U\0>24UX]51GVN@,]8#CZ
MR@4X8`1W0%_!R`-#``;ZJ@5]$`1ZX`+4UCH4(`1P(`12:C@$H`2Z`3H#0`0Y
M``01VS<`P`1S:@0V\!I*Y(VF@P"LL!Q#L`:&8P4(4`1&0"L>@`MP$(UCH`-I
M)9OI<1ZT*2ZA=`T^T*0G<`?G=@/LU00T4&-[-861ZD8L4*GT`F_QT'EY8`!4
ML*F=MSV%90,KT`:*UY&DFEA%]IUB6P>H-S[DR:H9.'`P\&11\`>BEJQ)D`$4
MT#<54+=$20(3(`2L$:5WP/\`R)JN@*L$,V`%6A!K$<">YTJK=_`'CD,48M`$
M6'`")(`$.M`#.C`!66"N@`NXZUH$7``3#0!R\3JOY&6OM4@'--"AJJNZ%O``
M/U`(17`"'1`)-)`##:"Z#8`#@G,'/@`$'4I"'1`!0``'H*`$$<")'-`!N4&"
M'Q``7\<*0'"\(&`!"-L!,,`#I%`$`N"'#\`"`8`#T\(*:P8"#9``0;`'.[``
M#:!BSZ(``7``I7F/^:@,Q<!XXY)XW6(-3T@'0.L#S9,'BOH$16!3C]J`YQ`'
MH18$3*L+/C`$>'`:N^`'GU$(T&D'-U`!59L'0P`'!B('-K"IH$<'E"`J?B`'
M?$#_`TX0!T7&N\+F!W5@2^`#GA\YPQ^IJN-YAJ_W!QRP!FKP!1[``#$H!$!0
M!!LP`0!@`%>`!50`!5/@$F-P!6?R!&C`!'Z[N>GJK%3`0&:@!D(0`T'@!$+`
M!$'``'WPE5/0!&XP7/?T!`R5-4>@N5;,K.MJ!&!`$QQ`OB;4H@5(@*4[P=+Q
MQ\A1`PR(&D0@"3O`!#_`!(J<7XF`&JRW9#6P"JP0!*SZ`\1!@D9``\3+'`':
M`\9F`T;0`Z1`"W30`X)#`]"V'<O1`T%0!#TP!,O``T$`![E0+#L0FX?GIW[:
M8CL;D:DTJ/T+A3AP!%'0!P30`GJ@'WI`,GV0#7'0!WUX_P%-VK0V0#([(`(=
MT`$G0+P70'T=4``?H(]]<`-42P<"0``'``?^D@,G$`#8:0<YX,TT)P%TX`<'
M0``"D$MZT`#9W`$-$`%#0+8Q_)%D.[9$]IVJNF0X',IT\`<K0`8WQP4_F0%W
M0`(%T4A9X#[U1Q&A^#^(0@0`RGH5,J(&.@-)<4P&P`(%L0$^$`(S\`?-1S\O
M,5IM@`;:QP4Q!**.):*//*"/7*)&4`4$8`&2V!)?(*]$5):&L-1,G7:[]M22
M<`BMDE14/=6@X$>F$%:GL-6DL`K681V1-"W9L3N$-X2PJ1XK5H3EYDF)5P<"
M27GC<`=`*[3W`<"/X6$$@`3IT/\'2L`Z=2`.?J"R?=,%A-*T/'`W<MHW5V`$
M#Z`%AO,%=A`'%HS!0]!(`/`#WX,$BO0`=G`'M&,X6*`!3`"J?5`'.\"+A@,%
M$C`$?$#0KAW#8XO0J8>VXVFY/=#0*&`Q50`&]?D`?Q`#*=`"`(`%&\,%6'`&
M/U-/OR6[3]#06?G</UD!4D`%8;`$;L`"*'"K'M`"%/`%5%%P8V!/8/`T5O!`
M?'.5T,V3,[#>?]`#4=D`-=$A2X#42MW4]@W5^!W5HG#)PG;55^U'J.#573W@
M8;6:9#W6T6+6N'`MPR.;:8T,MOG,XY&$\[$N<MU?3K`7=I($<O0$^VP`R*P.
M/@`"%?#_`N^@!U\@!1+``A1@.F.4`T.@!8[#`BS0`@[`!W6I!A0@`4$:!=V`
MP7>@`!9@``O`P7:PS!6``GR0![1C!A30`BT0`;2C`;SH`.-L.@;PY%'.BP?@
MPC-LT`4MT'P0DJS:>K:=@0T-`A,S$<L5!2^`Y6^0!5VP!BZS!?5'B0#0`27D
M!06P`B?P`B^P`"]P`#3^`B=PB`=PZ(.8`BBP`"=0-1S!:%HS`!%`-^ET?P4W
M$BY3!74Q!3<3!AV0`AP@ZBD``R>``H&.B`NP`#0>`2P0`3?*I`!0`"9$>YZ.
MU.0%"?:]U/F=WR.\.?O]WU,=8<1!X`3.U:=P'=JQ.Y)T5MQF_X_XB+/GP6*.
M5PUM?2[II@T7?@74%#/>S@85\`0Z,+<=H`/-3`-3<`1\@`=RT`5F@`!WT(YU
M8#I-.P1B$(*V``?DFE(X$`J-72L*,+54X`-QP!L-H`,,P@-D<#KFP'4>D`//
MH.\MP`>F8^5[L#4"$*A[\``MD`"E3=!ACJIUP`<C3^89V`-G;KD#-P)9\#YA
M$`7OM!$F\A.B!4UF4"(3D083QP9XQA1BL`1O5G_KMR194]Y9\P;-%13O5'19
ML')4,($4E7U/4`5;P!1AL,108`50`&=%X@5;LQ9F0$%@D`9/`P9H\"1I$`5M
M@)Z[1Q,N(1)=,-_S>M_WW>M0;=56W?_?PTX)`:X*J8`*6[T<8ST+RLX=)!8>
M(X:SN-P,CM=XXOP.P8,`=8#MHZ0N%UXX^MHW!F"T=@`"_64#=H`$"^\!>%`'
M1W`%-<`./%!(++`']GX$/98'C<0&2K@+>X`#Z3Y%%6`%/E#:'$"E-E`'1."7
MS>RD`^"O=+`'<G`#.U#QBR<Z;M`#HI(#=9`'W@G;L3WR)+_]XFG;WI^V?X`"
MCWL%-80%2FP&^3<%62!9YW<%71`Q80``*-`!SH0EU4T%<'8%$Y-.<`((2UQ9
M2U!44%-62XN'5%1+4EM-6E=776R85XN%D)U2D)184U--HUU=455LJF-C9U&M
M9ZM/:VYE55W_6(9_-G2^O\#!='?$Q<3#QL7(/GK-SLS.T=`VU-1ZU=?.-M=P
M.=UPX.'BW]U[.7OHZ>KK?GY[[?#P[^WH[7'W^''V]W[X?GT`\>!`($```CDW
M;N1)R#"ACQ-'.'Q`0+%B@B-->.@Y<.0$C2$$CD@`*.>(F!U]\."AT^$(BSUT
MQ!RI8Z=/'@U'`-"P4[,/C2]''N2I8,6'G3TM(B;QT<"EG*<7#4P10X6#D3AW
M`!QQT,<.@B,&M&3!8L'(#3YUGJ9=6Z<M6K=U!$#X0_=/#QT][N;52^</BBM-
MFDB1@@6+&3-12FE9HX8,F"E=IA`F<&+$F"=?NECY)(7*$T=8HCS1_V(F2Q8I
MAJ`TL6+F$Y5/B\QP>1(8<ALU:JYP;@V[DQE24&C7/O7D21M69\8T47-&#9LG
M5]"X^?)$LQDJO(1I1Y:LN_=GT<+[F';-6K5MULISZ^9M'#GVY<RMFS_?7;QX
M[^;MX\>_'_\X"P&4TD`%(5!'0GDLI!`>>>"A!T0GW*%0@@OQ@1$->.S!P1$'
M&,'&$0@T6-))*JW4TDM#R%0'0#?EA%)7=@P!E%`&4&&4'3>@T)$16FG0E1Q]
M7'1$!0:\8<`+1&CE`!Y/?74$6$:F0`<?<K3UE!Q\9/E6'6CQ(5==?^`EIEXZ
MZ-`7"EI,@845;'JA!19=@,'&&<FY`4`9L/^HX48;;H!@`1MI5('%)UAXDIH7
M40RRA2&.J#88%J1)$485Q8GV!7-/1#'%$E2(X05J1AI@!A:`D3*%9TV`T1A@
M@8VAYV6BD9*I:&QPH44447B1W7;`>.=K,7I`(TVPSXR'#7KF99/>-=[DT!XY
M[34+SCGT57O?M?1<VU\__N6#CT()"2@0008=R!"%#.;Q8$<^H)O@'!CQX"!$
M+S`Q!H@BFK0#'@#=<>(>*<[$(DX`H,13C%T$-92-7>7PPA$H)+E5'U?*,8<=
M$0QIP!$1A.2`'576@0,?#F@,,1QJ5:DEEUG"]65=99*9%UY]@7"%:,4%]@09
M992QLQL%@,!!`+3_):=&`!P,\$057"BRR=..1"VUU(8L805I7G1!RQEN='$<
MKI]`(?8;9)NQB!1<D(+KI<^)L445N#;!1BMXXHIK%U_@FJD8Q5FQZW:_*L,=
M,<,V,UYXT9QW;#/F51..M-!.&VVUE&=[GW[TO*//YIMWJT^W"X5^@[@$&H10
M0BI1V.`=$.K1H.H*Q-O'NA$,<$0"<:@T(AT"^GM$"WX$O&)*)0-PQ\%VW)&P
M4!78R%,."QRQ0%,2W'#E'',\94<>=^C8\<1RX(!#E4#"\7`**+<%EY;LH_4R
M76.6.:8/?W#0!1G,M5'J%%64D<8``0B`&]P`AC$$(`4@&,``+`"`5'#A_VF0
M,(`!%I$:TSAB":QJ0G&*@XLHD($`#0A``]20BK`=0FQF>(/85BB%*TPA"FYP
M#AIT!C<V>(U2=JL"&-"`!N%<86F5\%LOA!&XP!GN<,0*%C.@(:ST.!%9CFN6
ML[[Q+&DU:S[4LM:U,&>Y/7CK<U_\%H+X,`<%D8Y<!YE0@OH@@`D]A%T-*A$>
M8I<1?M%@0QO3P`UT9P`O`(A!.6@*BE0TL"<!(`<JR4'"#,`\YX'L#BL8TA$H
MD`<YV`$/1W@#0&H2AY9\[V-^J$`%Y@"C/.@H!3G@$EQ4V27VO<\N,]O+7N[P
MAQ.T@4YGZ$(3KB`V,9`!#0`(80S'X(8&C*`#`/\`FANT\(1/=0(*!H#"$J*9
MFB6X36Q:"$P3XC2&+B1S#5\`0``;X+,G%$(L%)3"&\P&B2PT`0I2V*`+X28W
M`("!-G;+YP93804N5($U0B1B$;^SQ"0>CHG:V(:R$@I%/3RNBE1TUA3A0+G*
M8>MREN/<?_;SK=#-(4MS8-`9"W0@!N'!#@)X@!LAU"XY"B1>*O$!#`Q`I`3L
M$2`W,``7YG`!#S3%)0`C)$#\D("-#>`#.%A#)LNX,!]<R6$T-<"2+(D'+E0`
M"@I(P`-`,"0)V(XK?F@"D1Z0``%$L@(G\,-;VM>REK7EE?*+61%Z,%=:GF`-
M;<!$%ZX@!BM@(0ME($/_,!LP```8=@`A-&P!SK"%*83A,(>1P@0E6XBH98$+
M:V(59+XP!F"ZP88`*``!"%"&*6B!35L@A#2E<!@*2H)-<'N"&&Y6A2J@00U@
MB%L3+*7/Z@RB"5Y0Q-\&-U!@(<YP!F7<>92[W/)08XJ0<X\4J95%^6C1/EMT
MQSSFT9__?!%<H:O#1T&:AY$:A`^O8Z,`/A!''T1R!3Y(B1QQ<`0MR*LK.K#`
M[>!0DYKDP0Y2>-(1_/J[/>S`"S-!G@TTL#$!O^$#-]C>$<R@!^W5(0D;DH`-
M*F:#+0CX20:(`!/4L!4[\&$(3?@P6`ZP@SFLCZUK]=)<ZB++(LPU+T6@WPI(
M_[$%+BR*"F'8@BB>X(81H"`%'$#!`*(`AC*X(0`#N((5'F$DLDDP-I"`0AC$
MD+8R?($,U#G%%YY,@`&H(0N76,,6Q&`8+7@J"HJ`PI3-9H4I/($4D]`4%;`@
MAC*P05-+<[,84O$<7&F!"WS%E16RH`4#[*JXRK@#>`YZ1/`@3J'*9=QZH.N>
M<4R1<LZJC^4NFA_L;LL?J%90Z/`@7I""U+P&2I`<"O(`/Z0+#A%H0@3@X-(^
M\&$-`;@#O_`PA`!,,@X"PBD.G(P&"4A@"A*(@QX(P`9+'DP./G!`&7#SA5KS
MI`]G`,`>0/84'[2D!7&HF!SVL&W<H*$%0\@!!Z*0`/^0U4$/:<"-&M*P`!Z,
M]\4L>_$K;7QC&].U!WWI@-E:8S:P-*\)94!L80&`&P*(H`$$`,`8MJ"%-ZCX
MXYEDTZ2\G(HL/(8-:N@LS[0@69J^80N*:&$6KF`&*VR!4\R\&6G,<-4W#*I(
M6]"$(:)YPD+`TP!2R`(5ID(5=?X!#I`N!A*)M42$)D[3Z%EH0M_C::Y+-!VA
MKB@7N9@Y>'C+<ZCV`X+4:,968T]+L$;O#5):D#TRR`XYJ`$<Y"O'/"2!#C7A
M5Q":0@%D]P2G--@!#YR5!#\\<@?(XXD<_+"#RO,@PE<:1EK4L@.N'L`/ZI;#
M$'QQAR'L@8PY0$G(ZK",.^S_860KBSU;WSICNAC\X#C.\1\:T)I%#-@#!8FD
M&%*^5S6!H0`!($#*V=#Q#B`@`="'O@.BGX`+/.`!'R`C6G"@`!=_@.+3`8,6
M*@`"LM9!)HR20IVW$`;U:^$+@?V"5`LB`*W270$?H/\#Z,]_@J!@"9'!!5KV
M0$_7'<-`7#X@:9:&..2A.,Z%#=G`+-,5458T+6)W#CEP`^JS@1RX%AFR79X3
M@OS@'VJT=@B2.]J7@G'7(/LG`#C`+RD1@P'!=[WF!TEP`>\7(IN4;#P8>3[H
M@U<B>4$H!WC``P*@*0G`).2SA%:R%E=")6NE2FX1A2S35E;X2G15<`17!+04
M`&\P_QA64`<\,`,9@`$Q8`<<P`6GT&2/81QK$`7,$05O$`=_D`%V:(<8<(=Z
MN(=Z.`-N<`8$<!P<@`<DD(<SL`-RH`51$QJ/(1M1P`8Q!`9'P(>46(EV^`=#
M\`:KD0BWXF@V`&D&)2S%PES+A2SJT0QP8`/P(0Y6)%&2@T7H0%U[<`-$(`,R
M4`(E<(NWB(N[:(LN@`=HAW;_<2ZBPW8)LD=8,EX?95X7$%)YT(*Y,X/#%H/3
MF&QQH`$@((D4H`<\V!4"@CPP\FW@>&WJ1FX'<Q,=H%0'X`-O$3*KYXY/`86S
MUU93V#X!YTJU9Q>W9W!SU1<-\(73]`<,$`1$H`,J\`<,EO]-GO(%I=`S;#``
MR_0&>L``14`$%GF1&,D$%ZF1&&D$,T`&;;!`:G`!?T`"/4`$02`#?[`9*\0%
M7!`&5N,F4U`&76``&(`$&)F3.IF3/<``/'`$7H`(6N`%7K`$O&"`RV!U2C0>
M4\<,6=<XC>,,DM-I5/0>80>+YD`MH+<!,\``7OF58/F5&2`#?!!&WB5&QZ@Z
M:;EVY64''S5>(X4`#W!).-""#4*#+E4BR68'<!`]1W`&`E!>W0B.WCB._44Q
M%6..0SAY''$$:7`!B*D^3$@^]=A*'$B/4YB9&^@^^7AP^TA7]-,!@Y`%3!`#
M/R`$J(D$)E`"^E4!`A9-II$V6>#_<7(``4B`FKB9F[JYFT`P`VI@6!8@`3*@
M`DR`FS\0`R[@FB#W81N#`2ZPF]`)G4C``'=07U@0!D'F!5Q0@,DP#$R91,>%
M7`V5:>IA'M/R.))3@>5076('#W*P`1!0!$PPG_19GTR@`R7``#@01L((7B;8
M$.>R(`(R7GQP1G)Y2<]X?2$E1P'1:]^(4PCP`B\@`'OPH.%HF#\(,AJ:F*'W
M%'@0H2=P`6K5@4UX)5)8A:MDF5MBA5W"2@,W5P47!$40!#;P!R`09-C!`\^)
MFS7``&-YBS$0`S+PE;U8`A@@`[<9G4J*FKT9!10W!AJ``32@FT,P`[9XI5AZ
MI;FHDCNZ_Z31.9W5V31+X`6TL9U0EPS"DJ8%12S)<HH.J"RI>)Z>!CD2Q9X5
M=2UVL`$,0`-&T*=^^J=&$`3Y.0?"Z#FADY9JZ9\)DCHPB"590CK6%X//6!!Y
MZ:"'MY<WT`W_M9<9ZH,_8DD=&JKD8P?N@`=4(IE-*(6MM#*;J3Y1J**LU$HO
M2G`U$`2U&@1Z4#\+AP(8D`1$(`1.D`0RP!(G<``4(`$LL`(KT`(M(`$",`<.
MD`(FP`!)ZJ70V9M0$`6O@`9[L*=.(`1$0`,8@`(<4*[E*C0<@*[G&@#.::U?
MR@!),&%*=RM,PYW$\)U(I*:'HU!.5)[*\EQR:I409:>@1G;O(/\')/`',["P
M#-NP#/L')8`#PG@/#7&,_@F@"&)2Z?*-RQ@0"B``U/BQE)J7,MB-.WBI#RJ.
M!W.A-0%\VD-NHJJA'`B/[UB9K-2!JVJ%-ZNJK/11")"/!!<$0ENK-5`#N=H`
MG7$%;$`7&4`'&T`7??`$:5``'3`"?^(_:U``$AH`:6`$`_D#8!NV8CNV8ZL#
M,T`+4>!A$4`7,>`#&4`734`V96-EZW08;Q`&1X`!&DFV?/L#1""V1<``0W`$
M5Q`&]%H%6\"=X3EUX&F*"Q65$CA15>F*X8"5UL4.V*(Y=V`$<14S>X$7=S$$
M-R""AZIJ%JL@%9LNJ@.#FW2I(",N'G#_?0)0J?SR;2:+LBSKJ829`"$P`QX@
MJHNY@4RX>:O'LZ[*LS"V):ZJHEHR7J]TJT(;O45;HP&`&E=P!@>P`@Y0D@&`
M`LAT!AV``B@``I_%!FT0``>P`!;@!D$`)N[[OO"KL*K0!%Q@!F+0!EZ@`W\0
M`6G`!M*T"8>090&,09,8OP;\OG%P!$]`*K55KSE0=<EU4$[I@,>B..C1=0'+
MBNI`L.Q@L-HRC`D1!QC[112"(*:+L0N1.J_S.B+5@WLI('D`?`)P233HPMXX
MF*V[LBH;>99T`2%``A,P`P\0>D*H%DZX>:BZ>O1HC\KK5DL<<,?;O,T[!S\+
M)K8:O=)KM'\P_P)1\`5L($)V`@!I($XB!&4=``(@T`!5VP%JC`(-\,8B(`(=
MT`%0!@`*),:8H&_AEDRXL08`<`9MT`19T!I;`!VC8`7PQ!FND<BRL<!:H`68
MP`:&95AN0`;$Y,>R$,D#(,F1+'Z`\02XY<#(Q8"-NSBEN"Q3F<%5=)5BEPX7
ME;G<!48:=78B?+$E+#HEK+'H8E(48K+=B`?Y5Q#4>,.^W+J<VJE`.&LAL`&H
MZ0(SH`"@RJ'PB*J2:<1+K+,HVJ+L4X66R<W*2$957!=8;*NWJL4GP$UCT`:D
MP&:I\&1_W`KPG%=7T&1L`$+E*EIJ4!UX<RG)U`:MX`8#4``"G1RE(/]E5>!"
MJ5!;"QS`O?$(@R$VUI1/5>`&LY)/%HTK50`KHN&2<)-/6/`'.5`X2A0>ILBO
M$5@>%(B>DON*%Z@.]@&"\J`M$]LYWE*Z`'K+J*O"&KO3J5/,-QS#]!>#KFN[
M,#*8&)JA%?,`&4`"2B`$0/`'T+R8[L@6J7J\W.Q6+W;-W;RJ4OB6VN?5X4P7
MXWS%MIJK)^!"4R!-4!`:!SW/AD4&PE$(DV`%47`_DGP"ZML`>S4&<O8%#8`"
M%N`J8``&`T```>`G#10%BD@IQ9$&:)`+:@)/G<#0<G8(+P2);@`W;F!G+XD*
M&&TW2],%:O!"B='171`&A^!H>S#*W_FOY9G_+(K3==%RGI,3B]7"RJ^<N68W
MR[RM=FP'+B;,EHNZPFK)PBSLTS`LPZR+W#V(S)&'F$%8$PB0`2H@!%`=S49,
MU4AL)4^(O/=(HO>XU2?*)=\LQ3)FQ5A<M$1+O>ND&JNQ9\71!?E&D\3A&:T1
M!L5!!FS0`#"`0!S`!E)P&;0!`#"P`AR`3.D\!@\9`&<0&%=`!1V7-;-R9]G*
M*$&Y0H*`<EQ#3'JBK>L4!M21*4W0!GF#*VXP!G;F9_N4T(@+T@75@";]1([+
M=7/*BA1UN>UY.6.'+?PIR_B`R\!]PL>(!W#``\BFPL6]RR_LRW@@PX>)NRZ\
MLKF;S!L*LW9P`6\;_]4FJMUL,=4WJ[R5R:(H"L7AG8+*2*!:\DKC7*M)D`0U
M4*.\AQIN-F6BH$,H1P:XH#40;C:D,@7ZW;TI,`(<L`92P`:!X:0HL`(I\+WI
M[,<#$,BC``5;8`9A4`JCD":J@9U8@%F:;G-ID,Y[,D!N$`5M8#5O4RFTH#69
M`LBB`09KL.)ZHRNK/<JFC'4/B(IU6I6I7+E9V<KUH%W8A1_`WBV%>I;@=;JH
MJSH*40=QP``E62+#K98DZ]-`G5*'Z<N'UZDY3(Y2'<UVL'];3IDE6K-8S;RJ
MZL2QQ\U9;=YFSCY4G(]#J][R#N=FPUI&M]9D,$``L`I3\$-0<!V/4'-E</^^
MXQM`:(`%J<4W:M``)]#PR.1E@EP%EBX&L/&_8A,)5-`$M54&8%!;HJ$I:,#A
M9&P!HL$SE`(&8*8INR7B-I0*>4,;LU);'[W:HDB*,JY0Z1FPL\T>U86!MGU=
M,9W;WB6"%&N"%CLA)0A>?0`'#%`"=_##MB;M@CGMQ)QL>2"RKHOM*AN.4VYM
MV%V.0RB\*9.JY"-[YY[N,;:9:;\R7DU&:.[5;_?N8$*T\J[>U,M.SX3:J@``
M%A```+`&:9`K@M!^5)`%7S#&WMM9>#(8`/AD'``#)]`!TU$=7\"063#IA3`8
M80,)9@`%8@`W>?4$C%8)8G#X:W`&`%0`"S``8$#_<9!A)[@E!DWP!3OT!1*_
M-&@`!J60*0?M*7^P!TZ)=4^I::BHBK3]+.AI@;[NRF2'4<$>C-SB'_UP`R)<
MPL%]]*JFPG.@IS7@`G2``4&@NHNJ$@VJESXM!RTX/%5?U#]XH>$(O##[]<4K
MO"2ZS6M_HEQMLTY\U6@."'R"@G.$?'.%`A!_C'\UCY"1-G\!9E!+2V9+5&)8
M7D]L(PLH(AUL3U!:6U!64T]3:B@H;%5746%156,%%AT!`01M96AK9VI/86%0
M7IEF;V;04E)+4%M;8EM<9E*>4E1A6F5L!`0M'&EL:%%N`6IL8%Q935-G9T]/
M35%L:4U-]UI<E/WQH\=&_\&"-A(FU'.P(!P;.7+`F4AQ8D0X$27"V;,G!\>/
M($'F\$.2(TD_)D^BW.,G3LLX,&&^C$DS3IX;-V[FS,,SIT^<-_#@X4FTCA,(
M*I+$8'!GJ%`\?9Y*E=JGJE6K>#X(>/#`SM4^7JW:\3J6;-FS=N2DE<-6[=JV
M:>W4D5-G+MVZ<^O>O5M'4-^_?@?Q^4O8;]W`?0<!1G2H,:)"@AL[1K"H4:3+
M->!0>H-IB0$H4JQ<P=($3`<6"SAP</.$RB4H4+`\R1+KQ)DN4KH\46.L`0<+
M`-2X.4,&#1DV8YY(L73%#);E5)9(D^8:=N?.5C*Y2C-@@#DT6J:0&0"`3)E[
M5O_\G1G394JN=%.JY(,2!8R!/WL8*F1XT*!_B!=I)%%&%6$444@((G@22R@U
MN.!),<WDDDPTX=333D!EJ--->`0E%$\?YO$!$Q"4F(,<>5`%U8I5/?755WDH
M((``<KP(%EACX8C6CFJUY>-8/^Z%5UM#TD6D8H,EB>1A>"7)I)-X'6;((9!1
M*=AC5!:22&6,)!&)EU[6,`D!;X#VA@&85,,%%E4T<,()('1PC&M49$&-%DVH
M<<(+;J0ACQ8`N`%`!R`,\$47R%5Q3Q?M>>'%%DUXX=HFL$FQ!1637H>))J!M
M\404Y+!``*)H?!'<%U]$\<064TPQAAOM?4H&&9]&(4;_/%G<Y\="_O6'D($6
M4701L!8=R)%'(H54TK(-?J0223+-!.V$%-IT$U'8`J533AU.A>V'"C@A@QYU
MI!C55"JZ:",>=3PP8QU7E:4C656AY6.0][*UUI#\&JD76W,-EMB3B"4&Y<&1
M-0D9EEH.HB5C5S)&62..8`;))`,8P)D!GVTRQ15A7#%&`P$``(`]K\7#Q155
M`'`"#"(`EP8:W07JQA560!'&%%LXR@47;W@R&A:8TDF%I3E+-]UU4G3Z!!@%
M!`!"&F2XP<87:H"AQ:I:5#&K,5_X<\\57G#16A-4F''?'KWVJA^`&A$;H$8A
M(9M@2L^NQ.RS$?8M(4T7;I@A_X8Z/94B488[E8<<"LB1KE!1G0M5Y#9&)>.[
M]=*[(X_Y]K@6D#WZ"[!>148Y,&*&+2FP8%(B&9G#L%<)>Y:,03:Q91;7D(1F
M&6_CC!E'!"]%JE6`T<88;1S36197-''%%F<4(`('*0RPA1IEE!&%`<%W[[WW
MVU#C6A;`!\^9--(IO0T5:WHS11=K[,.%%QQ+P888!E1PA`%87*&%%UC(7_`J
M8"E6J"(+N<)/0WHE+(PX\(%RLUM'[C;!!3$H;WNK282D%9/!70M#.]G0X8;R
M+6Q]BRJ2DQR+XG6C%^4!!S-2P.9F>)9\?:YSH\N+Z7:H),6T+C!`9!WK!E87
MV1D"8O^$J%V5(+8P1-RN2YA)0A)HD(/-2(<*1]`"`S8@`P%D$8%@8)1\\!2%
M-@#`-QW(`P/6N,82R."-)8C!!N9(QSG&X(XQF,`1PF`)*[SA"!&0P088@(8C
MA,\;5,!"-J20A5?((PLJ@&,<[RB#2=ZQ!)C$Y!WG*(,$F`%DRKC"%'2E'X9,
MQ`80=.#<!"1!"H+D01C,FTO^ID%H:<LGU]I63W)9PL.9$$0N4A>Z7!26L*R+
M#UP1P!QHJ+FWN*5S;[&#NV9$S6I:4V!$!(P/MZFZ;`:Q80][3,,<,Z4C2L:)
M7*K8(Z9(@W;NSHJ68H`,2##'$F3``0;80GNN(,I\=*$-!>#_P`$68((0D."@
M=4RH0NLX@RR^@0H&6$`(2C!'$L@``DV8QB82F04MO$&?7VC5%C"PT)(JE`09
MX($!HK`%:5SA";I:B$,*)#=A&<N5KX1E+)FEP6KY5%O;LE!0<VFX$2+.A"V:
M'.2&^92SO,B8+8+AC/B@H\S)RYGWBDOG'L``#'CUJV`-JPT2)B7`$%%)31+B
M-I?(UB,NS&'B'&>6GJA.&K!SBDFH8@#>$)HE_&$"3E`"$(2`@0M48`II:`,;
MV)`+``P`!2O@0`#88`0&,$$)F,VL9C$K!"%L5@E.:"@TH'`$%OQ!"$``[03^
M8(5M0.$;5=!"R,+#3S"@`0.>_:P2_W*[6]TR@0%!J``6H,"%*83!"J2$"+`"
M%*SE>@19K6PE@RX8RY30I"6TG"5,+*2A77X0J"3\D.)..,RDHG!R9JG<5_`@
M51DR\X98C>]8ZB(`#)#`!/C-KW[QNUHZS.%)925,6E?GNB!F23(1<XQ<DQA.
M):*38NV,L#O;6<4&L&JD+MAM9U&;@0,<X0E56(<;W*`&-0"``"(`P!'V``$D
M;/C%,(YQ9X'0T&=48`$82.V&=XL!M4&!8Q4P@!6*1H4FC.$+&'"!C)<,8R0P
M@`X5>$(K)`71/]P@E0\44+"DBU.]/8@EU(40M?JF0>YZD+O?]=!X?2G>$3)U
MJ5.I5[SHI?]>/,QA1CBXT0SQ!4TB&:F^$V#RAHTP@SO\US`_+)A:"X/-)AJQ
MG.!4<#@CA@@<X("N=I6PA*N8@BZ`80M_(`*,*TNQ4IOZ#R5PL:"9K(09:$QM
M+9B!#D8]@U/;^@]*7O62G1R$SQA7"\.U@I4CV%P"X31!.TUV=K4;+1#N$JA"
MQ8E40.1+HZ;HS8]#KWJW;6=JYGE'?="7Y^""0W_-Y0$8"/2J"7V''@)1FPE#
MM%J3:*7:N97!<+52$G%0Z4K3E9UVE6*FJP@",614"G\`0H8]FP$%O`&`6=C"
M%\``AOBY80U\-$`.6JSK)=/8`&;`TQL<@`$E9-@%3OA#&ASEA3#_.`H+6B##
M&DS6@(PEN>,R=G(-A&L%,40!5:"^<D6&52`N4W"G8>;;2Y;>4Y=H"-H?W%";
MPXLX$EX;V^45R[:-F:,6W5D`W[87#K%Z+W[5!=TF<(':U\YVM2.AT+)C4C9_
MV*0GC?.MY(P=[<1Y8''RV])SX#>F)ZSI"O-U"6'`0`8@X((88&`&">!"V+I0
MA3:<@0`6:```TA"0-]@@!!/8K^A'G]\9O.'T5K`"!?Z`@1*X``(9F,$8Q`;B
M$)=!#0,``0PX```I8(#TP-?O!"!`@S=405$S!\`8K#P@YA;KV,I2-@9[NNSM
M1EN7(<10FZM]=<4Q5860:Z%ZH5I,>5FE_[WS"IVXRPVP'/KH`2&8@?SG3W_Z
M_T$/KYOWP4Z7X"M-:8GXUF`"^!C\%E?_EFD(V$Z:T0#>@`G!TP969DA:@`9@
M$`5=\`5GX`91$P!N\&E`<P&+5R(EPD8DN$8C6((E<'IF8`5/$$!'H`"4$&2M
MX@J?<GQIX`:YAP(@X`94L`$B^(,C*((A,(0A`(09\`!F\`24QP8C!H%QT$"L
MA%.M]"Q@YB!YLP=-EX4B]!/1!G6_=&V_Y!3E%7XH]!7%Q$)B`6Y]P`=;`78Z
MPF<VI"]%TGY#PA7)-$U;@8=356"JXT-GE1B/)FGGA"5]!TY^%U?]-@>#IVGM
MQ`-59`%7T`7#1?\-4E`!9E`%8G`<77![;D`.%@`&9;`%2[`R/Q9D2X`%9_(]
MWL,QJK@_*Y@*GK`%^?,&4\`\F.`*BE(U`&`!(``"`=`%4>`,'`-RPE@!078$
M;X`&CL4&:@,-9Q(&BC5B)*8&7_`'<4`@J@1]KW1!899T$O*--=$26XA+WQ5U
M1Q4BX86.Z`)^ZV@C4#5G-%05;/@`<Q!N8P=-:1$EYB8Z>8%6A6$PJ?-N3H)-
MJ5,'A)AW`*AODV:(@O!W#GF(CS%X>)4$/,`#-."(?]`!I?$%6V`&5,""[Y,]
M8U`&R0<`;%`&K2(&63`-'_D_S.,*EH)`8;`)F]`$``%L9W()2W!ZS\#_*:"Q
M!*+4,UX`!4V`!F-@8@,0`#5#!HDU!F``8B5V/V)P#X]"!@W0`!W@!E\P#&Q0
M8@30``40*"83!=9((#<%?2KAC3L5+6Q9$X-S2V865#M!=8E3=7&&=2OT5.\X
M9U7E5'8@(_48AS:T+T;"%WO!%W(71-XTD&=%8`A#3GAW8'T'F7(5>`58@''U
MD(*73II6D9ZY!W]0`%Z`)\8E2D^`)VN0!E1S@X)R!E>`0-!`*8V$#TT@#[)Q
MFE1P)ISA!<^0FT?S!D-&C,_0&9<P!4L@!L?G!:;2"RC0``00*.2A?&.0!N?A
M/%K0!;4I#TW0!<8``&V0!@70`9JW@;A7,B9C_XW/AR!&1UW3E6QDEH5QT(5$
M`9<_05131W74!F=D&&>48X;;9E7O50=@IU7KAT,ZI$.%B9@`B3KN5G=1TJ`#
M9D[T5F_Z=DX(]G^628`$^)!^MXB>>9$6J5=6\$BTR5)+T%%-P"H#$)YG8)S6
M,0W5$`53T`15``6M,@_#%09O(`9#%@;YXQE<L),JN!R:T#31T8)2<'RY,&($
M<`*2]0N!PH1NT`0`0*-:0`4<B0E:H`52:GEN<`(4L`!6`P#M<$9JX)3,ERS'
M1H5I:840(F;,1BU")3B_1([`Q'WIB#CLV"(JQ*=VX`$?$*B".J@?`*B!B@=F
M`6X\H@!@(6YD5W9Y0?\D!]J/BC:0C*E_0]1#LA-I%4J(]L8P&PIX&BJJ&QIX
ME78!Z?2A%FF1%PF:#1`&8B`&S0-B9-`)(_H\:]`+(.":WM!2,-I15X`-Q?64
M4S!<4/!PL!$-.RD-IR<%SS"<,$I<[.,/72DHNS@`8U`/,P,&JHD&:&`+4S":
M5\`%D$(&R7.FR8,"HQ`<`=`!SPD`J7D%?Y`'"2)=TF=!<!JGX.@'<2F7=GIU
MW6=4ZJB?_+E441$6>1`#F;2P#(M))+!,,X0C]J@O!.I,!&H7,M(X0B(Z`BE@
M#=I#`596!/8PE&9.GLHPDHD#?&!I+)NAHMJR,/MWF.:9JDI%&<D%L9H/41#_
M!64P&L<5!E2Z`@L@`FJ@!=L0I$T3&U#0"9^D!6>`!9[P.\-I";RYDT(J!</(
M&:[U6F;0!&P`4`2@!L5!K,[3!<>!#V1@DU`;,B'6!&4P`&YP/.?:`>)I8KW0
M`&G`*+HQK_6:4U>X-P\R9A3"0=8WI]>7?7/I+>FXN"NRC@8[.5_A!W]0@I3+
M1C/P`5?E5.$&)#>$CY(J!P]0`R$0!%TQAWKQ;JU#,`#)?ZN35F]E;Y!IH;!;
MH2M+JOWFD"^;F9A)5ZMZD2!:D:")`K:%!K*J!;$Z/BTG!FG0`"!PIF3P!560
M>EPP#2L8K%MP!6N@!MFP!*VE-L^P'!HS#=/!DST9_P9<0`5;8+Q38#(%H)7]
M<`]/P)6O8ARN8`7J*Q^M`@8D-@;(DY2_4`#DH0:IN0;SD*)\*Q)V`TMJJ1+P
M22TG@68@%$)#16U?>%3`]#CLJ&U=UP>@&01,\,%(\,$BS`0AS`1_@+GS@B/J
M1VXK7*!V\0`T$`(R$`(TX`&C`R4."F^O\X\&L[I,Q$0(MI"T$X"T\W>)>)D:
MFL0MJXBI2K,5>9$[(+DKP`9GT`8(%''+80U9,#_Z=!YF9`QE8'!>P`U@\`[R
M$4;WL`7/D0G."@WADSX[N0WHLS5:$`7YP)JP\BGX\"D3=X%@8`QM<)KRP06Y
M(*-54*TFU@`IT`&JD96K$/^)JID&U4BOQ^(L.O6W#-S`',1+N"3!A`.&H,QF
M8AA,D=.XZO*?'/P'/&`$K-S*KMS*)[PY!<I^/C*I<U`$$&`"/6`"$%`$.+"@
MW#1@K+N@/0R02'2A`.AHD19.F'F9SIRAHVJJEMFRO+NJ%KD#.S`$.Q`'?[`"
MQ6#%68`-IZ<%"/0S*S,/8T``_+L&4RD&9N`%V5LJ,CJC_6`%&G6L94*<U'"L
MZ,,*4ZG'3_`J(U;(3]`\.SO/5R`<K!%B5WJ!48`G3"@<`]``*Z![NZ<&K14>
M:X`\:W#`":S`S3)]TT)+2^<'$PQMMQ2&HTS!())">`FYFA.Y?U!_-$U_'Y!^
M\37_RVXQJ?^B`"Z0`33@`C20`4*@``_ZH-SD;GWHPPE)LIY*F0XF.[9;:49\
MNY@)S51MJCB`JA#VN]BLS4/`S1W@!5?P!L8H0$$VC`,49**QI;4*/!Q#ULZP
M/\/(BJW8BMPS0#PYQCVY'$=0`>1+OE@PO6:P!>2K,6JR!5F`6-4*!F-@,C?#
M,3J*!6AP@P><$E6(R9DLN()+$O7IR9_M76MF=5;7?06[CN27.2^"![JC.V`B
M1;`-VSQ0(Z`#AYVS0X6)%W;@@WH``1L@!V1E5B"[P\6<?WK'=\>MD/_'8-'<
MS-(LS8#'H=%M:5S=")X)UF`=Q?$75MS=W=[]W>`=WN(]_][D7=Y?56OT.A(E
MT8VQ5$LD#1//-J=I)L&CG:?!9,JDS)]RMI<O0LNU_:C1]*@(JH^FHP`D\`<D
MH`"'1E;[)]R7ZD--3;M.K9"SVY"E6M7/C<0PF\1^1]WIE,W9K,U?/01#T+N:
MALTHGN(JCN(DWN(N_N(MGLUW0`=#,.,T3N)TD.,V3N)W<`<^0`<SWN,]KN-#
M#N1TX`-(K@<^H.1(WN1+_N1)KA#[,>4*L1%6F-F7+"W817W6-]\B-)\F5-IX
M>G7F5<KIPM__N3E]64."R7ZD(R2F(SIR$<P@JTV,1I`ZK&`7NG>OR]SU%MW-
MC<1'#-U:':H*X.$4(^**ON(DCO_B.?[HD![ICR[DE%[IEGX'#+'D2LX?F=[I
MOE)*,A7J_I%*V-A<&%$WKJ3>FCU]$_*-TU(AAIM+'L32=SIU;G:76;=U_%U^
M:FX6Z@<Z!`JID6IN=D&IV'34Q&RIE8H82(3<*$NRLT-OCO;,+JO5SHSA6$W5
M+,NRU<T(C?[B("[B.R#IY`[IEW[NE9[DF[[N3<[IH<[IOC+EPS+O`Z)*=*.-
M)I%T[,T@6;CEL,Z%:3;!=$G:W'=M&>S20I$C:.Z.\3@OCPH7`FYV<9Y#`3;<
M'JO4!H8DH)IO%'IWDJE$5PV1SSWRU+[MUHX#AVYI"G#HW?X'XK[HV%WN,H_N
M-(_IZP[_[YKNZ0:!$+SR[OZ1$69)4T-W;,]ER8!;70VL0=EB9BD-%/5==27T
MTDK50N:7AF:(%@XO=EE%RX:)F`EZNHZ).JF;?SW\X`SYJ6V%B&=?Q(1NU;B;
MU:/:S-N>\BJO`"T?XR/.XC)/[I8.Y#6O[E#^Y/RA[J44[SN_'WI@[Z1>+,(B
MA7Y[KYM=+:\.ZU[>K_(-]?;=CF5HRFC8^?OMES0T;A1;V_F"V\1N.@5#S(OY
ML6-OS!&>D,H=F8>`[6T?\M!\[;B[[77/LBG?\BONZ'LOZ93N]S3O`S;/[INN
MZ81/Y3R/$&_30$,'A7-S+.OY^.V9Y>'(V?\>.-V%?6P&AB$2_^8$._[]^52Z
M_EXU]-^VS8__0CK\0MS"7)`%=CJ)QO'0+J&5">U6K;M9#0@X<X.#@H5S@HF*
M.(R-"HZ-.!<0?Y5_0Y@[.YAW=W2?H*&AGIVEIJ>=/G=Z/JRNK:RML'HV-K2U
M>K>VN;6]<#DY<,+#P;_&O\![RLHYS,O/>W[2T]1^RM5^<=IQTMS;VMDW-WEY
MX^;BY.CCY7EX[>_N>.[D].3R>'WX]_OY]W9]``,"_">PH)V#!_L@7*@0H9R'
M$!_:B4A13ITZ#R]>S*BQ#A\^'D%^_!CRXDB-(D."-"ERY$="A/C,D3E3YLN1
M@VS.C*GS4")$AF`24E0H*$Q&0'$\BO_$=*DD2I:&:!KE2=2H3ZBRFE(E*U>N
M65Y]B-UURVLO7+QL'`/&%IFP8LF@06L&#9M=:=&Z9?NV+5NW..O6I3LGKO"Z
M>?/LQ8O7;I_C?OKZ$2QH4&'`A9@S'Z0XL3/$B14W9N2(L;3'TR1=MFR)<J5J
ME2YWUI0=FZ?0ET)W&DT:U-"BW+X;\6;D])&"XTTG6;K$R:IS4%JCB_4:EGHL
M'[BR[T)+5JU:8L6(N86SARXSNLWB+KMKK3U>:N"\]>6K;?!@P>S0O:.7&%X]
MR(\!*$\^`UU68$(':O8/0I9M!AIH%7W&T6@8D8:2'"FEYA)+K\%V4D<BW983
M;C3M=)--.J'_")102!GE6U%#K7C4',8Q19R-3BFEG"7/616=5G24,IUUUX4U
MG2U(:J>++<+8T%9X:ZUEWI3.K,?>--'DY1=?T_2UEW[IV$>/88?!(T\]_;4#
MD#Z/#8A/@0(1A.!E"S;4D((1<B8'A!:9UB=I%EF4(6HK=532:A^FQ*%J-:4X
MVXDC]J2B;C*^.%QO22&BZ5#((1=)<3?:N&,E/5+U(RITB"4++*S.<B0ML/9B
M5EJ^!`/ED\.09YY<=?EQ`PU%!!ML#=S<-=]>7'9S0Q(TT,!L$G3@85@YT]Z0
MV#W\U:/8FFX*")F=E,59YX*:W0GA9A+E"9IH'05J(8:I$7H:;"89_WHH2?7B
M=!-/C/9D&XE%O8C4BBW.:/#`B.1H8ZA*+:PC5*26>JI6JE9LG0TZ(,'$QDS\
M``<O:=&ZW5O`Y&JK,#J4]TMYO,YUC30\<(`&&323`8`2-U!S37SQ=2E?.380
M4#,958!`A#OGL(/M?MJBZ9B;;0YH6;A4,YB9N>BF6U'6?=K[9Z`H'5H2:HMJ
M&*]KJ36:8K^1FN@V3;6YR&*,=`,W7(U-X9CCWC@@`/$?/7KB1].$XV$#'5]1
MU]5T.G0@1A:/9P&&"W"0519:QMQZ\C!%3"&$-2VSW.LT/6RQ@`,2I!Y!&D+D
MC"Q]X.@5#CIT&)!ZZ@ZL(,(.A*&9K3W\0?]]#X&1\5.9@9/1J:!F$?&9YY_L
M=EVA]/9F6.C8B%I_$DRQP8U3I`!WC]-/1!WBDT^_":?(WNPW[#[#3(T*N(]!
MWL``!OCGKW_^,[B00^)?Z8HKF-"$%@@``0C4P!0H![*SZ"%7;XF@6X#A@R<D
M``U)6(9Z<M`G*[W'#T78P@4>*(P]1,`-25"%#6J0@R'D8"])N$$<<E"#)*Q"
M#T@CQQT,L!X]L"`-,43'TA;3&&T%:'A/>Q/5XB0NJR4$,PV1D-:V1B%V;<10
M@AJ;H09U+Y7,ZS6/\AZ*X,:]MSUJ)G*3VZ;H9JE(`,53#HLC))8"QZ<LQT>E
MP$,&8C`!$_CQCX#_=$$&5+"'Q`WI%:T@8`)2Q14-H,$(=.#!$'I`!QK0P58L
MK%P-:C"$.^P`2K^P@0'B\(8B5"D]'LC`#&;`AP]2HPA92$"6_)"#!'"!"0=(
M00N.X```."`'<;"!%YST@2-48`01Z``=SE$[=N3!!Q$H0Q(4\SMLG6DQ`D)B
M/PBTQ&XN#T_G.E?S]B0]L)GFBO)*E!>OYYIUEHU?)CH1B1SU/4<-17V;*MAO
MSL>BO'T*1^^38R/D!QU3!$F/)%""$!;*T(;^8)![.&0`6X$+`FK@AKEX0!B$
MP`(+1.`($@"`!'P`AQV8X8$X.,(1&D"!``0!&739P1'R\`8F6&-7"ACD_P1<
M,(,Y:*D]>^A!+%^(EP1L@0F[!,$>:-`%";Q0#P;PP0.\``<\+.`('!A"8?)0
MNU[<P0%@N,,XB)@MQC1FFTF$6C>KYD0H8HV*?'+>.2NDD0EQB%YFJY>']GH2
M2,WF7R5248ERTJB#(<Q\E1I8;P0:QSHJ16'N4QA!2Q&DJMP!H0IMJ&8?JH+_
M@>4KLK(!$9J0`.QX1:-"^"@(BF`$-%#@#G"@053Y8`8=#$&U+UW9'H9@`"<)
M(`P]@,8<,I#0A?*TE>Z1!BQEN1<_)"`+3#@!`)(0AR!4P:EQ\$%O!0"%:?H`
M!`$80CWH8`8#F-<`%5`##?Q#Q#2E]6EK,I!\X?_$Q&^22YP2\@Q%T,E?B(1M
MG8HJE&K,-F`![XN,W2/L&7,#G#;.+5,Q4B.-'%8CR-(1$O\,J!TM@:H\9F`#
M+@BQB$?L`B<,\G_7>96L%$G1C&[T``#X00Y:^]K8SM8,/8!##4Y`@"`\`QA2
M\*T6/@F-#PPRQ#W%$I:$*LMM[,&HT9UN=:\+!S_`P0!P$``5:'"#.W`@`#N@
M%E=[JY8<T($%95@O8\C:&'XH,:V5D=-\VWI?<TTQ0ER#GEW!YM\/B2U>`-90
M%T,DQ@*[[6UK8_!A&]Q/Q.:S*)"%7V,UC.'X_>T40:JL_5;)Z4YW^@\3*"21
MD$0=B]Z!U!H%P@'<D&/_&L.6!U&=@Q1T$-L5$*`&SZA!!>KP@`<HP`%;2)F6
M]O``5<Z@#M70$I.W].1;2I>ZUI7`'FX@2AMPE\MT^+)6T;%#X.6@!6R@P6+2
MU&8WFUMJ:Z6,?9W8/.=)T;]S+8TY";4:>>FUKRS)-VS":.@!'WI?A2U8W8[B
M1A<)+&&45AC?FG+AA35<?EG!"AU\542FG17%+0YM=D9[45CIX0%44,*J::T#
MU]Z!AC?600YX8&M<+Z,(4H`"%:``A3>PX0?8V$-(7N8>;@1!A$X"AA]8H(8?
M/+NZ3Y"`6A"P72GD.`\#:(!XV;'#+MG@A^+NSWNYE<2JA6LR#%GW\\BIM8FT
M_^MK9R=;V/+ZQ0V])E%CQ`UA)258!3-*1II"V&Y^$K`6D8_2&:YTX",=>$9`
MO,.=<(7B`+@JD,5*%[D@PA0N0(,=>,(&+0``$5;=ZB](@`8\2$"L:[K,`03`
MY?\3`!EJ4(0>Z``'8U"`#9)])6\$(0L+N)T$?J@$/9P`A3<80@!R[X`I5``.
M'UB#`QR`@B.`@'?VJ)WN<R<"\1(1K<;SUM0:=">VKMLAZ<HS.?GD)^KQES7M
M''!K!`RB=JJDL/-4L(CZS8>#YW,WYL/_&OL.4(=7V)]Y0W@;1BJHP!6Q8"2L
MHGAGP1UHX15(,`4I$`$2&`$'H`8N<`<',`8J5P,<L/\"$4`!:7`$-B`';D`!
M$8`"!M`!+K<'1=!;=.$'=.``3U`$=L%ST5`LVK`#(_`%55`%75`%:@`$>:`'
M%(`"=]`.3A``3<`%/.`&0D<%8O`"+1``T?(.<```/=B#5]`!3-`'BG%NWQ*&
M4T,NX)(\5_--9.=N^D5V\G9V74,:'>).^>9V!=97WC,B,:$V^E)&_E(W?!<<
M$0:(>H=PC%6(D45X"X<<AT<*$C51BC<+I)8=LY(D.G8"8]`&F-@&`"`$>_!5
M)\`#Y"$$'+`&55`#!%`Y/-`$:+``$3``J,<#`2`'[P$'"<`!.^!*V/`->Y$'
MP!($05`$03!-UJ('=)`.>+#_`YMT`S5P`WQP`!.`!*)(`$.`&'W``\SB+)84
MADC4)MP$)W,R7P-1+GBB)^ZV7]'3AM.C=@7F3JQ!;_ER$7@X=[*1A[0!?W_5
M=XUV3X^F6(W6<(5G80YGB))F>)<F)(OW"A>S'0NX)+I0.546!#^@`SW@>CU@
M*T.022]4`ZZ7`Z;4!RM@`BXP`=+E<MG@8SJC!S00!S\%'[#S%^`@#H`Q)LX$
M)GF@`&Z0`B```@T0`55E)CXI-6Y&/,.3#W5R/-L7CO?%(&\E$?KE(%)45WQ6
M3O^%?FWG?MCCCB8AC_7X/?/8E?,X6)9R/OH7EGX8@,?A6.^#-YV"87CC")%F
M'/*C_RK5022OD"2QLAV.1PLD`U/C`4'(\&/*8`<$T`"$V0`.<`?)QG,Y]SH\
MXR4O&1CF(&8SN0YQ@`<`$``#$`%)L&9,`U_:R"9O\D3)$XX)(HY*^3S.PS58
MY#49@3;X0H=ZQ5>PZ1JWP97R."EV%X]NQ']XIT]YUYN`EY8WTI84%E#$66EG
M>99Q61T)V!4*B9>0%XDF`Q<F(R6[,A<Y``(KP`$.0"RXR!YYH8O)L@TR-"WY
MH0[4$IEY$`>@D`/C%CSE!F?=DF[J%G:BB1E4!%=FEX[G]#48@CUNMW[UUAIR
M>'>U45A_57=D))9X%X@.JH^*58@*]X_])X"ADIS)*3](L/^A.E`'14DN91>B
M>[(NBS(OL:D1#,9@?``8<6`'3G$I>H.AQH&A2O$!"O`!.&JC..H!.7JC.9JC
M'O``'C"D1%JD0DJDO9:D2KJD3-JD3OJD4/H``C"E5%JE5GJE6)JE6KJE7(JE
M"%"E7XI`7SJE8AJF8GI`98JF:8I`%W`!"."F;EJF<LJF8AJG<FJG;9JG;?JF
M>MJG?@JG?_JG?!JHA-JG$L``R[$&:T`&'#`#(?"HD!JIDCJIE%JIEGJIF)JI
MD@H!G`H!C^JI(="IG1JJHEJJIGJJJ)JJJKJJK-JJKOJJL!JKLCJKM%JKMGJK
MN*JJ][,<*G4$;K`<P!JLPCJLQ%I2K,9ZK,B:K,JZK,S:K,[ZK-`:K=(ZK=1:
MK=9ZK<;:J[^*K=S:K=[ZK>`:KN(ZKN1:KN*JK>::KNJZKNS:KN[ZKO"JK.@:
/K_1:K_9ZK_B:K^X:"``[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>y15751y1497405.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y15751y1497405.gif
M1TE&.#EAS@"(`.8``'AX>-[>WG9V=D5%1>#@X$E)29^?G^7EY9J:FNGIZ?[^
M_AH:&G1T=#T]/4%!028F)BXN+C4U-3DY.2DI*9R<G)B8F')R<I*2DI:6EF]O
M;S$Q,924E"HJ*FUM;6MK:Y"0D(Z.CFAH:./CXVIJ:F5E961D9(J*BHR,C&!@
M8%965GY^?F)B8EE9682$A%Y>7H>'AX:&AEM;6UI:6H&!@5145("`@$Y.3E%1
M45)24DQ,3/GY^?'Q\2,C(R0D),C(R"4E)<G)R<O+R\[.SLK*RL;&QL?'Q\S,
MS,7%Q<W-S<3$Q,+"PL#`P,'!P</#P[^_O[V]O;N[N\_/S]'1T;Z^OM#0T+R\
MO-+2TM/3T[BXN+FYN7Q\?+JZNK>WM[:VMK.SL]34U'U]?;*RLJ^OK[6UM=75
MU;2TM+"PL+&QL=?7U];6UMG9V:VMK=C8V*RLK*FIJ7IZ>JZNKJNKJ]K:VGM[
M>Z2DI*JJJMO;VZBHJ"(B(AL;&R$A(1P<'"`@(!\?'QT='1X>'B'Y!```````
M+`````#.`(@```?_@`N">8(+A(5YB8)^B8Q[>7N1?GM_>WY^?Y=]F9>8FWV@
M?7RAI'QZH'JCJGRL>'BIK*NQK**BJJ>QI:.@NY]\?Z%_PL.9?9>5?XF1D,R*
M@X>%T=+3U,J/F)Y_N[%ZKG@\/>`]/P_E$S^&A(?K@H_+D?"2EI.3E)2=P/F;
MPKV?M;FH6ND9R(H@'CYX^A`DB)"A*8</_XU*"(O7OTV_B`D[=LG=(T@+/B:"
M1JWDM)'6)@&39?";-W$_R)$K^3&DNSR3K%F2E"D2IV'8^.53)4K;Q5&P3!TL
MJ+3@PE?=NKEBVHT/CZE+ESJTA6N6+Z/[L.VD9PF22)(F2Z(T.\_2/EX/_UU>
M[3&N;LR8T=0AVK/`CTUF]2I!"LJ)\+!1P&Q)9`C+8:J!`[UY8\A#::IOD`?V
M<+60QV.#+2.:FD4TV,:>8W.^&VG()+2U(^UE2IQXM-1O/'*'BUFNW$F1'X$[
MDM<1TVQ\_HR%*EW+UNA6G`_>CAQ7CV?<N5UYMNYML\N!X/1XUWYP^ZN'2+L&
M`S7[IZ7"-Q^UUDM_[[*.\XP_)WBUOVZZ/XSS0`]JH23?8/'@]]XQIPFS#UC-
MT;)*54XA])!4D4TFV7>X>2=.;B#V%XXX=(6C70_@61<9A17MXJ!&P+RS##/S
MM3:?1\%A,@\_M'SV$HCA`/B`3'GIE0Y@'C%27/];Q[7G1W*)P<654Y`I=9TI
M(5K)'1Y!AH@=.#^`"5-,=($9)C@@ND1>5.@I]!Q8#AH&CUEKW<2,)/7@XTEI
MCW'886YDWH5(.L^T0TB"G>3WTT:4T$:*1?L]=^$K4/5'Z8\N;1;@-R8"&&2)
M@098(@^!D@HJ.%QR=MU5F174''L.?M))3I?@)%(]@S&H$2VBG'+95=K-)>J0
MQ*H5TI$V*5E)GGL8HY%Q^D#H9E>V:85A;E%]R>J(='$*:(`_I*JFMZ^D2>I=
M/0PIJEU`CCM5FPKI\PE0L^UD+ZX^05O,+>B!IRVH,@TYP:`UQL;7G$HNV.B3
MAN43*RO:,+5?E9=&%U7_>*GJMNZHY9(S`000:!"!!`V4W(`$$D00`00<#+G9
M.#+Q%B:XF_D'5;9N*F21K&%AX_-QA`63RZ3!`KFQNN0\<)(U;)%5G)Q!>9)<
M+W]4Q%AUDB$4WL5>KBN.=A^37``-,J!`0@<6"/#&''-H\88`#&000@PX#-"`
M!A,,*&!O,GUH8I:7-M350,$\:8QQQ<VFG%&V@?92-[O!I&XY23MSHUF&)(KG
M1K,RV+`_U$X;5T'`5AIBMZ.6:.(W'$A00`HA,`!&"R!<<`$&%2"```4&]&X`
M!10@@,$%(+0P1P<R%"`!!`_DQK?,2'^ZI62$/^;JHZ;!>DI1U7,#&:?D@0I@
M_\"^#6ID7V5UA)-*[7%^F+R\DC;595%]!BR*(O8G*HEZ3!!!`2@00`M.<`$$
M](X."*3#'>Z@P#@XL`YN4&`">T>!"H!`"R%(P0"6=XZ[D,EEY.`8I;!5)4F9
M@CV_D(AH9G&IV^#F1)[RE`?+AY)TS*AI\.A(/CYGG)WQ8D6CL=A2<F.5;X2I
M6VB"69@>``$'L(`!,+B=`1-8ASJTH0YK$(,8LJC%,WA!#&?8XA;AL(8XU(&!
M!D#`!4?`@@UJH&6\T=M=T(0JW&1(.A82W2JX,BT?18=3(](?F>Q"N=Y(`R3J
MP(FM$)6:J"TN2@[R"C<.PAG^C-!#]]-8NOX7@AF`H/\"!DB@&^*P!C.<H0QG
M.`,7NE"&,:RR#%XH0QE8688PG,&68PC#&MIP131BP`0`R.``5C:!=)7#F(,$
M4G:R@R$+6>@\0[-*$"^US'\!+&!Q?(`B$CD2O^")'D]#G+,<M9PIW8(_I;M6
M=T88J`']0`,VR,`+-L`[!-[!#6L(8RJ],`8O>($+6X#"%K"`A2Q``0H$[4)!
M61D&6H91#'#H)1W2>($7`&`%.5@>L38JH/&%Z#I0F9]T6G@S[DBE=$D47[KN
MTAMBY6T0-3*$//*3GY]Q1%?^<-$L(J.0#/7GI*=3(@^8.(`0M``#4U1@%L\P
M!EER895/-2@7!+J%@$*!"4O_J`(4JC`%@58A"P.%I1?"8$LSF*$."/R=!;50
M@AP0,YL!&A")7A:N$5G%7Y3"$&9>:!W=<"D[XT.7S&3R4I#(U$Y+0MPU#'>:
M?:1P0@BIA?56!-B_7B5`NCG7#YJ(`A5<`)0*K&(6O=`%5V;AM$Y8PD"?X`0E
M5*$*K'V"0)?0!"=,0:M3V,(4E+"$KA[TJ5T(@QG:$`<&3I0"(```"H;9LD+*
M!&8DP@YYUO0C[O@U?V72K&#)]X`)>)<U!^-+YLRBPWNTCQAO2:%BJ,0-\T0G
M.W@XHIDVR8(Y?""I='"#%F/9T"Q@8:M+<,)!L0J%)RCA"#[PP1&:D`0E)($(
M/B`"_Q&:T-LE/.$)N<T"%TZ+A3&,(8P/7"`=$&`""Z3@;GE+&N6."+,RU2Q5
MW=+6"[DT*MU$+VDQ:ZDA8<J6'-$#&7I2W(M^@0NX"`0ADT&I*[*KNC)!8``9
M.`'N\EN',9(5"UWH0D"78.$I,*$(39A"$H!PA"0P@0A).,(0@$!F'SS8!VSV
M01&6H(0F/$&K`=4P%F9)5C&0L@TBOH`*2E"`"'`@FR!TF:?\]I]!<@FS@.IH
M8/EF3+[U9F"&4L:=AM.Y!K$GIQ&3B)LNE!G(A0D[*O5?"L#P6=[=(0YP2"4N
MNY`%KCH!MDPX@A*<`.<F,!@(02!S$XH`82`8`0A$0/`1DO_]X"&8N;=.N/-6
M![I*?YYA#6=$(`)>D`$<-*"YEEXQN.9:)LRB3E2#G*&*=:SC%`\,-F>QE>=\
MIHEA?+J<LE`('BUV4CMZB@,#($$+-@!:-[@!#@@/@Q>P/(:K5J&U1,`J$(IP
M!"8T8<T1AO`0@D#Q(4!8P11/0A$4S.74SC;`&.XJM7,9QC6X`8T?`$`,!J"!
MC3Y/;P!C\H#<&=<X^AS'[.[NI<MGPT/YF'W08M!RHK0-KGP&2Y4L5\W"@]D?
M.,`"\YSB/4O)U(6O]J!J;@(3UAP$(A1A"$,XPA&"+><B%`'82&A[$]AL=CF_
MV0=*$/,4;JW5"U>AJEO@`BS#H,7_XM(!`RT@P0`@$->@NXQ8.2:5.UNZ[A0[
M7NCL?@9*\*.D3K?'61AYF(1ZU904W:::=0&0!$)0NRFZ@9>IW$)I<\L$)CPA
M"48`LQ&&T`0B#`$)"`Z"$(*@]N'+V0<<%X(0DJT$"4?8S77FK=BG\`0FV+;`
M?X>"?YMJ;3$`>L0M"$&ABWEYR$,^Q^=O:=[:/?1+Y^W=B`P.@I:%N&P\R=Y-
M]\JHJ>/".@9ID!)``B_P6:'T:G'@1650!0K%54?@!!"66AS7!%%@!"(G!%20
M?&A@!7!F@0C&9@YV?"'G?$609@XV8$W`6[W55:^5!4U52V%D!BY'!Q108C2@
M4>4W.>MV_X/=]7X[Z%V8)W0O12BQ$1C'P"3V1ALI]#"P8"U2H13=X1^F0@X1
M@`(M\`$8$$IT$`=MP%1E@%!9H%I*P`1*$`0-Y@,,9@1&,'=6@`1$``1(<`4^
M8`14<`5(,`1HZ&Q`(`0^L`1,@'Q!$`01E@2]]W;0AU5.X`1-X`-,\%JW)E!C
M@`5><$LP^'(&\`%SX`(-P'A)LW[MMGX^>'GO%XK>]8D[R`&C6"/A!4YY,BOT
M$BNQ0@I)$8OBT0VH`E_[TP,:P`(J``)7F%]:"`==\%1/P`6T1P1/X'9CB&9(
M@`1)@`120'Q1\`5'4`1&<`540`1O"'P^,'P.5@1!D'9)D&!!8/\$SVAVNX5W
M8=A\:T9A8<AWVE=:M>1]E+@!,Z!X>.-^Y@"$0>>)/BB*HVB*HV@.I_@,UV`O
M/8$/G+`)]Y=3NO!TI"89US$BX,,!./`&)D!/OAAK9;!*7X4%MQ5Q2B`$B2@$
M1>",23`$5]"&<A`%1V`$9+!\06`%&NB2:=@$04`&0.!@0Q`%P/=F13!\%CB.
M2"`$:4=Q<L8$29!54#`%"25+J`2#QK5M'D`#F0@./1B*^C@!S<6)_CB*W@60
M`/F5RM`7N5)3GH->;[$2?I`+#EE24>$=4P<FZ3(`%F`"]Z546M106#!57'"(
M2#D%$[<$N><#U^@#7P!G5V`%1R`%SVC_F&C`AE$@![E'!=%X8,XH!$D@<CY@
M!5'@9B<(B&P&!':'8&XF8;*U@@7586-U!L/U<C)X`340`C<0`5WY`*8(A%[I
ME6&9FU_YCZ;(`2'!".1ED!S1)"^R'J,G,:6V(4OV?S'!`Q$@<!\`2O?4!F#4
MA5@@6UEP!%.@8%50!,TW@DA@!$'PC,YH!#Y`!F1`!$+PF$HP!&P0!;Z7F,0V
MA\!'!%%`!4/06T@Y!$)P!5$@!<NX9A/W8"$79@*&84LP!L%86H0'!\,%0=IV
M`0!`E1"@F[S9CQFJE1S:E;\Y`8>2+(UP#\@A-=A#%!#S#Q1S"E$72)'#`QRP
M:A>)``@T2F80_P;_505+D`4,QFNV=8)(<'9P&`51,`0O"01I@)-2\`5"``17
M@`9E1P5I0`4E^0544&;GZ6!"(`5H(`2ZEEIE9@1(P)/#AX9($&Q`8&%*D'=/
M`%8:QDIC14;8AE:_LP&#QEQ@>95>68H8^I6[V:&'U0R=PP@:<6_8PSA)`4TJ
M0DW>0D</,`!0-)U82`=KT%#1-@4[R@1798R9^8>$B78:2`9P2`;ZF:1#J09H
M,`12(`=6L'M?D`9`,`16<`5DR)Y4T*134`12H'Q6H(<55WV\57MTAHU6(`43
M)H:YE@34AU!=``=@!(-7E%85\`(C8`,<Q`'8^J%^BJW;VIN_V3*Z&?\2MH(3
ME:`H#[*6V0,IRX$+D^49'K).-!8.$6!4)E!`H31*_90%`G9K4V",8-:'N!>'
M^JF'JKJ-:6<%:I"?;/"849`&:1`$5T"J._F88R8%9%!V["F3G5E[1V!L:S>4
M0["91+FE:"B:;^=QZ7B(;1I<U[9%;1!!QW4"#&"AW)JM8*FMW^JG&&J*M_(.
M>J(CP)`-KZ(8SH$>I%8_X:,;>O``-P``5;@!!O1J8C!+6+`%7\A:2?`$1'!@
M)+E[K2H$7T`$5G!V9*`$1A`%0F`%`6`'5"`%;'"Q3_J,;VL$8$L%06H$Q4JK
MTZA\5V"!R19Q8JAK:^J`0'"207"!:&9QTWC_!%E5!7LY!F)@2F1D>!,%`@)P
M8F]DL]C:71]:LSC+K:-H=#U&HM&2A)'D"RQ1+9`!4N62)G\UKS,@917@:@=X
M!@0%!7VYE)K*N&?WDWB[C'\H!45@!41@!&F`!%9```EK!6SP!49*JU)*!M'X
M!44:!60@!6A8C4P:!<:&9L!V!;M*GE'PC40YAU:`;$I`C>1);$G98`+%!4UE
M!F"D2]GVFC+G`)FKN=^JN5JIK7[*%R,*3LAP'&GY%BB4;_WR/=,%+)GU`#8`
M`#!@`D@U493*!5ZP!;#%!4J@6TH`!6;&9K\WIG8X!/I)MT'P!5\@!6G`F>U)
MAXPIAW)@M[-*GFW[_XU1<`6)>6SD*9--.H(GZ6910&P1UGO(-YY$J6`B]W:[
MEG(=UD]C909DE&V]@P$JX`(.<*'Z6[.]N<5@":*.0!;FA5[ZL);]D`H18QL)
MK"*143I_A0?160-V>0$48$]MP$]3]018L`10$(954'$;>+9CBKQD<`17``0L
M/*4\B</5>+%&D,(G+*:.[(97D`;/"`114*QP%[)"@)Y%.G)QYY^J*@3+&&$M
M2:3*FFM%L(@7=E"0"$:L"0=2W#L;H`4IL#S9^C']V[D<ZK]>O$@"W%@&'&JU
M`2FD\1FT"!5EXBT_D`,"1$"]F%^EQ$H$E06YM6!+8)0_&01$.HY?$*170/_"
M0(#"3XH$I`JV$TC)+AF-;#">%@N^08`$<_B-:R8%X[O)8HIVFURDOY=V$):V
M^HEVU'BF2>`$8MA;@7=:7Y1/PO6R:)1&(,``L[FM_)O+NXFML4&NV*"0^J*0
MB9$*.C,Q28%D&0)4)Z('$!`#<_`"O$BC]@2AI>6XM?8$03`%:Y>(1T`%ANRE
M2)`&/K",;_<%;#`$:D#/:4#"U/L%9""KI+K.2_H%NT<%7W"^="L$:3"^5.`#
M1#JF0A"@:-BV:0"^:%N'[_R?MTJ&@;B(58!5@5=:W'=+9`2SOZ-&&>!6%(W%
MGFNSHW@-P:DK/20OKT(4DT45V>*$K.(9)-0`'@#_!B\@J0AT1?I4!D[@7[JU
MAW.G!)(LU-=HI<,+B.HIAVE@O&?:I53`!G\XU&D[R3B]I6M(!90I!:()U8E)
M!O!,!6::;!SWAT0ZATQJSR%;GE+`AV776[!U6UA&6@SZ17#@FL>%`2]``M^V
MO_JKFQ:=0\NR$S""G!&R#:011%6Q(AOB&1.``TY;K[YS!\15!G#02E_U!%D5
M!$X@<DQ@O+\7U$E@!4&@!,\XVO;-!G9+!D7`VO_IVFJ@?%*`JJ[-I4W:GL8Z
M!`^+!FB`P_8M?+2-U&J`U$L:O@K6TU?`!FH`?&NGS4008$Y`<5-0:W_W5;)$
M5F?0!FGE.Q@P!RQ@:%E<_]&_*6_LTR#0,GJ.9614T0?3=3,4`9%\\,8J?0$'
M1`>P/`9F<%J.RUM/X`-5`&%3L-6XQXQ4#6=%NM-%@,)!T*4QZ:2T:@5HD)]R
MP-_P^<T!>J9O^`5H0)[D:`5`#=0\#6?;2)ZBC`9R0`"?36QF>[A0ZFO"YVR'
M&(Y,('L%==#");\,?5P58`(=L'@2G<N27I`_85/%@(0_Y!SZAL:E=T<@!2(-
MD`$S8)>]"&C>IW"KA&6YM050[@0Y29X2*`1+P.&$C)Y%[:1Y2`:-_(?=[`.3
M;`1HP`9$B092T-,S2072FV#7FP9?D)C&BF`EN;`+BP:TO;7XB;`$$`#Q*89`
MH/\&9!!F2Q"'^WEGUZP$P^AAQCV)QC51!H!X*'#%T(W76KD3N:**CD)..EXU
ML4@55))7VF$=!2!`]4J=:T`'5P0'80"_6S`&2G!:_AH%4[!Q3.#:2@"^PTN>
M/(T&7[#EPG<%6PZ'5,"92)#"13"E1(#4(U?5QB8'ZHG3(R^3:E#F5[![<-:&
M0A``:I#M?<M;A)D&=E#42[!V5MI@B%AF4Z!06V![N"N_9A!+9F!&:14\%)H"
M,@[=7KD^]$8,^N(P9TQZM+`4U7%.6K%D!\$!-."T5CA%R1T&=[`&7@`%8W!:
M2C`&6P`$QT@%3K#532#*(>F&8SN>0"#L,>D#]`S(2(#_!FI@!&Q0U$)`!DDP
MVL;^=LA^O88I!500[&0@DZX-!':@[0L;LDUP!&`K`@<0`-B;RB$9`&A@C,UW
MR5ZJH\PX!?WD2EHU!G!@1@;G!O4K/(Y.`[1)T;W92$&Q'@RY7DRA,Z07V*RP
M3%NB!QJ``K,#`E!;@&Y@!J-T2F-0!1J,4#[`HT)0!?*I!)_M!&QXN$J`MEN.
MU=Q[C58@!U-`!R```@C@!EXP!4/M`\=;!-\LI3,/"$U"9&1#ADF#9&QV=FE!
M1$%7BR)L1CY*15=I45<'`4-,/FIH5$I$13Y&1D)-54X^14]07%QEMF%F:VUM
M=W0&!@@(&#`D`QH0',G*$WMY_W[/SWU_TW_2?=?7?WS6VWS>VGI]?'KCW7CA
MWGH\>N<]>.\2)&`O(!<;"'1U=V=M9F==8[B,<8*%BQ(H1)0\$:+DR)4E2H`D
MD2(DB1TE48(TL=($"9(B0[I@`&%`3!$U<IS0P4*%S)$H5M`$B%*$#)HK5Z3X
M(&,ES9<T9*Y8^:(F`($T;#06H2*'0``[/IB,.D4@P9<B2;X$H$+$QZ$C$&=!
M@;($RI,L9OSIBG/'#1U?%!!4^*#"A01D'"8H\_-GS[,]>Z;Q_3.8FA]IWJYM
MJ[8-W3C%>LB).\<N,I]W/!J,4/'BPP<,^-[J$F.FBY<G6*9PR:(D2Y`E2XHX
M`3+D2?^14ZB26`$2)`B0-$F0&&E2QP2%.U1T*%BN0(Z!.$R(#)&"!HF/FT)`
MHE%C)8IP(*DH#@DR/HH:`G:N$"%BQ0YZ'T((B)"2A,Q1(T6B,#(R/0J3)EVU
M`EL570#D15IB[,*++\!4@($)'=@003)Z39`'8'WY`1A??/4Q6#9\5&.-."2&
MTP<YY)0CCF4HDH,'#WC\,$`&G'UP`085&-#+&G6,X<4484!1AA-08!$$%DDH
MP40050`!!!%`''$$%9<@P404IP0Q$1%M>):%'`?HL`-S.C!!@0%(V(&$$CY\
M8<40/J1!Q4](1$&&>W:@P48`?#(BQ1!`4*&&"`2H=X04(J3_,<073ET!A!!I
MV$%%$D58P085Y*7A@Q-.!,$&$$Q,`4468Y11H!=EF!%''6[<84!<&%SP`@H-
M0`"!7H!=*-@TV?#:*XF*D5C.L.F,D^)EPU*&!P<Y6#"#"1=<4`$"Q]$1AQMA
M!"F&:4R<900644TA6Q!>);&>$:9H><6549)1!04?4$"'",J)P)P"=E30:A!&
M$$'&I$%4)YP0=K`15!I62.&=$598@5,`<@CA@P]4$'#`IT10P6<00J`APA>L
M9*+H1EL=@40012PQ991*.+$%%[F(`<<::[4%5S`G,'!#!,A<N"&'A%4CM(@C
M9H,--I(-FV)DYQB+(@]\<&"#!35`_XLC!16\=4=;96#A!D!8C$K$&$T<\805
M4T11-A%)')'R=$Q0(0@J1HQQ`0@8&)"``CHHQQP9<9T9A!HZ24&&$4!0YR9.
M,)&1!AIR,++)R5_8$8`:0[A]A1QHD">%&E\@L2@!:$CQA1$VX1<$&3X<X81T
M3])&A!-/.%'%J%V4$08<<)BACR_!8/"""[7^!5A@03]#S="(3;/-T<$>NZ(W
MC46VCHL0W,"`"B9\$`PPO;1UAQ=CQ,&%%UF<)<0:3W0;Q1-!,)'$_$<8X385
M3EAA<A+\EB&\]P>XUW+*](L[7,``WD$"=X90.B%$@0J+<-P7)CC!-#3%#H>;
MF'G44)$D5/^,`%)(',2>!$&<6`$)9%`#*H;0A%1T)0I&2$(3;$>D`IU!9G#(
MUAK"UPNYF"`#-LB5AOCB%\%(XS!&M`9CN'&T;JQ(>I=9FC<@0`,&:*$%>*M`
M7+16AS7L;@TWY!07@&"&*1`!"T:8@MO0U38A'($\]?.7$H00!#$(SP0F&(+?
MF).`-?RB#A10P07,\(5"1($-P4$#R&#B$RDX,F'=08(D[*"&*R0!"#BA@D2L
MP*<W"2%R2$B<(KN#$R&<T#=7B$(2?!"E)C"A"B\#2!>X<`;>^0,."_H%`BX`
M!K_XQ1D_VU4TEA>LYRFF&TY,)O42$YG(4#$#<VC!"3"0-P/0P2W_;JA#&&II
M!B_<K@Q%X`(3@.`%LQW!!ZH\PI*:P!MV+HH)EC2#K$SP`@H(88]V,,,O*K"U
M$W"/#ERX0@"<%(#J6`$E<O")(NP@ATI*(94$2P`;AE"$2*`!#:#@I!VD@`2F
MR($*+>&)X<C`T80)@0IN+%L28+.$)PC$#*D20QC*,`8SM"$.JW(#,"Y@O,!L
M*'D?6AZO1&1,;B1-',L\5CKZ(+4,:`$&)L"1-:])AS70X0QE6(,8O("^,``A
M#$L8FP_@YQ54*$$*4%H7Q5KWA2HL@0X`,,&SZ.`$(UB'#ED+AAGH(-<6S``$
M:PA.0I$@!S9<00AU<N!)35D4SEV!7#*1_P-:AW`G.5@I"D\AER.'T#`A7&IU
MAZ/"%5CY!;#0K@JTX`)`3(6%,IR!JSZRZ>\,\#-H$.8OR^L0-;"A#:+Q-D3/
M2\PQEWF-"=@@`V]H`;2FY8M>P($.;="J3,_@(Q^480M&X,(1IM"$)J"K"$U`
MJP_T]YN(7`$+1%C""U0``RSJZ`X(^,`&?G$&)U1@!BW(+QXO4(<K7<$.W4DH
M&AYG6(=)816+X`YX/$8`M1GA"F@@`$>^<(`O=,0*1$B#&H+0'B`H4)5?4)O<
MEK#2)F!!"5N8)18*%(8Q%$AW-Q2#5?>P`)_Y$K=$5!X21T2-Q1`5>LF\QK'"
MP8$;>$``,SA!%O_I0($X&*`.=("#&&0FLRJ8@0BTB((9N)`$+O@`"77%2'J_
MP":&)`X*\X.O"5KP`A.`X`/UN``%O$@!>M9`!3-X@7(_,P4[Y`=B.:'(@]F0
M!@U_@5\:&T41@!"``V`.9$-8!$4#((('^_F_Y)&L$IS"!)^$%PA.6`(3G)`%
M*&QA"UC(0A6R4)!3UV*;U[K0A8;H!V?TY0]Y&*HPM7%$7XECJ,(M&K"D,8$<
MC$``8-AO7K'YE@KX(RU3,$,2N@:$,E3A2$@0PA*,,!LEZ.9U#YG.$S9UABH8
M``0G</,%VF!-^,X`OS.8@P7:R]YZ8,`(:-AHG1S'AM(9(0B?DP/G-&G_032H
MC0A&\:P=C@"$`Z#!!U((0'?4T-$`(#(-`<B?&A`Q!#&_T@=5P,(25G.6+3QA
M"U-`S1A6#H<SU%I#SG#&$`USV\`41F@\-AKSGN<\HFZC!P,(`0/`H%QIT0$?
M\F+R!;:VNS*TP0ECR$(1RC@$(X&J-@G),(G5L`0&/L'#2#J#+RY@`0:T@.A^
M/3L`!("!)QA@S7ATLZ"L(`0^L8$-#D.)';X`!",4TG).8C`K[F17$:"A"5<@
M`*8V:H1+'8%/0R!85N1PG>R@RP=38`(7B,0%6:`<"K<[=16\\-H:T[B(OJSM
MS36T6VGX"MBN=_TWL.%$/#0`!=!\EHTH@`%?_]#!5:_*1QO"L(8JE,$+/C@#
M%,+Y;S5"H75*N,(1,M:V+VP!4%P@PA/:,`4#7.`$,)C!&\``@#F\H?QO,$`6
M[D#/%ES@"':@(QLB)IR3+8H0!$""%*@@!4:H23^D4RD;=01[0@1"(`(NP5!#
M('!'$&$<HP9Q8P4383)`H`3>]@1*D')-D`4H9W*W@QI<509Y,((WIBNU542V
M%335P!=\<!@<$GM"Y2&_=B(KT@`NT`%O\"PGX#V]YPMU8$T4L`MQX`5QH`18
MX%5C@%U84`1'4`4^``6NXP0A0V9%(`1.6`1I\P1A4`1>0`?;%PPML'9O(`!:
M\`8?``<&<`+/H@!8`/\GBX`?4A`Y5P`GJ/,%.R`'%J=_EA,Z&&<'TR$'I14%
MBO=X<E`$^18$E9-AGT`P1<`&.B%]ZI$D2^`$29!Y6&!R4&`[54`@8=!:/C."
M,)=Z*"AST``T*L@K.G:*13,TCZ$!+-`!2$8///@63P8\;>`&V\)]1Z@:S[<%
M9?-U4&@V9*`EI3`$W!8%49`V&^@#,`,$2U`'VW<!,T!^6C"-;Z!G`I``(I`%
M1R`"%68'(G`Y&'<`(C"'#:,&A18`9&`>(H`YA#431B!P%),`]"%P)_$)>U($
M%F0$YT$$A[9_X"41E5@$53!#KI!Y5?`$J,%J8[``I@<8"]!3,I=KMH5;'K+_
M*Z=(3!>I1,/U!T7F`=OS5Q\P+?ST'._5!G4P,STR!G!P<F,T!6$1!)18&Q6U
M!$C`-F!&&V>E!%4`"E@`:EX05F%`!QN`9RHP!V```P#@!#IP!D=0=Y]$CR=%
M!59@!)%R`!1Q!6I`!@0#8$41`#DA$\+!"-)!24?0%.P1``$3`#7Q"9G%.D+`
M&T[P!>G5,DHP0V"1!+=#($4R!K)F8\T`3!5I<Q5Y6S<W#<ASF*_'6WWP``5`
M`A90C4HF+;VG(V]1!W&@('>0BR[3!3Z0!=P%!?'#3D\P!%&0/T6@!$C0)*#B
M1LN'A=SF94H@!MWB?2V0@V&X`U>`!$F`@$&`E81U_P`.AP0)DWAR,&AL(`3G
M\05L0(YT1P9;@6_Q]W@!D`1XN):_07ELH`8^X(@`QT(Q!!]*$`0IIQ!+L`7=
MX@2J@05'Z)`T]I"RIB&!F6.$440JZ"'*LX(?<I%#M9]]P`,.<(,,H'LWL@'-
M!65;DTUN<"U;$`<<6`;=4@5-F`2AAH79=B7I19Z/LFT9FB17T`I!<`1MV`1F
M$`9OAT<M8`8+5P2&%P!I8`1V<`![5Q42!W`$P`95B!1(D&]YQU"H$P!\=QZ\
MB10^<#E`0&A#<!1#8`=14'?&*`?CL297<!MCI9>T,Q;JZ0JKYI`U)FLW=CS0
M\#-^H6-D6IB#41A*9$S3(/\!,>`!5-,"GK%+UF0`.O5[=Z`/1%@%0\@$9400
MVV4[4S`$G"($XY0Y0O`Z43">/K`$NW$$^C,%:[(%'!,&33`%<'`'&$`!*IH*
M56$'04``.U`)AZ4?ZD@%A_2B^'8ID/,Y>H(&@T`X09`&#;:D5N`#`+:DNTD`
M7X`H0J`5B7,%<S1.FT*>L\,$!T$6"MDM4.">(Y@'"]`,T%IKP$2*IFASAHEC
M&#E4,G@T?Y`]))`!```&)W`"%2!G\,5DOV`M=Q`&;;`%;7`&3``'6,`$8U")
M3!`J0S`%3@!F_Y85,D0%2P`>&+H$5.`Z:#4%_/($&>$%K2%.:FD3"="K"7``
M5"#_`B(@60'C%">569BE)HN`!(L`8%8I6=<1`'95"4A``$+@64(@4`JT<&[2
M)D1P,DPP!,\W!=[F!$V`@0>1@;?CK._II:`HG_(93$.$@F<ZIK<E&,\0(D=T
M3'T`="@`B\G5/1>`=#HU5;U0/EPP9:/'95V07DYP$/E:!4C0=4`@")@'9HMV
M)4-`!%'@.E20KYCD74``!1+1%0%P4E\@!PX#0FB0`'Q2CE8`G0&0;6!B!%%P
M41W#!G;""'1D*6]"%)BD!D20;Q"G!D"@@!S$0%EA!?"DL`#2!-NV!)7*73"Y
M!*[`I5UZ>B1H8\!T@D1T/->ZM$"#IDMD#1+``B%@`0#P_RQNUGM9HS53U05N
M<`9<T`9-X`5=T&5,T%($@2X+X6U!,$>RP1!-P!5>,5ZI>5+[*H%#@#^K(#JP
MBG'_=0"%>SE&(`([D!Z<)`<`-[%!H!]DD":N.A2.NR@6]QN5(`<TL97788Q^
M."=$H`:8H@93(B6GN:A:,CLZFWFAD@3.ZI#-:GK.^HFP>SR`>3Q@&J:IJ'.\
M]FO,@@(A@&QK!F?HFJYO00<)$@==$`<C-P8NY02A<A`^4*EG^W52V)J5BF%'
M,`1+(`75:P14$`I8,EY*8`0AM"@'IA56`";Q1TD.(YP'<`54P%#7T8Z*BW<*
M%#H/9ED/%2DL2P5IT'=^1C!Q$O^D08`$FL*50/`%2\`D\<.$1V"!8-$$+9,$
M%,RE%TR"SQJ?'!RM,!>F8TJF*QB#B%$B#<`"WWJ-6`0"U)(CP;#""CH&;C`J
M9R`+F<@:W+6!V9$%2/`$4+(%1]`*+$2P34!13N`0I?Q8NE$$Q!FB7U`Z$!84
M(J`F,G%@D1-A#L-0;XP>=K5WF"7$6GE"(68PG67`1^`XMJH*;+#,M8H&@9(&
MB)<_,TM1:8O'EZ`DKT/!%\S'\#EK%_*LH@B*O_071VM$MM5$Q@0!-D#"`E`#
MRE4/N\1D"#"G*[P%7Y,%:\!JK($%.]L5RW>W:.-=6R`=ST<$3(`$>(Q6AF@%
MV\85J23_!72'>":U=P)%<4VQM_'Q7W8`!'="!?Q(27;R"7$8>9)@2E\0OF00
M,9P$*(>+<?X2E\>),$$P4'-HC&_40@DQ3O/3"D?`NGO<##7FS5R:*S3VNF.Z
MU$J[M"(B-#PW/7@P`"R`>V^@`M($`N7Z"TEGF5=5!V(P!6V`!:AQ!&B6D"#7
M.O`S0T90!4K0<1/#!!*S!%,Z1U:`"E^`4LY,$P]5E2XJ4"J["'QR2&"9`-7!
M*$A`%"D]?ZA#>8)"$7>W"GN'0M+'!BMM!WY'>6APC@R42FK0!%^0!'3(-I<D
M/]OU!$)MU".XQZM=U!<<F-!J8S.7D83!F-2##>XL`Y`9KO2T_TN9FC='URK7
MU!99T`9<``5AD($ME05W:[8(P01=D#+P,S\,D02)*AQFU!V0D#"&0`86UG\G
M)`=!$:,MH0914(Z"V!)L>06&!P2%Y;<=+046-#ARH@A4L*.L<P5?`''5"3F;
MRPE6$`3^^T!#$`!'P'=6<)=X#`E,`%[MD]H3[-K@#+1$38)#-&N^%+N[U2&V
M/2S_V0`T$`,=````D%^>,9)7>W1S6@==V`5;]0365@53@%JSLP52P`6F&S9$
M@+?IY1]+X.-64%=V)1$$0P9`<%"/\@5"03B*4,6"J-]JH@;<:12#TV""XF@_
MFFTB8`4:HS!/47%-JG@"CEB>RE$$H_^<AT8E$1-",-DV95.!;+/*J2W4$^S'
M7?J7K_O'\DFM*4@8P14]Y]`'$)`#++`"%H!L>08"T'(CP(``5C4^=.`%4D9+
MLI`%3+"%YYE=3?($GDEBKT$N35*I<A-I&7,*&.<1F*W?":-X<6@Y"G0I$A8?
M42`%%:8Q>^MWY?BI:;"CE=84O9H>+TO8(/TF"*.<^A$%CX,Z1,!1#-<$%24E
M)\,FE3H$WPS.>\S:=U[4@4S.S4"TNZ:1C&$LWH`'$H`#+A`"&>`L?_4"T7)`
MD_Q[;I$M;C`&9W")83`%8^!69?`:6*!.X#([>GG0,"D%:2,%5R+:0I`Q5\"5
M&W05@FA*_7;_N`*E'[N^'4"@!NEA!U:QLNW("2#4'CM*`!1G%`\U$U=,G'8`
MMQQ5"7MWQ9C%60$P1U(07J"`"@U.H7H\YW7.NG4>X4(KK4M=BK4]]+Z%5$)&
M9`60`BC@`32B!?0$+5D$W`:P5VU0!G00!J2'W%!0;DD0E)K'3@`=3A78AK51
M@:*-Q\080CO:+VERDQ"&B$=!"ET>80^4`#:*[.KH$U&`OGM/4EB.\0TC<1%G
MLBYZ\:)%!HV8$<.(V?[KCZVC*4.P)D/0-JE9QW-^^4>]VJ\-K9POR&1Z#4CD
MG]13&7H0`3;@`B4P`@PP!S,`51^P7//U"X]>!@:00V*P!664!9XI_P8R?@:^
MF`7<B.-,4C\2"@I.LM"+)AX.!`L&7"F:\E\"Y8>$\P4B(-+Y9@00@UEH<"?]
M-Q-"&F'R72@=&P5]BXA^V&\+*`12P`83<Z2>(@6&./D%JW]L8@H5N&B8[YX0
MKNU)#0A[>7E^>8)[?GY[B'Y_B7]]?7Z1?9!\?'J7F7I]/P,T+B$=#&\M,"<O
M)A07%'2M809K=&MG;5M=65UM35U<2EY83%A>24100$U;5DQ00DM.2$T^0DE%
M0D8^/@11<DA1;%%#9%%!<G)&:E1L:%1I0@1(7P1";`%2<E=4!U?O5E8!;*C(
M"?"-P)4O=I`8(?`E"@$?<L;9`R).B)4O1?_D1"&2IH@1-DV6+"ER!%F1!2A3
MJE299T'+02]?+AHT$Q$B1XD:X6P4"5*?2WQ^`N4#(4<*%"0\,-"B(I6)"E#O
M(#``RXP;-V?<A&D3IDJ8)UC*,.$R9@L4+TZ2<%GBHPK),4^`3/&!+`@2NE2$
M`/$HI0@9(=;L#!DB1PH0.U)$J$%R0(@=*U$>7[''9IX<-$C4R*%"P'(`*U0"
M?$E\)<@7C&J`?`DP1$V:(6A\J"D"Y,B7(3ZH'"&"QID2'T>"!%F2LN7*XBQC
MHJ1I2%`BFSD?_9E.B=(?H$(S78IPXVB(#`*8GCIAX,*="@;B&+B3M4R;,W#:
M8!$SI<N97F+&.`G_,V;)+2!.0!$$%%#XD,041A!AFQ1'Y":%#T0(%T2#:7QQ
M!!+G1#:$/5$<\)$<CKD30&_;2!&`$5:($`0:(E!A!T%2V(&&B6H((44:Y4CQ
M$1)4J.$#CODL,<1K/J!!!!-(#+$$$3XTD<0131PGY7)2PF2E(HL\TDA.DE#G
MTW64:/*3'F3VX``-,:#P77@MO/`"`A<80($!;MQ!AQETB-&&%VN(448<7#P1
M1RYPE%%%%6=4\4070/BP!5M5;-%D$D:4]`45!J9A!1)2Y"7$%VP@<<059!1Q
M!1M#L&&7"$"000`0:;#A@QUV`!%`&D`08$40CPD4A1H$J6&'$"NJ,404_P$<
MULTX2`CF#A)7(/F%$DND84020R2A1!!-"$$%$4E,6>5R5AI"DW.&.,*((EM2
M%TE00;T;5"9XZ%&O'AP4D((+)7Q7R@PO@(#!!G140$<=%+1!1QQUP+%&'5W<
M(882<`QS1A98)%%&QE!4X8,3P1R!A<=.`!&$$AQA`X00O0W!*8]$%)%.$9?:
M2HX=040APA!6V'%$C-^<D\:P:-AA!#YI!-`C&T+DPUJ/IGYAA1QI7*&&$63H
MB,:V2$Q!T81&,)%$%-9848VXR!6GG$N&%'+(<WNHNRY/7E9RR4^1D,E'O?5J
MD`,+2'5@@19@M%G!"71<0`<<=%SEQAIK*/P$'/]Q5"$&%F.8<<L358S1Q!-A
M--$$%DLT`406)3L!8<E"(!$$$51802P1I0.!!AE$((&J$3BC$X00(D3A6!%(
M?(9$\$8<`"VK=K#Q13IVJ!$C$@08$40`UOQ5=12O1?'%840,$78:$39!^Q!2
M,&F@$N(:QQ*Y+AVRB$W.-<*(NI)4XNZ[>`L%%!X`[$$#<,""?GD``&"8P0PN
M`((*Q,D-=:##&>X0APJN@4]PZ((8OB(&+VPA&&5P0A,"A81@:*L(4'A2%10T
M$O0-@0A&0,(U@`"$*U@K"0<A`AOD0#,CH2,PUB!($0A@&(,(P1[_(`.(U/`7
M.0Q!,!>Y0O&00`8R$";_9[HAGS^4\`75B>H)-B*"$I`1);0A9P_D,M<B_H"(
MMD4G.G&;CB,@(4=+C.E_>N`!'GC`@PD,(`4QZ)<%WE`#4WS@`Q?`@`'@@(`X
MW,$-;7#D&2)W!C/<H0MA2-09F+"H(CB!"T%P0A:`L`4E*($+VEIA$98D!"$0
MX95V,4(KFS2$*P`A"6RP`A%NY0,C7*$D!.&5+@%2!("@XS4Q2I8:2F.'(F%M
M>/B0@JJL2(6]F`T<14@#%(X0A6($@21)"`D3S.B2XQ@B?BT1!"'FQR[HX,01
ME<@?'Z83+WAI9V_VPH,&;``X$H3``@)0H`E>\(&H(*!QZ[%D',(`22C<(0Q;
M__@*%U#7A2=Q@0E#J"@1L/`Y*!2A"5!@83$Z=80G)8$)3%!"$\@P&R$X\0@$
M"$(2FE:$<@RA"&C091I\1`8T^$5%1KC=83!CM#1D9H@^(`/3F&88-KS2"E"P
M'A&$T`0J(,$)+F,"#&D7KBFYKYSG-`Y-7((E0A1"$>LD!/[HZ)/JP`L3]](;
M#W[0`!H`[CN#?$,J$*DX`]"A#71B'"0K:(8UF&&27<#"&;;P01]`80Q#<(+'
M#@6$*J20&36=0NV,0(5J4NI79$!&+GOI1-E$PY?;LH<28G0$%[76:)%)WS)=
M!)N>R2P(4O@+&2#C@RLP20I3Z.81BI`$F29!=K\!`O]*V;>207@5)6U4)[O.
MFI,U8BF.\-Q2/.-YMTO@`:[VZ@$/./`)&:C)`QEX`QA>T`(,7&`J"+`3'<+0
MN##4(0Y8N.\8^A11RW:A"J>#`A*Z4"`H/*%K(5U"7(2@!":(,'=6I4+6AL`$
M(V!$"54K"0]Y@X0**PV'1MJ0-40`PXFP(PA7&",;<'>%(K@H"'^)V16:<*$I
M(&$)5&2"%)Y`!"L,X0E.*`+*CD#.=#JW$.4Z9_VFJY-V=4F.=Y,7WNYI+S[N
M$0)_9,$*1`$``)A@!A]PKP$V\$@$K*%.#KM#8>\PABP,*@OZX8(7A.R%SV7A
M"4K(F!&X`(4A@#0)/HA&,2+_E*2]C)$,UY*9$!JTM<-\RQ\^L`8;?F.')!S/
M"(11R+"00#[8O`X-)L,1&H8PA9HZ(0I4>$(:F``$*C@AI4Q8I<N2@*VN/M>Y
M,%%G<]@Y/^?<1$MRC`1/^'<WO6D"KGSX`0!Y$`$;`!(I&6"`"DS!P`I@8"H4
MD*^>\L0%.@"C#648@QB<L(0RG&&$9]CH-I_`!?-A80I#4,(38CV$1OE`"24M
M`OKX<00D=;.JUZ)>2=+G`RL420F\HY0<?&"B(.2*'\T\3#8ZHKM-*0&75(#"
M;98`A"<4@1Q3.`)5GS"A*0#:!V9L"9;BI\X%9"DG>6#CW.[WB'A.HIYXTP29
MR+3'_Q_PH`</>,`$'(`#-$$;`$PQ@0DV(#`#'#0.=/!VU+>@E2W`P0M>6.@2
MH+"&+BA!#%UH0AFX,`0N;($((P2P)Z?`!!^P&@A1`$WLC!L%(SCI"2=20A2D
M@&,J,($*W$K#$B)SW`#`CC61H<+S[$(^K`770D)(J=620`:V!*`*2S#"%+`:
M!1H;P0E*H((GO?I50K!M)FZ<F_UVLJ76SY$ZV'DK7/G8@Q\`/>@/@("^6.`"
M$HP`/%H8Z`DP\`$*(`#;?SU8![M>!C-DH19N`%D;`F0&CGK!H\,H7:!B%DYM
MM9V;9*`U$YH@R\CO9B,R,U`4?+`$!D%K"X]1PA&'()#<X/]JM%;+3128<)J2
ME$X*W]1%1<!WU0!O0"!&QR(2V.($Y71KS-%KY@(WSX$ETS4=V/4E^],'.Z='
M/S=7/Q!T$S`!',`!$]!L+)`F_9(!`%`#;@(")V!M&R`GZQ%U?;(G70`QYB8&
M8O`$9R`&&[4&6W<&6+!19@!Z68!*4,($2S`%3`ADKV0;5N`$FF4:1[!":B`-
ML0$$4@`-E05J3'`JHV$%3?`%,R8'5C"`:7`$5I1-5F`$4:!2:4@$9.`U1\"%
M53`:I?9"24`%29`6R1$3;@,3?K`<6<((;00W[Q0=P89SLI=//U=[("AT(P@!
ME,@!W!$#:1("(S!(;9(*%W`!'W#_?`=E)W&@,&M@7_SA!5E0?5Q7!D(`'R.D
M.46`24N0!&.`!2KU:DU`7*_D,M7$!%.@!/76%NT'!$M`!5=P8)5E!4<P!:O&
M!,WTA5:@!%5D.R_D8T&0AA@2!7M7$BV6#4Q`!NS'+8/W,;%S<;6A.E4R/[MF
M5C/!+C*W+NJR$W*4"/IC1SE')G-5>Q\8@B$(`1Q`B0()`0U@`Y@8.$O1`J9@
M`A]P`N\5)Z[0.(NC)WL2!E/@!6Y0!5P`!V=7*$7`)X%B=4\P!096&T=@8$\R
M7'VH64AR8U60!;WU:ICR!**'<$N@8TMP!"+0(+K4!&H0!;93!$1@-)R%)-T`
M&I;VAH*F_P8IY6I.@'9,T"`^0&I'0"WO(U:G]Q)HA25S5%U-=A-?HEW784?Z
MB`<]<'M!-X*3*)`:T)81\)8-<`.\MV4C(```,&TM``(F(#`0>5!N\%=AX$B9
M)`99(`9FD`1A``=`U@;]`0=G4`9;4`5PD`5)``5;T`11J2A38%D&5F%&8`1+
MF!8G$V12P&JZ@01R<2Q3D(U_=P4<1SXNI@09$1S$Q2FX=8VB\@4T%H4*`D9%
M\`1V!V!1`'H,=I7IA$YJ=%:]EB7JPA.M9X\](10:&%YFB9;^&)`#"0%N^981
M(`$2D&4QL`(E(#AOH`(`XXD?$(,5T`I^=0<*8YAK4!89-`4Z>/]*==`QD]D%
M73`%7,!G#I8%IK2$HE.+%%$$P*@Z\?8$@V<$3S"5NR@-T_B%W`(:2V`13>`Z
MT!`$3#`@,-9BMH13J.F:C3)X8M1B%9:381.5[&=.;$,(:O0VUZ4(;!2/9C6C
M<V0W0E$O/_<#'RAT(;B6;,F=W.F=#5"D^I(",K`"))`!%H!`,P`#>0D"?!DG
M4U$G"V-8]\D%<?`$7F`&8:>#4S`&9[`?8XHY3Q`266!@I2,ZK[:9;!<<"H:@
MP&@^+SEXRE4D]\8M:NAWRO4$9+"+`T(8MH011O`:Q#)3M=A-N=%@[#=3#6:@
M4)`VZ81&N596O/9R+S>C=&,)F%!E9^G_@3XZ`=FIG1&@`4/JG1)0I*HZ`#9`
M`\\6`A[0I`E4`WO9`A\@I5-1`7=@)U<1GV*`*&O@!/$1#'%@!D]0!O11!F@!
M.JC3!%.0!8>2!=*Z!2.9%DHP!2-97$T0(-J"!5@P!$>P)+>!44?0H,RH(,$P
MA[HQ%[AB!5*PAU<@#L+81=.0D_CF=B$Q!;N(4F4D)2W7-FT$L*KG9)O:!_<2
M0!_8CS^*G92XG4*:JJK:``XP`!0[``5P`S1``S+0>[$:'G,`,##P`B>P=%`1
M=72@9GO"%5"@.4Y0!Q`5,6:P!%WZK)?#!&)*(`K*.0KFA$_0LY<Y(4Y`;C&#
MK1\%!4X@1:`7_S9L$:Z@&0Q$4`4[)G*KMBLT$P0^H)O"L02O4V$.5H=]R!8=
MAU7O,Q.G5Q/NZ$Y@&2_NXHA[M(\/\`,+R[#:::H/"[%%Z@`36[$%L+>M>@.M
MRB\=`!X`,`?LU0(F8+@;L`$&8P"Q$`=N``=U(&=B``5=4*S(6JQ/8`9Q``58
MT'7DQ@5A4`;0&IE@@06,%9F_Z6!5H*]%0)*Q-@5;@*AQT015@"U+@'#`&'Y/
MF4)7(`7RQP3<H(5!,`4SYB15H(:MFPU54&$^,)*BTUS&<0B[=E;KU)6P-R\_
M`4!MRZ,\>IU`.K=TVYU$>K<26[$46P`YD+XV8`-RF0.M&@/^M(D"4/\#,P`&
M(-`"#GE0!Q5U?]D%E,-U:Y`%<+!!;C`,R1H'_W4&'@1Z6)!8O9"F9L<Y63`%
M#6RTK;L%$WQO(^EV3U`-6^`$!I<%;JB@5C`2#L818U2:TD-Y(8$&W!)R8A1.
M'U6[2O"2?59&7W5ZRME&-[H_],)SX@6J;[NPHCJ0#ON6J6JW>&N^>YN^[LN^
M.%!T*<`"-F`420JKT<84"D10((``&]`*>5(G[;$%=[`&7*!F.C@?:/$G:&%U
M8,<Y/?L$'0,%H_M!9B$2%-P%I;.9QXL$4.`U2Y`%L/,$1Z!Y9:!96W`%I;0;
M3Q`%2,!%4_5Y6HL$>"8JE#D<M;MV"F:T_JK_3O339/&D-WQCEK9G>Y`(MR,H
M@G)KJN&+JN.[Q'J+OE7,OC<@Q5,\Q3$@`WLKE[WW3UVF!2TP`U+ZB==V4&+P
M5Y&$D74P!@.<!7=0*(5R,7SR*%X0!ECG!670!=G<!6/0"ZO;,0U\BU`@-I9)
MR,\*!4H`K3=9,DS@!3@&H"A4!&Q@<G*PH;H1&_SW8R9#8TX8(/Z'!046J2L!
MHS7J)3JW;#O:HW`+@FHIM^!;MQ&;M['\Q+5<=*Z:`A@=`R>8)BA@`Q?+>VJ2
M`2HX`].F=,17S"8+!X^#!?4U"Q'#S7XB'Z!S!@86IEYP!@I\B]V\!?U)8-C*
M6#>),;&[!)@W!"\9_XQ5($(?A)I5D*\]%G+#6QJ4,EQGB"UDT#$TM`7!6,X*
M1JU3H!)H]([M,B^7H$=Y5'N0*'22J):C2JKA*[Y*;+X6^\10C+&NR@(L(`-Z
MC8DN@`)^70(K0`,YX*HHL`*!RP``\`9:`*52N@$(@!YR(E]F$$%E(`O;=@9U
MX`62609+H$$7(]1<D%B4&P839;I);6"?PV?+6X5_;%FK2ZU,L`77UW&AQX25
M`L(DN5JN-@TGE3N<-#9'L`4;N@1CX#7&\,$M"K#T9`D\UW-I+8FJ[-#@^];<
MV0`0B[<23;$Y4`#KR[X9B]%XG=<N,-Y]7=CB60+]$@(TP-W[XGN!*P`"D/]`
M`5-\QU<'C+L&?D5?>5+&]G5!D5N8<*`H76`&9J"#O>`%VIQ8&`P6W9RF=*S5
M_%D&=&RZ2H#:_#D&=8@%F+P$5X#.5F!R&P&@D)&3^W>F)54ZY?K'#=:S5:`$
M+Q$_T@%>")O6W@N01MR6U(W$XRNQL'R^ZDO+WSW%>(V),5#>*X`"Z)W>(2`*
M'L`"?CO%)4`"@C-(,V"K##DPQJ>_?V5)E!,+>&(&7C"YQVH&&Y/-R.HG$Y6F
M&*/@JWN$7?`H%,QG[`872\!G1-T%(O1N59@%(T'(=0@:$RP%Q=M9(M0H+4X1
MDC5^<KR+8\`VTC&=;7N6/!JJ;)V=.$[=J&K=JMK_XQ:[M]R]OK5\T>$M`QSM
MUX6=Y$N>ZA[0`;':Y.[KJBNP`AZ@%&``S*G@7A4`)W22WU%G2?,%=<Q\2<^*
MS7+F!6/09H]%%F6@K%@PK:+-;M(*T+D`!?ZAYK<H$MMT**:T!?H&H$!`QT$@
MAO)W!>%40T20!<23!%LP7*ZK4E60)?)298^HL/]8Q&S)RD(*UW9[MQ)=`)U.
MUS>`L1@MY'H]WJ9^WO[D3YHXZX$KTDR:`2G`J@34RQT`W\!LN*!(`1B``70P
M%7^5;5#7!HQS!WSBGH\5NEP0;F/@!6:GK'#1GUN@K+@0K:;+TZ)-P6F*!?X9
MF:)4!63`!.@^?D#`!55P_RP'0@^BTR!A0V.THZ]$/1<RNP63,";Y!'0]&K>K
M?,2NO./\KK?_[KX!;]>WC->D;O!('N4*O^0>(`J!V_`B;0$`E0$L\.FD3@)+
M:@'29IXCFTB.'2<&<,P'$W5B8"=M4`=G-@MBT(..V8,>U)]<`+MC8&ZXH)\Y
M;Q9P]JS_Q6[_Y02<(UFWRZ`-N@5V5U%65$ID,V^`!WH.9V"OX]5)\));X%UG
M7<K>F_5'#-<1>[=R_?6S'/`9*^I$;O:QCO9I/P(=</QN#_=PSP#P#0`"X`)@
M#TAV?_QV60IN<@*AZ/<(9;)0YU<2Q#A<(09P0.954`9P,/Y':,WW4<W5W.P3
M[O^M&.RMIJNLX!P2[T9A'B-&YPYO0P`(6TU404M,0TA$3T511%U+0TI51$10
M6%!5>CR;/P^>$Q,<'!"D$!JG$:FJ$1(-KJ\.`[*S`P6V.3:Y-[LT-"F_+#(Q
M+BXHQB4E),HD(2,C'AT=&=,9%M86#`P"V@(`WB@V!;XK*,HCVF\S-3,F%Q\5
M%!1T"'1T!O7U!G=Q!G%B;FW*E!GCY4P8,6&ZC.'B96"8,V>P9,DR!DN5*EL(
M=@D39DP9+ERR.*DR!@J1D5*43'&R)`@5)5N`1#G"A(B0(DZ.(&+Y94@5)D:"
M0,FR)$N/'T@?@!(URM0I#:LDL&H%*Y:#6+)L%<C!-9?_C1LX>OD"%J-L,6,K
MD#$+P1::-&K5KFWCULV;MSD`4.00E\)%#!0E/$R;H^5-"Q,@WF$P8(#"G<;V
M(DNF4R?./C,=.7KI4@5+F3-FQG@4^'$+E(58PJP9Z.2,%TM8@!QY`D6)$2=3
M;!N1=&3FDR1(@BAQ4F3(E$-2D@@"`L6DDRZ=E"XM]715*@E480W`FO46+ANX
MP(K]E4)8V6%H`2=C.Z*9M&C5XF9C8$&`_;IV`;P!H`6`AQ0%W/#+7R5T,$)]
M`FC1PF$;8%"!`?0P1@<%]^13!QUNG$'''6W`809$94SDF1<<E5'00&5TD2(7
M"L'14198B,90%TT\<8D22SAQ_X@13!`%1!)/5!$$$#[D!`003QQ!A7),.`'%
M%EPX6<8#'$P`05.HH'(==J\T<!4M!0RP%U?A[1(6#6$!PT(,:Q9SEGK*L,56
M-/!-<TTV]^'GS1M\SK&?%EJ`,0<#*8@YH`MK99"-%C6T\,&C"$3:V*2,U2'A
MAAO6X48<+G;1!1=FD&C0AV$(Q(5!7F31A1AB?$2B:05M(>L336R119+&=?$$
M$44\L403MSVAQ!!"X!A$KTWX4`473`!Q"1=-F9(*5*I@EYTKW'57`'A>\9(F
M><'(X!<QQJ"P`@G)K.6>6W9:,U\V`-B7WYY\OA%HH&#@*P`+6PG(@KD%,I`!
M`"J`@?_8"0XFW!@"%-!3#P(5WE%/'6UX.M"I!'6HFD"ENG:0&*'!X>(89I2!
MA8I9`+%$%5/L^L1'Q6V!Q1:_/D'<%TSL&D23-T%Q'$99;$&=EE-QB>V7LWC7
M+5AGDI?"FL(0\R8RZ<KIP=5T4G/G-O+.JU^?]H*1+Z#XY@N`"[;8\+0+Y'00
M@@7ZS?#""Q]<<$$%%T3Z(`80SU/A/?ZLP:H908=J!JNMAF&&X&LT;@8<7HCA
MFA<B<\91T"`U@6,76^0&96TJ/<&$$$U@,<471E3A`Q*&`.'$%E4T)VU4#61W
M5;9:+9WF6$^SL*99Y9JK7KK,/.-,UNUB0]>\]0)`&+Y:S)'_+Q@%%TQ]OB2$
M&6#4S)!`GP`MJ$#W!QA<L`'>#CZ(0`7YZ%-''7>XL89!<!C41AMBB.PA'&*L
M@?\870"-JUA5!C/4P0M8\$)(<`0%+HQA"4?80A>`LX20^,!U(BF2$X90.B7X
M``J_X<(6HF(M+WF)%K(8DRZ^T@NG/2T&XI):N:BF%CFUA5UP4=Y\ZH*?>ME+
M>M$CF]BH9[WK44\+';!!+6P@`Q:<*P2"&9@*#M,.$%P``W4K'\3ZQI@[2(P.
M;3C<&=K@!3.T(0YF>%S_[N<&S"!$#%Z`4A@0F+\Y;N9)&"F#CJJ0A509XC0Z
M6MD3?,"$*>P,"TU8PI..`(0M/*%:_U2Y'0JWPBU=?`L8Y3$/N6:HEA*$0%UN
M>8O6MJ:->.E)/W-(9?2>!RC"#+&(L*P!H<*$@U^@H!C*P`8`6C"#$YC@!!<`
M0?D^L+X*1`IBC-''&C;U/CBT85-KJ(R+Q%"'QL%A#9P*E:@*V(8$&F0E,/K4
MRDHR$BQ@820VRP)P3*.R)B!A"CY3EA.:8#0O(:T66]F6)6_00F"8QRQG64%:
MJ@;*9W0`&G!1U+NX=LH]%>8-@EKEV*8G-A5HH8A#%%L-5(`"[=F`!>512S7X
MM"`8?,`$'T@,!K08J8;U[8N5B0-`-,6IQIT1CFVXPP'%T"%68?,S;5A(%D!B
MFBD0)"1/@/]2%F@RA2Q`83;F=&03F%`%)SA!@4S8@G;`M)7OL+"?9`%H,<@A
M4.+9L!D&K5-<=+C0KN7G#7Z"*]F>-[U[!5%Z&0541>>P@@+$P@:],`:B2*"H
MZ+&C!2```4KMA@"6RB,?;JA'_,Y@&3?P+PYM`,W[,+L&_K4*FVG$7XH46`8^
MLBB.0?H4RQR8!28H02(T*X(#E9!574VA"]@"$YDLV;3>:7*3`UV&NISA#,&H
MU5TZS),IWYK*'P;1KD*47L'T:CWH#?&B*@A!#JYR@P'TS@7)Z(`VYM""&IA@
M;B9H!P+L5H$'V>,>.;V'%^/7AC5L"(UBB`,=TIA-#^5W#7,$<!K_0S(:$Y7A
M(6,(6D:X`$(156$)3<W)$SA7%"_@3I]?$8_3?'>>-Z&EANJ"XD'?,TKYX*F4
MW6CH?OB$2OVT\KG6)8P*,)K15\[``C9P0`-JD8*/&H,$T;"`17D)`Q.TP&Y7
M7)\\*H2/+T[LB_?35!W@$(?./LX?J@GC&.<7AL*E*$5G@$,77D<0J[(("[0)
MVA(J@68^*C`K8O)*AOL)TF``5'C)6(\-CP>?XZ[U>WERZUOIA4H_$>;0=[W7
MV*8+/;)==(@UL$`*7A&.&X`4,$"VSQM4(#<55/&*YV/8>R4K62<S4V+8!,@:
MS"BX+A@0?_Z;(\@LXD"2A4%F,I*@IXYS_S*B/"$D6=W,%O#YG5WP<RR^^]TP
MSD+#LWI@!-%`:`[_/!]L=$U>/+3+BN]BZ+BFDI7?!I1%RW9=BE9/!6\H@8X=
MD(,!X`"P;"M0!^"F'S"TX`4FM5NH(?2W>T16LO#3*1UDZH9J8M-#_JLR&R7'
M*H5LIE0@26!%.%(12R!5@E5XK4>>M*TR-0VD+XQAN=(2)SFUYZ#2ME-<JM%6
MNNBI+OO1S]>^UCRP\6F5]GIN7N=@T2.*&U\S#H$-3#BF%`QC/6\!P`R6?H*F
MFR]]R:10^_!A#R^ZP0TZQ:QE%R>RSE+YC/@K(\C.(%24*4X,8V`"0^+(!"Q$
M"0IS#-H8,LS/%/_P+AB_"V@-/]D,*"+TN'?:(5W@%:_">TW;8.MVGQ[Z;5=:
M5Z_1*R*Y+XJO#-S``1)P0-H`^Q<4R"D#TIW;"^Q6-WBX-)D26MB&OA@_G=I4
MFM=<IOP`PC^2P5$@H6)(_A`XACG*K`RV*@AG0/65WO:N3<0@:Y[7TIYFX%!K
MV6"K-KA1^(8>7MN#CCF@Y/J\<$<O7XX7HEZ-.#8!H`#S5_'*"X,K7J7/H`6^
M!.9*D]S2>S1&ZA*3KV0W!0>LQT&FFG('<!!3JX89HH$97I"`9S`0$)$0!]8%
M"=01?%1`Q[9A,B`,M\1))3<GT?86%D!M]8$G@59]AZ<G,1=S-$=S-P?_5ZPT
M-N`F-G@E-H_7<Q7U!BN@8SNV%3@@(#,$;1D@`'.`;X=A/G:3,,;$&))B#Q3"
M9%0G652V>I%5&<L41ARA.-KT.%!R8!TA?"33!0TD*G3&89VG@1OX;,@S2B&X
M0X%V;==W?2CH-7C1;=V7:)#G:)!75]<#>6\0`@7`)0/`"\,0`^?"#!FP:8?Q
M`K^D;QO0('I3?\=$(5+7A#J%=?#39&"77QJ#.%W6$62G(JXQ!@;!!:D!8&/P
M-+VS;%.C#'KF=P:5`22V<MA@;2)(??=A>-G6AKBX;7%5:'(E?F/CBW1%AW/@
M`0/`"A&P'04P((#!'M5`,`OR`E;D#AN`9.U%ER$,$P_'Y##R]6^8$EE>1'7[
M$`=3=CAI1!`?HD`GTGL0&`8=`D#'!SPS1'++<$,H)THE1A_N(H)KZ`W8EF+X
M87W7AQ?T`E<W9VC\P8*-1QB]^&UAHTIS8`$WT``1\`IA8@-_@2A7<R``(#;L
M<`*)@1B)<44KY2`,TUX3\C?RP(U.]HVF)H[_AW"+TP4%D8`!!#)4-C_+%`@`
!.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>y15751y1497406.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y15751y1497406.gif
M1TE&.#EAU0")`.8``!P<'$A(2&IJ:OO[^R@H*-#0T,[.SB4E)2,C(]W=W?/S
M\\K*RD9&1E965LC(R-/3TR(B(L+"PLS,S&AH:"HJ*N3DY-;6UL#`P%A86-34
MU,7%Q41$1,3$Q&9F9F1D9#T]/;:VMBPL+.SL["`@(%I:6F%A8=G9V3$Q,;R\
MO+Z^OMO;VT)"0KBXN%Q<7&!@8#DY.5Y>7KJZNC4U-4!`0"XN+JVMK9B8F**B
MHJ&AH:ZNKJ"@H)^?GU)24IZ>GJ^OKY:6EE%149V=G;"PL)F9F9R<G)J:FIN;
MF[&QL5-34Y65E5!04'1T='-S<T]/3[*RLI24E$M+2TY.3DQ,3'5U=7)R<DI*
M2DU-37EY>7AX>'9V=K.SLY.3DW=W=U145)*2DGM[>U5557!P<'Q\?&]O;X"`
M@'%Q<6UM;82$A'U]?6YN;H^/CY"0D'Y^?H6%A8*"@HB(B']_?Y&1D7IZ>H&!
M@8V-C:2DI*.CHY>7EZ6EI:RLK*NKJZ:FIJBHJ*>GIZFIJ:JJJB'Y!```````
M+`````#5`(D```?_@%4G!P0$!P@0$",`(R.*$`<'``@'D)$'%!2%D884A`<C
MGX8(A9J%EB,()QLK`6`!43P\+DQ<7&8M40P,,ZPO)R<T-"&9G`3$'UU@8+(\
M0++/0,Q=2,W5SM;52-L\U]W<V]M`0.#=T.78W^;:2DU6T4U144!64$U-0$KM
M\_--[4I1FE2Y9R5*@`!2`D`)4"4`@Q4,JC"`E<:#DA<$(``X!($`*0`@&3D*
MR2B1HU"@0&JD9"A1IU24)G&2!,%3"(92G$7!(("+&#83@!Q\\6+%BP\OB!DZ
MU3'3!VE=,&!`HJ1!`Q)`,'3IP@-#NF;JT*WCH>1;M'QDD8PS:^Y9V6?.__P!
M:8)$BCTI4JHH`=*PR4$H5:I(45)E`X.%`38</+AB@^(`K1P[9KCB0T,EM:B4
MB/(AA,E0`!YI'"V)),B3"$B>U!AR)&M%BU1N]"AC!@,K5*4T$+`$S14/4:Q(
M4;P!Z0L9Q!"0DA2BT(<F/,!<)2&=1`.I+;I<5V:U`9AKX=K"?18^&S:U>^=9
M(3O/7A,I\L;AG2?4G91=#B$[W&4X\:Z(4#26$`,?0&38!PRP\L$,!WWP@15+
M,)$%%E<(T,`,%#`BFX8A0:(()91`P))'CBB'B"(9S18)!:PU$AHE!S07XPQ]
M/=."&5RP@04,2##$R@HS?"!#,#2T9`P!,DA!@O\+4DEG%08D4"/5,]]5U59T
MW7`EBSYEJ;56/M&\)9]::JT'1"QS67'/0%"H&05@4,32$$[!,=0$%(_A%R1$
M!!HVD7\/-38#C5,4RL045V`1!@D?$'`238@XF@HH+%52R4:<I`93(02PF(BE
MAURRB'*5R$C`!TILTT14'L`Q!Q<E\'"088XA-60(F'"JR0D,(-%""S!,YQV4
MUPV+1`-(2(<$-<IPA:R7LE03C3->[D66$LS,X\PX[O@#$`_NU'/FFP$I%"=?
M4EBAA%T,S1I1@G].-!FM4.RR@A6!,7'%OF)DL0067Z31P`>>5!(I(1ZQ)E(B
MCW`:22*(/!P;*"A-^JG_ARC&*,-$RS8AG0!RT`%'&B4`EE=B1P%CBBF%T#!#
M%S"08!T&#6QEU;(V@\$5-<AZ)TL7:VG3S%KJH+77.%1!XTX4^\`'A3WXMID0
M0E!($<\&#>5519M5'S0G3ODY]JY#&]`8!1EML''&&6Z@P88<;,QA!A(O2((`
M2J"0=HA'&T&2RE(IQH:2(I((/D+"DI`82:0AS`!%-6#(;,85;;0A``:0,3#@
MH+_0@#`%S1V#(%E10<D=S>'47+-6QR)+#33;(EW65VBM9>V6=%73CKH\M.E/
M/;'4@Y?3FBO4;F'P-D2K%67GEUC9K`30QAMDK'U&&VRS/<<79H#Q06FD0$P(
M_\2S65+)I)9"<F+$EU`<2DV85F+))C1\L,%542!!@@=4N#%'&2Y0@O$.P@NB
MG*!3H(L-#++@!EE891D/Q,`RM-*LFE'C&5M9%NPVN"5R?,E:T!I'.^8"A'39
MPR!K@D44MO8TO\RI"E;PVF*<UPJRN4LR#'K#&^CPANM53H?8(\,;T"``033B
MB)#(B$LR,I+8$.X3C3@%J1H1B49\JA*CF`F,8F0_[30`"$N:@AOVY8*MP><^
ME7'0"31"`.QI@041^($'JI"LFBU+=>18AA>[P0QRB*<;T!$'7,`B-&?L11_<
MPD<4<@(?=>U.%P%XAT+4M(&`"&:&A7E>8ABDO/PPJ/^2.GS#]+`'Q.FY@91H
M2(/WGN@(C;P/-*U<R18E5I-6E@@F&;K;^$(D(DL5X@0K4(($E;&D,:QM#A-H
MPB[V9!P/<*$."4A`!DRP@`CX8`Y0N`X0KG*=99"`!US1F1Z3!KDN'*T<TBH:
M>;0Q#@S&@XY5"$ZY8+A(XW4-"/:8X5\"P"`")J85"VF(YB8#A36\P0VB[.'U
M3JG#,\P!;7`00QIX<(*[@>02+Q+1)D(E&E%)(GVN+(F)D@@BBH%H*2=XD)/`
MT((),(%[$YA"&*XP!S?0(0AXJ,$%$F"!GIK@`1=P0`2,``8H-.EF-?N.!G]F
MSG8Z@RNI6A9Y+IBT+]$..O?_^`<^MKK(@NPEAOBT0D06LS49!JA-"A'H;5;`
MUL8<Y`E;H,,6UJ"&Z?$PE`>=P_0.*@8S0$$&A-/$X2PAHL+V;32;(,!&1+*X
M1WD(HXOSV^$X=0P9!$!FX?S!$4"@A3^@P``1N,`%JNF`!#R@IPLP0`$*`%HM
MI"$`X%2=5FCF'7'>D5O1^L8U9D>.5,U.%M[BTCWR%P^RJ"E5X++".^0AUH3D
M)5WL"FA#\%2V&/J'3T"JP@JDH`8Z_,`+:HC#=^6Z!CJ0@0YQV$)W=\C#+PA`
M"FL$P"F8D[A./%$CE+(O2!`1@A%XAE-4)`2,2L$(@X5@&,"L@AI`<($"/"`#
M"]"`_P4><%H3&(`#$:#P-#,PX0E74PW+FIEVI@*&;=)6@A+L$AC*@BWH]`QH
M8=H+5:K5C7;^(TW!L4MP`".81=XF:P-J16&PMA\&O,>Z#FF(XS9`A_*"M[QJ
M,*@:IAP'.IPAE#QLLAKF(``PG&`C=U.LQ!S!-QIT9"..N$2G-$2QT)3"B>]K
MB2=(L93F4,`/!KA`!!R@VM1>0,(+<(`)+!`!#AA`!0EP@`0,,&$'+.`&+=!-
MZY(5%64X\!E2:4!9O**=<!R22]$B!WJPX4=]P`>1_O"'/,JU0J@A)H9E-4@D
MA[/"LOK%>9#90!+B\(3RQL$+<8CRE+?PANX:M+Q/Z*X:?O^0A#>$`0F#2)BC
MY+N(4"CVHKU<R:=D@K=01#&)'5&L8I5C/D[@P0`H2$$*_KR`%*0V`AI0;00B
M8(`%+$`"#S#!3QG]@`*@X`M5V68#?K8,;G!E55M)%3-2!>-H<65:T'&J/L@R
M%W#%J0K&Y8=R@5!)<L'B('8!S&T29+5=F.SC$X'7"J@<[#5X80V_!O8:Z%K>
M-T`9O5,N=A+HP`0KK#',=N-(*,)'B<,A+!(A*$GA,F*(O8E()0AL":<THH8'
M9\`!*"A``@:M6D;S%-ZJM4`&,K#U!!C@[`\P@!&^V1T(MD`KT9D*=!+^5$2J
M)2#<ZE+M$$GQ?'2+:5!(%6#NX0__'A@97^OB&DX2$H^#Q/!D27:(@:!PARDG
MP0O,ABL=O/"$)#Q!KEOX01Q&3P<UP/4)=V"V#=10AB9XSMJ2JF+3X7>:V,BW
M$*'(T"(<1HBDIT3-2P3`#+0`@@5,.`(HP+<)5EO-?N>;M0;(0+^C60`+\-0$
M&D"#=F1F%7!F&H)`:SB6H$JS&EN+2^.`L3Z0\`[H[,4NRB5,`.X4`"2P*4ZZ
M<.&M"<@*@29F,7ZB&,"V!5OP>6NP!5[@>4_V!-_U!.)U!W<P!#:0!!/X`UMP
M!T50!&J0!3X7*FMV"*%11:3@"1U!6+@'`0?&,/(3"IY12YVR(@9#`CV0`Q?`
M`?>F`7^V_UH%L'PH0&\9X`0H8`)YP`?U9@!;UV_3M`!$@&+1H1WC\!U906*M
MXPQ@D#MN`2X>1!;>PC3ZX!<`$1`3EP\`H0\(\29X,AAVX1?YT"[UM`'W02.,
MH3DPM`&!]P-/D&QK@'H.Z`5\F`2>UV1WX'E/P'D0&(@_P&QW<(%!\`9E(`5F
M-@D4<"(>(E]WXR&:DAHHR!&P$1I^DRDT40B1`@!D@(/SQEH6$&%_9@`.8`$%
M$`$+4``+@`)^0`<HH`$:\(JG96\%@&].T&7>T0(E(!7'0@+5L!7,0!=I<0V#
MU'=B&`]G<C19I29'MG_2^#2P17@P%!A=HP2'@1"M8'*(T1_]D?\$>?AK5297
MY'AZ$OA=?NB'-O`#[YAZJ6<#@3@$07`'SF8%,L`1E!")EH")-,$)8.9+GU`I
MO>01CN)+CH(%R%>#KKA:CB8!*>``JU5OH>4'*%!-?Z8!]&8`U%0`#G!:&J`&
MW\1]U@%./&`5VX=BRP`6VT)JU/(>3,,>:T*&!J%<]_`T.?$F<Z$79T(/\11/
MSE,O2!9)AB$1!P%ZS=9=X/4&+P=SX!5ZB4B/APB/$6@#0P"!-D"/0X`#.Q`'
M2U`%9O8)-4$JEX`(%D6"[;,)!2-@:%F0BA4`9W`#;Z0%Z<8"6C!OJ_@`\V8`
M&J!HL>AH%!F2NQAVK&AO/>4'9O`.3S+_%<5R.B66DE6(#["#-$Z%3U60#[$`
M?_(@DX2'$/@B#X$!9`&@!,(CE%ECC?RD)V,E!2U'@*.W:P=(!Y]G>G>(>O1X
M!UNIFUG)E3^`@1-8!#L0!'20!?!%12&2*XA@126A40:3*<M1B6IF"`!0!4&@
M!3O@`W89`3&@!4'%D:\H`1&0`AH`DO.V9]*76JKUEVF76F)':%\P3-=!,RN5
M+$I@C-+25#;F=[M3>+ZU#SR0%W<23\^%+P2J7#<)77<B!>,0&/>B3YKS'Q/!
MAS"G!IQWAUM`CJ:'>7-U@4D@@?08HJE7!$8P!$2@`T:`@410!'9`!&K`!`%P
M0"$(*D77/B?U_YSM4VX1XPD`<`)G<(]TH`-_``(@,&]$>@$IT(,.P&X.E@$@
M29&[Z&`%8(,+H`+Z5@`<M@!!4`96H!U1<3-@X!6U11;1H3-?Q%MA<AY'HQY*
M$'B+E"YN4II/TR::4S5PDG@)$1"0EW(+(2^M<'E\.`1)0&4NMW/!%F5/L)4_
M((&Z^8Y;6018V0,]8(\W8`1!T`,ZT`/#^09F$``4@#<J6!-*Q$LXBC@D2`I_
M4PE-(`!S<`<[L`,V0`0XY0,[@`,@P`(U(`1OQ)&.IG7KZ9$_M0!(:`$FH`(/
M\(H[&`-D@`$[T0)/XJQ288S283/)<IFBYA80]X6X@4^-IUS-!0OX$O]);T)/
M6W.:"3$G5?,0$N%<-E"HM(F`&7J`28"`<>!Y6)F;ZV@#1E"B06`$1$`$0Z`#
M.A`$.Y"I)UJKQ&D&#/"I#U-%B\`)KB1@AT`J<Y81>5,J2C`&<B`&BYH#?.`#
M>_`'>G`$6N`#()`'/H!\[A9H:<=A.`B+!5`!K`AO)B`!'-9OK)@'2\`=)/!V
MTF!!3N(=%P1.9)(/Y=$.NK-^5*$>_-`[66-&1:DY)=00,&0N)I0?@L$`4>`%
ME1=Z=@AL?IBH\#B!8KN5]%@$_6H$/4`$EOJJ=G`#F*H#<'NI02"W.%`$G!H`
ME)(WB\"PA!"):@:Q'I)8BO`"`N`&OSD$-S#_!'Q0`R"@!T*0`T+@!'7P!!^;
M`A)PB[`8DDY:3:]H`?6&K*NH;V,'N@Y`!QC0`B[0`EV!+#TK09$C'5,!-%]A
M2+`#'>`B+501&'A10M#5)NOB-=8E%/6R2.7"$!+Q-'_B$'?`@(*(@!:(>O-J
M`^+EH?>:>D30`R1ZJ3>``SBU`T10!SA0!WUP`SM@!SJP`YJ:J6I@!E)P;9#0
M7V3&=*0J/TV'*Y[@$2'@`5A`!G%0!WAP9;H9!#A`!'F@!420ERR0`O7V9QS@
M``Z@`1*P6L;*9P\03?36JXAF8?:&`QYP%2W%?4TB)5IA'6J16R<,'A3'`ZLV
M$-)8#V6A)GA1$%S3_[OUHKQVL36&T:?M`AE0,*]KX(>_:0.A-XB'R("!:+:Z
MF8%86<!!<`,#Z[9]H`,XH`-U(+#GJ[Y5;`=5K`8"L`$T<#C6)C^H\%&.@I!9
M5"0=`043T`%F0#UA<`9;,*EOT`-XP,4AZP=VB0)Z]F?S5DUAUXI(^HH<T(KD
M:7Q'N``L(`88X`%+PB3*T`+48174X0]*-4A(<[OL\0__,$!64W\E)"MGE$E0
MXS@`%2#_4;6[X'G,Y@5T0)M>D*$3R)5;V9M52015[+UV4*)]@`,X<`/=*ZL]
M4`=U`,Q]D`>]7,5#4*M)P`0;4%^B,(+SM0E)I$2Y<@(S0`("T`$"<`5>P/\%
M`K`&.C`$;.`&>X`'18`#>)`'>(`"/<B**D!H*&`!5NJD!5">]B:L?%FE]\R7
M!5`#+N`!`@T#)9`=$G0LWS%,Y>1'VL`-<`$0SR`<SF40A%$75B,%=3$1]B!`
ML#`<4T.'@+$?!E$%AG@'+C>/6S"!%)B5ZZB5;$L$-M`#1F`'0<#%/<#%ZGP#
MQ7S%.P"W=3`$=O`'?4"^Q`R^:U`&*\!1^6L,6`0CD^`1(0(Z)U`4'G`%'2`%
M<U!L8E#'-H`&5)`$*,`!0F`'?=`#1<H"-K`#MZ@!^:9OMAA4L.AU4TJ1(KD`
M%Y`%,!#0+A#0)5`"J_LK3M)PU%`E<Z$M]``NZ<+_-*LF',!3KO)0%L$1&+!5
MKHCQ/`EB0P%PAS:0@,PV!`6(>KW9J%RIO4:`MD20Q3<MMSUP`T_L!S<0U*]=
M!T1P`W^``WOPMGUPS'M0OEN0!DGM"4L]/XNS%!T1*IAP8,(@`R_``S#@`6S`
M!D3P`V'@`68@!G&P!D1P`<27!W7P!WO@!TD0!#6H:$88S_9&8179;P6@`A6P
M?*EU!Q,@`&;0`0*]UZN+`3``1B2@%=*Q8LW`#%01<641#]T"T>\0?PRA#U7#
M.XO1IK.B3\V3(#\`B+N9AR`JVEE)@?1H!)DZSG=`!';PJD;@RS-=!SO`!SA@
MQWB@`[LMG+M=`WZ0J<,<_[[$V0'?$Q,H0<U+$2FF@"O'<&`A\`$T8&10T`%4
M(``ST`!TT`,$6P,X0-8L@`)%&@,KKKC$EY'2Y&&A:P#]%@&@JW6L*`$L\`4>
M(`#QW0%H[@($'3.K,\+;8$[;@DAG8C5=Q7Z1%`#/^,D,(&/OL!!BA2=/(Q%^
MLC5``@00>(&HUZA:296%N`/[J@,D6K!VL,N96@=[@`-]\`>0O@?%[-UXP`<K
M[MUVL--^T`=\H`-Y<`-^@`<W0`<V?@SYRT2>(0J^5-R<0`Q%LC&\P,8M$`9B
M8&5K4`1[$-U:H`5/#D<<``(YX+@]R&'UK%I.2DV'IF@JP&C8AP/@/`$3(-#;
M[/_&'=`"%F*F6H$L)::,#,W"J8:MAP<%<\YJH#E`^U39MK'*#-AYZY@$A0B!
M((JO%"BK=:NIP+R^K_VVFOJVOGP#?&`'";_B<EO3>H`'?K`'YYP';TL'+?`"
MH(-%N!(Q8FS<=*8)*P(Z(=`X,1H`96!>7(`&:-!L/8T'XJL#-1`!F2M4R->#
MC-93\$;/UO>**A`!9&<"$.8#9U`&2U`&:;`$`E`"^^,"/:OFF58L4S$T'S2&
M[?=;[P%=#;%Q=J&U&$=6]W$;FW25\#C$N:GACVH#13`$7?FJ0="O:WO:`;_,
M9/T')MX#?&#J.HT'>+`'-[#WOVSW.%`#=>`'..`#=J#_!W6P!B5`,`AS#)40
MB:50"@JY":00.L"4),K0`9LG!D]PVD?`!UVI`WJ0`WL@!"D`1Z(55!,,6@^Y
M?!<\P2:0`+L8`3:P!!%"!510!O/M`1VP[2Y0`@+MK*HS<'\$#4WCPB(4O#AI
M0E93-?WA$`7R&(JAFW;8O'Y8B+;,TFH[G/M:M\/)VG)[OG5PJ:-^Q>,+ZG;`
M]S>0Z7H@\;TLOGF?Z7CP!RCK!VJP^!FA"?I/ZVP)"`<'!(,0A`2((8HO2@Q6
M*V)G7$-&.%M4:'1O;SU_0DY:%RP1&@L)%18.I`4+!0\/"18/%A8%#CMN3%1F
M64Q,:1UF`A,E+2TN)2X8&&!(_V`-2$`\/$C32M?45E;545%-40'A4.)041L,
MX!OAX0PKX7<_-O)#/TGQ=_(V/T,V1D9#.XCTV[$#QPT[=F[H*()CSPT<.HS<
M.-C#2$(\#>TX[+-GCY\;>W#TF(CC3Y\^>7SD^*.FPPH*$`Y00"#H`$U!B&SB
MS(D`$04*(0Z=4!(`R08!7.:X^>*&#A&`=OR`J''!21\M$5!$:&6`PX4%*"0L
MB&"@EJL'&5+<<9-&UY@R:<R82>.AA(<)'29X<-&B`;0&78`(YB%8R30@37A<
M:]+$2A0K30)881"@2I4`&Z!<#B=EW;D9^&S<@1=:WN@[1880"4*I1Y$@/0@2
MC(TG(/^.(!KMX""BH\Z.'CJ"^\%3IXZ=/GCV(*QS@\_!J#?JZ/'SQT>-/71*
M?$`P@@"%FHAX$NAI*"<AG$!I$/APX@.C!CRRQ(ECIP8*(7]N_)'JA,\?$`""
M<`$'&I"BRE</%.#*`F45H`$(;9@Q!1=4+,&$,&:$(8``)93008<PD("!B&!0
MT\5AA%T#1!0JKBB%%2^6T\1F`5`VCCKK,,#`$*?]@,]I^,3#3Q"K&1%<0$3L
M`)L..Q2Q@W(X[*!#;!H]9$</5_81!`YX<(2''740Y]$-?M2Q!QY\\'%<'WKD
MD,<>;[BD4W@'0("`(3AUE],@WAU"0`B"4'""#`&L@`$22$S_0<<3T-U`1`]^
MH`!"'M?=@)4##XS%P58%R&*``0XX0$M7.BQ!1186CM%6&%2$`<P$L'JPUX@D
M]$4-$DT(IBL0*GY3!3B227$9`U!,9EF-&PR[@16BQ2-::$'>\<]32>YF1!"P
M]>`:'CJ`Z=!(9^+0AT;#Z=!'<57R8>:7'NU11Q\YZ#9=0VKNT<<?-=30`QT3
M?%!>G^'Y=(@@$'QGGI]_A@#4"2=0L$(#+2PQAA?,)>2$'UH(,<0>?&B!@BJL
MB+6`!0G`HH(!8CEP<A]8E+&$A4Q<D<444TB<QAC##.-!!S`LXS,&2N0Z336'
MK0AC$U)T5FR--5ZFS@SGJ#.:/D^,_\9//E:SUL.C#$$$G$&[/3D2'S@@U&V:
M]HK9@T>^C6L''\B%U)$>=5`W;G(&\8'''WCD@<,;+;Q@$P4T_(0>!03$A+A-
M-,7DTP%!`14"#2>$(,,*&[1`PA=DH*'&#WCH48,6`#J1`@LZZ"%R*1HXH*`#
MK3R`0BL)L*!&&5S(3,7N3"PQ11F^R#7!,'@9LXQ?S$2#HC1!YQJ%9L*.(P44
MPH9S#F8!8.VC:/(D80,1_@P1Q)1!%#3E#C<$5+Z41.#A*'`/W?"UN_8>=Y"Z
M]Q)77`UOJQM5<C6`6]]N<*Z^[>`,'I#!"&@"L)[0Z3L_000#_V0PF22"!B$X
MP0P>%@PRE/\`"VO`P1$`A((<A(ET6L'4`PR@(%=(P`"EH(4).)"'-3"!#&>8
M@QRP,#.7^8X*91"&`,K0`5FU``,-($$7&O`,P"AF,(JYQF/`884J2($R5EA'
MH6;`O:L-X8NH*<(=6#.$&PPA-C=(#1'D%P2&/$1;"[$#00RB+??Q80\[^)(.
MN&0</8QK.LCQ0U1"DAP_^*=,98K.1_[`AQZ\@00G&$%Y`@4Y/@4%)X*XB4V\
MTS"!_410'V@"$J*0!0%T``M>2$*9:&.Z&.2!!:YS0"E440H6EH(5!:C!',YP
M!C2@P0UPV.$4>C$%*N0,+AWH@``TUS,7@*$+2.A",XJFJR9`H1S_F\&B%0,P
M@P"<Q@OY$,T0BI`:(]C@!O,8`@X@0@1I;4D'6ZH#'[JUI2@A9")R)$ZW=M`'
M==5&(SC@7[?T<(,`QH]C^BE.#MBTAQP<80\^L,,9.L```HR`3X$ZCT^"HE&9
M#$)/"E/$Y-+S@A=`30D8,`,)T!`;/>QM#T>(@8!&L0!5H"`#!F"0"E3P``=P
M8`$00L,;VJ")-XA!##&C`LU^EX4P2,@,.*M+"SRDN1)!$PF&`4(T$..-Z641
M1RN(@A2"9`,>;0\>/A+?]Y*D)(+TIF+:,A)!&`(_@_0!2U?*`TC\UE(\^&$E
M.^!#?R:R!QU0!R%Z^,-T]+`V/_8!!SY0_U.9[M`&#[S`HM[!"4<)(=+'85(F
M"/A):`N'.$6<H*0/DPL=SD`$=^G+!ZM!04Z](H2O%(`L*DB`!%PG`1R<00V\
MW`09VD"%*_AN9ADJ)A/"D(4RC$&9>X&!"XH(`QXD3QH\2`RNI,`8'EBQ"Y+!
M!X^FUL7;E-$&!"'2&HM@A!W8H'QU$(E(;O"E+]%+!^JZ`4%U0%\=X`$/K?T#
M0*WD!XXDM@[[Z<@?W&5"(Z#)#V=*K!VZ5`,CL`$#EQW$)FL26CIM%F"$4$\B
M)J<(H,B`6&`H`1.L]00]_""5/D!!#'S@!*U\Q0$H7$"!$G2$X&[B#7/0!!G$
M,(7>*7689@!>&/^XD(:XC"&Z'FJ`=)&8*U[ERC#>&$<4JO`CTXRS->0$7QH!
ML@,C%(&_8&+2VB`2!#RB+SKB*NP.[!"<Y=AK(MU"S@[RP#>]]:$YAG37N^Y%
MA'XF)(\:Z8%?34*I&@QA"5$X`>1^HC"#4?IQ-T$<XGP204J7N#T!J)4`2""7
M*YCA!WK`P2LYX%,'L"`&-2A05@KDTPC8X`U>(.H;>MF&-[!!#'"8`QHLA`4F
MY$ZIRQ5`&-YBAA+`8*K'@$$#I+%5(`!&,%$`0CCOP2-_E#6-16C?.,L7[B`8
M0<RM[4&4!"U';.G`A`GU07"B<Z8_K+.A.>B6//O@!WKY]5UGPHB9]//_I#X(
M00AX"((>R*8?'V!'`#,@K05SLNF$!05/@?K.G3XY8L2IAU`P,$<`FC"!-"@*
M!R!H'0JHP@(0R')V#OA8`4#PAC6LH1Y%C0,=A"T&,L#A"UA0*A>6T-QANFH"
M9MB%$4E0`A+`YQE@&-&)IF&:._"(O6;^S0U@4[X[&.0WCYT-'W!CIC2-CPBK
MV6,=ND4<+CV6O_[!5Q["E)S[_7?".N@(0H3@ASRP:3G($=-)ZN`$'^1!34?X
M0WZ^T`$,;("C08&\>0`U"!K<*8,SH5.@1+HXALV`Z5UP`1;F\`,1:H$.`M9`
M@3IE@MM^B@-$H,,6MA"')*CA#71H0Z_;,(==_W?N"D-?`O"$'P8FY$4`&7JR
M"^KB@A"U``8A0M0\\D$)\(UQ-03AS3BE%#_C!!8CR3$.1G9@R"(0MB1@PML\
ML?0;D<B+#^37PYO@QK$_^Y5NAO=##?+PWY#PK0=]4`.195C[H04JL0=9T`4S
M4$&(TV&#$$$R00.4%#F:-C@DIC`:Y`[/AP$MX`$N@P8@00=TP`(70!8.(BHO
M9`%]L`E&`%QSH`9K0`=>X`5#I0ER@`9L@`584#.^4VQ<@"II0`43$$3",#QV
M40Q\T0"J\46JL37G%ALVX(2Q$1OE`QP)X1Q=@CZO(4=YAQ'NHA%A8ASF@C=X
M14`[H`>]84BA(W]ZT/^&^_$V:,(Q-5!@?\!G^7(2BH=?'*-7=<,'-3!"3D`$
M96`%,D`(G18PF8=1WO$=D!,YG#92WD$#E\,#3(<$'A`&6*`&7@`'ZJ0%*9`"
M&F`+*^0Z?[`&3[`%/Z`&JJ@)=*`&N=>*PO4%:#!TNI`%,S,S:?`ROS,7<F$&
M>N$!T'<:`O$/_/`;/=!&E>`D;S1G:V<FMT%`-A`E\A4E:_-?.-!(]W(<=?!>
M[M,)`=0E_#4<?R!/"?8V?D<N")9J?1!9BH<'-<!(#A%^7>('/L!(/B`$HU,#
M:(`!#*`>/5%BFC8>G-8G?/(GYN%IGX1!,B`#+[`"3>`"+B``:_!?*.`$)!C_
M<QJ0`JH0`RA0!&_P!#U@`UOP!+EG<ZZH!KWFBFT`!W#`!CF(!5?`0UCP,J:R
M!+3(*FFP(27`7N!SC$D2'&RE3G,T9V7S$63"7W5`!!#F/@5!2,,Q85QRC7`3
M)NF#$.IV$FJ2'P_13VZ3)AQ!'7X0:'RP<&.I-^WH!V1I)5W"!]2Q8&P)`EJ@
M!T'P!2WP`3!A")=$`"(FD(E009Q%:9)#`QA46G]B4B30`6@P!Q23)/=X!)X(
M5!K``37`!4"`!>VT!2+I!6O@!:[(BF^@BFUP!KO&DFSP<U@`="]3?!:B5&,@
M##;`7K!1),`1&^LD$GMT$-&!)<KQ7SFP=;?1!U*2_QQNHQO.<4=T)C?<HAM*
M\B[F\B8=H3=U,QUCN3<0)G]]!V'ZIUAKPA'VPC?$$14NY8=MF`<8,Q4V0`4-
M\`&6IS@&^8""H#"3)Q-`03B"B4$/:%HR8&TB4@("L`1L()IY$`-Z\`F%]0-T
M@`0O@`%TL`-/H`8ZEP1/,(,B*(*XEWL_MGN]Q@9?<`7+Q04SF06M204"<34,
ML7;:,CX/L0/,L4YNDS;(41SCXU_%45\FX1_N8T+*H3?Z<Q"]<3]\-H\<PTAC
MN7`+AI4G\8XUD`/^T4]THVB)17\.P0?DZ2Z*EP/7H7\^$%$V@`8D(`,T```7
M%4'A47'C\1/J$5(EQE$[H?\>H,8`+[`!'L`%G'D%3_`#<9`&;8`"C80&&_`!
M9B`/,Z@&]C![6Z")<:"*JJAS;]`4;K![I/E[7+!<87`M2](#XY0DCK)'1L(D
M,PHF9O(N=8`;:;)']K(VS!&6Y^(N:S2.ZS1^;&0$?DA_9>)7<V@F?`8W)V%(
M0G`O/A"6$=5/:/('AJ4''N$F!F9X[L,FTZ%X;"($6L`'10`'9A``F`5BB%,P
MGV0X\QF)FS9Q?<(PZQ$&'1`%I$8&7P`'M?(&=\`'1A`'VM$$=&!&26`/9?4#
M6^`%3Y`$6["91-6*=#!<HDD&P^4&;,"AIL($23!&$K%UX:8M"M%>Z@:`_W4N
M23+_+CC`'&JREA=[+G_&)4P26'G`?_948/*S!_M'-N(B+B=Q+@B!`SEPG8GU
MCAR36'Q3'4>0+V1R1_N'+VE2C\S!-]3!!UDJ?_*D!\^:!T8P!SQ```!@")FG
M")^EE^DQGPKCK00I$S/0`"<``!2075:``3)P`@'0`&Z0E#9`!CRP`6$0$?HP
M&EY@I[5'DKBW!:'9!L#E!C[6!C@$!Q:R!-X6!#:@`TG"'+S1$`JAHE>B&^>R
M3D8P'72F-\IQ)AQCC?W4`]<1)GYX+O35$7D@!'!C$E]X1V?RCBB1!]-!GKJ*
MNG5S,2';=RNA7\*96`5&GHF'+RLA.CF@8&%)'4>P`W2P_P100`$`P$",&##W
M.3E_HAX>)4'H00`GP`1G4`4'``#.&Y@,T``8\`8ZL`5+L`$-\"CV`"0S"*$.
M2@<Z9[Z;<`;_.EQS,`=D@`5RL`1-$AMH-QM$@`-&L@?WJP/CB`>Q$1SPE'#Z
M53<$?'@=(1V@6X>%%03T-1W1T3<"!A+,^B;-8:4U\`GO(K3^<7AZD*5AR7_)
MT1'ZD@,Y4#8U()W\I@6'M[O]Q);N"#=2F@,^4`<D[#=K(`"/)TEZV9<*@Y=B
M2CB;UA,6M#@TX`$+(0`O`*:<]P*-D04_T"TDL`%E2P]3DZ\O]@,&VID_I@EG
MP))N<`5B<)KRJQM)<&Z5P"3I\_\/\+0'3@*'7/)?^O(N$W82J98<8VDF$^8N
M.!"7<1.LOLDM>X!>9:-X?,81]^('%\.6?."L*/$)6A!`TP%AQT%0;*EJ-1"`
MZB(=1R!(?7`$<&,'B;4W4DK(>F.`AD0$<!`%%-`=$DA:CEBUDP,>.C$"%Y43
M-/`&-:`#<>`"3#L""Z,.4&`&24!S/-`"@3LU0S"O/E*G:["O(DB29`":`GL%
M<\`%4Z`/<D5/XO,U!K%V^(MF!782_N4N4^D^?G`$#M<E:#(='%,'O>I_NVHE
M>S".'$%`;9<0T>'..R!@^\<1=6@<_"?#1U!X"/=N)VRZ$$9`(=M/.2`$>C!A
M>>`$<\C_EJ&:G4<P=RE!.H4W!&6P'0`SGQA4GQ`@F`Q$$XO#.(A0!EI")%3P
M`0`PO(L8`E"P!`O@!V\``U<0D@F;&O!0IZ=XBK=75.I;J&]P!;((/CZB;B6Z
M=KJ!)>#R7Z'#'/<S+H-7)L5Q$O:B)N]"?O$5'9IK'`6V!^1Y):::6!W<AM*Y
M4!QQ!$>0`UUR<-7A`RA18'QP!(O%?]11CQYQSM51!TF:6)P;M$*``R[U7Q>]
M8&BI!7@``G[0!AC022`M.9R'"`43$^!Q"!#``&K0!W56!&D@`V":62&P`B,X
MF6D0!SB`5D.0KPU:J*W8F:I8H78[!U>@;T#9)`4!-F2C+7@G_T=A$BY[(V!G
M,B[4X4?'$9:>ZP?X=4<P/,]@TA!EPV?%H7=V7*7@"3=,DB_"73<IT887PX9Y
M8-=L*=9.P-A]YP2,5(?U>"_^$:O[X03B<@0'YT=J[0-',)<88)>?=(&1HV&#
M\(\;!A,'P`/G]!1D\@,"4(A\TAYBL`=)(`!30`E%P#VA@8I/$(->('MR&P>B
M^0;?,R7`03YS1A#&@<=^G1!T1AQR/;-\\++WPB4@X=:")!UWY-5Z0P0(H9W!
MX1$#JECX:-8"YKE\0`2++`2FZP1&+M>+9B]&6Q)A(@16"@)C&8"#)7?J8D@#
M*A5^=\)Q/2YSLW"&5P?.BG!TX`$!\/\"E:8($G>M'D:\B1,"9N`%K"$MH;,&
M+5"(B;,>+F`#:X"GJU$$]V!U\&#A:Q#4<8!KKLC`=*8M!L$DN$&JQ6'5@W;)
MN(I@R-$<Q)H'#>TW!58'_,<QN7M'?T='!/01Q'''0?`N?H`E"[8?\M8WFLYG
M+XN/[X@O.I"DGW`Q=?,'FWS)^9(#;7C!Z#R'#FT'A^=0U0''-7"-XQB6?_@'
MC^PQ1_`#82`%,L!1AB.!?E*\AP`H`/`"G!`$4T,$`G8&"!H""```)S`!2>!S
MU6=UW.,])'ES-A#4(K@%_%4$5*CO7&('2X(0>(,<C!0Z_/8';DV>#F=(*"&E
M!%4?\^S/9*/_&TR)8`O6-U^B$`9_$0\M?UTRH/`"8>1XP6$IM$8;0&]B<&[2
M4'RF!7N@!8CLT*B+Y09/8WXHT5JP$D.+!T*@$2M!ZZ9[!"S``CEP!V:P`7@>
M,)KW'7K")UP[`='(A(]">#B`!5(@.$V;!L)V!_XK1O:J#Z(QJ&^[!;!(J1+!
M7[+Q$')&G`:!$.?"EOWTCGZD?_.\8`1TPGMC6']V''=TJOK4$3?PLL`.-TFJ
M6*@['?5(K(0M.N\8M'^HZ1[\6!<A8-6!C[%*N@'8ABJA$M1!*?*W?RL1LL#>
MAF&96$ZPT!?L`Z2C!V1``FANV17(O"%@)Y4$`0#``&_`'$HR)94@_W_\$@#"
M*P,MT`%70$X\HCUU^@,^G01>$`?G)B5?PU\*43<4H2X"M";C_1%,"E%L^>EO
MK7@BO&"J+KIW)!(=H7"8GR;Y0JQL8Z,(UC>(_+)MJ<)&SI;C:"[[(7^,](Y^
M]YQ>"0AY>4<^1SE\>GEZ?WIX/GY]?7A^?T='=3Z(=7Z+=7TY-7D@AC]?&"\$
M(P@$!!0'%*ZL$`<0!!``,@(]>7@X=40]03UU>G9L,!^W`')%04-%=]$V/S8V
M=TE>7DD_/40Z.\$Z-SV]=4:30;U\?'M]?GSN?7]_>_"*B8Q">7YX\(>)B_KL
MP8/'CCL\-R0)\S-P$K\^?/#4L4.IGI\:`__A\?F3I\:C1UH(*?HC1!\C=G]\
M0.33L8:\17E\Y,AAJ,8?3G[\Y-F3\V*-BZ`VU@BUAZ.>H4)`L,CQXPH)&1!N
M(0A!X,`!`JL06#T`8`2#,SOMW,"Q@\@-(SW<)9'C(LJ;($:(#!FRS<:0:S]^
M;+&Q9@M:<#N$]2"K0X<=.VEO\$FX"8^>@7_JS/N#)T^DG``I^]EDL1X]/'M"
M(^QSH\Z>B:(/>RHJ<-).3GOR_.&3\T@-4#>2J/D11`L+FYQ"46('2G;,&D)^
M)O_CQ$>H13F(^=CG)X>>/EK\"-&CK\:1CCI=6D>44DN>-R4\5*$`H%8K5Q2T
M5AT!($2)'3YN%-[_P;\.64]UX*%#$'#)-<0T-B21A#4_/.$%-T;H8,0-%.*`
MV(#ZX>"'.*1Y`I$>#"%53R,<*3+43WC4H$<FDLGFR75UW!!:'7P8-!$\DT#$
M$41X5/*'8C'--D@>3N@11!X%%!!!$')X`8(^_Y#$R7*,:`'=$?JLJ*)MR>61
M@TQZ',*233XPI\5L9:9$"2?K[(&#)#D(D\09,+S0W@@4L%+55:Y8M0(=->#0
M@PYF]3"$$4$0`4X0.]A01!$[W&%-@M%0H^`/A0VA'V`ZX,"(2SK40:,.D4C4
M1R*;N<,3'T(PPHDD?)Q81PXX2:(';9"P4]EU%-40T4V6R29/'GSH$$IE_['>
MHU,=$HB@P``#5%"'!V?DX(0=?_2Q$Y;TV)1MF$[D@$<?H2!'GG<^K)@2=X((
M,9-E6JCH!`A\'%+##N/BL4-L>SR68@]Q9-$$>ZKH2<M55IT@P&/"&&$''V7I
M,)@P9\UEQ!T'WO%#I94.-DX/@^%@H8!UZ+#'#O1$$HEJ?:1KT">G/B99MMH>
M$MT\M`'+R$TX-!(HB)[YZHYI>U#4"[D=A6:=BGA<\*P"(H@0+1HDS&&#%D^"
M`(*G7K(D!#S?020$/SD4M:N8'MWPAXK$>G?J17X<%E-'=H36ASYL\F+')G;<
M08<9&]`'P%6L$#X"`0&<X40?:)$5C,@#]F#$H_^2%D%$$=1,(ZD-/>Q0V`U^
M!/&P'9X3X4X>AN7AB4Z07)8M'K2N(X@?/GRM>DS:O73$'JV.*]"/$QV&0T2@
M@68:;35[0JOJV3("@@4#*%#!!19`W4,:+KR10`(5**"`!:36OB((/M0CA!;6
M'7&4$-CM=%N6AB3GT=KF=>W'$3?\M`^-INFP"$>TT<$?)+:#']!A#&"@`0"Z
MLHJJ5(4&'2`6YGX0%[38(`B<&X*![D"YS3%H4)K"@8QD5)1UR.@P-]B!'8A5
MKQS\(0B2$$+YQ!6923!"#Z#K`R9RD@.#O(8A>M""'1JQ$U[XQT(I:Y4>KE.#
MYMQ@B'\8HA^*X(,(1.__:0I(P!RR,`$N:*![WA.!`QZFG8Z`P#KG"V*LT'<$
M5B4B7$)H3@[Z<`2MC<T/(-!"4D#`")4@HH=U&`P>V$>)1O###ST82\/(\)0%
M%DY/'VA#'7;PJ&<487(*JH8&%X2H26DN47A`2Z<$%:H^V,%"^"&&;/8FEEDY
M9Q(2.8I'B"7`6!V!$NXXD6-<6#:#!#$V3GA'^33DPCS<@%CLVP0O_G`(;1FA
M?`:`%K04H(4HC$$7%8B>":17@1ND*10KW,X-;KG$4-CF;C2A34=$<1%FL@`$
M*G()=UA0N^G8A"9%LH-$RD>LNN&!"*$!V1-[\(8N(&!P"#C<+*R@ACZ0A8,)
M_[(#$205C2(<*`D6I<9<3BFR&Z0#'#':`4.*5L."0&*)M_)%C=3'$."MC2<"
M\L=TXJ8//GQG.J=:6VDJ4P]VZ*17^-O;.XQ3MAL,X0)Z$$`=3%`!$]P`""0(
MPP0F\(`!Z"`->5!`!+P@E.2<B1#A2I&48.<$0JRMC7J`YW3J"`(G*&(/M0O4
M:FBWAY_4XU0YZ`$?1!B;RJC0'3<HPJ#^\(,)0*5P!SA<&A1EN6<D(1IW"$*#
M.#:$'WA!#7?H@1T,LP-)2&*SA=&GVHZYCJ%1Q#FW$A=X]"&;$@&P&#QI6;_6
M(2I,M,,.Z:+,34"DB(>5;7:TNTX[]I!7%-AA#$AH0?\:8``$#'1``-!U@`CL
M(`<0#$`-_3I$<N!JG1S<8#M'Z$-SL)0#09C'"2HRSTQ4%,>D?(V[9YS'V&ZU
MF';40&V0($="XH8OTU`(IE]8`2WZ!(`J;,$.1J"D-1[U@VUH[`D:P]B"^K`#
M4>$`4CW80VE,V0=QI&4QDJ'$'"6"LW?TY&&$<`Q+%*&('B$B#]@ZW6DBPP=1
M&5-;[D"$#^P0BC,I@D6/D(<`BB"`%@0`"A@H00LPD(8O&$$$%7C`-G&`@3<\
MR7R@Z!<A"K&'YDRG(WHPQ)GRR`=XSK*)NYNE;(A[*V;6.!'UP$'1;@":`5HH
M(C'"@80BFXX^#`$+`3B!50#_0``NP,4(W/@!YB3UA"08(6,-3D(0;N"-)^*@
M(`71L(9V4*$\:*$72\163)P@UC`#A8G5(2[JZH"1;)5W(CVKS,-"(9N<_"0G
M0MA===Q*JQ<Y0@@HF"H;!!"`%71!`%?P0!ON8(<%%"`!!7A#!TKP!BWH<2A+
M+),.1'$;6=:DC;23(7=R((1V:*$H3D`O)V`B%D+0Z#"'080D_%!A(@3!/T\$
MC8;K5A;+$:%'1B!#"ZIP`@20`62"G2A>\M)@2V%L,'UX'!%P8#I/J,T@AS!(
M:6*;\9MLI*Y/)%:9<-T(/A1I'MEFA!/^0([JZ'8>TT')V/9@I7:,JP[&T6&*
MG."!_Q9X8`(8F,`7S-"!-Z!A`DV^0AB8(``/F'R(1T#O^-K*3)GDP5UE1==W
MTNV#>&G!![5;#ES5MX]*W-)=M_D.0NHQ"3P#M!N#XD^&T6(H0L7E!N4-PAN>
M4(1M0,-127#0%@+_@\I6H\*A*DB-?Q&$;["2(?P@1H<K\XZ!5`<1L]1)(MQ%
M&7@([2:225<B:K>1-[7I;1WYQ$QXRA-*S,8Q4FI`L:,P@1:T(`0T.($46D""
M#GA@#%3P0UD380CUW<;3)<%:'+]N[3RV-X_-88&[>F<)+^6D$'$[E4TDX:KK
M_$%D+&&$OB0VH;$``V0@(]"A"W,Y:&SLL9!M<#4>NR!%DO^."/[QI]'T8S+/
M=L87[8!R/.$1\I`MI<5,0M`/&]%2S703G=</D0$KPO(A\\8.H0`ZB'!BL]$"
M4``%/``%4H`&(*,&;,`%9N`!6_`D9+)YUM(JLB$3,P$*Y$5N.1`2UN8<954D
MSF$)P71U/Z0Z!S@N'`$:D9`M[Z!"HK)7G#8Q'X5^._`,_&$Y@1%A&!-_UJ`Q
M"B)"=B`,)6,8.H1"$^$'%+(RQ$`/C+`/2W03MH(9$:@B2U2#CR`;:?@V@[0B
M>A!BF[$.2\00Y((/8P()O881-;@#?$<$-=!6M@%/(0$"L?&&7B(_MK$M-3`1
MQN$1)Q),*L),^V`)G'!3X>4NZ\;_-IWG*Y/`$WM#&PC161$!#Z0A,0."%HTG
M.?PA#(DR.9=D!'6A(`OW6%O@#18R$?HA6B)C&ODB(ZWQ,-3Q&!(X$,122$>!
M$S\Q#U[B*V5B'?,`"NG#2SH!'J)V%/-P.G*X@!!A1B'Q-:<2$ZU7$71DB>+S
MB+;A5F%W%-:")?947@!4';D&(K1CB8:P#^4U4R96-Q!A,CH0-P%"C``B*!1G
M.46``XDRBXQ"!'$!%Y>T,0T7#?2768V'$)=6!XER;P*"`S"V-S'R#JZ18YY`
MC45!*]<1*\+%.RZW#JUS$F/#!YKU$YEX0_+T$W<CC>-8(J%`*R\U2.RS$67S
M&$!X'=7(_VM>8@FT4A)8(D->1A.W097DUC8^D'768H?/\0FW00G[@&=O8B%T
M-BX.:2$Z%".G!`[M9U%#P"B7M`.(0@2*ICG3H"#T5WB#\0T7-@S\``]&F$+\
M4XK'HP>DDH&(,"ZQ,13W,T>L1B,](C,VI#HE1$/SAC.*R1'9P@LC=8T#V")7
M%Q':$@J,`%='P0=?5C.[Y$(D@36>E@/01X-Z5$="P`)8\B180@@Z$2^_93LU
MN8TW\1"FL3;C:!I;J$$.]2:>`QBS.#G/$%E%8`,)9I%YL0T0-@V%YY`2@W]C
M432(T8JUA"]X4`1J@V^+$"L*N`X/@PB/D6V'0`^+T%("<0,@8O]*L",0)-4U
MJ%DJ)@()L'2>WW42!G$$%K(=0\5,?I`=+B>&J(E&/A"9'I$N7N($R4%NWV$E
MVX$<VY%K966!G]8RZB,C+J8(+<,\XZ(#F,8?^R)"-08ZOK`WER.7SG`@FO,H
MEK,@U<`QU,`-HC,8]1`,>R`.,!0C,-8/%M</IE</%38)-<!CD1`1=843K<*8
MM_(_^]`/-O1;;<<)08%2A^$MREA\VZ$9G$`/[5!>_?03W(%20[$V%X$^[+(B
MY;4=-(@E%&IR)Q(92W0$\1(9*K$\PY(3">%9\/DFJO(PH-%;(@0.6U@6C$(@
MG<*0"G8H1$`$V)FCU+`&O"%1>\,HPR#_0I!@-U`T$+SR"901*HD$8]BF0SHQ
M1S[#$IE`'NU$:K-R!)0!(BX4(#<Q1[3#DK%Q#V=8.XOI$9!`K&N4+65"7-41
M$DZ`/C?T!^2C!7141Y;`'6G4=95`H6?4',TA).16.^)2+U]3/J;!$#+B!\-S
MGBF9+1&S`Q17;^0@,H=R011G`X0B69B$H](0#0]B&`,B#-_@.7L@.I?6"QHF
M(XC`#GO5`X%B+:/3DK-QAV/19OPP2#6B*C@`;"_A&3N7'#46&WQH'HAZ%`^*
M&NER,TO4,N=I<B5!$VGXH*<2=;<B7E$73-QAB462:Y\0+M(7=>0#@W'T)%87
M-K)Q&Z!WI77#_WZ'002;=4H!<FD2@P-#(#+#T#EW5P>.5GAW00T.TFB2LC$V
MT!^)I"^!,2CFL"&;,`S?MQIZ1HI1Y#_S\"9+5!G6<B;DX@EC<W4UH&\7&S=,
MTXR]`#OYD1`^H`-0BDNH>74T5AU',43;AYK9PC2Y-E]>PA%8<FZ\Z0321P\T
M80E8@S[,AWVT1B2/41W(`0JS05RTLAFA<C](ZI$\A@?W5C2GH4/\<3**I`."
M901&8*]$\`>8DP1WL079L`5/4`UTX`6!(3*,X@OCLEEYD!:DLAJO9Q#SD!,M
MHT/7.XD7\4\;X0XIL1/.@0A?0T/K4$PY4Y48D2*<4`=C6J4>)P^VVO]FHZ<C
M<U0FIG1\`B&G*1$N9](J9.<1?#J;1ML<HC`3OM%6UI:#Y\8[O.41J26/I;4A
MI7&';W(:#V,#&K:<$Z=9OX`H<6$6=E!X97&\-O`$3[`%<?`$#1*VG:-"*10J
M%&(0!K$.!%$T!"$/\E!"EG<=VG(3BTD)CI`SBQ`F-;(1RB@$/<,1L:J&+J1#
MZ8)CVG&>8&<(]J"9/;*].P$0AS`(+@0EH'`^->@EU@:;+':(1)*5-U4#7Y<N
MN7:(-E$2;VQ\MV89!0L/B4`:_4(RH!$ZGN,?NJMG$T=QXE`';RDA"V8-@;<-
M:K#"7A`$%,>\=#9Q.9%IG0(1"`LZLY&$IO3_"%IVA]J"2]@""9S@*=JK)CP1
M$"L$#\&DK(-$)&6C(\%$$JQY3#,!KLDA$)Y7@*T%=BO"I[12'#7HOX]0MVP<
M3%C"QI;(K.FF#U9"K6DV'=<A(V+"$0:)&N*0$&/A"Q:W`WOU,,"`&(/2*7+Y
M#&_I#!B4(%NP,=IP!Q[UBIW5$*34I(@*&IT26Z("":QFPZD<"C@GK8A05P3!
M0KYB8RP!.R-!3B"B-OKXI(<`&2"";<L3)@;A$.E"K$M#%+J)IF]:@]]JJ\V*
M7B7A`Z-0@WQ*TK;Q$UWW)=8Q.\T*5U$T%"/R6:):-*8Q//Z$0^+@.>B*&)#<
MM'))*,U0%I<C#4FP_Q<_L,(@XXI&-00(!L,]P`]N<FGR%B-,2AP[$$11!)I%
M4PBQ(GRN1QWOR0BF-!*\($O=MD+7NS9K(PAD3;<TL@B-N(`%43:2`2+2&AH=
MD2YP]36WX1R]>H@Y:X.C!@)$,B_ATIC;(8]/HH^T<Q-[$X'MH&<)@2^DD4+Z
MDA`2X28Y'""OF&!%,"`'`A<Y^F!Z47B0,FEE&2,G@V^:Q8?XJ;U+M!@^H"%T
MZXTX)@\U)@38LC2ZI7DZ5%X@,CQE0ZK!810QMS0GFUN_A9JM$A&V9AD*VS8W
M\94GXD(7L2)9.9N%,!-Z0*%5+`K<D6[9.A3ADD?I<G*]<T_#V0LZX`2;@/^?
MW/Q$1+!7!=$YH=)XI]0-X-`-=_!H0]`#T8F%#K(Q$FEOBA(1#G-$DD`JQ8/!
M6%J[QM0J)M,1\"G<.<,+V95:&T$;>>P.=^@JF]$/T]A#=&I//.DK-/%E91(K
M+/D^W2%RB5T=5+G2%.H=S/1UY^,K@@#,1&()9P7>`XPU67EK3YHL-@&8#T-G
M;`(/H1&D_D$:I\27G$869$'4:%&ICQ:=<_&U',0-`2X7M#@.G0(Q&E8,H",J
MJ@$)KI(N.5-(@H!2+<,.97=(D[&_-^$N$'$;]2`<O-/C-W0<MY&XL2H/W28<
M=/0(/Y$L\FBT,:%'-(A>5Q<2EVL)(XT^Z483Z&/_TA0J0WK$'=(XOY(!$7MN
M>O0)8Q!ADMI<&4#L)IUSY3@0%P-R.?.W.11U!_9V*+7(NYZS68S2"\[K41;7
MNJ"#KBVY"/,3*]*,@/]C"$6!4KR`OVX=)DS<*I.Q);'B+G$^"-#AF%=W'=TE
M0^P#=C=D=4&"'.%2",RG#X00QE^2@V6U9665?"6A(E=)">:A(CUQ%/\#>S`B
M9Y[E"Y$P,@0Q#IX:#KJKNY7U#)/C09/R#-5@.1^)X-]@!!07#"CI2VNV#T5#
M*_V0$YM\*@D;*T)C$*VG0PG;9HN.5^\0L5:BOI_RUTC)TN6F',12W6]8)DI$
M:U\&LF!'$U@'](8@W-_A_U7I-@JY9AXE,M`JWEW,<RLVX8=238RG=*(SLE<V
M#<F"0A>Z&PS`4!9W`5G1D#'1:1<,7\X6XHHQ0HN((2.1@:Z>XO9W1@F*$>+2
M:!WZ:!X2`9;%@",QYQ/.'76[L@[5;4Y]1#LB\3]W'PEGM`^1<)3O4$>'\'76
M<A$GYU;Q`P+W0PCTV'R0'J&$H+I>8QU6$AT_X01%LQ-I/A"&\3`:%B.,`\FA
M_42$\@.4!#(@W.62$O9>3@WQ]]\8P[N3XZ[`P"@>QA\6\J(W\6^WXB8KY%V-
M0"Z@46.Z31'/WB\T<A'UDA.AD1D<SPX?<4LVP<;J`P^<@%YE`PI'P4)V4*W"
M+?_'+3$4+/%5YJ%>UH:/ZZ\%1;(\7@4((#Y_6GE'.79^>']\>T=_-7MZ>WT^
M=7Q\?7PYFGN2DWU!.W8[HD1&/39W07=VIT9W1$&I1*HV/T-;JG<VMKT_O'?`
MO#9&.CL[.#LW.$0[QWEV/9<X>'LW=GLZ.'^(>'I^=GE_/I,^-7_1?YY">7E[
M=GIZ=GC1]'Z/1W[D>7QZ0G_^]-E30X\/@GS^Z,E1`UV.''IJ^`#(!Z"A''_P
M"-%2(T]'/X7X.*DAY&$.)TY\,-1RY%".(T(V@B"7PX\0'TYN&NS8KUPD/C7P
MU/!SXP\.>GS\Z`"*ITXU'#WLU.DQZP;5(3N,_.A!9(C_#2)%AMQ),O:'C35/
MO#S9$N=)+V)>Q0KK522(C1X[AAC;0:2'#CLW]N"UT\<I-FYZEO;!X>>H'W29
M(GG\0P]/'X'EA-;HXP?C8\X)C_3)X:/>D85Y_.01HEI>OQP@;JX3(@EC'T,W
MCJ@LU!"C%GD0^1S1P@<$B)Q:C&N)J=+'1-W^M#P?[F>/S737P/71L0<')3ST
M;@0IBB?(T6W*I#TS8J.(G;!>>ZEZ,K:7%SIQ?KA-\N3'#[+!W"'@'4,4<8<.
M03ASPS+/[%!77<CHP!U?..C00QY$)*;##77<@`I@=FQCC5-X^.'7'N/DH<=J
MGOCA0W6I]3&/'DYH48</?7#D_]%-IPT2$#HI0>2$03GDH5(-..A64$=::#'2
M;C7`1D@?(/0A1`U'..&1DS7J<>,1)>)8AR3E_/$8ECA<4J(0?7#H1SB)%<%'
M-7;88400=@11U6!B%=&#5D]X)8R`0[SAAAMTO-'&&ENH)2"`2111A!%$.&-$
M6#V$)>F!72&CIY_+*.77>#I$LT<=YMTY1!!X_&4')-J,R4PV?%AF)3HJ852'
M07A@@@-G4?9A1R,$N5-''9U9*0DY!$7Y(@CNK)9C<T*X5$A,=@P)PAX`D72;
M'D7Y,=-#G&%GG67RM'J:))Y,8D<UVTA5H0Y%<+,'$<KP9:%>LI@U!#"WO/7#
M&6_00?\''&^\0?`9=*BQQ1IT)`&,O[BT=ZFD.-QY)Q&XQ/)GI7@0(=4Q[8W7
M!Z4-XDL5#BPS(M6I\'C"(1X<UOG'#D\$D6XAC-21PTWC8$)D-^_DH$5`\@P5
M44%6DG99-5%Y!)%-1Y#DPQ'"'8WE237<H(;1'@TUFCR3)&7D#0-Y)%4C=>C0
M%%=UX'%4GD6LAT-=>LHB3(%CD24Q+V+,<<47;9S11L-Q&/Z&&HP[6I99`K97
M!%E/L%>,$0[Z&82!61G!7@\XW&"@#ALCR-6[I41%LS(]=(?O-7$/5<<=/8"#
MS:F;[7.##LA2XD?<M>(A]PT)"73##2\V`FLW":E4W9O.J9C_`QXO2;?(2;?=
M:`>.6E07DQ])Z9$497[(4UHB+8YY;*N!.84,,KMSU96>5!4Q\:!BB77H&608
M_H48:&A#&]X0!P(NCG%/2`*`WA*Y7[#'/TDPPK\V]8,B]$(KJAB"!L62*3_I
M`"S.J-`H1O&N5Y%"&K+008YJD`@.":M6TKA!.+9!"8((JRG<H0PE%,(-&79C
M#W^X08FXQ9J"*`($1RM'1/2@FY*\I"4W`9]SPH&E-W'B"!Z16\QVL`>YU2&(
MV*A5A0C#(6WTX`Z!T<JD"F3!R`GH/S:X@AS$0(8VH$$,;)C#&<XPA_ZUP0L*
M:Y@7UI"?)QAR+0L$V"Z(`0SV2(H(_X.:5-TF-P1(#@$'JY+&I2CE%R-8Y4Y!
MF$H0$'2'PM1%#\KH5=OP4H<;\J$.(>J#94*D)L[T82#BT(8?+D,(1/AA2'AP
MSC<ZTI"`>`0<XS"3^%:3"#VL`QL"4<WZN`.8S>S@BXV8$^^88:$T$8%TI)N%
M#3!I00H*(PFWN`,:Y@@'+`20CP-4@^+>P`:#*2I1="`DX]20P/X,Z`X&VH58
M_&,#=$).0`:22R._XI])>>X4RUA57S"6H!YPQ3Q[J,O)9'&LP@"Q;77@8B-N
MX`1%P)(O7Q1*.`+2144$!A,UB88_@@F.?=0#(YG8`Q]>I=,<U%!XG$';)892
MIC]L`QO8>/^7$4+:`_%DI2ZDJU`M-N>54TS*!G(9%!>N,(4L8.%_<``K&PQW
M!C<LCJR*$F#"UN`%QC4*D6I)PA8DID`X/NZ-!A6&7=MS"_A(L&Y=`<N=GG$*
M\11!0J)`Q5Z"@#F^+(8[;5L0ZD:)MJ:\J7:HC)M49*2-;*BF([<9"/@4P:VA
M]&H?-6E3T#+RQ59V%![OP@O-\-3*#6WG&.\BPNX\5P192+`8K""0!<UB%ALL
MH:M>G0(3O,K5,*!!47O<X_[LF;![%@P_;]@"/N.PA2<PB@Y>\`)=UZ"&L>@5
M%UM0)$!YD3_X;,Z"EBQ&):GBL4KIEI.,A>0UTV0G"\V""-]098C_9-@'T/G.
M2^?JXF4R$8XWB4\>LCP5C!)SK#?I%'QFJ@$?)$05S(&.#U:)H=LJQ*$-U>E2
M20B"6"Q$(%8`;&*[,.X2EL"%*2P!"UB8`A?@X`8Q8($,9$`#'.#0!CCL$;J&
M&B!U^2?`.2@Y46IH&"';0DA&&?(^@US#+X@+N;<4E#TJEI2D-JC!2V6**@GB
M"YXR]L$TW8G#-'L&5+;1H5=51V:MR^GNQD2)@EB#$5U,2%,HP:%7TFQWA-GF
M*PL#&`XU=1N,W=`'/2R_D@EJ59MJ("/]\X,E,($)Q]4Q%Y:0!3E\`0M7R((8
MK@"'_O'1#6<PLAL&V(8YS!JM"7MRPAAV_]V"5?>Z4<:/=V\!,+UZ65`9+)`J
MBMN+#<XOQ7Y!\P[\PCICR$+-"Z+9-^LTE:8J0V:R%.(UZ[0,W@&F*7Q(1NNL
M8^&=ABA$\`O1'A)T#*CL`#RBV]`9XU.+.RB6JI*"A5X']"\!46$)96!"&,9`
MA4_KV,8Z7@(;5"T'-L!!#EB`PQS8@.J-\X\-L"[<&^#`ACJ*G-8%4X/"@ITP
MQL7ACVV)\ES-^Q]A;*%O_5EVP=LC%OG(8G,"LNI=0)DG]K"1LA_ZH"CP,@O0
M&2%-Z!%/Z^(64APPUCR[8UWHZO#--%&E#OSJD/"0D:G/A45/I4"0@[`ZYK@(
MZ%*WH"NG^V,&*O^4H>Y,:#@5&`[JKC*!"UC@`A?D<(7`?^$+5W@#&DK^U3W2
M<<@*X^/$R4!R-Z`AR$6V-1<HCZ@S>"$.!F,<`</KA?1V]PET>(+]VEI73EMP
MY_XV@L1P84$]Y9>-M5"%!.W["@4!^`:50IU12[&@:4/E3TO-V"R0@8H*=>@9
MKAC"'I;Q3;CKR>H<^UB!6"%F214#JXN<S_U^<'.R3$``Z!?`^<T0AB6$(0P)
M5RX5N.!PP6,A"U>X`AD0OP0WD&$.:.`&7]!C?40&8C!`;$!'>B1DB^-_:E!D
M=$`PB$('\?1K=#!7^'0'%,@X_\$67F`#C2(Q_I15RN9O?,4*<<%7\B'_'ZOP
M4)ZC%UYA%_\B#;UU4>9A41E3)Q95*5:Q*J.T&-/P33U023'66VK4;WO#7@$5
M=+LP#.K%"ZS7'QW0`1[@`250A1Y@!F:0?F4P!@I7!J'V:3-&:L?%!%?`!6CP
M/SW&!HBW53Z61V>P>'X4:P*4*`MS*'U45F1U.-:E<H>C9-6E!G&`%N05!W^#
M/[/7-\2`3@.R;+R07OZA09-"(%YA(+CP*<ZP0<!@41H#'V/V)P0"%@"%.1+5
M%358*0F5%W;!"_K!B+L@,8L$#$E`7H(X2%NP!?M4`E-X?NE'A1V0!G=G!A,P
M!530<&/X:9]&!5GP!5/05:0V!6+`!3YV!6)@_VI3P`9<\`67-W@<)P9P4`9C
M)09\!`=R!%UT)$!G<`5Z-&MFY06%PS#YI&1CP2BT&`?\-!;T,3'Z&%Y1)HCV
M&`P%=4Y/R$@#UT!857`59(*\$%``0B@[$"F]Q6E\=0HOUH3&YD:LR!]5Y@7^
M$0=Q<!]0%@8"T`'J)P!C,`$P<'X><'Z@-@$BV87%:(P'QP1E@`5,8&-9\&FI
M=GA3@`7'E0590&I<]05R\'^M=G_MM$X$LV-E-0>FQ@:UY@90J08])HXM9S!M
M,%:*<D]15GK]]'ESU5W\A(N#^#!J$%[@-5?T,01D06S\49&.V(C`H$'#P$#$
MYB\99"`8-%#$P(I->/\+<246Z/0$#I,$@]@PY&<P@)0P4-8"5%@"5U@")ND!
M)'E^4Q@&$W!W(BD`P.AI!Q>3"7=P-F9W8TAJH(8%A,<%0.E565`&<L`$:""-
M^6>&U8AX<AAD"",&7^!DB5(X)7<&*B<&L.9K%`B<*B=ZH;<&O_9K;6!6:(&+
MAD06Y+<6"51ZA-1=<J<*`&)(M]@?$`10;*EID".8-5>>;\$?C3)7:@$,X?4&
M@_0&C/*`!,.8^"1`$^`!+G"%'C"2^\F+5+B%6Y@&6C@&`L!^GE8&"0=_#1<&
M"_J92V",QUAC--:3IX9J<`!X9QAXJ'EJA:='NLD&^O=.;D!D>\0&:'`P!1/_
M7;E6,(4C0`-$!H;2:O0)2/($GPTSEFMACVOP74EP0/ETEFSQD?Z('[-HC]S5
MG?]!G:UX!]%I2/-8G5%&7K<(,8)XEHM3,%N@5BSJHF.U1W30`I`)F5@(H!-0
MIEMX?F7`BVE0H&DP!@+:A65@=WSW:7`JA@>'H#-6C'0::E30C`[W=\N5!5,@
M!W*@FM58:FF(!HMW!A9'9'201VPP5NHX!WH4J0JSCK"&,(I"HKLV!_D$9?C4
M,`930(S#,.ZH!E/F,&[U@(FR!H<3I:@:GZ3J7=0IB'?05JVHG)^ZG&T0;%2)
M3RIWJ04X@`K3G`+@`I19IAV@BY#9`L*XA5FX?F/`_WY;6*!UUZ:<J85F,`;<
MFG=N&@;)R*!Q2I-].@4)AW"@)G%YEZZ`!VI;5:A?L`1?$`8]>0679W'/!0>K
ME@5S8&1.208@6CCV&JD&2&1;.5;#.0=I16L$TS!\6#!FA7K5I9P)@R@*TS\0
MLRC'.:IJD`2(HUW!%GJ_E@2]BD\%XZF^)D!U5)1#5FN']P7Z:FMQ>)\=,`$U
M6X4D^8L%FG[H9P93*`!EL'#OQP1F$+3;VJ;<*I)HP`0"JH5A,*!C$`9MRJ!4
M0+5]ZFECD'!YEY,V-F,VA@8W!G@U-CB$)T=?4$=C%8%9H*BV-@=;Y0;_ND=-
M)@9XQ&M`MK"]5E8N:K#],_]K`^1_+GIKB(*`OQ:RN0:/!T2<B;*P"JLX168H
M<F`XM<8_1M8&@6.'9X!J<@`'^UD"+F"SO8A^/RN2TYH&:_JL9L`$T^JT:?"T
MV[IWI;N%!"J2:[JZ9F"Z[!>UGI9W?0IJ=I=P7-M59ZB;.*::I"8'@RI'"4BH
MJ*F;=W0%\CI_?#0%9%!QD3H'\CE`BB)/C&I6AT.'?T@P&F=K:""W@TM`/5I=
M?616W1M(([J56TD&MV8P;#!RS0FW5V!6U5AKA@)D9>4&63!K_2I'98L%-7O`
M5S@!SZJ+U3J2Z*?`PEB@Y^>F`#JMZ$>@1BNU6MBT95"@W%JT4<NF2/NGR7BG
M>4?_C!%W<&.X58,C!LD5E%-`E&8KKUD`>&C@3J96OEEY1\^%N2XJOT?V!C`J
M74/,/VB@1]7%/WJ$!7G4HGQD.`(8<@*HL$X69/\W5AOGLE!)>8'3/V]@K]J8
MALI[H85'C6P8KR,YA25`LPZL?F7:G^NG?GNG?FMZ=R:YK0,J`%EHNFO*!#O+
MLVT*PF4`C%E+M#09FG3:IWJG<`\ZALHHJ$&Y58%7P]18J('S!71@`Z@&>#\&
M!VB0?ZH&9+]Y@$ZV<4II@`!X>"2GFYLK9$;V/T%6E'5D.'T$<M>;AGPXHGK(
M/[%V!A6W>/\#0$2YN?I*?U*9C7@49'1[>#XF!S=,A>GW_[3X>7[KI\`/S)D3
M+`#PAWZM6[I4L*9WS(LBB<<6?'ZX:[K:_*;OMZU4.ZY+P'YEP`7M)X9=2\_'
MA7$YB6JK"9OJF(X^V55?!4"4=Y2#DX#>>+9E108:"FMX5(T)>`4EEX;:R$X@
M!T"5S&,`='E$UIQC]91?4%;_HZCQ*HUB,*CK)'A_IZ]8X(W./+:%)\GXG`7G
MAZSWJ<#+NI]ZG'Z!#*!/VZ:#7+M:",@6S'ZN*Y(30+07?'?!N'?O9Y(T"8S@
MFG>AZ85;"[TW&912O01R0&/YIUPT]@6"ZK4Q?&,E+:B%%VMWM-)N,#CZBG$@
M%]"+MU6$([XWS&IR8'F49X!S=/]'7\"&$"UD9+"V`!N'J$EX`%MRRPB4JHFH
MA8IC@??()9UC<E!J_S.HS9@%NIC&)%FM`!K!UER@(MD!4>O3"\>Z']RZ3/NT
M4]`!5(!^3+NF4UN@Q7C'<#JMO,N@,Y:ZNVMWRD6,8_"@O?MW8#AC-8QC64`%
MR*N:%+I5)KK)T+BV:3@%^9=C7?T&=$2H`<AQ0_:4;B"O8'7#-5R--YQQBT>H
MSKC5R-N&]P>4]7I_-]F36^55H[;8.@9JZ4J&7S!J"5>2`J"+90JN:]H!MVN2
M;UJZ@?QIIJN@K<N9[R>@T]K:8]`!1BO;H-V%:SIC0#L%K3NT05N,##>N\ZRG
M7=556^7_:8.*M4P0C:6)DV7`5<)[>&Z(>$3IR2[\/Z?F8X$C.&E8C6O=PA!M
MHES%:ES0KT-V:JPY:C6\M$%.:H**8\C8C.['NU6;=\?5NY[VR=2=!0J*C%30
MG]NJQY2YV=5*H-9JDD%[=P2:X+?;NDO@P51`K6TZ8RX)C$1K=YSYS82L=[#[
M?L7(YY\)AC-IWP_JU3$,E!@7>#IVAHJNFE_P:1BZ!(,3>((GC2-.?U\%UGB$
MFA?WH8PN!WT:C:H)>/A\7)%>:C8F!C<6>&A`C`^ZKL\(Y=F(!<KHC)ZY!%X8
MFCW9C,58!O*'H#5KLRH9U)T=P4%-P;@;U-J\P=M*H!.PX<3X;<T,]\$]W84$
MJKI16]I>>-PS>:!=B,(F[J<S]M[W5P9!V>0^IERI]G=;+6KY=X9@G=[(G'^+
M=X;<B'CZ9[UL0'CT2G\VIL^GIM752&,N#.F"U^C2G:YF.&J*W-O/+H;DNG<F
-[&D/.JXRJ:!+$`@`.S\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
